Page last updated: 2024-08-21

pyrazines and bortezomib

pyrazines has been researched along with bortezomib in 3832 studies

Research

Studies (3,832)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.03)18.2507
2000's1538 (40.14)29.6817
2010's2278 (59.45)24.3611
2020's15 (0.39)2.80

Authors

AuthorsStudies
Adams, J; Ara, G; Herbst, R; Palombella, VJ; Teicher, BA1
Adams, J; Chau, V; Elliott, PJ; Lightcap, ES; McCormack, TA; Pien, CS1
An, WG; Blagosklonny, MV; Hwang, SG; Trepel, JB1
Adams, J; Elliott, P; Frankel, A; Kerbel, RS; Man, S1
Cheson, BD; Gore-Langton, RE; Hillsamer, VL; Wright, J1
Bennink, JR; Chen, W; Crews, CM; Myung, J; Princiotta, MF; Schubert, U; Yewdell, JW1
Adams, J; Anderson, KC; Chauhan, D; Elliott, PJ; Hideshima, T; Palombella, VJ; Richardson, P1
Adams, J; Baldwin, AS; Cusack, JC; Elliott, P; Liu, R; Russo, SM; Tepper, JE1
Abendroth, K; Adams, J; Baldwin, AS; Cusack, JC; Elliott, PJ; Houston, M; Liu, R1
Adams, J; Chen, Z; Crowl Bancroft, C; Dong, G; Elliott, P; Sausville, E; Sunwoo, JB; Van Waes, C; Yeh, N1
Blagosklonny, MV1
Adams, J; Elliott, PJ1
Anderson, KC; Chauhan, D; Hideshima, T; Richardson, P; Schlossman, R1
Bold, RJ; McConkey, DJ; Virudachalam, S1
McBride, WH; Pajonk, F; Pervan, M; Sun, JR; Withers, HR1
Elliott, PJ; Ross, JS1
Bardag-Gorce, F; French, BA; French, SW; Gaal, K; Lue, YH; Marceau, N; Riley, NE; van Leeuwen, F; Yuan, QX1
Adams, J8
Berenson, JR; Ma, HM; Vescio, R1
Bardag-Gorce, F; French, BA; French, SW; Li, J1
Garber, K3
Blackman, RK; Bulawa, CE; Fleming, JA; Lightcap, ES; Sadis, S; Thoroddsen, V1
L'Allemain, G1
Tan, C; Waldmann, TA1
Adams, J; Anderson, KC; Castro, A; Chauhan, D; Dang, L; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, N; Palombella, V; Richardson, P1
Hussein, MA2
Daud, A; Munster, P; Spriggs, DR1
Schenkein, D1
Giles, FJ1
Cheson, BD4
Adams, J; Aghajanian, C; Canales, C; Daud, A; Dizon, DS; Elliott, PJ; Hensley, ML; Miller, V; Pezzulli, S; Pien, CS; Sabbatini, P; Soignet, S; Spriggs, DR1
Adams, J; Anderson, KC; Catley, LP; Goloubeva, O; Gupta, D; Hideshima, T; LeBlanc, R; Lentzsch, S; Mitsiades, CS; Mitsiades, N; Munshi, NC; Neuberg, D; Pien, CS; Richardson, PG1
Abbruzzese, JL; Chiao, PJ; Dong, QG; Evans, DB; Fujioka, S; McDonnell, TJ; Peng, B; Schmidt, C; Sclabas, GM; Tsao, MS; Wu, T1
Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Treon, SP1
Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, P; Schlossman, R1
Roodman, GD4
Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Schlossman, R; Tai, YT1
Adams, J; Anderson, JK; Baldwin, AS; Bhagat, R; Depcik-Smith, ND; Elliott, PJ; Esseltine, DL; Guerciolini, R; Lehman, MJ; Mitchell, BS; Novick, SC; O'Connor, OA; Orlowski, RZ; Pien, CS; Shea, TC; Soignet, SL; Stahl, S; Stinchcombe, TE1
Adams, J; Buckley, M; Elliott, PJ; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Ng, B; Perez-Soler, R1
Berenson, JR2
Anderson, KC6
Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M1
Abbruzzese, JL; Baker, C; Chiao, PJ; Dong, QG; Evans, DB; Frederick, WA; Fujioka, S; Schmidt, C; Sclabas, GM1
Mundy, GR; Oyajobi, BO1
Dees, EC; Orlowski, RZ2
Bailly, C; Lansiaux, A1
Adams, J; Altamirano, C; Berenson, JR; Borad, MJ; Frantzen, M; Friedman, JM; Ma, MH; Manyak, S; Mikail, A; Neeser, J; Parker, K; Roussos, E; Sjak-Shie, N; Vescio, RA; Wu, ZQ; Yang, HH1
Adams, J; Elliott, PJ; Holland, JF; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Perez-Soler, R1
Blazar, BR; Brooks, AD; Elliott, PJ; Koh, CY; Ma, W; Murphy, WJ; Raziuddin, A; Sayers, TJ; Seki, N; Zhang, X1
Boehncke, WH; Elliott, PJ; Zollner, TM1
Anderson, KC; Mitsiades, CS; Mitsiades, N; Richardson, PG; Treon, SP1
Mehta, J; Singhal, S1
Alsina, M; Djulbegovic, B; Durie, BG; Kumar, A; Loughran, T1
Cusack, JC1
Richardson, P4
Lenz, HJ1
Schoenfeldt, M; Wright, JJ; Zerivitz, K1
Twombly, R1
Ford, RJ; Lo, P; Pham, LV; Tamayo, AT; Yoshimura, LC1
Luker, GD; Luker, KE; Pica, CM; Piwnica-Worms, D; Song, J1
Liebes, L; Ling, YH; Perez-Soler, R; Zou, Y1
Hattori, Y1
Mitchell, BS1
Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Hideshima, T; Irwin, D; Jagannath, S; Kauffman, M; Kuter, D; Lee, S; Limentani, SA; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, D; Singhal, S; Srkalovic, G1
Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC1
Conrad, D; Dent, P; Grant, S; Rahmani, M; Subler, M; Yu, C1
Johnson, TR; Kraft, AS; Nesterov, A; Nikrad, M; Stone, K; Thompson, CB; Yeh, T; Zong, WX1
Frantz, S; Paramore, A1
Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S1
Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S1
Gisslinger, H; Kees, M1
Jäger, U1
Faix, JD1
Meisler, AI1
Dai, Y; Grant, S; Pei, XY2
Sussman, HE1
Adams, J; An, J; Belldegrun, A; Fisher, M; Rettig, MB; Sun, YP1
Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S1
Logothetis, C; McConkey, DJ; Papandreou, C; Pettaway, C; Song, R; Williams, S1
Berenson, JR; Schenkein, D; Vescio, R; Yang, HH1
Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Ohtake, Y; Podar, K; Shringarpure, R1
Dai, Y; Grant, S; Rahmani, M1
von Mehren, M1
McConkey, DJ; Williams, SA1
Goldman, B1
Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, PG1
Stanford, BL; Zondor, SD1
Shiotsu, Y1
Hu, WX; Shi, YW; Tang, LJ1
Bross, PF; Farrell, AT; Kane, RC; Pazdur, R1
D'Anneo, A; De Blasio, A; Giuliano, M; Tesoriere, G; Vento, R1
Dees, EC; O'Neil, B; Orlowski, RZ; Voorhees, PM1
Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE1
Bardag-Gorce, F; French, BA; French, SW; Li, J; Lue, YH; Montgomery, RO; Nan, L; Riley, NE1
McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R1
Anderson, KC; Hideshima, T; Richardson, PG2
Ikezoe, T; Kobayashi, M; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y1
Jákó, J; Mikala, G; Vályi-Nagy, I1
Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC; Mortenson, MM1
Anderson, KC; Auclair, D; Chauhan, D; Chen, LB; Hideshima, T; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K; Saxena, S1
Bardag-Gorce, F; French, SW; Li, J; Nan, L; Riley, N; Vu, J1
Barlogie, B1
Ikezoe, T; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y1
Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y1
Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M1
Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M1
Broad, RM; Denlinger, CE; Jones, DR; Keller, MD; Mayo, MW1
Orlowski, RZ6
Durrance, A1
Chen, SL1
Anderson, KC; Catley, L; Chauhan, D; Gribble, GW; Hideshima, T; Honda, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R; Shringarpure, R; Sporn, MB; Suh, N; Tai, YT1
Reddy, GK1
Gilles, F; Goy, A1
Harding, JC; Hess, JL; Mitra-Kaushik, S; Ratner, L1
Dent, P; Grant, S; Rahmani, M; Yu, C1
Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Shringarpure, R; Yew, PR1
Abbruzzese, JL; Chiao, PJ; Evans, DB; Fujioka, S; Huang, P; Li, Z; Niu, J; Pelicano, H; Peng, B; Schmidt, C; Sclabas, GM; Yao, A; Zhang, W1
Kaufman, J; Lonial, S1
Bonvini, P; Dalla Rosa, H; Rosolen, A; Vignes, N1
Aggarwal, BB; Bharti, A; Georgakis, GV; Li, Y; McConkey, D; Younes, A; Zheng, B1
Bisht, KS; Gius, D; Isaacs, JS; Mimnaugh, EG; Neckers, L; Vos, M; Xu, W; Yuan, X1
Barao, I; Blazar, BR; Liu, H; Murphy, WJ; O'Shaughnessy, MJ; Panoskaltsis-Mortari, A; Riordan, W; Sayers, TJ; Serody, JS; Sitcheran, R; Sun, K; Welniak, LA; Wysocki, C1
Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J1
Richardson, PG3
Adams, J; Daliani, DD; Dieringer, P; Elliott, P; Esseltine, D; Kim, J; Logothetis, CJ; Madden, T; Millikan, RE; Nix, D; Pagliaro, L; Papandreou, CN; Perez, C; Petrusich, A; Pien, CS; Tu, SM; Wang, X; Yang, H1
Adachi, M; Hinoda, Y; Imai, K; Kawamura, R; Minami, T; Zhang, Y; Zhao, X1
Koya, Y; Matsuoka, M; Nosaka, K; Satou, Y; Toyokuni, S; Yasunaga, JI1
Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S1
Adams, J; Kauffman, M1
Bold, R1
Alkan, S; Hsi, ED; Kelley, TW; Srkalovic, G1
An, J; Fisher, M; Rettig, MB; Sun, Y2
Anderson, KC; Chauhan, D; Cotter, FE; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R1
Abraham, S; Benson, K; Bradley, S; Bross, PF; Brower, ME; Farrell, AT; Gobburu, JV; Goheer, A; Kane, R; Lee, SL; Leighton, J; Liang, CY; Lostritto, RT; McGuinn, WD; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Verbois, SL; Wang, YC; Williams, G1
Bunn, PA1
Capriotti, T1
Lenz, HJ; Park, DJ1
Anderson, K; Hideshima, T; Mitsiades, C; Richardson, PG1
Bostrom, B; Brown, RE; Zhang, PL1
O'Connor, OA3
Cardoso, F; Durbecq, V; Picart, MJ; Ross, JS; Sotiriou, C1
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA1
Hatake, K; Mishima, Y; Terui, Y1
Matsuoka, M; Satou, Y1
Logothetis, CJ; Papandreou, CN1
Benbatoul, K; Laing, N; Poss, MA; Purandare, AV; Vaccaro, W; Wan, H1
Durrant, D; Lee, RM; Liu, J; Yang, HS1
Bacik, J; Drucker, B; Kondagunta, GV; Marion, S; Mazumdar, M; Motzer, RJ; Russo, P; Schwartz, L1
Hussar, DA1
Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D1
Edmund, NA; Moore, DT; Orlowski, RZ; Shi, YY; Small, GW; Somasundaram, S1
Politou, M; Rahemtulla, A; Terpos, E1
Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Irwin, D; Jagannath, S; Kauffman, M; Limentani, SA; Niesvizky, R; Richardson, PG; Schenkein, DP; Siegel, D1
Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK1
Anderson, KC; Chauhan, D; Hamasaki, M; Hideshima, H; Hideshima, T; Higgins, LS; Ishitsuka, K; Mitsiades, C; Munshi, NC; Navas, T; Nguyen, AN; Podar, K; Raje, N; Richardson, PG; Schreiner, G; Tai, YT1
Farah, M; Webster, JM; Wojcikiewicz, RJ; Xu, Q1
Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL2
Anderson, KC; Chauhan, D; Hideshima, T; Ishitsuka, K; Podar, K; Richardson, PG; Sattler, M; Shringarpure, R; Simoncini, M; Tai, YT1
Fribley, A; Wang, CY; Zeng, Q1
Kyle, RA; Rajkumar, SV1
Denlinger, CE; Jones, DR; Rundall, BK1
Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE1
Duff, SB; Gupta, S; Mehta, J1
Gudegast, C; Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U1
Black, KL; Koeffler, HP; Kumagai, T; Liu, G; Ong, JM; Yin, D; Zhou, H1
Arnulf, B; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Karam, JA; Kfoury, Y; Lepelletier, Y; Nasr, R1
Reddy, KG1
Duechler, M; Hilgarth, M; Hoelbl, A; Hubmann, R; Schwarzmeier, JD; Shehata, M1
Demaria, S; Formenti, SC; Liebes, L; Ng, B; Santori, FR; Vukmanovic, S1
Adamson, PC; Berg, SL; Bernstein, M; Blaney, SM; Ginsberg, J; Horton, T; Kitchen, B; Krailo, M; Neville, K1
Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P1
Klener, P; Spicka, I1
Callery, MP; Canete, JJ; Chandler, NM1
Korniluk, J; Wcisło, G; Wojtuń, S1
Benedict, W; Dinney, CP; Grossman, HB; Lashinger, L; McConkey, DJ; Millikan, R; Papageorgiou, A1
An, J; Fisher, M; Rettig, MB1
Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D1
Fisher, RI1
Broglio, K; Cabanillas, F; Dang, NH; Fayad, L; Gilles, F; Goy, A; Hagemeister, F; Hart, S; McLaughlin, P; Pro, B; Rodriguez, AM; Romaguera, JE; Samaniego, F; Samuels, B; Sarris, AH; Schenkein, D; Trehu, E; Wang, M; Younes, A1
Adams, J; Choi, E; Dumetrescu, O; Esseltine, D; Hamlin, P; MacGregor-Cortelli, B; Moskowitz, C; Muzzy, J; O'Connor, OA; Portlock, C; Schenkein, D; Straus, D; Stubblefield, M; Trehu, E; Wright, J; Zelenetz, AD1
Cooper, C; Liu, GY; Murphy, LC; Niu, YL; Santos, S; Watson, PH1
Adams, J; Allred, T; Collins, JM; Dees, EC; Esseltine, DL; Gabriel, DA; Garcia, RA; Green, M; Hall, MD; Ivanova, A; Johri, AR; Jones, PE; Kudrik, FJ; Lehman, MJ; Lindley, CM; Mitchell, BS; Natoli, S; Orlowski, RZ; Shea, TC; Trehu, EG; Van Deventer, HW; Voorhees, PM1
Dreicer, R; Price, N1
Belani, CP1
Schenkein, DP2
Cardinale, G; Gervasi, F; Pagnucco, G1
Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG3
Davies, FE; Morgan, GJ1
Hempstead, BL; Li, Y; Pearse, RN; Rafii, D; Swendeman, SL1
Anderson, KC; Hideshima, T; Rajkumar, SV; Richardson, PG1
Chaudhary, PM; Matta, H1
Dalton, WS; Holle, L; Jung, L1
Davidson, T; Schwartz, R1
Alexanian, R; Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Jagannath, S; Nix, D; Orlowski, RZ; Richardson, PG; Singhal, S; Srkalovic, G1
Carvajal-Vergara, X; Esparís-Ogando, A; Gutiérrez, N; López-Pérez, R; Mateo, G; Montero, JC; Pandiella, A; Parmo-Cabañas, M; San Miguel, JF; Tabera, S; Teixidó, J1
Jung, W; Schroers, R; Zettl, F1
Bruno, B; Fanin, R; Patriarca, F; Prosdocimo, S; Tomadini, V; Vasciaveo, A1
Kaplow, R1
Anderson, KC; Bonham, L; Chauhan, D; Hideshima, H; Hideshima, T; Ishitsuka, K; Kumar, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Singer, JW; Yasui, H1
Crawford, CL1
Bladé, J; Cibeira, MT; Montoto, S; Rosiñol, L1
Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J1
Berdel, WE; Bisping, G; Kienast, J; Kropff, MH; Tchinda, J; Volpert, S; Wenning, D1
Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL1
Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P1
Baronas, E; Daniels, JS; Gan, LS; Hsieh, F; Labutti, J; Miwa, G; Nix, D; Parsons, I; Pekol, T1
Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E1
Adams, J; Coultas, L; Johnson, T; Kraft, AS; Nikrad, M; Puthalalath, H1
Engelhardt, M; Maier, W; Müller, AM; Wäsch, R1
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J; Vollmer, CM1
Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S1
Chou, T1
Ahsan, MH; Purchio, AF; Sambucetti, LC; West, DB; Zhang, N; Zhu, L1
Magnuson, NS; McKenzie, IF; Shay, KP; Wang, Z; Xing, PX1
Dalton, WS1
Aghajanian, C1
Au, AW; Chim, CS; Lie, AK; Loong, F; Ooi, GC1
Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F1
Cebula, B; Duechler, M; Linke, A; Robak, T; Schwarzmeier, JD; Shehata, M; Smolewski, P1
Dubey, S; Schiller, JH1
Chiao, PJ; Davis, JJ; Dong, F; Fang, B; Guo, W; Teraishi, F; Wu, S; Zhang, L; Zhu, H1
Anderson, KC; Chauhan, D; Hideshima, T; Mitsiades, C; Richardson, P1
Fuchida, SI; Inaba, T; Nakano, S; Namura, K; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R1
Fleissner, C; Jakob, C; Kaiser, M; Krebbel, H; Possinger, K; Rosche, M; Schmid, P; Sezer, O; Zavrski, I1
Anderson, KC; Berkers, CR; Fiebiger, E; Galardy, PJ; Kessler, BM; Lichtman, E; Ovaa, H; Ploegh, HL; Verdoes, M1
Chng, WJ; Lau, LG; Mow, BM; Yusof, N1
Murphy, WJ; Sayers, TJ1
Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G1
Dorr, RT; Landowski, TH; Lynch, RM; Megli, CJ; Nullmeyer, KD1
Jagannath, S3
Böll, B; Borchmann, P; Engert, A; Hansen, H; Heuck, F; Pogge von Strandmann, E; Reiners, K; Rothe, A1
Edelman, MJ2
Nelson, JB; Smith, MR1
Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W1
Bradbury, J1
Andtbacka, R; McConkey, D; Nawrocki, ST1
Mimnaugh, EG; Neckers, LM1
Dinney, CP; Lashinger, LM; McConkey, DJ; Shrader, M; Williams, SA; Zhu, K1
Ballestrero, A; Belka, C; Boy, D; Brossart, P; Cirmena, G; Dal Bello, G; Nencioni, A; Patrone, F; Wesselborg, S; Wille, L1
Anderson, KC; Bradner, JE; Chauhan, D; Hideshima, T; Richardson, P; Schreiber, SL; Wong, J1
Ahsan, MH; Purchio, AF; West, DB; Zhang, N1
Rajkumar, SV5
Bruno, B; Gallamini, A; Mattei, D; Mordini, N; Rapezzi, D; Vigna Taglianti, R1
Agrawal, S; Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Morris, C; Oakervee, HE; Popat, R; Schenkein, D; Smith, P; Stec, J1
Camacho, E; Crowley, J; Durie, BG; Gabayan, E; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Schenkein, D; Wolf, J1
Dimopoulos, MA; Rahemtulla, A; Terpos, E1
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Agterof, MJ; Biesma, DH1
Dispenzieri, A3
Anver, MR; Blazar, BR; Murphy, WJ; Panoskaltsis-Mortari, A; Sayers, TJ; Sun, K; Welniak, LA; Wilkins, DE1
Dispenzieri, A; Goel, A; Greipp, PR; Mesa, RA; Russell, SJ; Witzig, TE1
Bankier, A; Drach, J; Kalhs, P; Krauth, MT; Valent, P1
Masuda, N; Yanase, N; Yokoba, M1
André, P; Chiadmi, F; Cisternino, S; Fain, O; Fontan, JE; Schlatter, J; Toledano, A1
Dunn, ST; Garrett, MW; Huang, S; Kaufman, KM; Kem, DC; Metcalf, JP; Patterson, E; Yu, X; Zhu, M1
Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S1
Azizi, L; Bories, D; Coppo, P; Fouillard, L; Garderet, L; Gorin, NC; Paubelle, E1
Heinrich, B1
Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG2
Drach, J; Kaufmann, H; Seidl, S1
Adams, J; Camphausen, K; Chang, AA; Chen, Z; Conley, BA; Druzgal, CH; Elsayed, YA; Gius, D; Lebowitz, PF; Mitchell, JB; Morris, JC; Rudy, SF; Sausville, EA; Sunwoo, JB; Van Waes, C1
Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C1
Chanan-Khan, A; Miller, KC1
Anderson, KC; Barlogie, B; Berenson, J; Esseltine, D; Hideshima, T; Irwin, D; Jagannath, S; Rajkumar, SV; Richardson, PG; Schenkein, D; Singhal, S; Xiao, H1
Bold, RJ; Davies, AM; Gandara, DG; Lara, PN; Mortenson, MM; Schlieman, MG; Virudachalam, S1
Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J1
Fernández, Y; Lowe, SW; Miller, TP; Opipari, AW; Rush, JL; Soengas, MS; Steiner, P; Verhaegen, M1
Adachi, M; Imai, K; Kawamura, R; Minami, T; Shinomura, Y; Zhang, Y1
Ganten, TM; Haas, TL; Herzer, K; Koschny, R; Li-Weber, M; Sykora, J; Walczak, H1
Delaney, TF; Harmon, DC; Mohiuddin, MM1
Biggs, JR; Garcia, M; Kraft, AS; Peterson, LF; Zhang, DE; Zhang, Y1
Linder, S; Shoshan, MC1
Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J1
Apperley, JF; Karadimitris, A; Kotsianidis, I; Politou, M; Rahemtulla, A; Terpos, E1
Brown, RE; Kennedy, TL; Law, A; Lun, M; Pellitteri, PK; Zhang, PL1
Davis, JJ; Dong, F; Fang, B; Guo, W; Teraishi, F; Wu, S; Zhang, L; Zhu, H1
Albanell, J; Gascon, P; Mellado, B; Montagut, C; Ross, JS; Rovira, A1
Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M1
Adimoolam, S; Chen, D; Kampa, K; Lopez, CD; Naumovski, L; Ramos, J; Sirisawad, M; Yu, Z; Zhu, Z1
Ahmad, K1
Albert, V; Andreeff, M; Carbone, A; Georgakis, GV; Humphreys, R; Li, Y; O'Brien, S; Younes, A; Younes, M1
Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Francis, D; Giusti, S; Giver, CR; Heffner, LT; Jagannath, S; Jaye, DL; Lonial, S; Orlowski, RZ; Richardson, PG; Schenkein, DP; Singhal, S; Torre, C; Waller, EK; Xiao, H1
Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T1
Gan, LS; Lu, C; Miwa, G; Uttamsingh, V1
Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R1
Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R1
Bladé, J; Cibeira, MT; Rosiñol, L1
Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK1
Alexandre, J1
Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG1
Aghajanian, C; Dizon, DS; Dupont, J; Raizer, JJ; Sabbatini, P; Spriggs, DR1
Adams, J; Boyden, J; Chachoua, A; Clark, JW; Eder, JP; Elliott, P; Farrell, K; Garcia-Carbonero, R; Hamilton, AL; Kinchla, N; Liebes, L; Muggia, FM; Pavlick, AC; Ryan, DP; Soma, V; Wright, J; Yee, H; Zeleniuch-Jacquotte, A1
Altun, M; Anderson, KC; Galardy, PJ; Hideshima, T; Kessler, BM; LeBlanc, R; Ploegh, HL; Shringarpure, R1
Anderson, KC; Farrell, AT; Pazdur, R1
Chaudhry, V; Umapathi, T1
Musch, A1
Anderson, KC; Carver, B; Chang, Y; Chauhan, D; He, D; Hideshima, T; Li, G; Mitsiades, N; Neri, P; Podar, K; Richardson, P; Schindler, J1
Campo, E; Colomer, D; Montserrat, E; Pérez-Galán, P; Roué, G; Villamor, N1
Glasmacher, A; von Lilienfeld-Toal, M1
Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M1
Drobyski, WR; Hari, P; Jacobs, P; Komorowski, R; Vodanovic-Jankovic, S1
Caccese, E; Cecchi, M; Messori, A1
Facon, T; Giaccone, G; Khayat, D; Ludwig, H1
Kroep, JR; Vandenbroucke, JP1
Adam, Z; Gregora, E; Hájek, R; Klener, P; Maisnar, V; Schutzova, M; Scudla, V; Spicka, I; Straub, J; Vytrasová, M1
Ferrant, A; Jacquemain, A; Knoops, L; Tennstedt, D; Theate, I; Van den Neste, E1
Joshua, DE1
Gullbo, J; Larsson, R; Lövborg, H; Nygren, P; Oberg, F; Rickardson, L1
Alexanian, R; Alsina, M; Anderson, K; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, DT; Singhal, S; Srkalovic, G; Trehu, E1
Brown, HJ; McBride, WH; Sun, R; Zack, JA1
Bachelez, H; Courtois, G; Dubertret, L; Jean-Louis, F; Laroche, L; Michel, L; Pellet, C; Sors, A1
Frost, P; Gera, J; Lichtenstein, A; Shi, Y; Yan, H1
Apperley, JF; Crawley, D; Lampert, I; Naresh, K; Politou, M; Rahemtulla, A; Terpos, E1
Aggarwal, BB; Gutierrez, AM; Lotan, R; Shishodia, S1
Anderson, K; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R1
Harousseau, JL; Moreau, P1
Sonneveld, P; Wu, KL1
Akiyama, M; Anderson, KC; Bailey, C; Chauhan, D; Davies, FE; Gu, X; Hideshima, T; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Morgan, G; Munshi, NC; Poulaki, V; Richardson, PG; Rosen, NS; Shringarpure, R1
Adjei, AA1
Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC2
Kiselyov, A1
Anderson, KC; Richardson, PG1
Bengston, AL; Denoyelle, C; Esteban, JA; Fernández, Y; Miller, TP; Soengas, MS; Tang, WH1
Zelenetz, A1
Alberca, M; Blanco, B; Carvajal-Vergara, X; López-Holgado, N; Maiso, P; Mateos, J; Pandiella, A; Pérez-Simón, JA; San Miguel, J; Sánchez-Abarca, LI; Schenkein, D; Vidriales, B; Villarón, E1
Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H1
Berg, SL; Blaney, SM; D'Argenio, DZ; Gannavarapu, A; Horton, TM; Plon, SE1
Einsele, H; Jackson, G; Miguel, JS; Moreau, P1
Herrington, JD; Jaskiewicz, AD; Wong, L1
Daniel, KG; Dou, QP; Kazi, A; Kuhn, DJ1
Andreesen, R; Grassinger, J; Hennemann, B; Südhoff, T1
Bay, JO; Blay, JY; Rixe, O; Spano, JP1
Abboud, CN; Bechelli, J; Lancet, JE; Liesveld, JL; Lu, C; Phillips, G; Rosell, KE1
Bosi, A; Ciolli, S; Gigli, F; Leoni, F; Rigacci, L1
Bogner, C; Decker, T; Peschel, C1
Leblond, V1
Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA1
Greipp, P1
Abbruzzese, JL; Boise, LH; Carew, JS; Chiao, PJ; Dunner, K; Huang, P; McConkey, DJ; Nawrocki, ST1
Abbruzzese, JL; Carew, JS; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pino, MS1
Bukowski, RM; Chawla-Sarkar, M; Chikamori, K; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Gudkov, AV; Hill, J; Mekhail, T; Rybicki, LR; Takigawa, N; Vaziri, SA1
Brooks, AD; Elliott, PJ; Murphy, WJ; Onksen, J; Ramirez, T; Sayers, TJ; Toh, U1
Berrebi, A1
Buisson, JP; Magdelenat, H; Monneret, C1
Govindan, R; Narra, V; Pillot, G; Subramanian, J1
Saunders, G1
Behrens, D; Cinatl, J; Doerr, HW; Fichtner, I; Haider, W; Mack, A; Michaelis, M; Rothweiler, F1
Anderson, KC; Catley, L1
He, M; Khuri, FR; Lin, N; Lonial, S; Sun, SY; Wang, B; Yue, P; Zhou, Z; Zou, W1
Anderson, KC; Dammacco, F; Hideshima, T; Ishitsuka, K; Kumar, S; Nico, B; Raje, N; Ribatti, D; Richardson, PG; Roccaro, AM; Shiraishi, N; Vacca, A; Yasui, H1
Anastasiadis, AG; Argyropoulou, P; Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Prassopoulos, P; Tsatalas, C1
Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P1
Orlowski, RZ; Voorhees, PM3
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH1
Brancolini, C; Demarchi, F1
Chizzolini, C; Dayer, JM; Fineschi, S; Guerne, PA; Reith, W1
Fujii, T; Kami, M; Kawabata, M; Matsumura, T; Miyakoshi, S; Narimatsu, H; Oshimi, K; Ozawa, K; Sasaki, M; Takatoku, M; Taniguchi, S; Yuji, K1
Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH1
Dispenzieri, A; Geyer, SM; Goel, A; Greiner, S; Peng, KW; Russell, SJ1
Furukawa, Y; Ishii, H; Kano, Y; Kobayashi, Y; Ozawa, K; Sutheesophon, K; Takatoku, MA1
Scagliotti, G1
Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N1
de la Loge, C; Dhawan, R; Dubois, D; Esseltine, D; Gupta, S; van de Velde, H; Viala, M1
Orlowski, RZ; Zeger, EL1
Jaehde, U; Scheulen, ME; Simons, S1
Anan, A; Baskin-Bey, ES; Bronk, SF; Gores, GJ; Shah, VH; Werneburg, NW1
Gallegos, R; Gan, LS; Li, P; Lu, C; Miwa, GT; Nix, D; Pusalkar, S; Uttamsingh, V; Xia, CQ1
Adachi, M; Hayashi, T; Ikeda, H; Ikeda, Y; Imai, K; Ishida, T; Nojima, M; Yasui, H1
Huang, DC; Sinicrope, FA; Yeung, BH1
Murakami, H1
Cho, CS; Eom, KS; Kim, CC; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS; Park, G1
Bonomi, P; Villaflor, V1
Fayad, L; Pro, B; Younes, A1
Lilenbaum, R; Raez, LE1
Chim, CS; Ooi, GC1
De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N1
Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A1
Dick, L; Hu, G; Li, H; Lin, G; Nathan, C; Wang, M; Xu, RM1
Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Irwin, DH; Jagannath, S; Rajkumar, SV; Richardson, PG; Singhal, S; Srkalovic, G1
Gaczynska, M; Osmulski, PA; Tan, X1
Dasmahapatra, G; Dent, P; Grant, S; Nguyen, TK1
Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ1
Bouley, J; Fisher, M; Henninger, N; Sicard, KM; Stagliano, NE1
Moskowitz, CH1
Braun, T; Carvalho, G; Castedo, M; Coquelle, A; Kroemer, G; Métivier, D; Mouhamad, S; Pequignot, MO; Vivet, S1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R1
Kaufman, JL; Lonial, S; Sinha, R1
Boise, LH; Carlson, LM; Gutman, DM; Harrington, WJ; Lee, KP; Obeng, EA1
Beehler, BC; Benmassaoud, L; Grover, GJ; Sleph, PG1
Sánchez-Serrano, I1
Colland, F2
Calvaruso, G; Carlisi, D; D'Anneo, A; Emanuele, S; Lauricella, M; Portanova, P; Tesoriere, G; Vassallo, B; Vento, R1
Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S1
Berkers, CR; Groll, M; Ovaa, H; Ploegh, HL1
Ballestrero, A; Brauer, KM; Brossart, P; Grünebach, F; Nencioni, A; Schmidt, SM; Schwarzenberg, K1
Chopp, M; Hozeska, A; Liu, X; Lu, M; Riordan, W; Stagliano, N; Zhang, L; Zhang, ZG1
Ann, DK; Boo, LM; Chen, Y; Chung, V; Liu, X; Nguyen, HV; Song, J; Yen, Y; Zhou, B; Zhu, L1
Albanell, J; Bosch, M; Codony-Servat, J; Domingo-Domenech, J; Gascon, P; Mellado, B; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, MA1
Coiteux, V; Facon, T; Leleu, X1
Kondagunta, GV; Motzer, RJ; Ronnen, EA1
Doihara, H; Fujita, T; Kawasaki, K; Ogasawara, Y; Shimizu, N; Takabatake, D; Takahashi, H; Tsukuda, K; Washio, K1
Badros, A; Gahres, N1
Mitsiades, C; Richardson, PG1
Coleman, M; Furman, RR; Leonard, JP1
O'Connor, OA; Paoluzzi, L1
Kyle, RA; Vincent Rajkumar, S1
Fei, XM; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wu, YJ; Zhang, JF1
Bazzaro, M; Lee, MK; Roden, RB; Santillan, A; Shih, IeM; Stirling, WL; Zoso, A1
Abbruzzese, JL; Andtbacka, RH; Bornmann, WG; Carew, JS; Chiao, PJ; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pal, A; Pino, MS; Xiong, H1
Bonavida, B; Comin-Anduix, B; Dissette, VB; Economou, JS; Garban, HJ; Glaspy, JA; McBride, WH; Owens, SK; Ribas, A; Schumacher, LY; Vo, DD1
Ferreri, AJ1
Ayuk, FA; Corradini, P; Goldschmidt, H; Hegenbart, U; Kröger, N; Lokhorst, HM; Montefusco, V; Nagler, A; Perez-Simon, JA; Raymakers, RA; San Miguel, JF; van de Donk, NW; van Oers, MH; Verdonck, LF; Zijlmans, M1
Kaufman, JL; Lonial, S1
Balkwill, F; Boral, A; Hoare, S; Joel, SP; Johnson, PW; Lister, TA; Maharaj, L; Millard, L; Radford, JA; Rohatiner, A; Schenkein, D; Strauss, SJ; Trehu, E; Vinnecombe, S1
Daniels, JS; Gan, LS; Huang, R; Labutti, J; Miwa, G; Parsons, I1
Handa, H; Murakami, H1
Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Perrone, G; Tacchetti, P; Tosi, P; Zamagni, E1
Anderson, KC; Chakravarty, S; Dugar, S; Haghnazari, E; Henson, M; Hideshima, T; Higgins, LS; Kapoun, AM; Kerr, I; Luedtke, G; Ma, JY; Mavunkel, B; Medicherla, S; Navas, TA; Nguyen, AN; O'Young, G; Perumattam, J; Protter, AA; Reddy, M; Schreiner, GF; Stebbins, EG1
Bohlius, J; Engert, A; Hülsewede, H; Kober, T1
Cebula, B; Duechler, M; Grzybowska-Izydorczyk, O; Linke, A; Robak, T; Shehata, M; Smolewski, P1
Arnold, AC; Back, TC; Hixon, JA; Khan, T; Lincoln, E; Lockett, S; Powell, D; Salcedo, R; Sayers, TJ; Stauffer, JK; Wigginton, JM; Williams, R1
Chan, KK; Chanan-Khan, A; Frankel, S; Liu, S; Marcucci, G; O'Connor, OA; Rolfe, M; Smith, EA; Teruya-Feldstein, J; Toner, LE; Wei, X1
Hess, U1
Giaccone, G; Voortman, J1
Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; McCrea, K; Sun, J1
Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R1
Soria, JC1
Awada, A; de Castro, G1
Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A1
Anderson, KC; Atadja, P; Catley, L; Chauhan, D; Hideshima, T; Kiziltepe, T; Munshi, NC; Neri, P; Tai, YT; Tassone, P; Weisberg, E1
Calvaruso, G; De Blasio, A; Giuliano, M; Portanova, P; Tesoriere, G; Vento, R1
Atadja, P; Carvajal-Vergara, X; Gutiérrez, N; López-Pérez, R; Maiso, P; Mateo, G; Ocio, EM; Pandiella, A; San Miguel, JF1
Alexanian, R; Alsina, M; Amato, AA; Anderson, KC; Barlogie, B; Berenson, J; Briemberg, H; Esseltine, D; Irwin, D; Jagannath, S; Limentani, S; Najarian, K; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schuster, M; Siegel, DS; Singhal, S; Srkalovic, G; Wen, PY1
Aizu-Yokota, E; Hatake, K; Kasahara, T; Kuniyoshi, R; Mishima, Y; Rokudai, A; Sonoda, Y; Terui, Y1
Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S1
Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS1
Albanell, J; Montagut, C; Rovira, A1
Agnese, V; Bazan, V; Russo, A; Santini, D; Terrasi, M1
Goranov, SE; Goranova-Marinova, VS1
Laurie, SA; Licitra, L1
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ1
Boccadoro, M; Bonifazi, F; Bruno, B; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
Davis, JJ; Dong, F; Fang, B; Guo, W; Liu, J; Sasazuki, T; Shirasawa, S; Teraishi, F; Zhang, L1
Anderson, KC; Chauhan, D; Crawford, LJ; Irvine, AE; Morris, TC; Ovaa, H; Walker, B1
Cloos, J; Kaspers, GJ; Vink, J1
Swieboda-Sadlej, A1
De Coster, R; Dyer, MJ; Kohlhaas, SL; Majid, A; Monbaliu, J; Walewska, RJ; Wheat, LM1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR1
Albrecht, JH; Anan, A; Baskin-Bey, ES; Bronk, SF; Gores, GJ; Isomoto, H; Mott, JL1
Allegue, F; López-Miragaya, MI; Pérez Castro, S; Romo, M1
Cavenagh, J; Joel, S; Oakervee, H; Popat, R1
Orlowski, RZ; Shi, YY; Small, GW1
Hussein, MA; Kalmadi, SR1
Cavo, M3
Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J1
Cavenagh, JD1
Bladé, J; San-Miguel, J1
Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Richardson, PG; Schenkein, DP; Singhal, S; Srkalovic, G1
Banti, A; Kaloutsi, V; Lazaridou, A; Terpos, E; Verrou, E; Zervas, K1
Berdel, WE; Bisping, G; Kienast, J; Kropff, M; Wenning, D1
Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A1
Colson, K; Jagannath, S; Richardson, P1
Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y1
Burtrum, D; Ludwig, DL; Moore, MA; Wu, KD; Zhou, L1
Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S1
Colson, K2
Anderson, KC; Bhole, D; Burger, R; Catley, L; Chauhan, D; Galardy, P; Hideshima, T; Kessler, B; Mitsiades, C; Munshi, NC; Ploegh, H; Podar, K; Shringarpure, R; Tai, YT; Tassone, P1
Kaluz, S; Kaluzová, M; Stanbridge, EJ2
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H2
Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W1
Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S1
Abrams, SI; Alvarez, G; Berg, M; Childs, R; Lundqvist, A; Schrump, DS; Suffredini, D1
Hess, G; Heussel, CP; Huber, C; Kreft, A; Wagner, V1
Armando, S; Nozza, A; Siracusano, L1
Ascensao, JL; Batra, RB; Boyer, JE; Schechter, GP1
Anderson, KC; Hunter, T; Joazeiro, CA1
Fribley, A; Wang, CY1
Hönemann, D; Kenealy, MK; Prince, HM1
Inaba, T; Kobayashi, Y; Shimazaki, C; Taniwaki, M1
Boral, A; Busam, K; Esseltine, D; Gerecitano, J; Gonen, M; Goy, A; MacGregor-Cortelli, B; Neylon, E; O'Connor, OA; Sachs, D; Schenkein, D; Teruya-Feldstein, J; Wright, J1
Mack, GS1
Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T1
Alloro, E; Brocca, MC; Coppi, MR; Mele, G; Pinna, S; Quarta, G1
Chandra, J; Keating, M; Krupnik, Y; McConkey, D; Palladino, M; Ruiz, S1
Hughes, M; Micallef-Eynaud, P1
Compton, J; Hrabeta-Robinson, E; Silberstein, GB; Van Horn, K1
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J1
Brignole, C; Cilli, M; Cioni, M; Corrias, MV; Di Paolo, D; Marimpietri, D; Nico, B; Pagnan, G; Pastorino, F; Pezzolo, A; Piccardi, F; Pistoia, V; Ponzoni, M; Ribatti, D1
Hideshima, T; Yasui, H1
Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Müller, C; Schulz, CO; Sezer, O; Zavrski, I1
Davies, MJ2
Barrick, M1
Chen, LJ; Li, JY; Qian, SX; Zheng, WJ; Zhu, GR1
Evenchik, B; Fribley, AM; Guan, JY; Hale, TJ; Kaufman, RJ; Park, BK; Soengas, MS; Wang, CY; Zeng, Q; Zhang, H1
Canfield, SE; McConkey, DJ; Williams, SA; Zhu, K1
Jin, J; Mai, W; Meng, H; Wang, L1
Ali, R; Kurt, M; Ozan, U; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A1
Frost, RA; Huber, D; Lang, CH1
Alvarez, JV; Frank, DA; Germain, D; Ishii, Y; Keselman, I; Logothetis, D; Mandeli, J; O'Connell, MJ; Pirkmaier, A; Waxman, S1
Alexander, HD; Cavanagh, JD; Drake, M; Finnegan, DP; Kettle, P; Matthews, C; Morris, TC; Popat, R; Wachsman, W1
Mimnaugh, EG; Neckers, L; Vos, M; Xu, W; Yuan, X1
Harousseau, JL8
Moreau, P1
Belch, A; Crump, M; Eisenhauer, EA; Gascoyne, RD; Klasa, R; Kouroukis, CT; Powers, J; Sehn, L; Wright, J1
Bours, V; Olivier, S; Robe, P1
Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M1
Degendorfer, P; Gomez-Abuin, G; Moore, MJ; Pond, G; Stadler, WM; Winquist, E; Wright, J1
Abbruzzese, JL; Andtbacka, R; Arumugam, T; Khanbolooki, S; Kurzrock, R; Logsdon, CD; McConkey, DJ; Nawrocki, ST; Pino, MS1
Adjei, AA; Carter, CA; Friday, BB; Kaufmann, SH; Kay, NE; Lai, JP; Roberts, LR; Sarkaria, J; Yang, L; Yu, C1
Arai, A; Koyama, T; Kurosu, T; Miki, T; Miura, O; Murakami, N; Oshikawa, G; Tohda, S1
Anderson, K; Ghobrial, I; Mitsiades, C; Richardson, PG1
Chang, H; Qi, X; Reece, D; Stewart, KA; Trieu, Y; Xu, W1
Barti-Juhász, H; Conte, P; Dominici, M; Douglas, L; Houghton, JA; Izeradjene, K; Kopper, L; Luca Cervo, G; Mihalik, R; Nagy, K; Peták, I; Spano, C; Székely-Szüts, K; Tillman, M1
Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; O'Connor, OA; Robertson, MJ; Shi, H; Stadtmauer, EA1
Arenillas, L; Bladé, J; Cibeira, MT; Mercadal, S; Muntañola, A; Salamero, O1
Alacacioglu, I; Ceneli, S; Demirkan, F; Lebe, B; Ozcan, MA; Ozsan, GH; Piskin, O; Turgut, N; Undar, B1
Anderson, KC; Brahmandam, M; Chauhan, D; Ghobrial, I; Hideshima, T; Munshi, N; Podar, K; Raje, N; Richardson, P; Schlossman, R; Velankar, M1
Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H1
Beck, A; Berkers, CR; Burg, D; Driessen, C; Gogel, J; Kammer, W; Kraus, M; Ovaa, H; Overkleeft, H; Reich, M; Rückrich, T1
Cavallo, F; Esseltine, D; Tricot, G; Yaccoby, S; Zangari, M1
Abonour, R; Juliar, BE; Smith, GG; Suvannasankha, A1
Cabanillas, M; Peteiro, C; Toribio, J1
Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX1
Okamoto, S1
Attal, M; Avet-Loiseau, H; Benboubker, L; Fuzibet, JG; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; Pegourie, B; Renaud, M; Stoppa, AM; Troncy, J1
Galimberti, S; Orciuolo, E; Petrini, M1
Heule, F; Lam, K; Sonneveld, P; Wu, KL1
Morris, AP; Sellin, JH; Umar, S; Wang, Y1
Watts, G1
Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S1
Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG1
McKenna, KE; Morris, TC; Ramadan, KM1
Berges, C; Daniel, V; Fuchs, D; Höh, A; Miltz, M; Naujokat, C; Opelz, G; Ovens, J; Sadeghi, M; Wieczorek, H1
Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I1
Ackermann, J; Drach, J; Kaufmann, H; Küenburg, E; Ludwig, H; Odelga, V; Sagaster, V; Wieser, R; Zielinski, C; Zojer, N1
Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F2
Anderson, KC; Cowan, JM; Facon, T; Harousseau, JL; Irwin, D; Jagannath, S; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Baer, MR; Minderman, H; O'Loughlin, KL; Zhou, Y1
Akatsuka, Y; Ito, K; Ito, Y; Iwata, K; Kiyono, T; Kodera, Y; Kondo, E; Kuzushima, K; Morishima, S; Morishima, Y; Nakanishi, T; Nawa, A; Takahashi, T; Torikai, H; Tsujimura, K1
Kenealy, M; Prince, HM1
Avonto, I; Boccadoro, M; Bringhen, S; Magarotto, V; Palumbo, A1
Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K1
Paydas, S2
Belloni, D; Caligaris-Cappio, F; Cangi, MG; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L1
Gupta, V; Malani, AK; Rangineni, R1
Chao, TH; Cusack, JC; Liu, R; Neuteboom, ST; Niu, W; Palladino, MA; Palombella, VJ; Pien, C; Xia, L1
Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P1
Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y1
Altavilla, G; Arrigo, C; Naro, C; Pitini, V1
Benet, I; García-Conde, J; Jantus-Lewintre, E; Sarsotti, E; Terol, MJ1
Chanan-Khan, AA; Kaufman, JL; Lonial, S; Mehta, J; Miller, KC; Munshi, NC; Richardson, PG; Schlossman, R; Singhal, S; Tariman, J1
Biehn, SE; Dees, EC; Garcia, RA; Lehman, MJ; Moore, DT; Orlowski, RZ; Voorhees, PM1
Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P1
Badran, B; Bex, F; Burny, A; Cardoso, F; Desmedt, C; Durbecq, V; Laes, JF; Lagneaux, L; Piccart, M; Ross, JS; Sotiriou, C; Willard-Gallo, K1
Sanders, PW; Ying, WZ; Zhang, HG1
Lonial, S5
Fu, YB; Meng, FY; Sun, QX; Xie, J; Zhou, GB1
Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S1
Ribatti, D; Vacca, A1
Anderson, KC; Dammacco, F; Hideshima, T; Ribatti, D; Richardson, PG; Roccaro, AM; Russo, D; Vacca, A1
Anselmino, A; Atzori, C; Cargnel, A; Mazza, F; Piccinini, M; Rinaudo, MT; Tronconi, E; Valerio, A1
Benedict, WF; Dinney, C; Kamat, A; McConkey, DJ; Papageorgiou, A1
Blank, JL; Bruzzese, FJ; Cao, Y; Daniels, JS; Dick, LR; Labutti, J; Mazzola, AM; Patil, AD; Reimer, CL; Rolfe, M; Solomon, MS; Stirling, M; Tian, Y; Tsu, CA; Weatherhead, GS; Williamson, MJ; Zhang, JX1
Aifantis, I; Alegre, ML; Buonamici, S; Ferrando, A; Kee, BL; Macaroun, S; Mandal, M; Mascarenhas, J; Meng, F; Miele, L; Palomero, T; Spaulding, C; Thompson, B; Vilimas, T1
Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H1
Arrue, I; García-Romero, D; Rodríguez-Peralto, JL; Sánchez-Largo, ME; Sanz-Robles, H; Vanaclocha, F1
Burton, AW; Cata, JP; Dougherty, PM; Giralt, S; Villareal, H; Weng, HR1
Rukavitsyn, OA1
Deggerich, A; Haubert, D; Kashkar, H; Krönke, M; Pongratz, C; Seeger, JM; Wiegmann, K; Yazdanpanah, B1
Anderson, KC; Bergsagel, PL; Boral, A; Broyl, A; Bryant, B; Chng, WJ; Esseltine, DL; Fergus, A; Huang, Y; Koenig, E; Mitsiades, C; Mulligan, G; Richardson, P; Roels, S; Schenkein, D; Shaughnessy, JD; Sonneveld, P; Trepicchio, WL; Zhan, F1
Dan, K; Gotoh, A; Hotta, T; Ikeda, Y; Ohyashiki, K; Oshimi, K; Usui, N2
Chan, TH; Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yan, B; Yang, H; Zhao, Y1
Bo, J; Da, WM; Gao, CJ; Huang, WR; Jing, Y; Li, R; Wang, QS; Wu, XX; Yu, L; Zhang, YZ1
Daniels, TR; Feldman, R; Li, W; Lichtenstein, A; Maxwell, CA; Penichet, ML; Pilarski, L; Reiman, T; Sen, S; Shi, Y1
Anderson, KC; Antón, IM; Calamito, M; de la Fuente, MA; Elkhal, A; Gallego, MD; Geha, RS; Ochs, HD; Ramesh, N; Rosen, FS; Sasahara, Y; Siminovitch, K; Suresh, K1
Bossi, M; Canta, A; Cavaletti, G; Ceresa, C; D'Incalci, M; De Coster, R; Gilardini, A; Marmiroli, P; Oggioni, N; Rigamonti, L; Rodriguez-Menendez, V1
Angitapalli, R; Dhodapkar, MV; Hutchinson, A; Jagannath, S; Kukreja, A; Mazumder, A; O'connor, OA; Vesole, D1
Cerniglia, GJ; Gupta, AK; Maity, A; Weber, CN1
Campo, E; Colomer, D; Pérez-Galán, P; Roué, G; Villamor, N1
Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S1
Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH1
Utsunomya, A1
Lorch, JH; Schmoll, HJ; Thomas, TO1
Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U1
Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C1
An, J; Rettig, MB1
Kim, CC; Kim, M; Kim, Y; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS; Moon, SJ; Park, G1
Cheriyath, V; Hussein, MA; Jacobs, BS1
Benedetti-Panici, P; Biffoni, M; Cognetti, F; Ferretti, G; Humphreys, R; Mariani, G; Pasquini, L; Peschle, C; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U1
Basso, G; Bonvini, P; Rosolen, A; Zorzi, E1
Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O1
Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P1
De Coster, R; Diels, L; Geerts, R; Hassler, S; Hemeryck, A; Janssen, C; Mamidi, RN; Monbaliu, J; van Beijsterveldt, L; Verhaeghe, T; Verluyten, W1
Walker, K1
Betlloch, I; Botella, C; Lucas, A; Mataix, J; Villarrubia, B1
Stadtmauer, EA; Stoopler, ET; Vogl, DT1
Brockman, AH; Hatsis, P; Paton, M; Wu, JT1
Charalambous, A; Dhodapkar, MV; Jagannath, S; Mazumder, A; Spisek, R; Vesole, DH1
Mileshkin, L; Prince, HM; Schenkel, B1
Engel, J; Fagbemi, S; Olatosi, B; Onitilo, AA1
Berrebi, A; Duek, A; Feldberg, E; Haran, M1
Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J1
Birle, DC; Hedley, DW1
Burger, R; Gramatzki, M; Hahn, S; Herrmann, K; Herrmann, M; Jäck, HM; Meister, S; Neubert, K; Schreiber, S; Schubert, U; Voll, RE; Wilhelm, S1
Chen, J; Pamarthy, D; Sun, Y; Tan, M; Wang, S; Wu, M; Yang, D; Zhang, H1
Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I1
Chanan-Khan, AA; Manochakian, R; Miller, KC2
Chew, E; Filshie, R; Wei, A1
Ganten, TM; Haas, TL; Kolb, A; Koschny, R; Sprick, MR; Stremmel, W; Sykora, J; Walczak, H1
Adamo, L; Anastasi, G; Conticello, C; De Maria, R; Eramo, A; Giuffrida, D; Giuffrida, R; Gulisano, M; Iannolo, G; Memeo, L; Vicari, L; Zeuner, A1
Low, E1
Chu, K; Jung, KH; Kim, BS; Kim, EH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC; Yoon, SS1
Ambinder, RF; Chen, J; Chong, JM; Foss, CA; Fox, JJ; Fu, DX; Lemas, V; Pomper, MG; Tanhehco, YC1
Adamson, PC; Blaney, SM; Bomgaars, LR; Brockman, AH; Horton, TM; Ingle, AM; Pati, D; Paton, M; Plon, SE; Thompson, PA; Wright, J1
Bruserud, Ø; Gjertsen, BT; Kalland, KH; Olsnes, AM; Ryningen, A; Stordrange, L; Øyan, AM1
Bruserud, O; Døskeland, AP; Ersvaer, E; Gjertsen, BT; Hatfield, K; Lorens, JB; Ryningen, A; Stapnes, C1
Chen, YB; Fu, WJ; Hou, J; Xi, H; Yang, SL; Yuan, ZG; Zhou, F1
Gault, RA; Mattingly, LH; Murphy, WJ1
Beier, C; Dörken, B; Lietz, A; Mathas, S; Pezzutto, A; Sebelin-Wulf, K; Subklewe, M1
Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Tesoriere, G; Vassallo, B; Vento, R1
Chen, CI; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ1
Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R1
Checinska, A; Giaccone, G; Kruyt, FA; Rodriguez, JA; Voortman, J1
Chen, X; Ding, WX; Ni, HM; Yin, XM; Yu, J; Zhang, L1
Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS1
Allen, P; Higginbottom, K; Joel, SP; Jüliger, S; Lister, TA; Maharaj, L; Schenkein, D; Strauss, SJ1
Iida, S5
Bonomini, S; Crugnola, M; Ferrari, L; Giuliani, N; Lazzaretti, M; Mancini, C; Martella, E; Morandi, F; Rizzoli, V; Tabilio, A; Tagliaferri, S1
Scheinfeld, N1
Dierlam, L; Lass, A; McConnell, EJ; Nowis, D; Palamarchuk, A; Wójcik, C1
Auradé, F; Chaligné, R; Gastinne, T; Giraudier, S; Gonin, P; Lacout, C; Pisani, DF; Tulliez, M; Vainchenker, W; Villeval, JL; Wagner-Ballon, O1
Belloc, F; de Verneuil, H; Lacombe, F; Mahon, FX; Milpied, N; Moreau-Gaudry, F; Pigneux, A; Praloran, V; Reiffers, J; Uhalde, M1
Caponigro, F; Iaffaioli, RV; Milano, A1
Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R1
Jung, CS; Khuri, FR; Sun, SY; Zhou, Z1
Banwait, S; Benz, CC; Hann, B; Marx, C; Park, JW; Scott, GK; Yau, C; Zhou, Y1
Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Lotze, C; Schüler, F1
Strobeck, M1
Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J1
Bergsagel, L; Bryant, B; Chng, WJ; Mulligan, G1
Ahmann, G; Bergsagel, PL; Bryant, B; Carpten, J; Chng, WJ; Chung, TH; Dispenzieri, A; Fonseca, R; Gertz, M; Greipp, P; Henderson, K; Kim, S; Kumar, S; Kyle, R; Lacy, M; Mulligan, G; Price-Troska, T; Rajkumar, SV; Vanwier, S1
Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D1
Atkins, JN; Chansky, K; Crowley, JJ; Davies, AM; Farneth, N; Franklin, WA; Gandara, DR; Guaglianone, PP; Gumerlock, PH; Lara, PN; Mack, PC1
Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M1
Carol, H; Houghton, PJ; Keir, ST; Keshelava, N; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J1
Jarois, T; Ju, D; Xie, Y; Xu, H1
Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Capalbo, S; Chiefa, A; Delia, M; Diomede, D; Liso, V1
D'Arena, G; Ferrara, F; Filardi, N; Gay, F; Guariglia, R; Guglielmelli, T; Musto, P; Palumbo, A; Pitini, V; Rossini, F1
Iida, S; Yano, H1
Janssen, JJ; Lokhorst, HM; Zweegman, S1
Castagna, L; Mazza, R; Nozza, A; Rahal, D; Santoro, A; Sarina, B; Todisco, E1
Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M1
Borchmann, P; Engert, A; Keller, U; Naumann, R; Rummel, M; Sezer, O; Trelle, S1
Fu, YB; Li, L; Meng, FY; Sun, QX1
Croucher, P; Dimopoulos, MA; Sezer, O; Terpos, E1
Bonuccelli, G; Capozza, F; Gazzerro, E; Lisanti, MP; Minetti, C; Sotgia, F1
Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H1
Bachmann, M; Bornhäuser, M; Rieber, EP; Schmitz, M; Straube, C; Wehner, R; Wendisch, M1
Germain, D; Ishii, Y; Waxman, S1
Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G1
Fang, B; Ma, J; Song, Y; Zhao, RC1
Wilkes, G1
Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P1
Chen, S; Hu, L; Khuri, FR; Liu, X; Lonial, S; Sun, SY; Yue, P1
Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A1
Berges, C; Daniel, V; Fuchs, D; Naujokat, C; Opelz, G2
Bueno, R; Gordon, GJ; Kindler, HL; Mani, M; Maulik, G; Mukhopadhyay, L; Salgia, R; Sugarbaker, DJ; Yeap, BY1
Cho, Y; Kim, BS; Kim, J; Kim, SJ; Seo, BK1
de la Vega, CM; Fernández, Y; Nikolovska-Coleska, Z; Riblett, M; Soengas, MS; Verhaegen, M; Wang, S; Wolter, KG1
Abouladze, M; Baudard, M; Dreano, M; Goldschmidt, H; Hose, D; Jourdan, M; Klein, B; Mahtouk, K; Moreaux, J; Rème, T; Robert, N; Romanelli, A; Rossi, JF; Vos, JD1
Advani, R; Badros, A; Branagan, AR; Cook, D; Hill, J; Hunter, ZR; Joyce, RM; Kaden, BR; Leleu, X; Mannion, B; Matous, J; Sharon, D; Songer, J; Steiss, R; Treon, SP1
Ahnert, P; Bauer, M; Ganten, TM; Haas, TL; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Sprick, MR; Sykora, J; Walczak, H1
Amiot, M; Bataille, R; Gomez-Bougie, P; Ménoret, E; Philippe, M; Robillard, N; Trichet, V; Wuillème-Toumi, S1
Burns, MJ; Cavallo, F; Elice, F; Esseltine, D; Neuwirth, R; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M1
Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR1
Mayor, S1
Brugnatelli, S; Brunetti, L; Corazza, GR; Gobbi, PG; Palladini, G; Perfetti, V; Sgarella, A1
Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M1
Hulin, C1
Banti, A; Gastari, V; Kaloutsi, V; Kartsios, C; Katodritou, E; Lazaraki, G; Lazaridou, A; Mihou, D; Verrou, E; Zervas, K1
Antonio, S; Daniele, V; Enrico, O; Gabriele, B; Giulia, C; Mario, P; Nadia, C; Sara, G1
Bhandari, M; Jagannath, S1
Bocchia, M; Cerase, A; Fabbri, A; Gozzetti, A; Lauria, F; Pirrotta, MT; Tarantino, A1
Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S1
Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ikeda, H; Ishitsuka, K; Kiziltepe, T; Ocio, EM; Okawa, Y; Pozzi, S; Raje, N; Shiraishi, N; Vallet, S; Yasui, H1
Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J1
Au, WY; Guo, T; Kwong, YL; Liang, RH; Shen, L; Srivastava, G; Tsuchiyama, J; Wong, KY; Wong, ML; Yuen, PW1
Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Krebbel, H; Manz, RA; Mieth, M; Sezer, O; Sterz, J; von Metzler, I1
Barlogie, B; Crowley, J; van Rhee, F1
Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C1
Bennett, MK; Chanan-Khan, AA; Chen, Q; Demo, SD; Kuhn, DJ; Orlowski, RZ; Shenk, KD; Strader, JS; Sun, CM; van Leeuwen, FW; Voorhees, PM1
Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M1
Cadranel, JL; Garfield, DH1
Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R1
Adena, M; Hertel, J; Prince, HM; Smith, DK1
Dimopoulos, MA; Sezer, O; Terpos, E1
Calvaruso, G; Giuliano, M; Pellerito, O; Portanova, P; Tesoriere, G; Vento, R1
Broglio, L; Buzio, S; Filosto, M; Mancuso, M; Padovani, A; Pelizzari, AM; Rinaldi, M; Rossi, G; Scarpelli, M; Tentorio, M1
Bartlett, NL; Blum, KA; Canellos, GP; Cheson, BD; Johnson, JL; Niedzwiecki, D1
Ali, R; Beksac, M; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A1
Berdel, WE; Bisping, G; Dechow, T; Einsele, H; Engelhardt, M; Heinecke, A; Hentrich, M; Kienast, J; Kröger, N; Kropff, M; Lang, N; Liebisch, P; Metzner, B; Salwender, H; Schuck, E; Sezer, O; Volpert, S; Wolf, HH1
Aujay, MA; Bennett, MK; Buchholz, TJ; Dajee, M; Demo, SD; Ho, MN; Jiang, J; Kirk, CJ; Laidig, GJ; Lewis, ER; Molineaux, CJ; Parlati, F; Shenk, KD; Smyth, MS; Sun, CM; Vallone, MK; Woo, TM1
Abou El Hassan, MA; Giaccone, G; Kruyt, FA; Resende, TP; Voortman, J1
Davies, FE; Kanagasabaphy, P; Morgan, GJ1
Cohen, JI; Kawada, J; Pesnicak, L; Zou, P1
Battolla, B; Canestraro, M; Capodanno, A; Casini, A; Collecchi, P; Fazzi, R; Galimberti, S; Mattii, L; Orciuolo, E; Pacini, S; Petrini, M; Piaggi, S; Simi, P; Trombi, L; Veroni, F1
Calderoni, A; Cornu, P; Freimann, H; Olie, R1
Tobinai, K2
Alomar, A; Dalmau, J; Fernández-Figueras, MT; Garcia-Navarro, X; Puig, L; Roe, E1
Jack, A1
Astori, C; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P1
Ben Mamoun, C; Witola, WH1
Davies, FE; Jenner, M; Morgan, GJ; Saso, R; Srikanth, M; Wu, P1
Amiot, M; Anderson, KC; Chauhan, D; Gouill, SL; Harousseau, JL; Hideshima, T; Opferman, JT; Podar, K; Tai, YT; Zhang, J; Zorn, E1
Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J1
Baumann, P; Bumeder, I; Emmerich, B; Meinhardt, G; Schmidmaier, R; Straka, C1
Chen, Y; Cheng, T; Di, G; Jin, W; Li, J; Li, W; Shao, Z; Wu, J; Yao, M1
Hsi, ED; Kung, J; Peng, X; Qiu, W; Yegappan, M; Yen-Lieberman, B; Zhao, X1
Astori, C; Castagnola, C; Corso, A; Dore, R; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P1
Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S1
Davies, AM; Gandara, DR; Lara, PN; Mack, PC1
Jacquemont, C; Taniguchi, T1
Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH1
Hatake, K1
Fassas, AB; Tricot, G1
Hatake, K; Terui, Y; Yokoyama, M1
Davidoff, AM; Dickson, PV; Hamner, JB; Ng, CY; Sims, TL; Spence, Y; Zhou, J1
Alsina, M; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, A; Cavenagh, J; Dalton, W; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Jakubowiak, A; Lacy, M; Lonial, S; Miguel, JS; Rajkumar, SV; Reece, D; Richardson, PG; Schenkein, D; Schuster, M; Sonneveld, P; Stadtmauer, E1
Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J1
Lü, SQ; Wang, JM; Yang, JM1
Alinari, L; Baccarani, M; de Vivo, A; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Sabattini, E; Stefoni, V; Tani, M; Zinzani, PL1
Sayers, T; Shanker, A1
Gao, SL; Shen, HW; Tang, ZY; Wu, YL1
Dhodapkar, MV; Spisek, R1
Bensinger, W1
Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R1
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D1
Buda, G; Canestraro, M; Fazzi, R; Galimberti, S; Guerrini, F; Khan, R; Maffei, R; Marasca, R; Orciuolo, E; Petrini, M1
Anderson, KC; Catley, L; Chauhan, D; Hideshima, H; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Munshi, NC; Ocio, E; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Tai, YT; Vallet, S; Yasui, H1
Li, X; Pennisi, A; Sawyer, JR; Shaughnessy, JD; Yaccoby, S; Zhan, F1
Ling, YH; Perez-Soler, R; Piperdi, B1
Doihara, H; Fujita, T; Ino, H; Murakami, M; Naito, M; Shimizu, N; Washio, K1
Drach, J; Graf, H; Lang, A; Ludwig, H; Meran, JG1
Etxebarria, J; Hernández, E; Lopez, O; Mateos-Mazon, J; Pérez-Simón, JA; San Miguel, JF1
Anderson, KC; Breitkreutz, I; Raab, MS1
Alegre, A; Bladé, J; de la Rubia, J; García-Sánchez, P; Gutiérrez, N; Herrero, C; Lahuerta, JJ; Liu, X; Mateos, MV; Oriol, A; Rosiñol, L; San Miguel, J; Sureda, A; Van de Velde, H1
Hanada, M; Iwamoto, Y; Matsunobu, T; Nakamura, T; Nakatani, F; Okada, T; Sakimura, R; Tanaka, K1
Bialik, TE; Demina, EA; Falaleeva, NA; Gromova, EG; Kochergina, NV; Kupryshina, NA; Osmanov, DSh; Riabukhina, IuE; Timofeeva, OL; Votiakova, OM1
Snively, A1
Amen, K1
McGee, L1
Branch, CD; Chada, S; Gopalan, B; Ramesh, R; Scott, A; Shanker, M1
Chacko, A; Fennell, DA; Mutti, L1
Banu, E; Beuzeboc, P; Guyader, C; Medioni, J; Oudard, S; Scotte, F1
Chim, CS2
Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V1
Matteson, DS1
Chim, CS; Wong, LG1
Abe, M; Asano, J; Choraku, M; Fujii, S; Hashimoto, T; Kagawa, K; Kitazoe, K; Matsumoto, T; Miki, H; Ozaki, S; Shigekiyo, Y; Takeuchi, K; Tanaka, O1
Dagher, R; Farrell, A; Justice, R; Kane, RC; Ko, CW; Pazdur, R; Sridhara, R1
Jin, F; Joshi, I; Smith, MR1
Ludwig, A; Meiners, S; Stangl, K; Stangl, V1
Abayomi, EA; Jacobs, P; Sissolak, G1
Kurtis, B; Lacouture, ME; Mekki, M; Newman, MA; Paiva, CM; Singhal, S1
Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C1
Hamamura, RS; Kobayashi, C; Kurashina, R; Ohyashiki, JH; Ohyashiki, K; Takaku, T; Zhang, Y1
Boe, A; Buffolino, S; Cedrone, M; Diverio, D; Foà, R; Lo-Coco, F; Mariani, G; Peschle, C; Riccioni, R; Riti, V; Senese, M; Testa, U1
Kotoula, V; McMillin, D; Miller, JW; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V1
Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG1
Han, XH; Kwak, LW; Qian, JF; Romaguera, J; Shi, YK; Wang, M; Yang, J; Yi, Q; Zhang, L1
Coleman, RL; Gershenson, DM; Johnston, TA; Landen, CN; Levenback, C; Milam, MR; Ramirez, PT1
Barbone, D; Darnowski, JW; Fennell, DA; Galvani, A; Gasparri, F; Gaudino, G; Mutti, L; Nici, L; Porta, C; Sartore-Bianchi, A1
Anderson, G; Belani, C; Feng, R; Lentzsch, S; Mapara, MY; Oton, A1
Esparza, J; Flores, A; Garrett, IR; Gupta, A; Mundy, GR; Muñoz, S; Oyajobi, BO; Zhao, M1
Avcu, F; Cetin, T; Nevruz, O; Ural, AU1
Cavenagh, JD; Oakervee, H; Popat, R1
Moran, E; Nencioni, A1
Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S1
Garber, AM; McClellan, MB1
Chagin, AS; Chrysis, D; Dantuma, NP; Eriksson, E; Fadeel, B; Menendez-Benito, V; Sävendahl, L; Takigawa, M; Zaman, F1
Barlogie, B; Garg, TK; Kellum, RE; Malaviarachchi, PA; Mulder, A; Shaughnessy, JD; Shi, J; Storrie, B; Szmania, SM; Tricot, GJ; van Rhee, F1
Badve, S; Bergan, R; Brown, JA; Engel, RH; Gradishar, WJ; O'Regan, RM; Rademaker, A; Von Roenn, JH1
Dytfeld, D; Komarnicki, M; Lewandowski, K; Matuszak, M1
Brandenburg, J; El Bissati, K; Günzl, A; Mamoun, CB; Reynolds, JM1
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX2
Ganser, A; Peest, D1
Björkstrand, B; Gahrton, G1
Ando, K; Hotta, T; Itoh, K; Kagami, Y; Kobayashi, Y; Maruyama, D; Minami, H; Morishima, Y; Nakata, M; Ogawa, Y; Ogura, M; Taji, H; Tobinai, K; Tsuchiya, T; Watanabe, T1
Dammacco, F; Merchionne, F; Perosa, F1
Fadeel, B; Sävendahl, L; Zaman, F1
Chen, Q; Corringham, RE; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Strader, JS; Voorhees, PM; Zaki, MH1
Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F1
Iannitto, E; Minardi, V; Tripodo, C1
Lin, ZH1
Al-Masri, H; Alkan, S; Meyer, P; Ni, H; Ozpuyan, F1
Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L1
Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG1
Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, GM; Varettoni, M; Zappasodi, P1
Fujii, H; Harada, Y; Kotobuki, Y; Nomura, S1
Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Kuckelkorn, U; Rademacher, J; Rosche, M; Rötzer, S; Sezer, O; Sterz, J; von Metzler, I1
Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A1
Agnese, V; Bazan, V; Cicero, G; Fratto, ME; Russo, A; Santini, D; Schiró, V; Tonini, G; Vincenzi, B1
Checińska, A; Giaccone, G; Voortman, J1
Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS1
Merlini, G; Palladini, G; Sitia, R1
Cavaletti, G; Nobile-Orazio, E1
Anagnostopoulos, A; Delibasi, S; Dimopoulos, MA; Kastritis, E; Mellou, S; Migkou, M; Nanas, J; Pamboukas, C; Psimenou, E; Roussou, M; Tassidou, A; Terpos, E; Toumanidis, S; Xilouri, I1
Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R1
Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A1
Chinnaiyan, AM; Fernandez, Y; Gratchouck, V; Jakubowiak, AJ; Nikiforov, MA; Riblett, M; Soengas, MS; Tang, WH; Varambally, S; Verhaegen, M; Zhuang, D1
Puthalakath, H; Strasser, A1
Chaudhary, U; Dunder, S; Green, M; Hayslip, J; Kraft, A; Meyer, M; Montero, AJ; Salzer, S; Sherman, C1
Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H1
Barr, P; Fisher, R; Friedberg, J1
Congdon, LM; Dorr, RT; Escalante, AM; Landowski, TH; Pourpak, A1
Faiman, B1
Brodmann, S; Cathomas, R; Girardi, V; Gyr Klaas, E; von Moos, R1
Gertz, MA4
Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F1
Handa, H; Murakami, H; Saitoh, T1
Ishida, T3
Gotoh, A; Ohyashiki, K1
Shimazaki, C1
Takatoku, M1
Kizaki, M1
Mateos, MV; San Miguel, JF1
Fang, BW; Zhang, YJ1
Christian, PA; Schwarze, SR; Thorpe, JA2
Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R1
Miwa, A2
Gastari, V; Hadjiaggelidou, C; Katodritou, E; Terpos, E; Verrou, E; Zervas, K1
Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R2
Baiocchi, RA; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Garzon, R; Huynh, L; Klisovic, RB; Lehmann, E; Liu, S; Liu, Z; Marcucci, G; Pang, J; Perrotti, D; Porcu, P; Takeki, M; Vukosavljevic, T; Wu, LC; Xie, Z; Yu, J1
Dirksen, WP; Fernandez, SA; Lairmore, MD; Nadella, MV; Rosol, TJ; Shu, ST; Thudi, NK; Werbeck, JL1
Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M1
Cai, Y; Chen, LE; Park, JW; Qi, WN; Urbaniak, JR1
Davies, FE; Morgan, GJ; Srikanth, M1
Ames, E; Barao, I; Hallett, WH; Hudig, D; Motarjemi, M; Murphy, WJ; Sayers, TJ; Shanker, A; Tamang, DL1
Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM1
Eom, KS; Han, K; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, MJ; Lee, S; Lim, J; Min, CK; Min, WS1
Agrawal, SG; Du, MQ; Gribben, JG; Jia, L; Liu, FT; Newland, AC; Ye, H1
Alvarez-Fernández, S; Colado, E; Garayoa, M; Maiso, P; Martín-Sánchez, J; Montero, JC; Ocio, EM; Pandiella, A; San Miguel, JF; Vidriales, MB1
Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S1
Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN1
Chun, YS; Huang, LE; Lee, DS; Park, JW; Shin, DH1
Dolcet, X; Encinas, M; Eritja, N; Llobet, D; Llombart-Cussac, A; Marti, RM; Matias-Guiu, X; Schoenenberger, JA; Sorolla, A; Yeramian, A1
Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M1
Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E1
Barlogie, B; Bryant, B; Mulligan, G; Shaughnessy, JD; Zhan, F1
Clay, D; Gauduchon, J; Marsaud, V; Renoir, JM; Seguin, A; Sola, B1
DiPersio, JF; Fisher, NM; Peles, S; Tomasson, MH; Trivedi, R; Uy, GL; Vij, R; Zhang, QJ1
Herrmann, M; Maseda, D; Meister, S; Neubert, K; Voll, RE1
Cavenagh, JD; Davies, FE; Jackson, GH; Morgan, GJ1
Canestaro, M; Ciancia, E; Fazzi, R; Galimberti, S; Marasca, R; Petrini, M1
De Aos, I; Garrett, MW; Huang, S; Kem, DC; Patterson, E; Yu, X1
Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V1
Berges, O; Decaudin, D; Kirova, YM; Servois, V1
Adler, AS; Chang, HY; Lin, M; Nuyten, DS; Regev, A; Segal, E; van de Vijver, MJ; Wong, DJ1
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; San-Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Anderson, KC; Carrasco, DR; Dranoff, G; Jinushi, M; Munshi, NC; Neuberg, D; Prabhala, RH; Ritz, J; Tai, YT; Vanneman, M1
Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A1
Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H1
Dietrich, PY; Favet, L; Kerl, K; Piguet, V; Sanchez-Politta, S1
Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Miltz, M; Naujokat, C; Opelz, G; Sadeghi, M1
Anderson, KC; Aronson, JP; Bouxsein, ML; Chhetri, S; Fulciniti, M; Glimcher, LH; Hideshima, T; Jones, DC; Lian, JB; Liu, JC; Mukherjee, S; Patel, C; Pozzi, S; Purton, LE; Raje, N; Scadden, DT; Schoonmaker, JA; Seo, YD; Stein, G; Vallet, S; Wein, MN1
Ribatti, D; Roccaro, AM; Vacca, A1
Carbone, R; Lacy, J; Loomis, R; Srimatkandada, P; Srimatkandada, S1
Chen, S; Dai, Y; Dent, P; Funk, VL; Grant, S; Kramer, LB1
Chaudhary, PM; Lu, G; Punj, V1
Chen, SJ; Chen, Z; Garcia, JF; Janin, A; Leboeuf, C; Li, JM; Liu, YY; Ma, J; Shen, ZX; Song, YP; Wang, L; Zhang, QL; Zhang, YW; Zhao, WL1
Chen, TC; Golden, EB; Hofman, FM; Kardosh, A; Louie, SG; Petasis, NA; Pyrko, P; Schönthal, AH; Uddin, J1
Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD1
Cascio, P; Cenci, S; Cerruti, F; Mariani, E; Oliva, L; Pasqualetto, E; Sitia, R1
Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT1
Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ1
Betlloch, I; Mataix, J; Palmero, F; Romero, A1
Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M1
Anargyrou, K; Angelopoulou, MK; Christoulas, D; Dimitriadou, EM; Dimopoulos, MA; Kalpadakis, C; Kyrtsonis, MC; Masouridis, S; Panayiotidis, P; Pangalis, GA; Pouli, A; Sachanas, S; Terpos, E; Tsionos, K; Tzenou, T; Vassilakopoulos, TP1
Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH1
Anaissie, E; Barlogie, B; Crowley, J; Haessler, J; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Zangari, M1
Hussein, K; Lasho, T; Mesa, RA; Pardanani, A; Rivera, C; Tefferi, A; Verstovsek, S; Wu, W1
Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL2
Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D1
Binder, A; Czuczman, MS; Deans, J; Gowda, A; Hernandez-Ilizaliturri, FJ; Kaur, H; Knight, J; Kotowski, A; Olejniczak, S; Starostik, P1
Anderson, KC; Azab, A; Azab, F; Burwick, N; Chauhan, D; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Palladino, MA; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
Alberti, D; Binger, K; Eickhoff, J; Geiger, P; Heideman, J; Kolesar, J; LoConte, NK; Marnocha, R; Thomas, JP; Utecht, K; Wilding, G1
Irvine, AE; McCloskey, SM; McMullin, MF; Walker, B1
Kalachand, R; Kelly, K; Murphy, P1
Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Callea, V; Caravita, T; Cascavilla, N; Falcone, A; Gay, F; Magarotto, V; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Ruggeri, M1
Carey, LA; Collichio, F; Collins, J; Dees, EC; Esseltine, D; Ivanova, A; Lindley, CM; O'Neil, BH; Orlowski, RZ; Riordan, WJ1
Anderson, KC; Azab, A; Azab, F; Brown, M; Burwick, N; Carrasco, DR; Eeckhoute, J; Farag, M; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Hunter, Z; Jia, X; Leleu, X; Melhem, MR; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP; Witzig, TE1
Drize, N; Nifontova, I; Petrova, T; Svinareva, D1
Caligaris-Cappio, F; Cozza, S; Ferrarini, M; Nerini-Molteni, S; Sitia, R1
Boulanger, E; Meignin, V; Oksenhendler, E1
Accornero, P; Bersani, F; Crepaldi, T; Miretti, S; Morotti, A; Ponzetto, C; Taulli, R1
Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L1
Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K1
Chim, CS; Hwang, YY; Shek, TW1
Fuchs, SY1
Bae, SH; Hyun, MS; Kim, MK; Lee, KH; Ryoo, HM; Sin, JI1
Kami, M; Tsubokura, M1
Liang, S; Liao, ZJ; Ma, WL; Meng, FY; Meng, W; Zheng, WL1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E1
Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Foot, N; Hallam, S; Morris, C; Oakervee, HE; Odeh, L; Popat, R1
Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM1
Aguirre Errasti, C; Alonso Alonso, JJ; Barreiro García, JG; Cánovas Fernández, A1
Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G1
Banerjee, AK; Chumakov, KM; Dragunsky, EM; Gudkov, AV; Neznanov, N; Neznanova, L; Wek, RC1
Kimpe, M; Nuyts, S; Prenen, H1
Andersen, TL; Boissy, P; Delaissé, JM; Kupisiewicz, K; Lund, T; Plesner, T1
Anderson, KC; Campbell, RM; Chauhan, D; Dios, AD; Hideshima, T; Ishitsuka, K; Kiziltepe, T; Munshi, N; Neri, P; Ocio, EM; Okawa, Y; Raje, N; Shen, Z; Shih, C; Shiraishi, N; Starling, JJ; Tamura, K; Tassone, P; Vallet, S1
Roberts, AW; Wei, AH1
Daibata, M; Gibellini, F; Lai, R; Lee, E; Mora-Jensen, H; Rizzatti, EG; Weniger, MA; Wiestner, A1
Barete, S; Bodemer, C; Dubreuil, P; Georgin-Lavialle, S; Hermine, O; Lepelletier, Y; Lortholary, O; Suarez, F1
Goy, A; Suh, KS1
Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V1
Annunziata, C; Fojo, T; Poruchynsky, MS; Robey, RW; Sackett, DL; Ward, Y1
Ding, Y; Huang, BH; Li, J; Luo, SK; Peng, AH; Su, C; Tong, XZ; Wang, HH; Zhao, Y; Zheng, D1
Brun, J1
Dekhuijzen, PN; Heunks, LM; Jin, B; Li, YP; Linkels, M; Ottenheijm, CA; Pigmans, CJ; van Hees, HW1
Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K1
Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M1
Encinas García, S; Izarzugaza Perón, Y; Khosravi Shahi, P; Pérez Manga, G; Sabin Domínguez, P1
Li, X; Pennisi, A; Yaccoby, S1
López-Pérez, R; Montero, JC; Pandiella, A; San Miguel, JF1
Adjei, AA; Atadja, P; Friday, BB; Sarkaria, J; Wigle, D; Yang, L; Yu, C1
Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP1
AbdulJabbar, A; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; El-Sayed, R; Hussain, AR; Uddin, S1
Hamaki, T; Kami, M; Kodama, Y; Kusumi, E; Matsumura, T; Miyakoshi, S; Narimatsu, H1
Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ1
Ghori, N; Hanada, S; Harada, M; Omary, MB; Toivola, DM1
Argiroffo, CB; Bongiovanni, M; Chizzolini, C; Dayer, JM; Djaafar, S; Donati, Y; Ferrari-Lacraz, S; Fineschi, S; Goffin, L; Naso, F; Pache, JC1
Dicker, AP; Kamer, S; Ren, Q1
An, C; Beenen, MA; Ellman, JA1
Carew, JS; Giles, FJ; Nawrocki, ST1
Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O1
Barmparousi, D; Dimopoulos, MA; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Psimenou, E; Roussou, M; Terpos, E1
Atiq, OT; Dragovich, T; Hochster, H; Kozuch, PS; Lenz, HJ; O'Neil, BH; Pipas, JM; Rocha-Lima, CM; Ryan, DP1
Kandasamy, K; Kraft, AS1
Dimopoulos, MA; Roussou, M; Terpos, E1
Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L1
Kahl, BS; Markovina, S; Miyamoto, S; Yang, DT; Young, KH1
Hahne, JC; Heider, U; Lamottke, B; Rademacher, J; Sezer, O; Sterz, J; Terpos, E; von Metzler, I1
Gladney, SP; Kaufman, JL; Lonial, S1
Bao, X; Chen, P; Gong, S; Guo, L; Lü, S; Song, N; Song, X; Wang, J; Yang, J; Zhou, H1
Bernstein, SH; Fisher, RI; Friedberg, JW; Jordan, CT; Kelly, J; Liesveld, J; Marquis, D; Mendler, JH; Rich, L; Rossi, RM; Voci, S1
Crawford, LJ; Irvine, AE; Walker, B1
Dimopoulos, MA; Kastritis, E; Rajkumar, SV1
Garderet, L; Gorin, NC; Isnard, F1
Cavallo, F; Esseltine, D; Fink, L; Guerrero, J; Prasad, HK; Zangari, M1
Armeanu, S; Baltz, KM; Bitzer, M; Krusch, M; Lauer, UM; Salih, HR; Smirnow, I; Steinle, A; Weiss, TS1
Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L1
Boyault, S; Brejon, S; Combaret, V; Iacono, I; Puisieux, A; Rousseau, R1
Belch, AR; Debes Marun, C; Kirshner, J; Martin, LD; Pilarski, LM; Reiman, T; Thulien, KJ1
Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yang, H1
Li, M; Murphy, WJ; Sayers, TJ; Sun, K; Welniak, LA1
Amann, K; Kalden, JR; Manz, RA; Maseda, D; Meister, S; Moser, K; Neubert, K; Voll, RE; Weisel, F; Wiethe, C; Winkler, TH1
Huang, B; Hung, CF; Monie, A; Tseng, CW; Wang, MC; Wu, CY; Wu, TC1
Barton, J; Farley, C; Greco, FA; Hainsworth, JD; Hon, J; Schreeder, M; Spigel, DR1
Liu, X; Wang, H; Xu, B1
Facon, T; Hulin, C; Moreau, P2
Bush, D; Carew, JS; Casero, RA; Cleveland, JL; Goodwin, A; Houghton, JA; Marton, LJ; Nawrocki, ST; Reddy, VK; Rehg, JE1
Bertoglio, J; Bréard, J; Mérino, D; Micheau, O; Ndozangue-Touriguine, O; Sebbagh, M1
Chen, L; Chen, Z; Gong, S; Guo, L; Lü, S; Wang, J; Yang, J; Zhou, H1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Assaraf, YG; Berkers, CR; Cloos, J; Debipersad, K; Dijkmans, BA; Franke, NE; Jansen, G; Kaspers, GL; Lemos, C; Oerlemans, R; Peters, GJ; Scheffer, GL; Scheper, RJ; van der Heijden, JW; van Zantwijk, I; Vojtekova, K; Ylstra, B1
Feng, R; Hager, JH; Hassig, CA; Lentzsch, S; Ma, H; Mapara, MY; Payne, JE; Smith, ND1
Grandis, JR; Johnson, DE; Li, C; Li, R1
Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F1
Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A1
Kolesar, J; Utecht, KN1
Argyriou, AA; Iconomou, G; Kalofonos, HP1
Allen, CT; Chen, Z; Colunga, A; Frenkel, V; Li, KC; Poff, JA; Traughber, B; Van Waes, C; Wood, BJ; Xie, J1
Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S1
Cvek, B; Dvorak, Z2
Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS1
Anderson, KC; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R1
Bi, YW; Gu, XH; He, XP; Li, XX; Pang, XY; Sun, WY; Yue, WM1
Bhagat, G; Furman, RR; Gardner, JR; Gonen, M; Gueorguiev, VD; Heaney, ML; Manova, K; O'Connor, OA; Paoluzzi, L; Scotto, L1
Armstrong, JL; Birch-Machin, MA; Brown, AM; Corazzari, M; Hill, D; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP1
Allen, C; Arun, P; Chen, Z; Nottingham, L; Saigal, K; Van Waes, C1
Han, K; Jung, S; Kim, M; Kim, Y; Lim, J; Min, CK; Min, WS1
Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C1
Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Nguyen, M; Pérez-Galán, P; Roué, G; Shore, GC; Villamor, N1
Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S1
McConkey, DJ2
Brandes, G; Buer, J; Carlomagno, T; Frank, R; Geffers, R; Gossler, A; Gütgemann, I; Kalesse, M; Kubicka, S; Malek, NP; Manns, MP; Menche, D; Nickeleit, I; Sasse, F; Sörensen, I; Steinmetz, H; Zender, S1
Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D1
Sayers, T1
Terpos, E2
Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M1
Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ1
de Jong, S; de Vries, EG; Oldenhuis, CN; Stegehuis, JH; Walenkamp, AM1
Chen, I; Chen-Kiang, S; Di Liberto, M; Garcia, J; Huang, X; Menu, E; Toogood, PL; Vanderkerken, K1
Agrawal, SG; Gribben, JG; Jia, L; Liu, FT; Movasaghi, Z; Newland, AC; Rehman, IU; Wyatt, PB1
Ohashi, K1
Gonullu, E; Hacihanefioglu, A; Tarkun, P1
Asaka, M; Fujita, N; Hashino, S; Imamura, M; Kahata, K; Kondo, T; Morita, R; Onozawa, M; Shirai, S1
Grune, T; Jung, T1
Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L1
Goldberg, SN1
Carew, JS; Cleveland, JL; Courage, JF; Giles, FJ; Houghton, JA; Huang, P; Maclean, KH; McConkey, DJ; Nawrocki, ST1
Driessen, C; Gogel, J; Hartmann, JT; Koscielniak, E; Kraus, M; Malenke, E; Müller, H; Ovaa, H; Overkleeft, H; Rückrich, T1
Bagain, L; Chen, Z; Lee, TL; Malhotra, PS; Nottingham, L; Ricker, JL; Van Waes, C; Yeh, NT1
Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W1
Beveridge, RA; Conner, TM; Doan, QD; LeBlanc, AL; Walters, IB1
Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM1
Dobra, K; Hjerpe, A1
Anderson, KC; Bladé, J; Boral, AL; Coleman, M; Esseltine, DL; Facon, T; Harousseau, JL; Irwin, D; Niesvizky, R; Rajkumar, SV; Richardson, PG; Rosiñol, L; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Aydin, NE; Celik, O; Elter, K; Gurates, B; Hascalik, S; Tagluk, ME1
Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG1
Bao, L; Huang, XJ; Lu, XJ; Zhang, XH; Zhang, Y; Zhu, HH1
Bagain, L; Chen, Z; Hager, GL; Karpova, T; McNally, JG; Silvin, C; Sung, MH; Van Waes, C; Voss, TC; Yang, X1
Berenson, JR; Yellin, O1
Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E1
Eom, HS; Huh, J; Kang, HJ; Kim, K; Kim, WS; Ko, YH; Lee, J; Park, K; Ryoo, BY; Suh, C1
Ahn, KS; Bae, EK; Kim, BK; Kim, BS; Lee, YY; Park, J; Yoon, SS1
Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C1
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L1
Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M1
Chen, KF; Cheng, AL; Huang, SY; Lu, YS; Yeh, KH; Yeh, PY1
Cochrane, M; Davidoff, AM; Gray, JT; McIntosh, J; Nathwani, AC; Ng, CY; Zhou, J1
Callander, NS; Kahl, BS; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Raschko, M; Werndli, JE1
Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Anderson, KC; Bladé, J; Cavenagh, J; Esseltine, DL; Harousseau, JL; Jakubowiak, AJ; Lonial, S; Rajkumar, SV; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P1
Adamo, L; Anastasi, G; Caruso, L; Conticello, C; Cupri, A; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gulisano, M; Iannolo, G; Moschetti, G; Palumbo, GA; Vicari, L1
He, Y; Hu, XX; Lü, SQ; Wang, JM; Yang, JM; Zhou, H1
Li, JY; Lu, H; Qian, SX; Qiu, HX; Shen, WY; Wang, LX; Wu, HX; Wu, YJ; Zhang, JF1
Al-Nawakil, C; Bardet, V; Bourry, E; Bouscary, D; Chapuis, N; Choquet, S; Dreyfus, F; Park, S; Roux, C; Tamburini, J1
Chen, X; Dong, H; Gao, G; Gu, H1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H1
Durie, BG1
Claxton, D; Fink, L; Talamo, G; Tricot, G; Zangari, M1
Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P1
Barrientos, J; Elstrom, R; Leonard, JP; Martin, P1
Golenkov, AK; Mitina, TA1
Do, YR; Joo, YD; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, K; Kim, SJ; Kwon, JH; Lee, HJ; Lee, JH; Lee, NR; Lee, WS; Nam, SH; Shin, HJ; Sohn, SK; Suh, C; Won, JH; Yoon, SS1
Acharya, M; Coiteux, V; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; van de Velde, H1
Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP1
Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA1
Clarke, PA; Powers, MV; Workman, P1
Eder, S; Enrich, J; Hochegger, K; Mayer, B; Mayer, G; Perco, P; Pirklbauer, M; Rosenkranz, AR; Rudnicki, M; Sarközi, R; Schramek, H; Wiesinger, M1
Ambinder, RF; Chen, J; Chong, JM; Foss, CA; Fox, JJ; Fu, DX; Fukayama, M; Hobbs, RF; Kowalski, J; Pomper, MG; Sgouros, G; Tanhehco, Y1
Hongming, H; Jian, H1
Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS1
Almasan, A; Gama, V; Matsuyama, S; Mazumder, S; Plesca, D1
Diehl, JA; Herlyn, M; Klein-Szanto, A; Lioni, M; Noma, K; Rustgi, AK; Smalley, KS; Snyder, A1
Dimopoulos, MA; Kastritis, E1
Ayturan, M; Driessen, C; Fissolo, N; Kraus, M; Overkleeft, H; Reich, M; Weissert, R1
Braiteh, F; Giralt, SA; Hymes, SR; Jones, R1
Colvin, LA; Fallon, M; Fleetwood-Walker, SM; Johnson, PR; Mitchell, R1
Agostinelli, C; Arpinati, M; Chirumbolo, G; Nicolini, B; Rondelli, D1
Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C1
Berden, JH; van der Vlag, J1
Huang, J; Jin, J; Pan, HZ; Yang, M1
Czuczman, MS; O'Connor, OA1
Liang, YM; Liu, H; Wang, QW; Wang, T; Zhu, XD1
Chen, LJ; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX1
Alfonsi, E; Corso, A; Costa, A; Lazzarino, M; Lozza, A; Mangiacavalli, S; Moglia, A; Piccolo, G; Ravaglia, S; Varettoni, M; Zappasodi, P1
Dick, L; Lin, G; Nathan, C; Tsu, C; Zhou, XK1
Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J1
Horiike, S; Inaba, T; Shimazaki, C; Shimura, K; Taniguchi, K; Taniwaki, M1
Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A1
Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S1
Bladé, J; Rosiñol, L1
Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P1
Batár, P; Kiss, A; Méhes, L; Telek, B; Udvardy, M1
Furukawa, Y; Kano, Y; Kikuchi, J; Mori, M; Muroi, K; Nagai, T; Noborio-Hatano, K; Nobuyoshi, M; Oh, I; Ozaki, K; Ozawa, K; Sato, K; Shimizu, R; Suzuki, T; Takatoku, M; Ueda, M; Wada, T1
Ahmed, M; Ajarim, D; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Belgaumi, A; Hussain, A; Uddin, S1
Jimenez, SA; Roman-Blas, JA1
Bachmann, AS1
Joyce, RM; Siddiqi, T1
Fonseca, R; Rajkumar, SV1
Adams, S; Barrett, AJ; Berg, M; Childs, R; Eniafe, R; Goldman, JM; Hensel, N; Keyvanfar, K; Lundqvist, A; Savani, BN; Sloand, EM; Yong, AS1
Bouchard, P; Brown, L; Carson, WE; Chaudhury, AR; Go, MR; Guenterberg, K; Guttridge, DC; Hade, E; Ladner, KJ; Lesinski, GB; Lewis, A; Quimper, M; Raig, ET; Shah, NN; Young, G1
Li, JY; Liu, P; Lu, H; Lu, SF; Shen, WY; Wang, LX; Wang, YR; Yang, H; Zhang, JF1
Chen, XP; Liang, W; Lou, YR; Lu, Y; Mu, QT; Ouyang, GF; Xu, W; Zhang, Y1
Casadonte, F; Focà, D; Macrina, L; Malara, N; Santoro, L; Savino, R; Scaramuzzino, M; Sesto, MF; Terracciano, R1
Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J1
Chastagner, P; Delfortrie, S; Labussiere, M; Pinel, S; Plenat, F1
Jin, J; Meng, H; Qian, W; Yang, C; Zhou, Y1
Bonavida, B; Huerta-Yepez, S; Jazirehi, AR; Martinez-Maza, O; Martinez-Paniagua, M; Umezawa, K; Vega, MI1
Amiot, BP; Burns, JM; Gloor, JM; Gores, GJ; Perry, DK; Pollinger, HS; Stegall, MD1
Khan, S; Li, X; Ling, W; Pennisi, A; Yaccoby, S; Zangari, M1
Anderson, KC; Crawford, B; Dhawan, R; Gupta, S; Irwin, D; Lee, SJ; Massaro, J; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P1
Aizawa, S; Heike, Y; Kim, SW; Kobayashi, Y; Maruyama, D; Nagase, K; Takahashi, N; Tobinai, K; Waki, F; Watanabe, T; Yamasaki, S; Yokoyama, H1
Chang, M; Lee, ML; Whitmore, GA1
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT1
Battleman, DS; LeBlanc, A; Richardson, PG; Schuster, M; Walters, IB; Wolf, J1
Littlehales, C1
Hamaki, T; Hori, A; Kami, M; Kishi, Y; Kodama, Y; Komatsu, T; Matsumura, T; Narimatsu, H; Takita, M; Tanaka, Y; Yuji, K1
Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N1
Palumbo, A; Rajkumar, SV1
Bazzaro, M; Bradner, J; Bristow, RE; Chan, KC; Lee, MK; Lin, Z; Mazitschek, R; Roden, RB; Santillan, A; Wang, MC1
Ayala, G; Ding, Y; Frolov, A; Harper, JW; Hayes, TG; Ittmann, MM; Kadmon, D; Li, R; Lynch, RG; MacDonnell, V; Miles, BJ; Mims, MP; Thompson, TC; Tsai, MJ; Wheeler, TM; Yan, J1
Fels, DR; Koong, AC; Koumenis, C; Kridel, SJ; Olson, M; Segan, AT; Spiotto, M; Ye, J1
Aleskog, A; Carlson, K; Larsson, R; Lindhagen, E; Nygren, P; Wiberg, K1
Plosker, GL1
Bladé, J; Cibeira, MT; Fernández de Larrea, C; Lloreta, J; Mascaró, JM; Rovira, M; Serra, N; Solé, M; Torras, A1
Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N1
Erin, N; Yerlikaya, A1
Chaganti, RS; Houldsworth, J; Olshen, AB; Petlakh, M1
Dammacco, F; Mangialardi, G; Ria, R; Vacca, A1
Coleman, M; Mark, T; Niesvizky, R1
DiPersio, JF; Fisher, NM; Goyal, SD; Oza, AY; Stockerl-Goldstein, K; Tomasson, MH; Uy, GL; Vij, R1
Drake, MT; Rajkumar, SV1
Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH1
Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK1
Brüning, A; Burger, P; Burges, A; Friese, K; Lenhard, M; Rahmeh, M; Vogel, M1
Bao, L; Huang, XJ; Lu, XJ; Zhang, XH1
Baiz, D; Dapas, B; Farra, R; Giansante, C; Grassi, G; Grassi, M; Guarnieri, G; Pozzato, G; Scaggiante, B; Uxa, L; Zennaro, C1
Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP1
Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM1
Furtado, M; Rule, S1
Kim, JH; Lee, SK; Lee, SW; Park, YB1
Abdalla, S; Hu, M; Karadimitris, A; Kotsianidis, I; Melo, V; Naresh, K; Rahemtulla, A; Reid, A; Spanoudakis, E; Terpos, E1
Guerciolini, R; Hsieh, FY; Miwa, G; Pekol, TM; Tengstrand, E1
Bladé, J; Cibeira, MT; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH1
Dimopoulos, MA; Gavriatopoulou, M; Hadjikonstantinou, V; Kastritis, E; Migkou, M; Zirogiannis, P1
Ding, J; Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Ri, M; Ueda, R; Utsunomiya, A; Yano, H1
Ambrus, JL; Islam, A1
Barbui, T; Barosi, G; Rambaldi, A1
Anderson, KC; Azab, AK; Azab, F; Burwick, N; Chen, C; Ghobrial, IM; Jia, X; Leleu, X; Melhem, MR; Ngo, HT; Novina, CD; Roccaro, AM; Rollins, BJ; Runnels, J; Sacco, A; Varticovski, L1
Bernstein, SH; Boral, AL; de Vos, S; Djulbegovic, B; Epner, E; Fisher, RI; Goy, A; Kahl, BS; Krishnan, A; Leonard, JP; Lonial, S; Nasta, S; O'Connor, OA; Robertson, MJ; Shi, H1
Au, WY; Kwong, YL; Liang, RH; Shen, L; Shimizu, N; Srivastava, G; Tsuchiyama, J; Wong, KY1
Cavaletti, G; Gilardini, A; Marmiroli, P1
Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J1
Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C1
Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M1
Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Weng, DH; Xing, H1
Alexiadis, M; Chu, S; Fuller, PJ1
Fladd, C; Huynh, L; Jiang, C; Ly, D; Rotin, D; Trzcinska-Daneluti, AM1
Allen, S; Mehta, J; Singhal, S; Vickrey, E1
Kami, M; Komatsu, T; Tsubokura, M1
Avvisati, G1
García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M1
Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ1
Barbone, D; Broaddus, VC; Fennell, DA; Yang, TM1
Anel, A; Balsas, P; Galán-Malo, P; López-Royuela, N; Marzo, I; Naval, J1
Alloway, RR; Arend, LJ; Brailey, P; Cardi, M; Everly, JJ; Everly, MJ; Govil, A; Mogilishetty, G; Rike, AH; Roy-Chaudhury, P; Susskind, B; Tevar, A; Wadih, G; Woodle, ES1
Kaporskaia, TS; Kiselev, IV1
Brossart, P; Fröhlich, E; Wahl, R1
Groll, M; Huber, R; Moroder, L1
Li, J; Liu, P; Lu, H; Xu, B1
Dmoszyńska, A1
Voelkel-Johnson, C1
Brady, JN; Dohoney, K; Janik, JE; Lee, MJ; Morris, JC; O'Mahony, D; Pise-Masison, CA; Radonovich, M; Trepel, J; Waldmann, TA1
Alt, C; Anderson, KC; Azab, AK; Azab, F; Burwick, N; Carlson, AL; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Kung, AL; Leleu, X; Lin, CP; Melhem, MR; Moreau, AS; Munshi, NC; Ngo, HT; Ospina, B; Pitsillides, C; Roccaro, AM; Rollins, BJ; Runnels, JM; Sacco, A; Wright, R1
Bernardi, P; Brancolini, C; Crivellato, E; Demarchi, F; Fontanini, A; Foti, C; Maestro, R; Potu, H1
Berdel, WE; Bisping, G; Gustavus, D; Hilberg, F; Kienast, J; Kropff, M; Mesters, RM; Müller-Tidow, C; Munzert, G; Roth, GJ; Stefanic, M; Stelljes, M; Volpert, S; Wenning, D1
Elliott, GI; Farshchi-Heydari, S; Howell, SB; Jandial, DD; Larson, CA; Wrasidlo, WJ1
Dawson, MA; Donovan, M; Hertzberg, M; Horvath, N; McLean, CA; Monaghan, K; Opat, SS; Prince, HM; Roberts, AW; Spencer, A; Taouk, Y; Zammit, M1
Anderson, KC; Carrasco, R; Chabner, B; Chauhan, D; Chhetri, S; Cirstea, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Mukherjee, S; Munshi, NC; Okawa, Y; Parikh, H; Podar, K; Pozzi, S; Raab, M; Raje, N; Richardson, PG; Rooney, M; Scadden, D; Sharma, S; Vallet, S1
Akazawa, H; Komuro, I1
Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y1
Amiot, M; Bataille, R; Descamps, G; Gomez-Bougie, P; Moreau, P; Venot, C1
Amato, AA; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Reece, D; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Wen, PY1
Prommer, EE1
Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Dentamaro, T; Fratoni, S; Giovannini, M; Niscola, P; Santeusanio, G; Scaramucci, L; Siniscalchi, A; Tendas, A1
Carrell, JA; Humphreys, R; Luster, TA; McCormick, K; Sun, D1
Eckhardt, SG; Kaufman, SA; Morrow, M; Pitts, TM; Tentler, JJ1
Liu, YP; Ma, YJ; Qu, XJ1
Kesarwala, AH; Piwnica-Worms, D; Samrakandi, MM1
Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG1
Hunter, P1
Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C1
Davies-Hill, T; Jin, L; Miida, T; Miyake, K; Pittaluga, S; Raffeld, M; Rudelius, M; Sebasigari, D; Tabe, Y1
Abaya, CD; Berenson, JR; Duvivier, H; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Yellin, O1
Cadenas, E; Chen, TC; Gaffney, KJ; Golden, EB; Kardosh, A; Lam, PY; Louie, SG; Petasis, NA; Schönthal, AH1
Aguirre-Ghiso, JA; Schewe, DM1
Cammarota, S; Cavaletti, G; Frigeni, B; Jann, S; Lanzani, F; Mattavelli, L; Petrò, D; Rossini, F1
Borrello, I; Chaudhry, V; Cornblath, DR; Ferguson, A; Polydefkis, M1
Higa, GM; Saad, AA; Sharma, M1
Barlogie, B; Chen, Y; Hu, B; Qiang, YW; Shaughnessy, JD; Shi, B; Zhong, Y1
Berg, M; Childs, R; Lundqvist, A; Smith, A; Yokoyama, H1
Eby, C1
Arenkiel, BR; Capecchi, MR; Cho, MJ; Guttridge, DC; Hansen, MS; Keller, C; McCleish, AT; Qualman, SJ; Rivera, OJ; Scott, MP; Taniguchi, E1
Du, ZX; Guan, Y; Meng, X; Wang, HQ; Zhang, HY1
Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Gonen, M; Gordon, L; Hamelers, R; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, JJ; Zelenetz, AD1
Bose, P; Gandhi, D; Ghabach, B; Ozer, H; Thompson, C1
Assaf, C; Heider, U; Lamottke, B; Mieth, M; Moebs, M; Rademacher, J; Sezer, O; von Metzler, I1
Ames, E; Hallett, WH; Murphy, WJ1
Hiepe, F; Voll, R1
Beck, A; Driessen, C; Gogel, J; Kalbacher, H; Kraus, M; Ovaa, H; Overkleeft, HS; Rückrich, T; Verdoes, M1
Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A1
Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Leis, JF; Mikhael, JR; Noble, B; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Spong, JE; Stewart, AK; Trudel, S; Zepeda, VH1
Abe, M; Fujii, S; Kagami, S; Kagawa, K; Lee, E; Matsumoto, T; Miki, H; Nakamura, S; Ozaki, S; Takeuchi, K; Takimoto, T; Tanaka, O; Watanabe, H; Yata, KI1
Abaya, CD; Berenson, JR; Cartmell, A; Duvivier, H; Eades, B; Flam, MS; Hilger, J; Nassir, Y; Patel, R; Swift, RA; Woytowitz, D; Yellin, O1
Armstrong, JL; Birch-Machin, MA; Flockhart, R; Hill, DS; Lovat, PE; Martin, S; Redfern, CP; Simpson, DG; Tonison, JJ1
Brignole, C; Carosio, R; Cilli, M; Di Paolo, D; Galietta, LJ; Loi, M; Marimpietri, D; Nico, B; Pagnan, G; Pastorino, F; Pezzolo, A; Piccardi, F; Pistoia, V; Ponzoni, M; Ribatti, D1
Fadeel, B; Feng, X; Henter, JI; Ji, C; Nordenskjöld, M; Ottosson, A; Wang, X; Zheng, C1
Barr, RJ; Cole, GW; Dyson, SW; Murase, JE; Theate, I; Wu, JJ1
Chen, XQ; Dong, HJ; Gao, GX; Gao, Y; Gu, HT; Pan, YZ; Zhu, HF1
Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP1
Chan, W; Heymach, J; McConkey, DJ; Wilkinson, M; Zhu, K1
Grandis, JR; Johnson, DE; Li, C; Li, R; Patel, NS; Zang, Y1
Anargyrou, K; Christoulas, D; Dimopoulos, MA; Kastritis, E; Katodritou, E; Michalis, E; Pouli, A; Terpos, E; Tsiftsakis, E; Tsionos, K; Verrou, E; Zervas, K1
Brauer, KM; Bringmann, A; Brossart, P; Held, SA; Schaub, A; von Schwarzenberg, K1
Chen, L; Chen, Z; Han, F; Li, J; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H1
Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A1
Chen, KF; Chen, PJ; Cheng, AL; Hsieh, HP; Hsu, C; Hsu, CH; Lu, YS; Yeh, PY1
Handa, H; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saitoh, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A1
Shiguang, Z; Tianhu, Z; Xinghan, L1
Brancolini, C; Demarchi, F; Foti, C1
Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D; Rahmani, M1
Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K1
Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I1
Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB1
Jang, HS; Kim, KM; Oh, KJ; Park, JW; Rhyu, IJ1
Chen, SJ; Chen, Z; Janin, A; Jiang, XX; Shen, ZX; Wang, L; Wu, WL; Yang, F; Zhang, QL; Zhang, YW; Zhao, WL1
Hirakawa, T; Inokuchi, K; Yokose, N1
Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J1
Bates, AL; Edwards, CM; Fowler, JA; Lwin, ST; Mundy, GR; Oyajobi, BO; Zhuang, J1
Grünberg, K; Sonneveld, P; Wittgen, BP; Wondergem, MJ; Zweegman, S1
Alexandrescu, DT; Dasanu, CA2
Berg, M; Childs, R; Fan, Y; Lundqvist, A; McCoy, P; Samsel, L; Tawab, A1
Dreyling, M; Hartmann, E; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Rosenwald, A; Weinkauf, M; Zimmermann, Y1
Guan, M; Hughes, A; Somlo, G; Yen, Y; Zhou, B; Zhu, L1
Chim, CS; Hwang, YY; Pang, C; Shek, TW1
Asmann, YW; David, CS; Rajagopalan, G; Tilahun, AY1
Chott, A; Formanek, M; Hauff, W; Jonak, C; Müllauer, L; Püspök, A; Raderer, M; Troch, M; Zielinski, CC1
Armitage, JO1
Cavenagh, J; Lonial, S1
Chen, Q; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Voorhees, PM1
Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O1
Geffray, L1
Balkaran, S; Gay, J; Ghobrial, I; Leleu, X; Morel, P; Pascal, L; Robu, D; Roccaro, A; Wemeau, M; Willekens, C1
Chen, S; Goldenberg, DM; Smith, MR; Stein, R; Zalath, M1
Guan, X; Koide, SS; Li, S; Miao, S; Song, W; Wang, L; Wang, Y; Zong, S1
Chen, C; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ1
Azab, AK; Azab, F; Ghobrial, IM; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A1
Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N1
Anderson, KC; Baccarani, M; Calabrese, E; Cavo, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Ikeda, H; Okawa, Y; Perrone, G; Raje, N; Santo, L1
Butcher, BE; Cannell, P; Horvath, N; Mikhael, JR; Prince, HM; Quach, H1
Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B1
Knauf, WU; Kornacker, M; Otremba, B; Overkamp, F1
Everly, MJ; Terasaki, PI2
Callahan, LA; Supinski, GS; Vanags, J1
Czuczman, MS; Dave, SS; Dunleavy, K; Grant, N; Jaffe, ES; Janik, JE; Pittaluga, S; Shovlin, M; Staudt, LM; Wilson, WH; Wright, G1
Ahn, KS; Ayyappan, V; Bae, EK; Kim, BK; Kim, BS; Lee, C; Lee, YY; Park, J; Yoon, SS1
Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J1
Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L1
Bradner, JE; Cohen, JI; Kawada, J; Mazitschek, R; Zou, P1
Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG1
Chen, L; Chen, X; Dong, B; Dong, H; Gao, G; Gao, Y; Gu, H1
Benninger, K; Carson, WE; Kreiner, M; Lesinski, GB; Quimper, M; Young, G1
Tsukamoto, S; Yokosawa, H1
Baumann, G; Fechner, M; Grimbo, N; Ludwig, A; Meiners, S; Stangl, K; Stangl, V; Wilck, N1
Dun, XY; Hou, J; Li, YH; Yuan, ZG1
Dudek, AZ; Franklin, M; Greeno, EW; Kratzke, RA; Kumar, P; Lesniewski-Kmak, K; Pandey, ON; Shehadeh, NJ1
Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L1
Adam, Z; Buchler, T; Buresova, L; Hajek, R; Krejci, M; Krivanova, A; Pour, L; Sandecka, V; Vorlicek, J; Zahradova, L1
Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I1
Delmonte, A; Ghielmini, M; Sessa, C1
Haane, C; Nehmann, N; Schumacher, U; Valentiner, U1
Balasubramanian, S; Bhalla, S; Buggy, J; David, K; Evens, AM; Gordon, LI; Mauro, L; Miller, R; Prachand, S; Sirisawad, M1
Bottini, A; Generali, D; Harris, AL; Mellor, HR; Milani, M; Pike, L; Rzymski, T1
Mohamed, AJ; Mohanram, V; Simonson, OE; Smith, CI; Spetz, AL; Yu, L1
Chen, Z; Gong, S; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H1
Abe, M1
Anderson, KC; Carrasco, RD; Chauhan, D; Hideshima, T; Ikeda, H; Mitsiades, C; Munshi, NC; Okawa, Y; Podar, K; Raje, N; Richardson, PG1
Curran, MP; McKeage, K1
Billet, A; Chaby, G; Chatelain, D; Christophe, O; Dadban, A; Damaj, G; Lenglet, A; Lok, C; Marolleau, JP; Royer, R; Thuillier, D; Vaida, I; Viseux, V1
Andreoli, A; Briere, J; Cavelier Balloy, B; Petit, A; Thomas, M1
Avenel-Audran, M; Croué, A; Dib, M; Hunault-Berger, M; Lissandre, S; Moles, MP; Tanguy-Schmidt, A; Zidane-Marinnes, M1
Godley, LA; Goodenbour, JM; Pan, T; Wickrema, A; Zhou, Y1
Li, J; Li, W; Luo, S; Su, C; Zou, WY1
Anderson, KC; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Richardson, PG; Roccaro, AM1
Dispenzieri, A; Gertz, MA; Kumar, S; Sadek, I1
Eller, K; Heininger, D; Huber, JM; Mayer, G; Rosenkranz, AR; Tagwerker, A1
Hertan, LM; Koumenis, C1
Dave, SD; Everly, MJ; Feroz, A; Idica, AK; Kaneku, H; Khemchandani, SI; Modi, PR; Shankar, V; Terasaki, PI; Trivedi, HL; Trivedi, VB; Vanikar, AV1
Berndt, N; Guida, WC; Kazi, A; Lawrence, H; McLaughlin, ML; Sebti, SM; Springett, GM; Yip, RM1
Baltaci, M; Böckle, BC; Sepp, NT; Weyrer, W1
Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J1
Biczó, G; Halm, G; Rakonczay, Z; Szabolcs, A; Takács, T; Tiszlavicz, L; Wittmann, T1
Cho, BS; Eom, HS; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, S; Min, CK; Min, WS1
Cakana, A; Comenzo, RL; Elsayed, YA; Fermand, JP; Hegenbart, U; Liu, X; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; Vescio, RA1
Cheong, JW; Jeong, TS; Kim, HJ; Kim, TY; Lee, DS; Lee, JH; Min, HJ; Oh, B; Park, J; Park, SB; Suh, C; Yoon, SS1
Jin, J; Liu, H; Tong, HY; Wei, JY; Yu, WJ; Zhang, FJ; Zhu, WF1
Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M1
Blanco, B; Caballero-Velazquez, T; Del Cañizo, C; Díez-Campelo, M; Gutierrez-Cossío, S; Hernández-Campo, P; Herrero-Sanchez, C; Pérez-Simón, JA; Rodriguez-Serrano, C; San Miguel, JF; Sánchez-Abarca, LI; Sánchez-Guijo, FM; Santamaría, C1
Rolfe, M; Smith, PG; Soucy, TA1
Benavides, A; Frost, P; Hoang, B; Lichtenstein, A; Shi, Y1
Boise, LH; Gutman, D; Morales, AA1
Algarotti, A; Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Pica, GM; Varettoni, M; Zappasodi, P1
Emadi, A; Ghosh, N1
Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR1
Knopf, KB; Moretto, JC; Waller, JM1
Powell, CA1
Amato, AA; Anderson, KC; Avigan, DE; Briemberg, HR; Chanan-Khan, AA; Doss, D; Esseltine, DL; Hassoun, H; Heffner, LT; Kesari, S; Kuter, DJ; Lonial, S; Mitsiades, C; Munshi, NC; Oaklander, AL; Richardson, PG; Schlossman, RL; Weller, E; Wen, PY; Xie, W1
Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T1
Accorsi, P; Antuzzi, G; Bavaro, P; Carrozza, F; Dell'Isola, M; Di Bartolomeo, P; Gigli, R; Giglio, G; Magri, M; Musacchio, M; Romito, S1
Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K1
Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH1
Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M1
Choi, EK; Jeong, SY; Kim, TH; Moon, AR; Seo, YW; Woo, HN1
Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG1
Aki, SZ; Erdem, O; Ozkurt, ZN; Sucak, GT; Yağci, M1
Testa, U1
Chen, YJ; Huang, RX; Huang, XC; Li, XL; Peng, MY; Xie, ZX; Yang, XG1
Albanell, J; Belda-Iniesta, C; Cejas, P; Chattopadhyay, S; Cortes-Sempere, M; de Castro-Carpeño, J; Gonzalez-Barón, M; Machado-Pinilla, R; Manguan-García, C; Moratilla, C; Nistal, M; Perona, R; Rodriguez-Fanjul, V; Rovira, A; Sánchez-Pérez, I; Tapia, M1
Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D1
Gajate, C; Mollinedo, F; Reis-Sobreiro, M1
Dahlmann, B; Kloss, A; Ludwig, A; Meiners, S1
Bryant, J; Clegg, A; Cooper, K; Green, C; Smith, A; Stephens, M; Takeda, A1
Alakus, H; Auer, T; Gamerith, G; Hilbe, W; Krugmann, J; Lindner, H; Loeffler-Ragg, J; Martin, HJ; Maser, E; Menzel, J; Mueller, D; Sarg, B; Schmid, KW; Schmitz, KJ; Skvortsov, S; Skvortsova, I; Zwierzina, H1
Chou, T; Hasegawa, Y; Hirose, T; Imai, Y; Ishiguro, T; Kawahara, F; Nagai, H1
Carew, JS; Esquivel, JA; Giles, FJ; Huang, P; Kelly, K; Mahalingam, D; Medina, EC; Mita, AC; Mita, MM; Nawrocki, ST; Swords, R; Zhang, H1
Chen, X; Ding, WX; Gao, W; Kang, JH; Liu, J; Ni, HM; Stolz, DB; Yin, XM1
Foley, PW; Hamilton, MS; Leyva, F1
Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G1
Bocchia, M; Defina, M; Gozzetti, A1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE1
Lattin, G; Sanders, O; Timpone, V1
Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y1
Berciano, MT; Casafont, I; Lafarga, M1
Chen, SL; Zhong, YP1
Fang, H; Hu, Z; Zhou, G1
Camacho, ES; Crowley, J; Durie, BG; Gabayan, AE; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Wolf, JL1
Cortelli, BM; Dumitrescu, O; Gerecitano, J; Hamelers, R; Hamlin, P; Lin, D; Moskowitz, C; Neylon, E; O'Connor, OA; Pappanicholaou, J; Portlock, C; Sarasohn, D; Straus, D; Wright, J; Zelenetz, AD; Zhang, Z1
Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V1
Littmann, L; Lüftenegger, D; Rössner, S; Schubert, U; Steinkasserer, A; Zinser, E1
Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL1
Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Jehan, Z; Munkarah, A; Uddin, S1
Alonso Vence, N; Bello Lopez, JL; Bendaña Lopez, A; Diaz Arias, J; Fraga Rodriguez, M; Sobas, MA1
Grandis, JR; Johnson, DE; Leeman-Neill, RJ; Li, C; Man, DS; Sen, M; Zang, Y1
Bolen, J1
Dewar, MR; Ghaffari, S; Grassian, A; Jagani, Z; Khosravi-Far, R; Kutok, JL; Melet, A; Miller, K; Ren, R; Rodin, HY; Santos, T; Song, K; Wu, C; Yeckes-Rodin, H1
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR1
Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F1
Bukowski, RM; Burk, R; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Hill, J; Rybicki, LR; Vaziri, SA1
Arkenbout, EK; Deming, CB; Hansen, BS; Hiroi, T; McDevitt, MA; Myers, TJ; Rade, JJ; Zhao, H1
Alloway, RR; Everly, JJ; Walsh, RC; Woodle, ES1
Dreyling, M; Issels, R; Lorenz, M; Milani, V; Pastore, A; Rieken, M; Weinkauf, M1
Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J1
Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H1
Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Varettoni, M; Zappasodi, P1
Gerecitano, J1
Cvek, B2
Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y1
Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H1
Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T; Nemoto, K1
Bult, H; De Meyer, GR; Herman, AG; Martinet, W; Van Herck, JL; Vrints, CJ1
De Biasi, M; Rezvani, K; Teng, Y1
Avezza, F; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Marmiroli, P; Meregalli, C; Oggioni, N1
Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Haessler, J; Nair, B; Shaughnessy, JD; van Rhee, F; Waheed, S; Zhou, Y1
Andersen, RJ; Kennah, M; Krystal, G; Mui, AL; Nodwell, M; Ong, CJ; Yau, TY1
Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X1
Schiff, D; van den Bent, MJ; Wen, PY1
Dave, SD; Everly, MJ; Feroz, A; Idica, A; Kaneku, H; Khemchandani, SI; Modi, PR; Shankar, V; Terasaki, PI; Trivedi, HL; Trivedi, VB; Vanikar, AV2
Baryshnikov, AIu; Golenkov, AK; Klinushkina, EF; Kogarko, IN; Liubimova, NV; Mitina, TA1
Aghajanian, C; Blessing, JA; Darcy, KM; DeGeest, K; Mannel, RS; Reid, G; Riordan, W; Rotmensch, J; Rubin, SC; Schilder, RJ1
Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE1
Gastl, G; Gunsilius, E; Kern, J; Sarg, B; Steurer, M; Untergasser, G; Zenzmaier, C1
Focosi, D1
Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F1
Daroczi, B; Dicker, AP; Kari, G; Ren, Q; Rodeck, U1
Afar, DE; Balasa, B; Barlogie, B; Chao, D; Dillon, M; Ganguly, B; Garg, TK; Li, X; Moreno-Bost, AM; Rice, AG; Shaughnessy, JD; Shi, J; Stone, MK; Szmania, SM; van Abbema, AM; van Rhee, F; Yaccoby, S; Yun, R; Zhan, F1
Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT1
Endo, T; Fujimoto, K; Goto, H; Kasahara, I; Koike, T; Nishio, M; Sato, N; Takeda, Y; Yamaguchi, K; Yamamoto, S1
Dun, X; Fu, W; Hou, J; Yuan, Z; Zhang, C1
Buda, G; Cecconi, N; Galimberti, S; Orciuolo, E; Petrini, M1
Antognoni, F; Barale, R; Brunori, M; Buda, G; Galimberti, S; Gentile, M; Maggini, V; Martino, A; Morabito, F; Orciuolo, E; Petrini, M; Rossi, AM1
Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB1
Bai, QX; Bai, YN; Chen, XQ; Gu, HT; Liang, R; Shu, MM; Wang, WQ; Wang, YW; Yang, L; Zhang, T; Zhang, YQ; Zhu, HF1
Bayik, M; Cetiner, M; Kaygusuz, I; Kocakaya, O; Tezcan, H; Uzay, A1
Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM1
Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Naujokat, C; Opelz, G; Sadeghi, M1
Ahmed, A; Al-Zoubi, A; Braun, T; Brozo, C; Campagnaro, E; Jakubowiak, AJ; Kaminski, MS; Kendall, T; Khaled, Y; Mineishi, S; Talpaz, M1
Orlowski, RZ; Shah, JJ1
Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL1
Barone, E; Mancuso, C1
Bachmann, AS; Clerc, J; Driessen, C; Dudler, R; Florea, BI; Groll, M; Huber, R; Kaiser, M; Kraus, M; Overkleeft, HS1
Cippitelli, M; Fionda, C; Iannitto, ML; Malgarini, G; Santoni, A; Soriani, A1
Ahnert, P; Bauer, M; Bockmuehl, U; Erdal, H; Ganten, TM; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Stremmel, W; Sykora, J; Walczak, H1
Belt, R; Boral, AL; Dakhil, SR; de Vos, S; Flowers, CR; Glenn, M; Goy, A; Gregory, SA; Hart, L; Holladay, C; Knapp, M; McLaughlin, P; Patel-Donnelly, D; Saleh, MN; Zhang, T1
Grant, S2
Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G1
Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W1
Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC1
Anargyrou, K; Carney, W; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Hamer, P; Kastritis, E; Leitzel, K; Lipton, A; Migkou, M; Shrivastava, V; Terpos, E1
San Miguel, JF2
Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E1
San Miguel, J1
DeMartino, GN1
Hamlin, P; MacGregor-Cortelli, B; Moskowitz, CH; Muzzy, J; O'Connor, O; Schenkein, DP; Straus, D; Trehu, E; Wright, J; Zelenetz, AD1
Stadtmauer, EA1
Mitsiades, CS2
Anderson, KC; Bandi, M; Bianchi, G; Brahmandam, M; Carrasco, R; Chauhan, D; Hideshima, T; Jaye, DL; Kumar, SK; Mitsiades, C; Munshi, N; Podar, K; Raje, N; Richardson, P; Singh, AV; Tai, YT1
Avcu, F; Aydur, E; Baran, Y; Basal, S; Beyzadeoglu, M; Dirican, B; Goktas, S; Pekel, A; Ural, AU; Yazici, S1
Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S1
Ciechanover, A; Navon, A1
Dowling, M; Hayat, A; Hayden, P; Meenaghan, T; Murray, M; O'Dwyer, M1
Conticello, C; Di Raimondo, F1
Agyin, JK; Nair, HB; Roy, SS; Santhamma, B; Tekmal, RR1
Hou, J; Jiang, H; Li, YH; Xi, H; Zhu, R; Zou, JF1
Chen, ST; Gaffney, KJ; Louie, SG; Petasis, NA; Schönthal, AH; Thomas, S1
Decaux, O; Karras, A1
Cavero, S; Español, I; Funes, C; García, MC; Ibáñez, J; Iturbe, T; López, MD; Martínez, A; Tejedor, A1
Barlogie, B; Chen, L; Entin, I; Epstein, J; Shaughnessy, JD; Wang, S; Wu, X; Xiong, W; Yaccoby, S; Zhan, F; Zhou, Y1
Chen, XY; Jiang, XX; Shen, ZX; Wu, WL; Zhang, QL; Zhao, WL1
Basler, M; Beck, U; Groettrup, M; Lauer, C1
Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K1
Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG1
Aichberger, KJ; Baumgartner, C; Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Kneidinger, M; Mayerhofer, M; Mirkina, I; Peter, B; Pickl, WF; Sillaber, C; Valent, P1
Duan, MH; Jiao, L; Li, J; Shen, T; Zhang, W; Zhao, YQ; Zhou, DB1
Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H1
Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M1
Akahane, D; Gotoh, M; Kitahara, T; Ohyashiki, K; Sakuta, J1
Gozzetti, A1
Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL1
Dunner, K; McConkey, DJ; Zhu, K1
Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM1
Brancolini, C; Florean, C; Foti, C; Gustincich, S; Pezzutto, A; Roncaglia, P; Tomasella, A1
Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y1
Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P1
Böll, B; Chalaris, A; Eichenauer, DA; Engert, A; Hansen, HP; Krell, HW; Reiners, KS; Rose-John, S; Simhadri, VL; Simhadri, VR; Vahdat, AM; von Strandmann, EP; Wiegmann, K1
Attal, M; Bourin, P; Laroche, M; Lemaire, O1
Benavidez, D; Eliseev, RA; Shapovalov, Y; Zuch, D1
Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M1
Almasan, A; Banerjee, AK; Fairchild, RL; Gasparian, AV; Gorbachev, AV; Gudkov, AV; Gurova, KV; Komarov, AP; Neznanov, N; Neznanova, L1
Bitter, M; Brunvand, MW1
Downey, HD; Dunn, D; Finn, JD; High, KA; Hui, D; Mingozzi, F; Pien, GC; Zhou, S1
Harvey, RD; Lonial, S; Nettles, J; Sun, SY; Wang, B1
Dereure, O; Guillot, B; Michot, C1
Khong, T; Monaghan, K; Smith, G; Spencer, A1
Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC1
D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A1
Kanda, Y1
Ozaki, S1
Belloni, D; Caligaris-Cappio, F; Dell'Antonio, G; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L1
Buda, G; Orciuolo, E; Pelosini, M; Petrini, M1
Becker, P; Bensinger, WI; Camacho, E; Capo, G; Crowley, J; Durie, BG; Hilger, J; Irwin, D; Jagannath, S; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Vesole, DH; Wolf, J1
Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH1
Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H1
Anasetti, C; Dalton, W; Meads, M; Parquet, N; Perez, LE1
Belardo, G; Piva, R; Santoro, MG1
Bhattacharya, N; Döhner, H; Führer, M; Idler, IS; Mertens, D; Sarno, A; Stilgenbauer, S; Zenz, T1
Berenson, JR; Campbell, RA; Chen, H; Li, ZW; Sanchez, E; Shalitin, D; Steinberg, J1
Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P1
Lupfer, C; Pastey, MK; Patton, KM1
Babcock, T; Bannerman, B; Cao, Y; Hatsis, P; Kupperman, E; Robertson, R; Silva, MD; Terkelsen, J; Williamson, MJ; Xia, C; Yu, L1
Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG1
Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN1
Aggarwal, BB; Pandey, MK; Sung, B1
Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K1
Dimopoulos, MA; Terpos, E1
Alarid, ET; Casa, AJ; Ellison-Zelski, SJ; Lee, AV; Powers, GL1
Veselý, K1
Adam, Z; Cermáková, Z; Feit, J; Hájek, R; Krejcí, M; Mayer, J; Pour, L; Vasků, V1
Bandi, P; Booth, CJ; Chisari, FV; Garcia, ML; Robek, MD1
Li, ZY; Lu, QX; Pan, XY; Sun, HY; Wu, SH; Xu, KL1
Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L1
Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM1
Caravita, T; de Fabritiis, P; Dentamaro, T; Perrotti, A; Siniscalchi, A; Tatangelo, P1
Huang, BH; Li, J; Su, C; Zeng, LJ; Zhao, Y1
Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C1
Dou, QP; Lonardo, F; Pass, HI; Puliyappadamba, VT; Rishi, AK; Ruckdeschel, JC; Sharma, S; Tarca, A; Wali, A; Wang, Y; Yang, H1
Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y1
Bölke, E; Bruch-Gerharz, D; Budach, W; Buhren, BA; Fenk, R; Gerber, PA; Haas, R; Homey, B; Reifenberger, J1
Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M1
Cherem, L; Kahan, BD; Kaposztas, Z; Katz, SM; Van Buren, CT1
Dong, X; Gao, SL; Jiang, RY; Peng, JP; Wang, J; Wu, YL; Xie, QP; Zhan, YC1
Chang, CC; Chang, TC; Chen, CH; Golubovskaya, VM; Hsu, C; Ko, BS; Kuo, CC; Liou, JY; Liu, CC; Shen, TL; Shen, YC; Shyue, SK1
Mateos, MV; San-Miguel, JF1
Gay, F; Palumbo, A3
Stewart, AK1
Ghobrial, IM; Stewart, AK1
AKIYAMA, H; KATO, I; KOBAYASHI, T; MIYAZAWA, M; NAJIMA, Y; NAKANO, M; OHASHI, K; SAKAMAKI, H; SAWADA, T; YAMASHITA, T1
Ding, Y; Gu, J; Huang, B; Li, J; Wang, Q; Zeng, L; Zhao, Y; Zheng, D1
Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C1
Dana, K; Hana, S; Jaroslav, M; Jiri, V; Lucie, K; Ludek, P; Marta, K; Martina, A; Miroslav, P; Roman, H; Tomas, B; Zdenek, A1
Chapman, C; Rosser, A; Swallow, G; Swann, RA1
Mehta, AB; Shah, AD; Watts, AJ; Wechalekar, AD1
Brancolini, C1
Armstrong, JL; Flockhart, R; Lovat, PE; Redfern, CP; Veal, GJ1
Childs, R; Lundqvist, A; Rao, S; Su, S1
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y1
Bauer, S; Brown, MF; Chatterjee, P; Chin, A; Duensing, A; Duensing, S; Fletcher, JA; Kuan, SF; Mühlenberg, T; Parry, JA; Rubin, BP; Seneviratne, D1
Cho, HS; Kim, JS; Kim, KH; Kim, SJ; Kim, SY; Lee, JI; Lim, JH; Park, CG; Shin, JS; Shin, JY; Yoon, IH1
Lin, MF; Ouyang, GF1
Jing, HM; Ke, XY; Yang, P; Zhang, WJ1
Azaïs, I; Brault, R; Debiais, F1
Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK1
Yaccoby, S1
Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T1
Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F1
Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Kittang, AO; Lassalle, P; Reikvam, H1
Ausserlechner, MJ; Bodner, M; David, R; Geiger, K; Hagenbuchner, J; Meister, B; Obexer, P; Porto, V; Villunger, A1
Bastida, J; Campos-Adsuar, C; Dehesa, L; Gómez-Duaso, J; Limeres-González, M1
Gartel, AL; Pandit, B4
Al Diab, AR; Al Momen, AK; Aleem, A; Niaz, F; Qayum, A1
Bortolotto, A; Camargo, J; Camargo, S; Canabarro, R; Costa, C; Felicetti, J; Fernandes, S; Machuca, T; Michelon, T; Neumann, J; Perin, F; Sanchez, L; Schio, S; Sporleder, H; Tarrasconi, H2
Gupta, S; Honig, NH; Kraus, JP; Kruger, WD; Singh, LR1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, J1
Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD1
Brancolini, C; Potu, H; Sgorbissa, A1
Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B1
Handa, H; Higeta, D; Hirato, J; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saito, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A1
Pondrom, S1
Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I1
Arvanitis, A; Caulder, E; Combs, AP; Favata, M; Fridman, JS; Kelley, JA; Li, J; Newton, R; Rogers, JD; Scherle, PA; Solomon, KA; Sparks, RB; Thomas, B; Vaddi, K; Wen, X1
Einsele, H2
Berkers, CR; Ovaa, H1
Li, J; Su, C; Wang, HH; Zeng, LJ; Zhao, Y1
Bauer, F; Dasanu, CA; Reale, MA1
Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y1
Huan, C; Zenilman, ME1
Dimopoulos, MA; Gillmore, JD; Hawkins, PN; Kastritis, E; Merlini, G; Palladini, G; Perfetti, V; Wechalekar, AD1
Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S1
Adamo, V; Bronte, G; Cicero, G; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A1
Calinski, D; Chanan-Khan, AA; Li, F; Ling, X; Zhou, M1
Campion, L; Charbonnel, C; Clément, M; Decaux, O; Gouraud, W; Loiseau, HA; Magrangeas, F; Minvielle, S1
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM1
Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E1
Duong, TQ; Jung, I; Keller, C; Kilcoyne, A; Lin, AL; Morgan, WW; Nelon, LD; Nowak, BM; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Taniguchi, E; Togao, O; Whitney, TG1
Chatta, G; Chen, E; Cooper, M; Egorin, M; Karol, M; Neuwirth, R; Rader, M; Ramalingam, S; Ramanathan, RK; Riordan, W; Trepicchio, W; Venkatakrishnan, K; von Moltke, L1
Beckwith, LG; Carson, KR; Mehta, J1
Barrett, JR; Bhalla, KN; Erickson, B; Ganapathy, V; Gopal, E; Hill, WD; Jackson, WH; Periyasamy-Thandavan, S; Raney, L; Samaddar, JS; Schoenlein, PV1
Dick, LR; Fleming, PE1
Anglicheau, D; Candon, S; Hermine, O; Legendre, C; Leruez, M; Loupy, A; Martinez, F; Nochy, D; Pallet, N; Rabant, M; Sberro-Soussan, R; Snanoudj, R; Suberbielle-Boissel, C; Thervet, E; Zuber, J1
Alden, CL; Cardoza, K; Csizmadia, E; Csizmadia, V; Fedyk, ER; Gallacher, M; Kadambi, VJ; O'Brien, L; Raczynski, A; Silverman, L; Simpson, C1
Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S1
Benedetti-Panici, P; Cognetti, F; Greggi, S; Mariani, G; Pasquini, L; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U1
Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R1
Czuczman, MS; Reddy, N1
Hou, J; Jiang, H; Ma, YL1
Kulharya, A; Shah, R; Ustun, C; Yuan, J1
El-Cheikh, J; Harousseau, JL; Mohty, B; Mohty, M; Moreau, P; Yakoub-Agha, I1
Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL1
Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E1
Alloway, RR; Arend, LJ; Brailey, P; Everly, JJ; Govil, A; Mogilishetty, G; Rike, AH; Roy-Chaudhury, P; Walsh, RC; Woodle, ES1
Chang, H; Hsiao, SC; Pei, SN; Wang, MC1
Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M1
Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y1
Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L1
Budinger, GR; Jain, M; Mutlu, GM; Weiss, CH1
Abken, H; Brinkmann, K; Coutelle, O; Hombach, AA; Kashkar, H; Krönke, M; Mauch, C; Schmidt, P; Seeger, JM; Wagner-Stippich, D; Zigrino, P1
Achatz, G; Luger, EO; Radbruch, A; Renz, H; Wegmann, M; Worm, M1
Alé, A; Bruna, J; Monbaliu, J; Navarro, X; Silverman, L; Udina, E; Vilches, JJ; Vynckier, A1
Aoki, K; Eda, H; Kato, S; Marumo, K; Ohkawa, K; Okawa, Y; Takada, K; Tanaka, T1
Chen, JF; Jin, J1
Basak, GW; Bil, J; Bojarczuk, K; Dabrowska-Iwanicka, A; Golab, J; Jakobisiak, M; Nowis, D; Sułek, K; Winiarska, M1
Adachi, S; Ashihara, E; Hatake, K; Hirashima, M; Horiike, S; Kobayashi, T; Kuroda, J; Oomizu, S; Sasaki, N; Takagi, T; Taniwaki, M; Taniyama, A; Terui, Y; Yamamoto, M; Yamauchi, A1
Alfonsi, E; Corso, A; De Amici, M; Lazzarino, M; Lozza, A; Mangiacavalli, S; Varettoni, M1
Buller, B; Chopp, M; Jiang, J; Jiang, Y; Liu, X; Morris, D; Zhang, L; Zhang, ZG; Zhao, D1
Celis, E; Lee, S; Sayers, TJ; Yagita, H1
Richards, T; Weber, D1
Burt Nabors, L; Carson, KA; Desideri, S; Grossman, SA; Lesser, G; Mikkelsen, T; Olson, JJ; Phuphanich, S; Rosenfeld, S; Supko, JG1
Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M1
Blackwell, TS; Kalomenidis, I; Karabela, SP; Kollintza, A; Magkouta, S; Moschos, C; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Theodoropoulou, P1
Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S1
Bocchia, M; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E; Oliva, S1
Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D1
Lu, Q; Lu, SF1
Assereto, S; Bonetto, A; Bonuccelli, G; Bruno, C; Cilli, M; Gazzerro, E; Lisanti, MP; Minetti, C; Pistorio, A; Scarfì, S; Sotgia, F; Zara, F1
Agirre, X; Albero, MP; Andreu, EJ; Franch, L; Ivorra, C; Pérez-Roger, I; Poch, E; Prosper, F; Vaquer, JM; Villanueva, JJ1
Hoevenaren, A; Hoevenaren, IA; Levenga, H; Minnema, MC; Raymakers, R; van Vulpen, LF1
Acharya, M; Burris, H; Chatta, G; Karol, M; Keith Stewart, A; Lonial, S; Mohrbacher, AF; Neuwirth, R; Reece, DE; Riordan, WJ; Shustik, C; Sullivan, D; Venkatakrishnan, K; von Moltke, LL; Zannikos, P1
Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L1
Chitambar, CR; Purpi, DP1
Chen, S; Deng, X; Khuri, FR; Li, C; Lonial, S; Sun, SY; Yue, P1
Chaudhary, R; Ghose, A; Taj, A; Tariq, Z1
Böhmig, GA; Drach, J; Geyeregger, R; Haidinger, M; Kikić, Z; Körmöczi, GF; Prikoszovich, T; Säemann, MD; Wahrmann, M; Weichhart, T1
Aguayo-Leiva, I; Carrillo-Gijon, R; Jaén-Olasolo, P; Vano-Galvan, S1
de Maat, MP; Leebeek, FW; Libourel, EJ; Sonneveld, P; van der Holt, B1
Gunsilius, E; Mitterer, M; Spizzo, G1
Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS1
Brocca, CM; Coppi, MR; Giannotta, A; Loseto, G; Mele, G; Melpignano, A; Pinna, S; Quarta, G1
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Mitsunaga, K; Noborio-Hatano, K; Nobuyoshi, M; Ozawa, K; Shimizu, R; Wada, T1
Ludwig, H; Zojer, N1
Dingli, D; Rajkumar, SV1
Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A1
Balkaran, S; Daudignon, A; Fernandez, J; Hautecoeur, A; Hivert, B; Lai, JL; Leleu, X; Lepelley, P; Morel, P; Poulain, S; Rossignol, J; Roumier, C; Soenen, V; Wemeau, M1
Aomatsu, K; Arao, T; Fujita, Y; Kaneda, H; Kotani, Y; Kudo, K; Matsumoto, K; Nishimura, Y; Nishio, K; Saijo, N; Tamura, D; Tanaka, K; Watanabe, T1
Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H1
Chen, C; Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Treon, SP1
Heider, U; Kaiser, M; Kleeberg, L; Rademacher, J; Sezer, O; von Metzler, I1
Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S1
Jagannath, S; Mazumder, A; Vesole, DH1
Guo, H; Mao, J; Sun, C; Wang, J; Zhou, X1
David, CS; Patel, R; Rajagopalan, G; Theuer, JE; Tilahun, AY1
Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS1
Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE1
Baou, M; Butterworth, M; Cohen, GM; Dinsdale, D; Dyer, MJ; Eldering, E; Kohlhaas, SL; Majid, A; Vogler, M; Walewska, R1
Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H; Suzuki, K1
Anderson, KC; Bandi, M; Bianchi, G; Calabrese, E; Carrasco, RD; Cirstea, D; Ecsedy, J; Görgün, G; Hideshima, T; Hu, Y; Ikeda, H; Mani, M; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Tai, YT; Zheng, M1
He, Q; Lin, M; Luo, P; Shen, J; Wang, Z; Yang, B; Zhu, D1
Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W1
Bambi, F; Barti-Juhasz, H; Bussolari, R; Cafarelli, L; Casali, C; Conte, P; De Santis, G; Dominici, M; Frassoldati, A; Grisendi, G; Horwitz, EM; Morandi, U; Paolucci, P; Petak, I; Rasini, V; Rossi, G; Scarabelli, L; Spano, C; Tagliazzucchi, M; Veronesi, E1
Goldschmidt, H; Ho, AD; Schmitt, S1
Hou, KZ; Liu, J; Liu, YP; Qu, JL; Qu, XJ; Xu, L; Zang, Y1
Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L1
Hatzidaki, E; Karagiannaki, A; Papandreou, CN; Patrikidou, A; Stathakis, NE; Tsapakidis, K; Voutsadakis, IA1
Dasanu, CA2
Benz, CC; Gibson, BW; Held, JM; Marx, C1
Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N1
Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S1
Kirk, AD1
Hara, T; Muroi, E; Ogawa, F; Sato, S; Shimizu, K; Yanaba, K; Yoshizaki, A1
Branch, DR; Chang, H; Jayakar, J; Jiang, H; Reece, D; Saha, MN1
Alexanian, R; Delasalle, K; Giralt, S; Wang, M1
Kumar, S3
Kahl, BS1
Gleason, C; Kaufman, J; Lonial, S1
Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A1
Caron, C; Debliquis, A; Itzhar-Baikian, N; Ojeda-Uribe, M1
Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Casassus, P; Doyen, C; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Leyvraz, S; Maisonneuve, H; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Pégourié, B; Stoppa, AM1
Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK1
Alvarez, M; Chizzolini, C; Goffin, L; Reith, W; Seguin-Estévez, Q1
Bruna, J; Clapés, V; Navarro, X; Petit, J; Velasco, R; Verdú, E1
Brooks, AD; Jacobsen, KM; Li, W; Sayers, TJ; Shanker, A1
Ben Salem, C; Biour, M; Bouraoui, K; Elouni, B; Sakhri, J; Zamy, M1
Kotani, T; Nakao, S; Okumura, H; Sawazaki, A; Takamatsu, H; Yamashita, T1
Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C1
Blank, JL; Burkhardt, AL; Chen, S; Chen, W; Driscoll, DL; Garcia, K; Gray, J; Hales, P; Leroy, PJ; Lightcap, ES; Lingaraj, T; Liu, XJ; Menon, S; Morgenstern, JP; Peters, T; Pickard, MD; Rabino, C; Rappoli, DM; Ringeling, J; Sappal, DS; Spelman, JJ; Yu, J1
Anichini, A; Bolognesi, M; Delia, D; Drago, C; Kashkar, H; Lecis, D; Manzoni, L; Mastrangelo, E; Scolastico, C; Seneci, P; Walczak, H1
Aldana-Masankgay, G; Cho, CH; Fan, D; Lee, CW; Milani, M; Sakamoto, KM; Sung, JJ; Wu, K; Wu, WK; Yu, J1
Daniel, C; Gückel, E; Hugo, C; Meister, S; Starke, C; Stief, A; Vogelbacher, R; Voll, R; Wittmann, S1
Aisa, Y; Iwabuchi, M; Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K1
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D1
Mateos, MV4
Dimopoulos, MA; Jagannath, S; Lonial, S1
Dhanasekaran, DN; Ha, JH; Jayaraman, M; Kim, SG; Kwak, MK; Lee, CH; Lee, S; Nam, CW; Yang, YM1
Cao, X; Cui, Y; Littlejohn, JE; Peddaboina, C; Smythe, WR; Zhang, L1
de Haan, CA; Drijfhout, JW; Kikkert, M; Posthuma, CC; Raaben, M; Rottier, PJ; Snijder, EJ; te Lintelo, EG; Verheije, MH1
de Haan, CA; Grinwis, GC; Raaben, M; Rottier, PJ1
Cavaletti, G; Jakubowiak, AJ1
Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, JM; Zinzani, PL1
Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S1
Adomat, H; Batey, RA; Chen, C; Cloos, J; Franke, NE; Guns, E; Jamal, N; Jansen, G; Kay, LE; Li, X; Li, ZH; Mao, X; Messner, H; Navon, A; Religa, TL; Rose, DR; Schimmer, AD; Sprangers, R; Trudel, S; Verbrugge, SE; Wang, X; Wood, TE; Zhang, Y1
Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL1
Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E1
Colby, TV; Fonseca, R; Khan, ML; Viggiano, RW1
Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH1
Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE1
Buffa, F; Hammond, E; Harris, AL; Mellor, HR; Milani, M; Pike, L; Pires, I; Ragoussis, I; Rzymski, T; Winchester, L1
Burnett, AK; Crooks, PA; Fegan, C; Hewamana, S; Pepper, C; Pratt, G; Walsby, EJ1
Akagi, Y; Fujii, T; Kage, M; Kusukawa, J; Miyagi, M; Sayers, TJ; Seki, N; Shirouzu, K; Toh, U; Yamana, H1
Abramczyk, P; Bil, J; Bugajski, M; Dabrowska-Iwanicka, A; Duszyński, J; Golab, J; Jakóbisiak, M; Kujawa, M; Mackiewicz, U; Maczewski, M; Malinowska, M; Nowis, D; Ratajska, A; Salwa, P; Siński, M; Wieckowski, MR; Wilczyński, GM; Winiarska, M; Wójcik, C1
Armstrong, JL; Birch-Machin, M; Fulda, S; Harbottle, A; Hill, DS; Hiscutt, EL; Kerr, R; Lovat, PE; Martin, S; Redfern, CP1
Everly, MJ; Jahr, F; Kaneku, H; Terasaki, PI; Trivedi, HL1
Everly, MJ2
Abdellatif, A; Achkar, K; Dilioglou, S; Gaber, AO; Jeroudi, A; Knight, R; Land, G; Patel, S; Raghavan, R; Suki, W1
Pavlakis, M1
Everly, MJ; Kittleson, M; Kobashigawa, JA; Patel, JK1
Chen, G; Lin, Z; Liu, S; Xiang, Y; Zhu, L1
Abbadie, O; Blanchol, G; Brouard, S; Cantarovich, D; Cesbron, A; Dantal, J; Giral, M; Gosselin, M; Hourmant, M; Lino, M; Mai, HL; Meurette, A; Soulillou, JP1
Alberú, J; Leyva, S; Marino-Vázquez, LA; Morales-Buenrostro, LE; Reyes-Loaeza, JA; Uribe-Uribe, N; Vega, O1
Dagher, NN; Lonze, BE; Montgomery, RA; Segev, DL; Simpkins, CE; Singer, AL; Zachary, AA1
Al Meshari, K1
Claas, FH; Doxiadis, II; Heidt, S; Mulder, A; Roelen, DL; Vergunst, M1
Haddad, T; Lopez-Cepero, M; Rolfe, M; Weston, M1
Lee, RA; Saidman, SL; Smith, RN; Wong, W; Zorn, E1
Chakkera, HA; Hamawi, K; Heilman, RL; Mazur, MJ; Mekeel, KL; Moss, AA; Mulligan, DC; Reddy, KS1
Böhmig, GA; Drach, J; Geyeregger, R; Haidinger, M; Kikić, Z; Raab, R; Säemann, MD; Wahrmann, M1
Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Sifontis, NM; Silva, P; Swami, A1
Basu, A; Lunz, J; Mapara, M; Morgan, C; Randhawa, P; Shapiro, R; Sharma, V; Tan, HP; Zeevi, A1
Legendre, C; Sberro-Soussan, R; Suberbielle-Boissel, C; Zuber, J1
Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW1
Alloway, R; Brailey, P; Girnita, A; Govil, A; Mogilishetty, G; Roy-Chaudhury, P; Tevar, A; Wall, GE; Walsh, RC; Woodle, ES1
Chan, L; Cooper, JE; Wiseman, AC2
Barth, RN; Cooper, M; Gurk-Turner, C; Hurley, H; KuKuruga, D; Manitpisitkul, W; Philosophe, B; Rasetto, F; Wilson, N1
Gonzalez, ML; Gonzalez-Pinto, IM; Island, ER; Rossique, M; Ruiz, P; Selvaggi, G; Smith, LJ; Solano, JP; Tekin, A; Tryphonopoulos, P; Tsai, HL; Tzakis, AG1
Bartos, C; Berry, J; Chan, KM; Chang, AC; Kamoun, M; Mahidhara, R; Samaniego, M; Stuckey, LJ; Wadhwa, A1
Alloway, RR; Eckman, PM; Kim, Y; Maurer, D; Thorsgard, M; Woodle, ES1
Alford, K; Hardinger, KL; Murillo, D2
Bloom, D; Djamali, A; Lorentzen, D; Mezrich, JD; Miller, KM; Muth, BL; Pirsch, JD; Sollinger, HW; Torrealba, J1
Boothpur, R; Brennan, DC; Torrence, S1
Aull, MJ; Dadhania, D; Hartono, C; Kapur, S; Saal, S1
Aull, MJ; Dadhania, D; Figueiro, J; Hartono, C; Kapur, S; Lubetzky, M; Saal, S1
Budde, K; Lachmann, N; Schönemann, C; Schütz, M; Waiser, J1
Abildgaard, N; Delaissé, JM; Garnero, P; Lund, T; Ormstrup, T; Pedersen, PT; Plesner, T; Søe, K1
Bolick, SC; Desai, S; Dessureault, S; Maurin, M; Smith, MA; Sotomayor, E; Tao, J; Wright, KL1
Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH1
Callandar, N; Dispenzieri, A; Fonseca, R; Greipp, PR; Jacobus, S; Vesole, DH1
Hirai, T; Yamaguchi, Y; Yamamura, M1
Chang, H; Jiang, NN; Qi, X; Reece, D; Trieu, Y; Xu, W1
Barosi, G; Campanelli, R; Facchetti, F; Fisogni, S; Gattoni, E; Goldberg, J; Guglielmelli, P; Hoffman, R; Marchioli, R; Vannucchi, AM1
Fadeel, B; Feng, X; Henter, JI; Nordenskjöld, M; Wang, Y; Yan, J; Zheng, C; Zierath, JR1
Birch-Machin, MA; Hill, DS; Lovat, PE; Martin, S; Paton, AW; Paton, JC; Redfern, CP1
Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Miyazaki, H; Mori, F; Nakashima, T; Ri, M; Shiotsu, Y; Ueda, R1
Bertsch, U; Goldschmidt, H; Schmitt, S1
Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E1
Adam, Z; Büchler, T; Feit, J; Hájek, R; Krejcí, M; Pour, L1
D'Rozario, J; Hanrahan, R; Lueck, C; Terwiel, E1
Hou, SY; Hu, R; Li, YC; Liu, ZG; Yang, W; Yang, Y; Yao, K; Zhang, R1
Jiang, M; Ruan, CG; Xie, LQ; Xue, LX1
Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ1
Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M1
Kurzrock, R; Subbiah, V; Trent, JC1
Brennan, SK; Kowalski, J; Matsui, W; Meade, B; Merchant, AA; Wang, Q1
Chang, I; Chen, X; Guan, J; Han, D; Kim, J; Wang, CY1
Bernstein, SH; Boral, AL; Bryant, B; Fisher, RI; Fleming, MD; Goy, A; McDonald, A; Mulligan, G; Pickard, MD; Shi, H; Trepicchio, W1
Capanu, M; Holen, KD; Ilson, DH; Kelsen, DP; Kemeny, MM; Kindler, HL; Power, DG; Shah, MA; Tang, L; Wright, JJ1
Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y1
Fujieda, A; Ishibashi, M; Iwamoto, T; Katayama, N; Masuya, M; Okuda, M1
Engelhardt, M; Felthaus, J; Follo, M; Hein, M; Ihorst, G; Ngo, BT; Wäsch, R; Wider, D1
Gertz, MA; Tadmor, T1
Gonzalez, E; Joeris, T; Kaufmann, SH; Kühl, AA; Loddenkemper, C; Mollenkopf, H; Schmidt, N; Steinhoff, U; Visekruna, A1
Bostrom, BC; Dubois, S; Eckroth, E; Gaynon, P; Glade-Bender, J; Hutchinson, R; Messinger, Y; Raetz, E; Sposto, R; van der Giessen, J1
Hu, HY; Lu, L; Shen, Y1
Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K1
Dudek, SE; Ludwig, S; Luig, C; Pauli, EK; Schubert, U1
Horak, KM; Huang, W; Li, J; Liang, Q; Molkentin, JD; Su, H; Tang, M; Tian, Z; Wang, X1
Callander, NS; Hematti, P; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Shi, Y; Trivedi, P; Xu, G1
Bornmann, W; Ford, RJ; Li, C; Pham, LV; Priebe, W; Tamayo, AT1
Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Kim, SG; Kim, SH; Lee, GW; Lee, HS; Lee, SM; Seol, YM; Shin, HJ; Song, MK; Yun, EY1
Isayama, R; Mizutani, R; Nakagawa, M; Shiga, K; Shimazaki, C; Tokuda, T1
Bhatt, S; Blasini, W; Cavallin, LE; Gentles, AJ; Lossos, IS; Mesri, EA; Natkunam, Y; Ramos, JC; Sarosiek, KA; Toomey, NL1
Blackman, BA; Brady, MM; Duong, T; Giles, FJ; Green, DP; Keller, C; Kilcoyne, A; McCarthy, SD; Michalek, JE; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Sledz, TJ; Tatiparthi, AK; Zarzabal, LA1
Chen, SJ; Janin, A; Jiang, XX; Leboeuf, C; Shi, WY; Wang, L; Xiao, D; Yang, F; Yao, Y; Zhao, WL1
Albitar, M; Anderson, KC; Badros, AZ; Berman, D; Jagannath, S; Messina, M; Richardson, PG; Tarantolo, S; Wolf, JL1
Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T1
Chang, I; Chen, Z; Kang, M; Song, J; Wang, CY1
Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H1
Barrett, C; Blackburn, C; Blank, JL; Bruzzese, FJ; Bump, N; Dick, LR; Fleming, P; Garcia, K; Gigstad, KM; Hales, P; Jones, M; Liu, JX; Olhava, EJ; Sappal, DS; Sintchak, MD; Soucy, TA; Tsu, C1
Fielding, K; Neeson, P; Quach, H; Ritchie, DS1
Dagher, NN; Locke, JE; Lonze, BE; Montgomery, RA; Segev, DL; Simpkins, CE; Singer, AL; Zachary, AA1
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M1
Atadja, P; Balusu, R; Bhalla, KN; Buckley, KM; Coothankandaswamy, V; Fiskus, W; Ha, K; Joshi, A; Nalluri, S; Rao, R; Savoie, A; Sotomayor, E; Tao, J1
Chen, J; Chopp, M; Jiang, H; Mahmood, A; Ning, R; Qu, C; Xiong, Y; Zhang, L1
Cai, Z; Chung, V; Guan, M; Huang, H; Yen, Y; Zheng, W; Zhu, L1
Badowska, W; Czyzewski, K; Juraszewska, E; Konatkowska, B; Kuzmicz, M; Malinowska, I; Olejnik, I; Pogorzala, M; Sobol, G; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanek, J; Szczepanski, T; Wysocki, M1
Frey, B; Gaipl, US; Lang, VR; Meister, S; Schett, G; Schlötzer-Schrehardt, U; Voll, RE1
Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Poon, T; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E; Xie, W1
Ajchenbaum-Cymbalista, F; Baran-Marszak, F; Boukhiar, M; Fagard, R; Gressin, R; Harel, S; Laguillier, C; Ledoux, D; Martin, A; Roger, C; Varin-Blank, N1
Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM1
Abdul-Jaleel, M; Candelaria-Quintana, D; Libby, E; Moualla, H; Rabinowitz, I1
Adamo, L; Amato, G; Anastasi, G; Colarossi, C; Conticello, C; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gorgone, A; Gulisano, M; Iannolo, G; Martinetti, D; Romano, A; Salomone, E1
Cos Arregui, E; González Asanza, C; Huerta Madrigal, A; Menchén Fernández-Pacheco, P; Merino Rodriguez, B; Nogales Rincón, O1
Boozari, B; Gürlevik, E; Kloos, A; Knocke, S; Kubicka, S; Kühnel, F; Manns, MP; Mundt, B; Schache, P; Strüver, N; Wirth, TC; Woller, N1
Burbury, K; Harrison, SJ; Joyce, T; Peinert, S; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M1
Wright, JJ1
Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T1
Mele, G; Melpignano, A; Pinna, S; Quarta, G1
Belanger, E; Benavides, A; Cappia, S; Frost, P; Gera, J; Guglielmelli, T; Hoang, B; Lichtenstein, A; Pezeshkpour, G; Shi, Y1
Elia, JR; Hirsch, ML; Kafri, T; Kantor, B; Lothrop, CD; Monahan, PE; Samulski, RJ; Sarkar, R; Sun, J; Tillson, DM1
Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T1
Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K1
Du, Z; Fan, M; Gu, W; Jiao, Y; Kim, JG; Nosrat, CA; Pavicevic, Z; Pfeffer, LM; Rao, SK; Rosebush, M; Samant, S1
Cho, YJ; Chung, EJ; Jung, SA; Kim, SW; Lee, JH; Moon, SW1
Bhende, PM; Damania, B; Dittmer, DP; Lim, MS; Park, SI1
Cho, SH; Jones, DR; Lee, JK; Liu, Y; Nagji, AS1
Aggarwal, BB; Kannappan, R; Yadav, VR1
Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC1
Anagnostopoulos, A; Athanasiou, E; Bougiouklis, D; Kaloyannidis, P; Palladas, P; Papadopoulou, A; Paraskeva, A; Yannaki, E; Yiangou, M1
Huang, HB; Wu, SQ; Zhan, R1
Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, F; Li, HH; Wang, FF; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY1
Carbone, A; Gloghini, A; Spina, M; Tirelli, U1
Chen, KF; Chen, PJ; Cheng, AL; Hou, DR; Lin, YC; Liu, CY; Liu, TH; Yu, HC1
Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP2
Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB1
Flowers, CR; Harvey, RD; Heffner, LT; Kaufman, J; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; McMillan, S; Nooka, A; Renfroe, H; Tighiouart, M; Torre, C; Waller, EK1
Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E1
Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K1
Vokurka, S1
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D1
Ackerman, E; Berenson, JR; Eades, B; Mapes, R; Swift, RA; Waterman, GN; Yellin, O1
Cavalli, F; Conconi, A; Devizzi, L; Ferreri, AJM; Lopez-Guillermo, A; Luminari, S; Martinelli, G; Rigacci, L; Vitolo, U; Zinzani, PL; Zucca, E1
Liang, Y; Seymour, RE; Sundberg, JP1
Coyne, PJ; Dodson, P; Parker, GL; Ramakrishnan, V; Smith, TJ1
Chen, Z; Ge, F; Jia, H; Li, L; Lu, C; Lu, X; Zeng, H1
He, Q; He, Y; Tan, D; Zhao, X1
Drach, J; Lamm, W; Lang, A; Ludwig, H; Müldür, E; Schauer-Stalzer, B; Willenbacher, W; Zielinski, CC; Zojer, N1
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Casassus, P; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Maisonneuve, H; Maloisel, F; Marit, G; Mathiot, C; Michallet, M; Mohty, M; Moreau, P; Petillon, MO; Webb, I1
Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G1
Adam, Z; Autzinger, EM; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Keil, F; Lang, A; Ludwig, H; Thaler, J; Tóthová, E; Womastek, I; Zojer, N1
Choi, I; Hata, H; Higuchi, M; Masaki, Y; Nagafuji, K; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K1
Berno, T; Briani, C; Campagnolo, M; Zambello, R1
Bocchia, M; Crupi, R; Defina, M; Gozzetti, A1
Abramowicz, D; Lemy, A; Toungouz, M1
Jang, SY; Jung, J; Lee, HK; Park, HT; Seo, SY; Shin, YK; Suh, DJ1
Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B1
Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X1
Boyer, M; Erlichman, C; Holen, K; Kim, GP; Mahoney, MR; Marshke, R; Mok, TS; Nowak, A; Philip, PA; Picus, J; Pitot, HC; Rubin, J; Szydlo, D; Wright, JJ1
Cohen, LJ; Humphreys, BD; Laubach, JP; Rennke, HG1
Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS1
Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C1
Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J1
Jin, L; Kojima, K; Konopleva, M; Miida, T; Pittaluga, S; Raffeld, M; Tabe, Y; Zhou, Y1
Bui, TN; Efuet, ET; Keyomarsi, K1
Golenkov, AK; Kataeva, EV; Klinushkina, EF; Lutskaia, TD; Mitina, TA; Trifonova, EV1
Bartczak, A; Chen, L; Edwards, A; Khattar, R; Levy, G; Liu, MF; Ma, XZ; McGilvray, ID; Zhang, J1
Bertsch, U; Broyl, A; Corthals, SL; de Knegt, Y; Durie, BG; el Jarari, L; Goldschmidt, H; Jongen, JL; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M1
Adini, I; Bischoff, J; Boscolo, E; Greenberger, S; Mulliken, JB1
Beysel, S; Yağci, M; Yeğın, ZA1
Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL1
Rummel, M1
Cheng, B; Cheung, YK; Lee, SM1
Besterman, J; Brady, H; Buglio, D; Heise, C; Khaskhely, NM; MacBeth, K; Mamidipudi, V; Martell, RE; Younes, A1
Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S1
Li, F; Rajendran, P; Sethi, G1
Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T1
Mey, UJ1
Carrier, L1
Adami, F; Cabrelle, A; Colpo, A; Gnoato, M; Gurrieri, C; Manni, S; Montini, B; Pavan, L; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Zambello, R1
Böhm, C; Jäck, HM; Lang, VR; Meister, S; Mielenz, D; Neubert, K; Schett, G; Voll, RE1
Akaogi, T; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Koshida, M; Kuroda, J; Matsumoto, Y; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Tanaka, T; Taniwaki, M; Uchiyama, H; Ueda, S; Ueda, Y; Uoshima, N1
Kolesar, JM; Pomplun, ML; Vanderloo, JP; Vermeulen, LC1
Bi, LJ; Ge, F; He, QY; Jia, HT; Li, LP; Lu, CH; Tao, SC; Xiao, CL; Xiong, S; Yin, XF1
Hagedorna-Tronina, R; Kraj, M; Kruk, B; Pogłód, R; Warzocha, K; Łetowska, M1
Ding, N; Harrison, SJ; Howman, R; Khot, A; Pitman, M; Thakerer, A; Thompson, PA1
Bangia, N; Belicha-Villanueva, A; Blickwedehl, J; Clements, JL; Czuczman, MS; Gibbs, J; Hernandez-Ilizaliturri, FJ; Mavis, C; Olejniczak, SH; Riaz, W1
Tsukamoto, S1
Cao, TM; Li, G; Liu, Y; Salama, M; Shi, L; Tricot, G; Wang, S; Wu, Y; Xiao, F; Xu, C; Xu, H; Yang, Y; Zangari, M; Zhan, F1
Cohen, N; Klein, S; Kravchenko-Balasha, N; Levitzki, A; Mizrachy-Schwartz, S1
Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P1
Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D1
Gong, Y; Liu, T; Meng, W; Xing, H1
Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H1
Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA1
Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH1
Connolly, G1
Cavallo, F; Esseltine, D; Gruenwald, JM; Kern, S; Kumar, NS; Pappas, L; Ranganathan, S; Suva, LJ; Tricot, G; Yaccoby, S; Zangari, M; Zhan, F1
Bendall, LJ; Bradstock, KF; Cisterne, A; Saunders, P; Weiss, J1
Giubellino, A; Linehan, WM; Neckers, L; Sourbier, C; Sudarshan, S; Valera-Romero, V; Yang, Y1
Fukunaga, K; Saeki, Y; Tanaka, K1
Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P1
Chapman, CM; Dunleavy, KM; Liu, P; Maric, I; Mo, CC; Mora-Jensen, H; Pérez-Galán, P; Pittaluga, S; Rader, C; Raghavachari, N; Rizzatti, EG; Shaffer, AL; Staudt, LM; Stennett, LS; Stetler-Stevenson, M; Weniger, MA; Wiestner, A; Wilson, WH; Yuan, C1
Fujita, H; Fukui, R; Hirai, M; Kadowaki, N; Kamihira, S; Kitawaki, T; Maeda, T; Miyachi, Y; Miyake, K; Takaori-Kondo, A; Uchiyama, T1
Chosa, M; Nagase, K; Tobinai, K; Watanabe, T1
He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J1
Palumbo, A2
Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G1
Hao, H; Hasegawa, S; Hirota, S; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H; Taniguchi, Y1
Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K1
Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M1
Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X1
Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Wang, W; Weng, DH; Xing, H1
Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S1
Bardag-Gorce, F; French, BA; French, SW; Li, J; Lin, A; Oliva, J1
Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C1
Everly, MJ; Hopfield, J; Kaneku, H; Terasaki, PI; Trivedi, HL1
Askar, M; Banning, S; Chiesa-Vottero, A; Fatica, R; Flechner, SM; Koo, A; Poggio, E; Srinivas, T; Stephany, BR1
Resmi, H1
Auwerda, JJ; Bertina, RM; de Maat, MP; Leebeek, FW; Osanto, S; Sonneveld, P; Yuana, Y1
Lei, M; Li, Y; Ma, Y; Shao, F; Wu, G; Yang, J; Yu, S; Yuan, Y; Zhao, X; Zhu, X; Zhu, Y1
Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A1
Bouley, DM; Denko, NC; Koong, AC; Lust, S; Niwa, M; Offner, F; Olson, M; Papandreou, I; Solow-Cordero, DE; Tam, A; Van Melckebeke, H1
Liedtke, M; Medeiros, BC1
Freiberg, AN; Holbrook, MR; Lake, M; Lee, B; Park, A; Pentecost, M; Torres, B; Wang, YE; Wolf, MC; Yun, TE1
Anderson, K; Laubach, J; Richardson, P1
Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R1
Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY1
Aaron, KJ; Basnayake, K; Sanders, PW; Wang, PX; Ying, WZ1
Campo, E; Colomer, D; López-Guerra, M; Mozos, A; Normant, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S1
Sargent, DJ1
Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K1
Ahn, KS; Jang, HJ; Kim, HJ; Kim, SH; Kim, SM; Na, YS; Park, KR1
Khosroshahi, A; Stone, JH1
Morgan, G2
Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN1
Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Shu, MM; Wang, YW; Yang, Y; Zhu, HF1
Bai, QX; Fan, LN; Huang, GS; Wang, L; Yang, LJ; Yue, P; Zhang, XY; Zhao, H; Zhu, J1
Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP1
Andreeff, M; Asou, H; Inaba, T; Jin, L; Kimura, S; Konopleva, M; Kuroda, J; Miida, T; Tabe, Y; Zhou, Y1
Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E1
Bernard, PS; Carey, LA; Chiu, WK; Collichio, FA; Dees, EC; Irvin, WJ; Ivanova, A; Orlowski, RZ; Perou, C; Stijleman, IJ1
Fukuhara, N; Harigae, H; Ichinohasama, R; Ishizawa, K; Ohba, R; Ohguchi, H; Okitsu, Y; Onishi, Y; Yamamoto, J1
Jeon, SH; Kim, DH; Kwan, J; Lee, WS; Park, KS; Park, SD; Shin, SH; Woo, SI; Yi, HG1
Gerlach, UA; Koch, M; Lachmann, N; Pascher, A; Schoenemann, C1
Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T1
Chen, WM; Yang, GZ1
Hanzawa, K; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Tokuhira, M; Tomikawa, T; Watanabe, R1
Chastagner, P; Labussière, M; Pinel, S; Plénat, F; Vandamme, M1
Fujiwara, S; Gotoh, K; Isobe, Y; Ito, Y; Iwata, S; Kawada, J; Kimura, H; Nishiyama, Y; Sugimoto, K; Ushijima, Y; Yano, S1
Ahn, KS; Chen, CY; Han, I; Jeong, SJ; Jung, JH; Kang, M; Kim, DK; Kim, SH; Kwon, TR; Lee, JW; Lee, SG; Yun, SM1
Aries, PM; Fröhlich, K; Gross, WL; Holle, JU; Moosig, F1
Che, XF; Itoh, M; Kawaguchi, T; Miyazawa, K; Moriya, S; Naito, M; Ohtomo, T; Tomoda, A1
Einsele, H; Knop, S; Kortüm, M1
Arai, J; Emi, N; Hasegawa, M; Hiki, Y; Ishii, J; Kato, M; Kondo, F; Murakami, K; Nabeshima, K; Nakai, S; Ohashi, A; Sugiyama, S; Tomita, M; Yamamoto, K; Yuzawa, Y1
Fu, BB; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yao, K; Zhang, R1
Chen, LJ; Li, CM; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W1
Laubach, J; Richardson, P1
Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M1
Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM1
Farquhar-Smith, P1
Li, QF; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF; Zhang, K1
Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P1
Blake, J; Brandner, S; D'Sa, S; Elliott, KJ; Lunn, MP; Rabin, N; Reilly, MM; Saifee, TA; Yong, KL1
Bowles, KM; MacEwan, DJ; Rushworth, SA1
Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T1
Ebert, B; Kisiela, M; Maser, E; Wsól, V1
Jane, EP; Pollack, IF; Premkumar, DR1
Anderson, KC; Buon, L; Delmore, J; Hayden, P; Jacobs, HM; Jakubikova, J; Laubach, J; Lengauer, C; McMillin, DW; Mitsiades, CS; Munshi, NC; Negri, J; Ooi, M; Richardson, PG; Schlossman, R1
Celiker, MY; Chang, TP; Ghosh, CC; Juvekar, A; Manna, S; Ramaswami, S; Vancurova, I; Vu, HY1
Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW1
Du, J; Fu, W; Hou, J; Huo, J; Jiang, H; Shi, J; Yi, Q; Yuan, Z; Zhang, C1
Broderick, E; Favis, R; Harousseau, JL; Levey, L; Meyers, M; Mulligan, G; Ricci, DS; Richardson, PG; Sun, Y; van de Velde, H1
Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S1
Bontscho, J; Kettritz, R; Luft, FC; Manz, RA; Schneider, W; Schreiber, A1
Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F1
De Baets, MH; Duimel, H; Gomez, AM; Losen, M; Manz, RA; Martínez-Martínez, P; Molenaar, PC; Phernambucq, M; van der Esch, E; Verheyen, F; Voll, RE; Vrolix, K1
Borrello, I; Ferguson, A; Ghosh, N; Huff, CA; Ye, X1
Boise, LH; Lonial, S2
Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M1
Chen, D; Dou, QP; Frezza, M; Kanwar, J; Schmitt, S1
Annunziata, CM; Burris, J; Driscoll, JJ1
André, S; Bayry, J; Delignat, S; Dimitrov, JD; Kaveri, SV; Lacroix-Desmazes, S; Meslier, Y1
Candoni, A; De Muro, M; De Stefano, V; Ferrara, F; Fianchi, L; Galieni, P; Gozzetti, A; Leone, G; Musto, P; Pagano, L; Petrucci, MT; Pogliani, EM; Pulsoni, A; Specchia, G; Valentini, CG; Venditti, A; Visani, G; Visco, C1
Arnulf, B; Asli, B; Belhadj, K; Bories, JC; Bouscary, D; Brouet, JC; Chandesris, O; Choquet, S; Fermand, JP; Ghez, D; Hermine, O; Karlin, L; Macro, M; Malphettes, M; Porcher, R; Soulier, J1
Chang, TC; Ko, BS; Liou, JY1
Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP1
Danchaivijitr, P; Rapoport, AP; Yared, J1
Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ1
Fujita, J; Kanakura, Y; Kang, S; Mizuki, M; Otsuka, M1
Ashcroft, J; Cavenagh, J; Cavet, J; Conn, J; Cook, G; Cook, M; Drake, M; Kazmi, M; Kettle, P; Marshall, S; Morris, C; Oakervee, H; Olujohungbe, A; Popat, R; Quinn, M; Snowden, J; Streetly, M; Tighe, J1
Ashcroft, J; Cook, G; Cromack, J; Feyler, S; Owen, R; Parrish, C1
Cavaletti, G1
Chen, ST; Dewar, R; Khosravi-Far, R; Miller, K; Yeckes-Rodin, H1
Burns, JM; Diwan, TS; Gloor, JM; Kremers, WK; Raghavaiah, S; Stegall, MD1
Braggio, E; Bruins, LA; Keats, JJ; Mousses, S; Schmidt, JE; Sereduk, C; Shi, CX; Stewart, AK; Tiedemann, R; Yin, H; Zhu, YX1
Borsini, W; Di Stasi, V; Donadio, V; Giannoccaro, MP; Gomis Pèrez, C; Liguori, R1
Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z1
Duensing, A; Duensing, S1
Co, JP; Dosani, I; Lucas, JG; Nwaogwugwu, UT; Sureshkumar, KK1
Cleary, MA; Laver, T; McMahon, S; Mellert, H; Schelter, JM; Sotillo, E; Thomas-Tikhonenko, A1
Gong, YP; Yang, X; Zheng, BH; Zhou, RQ1
Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ1
Ando, K; Kojima, M; Moriuchi, M; Nakamura, N; Ogawa, Y; Ohmachi, K; Tsuboi, K1
Amiot, M; Boccadoro, M; Cavallo, F; Descamps, G; Facon, T; Harousseau, JL; Hulin, C; Leleu, X; Mignard, D; Moreau, P1
Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C1
Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL1
Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W1
Dokos, C; Hatzitolios, A; Kaiafa, G; Savopoulos, C1
Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P1
Chan, KM; Chen, TC; Lee, CF; Lee, CS; Lee, WC; Wu, TJ1
Lacy, MQ; Tefferi, A1
Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ1
Baldisserotto, A; Destro, F; Gallerani, E; Gavioli, R; Marastoni, M; Marescotti, D; Sforza, F; Sicurella, M1
Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S1
Ahn, KS; Chen, CY; Jeong, SJ; Jung, JH; Kim, SH; Kim, SY; Kwon, TR; Lee, JC; Rhee, YH; Yoon, HJ; Zhu, S1
Chen, T; Fang, Y; Hu, Y; Jiang, X; Ma, D; Ma, Q; Meng, L; Tian, Y; Wang, B; Wang, S; Wu, P; Xia, X; Xu, G; Zhang, Q; Zhou, J1
Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E1
Du, ZX; Gao, YY; Liu, BQ; Meng, X; Niu, XF; Wang, HQ; Yan, Y; Zhang, HY1
Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z1
Bota, DA; Gong, X; Linskey, ME; Schwartz, PH1
Barbetti, V; Dello Sbarba, P; Giuntoli, S; Rovida, E; Tanturli, M1
Mateos, MV; San-Miguel, J1
Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Nexø, BA; Vangsted, AJ; Vogel, U1
Schots, R1
Li, J; Wu, XM; Zhang, DY1
Aujay, M; Azab, AK; Azab, F; Ghobrial, IM; Issa, GC; Liu, Y; Maiso, P; Morgan, B; Ngo, HT; Quang, P; Roccaro, AM; Sacco, A; Zhang, Y1
Amm, HM; Buchsbaum, DJ; Kuo, H; Li, Y; Steg, AD; Zhou, T1
Claxton, DF1
Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC1
Baum, W; Distler, JH; Frey, B; Gückel, E; Meister, S; Neubert, K; Polzer, K; Schett, G; Voll, RE; Zwerina, J1
Chen, XY; Jin, J; Li, WP; Rao, SM; Yan, FZ; Yan, JS; Yang, Y; Zhao, J1
Anderl, JL; Arastu-Kapur, S; Ball, AJ; Bennett, MK; Driessen, C; Kirk, CJ; Kraus, M; Lee, SJ; Muchamuel, T; Parlati, F; Shenk, KD1
Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H1
Fujisaki, T; Kan, S; Murakami, H; Muta, T; Nakanishi, H; Senba, S; Ueda, Y; Yasunaga, M1
Nishi, S1
Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A1
Anderson, K; Cakana, A; Deraedt, W; Dimopoulos, M; Esseltine, DL; Hou, J; Khuageva, N; Kropff, M; Liu, K; Mateos, MV; Petrucci, MT; Richardson, P; Robak, T; Rossiev, V; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H; Vekemans, MC1
Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L1
Adam, Z; Buchler, T; Gregora, E; Hajek, R; Krejci, M; Krivanova, A; Mayer, J; Minarik, J; Pour, L; Scudla, V; Straub, J; Zahradova, L1
Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I1
Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K1
Fang, Y; Tao, Y; Wang, J; Wang, L; Yang, D; Zhang, W; Zhou, H1
Chen, HJ; Chen, KF; Chen, PJ; Chen, YC; Cheng, AL; Hou, DR; Liu, CY; Yu, HC1
Bosi, A; Maratea, D; Messori, A; Nozzoli, C1
Bannerman, B; Berger, A; Bolen, J; Claiborne, C; Dick, L; Fleming, P; Hales, P; Jones, M; Kupperman, E; Manfredi, M; Monbaliu, J; Tsu, C; Xu, L; Yu, J1
Haga, M; Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N1
Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y1
Attal, M; Palumbo, A; Roussel, M1
Lonial, S; Mitsiades, CS; Richardson, PG1
Cheung, YK; Lee, SM1
Bagshaw, M; Banwait, R; Ghobrial, IM; Leduc, R; Leleu, X; Roper, N; Weller, E; Xie, W1
Cahu, X; Dauriac, C; Houot, R; Lamy, T; Marchand, T; Tas, P1
Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Wang, HT; Wu, B; Yang, W; Yao, K; Zhang, R1
Fu, K; Hao, XS; Ma, YL; Qian, ZZ; Wang, HQ1
Akimoto, T; Hamano, Y; Hanawa, S; Imai, T; Inoue, M; Kotoda, A; Kusano, E; Matsuyama, T; Muto, S; Ozawa, K; Saito, O; Ueda, M; Uehara, E; Yoshizawa, H; Yumura, W1
Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A1
Rule, S1
Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR1
Brodie, C; Brodie, S; Cazacu, S; Finniss, S; Goldstein, RS; Kahana, S; Lee, HK; Mikkelsen, T; Roitman, V; Slavin, S; Xiang, C1
Anand, M; Armanious, H; Belch, A; Gelebart, P; Lai, R1
Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M1
Antoch, G; Buchbender, C; Nawatny, J1
Gudkov, AV; Komarov, AP; Neznanov, N; Neznanova, L; Stanhope-Baker, P1
Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A1
Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J1
Ambinder, RF; Chen, J; Hayward, SD; Li, H; Shamay, M; Shirley, CM; Zahnow, CA1
Dreyling, M1
Dou, QP; Frezza, M; Yang, H1
Ding, T; Huang, J; Jin, J; Liu, H; Sun, X; Yang, M1
Bladé, J; Hajek, R; Harousseau, JL; Lantz, KC; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH1
Foli, A; Lavatelli, F; Merlini, G; Milani, P; Obici, L; Palladini, G; Russo, P1
Ciccarelli, B; Fulciniti, M; Gong, P; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Liu, X; Maghsoudi, K; Munshi, NC; O'Connor, OA; Patterson, CJ; Sheehy, P; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B1
Chen, J; Chen, L; Cheng, Q; Cross, B; Li, B; Yuan, ZM1
Correia, C; Dai, H; Kaufmann, SH; Lee, SH; Schmitz, I; Smith, AJ; Takahashi, R1
Delgado, ME; Devocelle, M; Düssmann, H; Laussmann, MA; Passante, E; Prehn, JH; Rauen, JA; Rehm, M; Würstle, ML1
Byrn, SR; Milton, MJ; Tishmack, PA; van de Velde, H1
Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B1
Debatin, KM; Fulda, S; Kappler, R; Naumann, I; von Schweinitz, D1
Dekhuijzen, R; Ennen, L; Heunks, L; Linkels, M; Ottenheijm, C; van Hees, H1
Alvarez Fernández, GM; de Alarcón Jiménez, RM; García Hernández, MA; Jimeno Griñó, C; Molina Núñez, M; Navarro Parreño, MJ; Roca Meroño, S; Zarco Pedrinaci, E1
Farrell, K; Soutar, R; Stobo, DB1
Bergsagel, PL; Chesi, M; Chng, WJ; Chung, TH; Fonseca, R; Gonzalez-Paz, N; Huang, GF; Mulligan, G; Ng, SB; Troska-Price, T1
Hayashi, T; Ikeda, H; Imai, K; Ishida, T; Kawakami, K; Kobayashi, T; Nishimura, S; Shinomura, Y; Takahashi, F; Yasui, H1
Azab, AK; Bahlis, NJ; Boise, LH; Brentnall, M; Duggan, P; Ghobrial, IM; Gratton, K; Klimowicz, AC; Lin, C; Mansoor, A; Neri, P; Ren, L; Stewart, DA; Tassone, P1
Aujay, M; Bahlis, N; Belch, A; Berno, T; Hetherington, KL; Jagannath, S; Jakubowiak, A; Keith Stewart, A; Kukreti, V; Lonial, S; Orlowski, RZ; Siegel, D; Singhal, S; Somlo, G; Tricot, G; Trudel, S; Vij, R; Wang, L; Zangari, M; Zhan, F1
Davies, A; Egorin, MJ; Hamilton, A; Ivy, SP; Leal, TB; Lenz, HJ; LoRusso, PA; Mani, S; Mier, J; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Remick, SC; Sarantopoulos, J; Shibata, S; Takimoto, CH; Venkatakrishnan, K; von Moltke, L; Wright, JJ1
Gharwan, H; Truica, CI1
Chott, A; Drach, J; Hoffmann, M; Kaufmann, H; Lamm, W; Raderer, M; Zielinski, C1
Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB1
Deckard, LA; Logsdon, NJ; Sontheimer, H; Spiller, SE1
Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G1
Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF1
Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C1
Moore, H; Romeril, K1
Arnulf, B; Cavet, J; Deraedt, W; Esseltine, DL; Feng, H; Girgis, S; Grishunina, M; Grosicki, S; Harousseau, JL; Karamanesht, I; Kropff, M; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, T; Shubina, A; van de Velde, H1
Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ1
Kyle, RA; Steensma, DP1
Boyd, KD; Davies, FE; Morgan, GJ1
Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M1
Goldschmidt, H; Moehler, T1
Gahrton, G1
Benevolo, G; Boccadoro, M; Botto, B; Evangelista, A; Frairia, C; Gay, F; Gentile, M; Larocca, A; Morabito, F; Palumbo, A; Pregno, P; Vitolo, U1
Abduljabbar, A; Abubaker, J; Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Alhomoud, S; Ashari, LH; Bavi, P; Bu, R; Hussain, AR; Jehan, Z; Prabhakaran, S; Sultana, M; Uddin, S1
Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G1
Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A1
Chen, XW; Xia, HL; Xia, RX2
Everly, JJ; Everly, MJ; Terasaki, PI1
Cristofanon, S; Debatin, KM; Fulda, S; Karpel-Massler, G; Nonnenmacher, L; Unterkircher, T; Vellanki, SH; Wirtz, CR1
Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T1
Bearden, J; Butler, W; Chen, CS; Garrett-Mayer, E; Golshayan, A; Kraft, AS; Lilly, M; Wahlquist, AE1
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P1
An, G; Chang, H; Han, Y; Hao, M; Li, C; Meng, H; Qiu, L; Xie, Z; Xu, Y; Yu, Z; Zhang, L1
Albitar, M; Alsina, M; Anderson, KC; Berman, D; Carroll, MP; Chanan-Khan, AA; Krishnan, AY; Lonial, S; Messina, M; Richardson, PG1
Chen, SM; Cui, XY; Han, XF; Ling, Z; Shao, M; Sun, L; Wang, F; Zhang, H1
Kupisiewicz, K1
Meerang, M; Ramadan, K1
Cheung, YK; Hershman, DL; Lee, SM; Leonard, JP; Martin, P1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Goh, YT; Han, ST; Hwang, WY; Linn, YC; Mya, DH; Tan, DC1
Fingerle-Rowson, G; Goldschmidt, H; Ho, AD; Neben, K; Pham, M; Schmitt, S; Storch-Hagenlocher, B1
Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M1
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Liu, K; Merlini, G; Palladini, G; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA1
Khan, ML; Stewart, AK1
An, G; Deng, SH; Li, CW; Li, Q; Liu, XP; Qi, JY; Qiu, LG; Wang, YF; Xu, Y; Zhao, YZ; Zou, DH1
Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH1
Chen, C; Hou, M; Zhao, CL1
Fink, L; Tricot, G; Zangari, M; Zhan, F1
Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM1
Bahram, S; Béné, MC; Davi, F; Gribben, JG; Herbrecht, R; Jacob, F; Leblond, V; Merle-Béral, H; Nadaud, S; Perrot, A; Pionneau, C; Vallat, L1
Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M1
Britton, M; Downey, SL; Filippov, DV; Florea, BI; Kisselev, AF; Mirabella, AC; Overkleeft, HS; Pletnev, AA; Shabaneh, TB; Verdoes, M1
Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T1
Djamali, A; Kim, J; Lorentzen, D; Mohamed, MA1
Czyz, M; Duechler, M; Wilczynski, J1
Sayers, TJ1
Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hanamura, I; Heuck, CJ; Nair, B; Qu, P; Shaughnessy, JD; Stephens, O; Tian, E; Usmani, S; van Rhee, F; Waheed, S; Williams, R; Zhang, Q; Zhou, Y1
Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE1
Brunson, CY; Costa, LJ; Milligan, L; Rivell, GL; Stuart, RK1
Bardag-Gorce, F1
Davare, MA; Hosoyama, T; Keller, C; Nelon, LD; Ohshima-Hosoyama, S1
Sherman, MY1
Coudert, L; Filion, C; Fournier, MJ; Gareau, C; Labelle, Y; Martel, D; Mazroui, R1
Andersson, BS; Champlin, RE; Decker, WK; Giralt, SA; Gocke, CD; Jones, RB; Jones, RJ; Lu, J; McMannis, JD; Ng, J; Nieto, Y; Parmar, S; Robinson, SN; Shah, N; Shpall, EJ; Steiner, D; Thomas, MW; Xing, D; Yang, H1
Graw, J; Lee, M; Pellegata, NS; Roncaroli, F; Theodoropoulou, M; Zatelli, MC1
Ciccarelli, B; Fulciniti, M; Gong, P; Hunter, Z; Liu, X; Maghsoudi, K; Munshi, NC; Patterson, CJ; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B1
Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T1
Blanco, B; Caballero-Velázquez, T; Inogés, S; Pérez-Simón, JA; Sánchez-Abarca, LI; Santamaría, C1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W1
Burnette, BL; Leung, N; Rajkumar, SV1
Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E1
Bagshaw, M; Banwait, R; Campigotto, F; Ghobrial, IM; Harris, B; Leduc, R; Leleu, X; O'Regan, K; Ramaiya, N; Weller, E; Yarar, D1
Curtit, E; Mansi, L; Viel, E; Vignot, S1
Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S1
Ishak, J; Rodrigues, F1
Alexanian, R; Delasalle, K; Fu, W; Hou, J; Song, S; Wang, J; Wang, M1
Alberú, J; Leyva, S; Marino-Vázquez, LA; Morales-Buenrostro, LE1
Al Meshari, K; Altalhi, M; Alzayer, F; Elgamal, H; Pall, A1
Böhmig, GA; Haidbauer, B; Regele, H; Schmidt, A; Schwaiger, E; Wahrmann, M; Werzowa, J1
Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Rao, S; Sifontis, NM; Silva, P1
Basu, A; Humar, A; Lunz, J; Mapara, M; Randhawa, P; Shapiro, R; Sharma, V; Tan, HP; Zeevi, A1
Legendre, C; Sberro-Soussan, R; Suberbielle-Boissel, C; Zuberl, J1
Auli, MJ; Dadhania, D; Hartono, C; Kapur, S; Leeser, D; Lubetzky, M; Walker, J1
Alberú, J; Leyva, S; Marino, LA; Morales-Buenrostro, LE1
Cooper, M; Drachenberg, C; Haririan, A; Kukuruga, D; Manitpisitkul, W; Nogueira, J; Philosophe, B; Wilson, NS1
Dytfeld, D; Friedman, J; Griffith, KA; Harvey, C; Jakubowiak, AJ; Kaminski, MS; Lebovic, D1
Boyette-Davis, JA; Cata, JP; Dougherty, PM; Driver, LC; Kennedy, WR; Wendelschafer-Crabb, G; Zhang, H1
Dunleavy, K; Liu, D; Munson, PJ; Pérez-Galán, P; Raghavachari, N; Rizzatti, EG; Tweito, MM; Wang, Q; Weniger, MA; White, T; Wiestner, A; Wilson, WH; Ye, Y1
Belani, CP; Davies, AM; Edelman, MJ; Gandara, DR; Gitlitz, B; Lara, PN; Longmate, J; Ramalingam, SS; Reckamp, K; Salgia, R; Villalona-Calero, M; Vokes, EE; Wright, JJ1
Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L1
Ju, S; Li, C; Wang, H; Wang, X; Wang, Y; Zhong, R1
Colado, E; de Queiroz Crusoe, E; Delgado, M; Fernandez-Lazaro, D; Garayoa, M; Garcia-Gomez, A; Gutierrez, NC; Lee, FY; Maiso, P; Martin-Sanchez, J; Ocio, EM; San-Segundo, L1
Tomás, JF1
Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Enny, C; Esseltine, DL; Hong, X; Mayer, J; Offner, F; Osmanov, EA; Rule, S; Scheliga, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Walewski, J; Zhu, E; Zinzani, PL1
Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B1
Fan, Y; Fu, BB; Hao, LC; Liao, AJ; Liu, ZG1
Bai, QX; Chen, JJ; Huang, GS; Yang, LJ; Zhang, XY; Zhao, H1
Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Wang, Y; Wu, W; Xu, L; Zhao, WL1
Hawley, RG; Hawley, TS; Riz, I; Toma, I; Zweier-Renn, LA1
Han, D; Liu, H; Liu, Y; Wang, C; Wang, Y; Wu, J; Xu, D; Yang, H; Ye, Y; Zhang, G; Zhao, S; Zhen, Y; Zheng, T1
Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE1
Balakrishnan, K; Gandhi, V1
Henderson, RA; McGhee, CN; Patel, D; Pradhan, MA; Vincent, AL1
Guo, F; He, G; Hu, X; Shen, Y; Sun, A; Xu, J1
Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X1
Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C1
Chen, F; Cryns, VL; Messersmith, PB; Su, J1
Dalal, N; Kozolff, M; Nabhan, C; Starr, A; Tolzien, K; Villines, D1
Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA1
Alloway, RR; Girnita, A; Woodle, ES1
Chen, XQ; Chen, YL; Cheng, YX; Jin, J; Liang, HX; Liu, Y; Zhang, B; Zhang, FX; Zhou, GB1
Aydin, F; Bayik, M; Firatli-Tuglular, T; Kaygusuz, I; Toptas, T; Uzay, A1
Mori, A; Takeda, K; Yanagida, M1
Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M1
Chiriva-Internati, M; Chui, K; Cobos, E; Jenkins, MR; John, CM; Mirandola, L; Yu, Y1
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A1
Harper, JW; Lim, HJ; Tan, MK1
Molica, S; Piro, E1
Li, XY; Ma, LM; Niu, YY; Ren, RR; Wang, T; Zhang, HP; Zhou, Y1
Hayakawa, Y; Hirata, Y; Kinoshita, H; Koike, K; Maeda, S; Nakagawa, H; Nakata, W; Sakamoto, K; Takahashi, R1
Reid, EG1
Burns, CJ; Khong, T; Monaghan, KA; Spencer, A1
Chung, JS; Eom, HS; Kang, HJ; Kim, CS; Kim, HJ; Kim, JS; Kim, K; Lee, DS; Lee, JH; Lee, JL; Lee, SJ; Park, JS; Seong, CM; Sohn, SK; Suh, C; Won, JH; Yoon, SS1
Fulda, S1
Avet-Loiseau, H; Corthals, SL; Goldschmidt, H; Hajek, R; Johnson, DC; Kuiper, R; Magrangeas, F; Morgan, GJ; Sonneveld, P; van der Holt, B1
de la Rubia, J; Roig, M1
Balyasnikova, IV; Ferguson, SD; Han, Y; Lesniak, MS; Liu, F1
Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L1
Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J1
Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME1
Fox, BA; Hu, HM; Jensen, SM; Twitty, CG1
Beaven, AW; Feldman, T; Ferraro, M; Ford, P; Goy, A; Ivanova, A; Moore, DT; Shea, TC; Smith, J1
O'Connell, C; Schroyens, W; Sykes, DB2
Ambinder, RF; Baechler, S; Esaias, C; Fu, DX; Hobbs, RF; Pomper, MG; Sgouros, G1
Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Kantarjian, H; McConkey, D; O'Brien, S; Santos, FP; Wright, J1
Ayaori, M; Hisada, T; Iizuka, M; Ikewaki, K; Komatsu, T; Nakaya, K; Ogura, M; Ohsuzu, F; Ozasa, H; Sasaki, M; Takiguchi, S; Terao, Y; Uto-Kondo, H; Yakushiji, E1
Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G1
Chang, H; Jiang, A; Reece, D1
Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Migkou, M; Terpos, E1
Bello, C; Comenzo, RL; Hassoun, H; Hoover, E; Landau, H; Nimer, SD; Riedel, ER1
Badelita, S; Coriu, D; Crisan, M; Dobrea, C; Dogaru, M; Ostroveanu, D; Talmaci, R1
Abonour, R; Benson, MD; Kramer, G; Suvannasankha, A1
Antolino, G; Bianchi, MP; De Biase, L; La Verde, G; Monarca, B; Moscetti, A; Porrini, R; Saltarelli, F1
Burr, DA; Cai, P; Callaghan, MU; Cruz, PG; Fribley, AM; Jacobs, RR; Kaufman, RJ; Kirchhoff, PD; Larsen, MJ; Larsen, SD; Miller, JR; Narula, N; Neubig, RR; Ron, D; Schultz, PJ; Sherman, DH; Showalter, HD; Tamayo-Castillo, G1
Blank, J; Callander, NS; Chang, JE; Choi, S; Eickhoff, JC; Gilbert, LA; Huie, MS; Kahl, BS; Kim, K; Longo, WL; McFarland, TA; Peterson, C; Rogers, ES; Volk, M; Werndli, JE; Yang, DT1
Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M1
Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P1
Budde, K; Lachmann, N; Liefeldt, L; Neumayer, HH; Rudolph, B; Schönemann, C; Schütz, M; Waiser, J1
Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L1
Bhagat, G; Bongero, D; Lipstein, M; Montanari, F; O'Connor, O; Paoluzzi, L1
Andrea, NT; Quillen, K; Sanchorawala, V; Seldin, DC; Sloan, JM1
Khong, T; Spencer, A1
Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX1
Hino, N; Omura, H; Tanaka, T; Yamasaki, R1
Begus-Nahrmann, Y; Beissbarth, T; Eick, D; Gorsler, T; Hennion, M; Hintermair, C; Hsu, C; Johnsen, SA; Kramer, F; Kremmer, E; Prenzel, T; Simons, M1
Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D1
Huang, CM; Lü, SQ; Song, NX; Wang, JM; Xu, XQ; Yang, JM; Zhou, H1
Fei, XM; Lu, H; Wang, CY; Wang, LX; Zhu, Y1
Sun, ZQ; Tan, DW1
An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP1
Al-Eisawi, Z; Beale, P; Chan, C; Huq, F; Yu, JQ1
Koh, LP; Poon, LM1
Bronson, R; Feldser, DM; Jacks, T; Meylan, E; Oliver, TG; Winslow, MM; Xue, W1
Falk, RH1
Dagli, F; Isik, A; Koca, SS; Ozercan, IH; Ozgen, M; Sahin, K; Tuzcu, M1
Kale, AJ; Lechner, A; McGlinchey, RP; Moore, BS1
Bacovsky, J; Lochman, P; Minarik, J; Pika, T; Scudla, V; Tichy, T; Zadrazil, J1
Alloway, RR; Brailey, P; Girnita, A; Walsh, RC; Woodle, ES1
Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M1
Gao, J; Wang, X; Xiao, C; Xing, X; Xiong, C; Ye, S1
Möller, J; Murthy, A; Nicklasson, L1
Asano, T; Ito, K; Sato, A; Sumitomo, M1
Tokuhira, M1
Ohmachi, K1
Bargay, J; Bengoechea, E; Bladé, J; de Arriba, F; Díaz-Mediavilla, J; Fernández, M; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martín-Ramos, ML; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ribera, JM; San Miguel, JF; Sureda, A; Teruel, AI; Vidriales, MB1
Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B1
Anolik, JH; Barnard, J; Conley, T; Goldman, BI; Ichikawa, HT; Jiang, J; Kirk, CJ; Lee, S; Looney, RJ; Muchamuel, T; Nevarez, S; Owen, T1
Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G1
Arnold, LA; Atkinson, JM; Boulos, N; Carcaboso, AM; Eden, C; Ellison, DW; Féau, C; Gajjar, A; Gibson, P; Gilbertson, RJ; Guy, RK; Johnson, RA; Koul, D; Kranenburg, TA; Mohankumar, KM; Phoenix, T; Poppleton, H; Priebe, W; Shelat, AA; Stewart, CF; Tong, Y; Wright, K; Yung, WK; Zhu, L1
Bousquet, A; Join-Lambert, O; Malfuson, JV; Martinaud, C; Soler, C1
Befani, CD; Bonanou, S; Hatzidaki, E; Liakos, P; Papandreou, CN; Patrikidou, A; Simos, G; Vlachostergios, PJ1
Jia, L; Joel, SP; Juliger, S; Kassam, S1
Bellovich, K; El-Ghoroury, M; Goel, SK; Granger, D; Marin, M; Qu, H1
Dean, J; Dickinson, M; Harrison, SJ; Januszewicz, H; Johnstone, R; Link, E; Neeson, P; Nichols, J; Prince, HM; Quach, H; Ritchie, DS; Ruell, S; Seymour, JF1
Dimopoulos, MA; Mateos, MV; Redman, K; Richardson, PG; Spicka, I1
Albrecht, P; Braun, SA; Hanneken, S; Methner, A1
Cserti-Gazdewich, C; Dzik, WH; Haspel, RL1
Bridoux, F; Fermand, JP; Hutchison, C1
Alloway, RR; Sadaka, B; Woodle, ES2
Bahlis, NJ; Boise, LH; Duggan, P; Gratton, K; Johnson, J; Klimowicz, A; Lonial, S; Mansoor, A; Neri, P; Ren, L; Stebner, E; Stewart, DA; Tassone, P1
Dimeski, G; Wood, P1
Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J1
Budinger, GR; Chandel, NS; Chiarella, SE; Ghosh, AK; Go, LH; Jain, M; Kamp, DW; Lam, AP; Mutlu, GM; Pardo, A; Rivera, S; Selman, M; Sznajder, JI; Urich, D; Varga, J; Wu, M; Zirk, A1
Kuwabara, S1
Sun, S; Tong, H; Tu, Y; Wang, G; Wei, W; Yao, F1
Della Donna, L; Lagadec, C; Pajonk, F1
Ghobrial, IM; Roccaro, AM; Sacco, A1
Grant, S; Holkova, B2
Assaraf, YG; Chan, ET; Cloos, J; Franke, NE; Geerke, DP; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; van Zantwijk, CH; Vojtekova, K; Zweegman, S1
Delforge, M1
Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC1
Berenson, JR; Bessudo, A; Boccia, RV; Chen, CS; Eades, B; Hilger, J; Hilger, JD; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Vescio, R; Wirtschafter, E; Yang, HH; Yellin, O; Yung, E1
Anderson, KC; Bandi, M; Chauhan, D; Raje, N; Ray, A; Richardson, P; Singh, AV1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I1
Gupta, A; Pandey, A; Sethi, S1
Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T1
Blosser, W; de Maria, R; Dowless, M; Low, J; Pallini, R; Ricci-Vitiani, L; Stancato, L1
Goel, A; Spitz, DR; Weiner, GJ1
Cheng, T; Mao, X; Pan, X; Zhang, X1
Baz, R; Chen, F; Li, M; Nefedova, Y; Pisklakova, A; Sullivan, DM1
Chang, D; Everly, M; Kittleson, M; Kobashigawa, J; Patel, J; Reed, E1
Alsina, M; Nishihori, T1
Balsas, P; Galán-Malo, P; Marzo, I; Naval, J1
Cuzzoni, E; De Iudicibus, S; Decorti, G; Piscianz, E; Tommasini, A; Valencic, E1
Doss, S; Hay, N; Sutcliffe, F1
Baráth, S; Bíró, T; Griger, Z; Gyetvai, Á; Kovács, I; Sipka, S; Tarr, T; Tóth, BI; Zeher, M1
Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J1
Johnson, DE; Li, C2
Al-Shabeeb, A; Allen, JD; Catalano, A; Fleming, S; Harrison, S; Ho, PJ; Horvath, N; Iland, H; Joshua, DE; Lau, EK; Ling, SC; Nikolic, A1
Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L1
Dong, W; Qian, J; Sun, L; Wang, M; Yang, J; Yi, Q; Zhang, L1
Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS1
Carew, JS; Coffey, M; Espitia, CM; Giles, FJ; Kelly, KR; Mahalingam, D; Nawrocki, ST; Oyajobi, BO1
Alé, A; Bruna, J; Jaramillo, J; Navarro, X; Udina, E; Velasco, R1
Chen, J; Curran, S; Dick, LR; Hjerpe, R; Kurz, T; Shpiro, N; Thomas, Y; Zemla, A1
Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A1
Fang, Y; He, Q; Jing, H; Luo, P; Song, H; Yang, B; Zhong, L; Zhou, X1
Chan, TH; Dou, QP; Kanwar, J; Mujtaba, T; Wan, SB1
Alexis Vigier, M; Arakelyan, N; Assouline, D; Bouabdallah, K; Caulet-Maugendre, S; Courby, S; Dartigeas, C; El Yamani, A; Fornecker, L; Gressin, R; Harousseau, JL; Houot, R; Le Gouill, S; Maisonneuve, H; Moles, MP; Mounier, C; Ojeda Uribe, M; Rodon, P; Sutton, L; Tournilhac, O1
Gotoh, K; Ito, Y; Iwata, S; Kamakura, M; Kawada, J; Kimura, H; Nishiyama, Y; Saito, T1
Molineaux, SM1
Arai, S; Ichikawa, M; Imai, Y; Kataoka, K; Kumano, K; Kurokawa, M; Nakagawa, M; Nannya, Y; Nishimoto, N; Sato, T; Shimabe, M; Shinohara, A; Watanabe-Okochi, N; Yoshimi, A1
Chen, Z; Fayad, L; Jung, HJ; Kwak, LW; McCarty, N; Romaguera, J; Wang, M2
Dalmau, J; Fett, NM; Shinohara, MM; Toporcer, MB; Vogl, DT1
Eto, Y; Higuchi, T; Ida, H; Kobayashi, H; Nishida, H; Nishiyama, Y; Ohashi, T; Shimada, Y1
Assaraf, YG; Chan, ET; Cloos, J; de Wilt, LH; Jansen, G; Kirk, CJ; Kruyt, FA; Peters, GJ; Schimmer, AD; van Meerloo, J1
Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O1
Gräwert, MA; Groll, M1
Chen, WM; Chen, XQ; Hou, J; Huang, XJ; Jin, J; Li, Y; Liu, ZG; Shen, ZX; Yuan, ZG1
Fei, XM; Hu, HJ; Li, JX; Li, JY; Lu, H1
Bai, H; Ling, YQ; Wang, CB; Wang, ML; Wu, B; Zhang, Q1
Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K1
Cipok, M; Deutsch, VR; Farnoushi, Y; Goldstein, RS; Jan, H; Kay, S; Naparstek, E; Ohana, A1
Chang, H; Chen, MH; Qi, C; Reece, D1
Kaiser, M; Krahn, D; Ottmann, C1
Bratengeier, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Meletis, J; Michalis, E; Pouli, A; Terpos, E; Zervas, K1
Ailawadhi, S; Bryant, B; Chanan-Khan, A; Gaile, DP; Lee, KP; Mashtare, T; Masood, A; Miecznikowski, J; Mulligan, G; Neuwirth, R; Sher, T; Stein, L; Wang, D; Wilding, GE1
Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B1
Berkers, CR; de Jong, A; Ovaa, H; Rodenko, B; Schuurman, KG1
Kakpakova, ES; Panischeva, LA; Rybalkina, EY; Stavrovskaya, AA1
Chen, HJ; Chen, KC; Chen, KF; Cheng, AL; Huang, CY; Wei, CC1
Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR1
He, Q; Li, L; Lin, M; Luo, P; Yang, B1
Guo, H; Mao, J; Qian, X; Sun, C; Sun, H1
Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J1
Benjamin, M; Gibbs, S1
Gong, X; Zhou, Y1
Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C1
Hou, K; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Xu, L; Zhang, L; Zhang, Y1
Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S1
Andrade, VC; Atanackovic, D; Caballero, OL; Camargo, AA; Colleoni, GW; Costa, ET; de Carvalho, F; Gregorio, JC; Masotti, C; Strauss, BE1
Budunova, IV; Kirsanov, KI; Lesovaya, EA; Yakubovskaya, MG; Yemelyanov, AY1
Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y1
Seol, DW1
Dang, N; De Bruyne, E; De Bryune, E; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D1
Churchill, E; Ma, Y; Mahaffey, CM; Martin, SM; McKnight, H; O'Donnell, RT; Tuscano, JM1
De Mesmaeker, P; Deleu, I; Dirix, LY; Prové, A; Rasschaert, M; Sas, L; Tjalma, WA; Trinh, XB; Van Dam, PA; Van de Velde, H; Van Laere, SJ; Vermeulen, PB; Vinken, P; Wojtasik, A1
Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E1
Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM1
Bansal, R; Boise, LH; Fink, EE; Hu, Q; Lee, KP; Liu, S; Mannava, S; Moparthy, KC; Nair, JR; Nikiforov, MA; Wawrzyniak, JA; Zhuang, D; Zucker, SN1
Gong, Y; Shan, Q; Yang, X; Zheng, B; Zhou, R1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J1
Bryant, J; Clegg, AJ; Cooper, K; Picot, J1
Liu, H; Song, CC; Song, CZ; Wang, QW1
Reece, D; Scott, E1
Bertsch, U; Blau, IW; Derigs, HG; Dührsen, U; Goldschmidt, H; Haenel, M; Hielscher, T; Ho, AD; Hose, D; Jauch, A; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Teschendorf, C; van de Velde, H; van der Holt, B; Weisel, K1
Knop, S2
Fonseca, R2
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE1
Agadjanian, H; Guo, X; Karlan, BY; Kwon, S; Miller, C; Nassanian, H; Orsulic, S; Taylor-Harding, B; Walsh, CS1
Li, LS; Shen, JK; Zhang, GS1
Huang, HB; Lin, J; Wu, SQ; Xu, ZZ; Zhan, R1
Appel, A1
Berglund, J1
Frazier, EA; Garcia, X; Harville, TO; Howard, EL; Jaquiss, RD; Knecht, KR; Mahle, WT; Morrow, WR; Pye, SE; Saylors, RL; Smith, RN; Woodle, ES1
Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS1
Ayub, B; Mangalmurti, S; Matsumura, ME1
Anderson, KC; Avet-Loiseau, H; Beksac, M; Bladé, J; Cavo, M; Chng, WJ; Comenzo, R; Delforge, M; Dimopoulos, M; Durie, BG; Einsele, H; Harousseau, JL; Jagannath, S; Jongen, JL; Lahuerta, JJ; Lee, JH; Lonial, S; Mateos, MV; Mazumder, A; Merlini, G; Miguel, JS; Moreau, P; Morgan, G; Munshi, N; Niesvizky, R; Orlowski, R; Palumbo, A; Rajkumar, SV; Richardson, PG; Sezer, O; Siegel, D; Sonneveld, P; Terpos, E; Usmani, S; Vesole, D; Voorhees, P; Wen, P1
Bachmann, AS; Ibarra-Rivera, TR; Opoku-Ansah, J; Pirrung, MC1
Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH1
Inazu, M; Itoh, M; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Naito, M; Takase, A; Tomoda, A1
Chan, KM; Kamoun, M; Stuckey, LJ1
Dou, QP; Mujtaba, T1
Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J1
Baumann, P; Junghanns, C; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Strobl, S1
Fehrenbach, H; Lunding, L; Manz, RA; Orinska, Z; Wegmann, M; Wong, DM1
Arastu-Kapur, S; Bennett, MK; Bergsagel, PL; Demo, S; Deu, E; Keats, J; Kirk, CJ; Suzuki, E1
Bhalla, P; Budunova, I; Iwadate, K; Karseladze, A; Ugolkov, A; Yang, X; Yemelyanov, A1
de Lima, M; Koreth, J; Reddy, P1
Terpos, E; Tricot, G; Zangari, M; Zhan, F1
Dreyling, M; Hiddemann, W; Hutter, G; Pastore, A; Rieken, M; Weigert, O; Weinkauf, M; Zimmermann, Y1
Al, M; Assaraf, YG; Chan, ET; de Gruijl, TD; den Uyl, D; Dijkmans, BA; Jansen, G; Kirk, CJ; Oerlemans, R; Peters, GJ; Scheffer, GL; Scheper, RJ; van der Heijden, JW; Verbrugge, SE1
Gil, L; Komarnicki, M; Rupa-Matysek, J1
Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Mukai, H; Ohyashiki, K; Sakai, H; Sugiyama, Y1
Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G1
Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Curran, WJ; Dicker, AP; Fogh, S; Kubicek, GJ; Machtay, M; Myers, TJ1
Banner, NR; Hodges, AM; Lyster, H; McDermott, A; Rice, AJ; Rose, ML; Smith, JD1
Anderson, KC; Buon, L; Delmore, JE; Hunter, ZR; Jacobs, HM; Kung, AL; McMillin, DW; Mitsiades, CS; Monrose, V; Richardson, PG; Smith, PG; Treon, SP; Yu, J1
Everly, MJ; Terasaki, PI; Trivedi, HL1
Anderson, KC; Bradner, J; Canavese, M; Cirstea, D; Eda, H; Hideshima, T; Jarpe, M; Jones, SS; Kung, AL; Mazitschek, R; Ogier, WC; Raje, N; Rodig, S; Santo, L; Scullen, T; Tamang, D; Tseng, JC; van Duzer, JH; Yang, M1
Beebe, DJ; Callander, NS; Kahl, BS; Miyamoto, S; Pak, C; Yang, DT; Young, EW1
Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB1
Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT1
Brandt, S; Chinratanalab, W; Englehardt, B; Goodman, S; Greer, JP; Jagasia, MH; Kassim, A; Morgan, DS; Oluwole, O; Reddy, N; Savani, BN1
Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Siddiqui, K; Uddin, S1
Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H1
Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL1
Airia, P; Cockwell, P; Cook, M; Grima, D; Heyne, N; Hutchison, CA; Schindler, R; Zickler, D1
Andreesen, R; Grube, M; Hafner, C; Hart, C; Wurm, S1
Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A1
Kisselev, AF; Overkleeft, HS; van der Linden, WA1
Amann, K; Benz, K; Daniel, C; Hainz, N; Meister, S; Neubert, K; Rauh, M; Thomas, S; Voll, RE; Wiesener, M1
Chapman, WC; Csontos, K; Glasgow, SC; Jia, J; Liaw, JM; Liu, W; Mohanakumar, T; Ramachandran, S; Upadhya, GA1
Besa, E; Bray, P; Caro, J; Dulau Florea, A; Mahipal, A; Sbenghe, MM1
Blackwell, TS; Cheng, DS; Gleaves, LA; Han, W; Kairi, CA; Kalomenidis, I; Karabela, SP; McMahon, F; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Stathopoulos, I; Vassiliou, S; Yull, FE; Zakynthinos, SG; Zaynagetdinov, R1
Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL1
Bladé, J; de Larrea, CF; Rosiñol, L1
Afar, DE; Anderson, KC; Bensinger, W; Benson, DM; Jakubowiak, AJ; Mohrbacher, A; Richardson, PG; Siegel, DS; Singhal, AK; Zimmerman, TM1
Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T1
Asano, T; Ito, K; Sato, A2
Berkowitz, A; Walker, S1
Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D1
Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M1
Chen, SJ; Chen, YL; Chen, Z; Cheng, X; Fang, HT; Feng, TT; Gao, L; Hu, ZG; Liu, Z; Ma, L; Pan, XF; Sheng, GQ; Xie, J; Yang, Y; Yu, XJ; Zhang, B; Zhang, FX; Zhao, HX; Zhen, T; Zhou, GB1
Gumber, MR; Kute, VB; Patel, HV; Shah, PR; Trivedi, HL; Vanikar, AV1
Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML1
Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Moon, JH; Park, HC; Sohn, SK; Yang, DH1
Digumarthi, R; Gundeti, S; Linga, VG; Mallavarapu, KM; Rajappa, S; Uppin, SG1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ1
Azakir, BA; Di Fulvio, S; Kinter, J; Sinnreich, M1
Fang, FM; Huang, CK; Huang, HY; Kang, HY; Lan, J; Lee, JC; Li, CF; Li, SH; Shiue, YL; Wang, JM; Wang, JW; Wang, YH; Wu, LC; Wu, WR; Yu, SC1
Befani, CD; Daliani, DD; Hatzidaki, E; Liakos, P; Moutzouris, G; Papandreou, CN; Patrikidou, A; Tsapakidis, K; Vlachostergios, PJ; Voutsadakis, IA1
Guthoff, M; Häring, HU; Heyne, N; Königsrainer, A; Schmid-Horch, B; Weisel, KC1
Bai, L; Du, BY; Miao, SY; Shen, Y; Song, W; Wang, LF1
Elemento, O; Houghtaling, BR; Kapoor, TM; Wacker, SA1
Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF1
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Pinney, JH; Rannigan, L; Venner, CP; Wechalekar, AD; Whelan, CJ1
Bello, N; Bergsagel, PL; Fonseca, R; Jimenez-Zepeda, VH; Mikhael, JR; Reeder, CB; Schuster, SR; Spong, J; Stewart, AK1
Gao, Y; Long, XX; Ping, BH1
Chen, WW; Huang, KK; Huang, M; Jiang, XJ; Meng, FY; Wang, Q; Wang, ZX; Wu, FQ; Zhou, HS1
Chen, J; Chuang, M; Jiang, D; Que, W1
Hu, XH; Shen, YY; Xu, JJ1
Li, LH; Tang, XW; Zhang, R1
Chen, CC; Chen, KC; Chen, KF; Cheng, AL; Lin, YC1
Cumová, J; Hájek, R; Jedličková, L; Potáčová, A; Potěšil, D; Sedo, O; Stejskal, K; Zdráhal, Z1
Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG1
Gallastegui, N; Groll, M1
Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S1
Gartel, AL; Wang, M1
Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O1
Bassell, GJ; Gross, C; Muddashetty, RS; Nalavadi, VC1
Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R1
Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M1
Imagawa, J; Kimura, A; Kinoshita, M; Mihara, K; Mino, T; Sakai, A; Yoshida, T1
Hussain, SM; Jasnosz, KM; Khan, AS; Ko, TY; Marcus, RJ; Parris, G; Sureshkumar, KK; Thai, NL; Tom, K; Vivas, CA1
Steiger, J; Zecher, D1
Iwama, K; Matsue, K; Nishida, Y; Takeuchi, M; Yamakura, M1
Ramchandren, R1
Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y1
Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X; Zhao, S1
Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR; Vukmer, NA1
Al-Husein, B; Al-Shabrawey, M; Bollag, WB; Choudhary, V; Davis, M; Dong, Z; El Gaish, M; Kaddour-Djebbar, I; Kumar, MV; Lakshmikanthan, V; Shirley, R; Zhong, R1
Gopinathan, G; Gribben, JG; Jia, L; Sukumar, JT1
Fehr, T; Gaspert, A1
Dowlati, A; Esseltine, DL; Hamilton, A; Ivy, P; LoRusso, PM; Mani, S; Mulkerin, D; Neuwirth, R; Ramanathan, RK; Rudek, MA; Sarantopoulos, J; Shibata, SI; Takimoto, CH; Venkatakrishnan, K1
Filipczak, PT; Glowala-Kosinska, M; Krawczyk, Z; Piglowski, W; Scieglinska, D1
Cao, Q; Dudek, AZ; Wang, H1
Cañueto, J; Contreras, T; García-Sanz, R; Gutiérrez, NC; Labrador, J; Román, C; Santos-Briz, A1
Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A1
Flanagan, L; Hellwig, CT; Huber, HJ; Laussmann, MA; Passante, E; Prehn, JH; Rehm, M; Tomiczek, B1
Chan, KM; Chou, HS; Eldeen, FZ; Lee, CF; Lee, WC; Soong, RS; Wu, TH; Wu, TJ1
Cirone, M; Conte, V; Di Renzo, L; Faggioni, A; Frati, L; Gonnella, R; Lotti, LV; Santarelli, R; Trivedi, P1
Boenisch, O; Denecke, C; Khalpey, Z; Pratschke, J; Reutzel-Selke, A; Sawitzki, B; Seifert, M; Tullius, SG; Volk, HD1
Dispenzieri, A; Kohut, IE; Warsame, R1
Brunetti, O; Ciavarella, S; Dammacco, F; Dominici, M; Grisendi, G; Silvestris, F; Tucci, M1
Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J1
Baugé, C; Boumédiene, K; Galéra, P; Girard, N; Leclercq, S1
Chinen, Y; Fuchida, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sakamoto, N; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Uchiyama, H; Yamamoto-Sugitani, M1
Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X1
D'Souza, J; Khandros, E; Thom, CS; Weiss, MJ1
Kwong, YL; Loong, F; Yeung, CK1
Miyata, Y; Mizuno, H; Nakao, N; Nakayama, T; Naoe, T; Nishiwaki, S; Saito, S; Takeshita, K1
Berkers, CR; Jones-Bolin, S; Leestemaker, Y; Ovaa, H; Ruggeri, B; Schuurman, KG; Williams, M1
Badgett, TC; Chen, QR; Cheuk, AT; Khan, J; Song, YK; Tsang, PS; Wei, JS1
Ang, AL; Goh, YT; Mok, SJ; Phipps, C; Tan, D1
Bardag-Gorce, F; French, SW; Li, J; Oliva, J1
Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN1
Gu, JL; Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zhou, ZH1
Bergsagel, PL; Chesi, M; Garbitt, VM; Johnstone, RW; Lefebure, M; Matthews, GM; Palmer, SE; Shortt, J; Stewart, AK1
Beckers, EA; Cornelis, T; Driessen, AL; Koek, GH; van der Sande, FM1
Barresi, MJ; Benaich, N; Bernardos, RL; Downes, GB; Hutson, LD; Khan, TM; Malone, CF; Russell, AR1
Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H1
Jimenez-Zepeda, VH1
Domján, G; Gadó, K1
Silvennoinen, R; Sinisalo, M; Wirta, O1
Bardag-Gorce, F; Bartrons, R; Bonaccorsi-Riani, E; Boncompagni, E; Carbonell, T; French, SW; Oliva, J; Padrissa-Altés, S; Roselló-Catafau, J; Zaouali, MA1
Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S1
Bartsch, DK; Brendel, C; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A1
Okur, E; Ulukaya, E; Yerlikaya, A1
Asano, Y; Kadono, T; Sato, S; Sugaya, M; Tada, Y; Yanaba, K1
Finegold, MJ; Grompe, M; Loza, LM; Paulk, NK1
Hasegawa, S; Hashimoto, M; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H1
Dispenzieri, A; Gertz, MA1
Canonico, S; D'Amico, M; Di Filippo, C; Ferretti, M; Freda, F; Petronella, P; Rossi, F; Scorzelli, M1
Eiam-Ong, S; Susantitaphong, P; Tiranathanagul, K1
Ballanti, S; Baraldi, A; Boccadoro, M; Brioli, A; Califano, C; Callea, V; Carella, AM; Cavo, M; Crippa, C; De Stefano, V; Derudas, D; Dessanti, ML; Donnarumma, D; Falcone, A; Ferrara, F; Furlan, A; Grasso, M; Marcatti, M; Masini, L; Musto, P; Nozza, A; Nozzoli, C; Palumbo, A; Pantani, L; Patriarca, F; Perrone, G; Petrucci, MT; Pezzi, A; Zamagni, E; Zambello, R1
Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF1
Cabanillas, F1
Giralt, S2
Kyle, RA1
Stockler, MR; Wilcken, NR1
Amerik, AY; Issaenko, OA1
Besio, R; Forlino, A; Giansanti, V; Gioia, R; Marini, JC; Merlini, G; Palladini, G; Panaroni, C; Rossi, A; Scovassi, IA; Tenni, R; Vezzoni, P; Villa, A; Villa, I; Villani, S1
Fu, B; Li, Y; Liao, A; Liu, Z; Pan, H; Wang, H; Wang, X; Yang, W1
Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D1
Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG1
Cheng, SH; Gumlaw, NK; Jiang, JL; Karman, J; Zhang, J; Zhu, Y1
Cheson, BD; Koprivnikar, JL1
Arias, A; Baumann, G; Dreger, H; Fechner, M; Hewing, B; Ludwig, A; Meiners, S; Stangl, K; Stangl, V; Wilck, N1
Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Shi, GM; Shi, YH; Yang, H; Zhou, J1
Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T1
Cooley, K; Fergusson, D; Fernandes, R; Fritz, H; Kennedy, DA; Seely, D1
Haensch, CA; Isenmann, S; Katona, I; Schlemmer, H; Stratogianni, A; Tosch, M; Weis, J1
Blanco, B; Caballero-Velázquez, T; Calderon, C; Carrancio, S; del Cañizo, C; Gutierrez-Cosio, S; Herrero, C; Pérez-Simón, JA; San Miguel, JF; Sánchez-Abarca, LI; Serrano, C1
Economou, JS; Jazirehi, AR1
Arcila, M; Gerecitano, J; Gonzalez, C; Gounder, S; Lin, D; McDonald, A; Mulligan, G; O'Connor, OA; Ogilvie, S; Teruya-Feldstein, J; Zhang, Z; Zheng, J1
Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I1
Juul, JS; Larsen, T; Marcussen, N; Pedersen, EB1
Bathini, V; Bradley, K; Hanrahan-Boshes, M; Hutchinson, L; Perez-Soler, R; Piperdi, B; Walsh, WV; Zhou, Z1
Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M1
Bessone, L; Carta, F; Gallo, V; Giribaldi, G; Khadjavi, A; Mandili, G; Minero, VG; Turrini, F1
Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Tseng, LM1
Chen, FT; Liu, YC; Yang, CH; Yang, CM1
Anderson, KC; Blumenthal, M; Cirstea, D; Fabre, C; French, M; Fulciniti, M; Gorgun, G; Hokenson, M; Hu, Y; Ikeda, H; Kawano, Y; Kertesz, NL; Kiziltepe, T; Malyankar, UM; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Patterson, JB; Pham, T; Richardson, PG; Santo, L; Tai, YT; Tam, V; Zeng, Q1
Cochran, MC; Eisenbrey, JR; Oum, KL; Wheatley, MA1
Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Wang, YW; Yang, Y1
Olie, RA; Taverna, C; Trojan, A; Voegeli, J; von Rohr, A1
Heo, DS; Hong, SW; Hong, YS; Jin, DH; Kim, KP; Kim, SM; Kim, TW; Lee, JL; Lee, JS; Shin, JS; Yoon, DH1
Chng, WJ; Goh, YT; Khin, MT; Koh, LP; Lee, LH; Ong, KH; Tan, D; Wong, SS1
Cao, XX; Duan, MH; Kang, WY; Li, J; Zhang, W; Zhou, DB1
Alsina, M; Bahlis, NJ; Belch, A; Gabrail, NY; Jagannath, S; Jakubowiak, AJ; Kaufman, JL; Kukreti, V; Kunkel, LA; Lee, P; Lonial, S; Matous, JV; McDonagh, KT; Orlowski, RZ; Reu, FJ; Rosen, P; Sebag, M; Siegel, DS; Stewart, AK; Vesole, DH; Vij, R; Wang, M; Wear, SM; Wong, AF1
Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W1
Jang, WS; Kang, HJ; Kim, A; Lee, JE; Lee, SJ; Lee, SS; Park, S1
Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H1
Feldman, T; Goy, A; Mato, AR1
Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S1
Korde, N; Kwok, M; Landgren, O1
Bai, C; Hu, X; Liu, J; Song, X; Wang, J1
Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N1
Arora, R; Brodsky, JL; Chang, Y; Dömling, A; Feng, H; Guastafierro, A; Moore, PS; Normolle, D; Shuda, M; Tolstov, Y; Toptan, T; Vogt, A; Vollmer, LL1
Jimenez-Zepeda, VH; John, R; Trudel, S; Vajpeyi, R1
Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M1
Backendorf, C; Lanz, HL; Noteborn, MH; Suijker, J1
Asimakopoulos, F; Callander, NS; Denu, RA; Dollar, BA; Escalante, LE; Hematti, P; Kim, J; Kuether, JP1
Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H1
Cantaffa, R; Carillio, G; Kropp, M; Lamberti, AG; Molica, S; Piro, E1
Bergamo, S; di Meo, N; Dondas, A; Trevisan, G1
Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M1
Anagnostopoulos, A; Athanasiou, E; Batsis, I; Fassas, A; Kaloyannidis, P; Papadopoulou, A; Yannaki, E; Yiangou, M; Zogas, N1
Chopp, M; Zhang, L; Zhang, ZG1
Bai, QX; Zhang, XY1
Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B1
Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ1
Feng, J; Li, Z; Ma, Y; Ren, H; Wang, Y; Zhao, J1
Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA1
Berenson, JR; Chen, H; Li, J; Li, M; Nichols, CM; Sanchez, E; Wang, C1
Barthelemy, M; Boulanger, F; Cossment, C; Facon, T; Fouquet, G; Le Ray, E; Leleu, X; Manier, S; Noel, MP; Prod'homme, C; Samarcq, P; Terriou, L1
Itoh, K; Sasaki, M; Yamaguchi, T1
Ferrara, R; Obeid, KM; Sharma, M1
Afqir, S; Belbaraka, R; Benjaafar, N; Elmajjaoui, S; Errihani, H; Ismaili, N; Tahri, A1
Choi, KS; Kim, EH; Kwon, TK; Park, SA; Yoon, MJ1
Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Trudel, S; Winter, A1
Huang, K; Li, Y; Ma, L; Nie, D; Wang, X; Wu, Y; Xiao, J; Xie, S; Yin, S1
Cavo, M; Harousseau, JL; Moreau, P; Orlowski, RZ; Palumbo, A; Richardson, PG; San Miguel, JF1
Alcántara, J; Bagazgoitia, L; Carrillo, R; Truchuelo, M; Velasco, D1
Rivella, S1
Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J1
Kim, WS; Lee, SJ; Park, C; Yeom, SY1
Yerlikaya, A1
Grantab, RH; Tannock, IF1
Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S1
Ikeda, D; Masuda, T; Momose, I; Nomoto, A; Ohba, S; Tatsuda, D1
Klintmalm, GB; O'Leary, JG; Paterno, F; Shiller, M; Susskind, B; Tillery, G; Trotter, J1
Chan, EY; Chim, CS; Kwong, YL; Lau, CW; Liang, R; Lie, AK; Liu, HS; Ma, ES; Sim, J; Tse, E; Wan, TS; Yip, SF1
Boland, R; D'Elia, N; Gonzalez-Pardo, V; Russo de Boland, A; Verstuyf, A1
Bolanos, L; Cloos, J; Cortelezzi, A; Cuzzola, M; Fang, J; Goyama, S; Jansen, G; Mulloy, JC; Oliva, EN; Rasch, C; Rhyasen, G; Rigolino, C; Starczynowski, DT; Varney, M; Wunderlich, M1
Martinon, F1
Aggarwal, BB; Ahn, KS; Cheung, LH; Cho, MJ; Ford, RJ; Hittelman, WN; Lyu, MA; Marks, JW; Pham, LV; Rosenblum, MG; Sung, B; Tamayo, AT1
Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M1
Chisholm, R; Houghton, J; O'Driscoll, BR; O'Riordan, D1
Arnulf, B; Cakana, A; Deraedt, W; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Moreau, P; Pylypenko, H; van de Velde, H1
Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS1
Bladé, J; Cibeira, MT; de Larrea, CF; Escoda, L; Rosiñol, L; Rovira, M; Solé, M; Tovar, N1
Bonvini, P; Peron, M; Rosolen, A1
Brunetti, GA; Cartoni, C; Cupelli, L; D'Elia, GM; Efficace, F; Federico, V; Grammatico, S; Niscola, P; Petrucci, MT; Scaramucci, L; Tendas, A; Truini, A1
Kawanami, M; Sato, MM; Tamura, M; Uyama, M1
Alimena, G; Breccia, M; Cartoni, C; Federico, V; Levi, A; Loglisci, G; Mansueto, G; Mercanti, C; Musto, P; Petrucci, MT1
Molica, S1
Hashimoto, S; Nakaseko, C; Sakai, S; Sakuma, I; Shimura, T; Takagi, T; Takeda, Y; Tanaka, H1
Charliński, G; Jedrzejczak, WW; Wiater, E1
Groll, M; Huber, EM1
Ewald, GA; Hassan, A; Joseph, SM; Klein, JL; Uy, GL; Wang, TF; Woodard, PK1
Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F1
Bretz, J; Chen, I; Chen-Kiang, S; Di Liberto, M; Ely, S; Hahn, WC; Huang, X; Jayabalan, D; Liang, J; Louie, T; Moore, MA; Niesvizky, R; Randolph, S; Shaffer, AL; Staudt, LM1
Cheung, J; Cornell, IS; Yau, AH1
Chopp, M; Kassis, H; Liu, X; Tang, T; Teng, H; Zhang, L; Zhang, ZG1
Esseltine, DL; Mulligan, G1
Kirk, CJ1
Kapoor, P; Rajkumar, SV; Ramakrishnan, V1
Broyl, A; Jongen, JL; Sonneveld, P1
Alloway, RR; Sadaka, B; Schmidt, NM; Shields, AR; Woodle, ES1
Augusti, V; Ballestrero, A; Carbone, F; Moran, E; Nencioni, A; Patrone, F1
Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M1
Liu, ZG; Wang, HT; Wang, JF1
Ao, L; Jang, ER; Kim, D; Kim, K; Kim, KB; Lee, DM; Lee, W; Wu, Y1
Guo, H; Shao, L; Sun, H; Xu, M; Zhou, X; Zhu, J1
Du, SH; Du, X; He, C; Jia, PM; Tong, JH; Zhou, L2
Guo, M; Hu, KX; Kang, Y; Qiao, JH; Sun, QY; Yu, CL; Zhao, YY1
Bigley, V; Collin, M; Hambleton, S; Jardine, L; Pagan, S; Wang, XN1
Al-Otaibi, T; Al-Waheeb, S; Gheith, O; Halim, M; Ibraheim, M; Muzeirei, I; Nair, P; Nampoory, N; Saied, T1
Haidl, F; Lund, T; Plesner, T1
Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C1
Borja-Cacho, D; Chinnakotla, S; Dunn, TB; Finger, E; Kandaswamy, R; Kim, Y; Krefting, P; Manivel, C; Matas, A; Maurer, D; Noreen, H; Pruett, T; Tamayo, G; Verghese, P1
Hardinger, KL; Murillo, D1
Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Gul, Z; Lum, L; Mellon-Reppen, S; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E1
Blanco, JF; Collins, L; Garayoa, M; Garcia-Gomez, A; Hornick, MC; Hurchla, MA; Kirk, CJ; Li, A; Ocio, EM; Pandiella, A; Piwnica-Worms, D; San Miguel, JF; Tomasson, MH; Vij, R; Weilbaecher, KN1
Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H1
Bitterman, PB; Dahlberg, PS; Issaenko, OA; Polunovsky, VA1
Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH1
De Becker, A; De Raeve, H; Van Camp, B; Van Riet, I; Vanderkerken, K; Xu, S1
Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W1
Chowdhury, RD; Driscoll, JJ1
An, N; Chen, SL; Hu, Y; Li, X; Liu, XH; Sun, WJ; Zhang, JJ; Zhong, YP1
Chen, M; Huang, BH; Li, J; Liu, JR; Xu, DR; Zheng, D; Zou, WY1
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H1
Takamatsu, Y1
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C1
Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI1
Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK1
Joshi, VR; Nagaraj, S; Sharma, V1
Gilbar, P; Seger, AC1
Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S1
Burlingame, AL; Hsu, GW; Mahrus, S; Nguyen, H; Shimbo, K; Trinidad, JC; Wells, JA1
Crotty, TB; Dunne, O; Fennelly, D; Holian, J; Ward, F; Watson, A1
Ahles, CP; Berenson, JR; Boccia, R; Bonavida, B; Chen, H; Crowley, J; Dreyer, MP; Kirk, DT; Kitto, A; Li, J; Li, M; Madden, E; Nichols, CM; Robinson, A; Sanchez, E; Swift, RA; Vescio, RA; Wang, CS; Waterman, GN; Yellin, O1
Anderson, KC; Bobb, K; Carrasco, RD; Cirstea, D; Fabre, C; Gorgun, G; Hideshima, T; Hu, Y; Kong, SY; Meshulam, J; Mimura, N; Minami, J; Ohguchi, H; Richardson, PG; Tai, YT; Zhang, J1
Agten, A; Cielen, N; Decramer, M; Dekhuijzen, RP; Gayan-Ramirez, G; Maes, K; Thomas, D; Van Hees, HW1
Laghi, F1
Bhaskar, B; Kassim, A; Paton, VE; Wamstad, K; White, D; Yi, J1
Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC1
Bacovsky, J; Langova, K; Minarik, J; Pika, T; Scudla, V1
Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A1
Amodio, N; Anderson, KC; Azab, AK; Blotta, S; Calimeri, T; Foresta, U; Jakubikova, J; Mitsiades, CS; Molica, S; Morabito, F; Munshi, NC; Neri, A; Roccaro, AM; Rossi, M; Tagliaferri, P; Tassone, P; Todoerti, K1
Li, XW; Yang, JR1
Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W1
Alloway, RR; Girnita, AL; Hanseman, DJ; Sadaka, B; Schmidt, N; Shields, AR; Walsh, RC; Woodle, ES1
Anderson, KC; Lokhorst, HM; Richardson, PG; van de Donk, NW1
Huh, JW; Kim, HJ; Kim, SY; Lee, JH; Lee, SD; Lee, YS; Oh, YM; Park, MK; Ro, JY1
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF1
Liu, X; Su, L; Xu, L1
Gilbar, PJ; Seger, AC2
Mehta, N; Niesvizky, R; Saxena, A1
Gertz, M1
Huang, KK; Jiang, XJ; Meng, FY; Qiao, L; Wang, Q; Wang, ZX; Wu, FQ; Yang, M; Ye, JY; Yi, ZS; Zhao, QX; Zhou, HS1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE1
Berenson, JR; Eshaghian, S1
Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E1
Borst, J; Rooswinkel, RW; van de Kooij, B; Verheij, M1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S2
Ai, L; Cui, G; Gowrea, B; Hu, Y; Li, M; Wang, Y1
Ahern, CH; Ames, MM; Blaney, SM; Espinoza-Delgado, I; Horton, TM; Ingle, AM; McGovern, RM; Muscal, JA; Reid, JM; Thompson, PA; Weigel, BJ1
Du, HF; Lv, HY; Meng, J; Meng, YF; Song, XN; Yu, LJ; Zhang, JQ1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI1
Banerjee, A; Gartel, AL; Halasi, M; Kabirov, K; Landolfi, J; Lyubimov, AV; Wang, M1
Baas, P; Busacca, S; Cakana, A; Donnellan, P; Fennell, DA; McCaffrey, J; McDowell, C; Meerbeeck, JV; Moulton, B; O'Byrne, KJ; Webb, G1
Kimby, E1
Chang, CL; Hsu, YT; Hung, CF; Wang, C; Wu, CC; Wu, TC; Yang, YC1
Bauer, F; Codreanu, I; Dasanu, CA; Padmanabhan, P; Rampurwala, M1
Dean, RA; Franck, WL; Gokce, E; Han, SO; Muddiman, DC; Oh, Y; Shows, A1
Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T; Yamakawa, M1
Cui, HX; Hu, W; Jiang, YH; Wang, Y; Yue, D; Zheng, RR1
Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN1
Cockwell, P; Cook, M; Stringer, S1
Bladé, J; Dimopoulos, MA; Kastritis, E1
Cockwell, P; Cook, M1
Haynes, R; Kyle, R; Leung, N; Winearls, CG1
Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M1
Chen, Z; Fayad, L; Kwak, LW; McCarty, N; Romaguera, J; Wang, M1
Cvek, B; Skrott, Z2
Baladandayuthapani, V; Berkova, Z; Bjorklund, CC; Davis, RE; Jones, RJ; Kuhn, DJ; Lin, P; Ma, W; Madden, TL; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Wei, C; Woessner, R1
Chang, TC; Chen, SC; Jan, YJ; Ko, BS; Liang, SM; Liou, JY; Liu, TA; Wang, J; Wu, YM1
Fuchida, S; Haruyama, H; Hatsuse, M; Itoh, S; Murakami, S; Okano, A; Shimazaki, C1
de Jong, S; de Wilt, LH; Jansen, G; Kroon, J; Kruyt, FA; Peters, GJ1
Bennett, GJ; Xiao, WH; Zheng, H1
Chan, DV; Gibson, HM; Hake, TS; Mishra, A; Porcu, P; Wong, HK1
Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Takashima, S; Yokota, N2
Basile, I; Cathiard, AM; Garcia, M; Gary-Bobo, M; Gleizes, M; Maynadier, M; Sheikh, MS; Shi, J; Vaillant, O; Wah, JL1
Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D1
Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P1
Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L1
Chen, Z; Jung, HJ; McCarty, N1
Jeong, SJ; Jung, JH; Kim, B; Kim, SH; Lee, MH; Sohn, EJ1
Suzuki, K2
Abbas, J; Costa, LJ; Kang, Y; Ortiz-Cruz, KL; Stuart, RK1
Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B1
Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L1
Hashimoto, N; Hattori, Y; Kato, J; Koda, Y; Mori, T; Okamoto, S; Sadahira, K; Shimizu, T; Tsukada, Y; Yamane, A; Yokoyama, K1
Botton, Sd; Boué, F; Bourhis, JH; Crickx, E; Danu, A; Ghez, D; Mariette, X; Miceli, C; Moreau, P; Pasquier, F; Ribrag, V; Wittnebel, S1
Chen, KF; Chen, MH; Huang, HP; Kuo, HY; Liu, CY; Shiau, CW; Tzeng, CH1
Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL1
Cai, Z; Han, X; He, J; Huang, H; Lin, M; Meng, X; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zheng, G; Zheng, W1
Lee, KY; Levacque, Z; Rosales, JL1
Ghielmini, M; Stathis, A1
Bantel, H; Kontermann, R; Krech, T; Länger, F; Lehner, F; Manns, MP; Nüssler, A; Pfizenmaier, K; Schulze-Osthoff, K; Siegemund, M; Vondran, F; Wahl, K1
Arima, N; Kawada, H1
Badros, A; Khan, RZ1
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y1
Cheng, H; Hu, X; Huang, C; Lü, S; Song, X; Wang, J; Wang, L; Yang, J1
Kim, JS; Lee, JW; Lee, MW; Roh, HS; Yu, HJ1
Fujisawa, K; Hirose, Y; Matsumoto, T; Murata, Y; Saeki, I; Sakaida, I; Takami, T; Terai, S; Yamamoto, N; Yamasaki, T1
Wang, X; Yao, C; Zhang, Z1
Bello, C; Comenzo, RL; Flombaum, C; Giralt, S; Hassoun, H; Hoover, E; Landau, H; Liu, J; Maurer, M; Riedel, E; Rosenzweig, MA1
Cakana, A; Deraedt, W; Domnikova, N; Doronin, VA; Esseltine, DL; Facon, T; Feng, H; Girgis, S; Hulin, C; Karamanesht, II; Kyselyova, MY; Leleu, X; Moreau, P; Schmidt, A; Skee, D; van de Velde, H; Venkatakrishnan, K; Vilchevska, KV1
Alsina, M; Anderson, KC; Bladé, J; Cavenagh, J; Dalton, W; Danaee, H; Esseltine, DL; Façon, T; Lichter, DI; Lonial, S; Mulligan, G; Niesvizky, R; Pickard, MD; Ricci, D; Richardson, PG; Shi, H; Sintchak, M; Sonneveld, P; Tayber, O; Trepicchio, WL; van de Velde, H1
Baran, Y; Sanlı-Mohamed, G; Turan, T1
Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM1
Synhaeve, NE; Tijssen, CC; van der Heul, C1
Akhundova, FM; Gal'tseva, IV; Gaponova, TV; Gretsov, EM; Kalinin, NN; Kuz'mina, LA; Mendeleeva, LP; Parovichnikova, EN; Pokrovskaia, OS; Savchenko, VG; Urnova, ES1
Bahlis, N; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; Lonial, S; Orlowski, RZ; Reiman, T; Siegel, DS; Somlo, G; Stewart, AK; Trudel, S; Vij, R; Wong, A1
Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM1
Azab, AK; Azab, F; Banwait, R; Flores, L; Ghobrial, IM; Jia, X; Maiso, P; Manier, S; Roccaro, AM; Sacco, A1
Altmann, A; Askoxylakis, V; Eisenhut, M; Haberkorn, U; Jesenofsky, R; Markert, A; Schöning, T1
Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK1
Bailey, C; Banugaria, SG; Conway, RL; Feldman, JD; Gera, R; Kishnani, PS; Kobori, JA; McGann, JK; Prater, SN; Rosenberg, AS; Tannenbaum, JA; Viskochil, D1
Adam, Z; Feit, J; Hájek, R; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V1
Brown, CO; Goel, A; Salem, K; Schibler, J1
Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T1
Chavez, M; Cohen, JI; Espey, MG; Levine, M; Shatzer, AN; Tu, H1
Joshi, KS; Manohar, SM; Shirsath, NP1
Cavenagh, J; Joel, S; Maharaj, L; Oakervee, H; Popat, R1
Heelan, K; McKenna, DB1
Ahmad, M; Badura, HE; El-Khattouti, A; Ghanjati, F; Haikel, Y; Hassan, M; Porzig, BB; Santourlidis, S; Selimovic, D1
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B1
Chari, A; Pri-Chen, H1
Harvey, RD; Kaufman, JL; Surati, M; Walker, BF; Wilson, N1
Buckstein, R; Caballero, D; Coiffier, B; Elsayed, YA; Enny, C; Esseltine, DL; Garicochea, B; Khuageva, NK; Soubeyran, P; Theocharous, P; Van Hoof, A; Walewski, J; Wang, H; Zhu, E; Zinzani, PL1
Yang, X1
Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L1
Fierabracci, A1
Ceder, R; Fadeel, B; Grafström, RC; Grandér, D; Hedenfalk, I; Heyman, M; Ottosson-Wadlund, A; Pokrovskaja, K; Preta, G; Robertson, JD; Söderhäll, S1
Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A1
Camara-Clayette, V; Hermine, O; Ribrag, V1
Barley, K; Chari, A; Jagannath, S; Osman, K1
Aisa, Y; Ito, C; Mihara, A; Nakazato, T1
Giralt, S; Landau, H; Rosenzweig, M1
Brem, GJ; Brüning, A; Mylonas, I1
Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Ghio, F; Orciuolo, E; Pelosini, M; Petrini, M1
Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL1
De Bruyne, E; Hu, J; Menu, E; Schots, R; Van Valckenborgh, E; Vanderkerken, K; Xu, D1
Kakpakova, ES; Kalitin, NN; Karamysheva, AF; Kostyukova, MN; Tupitsyn, NN1
Chang, MX; Jia, G; Lu, H; Lu, YJ; Ma, YP; Zhang, L1
Gosney, JR; Menzies, D; Thahseen, A; Williams, R1
Burbury, K; Doo, NW; Harrison, SJ; Joyce, T; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M1
Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA1
Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES1
Araujo, ME; Bates, SE; Bishton, M; Dai, Y; Grant, S; Harrison, SJ; Johnstone, RW; Lee, B; Piekarz, RL; Prince, HM1
Mita, N; Murata, S2
Ogura, M1
Burnett, CT; Santoro, FA1
Bouyssié, D; Burlet-Schiltz, O; Calligaris, D; Lutz, PG; Monsarrat, B; Uttenweiler-Joseph, S1
Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C1
Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P1
Brodie, C; Brodie, S; Cazacu, S; Finniss, SA; Kazimirsky, G; Lee, HK; Lemke, N; Margel, S; Mikklesen, T; Miller, C; Okhrimenko, H; Perlstein, B; Rempel, SA; Rosenblum, M; Umansky, F1
Bose, P; Grant, S1
Wirk, B1
Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O1
Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP1
Liang, Y; Liu, H1
Cao, B; Li, J; Mao, X1
Sun, Y; Zhao, Y1
Shi, Y; Wu, ZH1
Antonelou, MH; Margaritis, LH; Mpakou, VE; Papassideri, IS; Stravopodis, DJ; Velentzas, AD; Velentzas, PD1
Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF1
Bakhanashvili, M; Beery, E; Bulvick, S; Cohen, O; Kanfer, G; Lahav, M; Magen-Nativ, H; Nordenberg, J; Ram, R; Shilo, N; Uziel, O; Weiss, C; Wolach, O1
Li, J; Liu, T; Niu, T; Wei, Q; Yang, JR; Yang, YM; Zeng, K1
Ludwig, H; Sonneveld, P1
Cen, XN; Dong, YJ; Li, Y; Liu, W; Qiu, ZX; Ren, HY; Shi, YJ; Wang, LH; Yin, Y1
Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K1
Buac, D; Deshmukh, R; Dou, QP; Kona, FR; Mitra, B; Neslund-Dudas, C; Schmitt, S; Shen, M; Zhang, Z1
Cheng, Y; Harvey, H; Huber-Keener, KJ; Jefferson, LS; Kimball, SR; Ren, X; Shan, Y; Yang, JM; Zhang, L; Zhang, Y1
Chim, CS; Choi, PT; Lee, WK1
Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T1
Gertz, MA; Hayman, SR; Sher, T1
Hildebrandt, GC; Panu, LD; Shahan, JL1
Agosti, V; Amodio, N; Anderson, KC; Caraglia, M; Conforti, F; Di Martino, MT; Ferrarini, M; Foresta, U; Fulciniti, M; Gullà, AM; Leone, E; Leotta, M; Lionetti, M; Misso, G; Morabito, F; Munshi, NC; Neri, A; Pitari, MR; Rossi, M; Tagliaferri, P; Tassone, P1
Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L1
Beretta, M; Maeda, N; Mayer, B; Schmidt, K; Schrammel, A; Stessel, H; Wenzl, MV; Wölkart, G1
Benedetti, E; Jeon, H; Joseph, J; Oberholzer, J; Spaggiari, M; Thielke, J; Tzvetanov, I1
Henry, RW; Hovde, S; Hurchla, MA; Lansdell, TA; Tepe, JJ; Weilbaecher, KN; Xiang, J1
Bogenhagen, DF; Lee, J; Li, M; Lu, B; Morozov, YI; Nie, X; Suzuki, CK; Temiakov, D; Venkatesh, S1
Cavenagh, J; Cook, G; Cook, M; Davies, F; Elliott, P; Gumbleton, T; Jacobson, E; Oakervee, H; Plesner, T; Popat, R1
Anttila, P; Honkanen, T; Juvonen, V; Kairisto, V; Kuittinen, T; Lundán, T; Luukkaala, T; Opas, J; Pelliniemi, TT; Penttilä, K; Putkonen, M; Remes, K; Säily, M; Sikiö, A; Silvennoinen, R1
Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M1
Arora, S; Hussain, SM; Ko, TY; Marcus, RJ; Nath, P; Nigos, JG; Sureshkumar, KK1
Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A1
Blumenreich, MS; Dispenzieri, A; Mauermann, ML; Staff, NP1
Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H1
Chrysis, D; Eriksson, E; Heino, TJ; Sävendahl, L; Wehtje, H; Zaman, F1
Cavallo, F; Palumbo, A1
Locke, FL; Morgan, GJ1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H1
Camaschella, C; Campanella, A; Cenci, S; Fontana, F; Frenquelli, M; Marcatti, M; Santambrogio, P; Sitia, R; Tonon, G1
He, Q; Jing, H; Lin, N; Luo, P; Song, H; Yang, B; Yang, X; Ying, M; Zhong, L; Zhou, X1
Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH1
Arlow, T; Gammie, A; Scott, K; Wagenseller, A1
Andrulis, M; Bargou, RC; Beilhack, A; Bogen, B; Bumm, T; Chatterjee, M; Einsele, H; Heimberger, T; Riedel, S; Schraud, H; Stühmer, T1
Buurman, W; De Baets, MH; Gomez, AM; Losen, M; Martinez-Martinez, P; Molenaar, PC; Willcox, N1
Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zou, WY1
Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A1
Binkley, P; Blum, KA; Blum, W; Byrd, JC; Garzon, R; Geyer, S; Grever, MR; Jiang, Y; Johnston, JS; Kefauver, C; Klisovic, R; Marcucci, G; Phelps, MA; Walker, AR1
Hao, LM; Huang, JQ; Li, XM; Wang, SM; Wei, LY; Wu, HY1
Alexanian, R; Delasalle, K; Wang, M1
Auberger, J; Clausen, J; Greil, R; Hopfinger, G; Vogt, S1
Aggarwal, S; Bhargava, M; Khan, AA; Siraj, F1
Hao, P; Li, C; Li, X; Li, Y; Ma, C; Yu, S; Yu, Y; Zheng, L1
Bosly, A; Bouabdallah, R; Boue, F; Bron, D; Casasnovas, O; Coiffier, B; Delarue, R; Feugier, P; Haioun, C; Offner, F; Ribrag, V; Tilly, H1
Chen, X; Hu, C; Huang, Q; Liu, B; Ma, Y; Miao, P; Qian, L; Shen, L; Wang, L; Wang, P; Yu, Q; Yuan, X; Zhang, D; Zhang, J1
Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C1
Oh, DH; Opat, SS; Shortt, J1
Dou, QP; Guan, L; Guo, H; Huang, H; Li, B; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Tang, P; Xu, L; Yang, C; Zhang, C; Zhao, K1
Grosicki, S1
Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R1
Doki, N; Endo, I; Kakihana, K; Kamata, N; Kobayashi, T; Kojima, A; Ohashi, K; Oshikawa, G; Sakamaki, H; Tsuda, H1
Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A1
Atwal, S; D'Sa, S; Johnston, R; Khan, I; Moore, S; Narat, S; Percy, L; Rabin, N; Sachchithanantham, S; Schey, S; Streetly, M; Yong, K1
Gatt, ME; Palladini, G1
Chen, Q; Du, XL1
Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A1
Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST1
Barbone, D; Battula, S; Broaddus, VC; Bueno, R; Busacca, S; Cheung, P; Fennell, DA; Gray, SG; Longley, DB; Sugarbaker, DJ1
Bardag-Gorce, F; Bejaoui, M; Ben Abdennebi, H; Carbonell, T; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F1
Lonial, S; Miguel, JF1
McCarthy, PL1
Mina, R; Palumbo, A1
Berezniuk, I; Castro, LM; Dasgupta, S; Ferro, ES; Fricker, LD; Gelman, JS; Gozzo, FC; Sironi, J1
Heider, U; Kaiser, MF; Mieth, M; Sezer, O; von Metzler, I; Zang, C1
Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE1
Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C1
Ren, ZP; Sun, LP; Tong, QX1
Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G1
Fujiwara, S; Hata, H; Kawano, Y; Mitsuya, H; Nosaka, K; Okuno, Y; Yuki, H1
Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M1
Bagot, M; Bezier, M; Cordoliani, F; Delyon, J; Malphettes, M; Rybojad, M; Szalat, R1
Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF1
Dash, D; Kulkarni, PP; Nayak, MK1
Hatzidaki, E; Koukoulis, GK; Papandreou, CN; Stathakis, NE; Vlachostergios, PJ1
Fujino, Y; Goto-Koshino, Y; Kojima, K; Ohno, K; Tsujimoto, H1
Hoy, SM1
Fujisawa, K; Hara, K; Kinouchi, M; Kuribayashi, N; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D1
Bae, SH; Chung, JS; Eom, HS; Jo, DY; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Kim, YS; Lee, HS; Lee, JH; Min, CK; Mun, YC; Suh, C; Yoon, SS1
Bach, HH; Gamelli, RL; Laporte, HM; Majetschak, M; Wong, YM1
Ahn, JS; Bae, SY; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH1
Bastian, L; Eckert, C; Fichtner, I; Henze, G; Hof, J; Pfau, M; Prada, J; Seeger, K; Shalapour, S; von Stackelberg, A1
Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Jayabalan, DS; Lane, ME; Manco, M; Mark, TM; Mathews, L; Niesvizky, R; Pearse, RN; Pekle, K; Shore, TB; Skerret, D; Stern, J; Ward, M; Xiang, Z; Zafar, F1
Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H1
Admasie, J; Alici, E; Aschan, J; Barendse, M; Carlson, K; Deneberg, S; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Uttervall, K1
Chen, WM; Chen, ZZ; Shang, J; Wei, TN; Wu, WB1
Jia, G; Ma, YP; Zhang, L1
Collet, P; Marotte, H; Nizeica, V1
Chen, KF; Cheng, AL; Hou, DR; Lin, CS; Liu, CY; Shiau, CW; Yu, HC1
Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M1
Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D1
Akashi, K; Eto, T; Fujisaki, T; Henzan, T; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Ohno, Y; Takamatsu, Y; Takenaka, K; Teshima, T1
Bladé, J; Cibeira, MT; Díaz, T; Fernández de Larrea, C; Martín-Antonio, B; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N; Urbano-Ispizua, A1
Cai, J; Qing, X; Tan, J; Terasaki, PI1
Li, J; Zhou, DB1
Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D1
Bosman, MC; Quax, WJ; Schuringa, JJ; Vellenga, E1
Lin, B; Wang, Y1
Adam, Z; Cermáková, Z; Hájek, R; Král, Z; Krejčí, M; Mayer, J; Navrátil, M; Pospíšilová, Y; Pour, L; Sandecká, V; Stork, M; Zahradová, L1
Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V1
Hur, D; Jin, DH; Kim, D; Kim, JE; Lee, WJ; Wu, TC1
Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S1
Gillet, JP; Gottesman, MM; Varma, S1
Davies, FE; Fryer, RA; Graham, TJ; Morgan, GJ; Robinson, SP; Smith, EM; Walker-Samuel, S1
Biskup, E; Gniadecki, R; Kamstrup, MR; Manfé, V1
Ambinder, RF; Forde, PM; Gladstone, DE; Hourigan, CS1
Cao, Q; Miller, J; Warlick, ED1
Chao, A; Chen, HW; Chuang, WC; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH; Yen, TC1
Chen, J; Lin, J; Zeng, Z1
Bergsagel, PL; Chesi, M1
Dumontet, C; Plesa, A; Tagoug, I1
Downey, SL; Eastman, A; Goddard, AL; Kisselev, AF; Lucas, MM; Screen, M; Shabaneh, TB1
Han, J; Jeong, SH; Kim, HK; Kim, N; Ko, KS; Lee, SR; Rhee, BD; Song, IS1
Grabher, D; Heufler, C; Hofer, S; Ortner, D1
Hatano, Y; Iida, S; Ito, M; Iwamoto, K; Kitabayashi, A; Kume, M; Nara, M; Sawada, K; Tagawa, H; Takahashi, N; Teshima, K; Watanabe, A1
Cho, YH; Choi, BS; Choi, YJ; Chung, BH; Hong, YA; Kim, YS; Park, CW; Park, GS; Sun, IO; Yang, CW1
Doi, T; Fujimi, A; Hashimoto, A; Ishikawa, K; Kanisawa, Y; Matsuno, T; Minami, S; Okuda, T; Uemura, N1
Brandstetter, M; Engelhard, K; Förster, CY; Neuhaus, W; Schaible, EV; Scheffer, D; Thal, SC; Wunder, C1
Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW1
Aldini, G; Altomare, A; Fusi, C; Geppetti, P; Lodovici, M; Materazzi, S; Nassini, R; Patacchini, R; Trevisan, G1
Bauvois, B; Billard, C; Bouchet, S; Dauzonne, D; Piedfer, M; Tang, R1
Eriksson, E; Sävendahl, L; Zaman, F1
Lacy, MQ1
Burmester, GR; Buttgereit, F; Dörner, T; Egerer, K; Faustman, DL; Feist, E; Gaber-Elsner, T; Ghannam, K; Hahne, M; Kloetzel, PM; Kuckelkorn, U; Lesemann, K; Martinez-Gamboa, L; Naumann, L; Scheffler, S1
Du, X; Geng, S; Lai, P; Lin, S; Ling, W; Liu, X; Luo, C; Lv, M; Weng, J1
Chen, W; Gao, W; Geng, C; Li, Y; Wang, C; Zhang, L1
Lu, H; Sheng, Z; Yu, J; Zou, Y1
Abe, M; Fujii, S1
Chovan, JP; Li, AC; Ring, SC; Yu, E1
Biskup, E; Croce, CM; Gasparini, P; Gniadecki, R; Laganá, A; Manfè, V; Palmieri, D; Skov, AG; Willumsgaard, A; Woetmann, A; Ødum, N1
Goel, S; Lue, J; Mazumder, A1
Hájek, R; Kryukov, F; Kubiczková, L; Matějíková, J; Sedlaříková, L; Sevčíková, S1
Hu, Y; Wu, P; Zhang, J1
Catley, L; Connor, T; McGee, SL; Mottram, B; Sanchez, WY; Vuckovic, S; Whitehead, JP; Wilkinson, A1
Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S1
Horton, T; Hunger, SP1
Baughn, LB; Deshpande, R; Dolloff, NG; Janz, S; Linden, MA; Mansoor, A; Myers, CL; Sarver, A; Stessman, HA; Sunderland, JJ; Van Ness, BG; Walsh, SA; Xia, T; Zhan, F1
Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F1
Admon, A; Barnea, E; Bassani-Strenberg, M; Beer, I; Gutter-Kapon, L; Milner, E1
Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D1
Ames, MM; Erlichman, C; Hendrickson, AE; Menefee, M; Northfelt, D; Qin, R; Satele, D; Schenk, E; Toft, DO1
Minvielle, S; Moreau, P1
Chen, J; Li, S; Que, W1
Abe, A; Che, XF; Gotoh, A; Inazu, M; Kawaguchi, T; Komatsu, S; Miyazawa, K; Moriya, S; Tomoda, A1
Adjibade, P; Côté, MF; Coudert, L; Fournier, MJ; Gareau, C; Gaudreault, RC; Mazroui, R; Mellaoui, S; Sonenberg, N1
Cakana, A; Coiffier, B; Crump, M; de Vos, S; Elsayed, YA; Esseltine, DL; Favis, R; Gaffney, D; Henitz, ED; Hong, X; Karkera, JD; Li, W; Mayer, J; Mulligan, G; Offner, F; Osmanov, EA; Ricci, D; Romejko-Jarosinska, J; Rule, S; Schaffer, ME; Scheliga, A; Shapiro, A; Shpilberg, O; Teixeira, A; Theocharous, P; van de Velde, H; Zinzani, PL1
Conticello, C; Di Raimondo, F; Romano, A1
Arnulf, B; Attal, M; Benajiba, L; Caillot, D; Caulier, A; Chaleteix, C; Chrétien, ML; Facon, T; Fermand, JP; Fouquet, G; Garciaz, S; Garderet, L; Hebraud, B; Leleu, X; Loiseau, HA; Moreau, P; Pegourie, B; Regny, C; Roussel, M; Royer, B; Stoppa, AM; Szalat, R; Touzeau, C1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I1
Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT1
Bodeen, WJ; Han, YG; Marada, S; Ogden, SK; Stewart, DP1
Cassidy, J; Hochster, H1
Ando, K; Hotta, T; Iida, S; Ishii, M; Matsue, K; Matsumoto, M; Mukai, HY; Ogawa, Y; Ogura, M; Ohashi, K; Sakai, A; Suzuki, K; Terui, Y; Tobinai, K1
Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L1
Ambrosio, CE; Araujo, KP; Belizario, JE; Bonuccelli, G; Duarte, CN; Feder, D; Gaiad, TP; Lisanti, MP; Miglino, MA; Moreira, DF1
Anderson, K; Clynes, M; Delmore, J; Jakubikova, J; Klippel, S; Meiller, J; Mitsiades, CS; O'Connor, R; O'Gorman, P; Ooi, MG; Richardson, P1
Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J1
Anderl, J; Gupta, S; Kirk, C; Kruger, WD; Slifker, MJ; Wang, L1
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Nobuyoshi, M; Ohki, M; Park, SY; Shibayama, N; Sugiyama, K; Wada, T; Yamada, S1
Cao, ZG; Liu, M; Zhou, HW1
Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S1
Kim, JA; Kwak, JY; Lee, BH; Min, CK; Shin, SH; Yhim, HY1
Babcock, JT; He, Y; Hendricks, JW; Nguyen, HB; Quilliam, LA; Wek, RC1
Adams, GP; Balachandran, S; Chen, P; Nogusa, S; Peri, S; Shaller, C; Simmons, H; Thapa, RJ1
Besada, E; Koldingsnes, W; Nossent, JC; Vik, A1
Abildgaard, N; Ahlberg, L; Andersen, NF; Blimark, C; Carlson, K; Dahl, IM; Forsberg, K; Gedde-Dahl, T; Gimsing, P; Gregersen, H; Gruber, A; Guldbrandsen, N; Haukås, E; Hjertner, O; Kvam, AK; Laane, E; Lenhoff, S; Lindås, R; Mellqvist, UH; Nahi, H; Remes, K; Steingrimsdottir, H; Turesson, I; Waage, A; Westin, J1
Ramachandran, PV1
Banerjee, SK; Das, BC; Das, S; Evans, T; Kambhampati, S; Karki, R; Schinke, C; Thapa, P; Van Veldhuizen, P; Verma, A; Weiss, LM1
Friman, S; Hansson, S; Holgersson, J; Mjörnstedt, L; Stelin, G; Westphal, S1
Claas, FH; Heidt, S; Mulder, A; Roelen, DL; Vergunst, M1
Andreu, AL; Barreiro, E; de Kier Joffé, ED; Fermoselle, C; García-Arumí, E; Puente-Maestu, L; Puig-Vilanova, E; Tejedor, A; Urtreger, AJ1
Ashlock, BM; Bhatt, S; Diaz, LA; Lossos, IS; Mesri, EA; Ramos, JC; Toomey, NL1
Mahindra, A; Saini, N1
Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M1
Fulda, S; Jung, M; Rapino, F1
Befani, CD; Hatzidaki, E; Liakos, P; Papandreou, CN; Vlachostergios, PJ1
Aldinucci, D; Borghese, C; Carbone, A; Casagrande, N; Celegato, M; Colombatti, A1
Boland, R; González-Pardo, V; Russo de Boland, A; Verstuyf, A1
Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N1
Chai, J; Jiang, Y; Li, Y; Luo, H; Xiao, X; You, Y; Zhou, Y; Zhu, H; Zuo, X1
Balachandran, S; Chen, P; Cheung, M; Nogusa, S; Pei, J; Peri, S; Testa, JR; Thapa, RJ1
Altıkat, S; Boyaci, I; Cavga, FZ; Irmak, R; Kocacan, SA; Yerlikaya, A1
Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM1
Gartel, AL; Halasi, M; Hay, N; Nogueira, V; Pandit, B; Wang, M1
Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH1
Arakaki, H; Uchihara, JN1
An, G; Deng, SH; Feng, XY; Hao, M; Li, F; Qiu, LG; Sui, WW; Wang, YF; Xu, Y1
Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Lan, HF; Lu, J; Yuan, ZG; Zeng, TM; Zhang, CY; Zhou, F; Zhou, LL1
Gu, JL; Li, J; Liu, JR; Wang, HH; Xu, DR; Yan, MS; Zheng, D; Zou, WY1
Huang, XJ; Lu, J; Wang, H1
Andreeff, M; Carter, BZ; Davis, RE; Ma, W; Mak, DH; Mak, PY; Wang, Z1
Eiermann, T; Gräser, C; Koch, M; Kröger, N; Lehnhardt, A; Nashan, B; Pollok, JM; Thaiss, F; Verboom, M1
Chettab, K; Dumontet, C; Herveau, S; Huber, AL; Jordheim, LP; Manié, S; Matera, EL; Tagoug, I1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S1
Cerrato, C; Palumbo, A2
Hatano, Y; Ikeda, S; Ito, M; Nara, M; Oshima, K; Sawada, K; Seto, M; Tagawa, H; Teshima, K; Watanabe, A1
Cao, C; Dang, D; Janbain, M; Maalouf, B; Saba, J; Saba, NS; Safah, H1
Chen, FT; Yang, CH; Yang, CM1
Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C1
Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T1
Ahmed, M; Al-Kuraya, KS; Al-Obaisi, KA; Bu, R; Hussain, AR; Uddin, S1
Lin, YJ; Liu, XJ; Shang, BY; Zhen, YS; Zhen, YZ1
Chan, JY; Ho, DV; Lee, CS1
Dimopoulos, MA; Kastritis, E; Terpos, E1
Brissot, E; Gaugler, B; Mohty, M; Savani, BN1
Cao, B; Du, X; Mao, X; Zhang, Z; Zhao, C; Zhao, Y1
Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Kido, S; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, K1
Jongen, JL; Rampen, AJ; Scheltens-de Boer, M; Sonneveld, P; van den Bent, MJ; van Heuvel, I1
Hu, H; Liu, Y; Lu, L; Meng, W; Qing, Y; Shen, Y; Xu, J; Zhang, B1
Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A1
Dadhania, D; Everly, MJ; Friedlander, R; Kannabhiran, D; Putheti, P; Sharma, V; Tiongko, S; Walker-McDermott, JK1
Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T1
Baughn, LB; Janz, S; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F1
Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S1
Ahuja, HG; Blank, JH; Campbell, TC; Hernan, HR; Hoang, T; Huie, MS; Johnson, PH; Kim, K; Kirschling, RJ; Kolesar, JM; Larson, MM; Oettel, KR; Robinson, EG; Traynor, AM; Wims, ME; Zhang, C1
Baughn, LB; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B1
Li, Zw; Luo, M; Qiu, Jx; Wang, Y; Wen, Xf1
Arthur, K; Barbone, D; Broaddus, VC; Busacca, S; Chacko, AD; El-Tanani, M; Fennell, DA; Gaudino, G; Gorski, JJ; Gunasekharan, VK; Klabatsa, A; Mutti, L; Sheaff, M1
Ma, L; Shen, B; Sun, H; Sun, L; Sun, Y; Ye, Y; Yu, J; Zhang, D; Zhang, L; Zhu, C1
Gumulec, J; Hájek, R; Plonková, H1
Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K1
Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, YY; Zhang, X; Zhang, ZH; Zhu, XB1
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D1
Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R1
Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Pinney, JH; Roussel, M; Sachchithanantham, S; Venner, CP; Wechalekar, AD1
Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M1
Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G1
McNeil, C1
Carrie, D; Despas, F; Dumonteil, N; Galinier, M; Honton, B; Montastruc, JL; Pathak, A; Roussel, M; Rouvellat, C1
Azevedo, LM; Cogan, DP; Fisk, JS; Kuszpit, MR; Lansdell, TA; Ludwig, JR; Mosey, RA; Patten, GP; Tepe, JJ; Woloch, DK1
Baas, P; Cufer, T; Danson, S; Gaafar, RM; Grossi, F; Hasan, B; O'Brien, ME; Ottensmeier, C; Pallis, A; Popat, S; Price, A; Talbot, DC; Van Meerbeeck, JP1
Che, XF; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Yokoyama, T1
Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J1
Azzarà, A; Carulli, G; Ciabatti, E; Ciancia, EM; Ferreri, MI; Grassi, S; Marini, A; Ottaviano, V; Petrini, M; Rocco, M1
Horiike, S; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto-Sugitani, M1
Gesheva, VV; Nikolova-Ganeva, KA; Todorov, TA; Vassilev, TL; Voll, RE1
Bignon, E; Facon, T; Fermand, JP; Fitoussi, O; Fourrier-Réglat, A; Grelaud, A; Jové, J; Lassalle, R; Marit, G; Moore, N; Noize, P; Robinson, P; Rouyer, M; Thomaré, P1
Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM1
Farmer, DG; Kempert, P; Plant, AS; Said, J; Upadhyay, S; Venick, RS1
Geltink, RI; Grosveld, GC; Marshall, AD; Picchione, F1
Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN1
Wan, J1
Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G1
Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N1
Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY1
Gao, L; Shi, J; Tao, Y; Wang, H; Wu, X; Yang, G; Zhan, F1
Czuczman, MS; Czuczman, NM; Gu, JJ; Hernandez-Ilizaliturri, FJ; Kaufman, GP; Mavis, C; Skitzki, JJ1
Hou, L; Liu, T; Liu, ZG; Niu, T; Yang, JR; Yang, YM; Zeng, K1
Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A1
De Bruyne, E; De Bryune, E; De Raeve, H; Handisides, D; Hart, CP; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D; Xu, S1
Hata, H; Higuchi, M; Miyamoto, T; Morimoto, H; Muta, T; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K1
Bringhen, S; Cerrato, C; Magarotto, V; Palumbo, A; Pautasso, C1
Allain-Launay, E; Blancho, G; Blin, N; Cesbron, A; Moreau, A; Roussey, G; Ryckewaert, A1
Forsberg, PA; Mark, TM1
Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM1
Chng, WJ; Chung, TH; Fonseca, R; Mulligan, G1
Bell, S; Desmond, PV; Goldberg, R; Smith, E; Thompson, A1
Barton, MK1
Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M1
Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X1
Abe, D; Amagai, M; Hosokawa, R; Murakami, K; Ohyama, M; Okamoto, S; Yokoyama, K1
Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA1
Carew, JS; Coffey, M; Espitia, CM; Freeman, JW; Kelly, KR; Nawrocki, ST; Zhao, W1
Choi, W; Dinney, C; Guo, C; McConkey, DJ; Qi, W; Siefker-Radtke, A; White, MC1
Akashi, K; Choi, I; Ito, Y; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shiratsuchi, M; Takamatsu, Y; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G1
Kariya, R; Matsuda, K; Okada, S; Taura, M; Vaeteewoottacharn, K; Wongkham, C; Wongkham, S1
Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D1
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Koyama, D; Nobuyoshi, M; Wada, T; Yamada, S1
Egashira, N; Oishi, R1
Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A1
Bennett, GJ; Bryant, L; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Ryerse, J; Salvemini, D1
El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW1
Chang, TP; Gatla, HR; Manna, S; Phyo, SA; Ramaswami, S; Sanacora, S; Singha, B; Vancurova, I1
Chang, CI; Huang, KF; Ihara, K; Kuo, CI; Liao, JH; Wakatsuki, S; Wu, SH1
Attal, M; Bladé, J; Cakana, A; Cavo, M; Desai, A; Esseltine, DL; Goldschmidt, H; Lahuerta, JJ; Liu, K; Lokhorst, HM; Moreau, P; Rosiñol, L; Sonneveld, P; Tacchetti, P; van de Velde, H; Zamagni, E1
Joseph, C; Ribeiro, A; Seikaly, M; Thach, L; Twombley, K1
Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ1
Goebeler, M; Kneitz, H; Kolb-Mäurer, A1
Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG1
Bai, QX; Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Liang, R; Shu, MM; Yang, L; Zhang, T; Zhang, YQ1
Klánová, M; Špička, I1
Brugge, JS; Coloff, JL; Ince, TA; Iwanicki, MP; Kim, M; Kroemer, G; Ofengeim, D; Pan, L; Vakifahmetoglu-Norberg, H; Xia, HG; Yuan, J1
Brüning, A; Friese, K; Rahmeh, M1
Erdoğan, E; Genç, O; Savran, B; Yerlikaya, A1
Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN1
Li, J; Liu, SS; Tsui, J; Wang, HH; Wang, XY1
Wang, ZQ; Xie, JL; Zhou, XG1
Bakhous, A; Waheed, S; Zhu, H1
Chen, Z; Fayad, L; Kwak, L; McCarty, N; McLaughlin, P; Neelapu, SS; Pittman, EF; Romaguera, J; Wang, M1
Almeida, GM; Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S; Sampaio, P; Silva, FS1
Alsina, M; Coutre, SE; Gasparetto, C; Khan, M; Lonial, S; Mukhopadhyay, S; Ondovik, MS; Paley, CS; Richardson, PG; Schlossman, RL; Weber, DM1
Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR1
Ise, M; Kumagai, K; Sakai, C1
De Vita, S; Michieli, M; Quartuccio, L; Rupolo, M1
Cao, Y; Chapman, C; Friedman, J; Hamstra, D; Hayman, J; Lao, CD; Lawrence, T; Lee, O; Normolle, DP; Redman, BG; Schipper, M; Tsien, CI; Van Poznak, C1
Mangone, M; Marchi, E; O'Connor, OA; Zullo, K1
Morgan, GJ1
Chan, NG; Hsia, CC1
Beppu, M; Fujimaki, Y; Isose, S; Iwai, Y; Kuwabara, S; Misawa, S; Mitsuma, S; Nakaseko, C; Nasu, S; Ohmori, S; Ohwada, C; Sekiguchi, Y; Shibuya, K; Shimizu, N; Takeda, Y1
Mark, TM; Meadows, JP1
Guo, W; Jiao, G; Lou, Z; Lu, Q; Lu, X; Peng, X; Ren, T; Sun, Y; Zhang, S1
Jaffrey, SR; Jiang, X; Xu, G1
Belloni, D; Berenzi, A; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Girlanda, S; Mazzoleni, G; Ponzoni, M; Steimberg, N1
Childs, R; Cook, L; Jaffe, ES; Ramos, C; Vo, P1
Cicora, F; Mos, F; Paz, M; Roberti, J1
Attal, M; Avet-Loiseau, H; Blaise, D; Cornillon, J; El-Cheikh, J; Harousseau, JL; Labussière, H; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Morisset, S; Nicolini, FE; Reman, O; Sirvent, A; Sobh, M; Tabrizi, R1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K1
Bertsch, U; Blau, IW; Bos, GM; Croockewit, S; Duehrsen, U; el Jarari, L; Goldschmidt, H; Hänel, M; Jie, KS; Kersten, MJ; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; van de Velde, H; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Weisel, K; Wijermans, P; Wittebol, S; Zweegman, S1
Ma, LM; Zhao, J1
Cheng, ZY; Jia, ZQ; Li, AM; Wei, YT1
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L1
Dimopoulos, MA; García-Sanz, R; Gavriatopoulou, M; Gika, D; Kartasis, Z; Kastritis, E; Kyrtsonis, MC; Leleu, X; Merlini, G; Michalis, E; Morel, P; Palladini, G; Sonneveld, P; Tedeschi, A1
Behera, M; Boise, LH; Flowers, CR; Gleason, C; Kaufman, JL; Langston, A; Lonial, S; Nooka, AK; Waller, EK1
Guo, Y; Liu, R; Odusote, G; Priestley, RD; Qu, F1
Brnjic, S; D'Arcy, P; Fryknäs, M; Larsson, R; Linder, S; Mazurkiewicz, M; Sun, C; Zhang, X1
Anderson, KC; Bladé, J; Bourquelot, PM; Günther, A; LeBlanc, R; Mishra, KK; Mu, S; Richardson, PG; San-Miguel, JF; Sezer, O; Siegel, D; Sopala, M; Sutherland, H; Victoria Mateos, M1
Brown, KJ; Cakir, E; Coley, W; Dillingham, BC; Hathout, Y; Kinder, TB; Nagaraju, K; Rayavarapu, S; Tappeta, K; Van der Meulen, JH1
Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS1
Cheung, G; Chung, KC; Erdmann, N; Keats, JJ; Leung-Hagesteijn, C; Reece, DE; Stewart, AK; Tiedemann, RE1
Ahn, C; Han, M; Jeon, HJ; Jeong, JC; Kim, MG; Kim, YJ; Koo, TY; Kwon, HY; Park, HC; Yang, J1
Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H1
Bader, M; Grassner, L; Knight, AM; Loprinzi, CL; Paz, J; Podratz, JL; Staff, NP; Trushina, E; Windebank, AJ1
Chen, CC; Cron, KR; D'Andrea, AD; Hsieh, G; Kozono, D; Kushwaha, DS; Merzon, D; Rameseder, J; Zhu, K1
Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L1
Baum, C; Deuse, T; Reichenspurner, H1
Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Manios, E; Migkou, M; Papadimitriou, C; Roussou, M; Terpos, E1
Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L1
Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F1
Alinari, L; Baiocchi, RA; Blum, KA; Byrd, JC; Johnston, JS; Li, X; Lin, TS; Lustberg, ME; Porcu, P1
Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C1
Sommer, T; Wolf, DH1
Cho, NH; Choi, HK; Chun, YJ; Im, HJ; Kim, D; Kwon, Y; Park, N; Park, YS; Shin, S; Sung, CH; Ye, DJ1
Anderl, J; Assaraf, YG; Cloos, J; de Haas, V; Degenhardt, J; Franke, NE; Horton, TM; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; Zweegman, S1
Berciano, MT; Casafont, I; Lafarga, M; Palanca, A2
Lin, M; Niu, S; Sheng, Z; Zou, Y1
Nace, RA; Russell, SJ; Yarde, DN1
Bardini, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Dorsey, SG; Fazio, G; Meregalli, C; Oggioni, N; Quartu, M; Renn, CL; Sala, B; Serra, MP; Shanks, K1
Bernard, M; Bosq, J; Camara-Clayette, V; Fest, T; Koscielny, S; Lamy, T; Lazar, V; Lenoir, G; Ribrag, V; Roux, S1
Afek, A; Arad, M; Aravot, D; El-Ani, D; Eldar, M; Hochhauser, E; Issac, A; Katz, G; Kurtzwald-Josefson, E; Seidman, CE; Seidman, JG; Shainberg, A1
Al-Salihi, M; Herhaus, L; Macartney, T; Sapkota, GP; Weidlich, S1
Guzman, ML; Hayslip, J; Howard, DS; Jordan, CT; Liesveld, J; Phillips, GL; Weiss, H1
Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K1
Drach, J; Drach-Schauer, B; Eder, S; Lamm, W1
Ballester, G; Ballester, O; Yaqub, S1
Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yoon, JH1
Jeong, J; Lee, KH; Yoo, CG1
Ahmed, EH; Bernot, KM; Blum, W; Brook, DL; Caligiuri, MA; Dickerson, KE; Dorrance, AM; Garman, S; Lee, RJ; Liu, S; Marcucci, G; Marcucci, GG; McConnell, KK; Mundy-Bosse, BL; Muñoz, MR; Nemer, JS; Santhanam, R; Siebenaler, RF; Whitman, SP; Yang, X; Zhang, J; Zhang, M; Zhang, X; Zorko, NA1
Adami, F; Brancalion, A; Cabrelle, A; Cappellesso, R; Colpo, A; Di Maggio, SA; Gurrieri, C; Mandato, E; Manni, S; Marino, F; Piazza, F; Pizzi, M; Semenzato, G; Trentin, L; Tubi, LQ; Zaffino, F; Zambello, R1
Cirone, M; D'Orazi, G; Di Renzo, L; Faggioni, A; Frati, L; Garufi, A; Gonnella, R; Granato, M; Lotti, LV; Santarelli, R; Trivedi, P1
Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J1
Abt, PL; Lou, Y; Naji, A; Noorchashm, H; Parsons, RF; Redfield, RR; Rodriguez, E; Rostami, S1
Al-Homsi, AS; Kouttab, N; Lai, Z; Roy, TS1
Chen, SJ; Guo, Y; Janin, A; Leboeuf, C; Romero, M; Wang, L; Wu, LL; Xue, K; Yan, ZX; Zhang, QL; Zhao, WL1
Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X1
Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J1
Atanackovic, D; Schilling, G1
Kuna, M; Mikecin, AM; Raucher, D; Walker, LR1
Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ1
Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J1
de Jong, H; Schreuder, MF; van Balen, T; van de Kar, NC1
Babina, M; Mudnakudu Nagaraju, KK; Worm, M1
Alvarez, R; Cabeçadas, J; Calaminici, M; Clear, AJ; Coutinho, R; Gomes da Silva, M; Gribben, JG; Lee, A; Matthews, J; Owen, A; Wilson, A1
Chatziaggelidou, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kyrtsonis, MC; Spyridis, N; Stefanoudaki, A; Symeonidis, A; Terpos, E; Verrou, E; Zervas, K1
An, M; Hu, J; Hu, R; Li, X; Ruan, K; Shen, J; Song, G; Wu, N1
Fujiwara, S; Hata, H; Kawano, Y; Kikukawa, Y; Mitsuya, H; Okuno, Y; Wada, N1
Abdennebi, HB; Bardag-Gorce, F; Bejaoui, M; Carbonell, T; Folch-Puy, E; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA1
Anderson, K; Hideshima, T; Laubach, J; Richardson, P1
Moreau, P; Touzeau, C2
Liu, H; McCarthy, P1
Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA1
Blouin, JM; Costet, P; de Verneuil, H; Duchartre, Y; Ged, C; Lain, A; Lalanne, M; Millet, O; Richard, E1
Cain, R; Waight, CC1
Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL1
Chen, Y; Deng, Y; Deng, ZK; He, ZM; Li, YY; Tao, SD; Yu, L; Zhang, X1
Han, J; Heo, HJ; Jeong, SH; Jeong, YJ; Kim, HK; Kim, N; Ko, KS; Ko, TH; Lee, SR; Rhee, BD; Song, IS; Youm, JB1
Lentzsch, S; Schecter, J1
Akria, L; Azoulay, D; Ben-Yehuda, D; Braester, A; Gatt, ME; Horowitz, N; Lavie, D; Perlman, R; Suriu, C1
Hagihara, M; Hattori, Y; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Tomita, N; Yamamoto, E; Yamazaki, E1
Burlingame, AL; Julien, O; Urisman, A; Weissman, JS; Wells, JA; Wiita, AP; Wiita, PJ; Ziv, E1
Fu, CC; Gu, B; Jin, S; Li, WY; Liu, H; Ma, L; Sun, AN; Wu, DP; Wu, Q; Xin, X; Xue, SL; Zhao, SF; Zhu, XM1
Cheng, B; Gong, L; Jing, Y; Tang, X; Wu, GJ; Xu, M; Yang, B; Zheng, P1
Baughn, LB; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F1
Kost, CK; Li, S; Li, Y; Martin, DS; Wang, X1
Reisman, SA1
An, G; Deng, S; Qiu, L; Shi, L; Shizhen, Z; Sui, W; Xie, Z; Xu, Y; Zhan, F1
Anaclerico, B; Annino, L; Arcese, W; Avvisati, G; Cerchiara, E; Chierichini, A; Cudillo, L; De Fabritiis, P; Dentamaro, T; Giannotti, F; Marchesi, F; Mengarelli, A; Monarca, B; Montefusco, E; Petti, MC; Picardi, A; Porrini, R; Romeo, A; Tendas, A; Tirindelli, MC1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL1
Akar, M; Aktan Kosker, T; Buyukasik, S; Ersoy, O; Solakoglu, T1
Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J1
Alsop, K; Au-Yeung, G; Bowtell, DD; D'Andrea, AD; Davis, S; Etemadmoghadam, D; George, J; Hahn, WC; Mitchell, G; Simpson, K; Weir, BA1
Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D1
Van Damme, P1
Engelhardt, M; Fiebig, HH; Klingner, K; May, AM; Schueler, J; Siegers, GM; Wäsch, R; Wider, D1
Gahrton, G; Krishnan, A1
Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N1
Cao, B; Chen, G; Du, X; Han, K; Li, J; Mao, X; Shi, M; Tang, J; Wang, M; Xu, X; Zhang, Z1
Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ1
Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV1
Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME1
Akashi, K; Aoki, T; Ito, Y; Kamimura, T; Miyamoto, T; Yokota, N1
Malard, F; Mohty, B; Mohty, M; Moreau, P; Savani, B; Terpos, E1
Barbee, MS; Harvey, RD; Hutcherson, DA; Kaufman, JL; Lonial, S; McKibbin, T; Shah, KS; Surati, M; Valla, K; Wilson, NM1
Al-Homsi, AS; Al-Malki, MM; Junghans, RP; Kouttab, N; Lai, Z; Roy, TS1
Fulda, S; Naumann, I; Rapino, F1
Alloway, RR; Cardi, M; Ejaz, NS; Girnita, AL; Mogilishetty, G; Sadaka, B; Shields, AR; Woodle, ES1
Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, ZS; Zhang, X; Zhang, ZH; Zhu, XB1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S1
Ahn, KS; Bae, EK; Choi, JH; Jung, WJ; Lee, C; Park, J; Yoon, SS1
Khan, S; Li, WH; Sun, SR; Tang, Z; Wan, JN; Wang, CH; Yao, F; Zhang, YM; Zhu, S1
Cavallo, F; Cerrato, C; Mina, R; Palumbo, A1
Dou, QP; Hua, X; Huang, H; Li, S; Li, X; Liu, J; Liu, N; Liu, S; Xu, L; Yang, C; Zhao, C1
Bokhari, SW; Jones, FM1
Alesiani, F; Discepoli, G; Leoni, P; Liberati, S; Morelli, MB; Nabissi, M; Offidani, M; Olivieri, A; Santoni, G; Santoni, M1
Chen, L; Fu, JX; Ju, SG; Li, J; Wang, ZY; Yuan, YQ1
An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D1
Gaut, D; Hu, K; Koeffler, HP; Lin, L; Yan, H; Yin, D1
Condelli, V; Esposito, F; Landriscina, M; Lettini, G; Maddalena, F; Matassa, DS; Sisinni, L1
De Maeyer, N; Delforge, M; Dierickx, D; Meersseman, W; Wauters, J1
Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A1
Fadeel, B; Feng, X; Henter, JI; Ji, C; Ma, D; Shao, N; Wang, J; Wang, X; Zheng, C1
Chiba, S; Furukawa, Y; Hiraoka, N; Kikuchi, J; Koyama, D; Kurosawa, H; Wada, T1
Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K1
Brooks, TR; Carson, WE; Dao, TV; Grignol, VP; Hade, EM; Kendra, KL; Kondalasula, SV; Lesinski, GB; Luedke, EA; Markowitz, J; Mundy-Bosse, BL; Olencki, T; Paul, BK1
Alexanian, R; Delasalle, K; Handy, B; Qazilbash, M; Wang, M; Wang, S; Weber, D1
Hahn, T; McCarthy, PL1
Anderson, KC; Carrasco, RD; Chauhan, D; D'Arcy, P; Hu, Y; Linder, S; Ray, A; Richardson, P; Tai, YT; Tian, Z; Wang, X1
Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR1
Baldassarre, FG; Cheung, MC; Haynes, AE; Imrie, K; Kouroukis, CT; Reece, DE1
Canta, A; Carozzi, V; Cavaletti, G; Chiorazzi, A; Meregalli, C; Monbaliu, J; Oggioni, N; Sala, B; VAN DE Velde, H1
Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y1
Baldini, L; Capelli, C; Chiaramonte, R; D'Anca, M; Fabris, S; Inghirami, G; Introna, M; Lombardi, L; Mosca, L; Neri, A; Nobili, L; Pellegrino, E; Piva, R; Todoerti, K; Verdelli, D1
Cao, Y; Farjam, R; Feng, FY; Gomez-Hassan, D; Hayman, JA; Lawrence, TS; Tsien, CI1
Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Miyao, M; Miyazawa, M; Mukai, HY; Ogawa, Y; Ohyashiki, K; Sakai, F; Sugiyama, Y; Yoshizawa, K1
Anchoori, RK; Chen, X; Hung, CF; Jiang, R; Karanam, B; Matsui, W; Orlowski, RZ; Peng, S; Roden, RB; Rudek, MA; Tanno, T; Walters, KJ; Wang, JW; Zhao, M1
Anderson, KC; Berenson, JR; Berger, A; Bernard, H; Blakemore, SJ; Bolen, JB; Chattopadhyay, N; Di Bacco, A; Dorner, AJ; Esseltine, DL; Jagannath, S; Koenig, E; Li, B; Lichter, DI; Lonial, S; Mulligan, G; Neuwirth, R; Orlowski, RZ; Ricci, D; Richardson, PG; San Miguel, JF; Schu, M; Sonneveld, P; Stadtmauer, EA; Trepicchio, W; van de Velde, H1
Bennett, DL; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Colombo, M; Foudah, D; La Russa, F; Marmiroli, P; Meregalli, C; Miloso, M; Nicolini, G; Oggioni, N; Sala, B1
Chen, KF; Hou, DR; Huang, AC; Shiau, CW; Wang, CY; Yu, HC1
Chen, RL; Huang, BT; Li, BS; Tan, Y; Zeng, QC; Zhao, WH1
Chang, TP; Gatla, HR; Manna, S; Poltoratsky, V; Sanacora, S; Singha, B; Vancura, A; Vancurova, I1
Barthel, BG; Kostoff, D; Saad, SA; Zobniw, CM1
Alarid, ET; Bickford, B; Powers, GL; Rajbhandari, P; Solodin, NM1
Ma, A; Mazepa, MA; Moll, S; Park, YA; Raval, JS1
Anderson, KC; Mitsiades, CS; Ocio, EM; Orlowski, RZ1
Furukawa, Y; Hatano, K; Kikuchi, J; Nagai, T; Ozawa, K; Sripayap, P1
Delimpasi, S; Dimopoulos, MA; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Konstantopoulos, K; Kyrtsonis, MC; Michael, M; Michalis, E; Parcharidou, A; Pouli, A; Repousis, P; Symeonidis, A; Terpos, E; Vassou, A1
Cheng, Q; Jin, Y; Liang, Y; Liu, H; Ma, S; Wang, Y; Wu, D; Wu, Y; Zhang, Y; Zheng, D1
Chen, BY; Chen, WM; Liao, LS; Lin, Y; Qu, S; Wei, TN1
Grandjean, C; Horger, M; Oehrlein, K; Schulze, M; Spira, D; Weisel, K; Zago, M1
Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ1
Alvarez-Berríos, MP; Castillo, A; Rinaldi, C; Torres-Lugo, M1
Anderson, CD; Busch, RA; Chapman, WC; Dines, JN; Gunter, KL; Jia, J; Knolhoff, BL; Mohanakumar, T; Ramachandran, S; Sarma, NJ; Tiriveedhi, V; Upadhya, GA1
Domenicotti, C; Fenoglio, D; Furfaro, AL; Marinari, UM; Moretta, L; Nitti, M; Parodi, A; Passalacqua, M; Piras, S; Pronzato, MA; Traverso, N1
Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A1
Borzym-Kluczyk, M; Cechowska-Pasko, M; Krętowski, R2
Chen, W; Chen, Z; Gong, D; Huang, X; Liu, Z; Wang, Q; Zeng, C; Zhang, H1
Ambati, SR; Chiosis, G; Kosugi, K; Lopes, EC; Meyers, PA; Mony, U; Moore, MA; Moreira, AL; Shah, SK; Taldone, T; Zehir, A1
Berno, T; Kamalakar, A; Pappas, L; Suva, LJ; Tricot, G; Xu, H; Yang, Y; Yoon, D; Zangari, M; Zeng, M1
Aylı, M; Cevik, C; Mandıroğlu, S1
Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C1
Gupta, K; Klimenkova, O; Klimiankou, M; Kuznetsova, I; Meyer, J; Moore, MA; Skokowa, J; Welte, K; Zeidler, C1
Zhang, J; Zhong, Y1
Beck, P; Cui, H; Dubiella, C; Groll, M; Krüger, A; Schmidt, B; Stein, ML; Voss, C1
Avan, A; Cavaletti, G; Ceresa, C; Geldof, AA; Giovannetti, E; Peters, GJ1
Alé, A; Bruna, J; Monbaliu, J; Morell, M; Navarro, X; Udina, E; van de Velde, H1
Choi, NR; Hoang, MD; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Lee, YK; Lim, MS; Nguyen-Pham, TN; Vo, MC1
Cebotaru, L; Cebotaru, V; Guggino, WB; Rapino, D1
Anderl, J; Assaraf, YG; Blank, JL; Cloos, J; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; van de Ven, PM; van Meerloo, J; Zweegman, S1
Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH1
Cirone, M; D'Orazi, G; Faggioni, A; Farina, A; Gonnella, R; Granato, M; Santarelli, R1
Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W1
Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK1
Berenson, JR; Bessudo, A; Boccia, RV; Dichmann, R; Eshaghian, S; Gravenor, D; Hilger, JD; Nassir, Y; Patel-Donnelly, D; Stampleman, L; Swift, RA; Vescio, RA; Yellin, O1
Chung, M; Hartono, C; Kuo, SF; Muthukumar, T; Seshan, SV1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM1
Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M1
Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R1
Bryant, J; Clegg, A; Cooper, K; Picot, J1
Hata, T; Li, C; Two, AM1
Advani, RH; Chang, JE; Gascoyne, RD; Horning, SJ; Kahl, BS; Li, H; Paietta, EM; Smith, MR; Yang, DT1
Attal, M; Einsele, H; Giralt, S; McCarthy, PL1
Chan, EY; Chim, CS; Ho, S; Kwong, YL; Lie, AK; Liu, H; Wong, M1
Chang, CC; Choi, DS; Jiang, B; Su, J; Wen, J; Zhang, L; Zhang, W; Zhou, X1
Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S1
Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z1
Anderson, KC; Hide, M; Hideshima, H; Hideshima, T; Ikeda, H; Iwasaki, A; Yoshida, Y1
Blum, KA; Maddocks, K1
Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K1
Bartlett, DL; Kim, SY; Lee, YJ; Song, X; Zhang, L1
Shang, Z; Wei, J; Xiao, Y; Yin, J1
Midorikawa, K; Nagata, A; Noto, S; Ootsubo, K; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K1
Boccadoro, M; Corradini, P; Crippa, C; Gambella, M; Gay, F; Ladetto, M; Omedè, P; Palumbo, A; Passera, R; Rocci, A; Romano, A; Rossi, D1
Ahn, KS; Chng, WJ; Kannaiyan, R; Kumar, AP; Li, F; Mustafa, N; Sethi, G; Siveen, KS1
Bergqvist, M; Bergström, S; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, M; Lennartsson, J; Navani, S; Pontén, F; Sooman, L; Tsakonas, G; Wu, X1
Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ1
Anderson, LM; Biswas, D; Holland, RJ; Ji, X; Keefer, LK; Kim, Y; Kumari, V; Luthers, CE; Maciag, AE; Morris, NL; Saavedra, JE; Sehareen, WS1
Delafontaine, P; Godard, MP; He, Y; Shen, CC; Song, YH; Wang, JJ; Wang, TX; Xing, SS; Yang, ST; Yang, XL; Yue, YY; Zhang, SB; Zhao, Q1
Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK1
Lentzsch, S1
Chauncey, T; Deauna-Limayo, D; Dong, Z; Liu, D; Pilz, R; Wang, HY; Wang-Rodriguez, J; Yan, M; Zhao, F1
Cui, Y; Huang, ZZ; Li, D; Liu, XG; Pang, RP; Su, YM; Wei, JY; Xin, WJ; Xue, Z; Zhang, J1
Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES1
Bonnet, A; Bourcier, J; Chauvin, C; Lok, A; Mahé, B; Mocquard, J; Moreau, P; Redelsperger, L; Thomaré, P; Touzeau, C1
Cao, JY; Cao, MN; Cao, XC; Gao, AH; Gao, LX; Han, MM; Li, J; Sheng, L; Su, MB; Wang, MK; Xu, L; Zhou, YB1
Chairopoulos, K; Kilindireas, K; Koulieris, E; Koutra, E; Kyrtsonis, MC; Maltezas, D; Pangalis, GA; Pessach, I; Sachanas, SP; Tzenou, T; Zaroulis, CK1
Ji, Z; Jiang, X; Lei, Y; Li, H; Sun, M; Wu, G1
Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q1
Kazi, A; Lawrence, HR; Ozcan, S; Sebti, SM; Sun, Y; Tecleab, A1
Cheung, YK1
Akar, FG; Chaanine, AH; Hajjar, RJ; Jin, D; Kohlbrenner, E; Kovacic, JC; Nonnenmacher, M; Weber, T1
Baiz, D; Chiaretti, S; Consoloni, L; Dapas, B; Farra, R; Fiotti, N; Grassi, G; Pozzato, G; Scaggiante, B; Zanconati, F1
Cavallo, F; Genadieva-Stavric, S; Palumbo, A1
Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN1
Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N1
Cohen, P1
Eksborg, S; Eriksson, E; Johnsen, JI; Kogner, P; Perup, LS; Sävendahl, L; Wickström, M1
Bodie, WW; Chen, S; Dai, Y; Felthousen, J; Grant, S; Kramer, LB; Orlowski, RZ; Pei, XY; Sanderson, MW; Takabatake, Y; Youssefian, LE; Zhou, L1
Shah, BK; Sharma, LR; Subedi, A1
Amin, HM; Chen, Z; He, Y; Shen, C; Song, YH; Wang, Y; Wu, D; Xing, S; Yang, S; Yue, Y1
Appel, GB; Bomback, AS; Canetta, PA; D'Agati, V; Dillon, JJ; Leung, N; Patel, K1
Höke, A; Ray, M1
Barreiro, E; Chacon-Cabrera, A; de Kier Joffé, ED; Diament, MJ; Fermoselle, C; Mateu-Jimenez, M; Sandri, M; Urtreger, AJ1
Barchnicka, A; Grosicka, A; Grosicki, S; Jurczyszyn, A1
Fischer, U; Hoffmann, MJ; Jung, M; Niegisch, G; Rosik, L; Schulz, WA1
Coccia, M; La Frazia, S; Riccio, A; Rossi, A; Santoro, MG; Trotta, E1
Aoi, Y; Kapoor, TM; Kawashima, SA; Sato, M; Shirahige, K; Sutani, T1
Dong, LW; Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Shi, HG; Wang, HY; Xi, H; Ye, F; Zhang, CY; Zhang, J1
Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC1
Dudem, S; Jain, N; Kalivendi, SV; Vangala, JR1
Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH1
Carmignac, V; Durbeej, M; Fontes-Oliveira, CC; Holmberg, J; Körner, Z1
Avigan, D; Kufe, D; Kufe, T; Yin, L1
Alloway, RR; Budde, K; Dürr, M; Ejaz, NS; Halleck, F; Woodle, ES1
Blommestein, HM; Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Uyl-de Groot, CA1
Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A1
Matevosyan, K; Rutherford, C; Sarode, R; Shen, YM; Yates, S1
Corchete, LA; Garayoa, M; García-Sanz, R; Gutiérrez, NC; Krzeminski, P; Ocio, EM; Paíno, T; Paiva, B; Redondo, A; San-Miguel, JF; San-Segundo, L; Sarasquete, ME1
Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y1
Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M1
Fu, R; Gao, S; Liu, H; Shao, Z; Song, J; Wang, G; Wang, H; Xing, L1
Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y1
Coombs, KM; Ezatti, P; Shahiduzzaman, M; Xin, G1
Johnson, CS; Kalra, VK; Meng, Z; Pullarkat, V; Tahara, SM1
Matsue, K; Morita, T; Tanimoto, T; Ugai, T1
Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C1
Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K1
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E1
Hudson, MB; Kavazis, AN; Nelson, WB; Powers, SK; Smuder, AJ1
Andoh, T; Kitamura, R; Kuraishi, Y; Mizoguchi, S; Saito, Y; Takahata, H1
Iida, S; Ri, M1
Ashikaga, T; Keino, D; Kinoshita, A; Kondoh, K; Morimoto, M; Ohyama, R; Yamashita, A1
Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M1
Abildgaard, N; Godskesen, L; Kjeldsen, J; Krag, A1
Furukawa, Y; Kikuchi, J; Koyama, D; Mukai, HY1
Böhmig, GA; Bond, G; Eskandary, F; Haslacher, H; Kikic, Z; Marinova, L; Oberbauer, R; Regele, H; Schwaiger, E; Wahrmann, M; Winzer, C1
Bernal, L; Boise, LH; Chen, J; Gu, Y; Harvey, RD; Kaufman, JL; Lonial, S; Matulis, SM; Sun, SY; Torre, C1
Balsas, P; Campo, E; Colomer, D; Martínez, A; Montraveta, A; Moros, A; Normant, E; Pérez-Galán, P; Rodríguez, V; Roué, G; Saborit-Villarroya, I; Sandy, P; Wiestner, A1
Chuang, WH; Hsu, LF; Huang, SY; Hwang, SM; Liao, YH; Lin, HH; Sheen, YS; Wu, SJ1
Claes, DJ; Goebel, J; Yin, H1
Ahn, SY; Choi, CW; Joo, YD; Jung, SH; Kim, K; Kim, SJ; Lee, JJ; Lee, SM; Lee, WS1
Levy, Y; Maisel, C; Robinson, S; Tong, AW1
Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST1
Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S1
Cashen, A; Cheng, EH; DiPersio, J; Hsieh, JJ; Kunkle, L; Liu, H; Pham, CG; Piwnica-Worms, DR; Vij, R; Westergard, TD1
Bloomfield, CD; Carson, WE; de la Chapelle, A; Eisfeld, AK; Hoag, KW; Huang, X; Jarvinen, TM; Leffel, B; Marcucci, G; Markowitz, J; Patel, R; Perrotti, D; Santhanam, R; Schwind, S; Walker, CJ1
Anderl, JL; Assaraf, YG; Cloos, J; Jansen, G; Kale, AJ; Kaspers, GJ; Moore, BS; Niewerth, D; Riethoff, LF; van Meerloo, J; Zweegman, S1
Gao, ZY; Hu, W; Wang, W1
An, G; Chang, H; Cheng, T; Deng, S; Hao, M; Li, F; Qi, J; Qin, X; Qin, Y; Qiu, L; Ru, K; Shi, L; Sui, W; Wang, H; Wang, J; Xu, Y; Yao, H; Yi, S; Zhu, G1
Issaragrisil, S; Kheolamai, P; Klincumhom, N; Manochantr, S; Sanvoranart, T; Supokawej, A; U-Pratya, Y; Wattanapanitch, M1
Alì, G; Bellelli, R; Castellone, MD; Fontanini, G; Gutkind, JS; Laukkanen, MO; Santoro, M; Teramoto, H1
Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R1
Fujishima, Y; Ishida, Y; Ito, S; Kowata, S; Murai, K; Shimoyama, T; Yashima-Abo, A1
Adam, Z; Krejčí, M; Pour, L; Ševčíková, E1
Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z1
Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K1
Aubert, O; Durrbach, A; Francois, H; Gauthe, R; Obada, EN; Suberbielle, C1
Evens, AM; Gordon, LI; Helenowski, I; Lossos, IS; Millenson, M; Rosen, ST; Smith, MR; Winter, JN1
Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L1
Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H1
Drews, O; Feldner, A; Hecker, M; Korff, T; Meyer, R; Pfisterer, L1
Cho, J; Kang, D; Kim, K; Kim, SJ; Lee, JY1
Chiang, AK; Hui, KF1
Atkins, GB; Jain, MK; Lin, Z; Nayak, L; Schmaier, AH; Shi, H1
Burgstaller, G; Cei, D; Eickelberg, O; Lentner, B; Lenz, AG; Meiners, S; Schmid, O; Schmidmeir, M; Semren, N; Stoeger, T1
Burhenne, J; Clemens, J; Haefeli, WE; Hose, D; Longo, M; Seckinger, A; Weiss, J1
Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB1
Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H1
Ding, Y; Ju, S; Mao, L; Shi, F; Wang, Y; Wu, X; Zhu, W1
Bao, L; Huang, X; Jiang, B; Lai, Y; Li, J; Li, L; Liu, Y; Lu, J; Qin, Y; Shi, H; Wang, Y; Zhu, H1
Abdi, J; Garssen, J; Mutis, T; Redegeld, FA1
Leffell, MS; Montgomery, RA; Philogene, MC; Sikorski, P; Zachary, AA1
Aki, T; Funakoshi, T; Uemura, K; Unuma, K; Watanabe, M1
Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT1
Khan, F; Linden, MA; Vercellotti, GM; Zantek, ND1
Agnelli, L; Anderson, KC; Antonini, E; Bertilaccio, MT; Blandino, G; Caligaris-Cappio, F; Carrasco, R; Cottini, F; Dori, M; Hideshima, T; Kimmelman, AC; Kuehl, WM; Marcatti, M; Neri, A; Ponzoni, M; Richardson, PG; Sattler, M; ten Hacken, E; Tonon, G; Wong, KK; Xu, C1
Butani, L; Gallay, B; Nguyen, S1
Bailey, Z; Bolyard, C; Caligiuri, MA; Cripe, TP; Eaves, D; He, S; Hurwitz, BS; Kaur, B; Old, M; Parris, DS; Rath, KS; Selvendiran, K; Yoo, JY; Yu, J; Yu, JG; Zhang, J1
Chambers, JE; Clarke, HJ; Liniker, E; Marciniak, SJ1
Aktan, C; Cömert, M; Gündüz, C; Kaymaz, BT; Kiper, HD; Kosova, B; Sahin, F; Saydam, G; Selvi, AF; Selvi, N1
Blommestein, HM; Franken, MG; Huijgens, PC; Uyl-de Groot, CA; van Agthoven, M; Verelst, SG1
Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H1
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G1
Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP1
Hong, SY; Kang, S; Min, J; Moon, H; Shin, HH; Yang, HJ1
Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N1
Hata, H; Mitsuya, H; Nishimura, N; Nosaka, K; Okuno, Y1
Al-Salihi, MA; Bruce, D; Cummins, TD; Dingwell, KS; Ewan, R; Herhaus, L; Macartney, T; Sapkota, GP; Smith, JC; Vogt, J; Wasmus, L; Weidlich, S1
Choi, BS; Chung, BH; Jeon, H; Jo, IH; Kim, JI; Kim, YS; Moon, IS; Park, CW; Park, Y; Yang, CW; Yang, KS1
Gurocak, S; Kiliccioglu, I; Konac, E; Varol, N; Yucel Bilen, C1
Chen, L; Gao, L; Hu, X; Lyu, S; Qiu, H; Song, X; Wang, J; Xu, L; Xu, X; Yang, J; Zhang, W1
Bridoux, F; Comenzo, RL; Decaux, O; Gillmore, J; Hari, P; Hawkins, PN; Jaccard, A; Lavergne, D; Lazaro, E; Macro, M; Mercie, P; Mohty, D; Morel, P; Pellegrin, JL; Roussel, M; Venner, CP; Wechalekar, AD1
Avigdor, A; Duek, A; Freidman, T; Kedmi, M; Leiba, M; Leiba, R; Nagler, A; Weiss, M1
Barchnicka, A; Blajer-Olszewska, B; Blonska, D; Boguradzki, P; Charlinski, G; Dawidowska, D; Dmoszynska, A; Druzd-Sitek, A; Dzierzak-Mietla, M; Gawron, L; Gontarska, A; Grygoruk-Wisniowska, I; Grzasko, N; Holojda, J; Iskierka, E; Jachalska, A; Jurczyszyn, A; Kopacz, A; Lech-Maranda, E; Madro, E; Masternak, A; Nowicki, A; Olszewska-Szopa, M; Potoczek, S; Rybicka, M; Rymko, M; Rzepecki, P; Soroka-Wojtaszko, M; Subocz, E; Swiderska, A; Swistek, W; Torosian, T; Usnarska-Zubkiewicz, L; Walter-Croneck, A; Wisniewska-Piaty, K; Zielinska, P1
Badros, AZ; Bao, T; Dorsey, SG; Goloubeva, O; Hester, L; Lao, L; Lapidus, R; Medeiros, M; Pelser, C; Porter, N; Primrose, J; Sadowska, M1
Boi, M; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Del Fiacco, M; Dorsey, SG; Marmiroli, P; Melis, T; Meregalli, C; Picci, C; Poddighe, L; Quartu, M; Renn, CL; Serra, MP1
Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S1
Abe, Y; Honda, Y; Iki, S; Inoue, J; Miyazaki, K; Sekine, E; Shingaki, S; Suzuki, K; Tsukada, N1
Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y1
Anderson, KC; Bianchi, G; Richardson, PG1
Amiri, KI; Benson, AB; Berlin, J; Ciombor, KK; Feng, Y; Horton, L; Kauh, JS; Mulcahy, M; Powell, M; Richmond, A; Short, SP; Staley, C; Su, Y1
Ashley, JD; Bilgicer, B; Kiziltepe, T; Schroeder, VA; Stefanick, JF; Suckow, MA1
Fu, BB; Li, J; Li, YC; Liao, AJ; Liu, ZG; Wang, HH; Yang, W; Yang, Y; Zhang, R1
Nixon, NA; Parhar, K1
Dougherty, PM; Robinson, CR; Zhang, H2
Bringhen, S; Donato, F; Gay, F; Mina, R; Palumbo, A; Troia, R1
El-Shentenawy, A; Mohammed, AA1
Gatla, HR; Persaud, V; Singha, B; Vancurova, I1
Gatla, HR; Phyo, SA; Singha, B; Vancurova, I1
Chang, TP; Sanacora, S; Vancurova, I1
Draber, P; Graves, J; Montinaro, A; Newsom-Davis, T; Prieske, K; Prieske, S; Tuthill, MH; von Karstedt, S; Walczak, H; Zinngrebe, J1
Chen, X; Dou, QP; Guan, L; Hua, X; Huang, H; Lan, X; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Wang, S; Wang, X; Yang, C; Yi, S; Zhang, P; Zhao, C; Zhou, P1
Huang, HB; Niu, WY; Wu, SQ; Xu, ZZ; Zhan, R1
Johnson, DE; Kirk, CJ; Zang, Y1
Cai, Z; Fu, J; Han, X; He, J; Huang, H; Huang, W; Li, L; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zhang, X; Zhao, Y; Zheng, G; Zheng, W1
Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G1
De Bruyne, E; De Wever, O; Hendrix, A; Hernot, S; Lahoutte, T; Lemaire, M; Menu, E; Van Valckenborgh, E; Vanderkerken, K; Wang, J1
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ2
de Zoysa, JR; Hutchison, CA; Lam-Po-Tang, M; Tan, J1
Aggarwal, S; Fagoaga, OR; L'Ecuyer, TJ; Zinn, MD1
Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E1
Abu Jawdeh, BG; Alachkar, N; Arend, LJ; Bhasin, B; Gupta, G; Kraus, E; Montgomery, RA; Rabb, H; Racusen, LC; Trollinger, B; Zachary, AA1
Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q1
Ding, SH; Wang, QS; Wang, YS; Wang, ZT; Wu, F1
Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T1
Bai, Q; Chen, X; Liang, R; Liu, H; Liu, L; Liu, M; Shi, B; Tian, D; Zhang, Y1
Cerchia, C; Ettari, R; Grasso, S; Lavecchia, A; Micale, N; Novellino, E; Pinto, A; Scarbaci, K; Schirmeister, T; Troiano, V; Zappalà, M1
Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K1
Eriksson, E; Hou, M; Jahnukainen, K; Meinhardt, A; Sävendahl, L; Söder, O; Svechnikov, K1
Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J1
Atsumi, M; Ito, T; Kameda, K; Kiba, T; Kido, M; Kimura, A; Miyamae, F; Nakashima, T; Niimi, H; Okikawa, Y; Shitakubo, Y; Sumitani, Y; Tanaka, S1
Hu, C; Liu, J; Tian, Y; Tian, Z; Wang, C; Wang, X1
Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W1
Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I1
Asahina, M; Ikeda, S; Kuwabara, S; Sano, K; Shiojiri, T; Sugiyama, A; Takeda, Y1
Baritaki, S; Berenson, JR; Bonavida, B; Chen, H; Del Lourdes Cebrera-Muñoz, M; Huerta-Yepez, S; Liu, H; Maldonado-Valenzuela, A; Rivera-Pazos, C; Valencia-Hipolito, A; Vega, MI1
Buurman, WA; De Baets, MH; Duimel, H; Gomez, AM; Hummel, J; Losen, M; Martinez-Martinez, P; Molenaar, PC; Nogales-Gadea, G; Saxena, A; Verheyen, F; Vrolix, K; Willcox, N1
Grob, SR; Jakobiec, FA; Rashid, A; Yoon, MK1
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M1
Bergsagel, PL; Chen, C; Fonseca, R; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S; Vohra, H1
Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO1
Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K1
Güngör, T; Waespe, N; Zeilhofer, U1
Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H1
Curtis, BR; Davies, SM; Filipovich, AH; Grimley, MS; Jodele, S; Jordan, MB; Khandelwal, P; Marsh, R1
Baron, R; Basto, P; Bertrand, N; Farokhzad, OC; Ghobrial, IM; Glavey, S; Kamaly, N; Liu, J; Lu, ZN; Manier, S; Memarzadeh, M; Mishima, Y; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Sacco, A; Seevaratnam, D; Shi, J; Swami, A; Wu, J; Zhang, S; Zhang, Y1
Amaravadi, RK; Bradner, JE; Chang, YC; Davis, LE; Heitjan, DF; Kaplan, J; Mallon, G; Nichols, CW; Paul, TM; Piao, S; Pontiggia, L; Porter, DL; Rangwala, R; Scott, EC; Stadtmauer, EA; Tan, KS; Vogl, DT1
Numata, H; Ohgiya, D; Sasao, T; Suyama, T; Tsuboi, K; Tsuchiya, T; Watanabe, S1
Choi, DR; Han, B; Jung, JY; Kim, HJ; Kim, HY; Zang, DY1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ1
Goldberg, AL; Sha, Z2
Itoh, K; Liu, T; Maruyama, A; Mimura, J; Ohyama, C; Okada, T; Sato, H; Ye, P1
Chen, S; Dai, Y; Grant, S; Jones, R; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L1
Dolloff, NG; Harding, T; Lulla, A; Mansoor, A; Mitra, A; Myers, CL; Stessman, HA; Van Ness, BG; Xia, T1
Chen, D; Dou, QP; Guan, F; Wang, H; Yang, H1
Abedi, M; Ames, E; Blazar, BR; Chen, M; Grossenbacher, SK; Jagdeo, J; Mirsoian, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J1
Kaneko, T; Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Osawa, T; Yamada, H1
Kato, H; Kinoshita, T1
Yagi, H1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ1
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H1
Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H1
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S1
de Waal, TT; Gorter, MH; Tascilar, M1
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP1
Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M1
Cantarovich, D; Castagnet, S; Cesbron, A; Couvrat-Desvergnes, G; Giral, M; Renaudin, K; Touzot, M1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G1
Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA1
Joks, M; Jurczyszyn, A; Komarnicki, M; Machaczka, M; Skotnicki, AB1
Creamer, A; Gaastra, B; Odogwu, S; Whitelaw, B1
Marks, SD1
Becherini, P; Brignole, C; Cilli, M; Cossu, I; Destefanis, E; Di Paolo, D; Emionite, L; Giacomini, A; Loi, M; Pastorino, F; Perri, P; Piaggio, F; Ponzoni, M1
Cai, Z; Han, XY; He, DH; He, JS; Huang, H; Li, Y; Wang, LJ; Wu, C; Wu, WJ; Yang, L; Yang, Y; Yi, Q; Zhao, Y; Zheng, GF; Zi, FM1
Almeida, GM; Coelho, MA; Frasco, MF; Pereira, Mdo C; Santos-Silva, F1
Chang, PY; Chao, TY; Chen, JH; Chen, YC; Dai, MS; Ho, CL; Huang, TC; Kao, WY; Wu, YY1
Choi, YJ; Eom, KS; Jo, DY; Joo, YD; Kang, HJ; Kim, BS; Kim, CS; Kim, JS; Kim, SH; Kim, SJ; Kim, YJ; Kim, YS; Kwak, JY; Lee, JJ; Min, CK; Mun, YC; Park, CY; Park, JS; Suh, C; Yoon, SS1
Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y1
Azadeh, N; Fonseca, R; Kelemen, K1
Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L1
Fu, R; Guan, J; Li, L; Liu, H; Mei, S; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y; Xing, L1
Basset, M; Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Perlini, S; Vidus Rosin, M1
Nekova, TS; Stuhler, G1
Abedi, M; Blazar, BR; Chen, M; Hagino, T; Hsiao, HH; Mall, C; Monjazeb, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J1
Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N1
Argyriou, AA; Bruna, J; Cavaletti, G; Kalofonos, HP; Kyritsis, AP1
Aujesky, D; Oestmann, A1
Hoseki, J; Maharjan, S; Oku, M; Sakai, Y; Tsuda, M1
Castro, LM; Dasgupta, S; Dulman, R; Ferro, ES; Fricker, LD; Schmidt, M; Yang, C1
Beimler, J; Breitkreutz, I; Egerer, G; Goldschmidt, H; Heiss, C; Ho, AD; Jäger, D; Neben, K; Perne, A; Raab, MS; Zeier, M1
Dou, QP; Zonder, JA1
Luesutthiviboon, L; Namkhanisorn, K; Nimkietkajorn, V; Ruangkanchanasetr, P; Satirapoj, B; Suaywan, K; Termmathurapoj, S1
Chung, MH; Kim, HS; Kim, I; Kim, KS; Koh, Y; Kwon, JH; Lee, SY; Park, S; Suh, SY; Yoon, SS1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI1
Auger, MJ; Bowles, KM; Murray, MY1
Bamford, RN; Conlon, KC; Ju, W; Maeda, M; Nakagawa, M; Petrus, MN; Waldmann, TA; Yu, P; Zhang, M1
Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J1
Bianchi, E; Cerretani, D; Ghelardini, C; Menicacci, C1
Fujiwara, K; Higo, H; Inomata, T; Kameyama, N; Makimoto, G; Matsushita, M; Rai, K; Sato, K; Shibayama, T; Sunami, K; Watanabe, H1
Ho, CH; Lo, CP; Tu, MC1
Abdel-Azim, H; Kapoor, N; Mahadeo, K; Mehta, B; Tang, S; Zaw, R1
Bachs, O; Coll, MJ; Gascón, P; Girós, M; Guerrero, M; Macías-Vidal, J; Serratosa, J1
Chim, CS; Wong, KY1
Cerase, A; Gozzetti, A1
Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L1
Akpek, G; Armstrong, E; Elekes, A; Freytes, CO; Kato, K; Patil, S; Ratanatharathorn, V; Reece, DE; Rodriguez, TE; Sahovic, E; Shaughnessy, PJ; Smith, A; Solomon, SR; Stadtmauer, EA; Toro, JJ; Tricot, GJ; White, DJ; Yeh, RF; Yu, LH; Zhao, C1
Al-Khalili, L; Cuesta, PG; de Castro Barbosa, T; Katayama, M; Massart, J; Nyström, AC; Oscarsson, J; Osler, ME; Ostling, J; Zierath, JR1
Azakir, BA; Di Fulvio, S; Erne, B; Sinnreich, M; Stirnimann, G1
Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK1
Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D1
Christian, J; Häcker, G; Krämer, OH; Paul, MC; Saur, D; Schmid, RM; Schneider, G; Stauber, RH; Stojanovic, N; Wirth, M1
Drucker, L; Gottfried, M; Zismanov, V1
Chiang, AK; Hui, KF; Leung, YY; Middeldorp, JM; Yeung, PL1
Cohen, C; Hosoba, S; Jaye, DL; Roback, JD; Waller, EK1
Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E1
Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E1
Bastani, B; Fesler, M; Jasim, S; Mahmud, G1
Chen, A; Guo, F; Hu, W; Li, F; Zhang, W1
Ju, D; Xie, Y1
Bernstein, D; Chen, S; Hollander, SA; Kaufman, BD; Maeda, K; May, LJ; Rosenthal, DN; Tyan, DB; Yeh, J1
Asano, T; Isono, M; Ito, K; Sato, A1
Merlini, G; Palladini, G1
Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y1
Martin, TG1
Hamdy, AA; Neemat, K; Rania, K; Tarek, M1
Mateos, MV; Miguel, JF1
Vij, R1
Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C1
Magenau, JM; Reddy, P1
Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M1
Bladé, J; Cakana, A; Comenzo, RL; Enny, C; Esseltine, DL; Fermand, JP; Hassoun, H; Heffner, L; Hegenbart, U; Kukreti, V; Merlini, G; Palladini, G; Pei, L; Reece, DE; Sanchorawala, V; van de Velde, H; Vescio, RA1
Chen, S; Dai, Y; Grant, S; Jones, R; Kmieciak, M; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L1
Chinen, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M; Tatekawa, S; Tsukamoto, T; Yamamoto-Sugitani, M1
Ahn, JS; Jang, HC; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH1
Hummers, LK1
Amm, HM; Burke, MR; Dobbin, ZC; Jeong, DH; Katre, AA; Landen, CN; Steg, AD1
Delić, J; Gobec, M; Markovič, T; Mlinarič-Raščan, I; Prijatelj, M1
Reiter, RJ; Vriend, J1
Franco, OE; Hayward, SW; Jin, R; Matusik, RJ; Wang, J; Wang, Y; Yamashita, H; Yu, X1
Vincent Rajkumar, S1
Chen, P; Chen, Z; Gao, X; Hou, J; Hu, R; Ruan, K; Tao, Y; Wang, H; Yang, M; Yu, T; Zhang, T; Zhang, Y1
Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H1
Balkaya, M; Boehmerle, W; Endres, M; Huehnchen, P; Peruzzaro, S1
Koeppen, S1
Anderson, KC; Driscoll, JJ; Jagannathan, S; Vad, N; Vallabhapurapu, S1
Beksac, M; Bengoudifa, BR; Binlich, F; Bladé, J; Cavenagh, JD; Chen, W; Chuncharunee, S; Corradini, P; Corrado, C; de la Rubia, J; Dimopoulos, MA; Einsele, H; Elghandour, A; Gimsing, P; Günther, A; Hou, J; Hungria, VT; Jedrzejczak, WW; Kaufman, JL; LeBlanc, R; Lee, JH; Lee, JJ; Lonial, S; Moreau, P; Nahi, H; Nakorn, TN; Numbenjapon, T; Ocio, EM; Pulini, S; Qiu, L; Richardson, PG; Salwender, H; San-Miguel, JF; Schlossman, RL; Shelekhova, T; Siritanaratkul, N; Sohn, SK; Sopala, M; Tan, D; Veskovski, L; Wang, MC; Warzocha, K; White, D; Yong, K; Yoon, SS1
Cai, Q; Gao, Y; Wang, C; Wei, D; Wei, J; Zhao, C; Zhao, M1
Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y1
Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M1
Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH1
Abbott, DH; Kropp, J; Ringelstetter, AK; Roti Roti, EC; Salih, SM1
Cahu, J; DaCosta, L; Gaudichon, J; Martens, AC; Milano, F; Renoir, JM; Sola, B1
Chu, SH; Cleeland, CS; Geng, Y; Lee, ES; Lee, YJ; Wang, XS1
Anderson, KC; Ataman, O; Beksac, M; Benboubker, L; Couturier, C; Dimopoulos, MA; Facon, T; Feng, H; Orlowski, RZ; Potamianou, A; Richardson, PG; Roddie, H; Sonneveld, P; van de Velde, H1
Buchner, K; Eulberg, D; Facchetti, F; Ghobrial, IM; Klussmann, S; Kruschinski, A; Lonardi, S; Maasch, C; Maiso, P; Mishima, Y; Moschetta, M; Purschke, WG; Reagan, MR; Roccaro, AM; Rossi, G; Sacco, A; Ungari, M; Vater, A; Vonhoff, S; Zboralski, D; Zöllner, S1
Batalo, MS; Bose, P; Grant, S; Holkova, B1
Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L1
Hobeika, L; Self, SE; Velez, JC1
Ishitsuka, K; Katsuya, H; Kunami, N; Nogami, R; Tamura, K1
Abdi, J; Faber, J; Garssen, J; Redegeld, FA1
Aoyama, M; Hamasaki, Y; Imataki, O; Kida, J; Kubo, H; Ohue, Y; Oku, M; Ota, S; Uemura, M1
Wang, Y; Zhang, Z; Zhou, W1
Bauer, M; Boehm, C; Ganten, TM; Haas, TL; Holland, H; Keller, M; Koschny, R; Koschny, T; Krupp, W; Meixensberger, J; Mueller, WC; Sinn, P; Sprick, MR; Walczak, H; Xu, LX1
Bandekar, R; Bladé, J; Cavenagh, JD; Dimopoulos, MA; Gercheva, L; Goranova-Marinova, V; Maiolino, A; Masszi, T; Orlowski, RZ; Puchalski, TA; Reddy, M; Robak, T; Rossi, JF; Samoylova, O; Špička, I; Sutherland, H; Suvorov, A; van de Velde, H; Williams, C; Xie, H1
Imai, K1
Shibayama, H1
Nakaseko, C1
Tsurumi, H1
Huang, Z; Liu, P; Shu, Y; Wu, Y; Xu, J; Zhou, X; Zhu, W1
Acılan, C; Baykal, AT; Boyacı, I; Okur, E; Ulukaya, E; Yerlikaya, A1
Anderson, KC; Chauhan, D; Cirstea, D; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Kikuchi, S; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Richardson, PG; Suzuki, R; Tai, YT; Utsugi, T; Yoshida, Y1
Niles, AL; Riss, TL1
Bychkov, ML; Dolgikh, DA; Gasparian, ME; Kirpichnikov, MP1
Bátorová, A; Mistrík, M; Roziaková, L1
Bearss, DJ; Carpenter, K; Meng, L; Mollard, A; Sharma, S; Tricot, G; Vankayalapati, H; Warner, SL; Zhan, F1
Ando, M; Bouchier-Hayes, L; Brenner, MK; Dotti, G; Hoyos, V; Ramos, CA; Tao, W; Yagyu, S1
Basnayake, K; Talbot, B; Wright, D1
Lovat, PE; Martin, S; Redfern, CP1
Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M1
Jia, ZQ; Rong, HQ; Su, W; Tao, J; Wei, YL; Wei, YT; Yu, CX1
Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P1
Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W1
Ayaz, B; Bullenkamp, J; Kulms, D; Odell, E; Raulf, N; Tavassoli, M; Thavaraj, S; Walczak, H1
Cooper, ML; DiPersio, JF; Eissenberg, L; Ghobadi, A; Holt, MS; Rettig, MP; Ritchey, JK1
Cheungpasitporn, W; Fervenza, FC; Gertz, MA; Leung, N; Sethi, S1
Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K1
Morrison, VA1
Bartlett, DL; Kim, SY; Kwon, YT; Lee, YJ; Song, X; Tang, D; Zhang, L1
Ádám, E; Andrikovics, H; Balassa, K; Koszarska, M; Kozma, A; Masszi, T; Mikala, G; Tordai, A; Varga, G1
Chudej, J; Chudý, P; Dobrota, D; Hatok, J; Kliková, K; Pilchová, I; Račay, P; Štefaniková, A1
Dessanti, ML; Ensoli, F; Gumenyuk, S; Marchesi, F; Maschio, M; Mengarelli, A; Palombi, F; Pimpinelli, F; Pisani, F; Romano, A; Spadea, A1
Chung, S; Jeon, J; Kamm, RD; Kasuya, J; Kim, C1
Dewan, VN; Grannis, CH; Wang, RC1
Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ1
Chao, A; Chen, GC; Chuang, WC; Huang, WP; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH1
Adamová, D; Bačovský, J; Krejčí, K; Minařík, J; Pika, T; Sčudla, V; Srovnalík, K; Tichý, T; Zadražil, J1
Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP1
Fei, X; Li, J; Lu, H; Tang, Y; Xu, X; Yang, J; Zhu, Y1
Bay, JO; Ravinet, A; Tournilhac, O1
Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG1
Che, XF; Gotoh, A; Hiramoto, M; Hirota, A; Inazu, M; Kawai, Y; Kokuba, H; Komatsu, S; Miyazawa, K; Moriya, S; Yamasaki, K1
Chang, HY; Chen, NN; Huang, HC; Huang, TC; Juan, HF1
Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H1
Cao, D; Guo, T; Hu, Y; Jin, L; Yu, W; Zhou, H1
Ahmed, M; Goldberg, SN; Kumar, G; Levchenko, T; Moussa, M; Sawant, RR; Torchilin, V1
Choe, SK; Kim, SG; Kim, SJ; Lee, JN; Lim, JY; Park, R1
Acharya, C; An, G; Cheng, T; Deng, S; Feng, X; Hao, M; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, Y; Zou, D1
Burhenne, J; Clemens, J; Haefeli, WE; Hose, D; Longo, M; Seckinger, A; Theile, D; Weiss, J1
Driscoll, JJ; Jaganathan, S; Malek, E; Vallabhapurapu, S1
Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A1
Brown, RE; Nguyen, ND; Quesada, AE; Rios, A1
Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ1
Campo, E; Rule, S1
Bittner, S; Ehrenschwender, M; Seibold, K; Wajant, H1
Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM1
Ahn, YS; Han, SH; Jeong, SJ; Kim, JM; Kim, JS; Shin, JS; Woo, JH1
Bouwman, P; Greco, D; Gu, Y; Jonkers, J; Kuznetsov, SG; Saarela, J; Yadav, B1
Ando, Y; Fujiwara, S; Hata, H; Iida, S; Kawano, Y; Kikukawa, Y; Mitsuya, H; Nakashima, T; Okuno, Y; Ri, M; Shiotsu, Y; Tasaki, M; Ueda, M; Wada, N; Yoshinaga, K1
Hengstler, JG; Schad, A; Schmidt, M; Sleeman, JP; Thaler, S; Thiede, G1
Ahn, JS; Ahn, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH1
Abu Jawdeh, BG; Alloway, RR; Brailey, P; Cardi, MA; Ejaz, NS; Girnita, A; Govil, A; Mogilishetty, G; Roy-Chaudhury, P; Sadaka, B; Shields, AR; Walsh, RC; Woodle, ES1
Atisha-Fregoso, Y; Jakez-Ocampo, J; Llorente, L1
Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D1
Dong, F; Jing, HM; Ke, XY; Liu, Y; Wan, WL; Wang, J; Wang, JJ; Zhang, W1
Li, Y; Qin, H; Tao, Q; Wang, H; Wang, Y; Wang, Z; Xiao, W; Xiong, S; Zhai, Z; Zhang, L1
Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H1
Manning, ML; Mason-Osann, E; Onda, M; Pastan, I1
Aziz, M; Bertrand, J; Coëffier, M; Déchelotte, P; Guérin, C; Herranen, A; Loeuillard, E; Marion-Letellier, R; Melchior, C; Savoye, G1
Behler, C; Efebera, YA; Girnius, SK; Grady, T; Han, A; Hayes, TG; Houranieh, A; Kambhampati, S; Klein, CE; Lee, S; Lichtenstein, A; Mehta, P; Mohiuddin, A; Munshi, NC; Prabhala, RH; Roodman, GD; Rose, MG; Yellapragada, SV; Zimelman, A1
Alexander, T; Bokarewa, M; Brisslert, M; Dörner, T; Dürr, M; Engelmann, R; Frölich, D; Giesecke, C; Grün, JR; Kühl, AA; Luda, K; Mei, HE; Perka, C; Radbruch, A; Scheel, T; Schmidt, S; Wirries, I1
Gu, Y; Hu, Y; Shen, Y; Shu, Y; Sun, Y; Wang, L; Wu, X; Xu, Q1
Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST1
Armenteros, E; Downward, J; Herledan, G; Kumar, M; Lach, A; Percy, L; Smith, D; Stubbs, M; Yong, K1
Gu, J; Huang, B; Li, J; Liu, J; Wang, H; Xu, D; Zheng, D; Zou, W1
Bladé, J; Fernández de Larrea, C; Rosiñol, L1
Yakovlev, AA; Yakovleva, MV1
Arnulf, B; Deraedt, W; Esseltine, DL; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, P; van de Velde, H1
Pallavi, R1
Areethamsirikul, N; Chen, C; Chu, CM; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S1
Groll, M; Heinemeyer, W; Huber, EM1
Gu, Y; Zhang, B1
Blancho, G; Branchereau, J; Breimer, ME; Charreau, B; Châtelais, M; Cowan, PJ; Cozzi, E; Crossan, C; d'Apice, AJ; Daha, MR; Dilek, N; Diswall, M; Duchi, R; Galli, C; Hervouet, J; Klar, N; Lagutina, I; Lazzari, G; Le Bas-Bernardet, S; Minault, D; Nottle, MB; Perota, A; Poirier, N; Renaudin, K; Robson, SC; Sachs, DH; Salvaris, EJ; Scobie, L; Simioni, P; Soulillou, JP; Takeuchi, Y; Tillou, X; Vanhove, B; Yamada, K1
Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES1
Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ1
Hashimoto, Y; Iida, S; Kimura, Y; Kizaki, M; Nemoto-Anan, T; Ri, M; Sagawa, M; Tabayashi, T; Tokuhira, M; Tomikawa, T; Watanabe, R1
Takahashi, N1
Furukawa, Y; Kikuchi, J1
Nakaseko, C; Sakaida, E; Takeda, Y1
Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S1
Augustson, B; Baker, B; Campbell, P; Catalano, J; Copeman, M; Dean, J; Feng, H; Harrison, SJ; Link, E; Prince, HM; Quach, H; Romeril, K; Schwarer, A; Spencer, A; Van De Velde, H1
Abe, Y; Achira, M; Ando, K; Iizuka, K; Kojima, M; Kuroda, J; Maruyama, D; Ogura, M; Suzuki, K; Suzuki, T; Taniwaki, M; Tobinai, K1
Castillo, JJ; Ghobrial, IM; Treon, SP1
Anusha, C; Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K1
Assaraf, YG; Cloos, J; Jansen, G; Kaspers, GJ; Niewerth, D; Zweegman, S1
Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A1
Chang, TP; Poltoratsky, V; Vancurova, I1
Li, YL1
Shen, Q; Zhuang, Y1
Ahn, KS; Kim, C; Kim, SH; Lee, JH; Sethi, G1
Castillo, JJ; Ghobrial, IM; Leblebjian, H; Noonan, K; Paba-Prada, C; Treon, SP1
Alexander, T; Burmester, GR; Cheng, Q; Hiepe, F; Hoyer, BF; Klotsche, J; Kühl, AA; Lorenz, HM; Radbruch, A; Rech, J; Rubbert-Roth, A; Sarfert, R; Schett, G; Taddeo, A; Voll, RE; Waka, A; Wiesener, M1
Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L1
Chauhan, P; Hart, KM; Liu, CG; Liu, R; Liu, X; Mao, X; Wang, L; Wei, S; Yang, WH; Yi, B; Zhang, W1
Ding, X; Matsuo, K; Xu, L; Yang, J; Zheng, L1
Chen, S; Chen, W; Dong, Y; He, X; Liang, C; Ma, J; Zhang, B; Zhang, X1
Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J1
Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Morisaki, M; Yokoyama, T1
Chirgwin, JM; Suvannasankha, A1
Aljawai, Y; Asara, JM; Ghobrial, IM; Huynh, D; Kimmelman, AC; Maiso, P; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A1
Tanday, S1
Benner, A; Bochtler, T; Goldschmidt, H; Granzow, M; Hegenbart, U; Ho, AD; Hose, D; Jauch, A; Kimmich, C; Kunz, C; Schönland, SO; Seckinger, A1
Bertsch, U; Blau, IW; Dürig, J; Gerecke, C; Goldschmidt, H; Haenel, M; Hielscher, T; Hillengass, J; Hose, D; Huegle-Doerr, B; Jauch, A; Kunz, C; Lindemann, HW; Mai, EK; Merz, M; Munder, M; Neben, K; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Schurich, B; Seckinger, A; Weisel, K; Zeis, M1
Açikel, C; Altayli, E; Astarci, E; Avcu, F; Elçi, MP; İde, T; Ilikçi Sağkan, R; Koru, Ö; Öngörü, Ö; Özenç, S; Sarper, M; Tok, D; Ural, AU1
Chang, TP; Sanacora, S; Urdinez, J; Vancurova, I1
Chai, X; Fang, B; Huang, H; Li, Y; Lin, Q; Song, Y; Xia, Q; Yu, F; Zhang, Y; Zhou, J1
Abu Jawdeh, BG; Alloway, RR; Cardi, MA; Ejaz, NS; Sadaka, B; Shields, AR; Wadih, G; Witte, D; Woodle, ES1
Oza, A; Rajkumar, SV1
Adler, AI; Burke, MJ; George, E1
Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S1
Izumi, T1
Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK1
Agrawal, N; Buxton, A; Chen, L; Cole, PD; De Alarcon, PA; Drachtman, RA; Guillerman, RP; Hogan, SM; Horton, TM; Howard, SC; Liu, H; López-Terrada, D; McCarten, K; Mrazek, MD; Schwartz, CL; Sheehan, AM; Trippet, TM; Voss, S; Wu, MF1
Borsi, E; Brioli, A; Cavo, M; De Sanctis, LB; Mancini, E; Mancuso, K; Marzocchi, G; Pantani, L; Pezzi, A; Rizzo, R; Rocchi, S; Santoro, A; Santostefano, M; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA1
Cho, Y; Fujisawa, F; Hori, M; Kamoshita, M; Katsura, Y; Kojima, H; Komeno, T; Kudo, D; Mukai, HY; Okoshi, Y; Ota, I; Sasaki, K; Shimizu, S; Shinagawa, A; Tanaka, K; Yoshida, C1
Bay, JO1
Gotoh, Y; Ihara, K; Inomata, H; Kato, J; Koyama, R; Miyajima, N; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Yamauchi, N1
Cai, G; Fu, J; Li, W; Xie, N; Zhang, S; Zhao, J1
Keller, S; Leibundgut, K; Mueller, BU; Novak, U; Pabst, T; Seipel, K; Taleghani, BM1
Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC1
Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X1
Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W1
Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Harano, H; Hashimoto, C; Hattori, Y; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Kuwabara, H; Matsumoto, K; Numata, A; Sakai, R; Taguchi, J; Takemura, S; Tanaka, M; Tomita, N; Watanabe, R; Yamazaki, E1
Chiba, S; Hasegawa, Y; Ito, Y; Kurita, N; Miyamoto, K; Obara, N; Ogawa, S; Otsu, K; Sakata, A; Sakata-Yanagimoto, M; Seki, M; Yokoyama, Y1
Basset, M; Foli, A; Gillmore, J; Hawkins, P; Lachmann, H; Merlini, G; Milani, P; Palladini, G; Sachchithanantham, S; Wechalekar, AD1
Treon, SP1
Miyamoto, K; Saigo, K; Takenokuchi, M; Taniguchi, T1
Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W1
Fenichel, MP1
Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H1
Gazdic, T; Kautzner, J; Kment, M; Kubanek, M; Malek, I; Pagacova, L; Svobodova, E; Viklicky, O1
Katzel, JA; Lee-Ma, A; Vesole, DH1
Bender, S; Bonaud, A; Bridoux, F; Cogné, M; Delpy, L; Druilhe, A; Javaugue, V; Lacombe, C; Oblet, C; Quellard, N; Sirac, C; Srour, N; Touchard, G1
Dai, Y; Doeppner, TR; Hermann, DM; Jin, F; Kuckelkorn, U; Li, F; Li, W; Li, X; Li, Z; Liu, L; Qiu, L; Zang, M; Zhou, W1
Aoufouchi, S; De Smet, A; Delbos, F; Gelot, C; Guerrera, IC; Reynaud, CA; Weill, JC1
Kang, JH; Kim, HH; Kim, HJ; Kim, JY; Kim, YG; Lee, Y1
Beissbarth, T; Cormet-Boyaka, E; Dobbelstein, M; Edmunds, S; Gaedcke, J; Ghadimi, M; Krüger, E; Levine, AJ; Markert, E; Moll, UM; Schulz, R; Zhang, X1
Abernethy, DR; Chudasama, VL; Mager, DE; Ovacik, MA1
Cowan, AJ; Frayo, SL; Gopal, AK; Green, DJ; Pagel, JM; Palanca-Wessels, MC; Press, OW1
Aline-Fardin, A; Aucouturier, P; Bender, S; Boffa, JJ; Brahimi, S; Buob, D; Fabiani, B; Garderet, L; Mothy, M; Ronco, P; Verpont, MC1
Böhmig, GA; Bond, G; Eskandary, F; Halloran, P; Haslacher, H; Kikić, Z; Kozakowski, N; Oberbauer, R; Ramassar, V; Regele, H; Wahrmann, M1
Huh, KH; Jeong, HJ; Kim, BS; Kim, YS; Lee, J; Lee, JG; Lim, BJ; Park, Y1
Guo, S; Li, X; Qu, F; Tian, C; Xia, B; Yu, Y; Zhang, L; Zhang, Y1
Abounader, D; Bolwell, B; Dean, R; Gerds, AT; Hamilton, BK; Hill, B; Hong, S; Jagadeesh, D; Kalaycio, ME; Liu, HD; Majhail, NS; Pohlman, B; Reu, F; Rybicki, L; Samaras, C; Sobecks, R; Valent, J1
Chakraborty, R; Gertz, MA1
Chen, H; Hao, QY; Huang, XJ; Liu, KY; Lu, J; Wen, L1
Tew, KD1
An, N; Chen, SL; Huang, ZX; Li, X; Shen, M1
Gaynon, PS1
Ma, J; Shao, ZH; Wang, YH; Zhang, LL1
Chen, JF; Li, YX; Meng, XY; Xiao, LF; Zeng, ZH; Zhang, R1
Bostrom, BC; Messinger, YH1
Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF1
Gao, D; Liu, D; Ma, X; Sun, M; Xu, D; Yu, H1
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J1
Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK1
Egashira, N; Yamamoto, S1
Chiba, T; Iseki, T; Isshiki, Y; Iwama, A; Koide, S; Lennox, W; Mimura, N; Mitsukawa, S; Miyota, M; Muto, T; Nagai, Y; Nakajima-Takagi, Y; Nakaseko, C; Ohwada, C; Oshima, M; Oshima-Hasegawa, N; Rizk, M; Rizq, O; Sakaida, E; Saraya, A; Sheedy, J; Takeda, Y; Takeuchi, M; Tsukamoto, S; Weetall, M; Yokote, K1
Gul, E; Gyger, M; Jazubowiak, A; Kaufman, J; Khan, S; Lau, A; Le, LW; LeBlanc, R; Li, Z; Paul, H; Trudel, S; White, D1
Garrido, D; Riva, E1
Gogal, RM; Laver, T; Lee, BM1
Sak, K1
Callander, NS; Hematti, P; Mark, C; Miyamoto, S; Warrick, J1
Meiners, S; Meul, T; Schlesser, C; Stathopoulos, G1
Cui, Y; Ding, H; Gao, Y; Huang, J; Lin, Z; Liu, T; Luo, H; Niu, T; Qu, Y; Wang, F; Xu, J; Yang, Y; Yang, Z; Ye, L; Zhai, X; Zhang, L; Zheng, Y1
Allman, D; Alloway, RR; Brailey, P; Burg, AA; Castro-Rojas, CM; Gehman, JM; Hildeman, DA; Rike-Shields, A; Roskin, KM; Rossi, AP; Tremblay, S; Woodle, ES1
Berman, AY; Carpenter, AE; Cimini, BA; Han, Y; Kapoor, TM; Kelley, ME; Singh, S; Stirling, DR; Way, GP1
Devasia, AJ; Lancman, G; Stewart, AK1
Anderson, LD; Banerjee, R; Cowan, AJ; Kaur, G; McCaughan, G; Mehra, N; Rajkumar, SV; Wang, B1

Reviews

625 review(s) available for pyrazines and bortezomib

ArticleYear
New agents in cancer clinical trials.
    Oncogene, 2000, Dec-27, Volume: 19, Issue:56

    Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat

2000
The proteasome: a new target for novel drug therapies.
    American journal of clinical pathology, 2001, Volume: 116, Issue:5

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines

2001
Proteasome inhibition in cancer: development of PS-341.
    Seminars in oncology, 2001, Volume: 28, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship

2001
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Seminars in oncology, 2001, Volume: 28, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; I-kappa B Proteins; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Polymorphism, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2001
[Update on . . . the proteasome inhibitor PS341].
    Bulletin du cancer, 2002, Volume: 89, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines

2002
Development of the proteasome inhibitor PS-341.
    The oncologist, 2002, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Mice; Mice, Nude; Multicenter Studies as Topic; Protease Inhibitors; Pyrazines; Rats

2002
Proteasome inhibition: a novel approach to cancer therapy.
    Trends in molecular medicine, 2002, Volume: 8, Issue:4 Suppl

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2002
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome

2002
New drugs in gynecologic cancer.
    Current treatment options in oncology, 2001, Volume: 2, Issue:2

    Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab

2001
Proteasome inhibitors in the treatment of B-cell malignancies.
    Clinical lymphoma, 2002, Volume: 3, Issue:1

    Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome

2002
New drugs in acute myeloid leukemia.
    Current oncology reports, 2002, Volume: 4, Issue:5

    Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides

2002
Hematologic malignancies: new developments and future treatments.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides

2002
Proteasome inhibitors as new anticancer drugs.
    Current opinion in oncology, 2002, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Transcription Factors; Tumor Cells, Cultured

2002
Advances in the biology and treatment of myeloma bone disease.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid

2002
Moving disease biology from the laboratory to the clinic.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Endothelial Growth Factors; Humans; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Interferons; Killer Cells, Natural; Lymphokines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Signal Transduction; Stem Cell Transplantation; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
High-dose therapy and immunomodulatory drugs in multiple myeloma.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide

2002
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
    Breast cancer research : BCR, 2003, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials as Topic; Cysteine Endopeptidases; Female; Humans; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitins

2003
Potential for proteasome inhibition in the treatment of cancer.
    Drug discovery today, 2003, Apr-01, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
Proteasome inhibition: a new anti-inflammatory strategy.
    Journal of molecular medicine (Berlin, Germany), 2003, Volume: 81, Issue:4

    Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Asthma; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Inflammation; Lysine; Models, Biological; Models, Chemical; Multienzyme Complexes; Multiple Sclerosis; Neoplasms; NF-kappa B; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Psoriasis; Pyrazines; Reperfusion Injury

2003
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
    Seminars in oncology, 2003, Volume: 30, Issue:2

    Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Protease Inhibitors; Pyrazines; Thalidomide; Thiazoles; Waldenstrom Macroglobulinemia

2003
Novel therapies in multiple myeloma.
    International journal of hematology, 2003, Volume: 77, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2003
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
    The Lancet. Oncology, 2003, Volume: 4, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2003
The proteasome: structure, function, and role in the cell.
    Cancer treatment reviews, 2003, Volume: 29 Suppl 1

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Multienzyme Complexes; Neoplasms; Polyubiquitin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
    Cancer treatment reviews, 2003, Volume: 29 Suppl 1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
Clinical update: proteasome inhibitors in hematologic malignancies.
    Cancer treatment reviews, 2003, Volume: 29 Suppl 1

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Down-Regulation; Drug Administration Schedule; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured

2003
Clinical update: proteasome inhibitors in solid tumors.
    Cancer treatment reviews, 2003, Volume: 29 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Drug Interactions; Humans; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53

2003
[Thalidomide treatment in multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:5

    Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide

2003
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 1

    Topics: Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Ubiquitin

2003
Therapy strategies for multiple myeloma: current status.
    Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14

    Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous

2003
New therapeutic strategies for soft tissue sarcomas.
    Current treatment options in oncology, 2003, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin

2003
Bortezomib treatment for multiple myeloma.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:12

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines

2003
[Current screening for molecular target therapy of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib

2003
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
    The oncologist, 2003, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration

2003
Apoptosis meets proteasome, an invaluable therapeutic target of anticancer drugs.
    The Italian journal of biochemistry, 2003, Volume: 52, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Leupeptins; Models, Biological; Multienzyme Complexes; Neoplasms; Peptide Hydrolases; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
The proteasome as a target for cancer therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-15, Volume: 9, Issue:17

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Catalysis; Clinical Trials as Topic; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Models, Biological; Multienzyme Complexes; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2003
Targeting proteasome inhibition in hematologic malignancies.
    Reviews in clinical and experimental hematology, 2003, Volume: 7, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Hematologic Neoplasms; Humans; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines

2003
[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
    Orvosi hetilap, 2004, Jan-11, Volume: 145, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic

2004
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
    Seminars in oncology, 2004, Volume: 31, Issue:1 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines

2004
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Seminars in hematology, 2003, Volume: 40, Issue:4 Suppl 4

    Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities

2003
Bortezomib and its role in the management of patients with multiple myeloma.
    Expert review of anticancer therapy, 2004, Volume: 4, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
    Clinical lymphoma, 2004, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines

2004
The proteasome: a suitable antineoplastic target.
    Nature reviews. Cancer, 2004, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Transformation, Neoplastic; Cysteine Endopeptidases; Endopeptidases; Humans; Multienzyme Complexes; Nuclear Proteins; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction

2004
Multiple myeloma: the role of transplant and novel treatment strategies.
    Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 4

    Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2004
The development of proteasome inhibitors as anticancer drugs.
    Cancer cell, 2004, Volume: 5, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Ubiquitins

2004
A review of the proteasome inhibitor bortezomib in multiple myeloma.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Dexamethasone; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines

2004
Development of the proteasome inhibitor Velcade (Bortezomib).
    Cancer investigation, 2004, Volume: 22, Issue:2

    Topics: Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Design; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin-Activating Enzymes

2004
The potential role of proteasome inhibitors in the treatment of lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines

2004
New oncology strategy: molecular targeting of cancer cells.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2004, Volume: 13, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A

2004
The role of proteasome inhibitors in solid tumors.
    Annals of medicine, 2004, Volume: 36, Issue:4

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
Proteasome inhibition in hematologic malignancies.
    Annals of medicine, 2004, Volume: 36, Issue:4

    Topics: Asthenia; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Diarrhea; Hematologic Neoplasms; Humans; Multienzyme Complexes; Nausea; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis; Treatment Outcome

2004
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
    Current treatment options in oncology, 2004, Volume: 5, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Risk Assessment; Survival Rate

2004
Targeting the ubiquitin-proteasome pathway in breast cancer.
    Clinical breast cancer, 2004, Volume: 5, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Molecular Biology; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Proteasome Endopeptidase Complex; Protein Transport; Pyrazines; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Ubiquitin

2004
[Proteasome inhibitors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
[Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:7

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; Leukemia-Lymphoma, Adult T-Cell; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines

2004
Bortezomib as a potential treatment for prostate cancer.
    Cancer research, 2004, Aug-01, Volume: 64, Issue:15

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Male; Multienzyme Complexes; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
Multiple myeloma.
    The New England journal of medicine, 2004, Oct-28, Volume: 351, Issue:18

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide

2004
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
    Clinical journal of oncology nursing, 2004, Volume: 8, Issue:5

    Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance

2004
[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Aktuelle Urologie, 2004, Volume: 35, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostate-Specific Antigen; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2004
[The role of proteasome in pathophysiology of cancer cachexia].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2004, Volume: 17 Suppl 1

    Topics: Boronic Acids; Bortezomib; Cachexia; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
Use of proteasome inhibition in the treatment of lung cancer.
    Clinical lung cancer, 2004, Volume: 6 Suppl 2

    Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2004
Targeting multiple myeloma cells and their bone marrow microenvironment.
    Annals of the New York Academy of Sciences, 2004, Volume: 1028

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide

2004
Proteasome inhibition in the treatment of cancer.
    Cell cycle (Georgetown, Tex.), 2005, Volume: 4, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cyclins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2005
Evolving treatment strategies for myeloma.
    British journal of cancer, 2005, Jan-31, Volume: 92, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2005
Proteasome inhibition as a novel therapeutic target in human cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2005
Discovery, Development, and clinical applications of bortezomib.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors

2004
Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors

2004
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005
[Multiple myeloma--recent advances in diagnosis and treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid

2005
The proteasome.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Neoplasms; NF-kappaB-Inducing Kinase; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Pyrazines; Structure-Activity Relationship

2004
Clinical update: novel targets in gynecologic malignancies.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 16

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cisplatin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; NF-kappaB-Inducing Kinase; Ovarian Neoplasms; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines

2004
Clinical update: novel targets in multiple myeloma.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 16

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2004
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
    The oncologist, 2005, Volume: 10, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Medical Oncology; Pemetrexed; Pyrazines

2005
Proteasome inhibitor therapy in multiple myeloma.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2005
Proteasome: an emerging target for cancer therapy.
    Anti-cancer drugs, 2005, Volume: 16, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity; Treatment Outcome

2005
Targeted therapy in multiple myeloma.
    Cancer control : journal of the Moffitt Cancer Center, 2005, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide

2005
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
    Cancer immunology, immunotherapy : CII, 2006, Volume: 55, Issue:1

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2006
Treatment of myeloma in patients not eligible for transplantation.
    Current treatment options in oncology, 2005, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide

2005
Future therapies in hormone-refractory prostate cancer.
    Urology, 2005, Volume: 65, Issue:5 Suppl

    Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide

2005
Proteasome inhibitors in cancer therapy.
    Methods in molecular biology (Clifton, N.J.), 2005, Volume: 301

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
Novel approaches to the management of myeloma.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide

2005
Current treatment options for myeloma.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine

2005
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine

2005
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Expert review of anticancer therapy, 2005, Volume: 5, Issue:3

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2005
Treatment of mantle cell lymphoma: targeting the microenvironment.
    Expert review of anticancer therapy, 2005, Volume: 5, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rituximab; Thalidomide

2005
Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2005, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Lysosomes; Neoplasms; Pyrazines

2005
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines

2005
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
Toxic neuropathy.
    Current opinion in neurology, 2005, Volume: 18, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide

2005
The current status of thalidomide in the management of multiple myeloma.
    Acta haematologica, 2005, Volume: 114 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha

2005
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Cancer, 2005, Nov-01, Volume: 104, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Models, Molecular; Multiple Myeloma; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2005
Emerging trends in the clinical use of bortezomib in multiple myeloma.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation, Autologous

2005
Evolving role of stem cell transplantation in multiple myeloma.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2005
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:2

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Immunosuppressive Agents; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Treatment Outcome; Vincristine

2005
Proteasome inhibitors as therapeutics.
    Essays in biochemistry, 2005, Volume: 41

    Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
Preclinical data with bortezomib in lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2005
Sequencing bortezomib with chemotherapy and targeted agents.
    Clinical lung cancer, 2005, Volume: 7 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Drug Interactions; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2005
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines

2005
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents

2005
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
    Clinical lung cancer, 2005, Volume: 7 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ubiquitin

2005
Bortezomib: a novel therapy approved for multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2003
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Cancer treatment reviews, 2005, Volume: 31, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Pyrazines; Treatment Outcome

2005
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
    Current cancer drug targets, 2005, Volume: 5, Issue:7

    Topics: Acetylcysteine; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
Proteasome inhibition: a new approach for the treatment of malignancies.
    Bulletin du cancer, 2005, Volume: 92, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia

2005
Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:2

    Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin

2006
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Seminars in hematology, 2005, Volume: 42, Issue:4 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide

2005
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Seminars in hematology, 2005, Volume: 42, Issue:4 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide

2005
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:3

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Multicenter Studies as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2005
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
    Annales pharmaceutiques francaises, 2005, Volume: 63, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin

2005
Overview of drug therapy for multiple myeloma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide

2005
A practical update on the use of bortezomib in the management of multiple myeloma.
    The oncologist, 2006, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Survival Analysis; Thrombocytopenia

2006
The proteasome and proteasome inhibitors in cancer therapy.
    Annual review of pharmacology and toxicology, 2006, Volume: 46

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2006
Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2005, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondria; Mitochondrial Proteins; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Tumor Necrosis Factor; Ubiquitin; Ubiquitin-Protein Ligases

2005
Bortezomib: proteasome inhibition as an effective anticancer therapy.
    Annual review of medicine, 2006, Volume: 57

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Pyrazines

2006
Proteasome inhibitors in lung cancer.
    Critical reviews in oncology/hematology, 2006, Volume: 58, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2006
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2006
[Bortezomib].
    Deutsche medizinische Wochenschrift (1946), 2006, Feb-03, Volume: 131, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines

2006
[New strategy for the treatment of multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning

2005
Other compounds and targets in non-small cell lung cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Ligands; Lung Neoplasms; Membrane Glycoproteins; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
New developments in chemotherapy for advanced non-small cell lung cancer.
    Current opinion in oncology, 2006, Volume: 18, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines

2006
Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.
    Current medicinal chemistry, 2006, Volume: 13, Issue:2

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Drug Design; Humans; Ligands; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity

2006
Mantle cell lymphomas.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Predictive Value of Tests; Pyrazines; Survival Rate

2005
New treatments for multiple myeloma.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2005
Novel treatment approaches for patients with multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide

2006
Success in translational research: lessons from the development of bortezomib.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Industry; Intellectual Property; Models, Economic; NF-kappa B; Pharmacology; Pharmacology, Clinical; Pyrazines; Research; United States

2006
[Prognostic factors and new treatments of multiple myeloma].
    La Revue du praticien, 2006, Jan-15, Volume: 56, Issue:1

    Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2006
Bortezomib: proteasome inhibition as an effective anticancer therapy.
    Future oncology (London, England), 2005, Volume: 1, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Forecasting; Humans; Neoplasms; Proteasome Inhibitors; Pyrazines

2005
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
    Future oncology (London, England), 2006, Volume: 2, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Design; Female; Humans; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin

2006
Pharmacotherapy of multiple myeloma.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines

2006
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    International journal of cancer, 2006, Sep-01, Volume: 119, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome

2006
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2006, Volume: 20, Issue:1

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines

2006
Treatment of multiple myeloma: an emphasis on new developments.
    Annals of medicine, 2006, Volume: 38, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2006
Proteasome inhibition: novel therapy for multiple myeloma.
    Onkologie, 2006, Volume: 29, Issue:4

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Practice Patterns, Physicians'; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2006
[New treatment strategy of multiple myeloma for cure].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Medical Oncology; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide

2006
Fourth biannual report of the Cochrane Haematological Malignancies Group.
    Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine

2006
[The plasma cell myeloma--molecular pathogenesis and target therapies].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors

2006
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
    Current opinion in oncology, 2006, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Thalidomide

2006
The proteasome: a novel target for anticancer therapy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Drug Design; Humans; Multiple Myeloma; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Randomized Controlled Trials as Topic; Ubiquitin

2006
Apoptosis: a relevant tool for anticancer therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Capsid Proteins; Humans; Inhibitor of Apoptosis Proteins; Ligands; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasms; Pyrazines; Receptors, Death Domain; Sulindac; Survivin; TNF-Related Apoptosis-Inducing Ligand

2006
Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
    Folia medica, 2005, Volume: 47, Issue:3-4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Molecular Structure; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines

2005
Systemic therapy in the palliative management of advanced salivary gland cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab

2006
Proteasome inhibition as novel treatment strategy in leukaemia.
    British journal of haematology, 2006, Volume: 134, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Forecasting; Humans; Leukemia; NF-kappa B; Protease Inhibitors; Pyrazines; Ubiquitin

2006
[Current therapy for multiple myeloma].
    Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 114, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide

2005
Bortezomib for multiple myeloma.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multiple Myeloma; Product Surveillance, Postmarketing; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic

2006
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Acta haematologica, 2006, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2006
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Leukemia, 2006, Volume: 20, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Separation; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Stem Cells

2006
Proteasome inhibition in multiple myeloma.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Ubiquitin

2006
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Nature clinical practice. Oncology, 2006, Volume: 3, Issue:7

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome

2006
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia

2006
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Current cancer drug targets, 2006, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A

2006
Emerging role of novel combinations for induction therapy in multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Thalidomide; Treatment Outcome

2006
[Proteasome inhibitor bortezomib as an anticancer drug].
    Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2006, Volume: 51, Issue:10 Suppl

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Clinical Trials as Topic; Cytokines; Heat-Shock Proteins; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2006
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide

2006
Advances in the treatment of multiple myeloma: a nursing perspective.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome

2006
[New drugs for myeloma].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Pt 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2006
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
    Biochemical pharmacology, 2006, Oct-30, Volume: 72, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Glucocorticoids; Humans; I-kappa B Kinase; Multiple Myeloma; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines

2006
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Current opinion in oncology, 2006, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines

2006
Response to bortezomib and activation of osteoblasts in multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2

    Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Osteoprotegerin; Parathyroid Hormone; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2006
[Recent progress in diagnosis of and therapy for multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Sep-10, Volume: 95, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide

2006
Targeting ubiquitin in cancers.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:18

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin

2006
Proteasome inhibitors: antitumor effects and beyond.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction

2007
Current status of new drugs for the treatment of patients with multiple myeloma.
    Internal medicine journal, 2006, Volume: 36, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2006
Investigational treatments for multiple myeloma.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Remission Induction; Risk Factors; Salvage Therapy; Thalidomide; Treatment Outcome

2006
Bortezomib as an antitumor agent.
    Current pharmaceutical biotechnology, 2006, Volume: 7, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin

2006
[Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:10

    Topics: Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Remission Induction; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2006
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2006, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechin; Clinical Trials as Topic; Curcumin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genistein; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Structure-Activity Relationship; Ubiquitin

2006
[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:12

    Topics: Benzamides; Boronic Acids; Bortezomib; Carrier State; Cyclohexanones; HIV Protease Inhibitors; Human T-lymphotropic virus 1; Humans; Infectious Disease Transmission, Vertical; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Ritonavir; Stem Cell Transplantation; Transplantation, Homologous

2006
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Drugs in R&D, 2007, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic

2007
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Oncology, 2006, Volume: 70, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide

2006
Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Drug Synergism; Humans; Models, Biological; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Treatment Outcome

2007
The emerging role of novel therapies for the treatment of relapsed myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide

2007
The proteasome and its inhibitors in immune regulation and immune disorders.
    Critical reviews in immunology, 2006, Volume: 26, Issue:6

    Topics: Animals; Antigen Presentation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Therapy; Humans; Immune System; Immune System Diseases; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction

2006
Use of systemic proteasome inhibition as an immune-modulating agent in disease.
    Endocrine, metabolic & immune disorders drug targets, 2007, Volume: 7, Issue:1

    Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; NF-kappa B; Proteasome Inhibitors; Pyrazines

2007
Emerging drugs in multiple myeloma.
    Expert opinion on emerging drugs, 2007, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2007
[Recent progress in the treatment of multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:2

    Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide

2007
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
    Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles

2007
The proteasome: a worthwhile target for the treatment of solid tumours?
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2007
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones

2007
[Proteasome inhibitors for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2007
Myeloma bone disease and proteasome inhibition therapies.
    Blood, 2007, Aug-15, Volume: 110, Issue:4

    Topics: Bone Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines

2007
Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Anti-cancer agents in medicinal chemistry, 2007, Volume: 7, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2007
[New treatment of multiple myeloma].
    La Revue de medecine interne, 2007, Volume: 28, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2007
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7 Suppl 4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2007
New drugs for myeloma.
    The oncologist, 2007, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome

2007
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
    European journal of haematology, 2007, Volume: 79, Issue:2

    Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2007
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
    Leukemia, 2007, Volume: 21, Issue:9

    Topics: Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines

2007
Proteasome inhibition and multiple myeloma.
    Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines

2007
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2007
Bortezomib-associated cutaneous vasculitis.
    The British journal of dermatology, 2007, Volume: 157, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Skin Diseases, Vascular; Vasculitis

2007
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Cancer, 2007, Sep-01, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2007
Incorporating bortezomib into the treatment of lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lung Neoplasms; Pyrazines

2007
[Breast cancer and Her-2].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2007
Tandem transplants in the treatment of multiple myeloma. Pro.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2004
[Recent progress in rituximab therapy and its resistance--how do we overcome?].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine

2007
[Effects of proteasome inhibitors on leukemias].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Leukemia; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2007
Sensitizing tumor cells to immune-mediated cytotoxicity.
    Advances in experimental medicine and biology, 2007, Volume: 601

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Humans; Immune System; Immunotherapy; Killer Cells, Natural; Ligands; Neoplasms; Proteasome Inhibitors; Pyrazines; Tumor Necrosis Factor-alpha

2007
Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
    Cell cycle (Georgetown, Tex.), 2007, Aug-15, Volume: 6, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dendritic Cells; Heat-Shock Proteins; Humans; Models, Biological; Neoplasms; Pyrazines; T-Lymphocytes

2007
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
    Current treatment options in oncology, 2007, Volume: 8, Issue:2

    Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide

2007
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:7

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide

2007
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
    The oncologist, 2007, Volume: 12, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Female; Humans; Male; Multiple Myeloma; Pyrazines

2007
Targeted treatments to improve stem cell outcome: old and new drugs.
    Bone marrow transplantation, 2007, Volume: 40, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2007
Management of novel therapeutics' side effects: a nurse-centric model.
    ONS connect, 2007, Volume: 22, Issue:8 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nursing; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Advocacy; Patient Education as Topic; Pyrazines; Thalidomide

2007
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Oncogene, 2008, Feb-21, Volume: 27, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Gene Expression Regulation, Enzymologic; Humans; Multigene Family; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2008
[New targeted therapies in hormone-refractory prostate cancer].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cancer Vaccines; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin-1; Epothilones; Humans; Male; Oligonucleotides, Antisense; Organoplatinum Compounds; Prostatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Taxoids

2007
alpha-Amido boronic acids: a synthetic challenge and their properties as serine protease inhibitors.
    Medicinal research reviews, 2008, Volume: 28, Issue:2

    Topics: Boronic Acids; Bortezomib; Pyrazines; Serine Proteinase Inhibitors

2008
Proteasome inhibitors: poisons and remedies.
    Medicinal research reviews, 2008, Volume: 28, Issue:2

    Topics: Binding Sites; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Threonine

2008
Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2007, Volume: 37, Issue:1

    Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Cycle; Cell Differentiation; Clinical Trials, Phase II as Topic; Endoplasmic Reticulum; Humans; Lymphoma; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2007
[Multiple myeloma and intravenous immunoglobulins].
    La Revue de medecine interne, 2007, Volume: 28 Spec No 2

    Topics: Agammaglobulinemia; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins, Intravenous; Infections; Male; Multicenter Studies as Topic; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Time Factors

2007
Novel therapies in myeloma.
    Current opinion in hematology, 2007, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2007
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Humans; Leukocyte Common Antigens; Mice; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Stem Cell Transplantation; Stem Cells; Transplantation Conditioning

2007
Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
    International journal of clinical oncology, 2007, Volume: 12, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2007
The role of proteasome in malignant diseases.
    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Ubiquitin

2007
[Therapy of multiple myeloma: indications and options].
    Der Internist, 2007, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden

2007
High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Seminars in hematology, 2007, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Registries; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2007
New therapies in multiple myeloma.
    Clinical and experimental medicine, 2007, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2007
[Issues related to basic research on uterine and ovarian tumor pathology].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2007, Volume: 36, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Human papillomavirus 16; Humans; Ovarian Neoplasms; Papillomavirus Infections; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Trastuzumab; Tumor Suppressor Protein p53; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms

2007
Management of relapsed and relapsed refractory myeloma.
    Hematology/oncology clinics of North America, 2007, Volume: 21, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide

2007
[Pharmacological and clinical profile of Bortezomib (Velcade)].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2007, Volume: 130, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Pyrazines

2007
Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
    Expert opinion on therapeutic targets, 2007, Volume: 11, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines

2007
The treatment of relapsed and refractory multiple myeloma.
    Hematology. American Society of Hematology. Education Program, 2007

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2007
The role of bortezomib in the treatment of lymphoma.
    Cancer investigation, 2007, Volume: 25, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines

2007
Clinical updates and nursing considerations for patients with multiple myeloma.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome

2007
Severe hyponatremia in a patient with mantle cell lymphoma treated with bortezomib: a case report and review of the literature.
    Onkologie, 2007, Volume: 30, Issue:12

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Hyponatremia; Lymphoma, Mantle-Cell; Pyrazines

2007
[Diagnosis and management guideline for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2007
[Chemotherapy for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine

2007
[Role of bortezomib in the treatment of multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide

2007
[Role of stem cell transplantation in treatment of multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous

2007
[Molecular targeting therapy for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A

2007
[Situation of translational research and development of molecular-targeted agents for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Animals; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Drug Design; Gene Targeting; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines

2007
Bortezomib in multiple myeloma.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Metabolic Networks and Pathways; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2007
[Progress in the study of proteasome inhibitor inducing hepatic stellate cell apoptosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:11

    Topics: Apoptosis; Boronic Acids; Bortezomib; Hepatic Stellate Cells; Protease Inhibitors; Pyrazines

2007
[Advances in therapeutic strategies for multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide

2007
An update on drug combinations for treatment of myeloma.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome

2008
Combination treatment approaches and novel therapies for lymphoma.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:8 Suppl 12

    Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation

2007
Position statement on the use of bortezomib in multiple myeloma.
    International journal of laboratory hematology, 2008, Volume: 30, Issue:1

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2008
Bortezomib in the treatment of cancer.
    Recent patents on anti-cancer drug discovery, 2006, Volume: 1, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Patents as Topic; Proteasome Inhibitors; Pyrazines; Signal Transduction

2006
[Molecular-targeted therapy for prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazines; Thalidomide

2008
Multiple myeloma: novel approaches for relapsed disease.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide

2007
The therapeutic potential of the proteasome in leukaemia.
    Hematological oncology, 2008, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Gene Expression Regulation, Leukemic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence

2008
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab

2008
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
    Current opinion in oncology, 2008, Volume: 20, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A

2008
Bortezomib: putting mantle cell lymphoma on death row.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:4

    Topics: Apoptosis Regulatory Proteins; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines

2008
[Current concepts and treatment advances in systemic mastocytosis].
    La Revue de medecine interne, 2009, Volume: 30, Issue:1

    Topics: Adult; Boronic Acids; Bortezomib; Child; Forecasting; Humans; Immunohistochemistry; Immunosuppressive Agents; Mastocytosis, Systemic; Mutation; Prognosis; Protease Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Sirolimus; Stem Cell Transplantation; Transduction, Genetic; World Health Organization

2009
Bortezomib in mantle cell lymphoma.
    Future oncology (London, England), 2008, Volume: 4, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2008
Current therapy of myeloma induced renal failure.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:5

    Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide

2008
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Cancer letters, 2008, Sep-28, Volume: 269, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Mitochondria; Neoplasms; Pyrazines; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand

2008
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:5

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency; Treatment Outcome

2008
Bortezomib in multiple myeloma.
    Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines

2008
The potential of proteasome inhibitors in cancer therapy.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Ubiquitin; Ubiquitination

2008
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
    Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Hematologic Neoplasms; Humans; Leukemia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2008
Treatment of plasma cell dyscrasias with lenalidomide.
    Leukemia, 2008, Volume: 22, Issue:7

    Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia

2008
Maintenance treatment in multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19 Suppl 4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide

2008
Pathogenesis and treatment of renal failure in multiple myeloma.
    Leukemia, 2008, Volume: 22, Issue:8

    Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide

2008
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
    Current protein & peptide science, 2008, Volume: 9, Issue:3

    Topics: Acetylcysteine; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Curcumin; Humans; Neoplasms; Pentacyclic Triterpenes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Triterpenes; Ubiquitin

2008
Frontline treatment of multiple myeloma in elderly patients.
    Blood reviews, 2008, Volume: 22, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide

2008
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jul-01, Volume: 65, Issue:13

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines

2008
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
    Blood, 2008, Sep-01, Volume: 112, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Risk Factors

2008
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
    Drug discovery today, 2008, Volume: 13, Issue:15-16

    Topics: Alcohol Deterrents; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disulfiram; Drug Screening Assays, Antitumor; Forecasting; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thiocarbamates; Ubiquitin

2008
Bortezomib in the front-line treatment of multiple myeloma.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2008
Treatment of relapsed and refractory myeloma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome

2008
Targeting TRAIL death receptors.
    Current opinion in pharmacology, 2008, Volume: 8, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Glioma; HLA-DR4 Antigen; HLA-DR5 Antigen; Humans; Neoplasms; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand

2008
[Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Transplantation; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Transplantation, Homologous

2008
The proteasome and its role in the degradation of oxidized proteins.
    IUBMB life, 2008, Volume: 60, Issue:11

    Topics: Aging; Animals; Antioxidants; Boronic Acids; Bortezomib; Humans; Models, Biological; Multienzyme Complexes; Oxidation-Reduction; Oxidative Stress; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Substrate Specificity; Ubiquitin; Ubiquitination

2008
New drugs in multiple myeloma.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2008
Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat

2008
The role of novel drugs in multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2008
Proteasome inhibition: a new therapeutic option in lupus nephritis?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:12

    Topics: Animals; Antibodies, Antinuclear; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Lupus Nephritis; Mice; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2008
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
    Leukemia & lymphoma, 2008, Volume: 49 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide

2008
[Treatment for multiple myeloma: current status and future strategy in Japan].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous

2008
Advances in therapy of multiple myeloma.
    Current opinion in oncology, 2008, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome

2008
Novel targets for myeloma bone disease.
    Expert opinion on therapeutic targets, 2008, Volume: 12, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Denosumab; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; RANK Ligand

2008
Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis.
    International reviews of immunology, 2008, Volume: 27, Issue:5

    Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Humans; Immunosuppression Therapy; Inflammation; Mice; NF-kappa B; Nuclear Localization Signals; Oligodeoxyribonucleotides; Pyrazines; Rats; Signal Transduction

2008
Practical considerations for multiple myeloma: an overview of recent data and current options.
    Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide

2008
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Thrombosis research, 2009, Volume: 123, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism

2009
Treatment of newly diagnosed myeloma.
    Leukemia, 2009, Volume: 23, Issue:3

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning

2009
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
    Drugs, 2008, Volume: 68, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines

2008
Pathogenesis of myeloma bone disease.
    Leukemia, 2009, Volume: 23, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Denosumab; Fractures, Spontaneous; Glucocorticoids; Humans; Hypercalcemia; Immunologic Factors; Interleukins; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteoclasts; Osteolysis; Pyrazines; RANK Ligand; Stromal Cells; Wnt Proteins

2009
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-01, Volume: 27, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Waldenstrom Macroglobulinemia

2009
From palliation to epigenetic therapy in myelofibrosis.
    Hematology. American Society of Hematology. Education Program, 2008

    Topics: Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Epigenesis, Genetic; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Janus Kinase 2; Mutation; Palliative Care; Primary Myelofibrosis; Pyrazines; Radiotherapy; Signal Transduction; Splenectomy; Transplantation, Homologous

2008
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
    Current medicinal chemistry, 2008, Volume: 15, Issue:29

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Demyelinating Diseases; Humans; Myelin Sheath; Neoplasms; Neurotoxicity Syndromes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2008
The persisting challenge of selective and specific proteasome inhibition.
    Journal of peptide science : an official publication of the European Peptide Society, 2009, Volume: 15, Issue:2

    Topics: Boronic Acids; Bortezomib; Catalytic Domain; Drug Design; Humans; Models, Molecular; Molecular Structure; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines

2009
Diagnosis and the current trends in multiple myeloma therapy.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide

2008
Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
    EMBO reports, 2009, Volume: 10, Issue:2

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boron; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Carbon; Drug Design; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Pyrazines

2009
Treatment of multiple myeloma in the targeted therapy era.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning

2009
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
    British journal of haematology, 2009, Volume: 145, Issue:2

    Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans; Immunosuppressive Agents; Paraproteinemias; Protease Inhibitors; Pyrazines; Retrospective Studies; Thalidomide; Thrombosis

2009
[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man].
    Zeitschrift fur Rheumatologie, 2009, Volume: 68, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Immunotherapy; Lupus Erythematosus, Systemic; Mice; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome

2009
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
    Cardiovascular & hematological disorders drug targets, 2009, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lactones; Leukemia; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles

2009
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous

2009
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    British journal of haematology, 2009, Volume: 145, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide

2009
Bortezomib and Waldenstrom's macroglobulinemia.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Pyrazines; Waldenstrom Macroglobulinemia

2009
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Waldenstrom Macroglobulinemia

2009
Role of proteasome inhibition in Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1

    Topics: Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia

2009
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
    Current opinion in hematology, 2009, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine

2009
Monitoring and treating posttransplant human leukocyte antigen antibodies.
    Human immunology, 2009, Volume: 70, Issue:8

    Topics: Antibody Formation; Boronic Acids; Bortezomib; Cyclophosphamide; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Isoantibodies; Monitoring, Physiologic; Organ Transplantation; Plasmapheresis; Prognosis; Pyrazines; Risk Factors; Serologic Tests; Transplantation

2009
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
    Seminars in hematology, 2009, Volume: 46, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines

2009
Targeting the proteasome pathway.
    Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:5

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins

2009
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
    The oncologist, 2009, Volume: 14, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Clinical Trials as Topic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Proteasome Inhibitors; Protein Kinase C; Pyrazines; Sirolimus

2009
[Multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5

    Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Fractures, Bone; Humans; Hypercalcemia; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Protease Inhibitors; Pyrazines

2009
Bortezomib: a review of its use in patients with multiple myeloma.
    Drugs, 2009, Volume: 69, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines

2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia

2009
Multiple myeloma.
    Lancet (London, England), 2009, Jul-25, Volume: 374, Issue:9686

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome

2009
Proteasome inhibitors in cancer therapy.
    Current drug targets, 2009, Volume: 10, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Pyrazines

2009
Proteasome inhibition for antibody-mediated rejection.
    Current opinion in organ transplantation, 2009, Volume: 14, Issue:6

    Topics: Animals; Antibodies; Boronic Acids; Bortezomib; Disease Models, Animal; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2009
The future of small molecule inhibitors in lymphoma.
    Current oncology reports, 2009, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Forecasting; Histone Deacetylases; Humans; Lymphoma; Oligopeptides; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2009
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration

2009
Proteasome inhibitors in the treatment of multiple myeloma.
    Leukemia, 2009, Volume: 23, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lactones; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles

2009
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
    Leukemia, 2009, Volume: 23, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome

2009
[Current treatment of follicular lymphoma].
    Revue medicale suisse, 2009, Aug-26, Volume: 5, Issue:214

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Prednisone; Prognosis; Pyrazines; Radioimmunotherapy; Radiotherapy, Adjuvant; Risk Factors; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine

2009
Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Translocation, Genetic

2004
Proteasome inhibition: mechanism of action.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2004
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2004
Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2004
The 26 S proteasome: from basic mechanisms to drug targeting.
    The Journal of biological chemistry, 2009, Dec-04, Volume: 284, Issue:49

    Topics: Adenosine Triphosphate; Animals; Boronic Acids; Bortezomib; Cell Cycle; Cytosol; Drug Delivery Systems; Endoplasmic Reticulum; Gene Expression Regulation; Humans; Proteasome Endopeptidase Complex; Protein Denaturation; Protein Folding; Pyrazines; Transcription Factors; Transcription, Genetic; Ubiquitin

2009
Novel therapies in the treatment of multiple myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2009, Volume: 7, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide

2009
Multiple myeloma, painful neuropathy, acupuncture?
    American journal of clinical oncology, 2009, Volume: 32, Issue:3

    Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pain; Pain Management; Peripheral Nervous System Diseases; Pyrazines; Thalidomide

2009
[Hematopoietic stem cell transplantation for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine

2009
[New treatment strategies for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine

2009
[IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
    Vnitrni lekarstvi, 2009, Volume: 55, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Skin Diseases, Vesiculobullous

2009
How to treat a newly diagnosed young patient with multiple myeloma.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning

2009
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis

2009
Novel therapies for relapsed myeloma.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide

2009
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide

2009
Future directions in immunomodulatory therapy.
    Medical oncology (Northwood, London, England), 2010, Volume: 27 Suppl 1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines

2010
Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated?
    Current molecular pharmacology, 2008, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin

2008
New treatments for myeloma.
    Joint bone spine, 2010, Volume: 77, Issue:1

    Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide

2010
Osteoblastogenesis and tumor growth in myeloma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Tumor Burden

2010
Bortezomib.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2010
The therapeutic potential of deubiquitinating enzyme inhibitors.
    Biochemical Society transactions, 2010, Volume: 38, Issue:Pt 1

    Topics: Animals; Boronic Acids; Bortezomib; Endopeptidases; Humans; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Ubiquitination; Viruses

2010
Current multiple myeloma treatment strategies with novel agents: a European perspective.
    The oncologist, 2010, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2010
New developments in the treatment of patients with multiple myeloma.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide

2010
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Drug discovery today, 2010, Volume: 15, Issue:5-6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2010
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Pyrazines

2010
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
    Haematologica, 2010, Volume: 95, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide

2010
Proteasomal regulation of pulmonary fibrosis.
    Proceedings of the American Thoracic Society, 2010, Volume: 7, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulmonary Fibrosis; Pyrazines; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Ubiquitin

2010
Allergy for a lifetime?
    Allergology international : official journal of the Japanese Society of Allergology, 2010, Volume: 59, Issue:1

    Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Activation Factor Receptor; Boronic Acids; Bortezomib; Cell Survival; Drug Resistance; Humans; Hypersensitivity; Immunoglobulin E; Immunologic Memory; Immunotherapy; Lymphocyte Depletion; Omalizumab; Plasma Cells; Pyrazines; Recombinant Fusion Proteins; Tumor Necrosis Factor Ligand Superfamily Member 13

2010
Advances in treatment for relapses and refractory multiple myeloma.
    Medical oncology (Northwood, London, England), 2010, Volume: 27 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide

2010
Novel agents in development for peripheral T-cell lymphoma.
    Seminars in hematology, 2010, Volume: 47 Suppl 1

    Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide

2010
How best to use new therapies in multiple myeloma.
    Blood reviews, 2010, Volume: 24, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence

2010
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Nucleosides; Pyrazines; Recurrence; Rituximab; Signal Transduction; Waldenstrom Macroglobulinemia

2010
[Molecular-targeted therapy of multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2010, Jan-10, Volume: 99, Issue:1

    Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2010
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Vnitrni lekarstvi, 2010, Volume: 56, Issue:3

    Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide

2010
Role of autologous stem cell transplantation in multiple myeloma.
    Current hematologic malignancy reports, 2007, Volume: 2, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2007
Current status of bortezomib in the treatment of multiple myeloma.
    Current hematologic malignancy reports, 2007, Volume: 2, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Kidney Failure, Chronic; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Stromal Cells; Transplantation, Autologous

2007
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
    Current hematologic malignancy reports, 2009, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome

2009
Treatment of relapsed and refractory myeloma.
    Current hematologic malignancy reports, 2009, Volume: 4, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide

2009
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
    Swiss medical weekly, 2010, Volume: 140

    Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide

2010
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2010, Volume: 13, Issue:3

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoribonucleases; Histone Deacetylase 6; Histone Deacetylases; Humans; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Membrane Proteins; Microtubule-Associated Proteins; Multiprotein Complexes; Neoplasms; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proteins; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitinated Proteins; Ubiquitins

2010
Management of treatment-related adverse events in patients with multiple myeloma.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism

2010
Multiple myeloma - current issues and controversies.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2010
Optimising patient outcomes in myeloma.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome

2010
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Leukemia research, 2010, Volume: 34, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic

2010
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines

2010
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2010
[Proteasome inhibitor].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Physiological Phenomena; Clinical Trials as Topic; Drug Design; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2010
Drug-mediated and cellular immunotherapy in multiple myeloma.
    Immunotherapy, 2010, Volume: 2, Issue:2

    Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape

2010
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Aug-15, Volume: 16, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Pyrazines

2010
Plasma cell leukaemia and other aggressive plasma cell malignancies.
    British journal of haematology, 2010, Volume: 150, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide

2010
Therapeutic options for HIV-associated lymphomas.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:15

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Epstein-Barr Virus Infections; HIV Infections; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Pyrazines; Rituximab; Treatment Outcome

2010
[Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transplantation, Homologous

2010
Bortezomib: a new player in pre- and post-transplant desensitization?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:11

    Topics: Boronic Acids; Bortezomib; Dendritic Cells; Desensitization, Immunologic; Graft Rejection; HLA Antigens; Humans; Isoantibodies; Kidney Transplantation; NF-kappa B; Pyrazines

2010
The spectrum of kidney involvement in lymphoma: a case report and review of the literature.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 56, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Prognosis; Pyrazines; Renal Insufficiency; Rituximab; Treatment Outcome

2010
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    European journal of haematology, 2010, Volume: 85, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide

2010
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 6

    Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide

2010
[Current treatment strategies for multiple myeloma].
    Therapeutische Umschau. Revue therapeutique, 2010, Volume: 67, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide

2010
[Study on natural products for drug development].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:10

    Topics: Animals; Antineoplastic Agents; Aspergillus; Axinella; Biological Products; Boronic Acids; Bortezomib; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Indole Alkaloids; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases

2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    The Lancet. Oncology, 2010, Volume: 11, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome

2010
[Proteasome inhibitors].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33

    Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous

2010
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2010
Plasma cell leukemia: concepts and management.
    Expert review of hematology, 2010, Volume: 3, Issue:5

    Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2010
Multiple myeloma.
    Annual review of medicine, 2011, Volume: 62

    Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2011
Targeted therapy in lymphoma.
    Journal of hematology & oncology, 2010, Nov-23, Volume: 3

    Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis

2010
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
    American journal of hematology, 2011, Volume: 86, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2011
Treatment approaches to IgG4-related systemic disease.
    Current opinion in rheumatology, 2011, Volume: 23, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunoglobulin G; Immunosuppressive Agents; Pancreatitis; Prognosis; Pyrazines; Recurrence; Rituximab

2011
Ten years of improvement in the management of multiple myeloma: 2000-2010.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2010
Clinical impact of chromosomal aberrations in multiple myeloma.
    Journal of internal medicine, 2011, Volume: 269, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome

2011
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
    Future oncology (London, England), 2011, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Disease; Humans; Immunomodulation; Models, Animal; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2011
Chemotherapy-induced neuropathic pain.
    Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neuralgia; Pyrazines; Thalidomide

2011
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Current cancer drug targets, 2011, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2011
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
    American journal of therapeutics, 2012, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation

2012
Focal adhesion kinase as a therapeutic target of bortezomib.
    Anti-cancer agents in medicinal chemistry, 2010, Volume: 10, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Pyrazines

2010
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.
    Oncotarget, 2010, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gastrointestinal Stromal Tumors; Histones; Humans; Proto-Oncogene Proteins c-kit; Pyrazines

2010
Antibody-mediated rejection in kidney transplantation: an update.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Formation; Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Prognosis; Protease Inhibitors; Pyrazines

2011
Management of older patients with multiple myeloma.
    Blood reviews, 2011, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2011
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Expert review of hematology, 2011, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2011
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide

2011
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
    Current hematologic malignancy reports, 2011, Volume: 6, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2011
[Classification and synthesis of ubiquitin-proteasome inhibitor].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:12

    Topics: Acetylcysteine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Dipeptides; Humans; Multiple Myeloma; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2009
[Immunosuppressive agents in kidney transplantation].
    Nihon Jinzo Gakkai shi, 2011, Volume: 53, Issue:1

    Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases

2011
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
    Current hematologic malignancy reports, 2011, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome

2011
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
    PharmacoEconomics, 2011, Volume: 29, Issue:4

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2011
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-15, Volume: 17, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Female; Humans; Male; Medical Oncology; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2011
Treatment options for relapsed and refractory multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-15, Volume: 17, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide

2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
    The oncologist, 2011, Volume: 16, Issue:4

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2011
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:14

    Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia

2011
[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:2

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chronic Disease; Combined Modality Therapy; Dexamethasone; Down-Regulation; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin lambda-Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Remission Induction; Renal Dialysis; Transplantation, Autologous

2011
[Current treatment of AL amyloidosis].
    Nephrologie & therapeutique, 2011, Volume: 7, Issue:6

    Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide

2011
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Blood reviews, 2011, Volume: 25, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2011
The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Current pharmaceutical design, 2011, Volume: 17, Issue:15

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2011
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
    Internal medicine journal, 2011, Volume: 41, Issue:4

    Topics: ADAM Proteins; ADAMTS13 Protein; Boronic Acids; Bortezomib; Female; Fever of Unknown Origin; Humans; Middle Aged; Multiple Myeloma; Purpura, Thrombotic Thrombocytopenic; Pyrazines

2011
Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Alkylating Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromatin; Histone Deacetylase Inhibitors; Humans; Janus Kinase 2; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Unfolded Protein Response; Wnt Proteins

2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2011
Therapy of relapsed and refractory multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide

2011
[New insights in the treatment of myeloma with renal failure].
    Nephrologie & therapeutique, 2011, Volume: 7, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide

2011
Role of proteasome inhibition in sensitized transplant candidates.
    Chinese medical journal, 2011, Volume: 124, Issue:5

    Topics: Boronic Acids; Bortezomib; Graft Rejection; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplants

2011
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Danish medical bulletin, 2011, Volume: 58, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Bone and Bones; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Multiple Myeloma; Osteoblasts; Osteoclasts; Protease Inhibitors; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; Wnt Proteins

2011
Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy.
    FEBS letters, 2011, Sep-16, Volume: 585, Issue:18

    Topics: Animals; Boronic Acids; Bortezomib; DNA Breaks, Double-Stranded; DNA Repair; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin

2011
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; Risk; Thalidomide; Venous Thromboembolism

2011
Novel proteasome inhibitors to overcome bortezomib resistance.
    Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13

    Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination

2011
Desensitization across the HLA barrier in kidney transplantaion.
    Frontiers in bioscience (Scholar edition), 2011, 06-01, Volume: 3, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Female; Flow Cytometry; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Plasmapheresis; Pyrazines; Rituximab; Sensitivity and Specificity; Sex Factors; Treatment Outcome

2011
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.
    Archivum immunologiae et therapiae experimentalis, 2011, Volume: 59, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cytokines; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Inflammation; Mice; Models, Biological; Neoplasms; NF-kappa B; Pyrazines; Signal Transduction; Transcription Factors; Tumor Suppressor Protein p53

2011
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
    Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:8

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2011
New agents in follicular lymphoma.
    Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment

2011
[EGFR/HER1: a target life].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins

2012
A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?
    Acta haematologica, 2011, Volume: 126, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Humans; Kidney; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2011
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.
    Current opinion in oncology, 2011, Volume: 23, Issue:5

    Topics: Boronic Acids; Bortezomib; Carcinoma; Epstein-Barr Virus Infections; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Herpesvirus 8, Human; Humans; Incidence; Lymphoma; Proteasome Inhibitors; Pyrazines; Sarcoma, Kaposi; Virus Latency; Virus Physiological Phenomena

2011
Bortezomib for previously untreated multiple myeloma.
    Expert review of hematology, 2011, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic

2011
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Hematological oncology, 2012, Volume: 30, Issue:2

    Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous

2012
Genomic stratification of multiple myeloma treated with novel agents.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide

2012
Proteasome inhibitor therapy for antibody-mediated rejection.
    Pediatric transplantation, 2011, Volume: 15, Issue:6

    Topics: Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Humans; Kidney Transplantation; Plasma Cells; Prospective Studies; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2011
[Current treatment strategies with novel agents for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:8

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous

2011
[Present status and perspective of targeted therapy for B-cell lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:8

    Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat

2011
Clinical and investigational use of proteasome inhibitors for transplant rejection.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:11

    Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2011
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A

2010
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia

2011
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
    Expert review of hematology, 2011, Volume: 4, Issue:5

    Topics: Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2011
Bortezomib for previously untreated multiple myeloma.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:16

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous

2011
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 58, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous

2011
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy

2012
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Cancer control : journal of the Moffitt Cancer Center, 2011, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2011
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
    Chemical communications (Cambridge, England), 2012, Feb-01, Volume: 48, Issue:10

    Topics: Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship

2012
Macrocyclic proteasome inhibitors.
    Current medicinal chemistry, 2011, Volume: 18, Issue:33

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Macrocyclic Compounds; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2011
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:11

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2011
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:41

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide

2011
The state of therapy for removal of alloantibody producing plasma cells in transplantation.
    Seminars in immunology, 2012, Volume: 24, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Mice; Plasma Cells; Protease Inhibitors; Pyrazines; Treatment Outcome

2012
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
    Leukemia, 2012, Volume: 26, Issue:4

    Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Thalidomide

2012
Advances in the understanding of mechanisms and therapeutic use of bortezomib.
    Discovery medicine, 2011, Volume: 12, Issue:67

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin

2011
Emerging therapies in hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:1 Suppl

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat

2012
Impact of bortezomib on bone health in myeloma: a review of current evidence.
    Cancer treatment reviews, 2012, Volume: 38, Issue:8

    Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Osteogenesis; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic

2012
[Thrombotic complications following the treatment of multiple myeloma with new agents].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 31, Issue:186

    Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis

2011
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:3 Pt 1

    Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines

2012
Management of myeloma-associated renal dysfunction in the era of novel therapies.
    Expert review of hematology, 2012, Volume: 5, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide

2012
Proteasome inhibitors: an expanding army attacking a unique target.
    Chemistry & biology, 2012, Jan-27, Volume: 19, Issue:1

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lactones; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
[Current treatment of acute myeloid leukaemia in adults].
    Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7

    Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin

2012
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome

2012
Latest advances and current challenges in the treatment of multiple myeloma.
    Nature reviews. Clinical oncology, 2012, Feb-21, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide

2012
Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Clinical nephrology, 2012, Volume: 77, Issue:3

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2012
Future trends in organ transplant recipients--important issues for dermatologists.
    Current problems in dermatology, 2012, Volume: 43

    Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Forecasting; Graft Survival; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Organ Transplantation; Pyrazines; Recombinant Fusion Proteins; Risk Assessment; Rituximab; Skin Neoplasms

2012
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
    The oncologist, 2012, Volume: 17, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide

2012
Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:6

    Topics: Acute Disease; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Chronic Disease; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbent Techniques; Isoantibodies; Kidney Transplantation; Plasma Exchange; Pyrazines; Rituximab; Splenectomy

2012
[Multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid

2012
Light chain deposition disease: novel biological insights and treatment advances.
    International journal of laboratory hematology, 2012, Volume: 34, Issue:4

    Topics: Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kidney Failure, Chronic; Male; Middle Aged; Multiple Organ Failure; Pyrazines

2012
[AL amyloidosis].
    Orvosi hetilap, 2012, Apr-15, Volume: 153, Issue:15

    Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2012
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
    Annals of hematology, 2012, Volume: 91, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide

2012
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
    Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:2

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide

2012
Green tea and lung cancer: a systematic review.
    Integrative cancer therapies, 2013, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Damage; Herb-Drug Interactions; Humans; Lung Neoplasms; Maximum Tolerated Dose; Phytotherapy; Plant Extracts; Pyrazines; Tea

2013
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
    The oncologist, 2012, Volume: 17, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translational Research, Biomedical

2012
European perspective on multiple myeloma treatment strategies: update following recent congresses.
    The oncologist, 2012, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2012
The neurovascular unit and combination treatment strategies for stroke.
    Trends in pharmacological sciences, 2012, Volume: 33, Issue:8

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebral Hemorrhage; Drug Therapy, Combination; Erythropoietin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Minocycline; Pyrazines; Stroke; Tissue Plasminogen Activator

2012
Proteasome inhibitors in multiple myeloma: 10 years later.
    Blood, 2012, Aug-02, Volume: 120, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Humans; Medical Oncology; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors

2012
Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
    Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Middle Aged; Pyrazines; Sweet Syndrome

2012
Targeting endoplasmic reticulum signaling pathways in cancer.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; HIV Protease Inhibitors; Humans; Neoplasms; Proteasome Endopeptidase Complex; Protein Folding; Pyrazines; Signal Transduction

2012
Proteasome inhibitors in mantle cell lymphoma.
    Best practice & research. Clinical haematology, 2012, Volume: 25, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Signal Transduction; Survival Analysis

2012
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure

2012
[Development and clinical application of novel proteasome inhibitors].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:4

    Topics: Boronic Acids; Bortezomib; Drug Design; Drug Therapy, Combination; Drug Tolerance; Lymphoma; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic

2012
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Angewandte Chemie (International ed. in English), 2012, Aug-27, Volume: 51, Issue:35

    Topics: Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; T-Lymphocytes

2012
An historic perspective of proteasome inhibition.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Hematologic Neoplasms; History, 20th Century; History, 21st Century; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin

2012
Discovery and development of second-generation proteasome inhibitors.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship

2012
Bortezomib combination therapy in multiple myeloma.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Quality of Life

2012
Proteasome inhibition for antibody-mediated allograft rejection.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Animals; Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Graft Rejection; Humans; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
    Seminars in hematology, 2012, Volume: 49, Issue:3

    Topics: Animals; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Proteasome inhibitors.
    Progress in molecular biology and translational science, 2012, Volume: 109

    Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
[A research advance on bortezomib-induced peripheral neuropathy].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:2

    Topics: Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Pyrazines

2012
Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2012, Volume: 10, Issue:4

    Topics: Adult; Antibodies; Biopsy; Boronic Acids; Bortezomib; Chronic Disease; Drug Therapy, Combination; Female; Graft Rejection; Humans; Immunity, Humoral; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2012
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Annals of hematology, 2012, Volume: 91, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide

2012
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
    Cancer letters, 2012, Dec-28, Volume: 325, Issue:2

    Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Synergism; Forecasting; Humans; Inclusion Bodies; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Translational Research, Biomedical; Ubiquitin

2012
How I treat plasma cell leukemia.
    Blood, 2012, Sep-20, Volume: 120, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Middle Aged; Prognosis; Pyrazines; Transplantation, Autologous

2012
Waldenström macroglobulinemia: my way.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Pyrazines; Rituximab; Survival Analysis; Thalidomide; Waldenstrom Macroglobulinemia

2013
Multiple myeloma: improved outcomes with new therapeutic approaches.
    Current opinion in supportive and palliative care, 2012, Volume: 6, Issue:3

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome

2012
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
    Current hematologic malignancy reports, 2012, Volume: 7, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Lenalidomide; Lymphoma, Follicular; Pyrazines; Rituximab; Thalidomide; Tumor Microenvironment

2012
Achieving an early myeloma response in patients with kidney impairment.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors

2012
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide

2012
The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Dialysis

2012
Myeloma kidney: improving clinical outcomes?
    Advances in chronic kidney disease, 2012, Volume: 19, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Multiple Myeloma; Plasma Exchange; Prognosis; Proteasome Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation

2012
Fifty years of melphalan use in hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2013
Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
    Critical reviews in oncology/hematology, 2013, Volume: 85, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2013
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
    Acta haematologica, 2012, Volume: 128, Issue:4

    Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines

2012
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
    Clinical and experimental nephrology, 2012, Volume: 16, Issue:5

    Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide

2012
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
    Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:5

    Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide

2012
Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
    International journal of dermatology, 2012, Volume: 51, Issue:12

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome

2012
Proteasome inhibitors: a new perspective for treating autoimmune diseases.
    Current drug targets, 2012, Volume: 13, Issue:13

    Topics: Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2012
Emerging agents for the treatment of mantle cell lymphoma.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:9

    Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting

2012
Light-chain amyloidosis: SCT, novel agents and beyond.
    Bone marrow transplantation, 2013, Volume: 48, Issue:8

    Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide

2013
Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
    Current pharmaceutical design, 2013, Volume: 19, Issue:18

    Topics: Animals; Antibodies; B-Lymphocytes; Boronic Acids; Bortezomib; Dendritic Cells; Drug Design; Graft Rejection; Graft vs Host Disease; Humans; Organ Transplantation; Proteasome Inhibitors; Pyrazines; T-Lymphocytes

2013
Dissecting bortezomib: development, application, adverse effects and future direction.
    Current pharmaceutical design, 2013, Volume: 19, Issue:18

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2013
Cullin-RING Ligases as attractive anti-cancer targets.
    Current pharmaceutical design, 2013, Volume: 19, Issue:18

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin-Protein Ligases

2013
When ubiquitin meets NF-κB: a trove for anti-cancer drug development.
    Current pharmaceutical design, 2013, Volume: 19, Issue:18

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination

2013
Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.
    Acta haematologica, 2013, Volume: 129, Issue:2

    Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoadjuvant Therapy; POEMS Syndrome; Pyrazines; Remission Induction

2013
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Leukemia research, 2012, Volume: 36 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors

2012
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
    Leukemia research, 2012, Volume: 36 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors

2012
From bortezomib to other inhibitors of the proteasome and beyond.
    Current pharmaceutical design, 2013, Volume: 19, Issue:22

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines

2013
The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
    Transplantation proceedings, 2012, Volume: 44, Issue:10

    Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Drug Substitution; Female; Graft Rejection; Graft Survival; Histocompatibility; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney; Kidney Transplantation; Male; Middle Aged; Pyrazines; Time Factors; Treatment Outcome

2012
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid

2012
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome

2012
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
    Annals of the New York Academy of Sciences, 2012, Volume: 1274

    Topics: Autoantibodies; Boronic Acids; Bortezomib; Humans; Myasthenia Gravis; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2012
Carfilzomib (Kryprolis) for multiple myeloma.
    The Medical letter on drugs and therapeutics, 2012, Dec-24, Volume: 54, Issue:1406

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines

2012
[Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012, Volume: 65, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines

2012
Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Recovery of Function; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vincristine

2013
Current therapeutic strategy for multiple myeloma.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid

2013
Light chain amyloidosis 2012: a new era.
    British journal of haematology, 2013, Volume: 160, Issue:5

    Topics: Alkylating Agents; Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Forecasting; Humans; Immunoglobulin Light Chains; Immunologic Factors; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrazines; Risk; Severity of Illness Index; Stem Cell Transplantation; Troponin C; Troponin T

2013
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
    Acta haematologica, 2013, Volume: 129, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Thrombocytopenia; Valproic Acid

2013
Induction therapy for newly diagnosed multiple myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2013
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid

2013
Part II: role of maintenance therapy in transplant-ineligible patients.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine

2013
[Advanced in studies of proteasome inhibitor bortezomib and hepatic disease].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:9

    Topics: Boronic Acids; Bortezomib; Humans; Liver Diseases; Proteasome Inhibitors; Pyrazines

2012
Subcutaneous bortezomib: in multiple myeloma.
    Drugs, 2013, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Injections, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome

2013
Humoral theory of transplantation: some hot topics.
    British medical bulletin, 2013, Volume: 105

    Topics: Antibodies; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Complement C4b; Graft Rejection; Humans; Isoantibodies; Peptide Fragments; Pyrazines; Rituximab; Transplantation

2013
New advances in the diagnosis and treatment of POEMS syndrome.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A

2013
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Vnitrni lekarstvi, 2013, Volume: 59, Issue:1

    Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide

2013
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
    Annals of hematology, 2013, Volume: 92, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine

2013
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
    International journal of hematology, 2013, Volume: 97, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosomes, Human; Cyclin D; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Incidence; Multiple Myeloma; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Risk Factors; Sex Factors; Somatic Hypermutation, Immunoglobulin; Survival Rate; Translocation, Genetic; Trisomy; United States

2013
Continuous treatment with new agents for newly diagnosed multiple myeloma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome

2013
[Proteasome inhibitors in treatment of multiple myeloma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines

2013
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine

2013
Bortezomib for the treatment of previously untreated multiple myeloma.
    Immunotherapy, 2013, Volume: 5, Issue:4

    Topics: Boronic Acids; Bortezomib; Drug Evaluation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction

2013
New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes

2003
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
    International journal of hematology, 2013, Volume: 97, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryoglobulinemia; Female; Humans; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome; Vasculitis

2013
Boron chemicals in diagnosis and therapeutics.
    Future medicinal chemistry, 2013, Volume: 5, Issue:6

    Topics: Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Fluorescent Dyes; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species

2013
Therapeutic strategies for the treatment of multiple myeloma.
    Discovery medicine, 2013, Volume: 15, Issue:83

    Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide

2013
Diagnosis and therapy of multiple myeloma.
    The Korean journal of internal medicine, 2013, Volume: 28, Issue:3

    Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide

2013
Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
    Onkologie, 2013, Volume: 36, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Large-Cell, Immunoblastic; Male; Middle Aged; Pyrazines; Treatment Outcome

2013
Current treatments for renal failure due to multiple myeloma.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Transplantation; Multiple Myeloma; Pyrazines; Renal Insufficiency

2013
Effects of bortezomib on the immune system: a focus on immune regulation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immune System; Multiple Myeloma; Pyrazines

2013
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2013
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide

2013
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Multiple Myeloma; Polyneuropathies; Pyrazines; Thalidomide; Treatment Outcome

2013
[Treatment for POEMS syndrome with subcutaneous administration of bortezomib followed by autologous peripheral blood stem cell transplantation: a case report and literatures review].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:6

    Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Transplantation, Autologous

2013
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines

2013
[Peripheral neuropathy induced by anticancer drugs].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cold Temperature; Drugs, Chinese Herbal; Humans; Hyperalgesia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sensation Disorders; Vincristine; Vitamin B 12

2013
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous

2013
[Multiple myeloma].
    Vnitrni lekarstvi, 2013, Volume: 59, Issue:7

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide

2013
Management of double-refractory multiple myeloma.
    Current hematologic malignancy reports, 2013, Volume: 8, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide

2013
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
    Cancer, 2013, Dec-01, Volume: 119, Issue:23

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate

2013
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome

2014
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Cancer investigation, 2013, Volume: 31, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2013
Second autologous transplant as salvage therapy in multiple myeloma.
    British journal of haematology, 2013, Volume: 163, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Interferon-alpha; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Reoperation; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2013
Clinical translation in multiple myeloma: from bench to bedside.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2013
Initial treatment of transplant candidates with multiple myeloma.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2013
New developments in post-transplant maintenance treatment of multiple myeloma.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
    Current hematologic malignancy reports, 2013, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide

2013
Management of antibody-mediated rejection in transplantation.
    The Surgical clinics of North America, 2013, Volume: 93, Issue:6

    Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbent Techniques; Kidney Transplantation; Plasma Cells; Plasmapheresis; Pyrazines; Rituximab; Splenectomy

2013
Allogeneic transplantation in multiple myeloma.
    Expert review of hematology, 2014, Volume: 7, Issue:1

    Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Gamma Rays; Graft vs Host Disease; Histocompatibility Testing; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous

2014
The effects of bortezomib on bone disease in patients with multiple myeloma.
    Cancer, 2014, Mar-01, Volume: 120, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evidence-Based Medicine; Humans; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Pyrazines; Signal Transduction

2014
Role of consolidation/maintenance therapy in multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2013
Hyperammonemia, resolved by chemotherapy.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Coma; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Humans; Hyperammonemia; Paraproteinemias; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Respiration, Artificial

2014
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
    Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013

    Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning

2013
Future agents and treatment directions in multiple myeloma.
    Expert review of hematology, 2014, Volume: 7, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines

2014
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    Expert review of hematology, 2014, Volume: 7, Issue:1

    Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2014
Ibrutinib in B-cell Lymphomas.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome

2014
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Diseases; Humans; Incidence; Neoplasms; Odds Ratio; Pyrazines; Risk

2014
New approaches to management of multiple myeloma.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome

2014
Bortezomib-induced acute congestive heart failure: a case report and review of literature.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Acute Disease; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Heart Failure; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines

2014
Rodent models of chemotherapy-induced peripheral neuropathy.
    ILAR journal, 2014, Volume: 54, Issue:3

    Topics: Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Mice; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Rats; Vincristine

2014
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
    Antioxidants & redox signaling, 2014, Dec-10, Volume: 21, Issue:17

    Topics: Boronic Acids; Bortezomib; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Pyrazines

2014
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:3

    Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors

2014
[Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Octreotide; Pancreatitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine

2014
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
    Expert opinion on biological therapy, 2014, Volume: 14, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment

2014
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia

2014
Bortezomib.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines

2014
Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Immunotherapy, 2014, Volume: 6, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting

2014
Endoplasmic reticulum stress in malignancy.
    Cancer cell, 2014, May-12, Volume: 25, Issue:5

    Topics: Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Neoplasms; Neovascularization, Pathologic; Protein Folding; Protein Serine-Threonine Kinases; Pyrazines; Unfolded Protein Response

2014
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    British journal of haematology, 2014, Volume: 166, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide

2014
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
    Critical reviews in oncology/hematology, 2014, Volume: 92, Issue:2

    Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2014
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Drug Design; Humans; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Pyrazines

2014
Advanced thyroid cancers: new era of treatment.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

    Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms

2014
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines

2014
[Molecular target therapy for non-Hodgkin lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Pyrazines; Rituximab; Signal Transduction

2014
[Proteasome inhibitor].
    Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin

2014
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome

2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
    Blood, 2014, Aug-28, Volume: 124, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2014
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
    European journal of haematology, 2015, Volume: 94, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome

2015
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Leukemia research, 2014, Volume: 38, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome

2014
Bortezomib-induced peripheral neurotoxicity: an update.
    Archives of toxicology, 2014, Volume: 88, Issue:9

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Incidence; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Risk Factors; Severity of Illness Index

2014
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Current cancer drug targets, 2014, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin-Protein Ligase Complexes; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases; Ubiquitination

2014
Overcoming bortezomib resistance in multiple myeloma.
    Biochemical Society transactions, 2014, Volume: 42, Issue:4

    Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines

2014
Novel agents in CNS myeloma treatment.
    Central nervous system agents in medicinal chemistry, 2014, Volume: 14, Issue:1

    Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Thalidomide; Treatment Outcome

2014
Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.
    Transfusion, 2015, Volume: 55, Issue:2

    Topics: Allografts; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Count; Male; Middle Aged; Plasma Cells; Pyrazines; Recovery of Function

2015
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
    Oncology (Williston Park, N.Y.), 2013, Volume: 27 Suppl 3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence

2013
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2

    Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2011
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Recurrence

2011
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism

2011
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence

2011
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
    Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2014
Scleromyxedema.
    Current opinion in rheumatology, 2014, Volume: 26, Issue:6

    Topics: Boronic Acids; Bortezomib; Humans; Immunoglobulins, Intravenous; Pyrazines; Scleromyxedema; Thalidomide; Treatment Outcome

2014
Melatonin as a proteasome inhibitor. Is there any clinical evidence?
    Life sciences, 2014, Oct-12, Volume: 115, Issue:1-2

    Topics: Animals; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Caspases; Humans; Melatonin; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2014
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    American journal of hematology, 2014, Volume: 89, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic

2014
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine

2014
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Oncology research and treatment, 2014, Volume: 37, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome

2014
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:2

    Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbamazepine; Central Nervous System; Cyclohexanols; Duloxetine Hydrochloride; Epothilones; Humans; Neoplasms; Neuralgia; Oxcarbazepine; Peripheral Nervous System Diseases; Pyrazines; Taxoids; Thalidomide; Thiophenes; Venlafaxine Hydrochloride; Vinca Alkaloids

2015
Bortezomib for the treatment of non-Hodgkin's lymphoma.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:16

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Inhibitors; Pyrazines

2014
Pomalidomide for multiple myeloma.
    Expert review of hematology, 2014, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide

2014
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult

2014
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide

2014
[Treatment of transplant-eligible symptomatic multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning

2014
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide

2014
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.
    Future oncology (London, England), 2014, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Neoplasms; Pyrazines; Treatment Outcome

2014
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2014, Volume: 27, Issue:5

    Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide

2014
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59 Suppl 5

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Infections; Boronic Acids; Bortezomib; Female; Humans; Immune Tolerance; Male; Middle Aged; Mycoses; Neoplasms; Opportunistic Infections; Pyrazines; Tumor Necrosis Factor-alpha; Virus Diseases

2014
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    American journal of hematology, 2014, Volume: 89, Issue:12

    Topics: Age Factors; Amyloidosis; Antineoplastic Agents; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Pyrazines; Stem Cell Transplantation; Subcutaneous Fat; Survival Analysis; Troponin T

2014
[Plasma cell leukemia].
    Bulletin du cancer, 2014, Volume: 101, Issue:11

    Topics: Aged; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Prognosis; Pyrazines; Rare Diseases; Thalidomide

2014
Current treatment landscape for relapsed and/or refractory multiple myeloma.
    Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome

2015
Mantle cell lymphoma: evolving management strategies.
    Blood, 2015, Jan-01, Volume: 125, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Humans; Lymphoma, Mantle-Cell; Medical Oncology; Mutation; Positron-Emission Tomography; Prognosis; Pyrazines; Rituximab; Treatment Outcome

2015
Targeting the bone marrow microenvironment in multiple myeloma.
    Immunological reviews, 2015, Volume: 263, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment

2015
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus

2015
Treatment-related symptom management in patients with multiple myeloma: a review.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide

2015
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
    Cancer treatment and research, 2015, Volume: 165

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia

2015
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2015, Volume: 18

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Proteasome Inhibitors; Pyrazines

2015
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    The oncologist, 2015, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide

2015
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
    Breast cancer research : BCR, 2014, Volume: 16, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta

2014
Waldenstrom macroglobulinemia: prognosis and management.
    Blood cancer journal, 2015, Mar-27, Volume: 5

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia

2015
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Clinical therapeutics, 2019, Volume: 41, Issue:11

    Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome

2019
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
    International journal of molecular sciences, 2021, Jan-17, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines

2021

Trials

533 trial(s) available for pyrazines and bortezomib

ArticleYear
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors

2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-15, Volume: 20, Issue:22

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; United States

2002
A phase 2 study of bortezomib in relapsed, refractory myeloma.
    The New England journal of medicine, 2003, Jun-26, Volume: 348, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Multienzyme Complexes; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence

2003
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
    Clinical lymphoma, 2003, Volume: 4, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Safety; Treatment Outcome

2003
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome

2004
New developments with bortezomib in treating multiple myeloma.
    Clinical lymphoma, 2004, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome

2004
Phase I study of bortezomib in refractory or relapsed acute leukemias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors

2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multienzyme Complexes; Neoplasms; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Statistics, Nonparametric

2004
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Models, Chemical; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; United States; United States Food and Drug Administration

2004
Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome

2004
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2004
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
    British journal of haematology, 2004, Volume: 127, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate

2004
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
    Managed care interface, 2004, Volume: 17, Issue:9

    Topics: Boronic Acids; Bortezomib; Cost-Benefit Analysis; Delphi Technique; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2004
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-01, Volume: 22, Issue:23

    Topics: Biological Availability; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms; Probability; Proportional Hazards Models; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Risk Assessment; Salvage Therapy; Survival Rate; Treatment Outcome

2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Survival Rate; Treatment Outcome

2005
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Protease Inhibitors; Pyrazines

2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
    Blood, 2005, Apr-15, Volume: 105, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Hematologic Neoplasms; Humans; Liposomes; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2005
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Clinical prostate cancer, 2004, Volume: 3, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids

2004
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome

2005
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting

2005
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Cancer, 2005, Jun-15, Volume: 103, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure

2005
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
    British journal of haematology, 2005, Volume: 129, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Treatment Outcome

2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
    British journal of haematology, 2005, Volume: 129, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome

2005
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    The New England journal of medicine, 2005, Jun-16, Volume: 352, Issue:24

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate

2005
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
    Haematologica, 2005, Volume: 90, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome

2005
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
    Blood, 2005, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53

2005
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome

2005
Proteasome inhibitor for treatment of multiple myeloma.
    The Lancet. Oncology, 2005, Volume: 6, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome

2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
    Blood, 2005, Dec-01, Volume: 106, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Risk Factors; Thrombocytopenia; Treatment Outcome

2005
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Journal of Korean medical science, 2005, Volume: 20, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors

2005
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
    Leukemia research, 2006, Volume: 30, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous

2006
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazines

2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Nervous System; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Cancer, 2005, Nov-15, Volume: 104, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Time Factors; Treatment Outcome

2005
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:3

    Topics: Boronic Acids; Bortezomib; Clinical Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Patient Selection; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy

2003
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome

2006
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5

    Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome

2006
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-20, Volume: 24, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome

2006
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-20, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Europe; Female; Humans; Male; Middle Aged; Multiple Myeloma; Patient Satisfaction; Predictive Value of Tests; Prognosis; Pyrazines; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2006
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
    Blood, 2006, Feb-15, Volume: 107, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome

2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Cancer, 2006, Mar-15, Volume: 106, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome

2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-15, Volume: 12, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome

2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cytokines; Doxorubicin; Female; Humans; Lymphoma; Male; Middle Aged; Pyrazines; Recurrence; Tumor Necrosis Factor-alpha

2006
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Experimental hematology, 2006, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous

2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines

2006
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2007
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
    Blood, 2006, Oct-01, Volume: 108, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines

2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide

2006
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Treatment Outcome

2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cancer, 2006, Sep-01, Volume: 107, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine

2006
Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.
    International journal of hematology, 2006, Volume: 84, Issue:1

    Topics: Adult; Aged; Anti-Inflammatory Agents; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous

2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
    British journal of haematology, 2006, Volume: 134, Issue:4

    Topics: Aged; Boronic Acids; Bortezomib; Drug Hypersensitivity; Female; Humans; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Protease Inhibitors; Pyrazines; Skin; Skin Diseases, Vascular; Treatment Outcome

2006
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
    European journal of haematology, 2006, Volume: 77, Issue:3

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteolysis; Protease Inhibitors; Pyrazines

2006
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Survival Rate; Treatment Outcome

2007
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
    Investigational new drugs, 2007, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Survival Analysis; Urologic Neoplasms; Urothelium

2007
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2006
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate

2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Cancer, 2006, Nov-15, Volume: 107, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2006
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
    Haematologica, 2006, Volume: 91, Issue:11

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous

2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States

2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Cancer, 2006, Dec-01, Volume: 107, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines

2006
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Cohort Studies; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Survival Analysis

2007
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
    Annals of hematology, 2007, Volume: 86, Issue:3

    Topics: Aged; Boronic Acids; Bortezomib; Doxorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Time Factors; Treatment Outcome

2007
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
    Blood, 2007, Apr-01, Volume: 109, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide

2007
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
    Blood, 2007, Apr-15, Volume: 109, Issue:8

    Topics: Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2007
Targeting aurora kinases as therapy in multiple myeloma.
    Blood, 2007, May-01, Volume: 109, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Boronic Acids; Bortezomib; Cell Line, Transformed; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Matrix Proteins; G2 Phase; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematopoietic Stem Cells; Histones; Humans; Hyaluronan Receptors; Interleukin-6; Lymphocytes; Multiple Myeloma; Mutation; Phosphorylation; Ploidies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazines

2007
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2006
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome

2006
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids

2007
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-01, Volume: 13, Issue:5

    Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Humans; I-kappa B Kinase; Immunoblotting; Infant; Leukemia; Male; Maximum Tolerated Dose; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines

2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Boronic Acids; Bortezomib; Canada; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Protease Inhibitors; Pyrazines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Outcome; Waldenstrom Macroglobulinemia

2007
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome

2007
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous

2007
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
    Blood, 2007, Apr-15, Volume: 109, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Ploidies; Pyrazines; Recurrence; Survival Rate

2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
    Cancer research, 2007, Apr-01, Volume: 67, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Diploidy; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Multigene Family; Multiple Myeloma; Prognosis; Protein Biosynthesis; Pyrazines; Trisomy

2007
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome

2006
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Pyrazines; Remission Induction; Risk Assessment; Survival Analysis

2006
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    Blood, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous

2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    British journal of haematology, 2007, Volume: 137, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia

2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Haematologica, 2007, Volume: 92, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine

2007
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
    Haematologica, 2007, Volume: 92, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Treatment Failure

2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Blood, 2007, Sep-01, Volume: 110, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Immunoglobulin M; Male; Middle Aged; Pyrazines; Recurrence; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia

2007
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Clinical genitourinary cancer, 2007, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome

2007
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome

2007
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-15, Volume: 13, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines

2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2007
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Adult; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis; Treatment Failure

2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
    British journal of haematology, 2007, Volume: 138, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chi-Square Distribution; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate

2007
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Cancer, 2007, Sep-01, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2007
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
    European journal of haematology, 2007, Volume: 79, Issue:3

    Topics: Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy; Simvastatin

2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines

2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
    Blood, 2007, Nov-15, Volume: 110, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome

2007
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Skin Neoplasms; Treatment Outcome

2007
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Linear Models; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous

2007
[Velcade in multiple myeloma].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2007
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
    International journal of hematology, 2007, Volume: 86, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines; Treatment Outcome

2007
Bortezomib for the treatment of mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Female; Humans; Lymphoma, Mantle-Cell; Male; Prospective Studies; Pyrazines; United States; United States Food and Drug Administration

2007
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Proteasome Inhibitors; Pyrazines

2008
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    The Journal of urology, 2007, Volume: 178, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome

2007
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
    Cancer investigation, 2007, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome

2007
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Cancer science, 2008, Volume: 99, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines

2008
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome

2007
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.
    BMC cancer, 2007, Dec-03, Volume: 7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Pyrazoles; Sulfonamides

2007
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States

2007
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis

2007
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:12

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Electrophoresis; Female; Humans; Immunoglobulin Light Chains; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Recurrence

2007
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome

2008
Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:9

    Topics: Adult; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Multiple Myeloma; Osteoclasts; Patient Selection; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous

2007
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
    Laboratory investigation; a journal of technical methods and pathology, 2008, Volume: 88, Issue:3

    Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin

2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
    Leukemia, 2008, Volume: 22, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Survival Analysis; Treatment Outcome

2008
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome

2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms

2008
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Cancer, 2008, Apr-01, Volume: 112, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide

2008
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
    British journal of haematology, 2008, Volume: 140, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Epidemiologic Methods; Female; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Treatment Outcome

2008
Bortezomib therapy in myelofibrosis: a phase II clinical trial.
    Leukemia, 2008, Volume: 22, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Primary Myelofibrosis; Pyrazines

2008
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome

2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Haematologica, 2008, Volume: 93, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis

2008
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Treatment Outcome; Ubiquitination

2008
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy

2008
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome

2008
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    British journal of haematology, 2008, Volume: 141, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Treatment Outcome

2008
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    American journal of clinical oncology, 2008, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines

2008
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    British journal of haematology, 2008, Volume: 141, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2008
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
    Leukemia, 2008, Volume: 22, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2008
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome

2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
    British journal of cancer, 2008, May-06, Volume: 98, Issue:9

    Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting

2008
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Annals of hematology, 2008, Volume: 87, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia

2008
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Pyrazines; Survival Rate

2008
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines

2008
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Haematologica, 2008, Volume: 93, Issue:6

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Factor V; Female; Hemostasis; Humans; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Platelet Aggregation; Protein C; Pyrazines; Recurrence; Treatment Outcome

2008
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Cancer, 2008, Aug-15, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis

2008
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
    Leukemia, 2008, Volume: 22, Issue:10

    Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13

2008
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
    Investigational new drugs, 2009, Volume: 27, Issue:1

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia

2009
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome

2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis

2008
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Zhonghua nei ke za zhi, 2008, Volume: 47, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome

2008
[Bortezomib-based combination therapy for newly diagnosed multiple myeloma].
    Zhonghua nei ke za zhi, 2008, Volume: 47, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome; Vincristine

2008
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proteasome Endopeptidase Complex; Pyrazines; Vincristine

2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation

2008
[Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines

2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome

2008
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
    Haematologica, 2008, Volume: 93, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Routes; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Proteasome Inhibitors; Pyrazines

2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Leukemia, 2008, Volume: 22, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide

2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2008
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Pyrazines; Survival Rate

2009
Update on recent developments for patients with newly diagnosed multiple myeloma.
    Annals of the New York Academy of Sciences, 2008, Volume: 1138

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2008
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult

2008
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Treatment Outcome

2008
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Flow Cytometry; Histone Acetyltransferases; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; NF-kappa B; Nuclear Receptor Coactivator 3; Phosphorylcholine; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Trans-Activators

2008
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
    Bone marrow transplantation, 2009, Volume: 43, Issue:10

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Lymphocyte Subsets; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Autologous; Treatment Outcome; Virus Activation

2009
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    British journal of haematology, 2009, Volume: 144, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome

2009
[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Zhonghua yi xue za zhi, 2008, Jul-08, Volume: 88, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Treatment Outcome

2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome

2009
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
    International journal of hematology, 2009, Volume: 89, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome

2009
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
    International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome

2009
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome

2009
[Experience with velcade administration in multiple myeloma].
    Terapevticheskii arkhiv, 2008, Volume: 80, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Multiple; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines

2008
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    British journal of haematology, 2009, Volume: 144, Issue:6

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Statistics, Nonparametric; Survival Rate

2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    British journal of haematology, 2009, Volume: 144, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia

2009
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Ethylenediamines; Humans; Maximum Tolerated Dose; Multiple Myeloma; Organophosphonates; Platelet Count; Pyrazines; Radioisotopes; Recurrence; Samarium

2009
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
    Journal of the peripheral nervous system : JPNS, 2008, Volume: 13, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines

2008
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
    British journal of haematology, 2009, Volume: 145, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Remission Induction

2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
    Leukemia, 2009, Volume: 23, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Treatment Outcome

2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
    European journal of haematology, 2009, Volume: 82, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome

2009
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
    Haematologica, 2009, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cystatin C; Female; Humans; Immunoassay; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome

2009
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
    Annals of hematology, 2009, Volume: 88, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction

2009
A phase II study of bortezomib in patients with MALT lymphoma.
    Haematologica, 2009, Volume: 94, Issue:5

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nausea; Nervous System Diseases; Pyrazines; Treatment Outcome

2009
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis

2009
Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.
    Onkologie, 2009, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Germany; Hematology; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Physicians' Offices; Pyrazines; Secondary Prevention; Treatment Outcome

2009
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines

2009
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Clinical pharmacokinetics, 2009, Volume: 48, Issue:3

    Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines

2009
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
    British journal of cancer, 2009, May-05, Volume: 100, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B; Pyrazines; Young Adult

2009
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Salvage Therapy; Steroids; Thalidomide; Treatment Outcome

2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
    Blood, 2009, Aug-20, Volume: 114, Issue:8

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Treatment Outcome

2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia

2009
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis

2010
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency

2010
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Cancer, 2009, Oct-01, Volume: 115, Issue:19

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine

2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
    British journal of haematology, 2009, Volume: 146, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome

2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
    British journal of haematology, 2009, Volume: 146, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Protease Inhibitors; Pyrazines

2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome

2009
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
    British journal of haematology, 2009, Volume: 147, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2009
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-15, Volume: 15, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat

2009
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Risk Factors

2010
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia

2010
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids

2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2009, Volume: 115, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Young Adult

2009
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous

2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunohistochemistry; Membrane Glycoproteins; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Transplantation, Heterologous

2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    British journal of haematology, 2009, Volume: 147, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome

2009
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence

2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome

2010
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Stem Cell Transplantation; Survival Analysis

2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Feasibility Studies; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab; Treatment Outcome

2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2010
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2009
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome

2010
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Renal Insufficiency; Treatment Outcome

2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome

2009
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2010
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Blood, 2010, Jan-07, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2010
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    British journal of haematology, 2010, Volume: 148, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2010
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Annals of hematology, 2010, Volume: 89, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Survival Rate; Thalidomide; Treatment Outcome

2010
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
    Blood, 2010, Jan-21, Volume: 115, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome

2010
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome

2010
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
    Annals of hematology, 2010, Volume: 89, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome

2010
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
    European journal of haematology, 2010, Volume: 84, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Recurrence; Thrombospondins

2010
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome

2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome

2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome

2010
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Clinical therapeutics, 2009, Volume: 31 Pt 2

    Topics: Antifungal Agents; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Prospective Studies; Pyrazines

2009
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
    Blood, 2010, May-27, Volume: 115, Issue:21

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide

2010
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
    International journal of radiation oncology, biology, physics, 2010, Oct-01, Volume: 78, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography

2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-10, Volume: 28, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia

2010
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
    Anticancer research, 2010, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines

2010
Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
    British journal of haematology, 2010, Volume: 149, Issue:6

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Neuralgia; Prospective Studies; Pyrazines; Th2 Cells

2010
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
    Journal of neuro-oncology, 2010, Volume: 100, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome

2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2011
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Tumor Burden

2010
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Annals of hematology, 2010, Volume: 89, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome

2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States

2010
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome

2010
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
    Blood, 2010, Apr-22, Volume: 115, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Multiple Myeloma; Neoplasm Staging; Pyrazines

2010
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
    Leukemia, 2010, Volume: 24, Issue:6

    Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukapheresis; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous

2010
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
    Annals of hematology, 2010, Volume: 89, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine

2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
    Leukemia, 2010, Volume: 24, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome

2010
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
    European journal of haematology, 2010, Volume: 85, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Pyrazines

2010
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome

2010
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Primary Myelofibrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Risk; Salvage Therapy; Thrombocytopenia; Treatment Failure; Young Adult

2010
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
    Leukemia research, 2010, Volume: 34, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome

2010
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms

2010
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Retrospective Studies; Survival Rate; Treatment Outcome

2010
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
    Investigational new drugs, 2011, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Protease Inhibitors; Pyrazines; Stomach Neoplasms; Treatment Outcome

2011
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
    American journal of hematology, 2010, Volume: 85, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome

2010
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
    Pediatric blood & cancer, 2010, Volume: 55, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome; Vincristine

2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
    British journal of haematology, 2010, Volume: 150, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HSP70 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Platelet Count; Pyrazines; Recurrence; Treatment Outcome

2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Blood, 2010, Nov-11, Volume: 116, Issue:19

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome

2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Rituximab; Time Factors; Waldenstrom Macroglobulinemia

2010
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
    Haematologica, 2010, Volume: 95, Issue:11

    Topics: Aged; Aged, 80 and over; Autocrine Communication; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Interleukin-10; Interleukin-6; Janus Kinases; Lymphoma, Mantle-Cell; Male; Middle Aged; Phosphorylation; Protease Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Signal Transduction; STAT3 Transcription Factor

2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Cancer, 2010, Dec-01, Volume: 116, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine

2010
Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
    Anatomical record (Hoboken, N.J. : 2007), 2010, Volume: 293, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome; Young Adult

2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    British journal of haematology, 2010, Volume: 151, Issue:1

    Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine

2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome

2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation Conditioning

2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
    Blood, 2010, Dec-02, Volume: 116, Issue:23

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2010
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Pyrazines; Recurrence; Treatment Failure; Treatment Outcome

2011
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.
    Journal of pain and symptom management, 2010, Volume: 40, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Taxoids; Transcutaneous Electric Nerve Stimulation; Treatment Outcome

2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Staging; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine

2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2010
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
    International journal of hematology, 2010, Volume: 92, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Asia; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; North America; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2012
[Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention

2010
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Europe; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine; Young Adult

2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
    European journal of haematology, 2011, Volume: 86, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors

2011
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    British journal of haematology, 2010, Volume: 151, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia

2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States

2012
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome

2010
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
    Blood, 2011, Jan-13, Volume: 117, Issue:2

    Topics: ADP-ribosyl Cyclase 1; Aged; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lymphoma, Mantle-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines

2011
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
    Leukemia research, 2011, Volume: 35, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins

2011
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cell-Derived Microparticles; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Thromboplastin; Venous Thrombosis; Vincristine

2011
[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
    Zhonghua nei ke za zhi, 2010, Volume: 49, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Vincristine

2010
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
    Journal of translational medicine, 2010, Nov-26, Volume: 8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Calcium-Calmodulin-Dependent Protein Kinases; Death-Associated Protein Kinases; Dexamethasone; Disease-Free Survival; Factor Analysis, Statistical; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous

2010
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
    American journal of clinical oncology, 2011, Volume: 34, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines

2011
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Reoperation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2010
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
    Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Polyethylene Glycols; Pyrazines; Survival Analysis; Treatment Outcome

2010
Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma.
    Leukemia research, 2011, Volume: 35, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome

2011
[Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Young Adult

2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-20, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult

2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones

2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Blood, 2011, Mar-10, Volume: 117, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab

2011
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
    British journal of haematology, 2011, Volume: 152, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome

2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
    Cancer, 2011, Aug-01, Volume: 117, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis

2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
    Clinical lung cancer, 2011, Volume: 12, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids

2011
The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
    Transplantation, 2011, Mar-15, Volume: 91, Issue:5

    Topics: Adult; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Graft Rejection; Humans; Incidence; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Plasma Cells; Plasma Exchange; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tissue Donors; Treatment Outcome

2011
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
    Leukemia, 2011, Volume: 25, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tissue Distribution; Treatment Outcome

2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
    Leukemia & lymphoma, 2011, Volume: 52, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical

2011
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
    Cancer, 2011, Aug-15, Volume: 117, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence

2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    The Lancet. Oncology, 2011, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Sirolimus

2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

    Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome

2011
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous

2012
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
    European journal of haematology, 2011, Volume: 86, Issue:5

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant

2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Erythrocyte Transfusion; Female; Hematinics; Humans; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Survival Rate; Thromboembolism

2011
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein

2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Male; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia

2011
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Annals of hematology, 2011, Volume: 90, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide; Treatment Outcome

2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure

2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
    European journal of haematology, 2011, Volume: 86, Issue:6

    Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Osteogenesis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Treatment Outcome

2011
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
    Haematologica, 2011, Volume: 96, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome

2011
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
    The Lancet. Oncology, 2011, Volume: 12, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Blood Cells; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; South America; Treatment Outcome

2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
    Cancer, 2011, May-01, Volume: 117, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Salvage Therapy

2011
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
    British journal of haematology, 2011, Volume: 154, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult

2011
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.
    Cancer biology & therapy, 2011, Jul-15, Volume: 12, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines

2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
    British journal of haematology, 2011, Volume: 153, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
    British journal of haematology, 2011, Volume: 154, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome

2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
    Blood, 2011, Jul-28, Volume: 118, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protease Inhibitors; Pyrazines; Recurrence

2011
Carfilzomib: a novel second-generation proteasome inhibitor.
    Future oncology (London, England), 2011, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia

2011
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
    Blood, 2011, Jul-21, Volume: 118, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide

2011
[The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
    Zhonghua nei ke za zhi, 2011, Volume: 50, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2011
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors

2011
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2011
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome

2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrazines; Radiography; Radiopharmaceuticals; Rituximab; Waldenstrom Macroglobulinemia

2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
    Blood, 2011, Sep-15, Volume: 118, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome

2011
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-bas
    Leukemia & lymphoma, 2011, Volume: 52, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Models, Statistical; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome

2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; California; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome

2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Infusion Pumps; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Rituximab; Young Adult

2011
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome

2011
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Pyrazines; Rituximab; Treatment Outcome

2012
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:11

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome

2011
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed
    Annals of hematology, 2012, Volume: 91, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2012
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
    Haematologica, 2011, Volume: 96, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Factors

2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-01, Volume: 29, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Cyclophosphamide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vincristine

2011
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-01, Volume: 29, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome

2011
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Radioimmunotherapy; Salvage Therapy; Survival Rate

2012
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide

2012
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Remission Induction; Rituximab; Treatment Outcome; Vincristine

2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Blood, 2011, Nov-24, Volume: 118, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome

2011
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult

2012
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
    Haematologica, 2011, Volume: 96, Issue:12

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
    Cancer, 2012, May-01, Volume: 118, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning

2012
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
    Blood, 2011, Oct-27, Volume: 118, Issue:17

    Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; DNA, Neoplasm; Drug Administration Schedule; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Ploidies; Prognosis; Pyrazines; Time Factors; Treatment Outcome

2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Blood, 2011, Dec-08, Volume: 118, Issue:24

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Depsipeptides; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Survival Analysis; Thrombocytopenia

2011
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
    Immunotherapy, 2011, Volume: 3, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2011
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
    British journal of haematology, 2011, Volume: 155, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Prospective Studies; Pyrazines

2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Blood, 2011, Nov-24, Volume: 118, Issue:22

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2011
Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2011, Volume: 30, Issue:12

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Infections; Isoantibodies; Male; Middle Aged; Pilot Projects; Plasmapheresis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Assessment; Risk Factors; Rituximab; Treatment Outcome

2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-10, Volume: 29, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence

2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chlorambucil; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Pyrazines; Rituximab; Treatment Outcome

2012
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Chinese medical journal, 2011, Volume: 124, Issue:19

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines

2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Clinical pharmacokinetics, 2011, Dec-01, Volume: 50, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Dexamethasone; Drug Combinations; Enzyme Induction; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Rifampin

2011
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat

2012
Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
    The Journal of international medical research, 2011, Volume: 39, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2011
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
    Oncology reports, 2012, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Boronic Acids; Bortezomib; Breast Neoplasms; Cytokines; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tamoxifen

2012
Emergence of central nervous system myeloma in the era of novel agents.
    Hematological oncology, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous

2012
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Blood, 2012, Jan-26, Volume: 119, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Smith-Magenis Syndrome; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Young Adult

2012
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
    Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate

2012
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate

2012
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2012
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult

2012
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:1

    Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Leukocytes, Mononuclear; Mutation; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2012
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
    International journal of radiation oncology, biology, physics, 2012, Jul-15, Volume: 83, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Radiotherapy Dosage; Therapeutics

2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome

2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome

2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2012
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Oral oncology, 2012, Volume: 48, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; In Vitro Techniques; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Polymerase Chain Reaction; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Signal Transduction

2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
    Leukemia, 2012, Volume: 26, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide

2012
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    European journal of haematology, 2012, Volume: 88, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-15, Volume: 18, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Dosage Calculations; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Neoplasms; Pyrazines

2012
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines

2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
    European journal of haematology, 2012, Volume: 88, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide

2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
    Blood, 2012, May-10, Volume: 119, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome

2012
Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia.
    Blood, 2012, May-31, Volume: 119, Issue:22

    Topics: Alpha-Globulins; Animals; Antineoplastic Agents; beta-Thalassemia; Boronic Acids; Bortezomib; Cells, Cultured; Child; Child, Preschool; Erythroid Precursor Cells; Female; Humans; Male; Mice; Mice, Transgenic; Mutation; Nuclear Respiratory Factor 1; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitination

2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
    European journal of haematology, 2012, Volume: 89, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome

2012
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Blood, 2012, Jul-05, Volume: 120, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous

2012
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
    British journal of haematology, 2012, Volume: 158, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Proteins; Protein Array Analysis; Pyrazines; Recurrence; Treatment Outcome

2012
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazines; Survival Rate; Treatment Outcome; United States; Vascular Endothelial Growth Factor A

2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Cancer, 2012, Jul-15, Volume: 118, Issue:14

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine

2012
The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.
    European journal of haematology, 2012, Volume: 89, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Risk Factors; Singapore; Survival Rate; Time Factors

2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
    Blood, 2012, Jun-14, Volume: 119, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Demography; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Recurrence; Time Factors; Treatment Outcome

2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
    Blood, 2012, Jun-21, Volume: 119, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic

2012
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    British journal of haematology, 2012, Volume: 158, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome

2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
    Clinical nuclear medicine, 2012, Volume: 37, Issue:6

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure

2012
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult

2012
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult

2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
    Blood, 2012, Aug-23, Volume: 120, Issue:8

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide

2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
    Haematologica, 2012, Volume: 97, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate

2012
[Clinical study of bortezomib for treating multiple myeloma with renal impairment].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency

2012
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
    Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Female; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous

2012
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Prednisone; Pyrazines; Vincristine

2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Head & neck, 2013, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2013
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Blood, 2012, Aug-23, Volume: 120, Issue:8

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cells; Thalidomide; Transplantation, Autologous

2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-20, Volume: 30, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Vincristine

2012
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    Cancer, 2013, Jan-15, Volume: 119, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrazines; Treatment Outcome

2013
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous

2012
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2012
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26

    Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors

2012
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
    Pediatric blood & cancer, 2013, Volume: 60, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Hydroxamic Acids; Infant; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines; Vorinostat; Young Adult

2013
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
    Blood, 2012, Sep-27, Volume: 120, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide

2012
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9

    Topics: Aged; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survival Rate

2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes

2013
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
    Leukemia, 2013, Volume: 27, Issue:4

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Pyrazines; Stem Cell Transplantation

2013
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
    Clinical pharmacokinetics, 2012, Volume: 51, Issue:12

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence

2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
    Blood, 2012, Nov-29, Volume: 120, Issue:23

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Recurrence; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome

2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Pyrazines; Secondary Prevention

2012
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Synergism; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Vorinostat

2012
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat

2012
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
    Journal of hematology & oncology, 2012, Oct-22, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Rituximab

2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-10, Volume: 31, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Risk Assessment; Thalidomide

2013
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
    Cancer, 2013, Mar-01, Volume: 119, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence

2013
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7

    Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome

2013
[Current development of new drugs in malignant lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat

2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors

2013
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome

2013
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Dehydration; Drug Resistance, Neoplasm; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Resveratrol; Salvage Therapy; Stilbenes; Treatment Failure; Vomiting

2013
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
    British journal of haematology, 2013, Volume: 160, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Transplantation, Autologous; Young Adult

2013
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    European journal of haematology, 2013, Volume: 90, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide

2013
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
    American journal of hematology, 2013, Volume: 88, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia

2013
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-01, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome

2013
Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
    European journal of haematology, 2013, Volume: 90, Issue:2

    Topics: Adipose Tissue; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies

2013
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
    Blood, 2013, Mar-14, Volume: 121, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome

2013
Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Chinese medical journal, 2012, Volume: 125, Issue:24

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Electrocardiography; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrazines; Recurrence; Torsades de Pointes; Treatment Outcome

2013
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Survival Rate

2013
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome

2013
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult

2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
    Blood, 2013, Mar-14, Volume: 121, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome

2013
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms

2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-15, Volume: 19, Issue:6

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Filgrastim; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplastic Stem Cells; Pyrazines; Recombinant Proteins; Signal Transduction

2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
    Cancer investigation, 2013, Volume: 31, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence

2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy

2013
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome

2013
Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Treatment Outcome

2013
[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:1

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency

2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
    Blood, 2013, Jun-06, Volume: 121, Issue:23

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous

2013
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines

2014
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
    Haematologica, 2013, Volume: 98, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome

2013
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
    Investigational new drugs, 2014, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vorinostat

2014
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide

2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prospective Studies; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2013
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
    Oncotarget, 2013, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome

2013
[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine

2013
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
    International journal of hematology, 2013, Volume: 98, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate

2013
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    International journal of hematology, 2013, Volume: 98, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning; Transplantation, Autologous

2013
The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    The Journal of biological chemistry, 2013, Aug-30, Volume: 288, Issue:35

    Topics: Administration, Oral; Animals; Anisoles; Antineoplastic Agents; Azepines; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines

2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult

2013
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukocytes, Mononuclear; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Proto-Oncogene Proteins c-akt; Pyrazines; Time Factors; Transcription, Genetic; Vorinostat

2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
    British journal of haematology, 2013, Volume: 163, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome

2013
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
    Blood, 2013, Oct-03, Volume: 122, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Pyrazines

2013
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2014
Concurrent whole brain radiotherapy and bortezomib for brain metastasis.
    Radiation oncology (London, England), 2013, Aug-21, Volume: 8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines

2013
Pralatrexate pharmacology and clinical development.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration

2013
Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
    Experimental hematology, 2013, Volume: 41, Issue:12

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
    Haematologica, 2014, Volume: 99, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Transplantation, Autologous; Treatment Outcome

2014
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide

2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Blood, 2013, Nov-07, Volume: 122, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia

2013
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
    Cancer, 2013, Dec-01, Volume: 119, Issue:23

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate

2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Panobinostat; Pyrazines

2013
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult

2013
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden

2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Cancer, 2011, Jun-01, Volume: 117, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Proteasome Inhibitors; Pyrazines; Receptors, IgG; Recurrence; Rituximab; Treatment Outcome

2011
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Salvage Therapy; Survival Rate; Vorinostat

2013
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
    Leukemia research, 2013, Volume: 37, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Survival Rate

2013
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Cancer investigation, 2013, Volume: 31, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat; Young Adult

2013
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat

2014
[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:10

    Topics: Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction

2013
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
    Haematologica, 2014, Volume: 99, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Follow-Up Studies; Gene Dosage; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Rate

2014
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
    Blood, 2014, Feb-13, Volume: 123, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis

2014
Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.
    Transplant immunology, 2014, Volume: 30, Issue:1

    Topics: Antigen Presentation; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclophosphamide; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Proteins; Immunosuppressive Agents; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; NF-kappa B; Postoperative Care; Pyrazines

2014
Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:12

    Topics: Adult; Animals; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft Rejection; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Pyrazines; Rabbits; Renal Insufficiency; Rituximab; Treatment Outcome

2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytokines; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrazines; Recombinant Proteins; Treatment Outcome

2014
Value of novel agents and intensive therapy for patients with multiple myeloma.
    Bone marrow transplantation, 2014, Volume: 49, Issue:3

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
    Blood, 2014, Jan-30, Volume: 123, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; GTP Phosphohydrolases; Humans; Membrane Proteins; Multiple Myeloma; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Survival Analysis

2014
[Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:6

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Diphosphonates; Drug Therapy, Combination; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand

2013
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    BMC medicine, 2014, Jan-06, Volume: 12

    Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Rate; Transplantation, Autologous

2014
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Molecular oncology, 2014, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Purines; Pyrazines; Sarcoma, Ewing; Xenograft Model Antitumor Assays

2014
Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
    Experimental hematology, 2014, Volume: 42, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Death; Cytokines; Dendritic Cells; Down-Regulation; Female; Humans; Male; Multiple Myeloma; Pyrazines; STAT3 Transcription Factor; Triterpenes; Tumor Cells, Cultured; Up-Regulation

2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
    Blood, 2014, Mar-20, Volume: 123, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome

2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
    Blood, 2014, Mar-06, Volume: 123, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome

2014
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.
    Leukemia, 2014, Volume: 28, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Substitution; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Pyrazines; Treatment Outcome

2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous

2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome

2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
    Blood, 2014, Mar-13, Volume: 123, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Rituximab; Survival Rate; Vincristine

2014
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
    Haematologica, 2014, Volume: 99, Issue:2

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Regulatory Factor X Transcription Factors; Survival Rate; Transcription Factors; X-Box Binding Protein 1

2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome

2014
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
    Investigational new drugs, 2014, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms

2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
    British journal of haematology, 2014, Volume: 165, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome

2014
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, Volume: 17, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Cost-Benefit Analysis; Feasibility Studies; Follow-Up Studies; Health Policy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Netherlands; Outcome Assessment, Health Care; Policy Making; Pyrazines; Reimbursement Mechanisms; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Uncertainty

2014
Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
    Hemoglobin, 2014, Volume: 38, Issue:3

    Topics: Active Transport, Cell Nucleus; Anemia, Sickle Cell; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Erythroid Precursor Cells; Female; Fetal Hemoglobin; Humans; K562 Cells; Male; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic

2014
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome

2014
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Trials, 2014, Apr-03, Volume: 15

    Topics: Administration, Intravenous; Austria; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Clinical Protocols; Double-Blind Method; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney; Kidney Transplantation; Proteasome Inhibitors; Pyrazines; Research Design; Sample Size; Time Factors; Treatment Outcome

2014
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Annals of hematology, 2014, Volume: 93, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Patient Selection; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Young Adult

2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
    British journal of haematology, 2014, Volume: 166, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome

2014
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    European journal of haematology, 2014, Volume: 93, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome

2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    Blood, 2014, Jun-26, Volume: 123, Issue:26

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate

2014
A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Integrative cancer therapies, 2014, Volume: 13, Issue:5

    Topics: Acupuncture Therapy; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Feasibility Studies; Humans; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Time Factors; Treatment Outcome

2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
    Journal of hematology & oncology, 2014, May-09, Volume: 7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Time Factors; Treatment Outcome

2014
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Chemokine CCL5; Cytokines; Disease-Free Survival; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous

2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
    Blood, 2014, Aug-07, Volume: 124, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome

2014
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
    British journal of haematology, 2014, Volume: 167, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate

2014
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:10

    Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult

2014
Bortezomib for refractory autoimmunity in pediatrics.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Autoimmunity; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Male; Neutropenia; Plasma Cells; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Rituximab; Thrombocytopenia

2014
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
    Autophagy, 2014, Volume: 10, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence

2014
Treatment of chronic graft-versus-host disease with bortezomib.
    Blood, 2014, Sep-04, Volume: 124, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Scleroderma, Systemic; Skin; Transplantation, Homologous; Treatment Outcome; Tumor Cells, Cultured

2014
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines

2014
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous

2015
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    British journal of haematology, 2014, Volume: 166, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome

2014
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
    BioMed research international, 2014, Volume: 2014

    Topics: Adult; Biomarkers; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Steroids; Treatment Outcome

2014
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning

2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
    Blood, 2014, Sep-18, Volume: 124, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2014
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Pyrazines; Survival Rate; Transplantation Conditioning

2014
Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
    Science translational medicine, 2014, Aug-20, Volume: 6, Issue:250

    Topics: Administration, Intravenous; Adult; Alleles; Boronic Acids; Bortezomib; Cell Membrane; Cells, Cultured; Dysferlin; Humans; Male; Membrane Proteins; Monocytes; Muscle Proteins; Muscular Dystrophies; Mutation, Missense; Myoblasts; Proteasome Inhibitors; Pyrazines

2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
    British journal of haematology, 2015, Volume: 168, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine

2015
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
    American journal of hematology, 2014, Volume: 89, Issue:12

    Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neurogenesis; Peripheral Nervous System Diseases; Plasma Cells; Pyrazines; Survival Analysis; Syndecan-1; Thalidomide; Transplantation, Autologous

2014
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; NF-kappa B; Nootropic Agents; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Severity of Illness Index; Treatment Outcome

2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
    Blood, 2014, Oct-16, Volume: 124, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis

2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prognosis; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome

2014
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis

2015
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-15, Volume: 20, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome

2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
    American journal of hematology, 2015, Volume: 90, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Double-Blind Method; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2015
NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
    British journal of haematology, 2015, Volume: 168, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Homozygote; Humans; Male; Middle Aged; Multiple Myeloma; NF-kappa B p50 Subunit; Polymorphism, Genetic; Pyrazines; Retrospective Studies; Sequence Deletion; Survival Rate

2015
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
    Oncotarget, 2014, Nov-15, Volume: 5, Issue:21

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2014
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
    Haematologica, 2015, Volume: 100, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate

2015
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
    Experimental hematology, 2015, Volume: 43, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Mutation; Predictive Value of Tests; Pyrazines; Risk Factors; Survival Analysis; Thalidomide

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
    BioMed research international, 2014, Volume: 2014

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2014
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
    American journal of hematology, 2015, Volume: 90, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis

2015
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
    British journal of haematology, 2015, Volume: 169, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate; Veterans

2015
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
    Haematologica, 2015, Volume: 100, Issue:5

    Topics: Administration, Cutaneous; Administration, Intravenous; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Renal Insufficiency; Treatment Outcome

2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
    American journal of hematology, 2015, Volume: 90, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome

2015
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
    International journal of hematology, 2015, Volume: 101, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Interleukin-6; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines

2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
    Annals of the rheumatic diseases, 2015, Volume: 74, Issue:7

    Topics: Administration, Intravenous; Adult; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; DNA; Drug Therapy, Combination; Female; Germany; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
    The New England journal of medicine, 2015, Mar-05, Volume: 372, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine

2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
    Leukemia, 2015, Volume: 29, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Remission Induction; Survival Rate

2015
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
    British journal of haematology, 2015, Volume: 170, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide

2015
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
    British journal of haematology, 2015, Volume: 170, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Disease-Free Survival; Hodgkin Disease; Humans; Ifosfamide; Neoplasm Recurrence, Local; Pyrazines; Vinblastine; Vinorelbine; Young Adult

2015
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
    Acta haematologica, 2015, Volume: 134, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Susceptibility; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Pyrazines

2015
Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
    Clinical transplants, 2014

    Topics: Aged; Austria; Biomarkers; Boronic Acids; Bortezomib; Cross-Sectional Studies; Double-Blind Method; Drug Administration Schedule; Female; Graft Rejection; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Pyrazines; Risk Factors; Serologic Tests; Time Factors; Treatment Outcome

2014
[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
    Zhongguo shi yan xue ye xue za zhi, 2017, Volume: 25, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Vitamin B 12; Vitamins

2017
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Imidazoles; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines

2021

Other Studies

2677 other study(ies) available for pyrazines and bortezomib

ArticleYear
The proteasome inhibitor PS-341 in cancer therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dipeptides; Drug Synergism; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Ubiquitins

1999
Proteasome inhibition measurements: clinical application.
    Clinical chemistry, 2000, Volume: 46, Issue:5

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; In Vitro Techniques; Kinetics; Male; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence

2000
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    Leukemia, 2000, Volume: 14, Issue:7

    Topics: Acetylcysteine; Acrylates; Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Calpain; Cathepsins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Synergism; Genes, p53; Humans; Jurkat Cells; Leupeptins; Multienzyme Complexes; Neoplasm Proteins; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells

2000
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma; Caspase Inhibitors; Caspases; Cell Adhesion; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Female; Humans; Male; Ovarian Neoplasms; Phosphorylation; Prostatic Neoplasms; Protease Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein

2000
Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:11

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hematologic Neoplasms; Humans; Neoplasms; Protease Inhibitors; Pyrazines

2000
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Jan-16, Volume: 98, Issue:2

    Topics: Amino Acid Chloromethyl Ketones; Aminopeptidases; Animals; Antigen Presentation; Antigens; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Survival; Cysteine Endopeptidases; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Resistance; Endopeptidases; Enzyme Activation; H-2 Antigens; Leupeptins; Lymphoma, T-Cell; Mice; Multienzyme Complexes; Neoplasm Proteins; Oligopeptides; Peptide Fragments; Phenols; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Selection, Genetic; Serine Endopeptidases; Sulfones; Thymus Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tyramine; Ubiquitins

2001
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Cancer research, 2001, Apr-01, Volume: 61, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Growth Inhibitors; Humans; I-kappa B Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Stromal Cells; Tumor Cells, Cultured

2001
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    International journal of radiation oncology, biology, physics, 2001, May-01, Volume: 50, Issue:1

    Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Cysteine Endopeptidases; DNA-Binding Proteins; Female; Humans; I-kappa B Proteins; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Repressor Proteins; Transduction, Genetic; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cancer research, 2001, May-01, Volume: 61, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Colorectal Neoplasms; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cysteine Endopeptidases; Cytokines; Disease Models, Animal; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
    Leukemia, 2001, Volume: 15, Issue:6

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles

2001
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Oncogene, 2001, Jul-27, Volume: 20, Issue:33

    Topics: Antigens, CD; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cysteine Endopeptidases; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4; Intercellular Adhesion Molecule-1; Interleukin-6; Lymphocyte Function-Associated Antigen-1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Biological; Mucin-1; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Stromal Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2001
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
    The Journal of surgical research, 2001, Volume: 100, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Molecular pathways that modify tumor radiation response.
    American journal of clinical oncology, 2001, Volume: 24, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Synergism; Humans; Leupeptins; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Signal Transduction; Tumor Cells, Cultured; Ubiquitins

2001
Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin.
    Experimental and molecular pathology, 2001, Volume: 71, Issue:3

    Topics: Animals; Antifungal Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Frameshift Mutation; Galactosamine; Hepatocytes; Liver; Male; Mice; Mice, Inbred C3H; Microscopy, Fluorescence; Multienzyme Complexes; Proteasome Endopeptidase Complex; Proteins; Pyrans; Pyrazines; Spiro Compounds; Thioacetamide; Ubiquitin

2001
Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341.
    Free radical biology & medicine, 2002, Jan-01, Volume: 32, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Chymases; Cytochrome P-450 CYP2E1; Ethanol; Liver; Male; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Serine Endopeptidases; Substance Withdrawal Syndrome

2002
Cancer research. Taking garbage in, tossing cancer out?
    Science (New York, N.Y.), 2002, Jan-25, Volume: 295, Issue:5555

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines

2002
Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Feb-05, Volume: 99, Issue:3

    Topics: Boronic Acids; Bortezomib; Cell Nucleus; Cysteine Endopeptidases; DNA Repair; DNA, Fungal; Fungal Proteins; Gene Deletion; Gene Expression Profiling; Genome, Fungal; Genomics; Microbial Sensitivity Tests; Multienzyme Complexes; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA, Fungal; Saccharomyces cerevisiae; Transcription, Genetic

2002
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
    Cancer research, 2002, Feb-15, Volume: 62, Issue:4

    Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Daclizumab; DNA-Binding Proteins; DNA, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Immunoglobulin G; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monocytes; Multienzyme Complexes; Neutrophils; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, IgG

2002
NF-kappa B as a therapeutic target in multiple myeloma.
    The Journal of biological chemistry, 2002, May-10, Volume: 277, Issue:19

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Immunoblotting; Intercellular Adhesion Molecule-1; Models, Chemical; Multiple Myeloma; NF-kappa B; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured; Up-Regulation

2002
Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines

2001
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    Cancer research, 2002, Sep-01, Volume: 62, Issue:17

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Dose-Response Relationship, Drug; Humans; Male; Mice; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2002
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Oncogene, 2002, Sep-19, Volume: 21, Issue:42

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Differentiation; Cell Division; Chloramphenicol O-Acetyltransferase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation; HeLa Cells; Humans; I-kappa B Proteins; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Promoter Regions, Genetic; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrophosphatases; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation

2002
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Oct-29, Volume: 99, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Down-Regulation; Gene Expression Profiling; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor I; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin

2002
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
    Blood, 2003, Feb-15, Volume: 101, Issue:4

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle Proteins; Cell Death; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Activation; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Nuclear Proteins; Phosphorylation; Phosphoserine; Protease Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2003
Role of the bone marrow microenvironment in multiple myeloma.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:11

    Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
    Blood, 2003, Mar-15, Volume: 101, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Recurrence; Tumor Cells, Cultured

2003
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:10

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cysteine Endopeptidases; DNA Fragmentation; Flow Cytometry; G2 Phase; Humans; Mitosis; Models, Biological; Multienzyme Complexes; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Subcellular Fractions; Time Factors; Tosylphenylalanyl Chloromethyl Ketone; Tumor Cells, Cultured

2002
Function of nuclear factor kappaB in pancreatic cancer metastasis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1

    Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Phenotype; Pyrazines; Retroviridae; Time Factors; Tumor Cells, Cultured

2003
Moving disease biology from the lab to the clinic.
    Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl

    Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide

2003
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl

    Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor

2003
[Perspectives on the oncologist pharmacopoeia].
    Bulletin du cancer, 2003, Volume: 90, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin

2003
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:3

    Topics: Active Transport, Cell Nucleus; Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Nucleus; Cell Survival; Cysteine Endopeptidases; Cytosol; Dose-Response Relationship, Drug; Genes, Dominant; Humans; I-kappa B Proteins; Melphalan; Microscopy, Fluorescence; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured; Ubiquitin

2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:3

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dose-Response Relationship, Drug; G2 Phase; Humans; Immunohistochemistry; Lung Neoplasms; Microtubules; Mitosis; Multienzyme Complexes; Mutation; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation

2003
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
    Blood, 2003, Jul-01, Volume: 102, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bone Marrow Purging; Boronic Acids; Bortezomib; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Disease-Free Survival; Drug Synergism; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Neoplasms, Experimental; Protease Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Isogeneic; Treatment Outcome; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2003
Clinical trials referral resource. Current clinical trials of bortezomib.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Neoplasms; Patient Selection; Protease Inhibitors; Pyrazines; United States

2003
First proteasome inhibitor approved for multiple myeloma.
    Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Approval; Drugs, Investigational; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; United States; United States Food and Drug Administration

2003
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
    Journal of immunology (Baltimore, Md. : 1950), 2003, Jul-01, Volume: 171, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-X Protein; Biopsy; Boronic Acids; Bortezomib; Cell Cycle; Growth Inhibitors; Humans; Hydrolysis; I-kappa B Proteins; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Minor Histocompatibility Antigens; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Organic Chemicals; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Cells, Cultured

2003
Imaging 26S proteasome activity and inhibition in living mice.
    Nature medicine, 2003, Volume: 9, Issue:7

    Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Coleoptera; Cysteine Proteinase Inhibitors; Genes, Reporter; HeLa Cells; Humans; Kinetics; Leupeptins; Luciferases; Luminescent Measurements; Male; Mice; Mice, Nude; Molecular Biology; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines; Transfection; Ubiquitin; Xenograft Model Antitumor Assays

2003
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
    The Journal of biological chemistry, 2003, Sep-05, Volume: 278, Issue:36

    Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Survival; Cysteine Endopeptidases; Cytochrome c Group; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Immunoblotting; Indicators and Reagents; Lung Neoplasms; Membrane Potentials; Mitochondria; Models, Chemical; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2003
The proteasome--an emerging therapeutic target in cancer.
    The New England journal of medicine, 2003, Jun-26, Volume: 348, Issue:26

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Peptide Hydrolases; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
Bortezomib (velcade) for multiple myeloma.
    The Medical letter on drugs and therapeutics, 2003, Jul-21, Volume: 45, Issue:1161

    Topics: Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Fees, Pharmaceutical; Humans; Multiple Myeloma; Nausea; Pyrazines

2003
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Blood, 2003, Nov-15, Volume: 102, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Butyrates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Pyrazines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Vorinostat

2003
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
    Oncogene, 2003, Aug-07, Volume: 22, Issue:32

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 9; Caspases; Humans; Membrane Glycoproteins; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2003
Bortezomib.
    Nature reviews. Drug discovery, 2003, Volume: 2, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Industry; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome; United States

2003
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Haematologica, 2003, Volume: 88, Issue:8

    Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines

2003
Can smart bombs win the war on cancer? By pinpointing abnormalities specific to tumor cells, a novel generation of cancer drugs may usher in a whole new era of cancer treatment.
    Harvard health letter, 2003, Volume: 28, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Neoplasms; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrazines

2003
Molecule of the month. Bortezomib.
    Drug news & perspectives, 2003, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; National Institutes of Health (U.S.); Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; United States

2003
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
    The Journal of surgical research, 2003, Volume: 113, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2003
Innovative strategies in lymphoma therapy.
    Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14

    Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine

2003
Bortezomib in multiple myeloma.
    The New England journal of medicine, 2003, Sep-25, Volume: 349, Issue:13

    Topics: Boronic Acids; Bortezomib; Disease Progression; Humans; Multiple Myeloma; Paraproteins; Protease Inhibitors; Pyrazines

2003
Bortezomib in multiple myeloma.
    The New England journal of medicine, 2003, Sep-25, Volume: 349, Issue:13

    Topics: Amyloid beta-Peptides; Boronic Acids; Bortezomib; Diagnostic Techniques, Neurological; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines

2003
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
    Leukemia, 2003, Volume: 17, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Cytochrome c Group; Dexamethasone; Humans; Membrane Potentials; Mitochondria; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured

2003
Promoting proteasomes: trash to treasure.
    Drug discovery today, 2003, Oct-01, Volume: 8, Issue:19

    Topics: Allosteric Regulation; Antimicrobial Cationic Peptides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2003
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Androgens; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Survival; Cysteine Endopeptidases; Drug Interactions; Electrophoretic Mobility Shift Assay; Humans; Luciferases; Male; Membrane Glycoproteins; Multienzyme Complexes; NF-kappa B; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2003
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein

2003
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:9

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Endothelium, Vascular; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
    Cancer research, 2003, Oct-01, Volume: 63, Issue:19

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Leupeptins; Lymphoma; Molecular Chaperones; Multienzyme Complexes; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Transfection

2003
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Oncogene, 2003, Oct-16, Volume: 22, Issue:46

    Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells

2003
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
    Cancer research, 2003, Nov-01, Volume: 63, Issue:21

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Humans; Male; Nuclear Proteins; Oncogene Proteins, Viral; Papillomaviridae; Peptide Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Subcellular Fractions; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53

2003
Combinations of targeted therapies take aim at multiple pathways.
    Journal of the National Cancer Institute, 2003, Nov-19, Volume: 95, Issue:22

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design

2003
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
    Oncogene, 2003, Nov-20, Volume: 22, Issue:52

    Topics: Boronic Acids; Bortezomib; Caspases; Contactins; Cysteine Endopeptidases; Down-Regulation; Humans; Interleukin-6; Multienzyme Complexes; Multiple Myeloma; Neural Cell Adhesion Molecules; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction

2003
[Gene expression profile changes in human multiple myeloma].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2003, Volume: 28, Issue:3

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Epidermal Growth Factor; Female; Gene Expression; Gene Expression Profiling; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Protein Tyrosine Phosphatases; Pyrazines; RNA, Messenger

2003
The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation.
    Experimental and molecular pathology, 2004, Volume: 76, Issue:1

    Topics: Actins; Animals; Boronic Acids; Bortezomib; Cell Membrane; Cells, Cultured; Chlormethiazole; Dicarbethoxydihydrocollidine; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Fluorescent Antibody Technique, Indirect; Hepatocytes; Inclusion Bodies; Keratins; Male; Membrane Proteins; Mice; Mice, Inbred C3H; Microscopy, Confocal; Phosphoproteins; Protease Inhibitors; Pyrazines; Zonula Occludens-1 Protein

2004
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:1

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2004
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
    Cancer science, 2004, Volume: 95, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme-Linked Immunosorbent Assay; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Suppressor Protein p53

2004
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Apoptosis : an international journal on programmed cell death, 2004, Volume: 9, Issue:2

    Topics: 2-Methoxyestradiol; Actins; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Estradiol; Heat-Shock Proteins; Humans; Multiple Myeloma; Peptides; Proteasome Inhibitors; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2004
Proteasome inhibition induces cytokeratin accumulation in vivo.
    Experimental and molecular pathology, 2004, Volume: 76, Issue:2

    Topics: Alcoholism; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Endopeptidases; Heat-Shock Proteins; Hepatocytes; Keratins; Liver; Liver Diseases, Alcoholic; Male; Mice; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats

2004
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
    Cancer science, 2004, Volume: 95, Issue:3

    Topics: Androgens; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Line; Down-Regulation; Humans; In Situ Nick-End Labeling; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Receptors, Androgen

2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A

2004
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Blood, 2004, Jul-15, Volume: 104, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators

2004
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2004
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    The Journal of thoracic and cardiovascular surgery, 2004, Volume: 127, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Butyrates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cysteine Endopeptidases; Histone Deacetylases; Humans; Interleukin-8; Lung Neoplasms; Multienzyme Complexes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tumor Cells, Cultured

2004
Proteinase inhibitors - IBC's Third International Conference. New approaches, new discoveries, new targets.
    IDrugs : the investigational drugs journal, 2004, Volume: 7, Issue:2

    Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Boronic Acids; Bortezomib; Cathepsins; Drug Evaluation, Preclinical; Endopeptidases; Humans; Inflammation; Peptide Library; Protease Inhibitors; Pyrazines

2004
[Targeted in therapies multiple myeloma].
    Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Blood, 2004, Apr-15, Volume: 103, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Mutation; NF-kappa B; Oleanolic Acid; Protease Inhibitors; Pyrazines; Recombinant Proteins; Transfection

2004
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants.
    Blood, 2004, Aug-01, Volume: 104, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Crosses, Genetic; Cysteine Endopeptidases; DNA Replication; Genes, pX; HTLV-I Infections; Humans; Interleukin-10; Interleukin-6; Leukemia, T-Cell; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2004
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
    Experimental cell research, 2004, May-01, Volume: 295, Issue:2

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cytochromes c; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Models, Biological; Protease Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species; Signal Transduction; U937 Cells

2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
    Oncogene, 2004, Apr-29, Volume: 23, Issue:20

    Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligase Complexes

2004
Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.
    The Journal of biological chemistry, 2004, Jun-25, Volume: 279, Issue:26

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Doxycycline; Fibroblasts; Humans; I-kappa B Kinase; I-kappa B Proteins; Mice; NF-kappa B; Nuclear Proteins; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Superoxides; Transcription Factor RelA; Tumor Suppressor Protein p53; Up-Regulation

2004
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
    Cancer research, 2004, May-01, Volume: 64, Issue:9

    Topics: Animals; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Fractionation; Chlorocebus aethiops; COS Cells; Cysteine Endopeptidases; Detergents; Down-Regulation; Humans; Lactams, Macrocyclic; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Rifabutin; Transfection; Ubiquitin; Ubiquitin-Protein Ligases

2004
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9

    Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carrier Proteins; Caspases; CD40 Antigens; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Hodgkin Disease; Humans; I-kappa B Proteins; Ki-1 Antigen; Membrane Glycoproteins; Multienzyme Complexes; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Tumor Necrosis Factor-alpha

2004
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:5

    Topics: Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Viral; Cycloheximide; Detergents; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Quinones; Repressor Proteins; Rifabutin; Solubility; Ubiquitins; Vacuoles

2004
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, May-25, Volume: 101, Issue:21

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Protease Inhibitors; Pyrazines; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Homologous

2004
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-01, Volume: 10, Issue:11

    Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein

2004
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-01, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Annexin A5; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line, Tumor; Cinnamates; Colonic Neoplasms; Depsipeptides; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Free Radicals; Gastrointestinal Neoplasms; Histones; Humans; Microscopy, Confocal; Oligopeptides; Oxygen; Phosphorylation; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors

2004
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Leukemia, 2004, Volume: 18, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Cysteine Endopeptidases; HTLV-I Infections; Humans; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous

2004
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2004
"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
    Cancer investigation, 2004, Volume: 22, Issue:2

    Topics: Biomedical Research; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Industry; Federal Government; Humans; Interinstitutional Relations; Neoplasms; Protease Inhibitors; Pyrazines

2004
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Leukemia research, 2004, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured

2004
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Kidney Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Blood, 2004, Oct-15, Volume: 104, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Survival; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; GABA-A Receptor Antagonists; Humans; Insulin-Like Growth Factor I; Interleukin-6; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Stromal Cells; Superoxides; Tumor Cells, Cultured

2004
Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
    Annals of clinical and laboratory science, 2004,Spring, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Dexamethasone; Humans; Male; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence

2004
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide

2004
Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
    Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18

    Topics: Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stereoisomerism; Structure-Activity Relationship

2004
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    Leukemia, 2004, Volume: 18, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Division; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Synergism; Humans; Lymphoma; Membrane Glycoproteins; NF-kappa B; Paclitaxel; Pleural Effusion, Malignant; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2004
The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.
    Biochemical and biophysical research communications, 2004, Sep-03, Volume: 321, Issue:4

    Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Mitochondria; Peptide Fragments; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Kinase C; Protein Kinase C-delta; Pyrazines; U937 Cells

2004
New drugs 04. Part III.
    Nursing, 2004, Volume: 34, Issue:9

    Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides

2004
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
    Molecular pharmacology, 2004, Volume: 66, Issue:6

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Fibroblasts; Genes, myc; Humans; Immediate-Early Proteins; Mice; Mice, Knockout; Mice, Nude; Phosphoprotein Phosphatases; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Pyrazines; Recombinant Proteins; Transplantation, Heterologous

2004
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:10

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome

2004
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:4

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2004
Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome

2004
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
    ONS news, 2004, Volume: 19, Issue:9 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Oncogene, 2004, Nov-18, Volume: 23, Issue:54

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Heat-Shock Proteins; Humans; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines

2004
Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcium Channels; Cell Line; Cells, Cultured; Dithiothreitol; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; HeLa Cells; Histones; Humans; I-kappa B Proteins; Inositol 1,4,5-Trisphosphate Receptors; Mice; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Inhibitors; Protein Binding; Pyrazines; Receptors, Cytoplasmic and Nuclear; Time Factors; Ubiquitin; Ubiquitin-Conjugating Enzymes

2004
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
    Annals of clinical and laboratory science, 2004,Summer, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus

2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
    Cancer research, 2004, Oct-15, Volume: 64, Issue:20

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Caveolin 1; Caveolins; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Endothelium, Vascular; Humans; Multiple Myeloma; Phosphorylation; Proteins; Pyrazines; Recombinant Proteins; Retinoblastoma-Like Protein p130; src-Family Kinases; Transfection; Tyrosine; Vascular Endothelial Growth Factor A

2004
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Molecular and cellular biology, 2004, Volume: 24, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Gene Expression Profiling; Head and Neck Neoplasms; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction

2004
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    The Journal of thoracic and cardiovascular surgery, 2004, Volume: 128, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mitochondria; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Vorinostat

2004
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Oncogene, 2005, Jan-13, Volume: 24, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Glioblastoma; Humans; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2005
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
    Oncogene, 2005, Jan-13, Volume: 24, Issue:3

    Topics: Adult; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Ceramides; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
Activity of bortezomib in advanced non-small-cell lung cancer.
    Clinical lung cancer, 2004, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids

2004
Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
    Leukemia, 2005, Volume: 19, Issue:2

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptor, Notch2; Receptors, Cell Surface; Receptors, IgE; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2005
Select forms of tumor cell apoptosis induce dendritic cell maturation.
    Journal of leukocyte biology, 2005, Volume: 77, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; fas Receptor; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Pyrazines; Signal Transduction; Tamoxifen

2005
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Cancer research, 2004, Dec-01, Volume: 64, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation

2004
[Proteasome inhibitors--new option in the treatment of tumor diseases].
    Casopis lekaru ceskych, 2004, Volume: 143, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2004
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2004, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured

2004
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
    Cancer research, 2004, Dec-15, Volume: 64, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Caspase 8; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Humans; Interferon Type I; Membrane Glycoproteins; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms

2004
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
    Oncogene, 2005, Feb-24, Volume: 24, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; Cell Survival; Genes, Tumor Suppressor; Humans; Kidney Neoplasms; NF-kappa B; Paclitaxel; Pyrazines; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein

2005
Bortezomib is an efficient agent in plasma cell leukemias.
    International journal of cancer, 2005, Apr-20, Volume: 114, Issue:4

    Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors

2005
Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines

2005
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Antigens, Neoplasm; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Intraductal, Noninfiltrating; Cell Hypoxia; Cell Survival; Down-Regulation; Estrogen Receptor alpha; Female; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Monosaccharide Transport Proteins; Neoplasm Invasiveness; Oxygen; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2004
Emerging advances in the management of lung cancer.
    Clinical lung cancer, 2004, Volume: 6 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids

2004
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival.
    Blood, 2005, Jun-01, Volume: 105, Issue:11

    Topics: Autocrine Communication; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dexamethasone; Humans; Multiple Myeloma; Nerve Growth Factors; Paracrine Communication; Pyrazines; Receptor, trkB; Signal Transduction; Stromal Cells

2005
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells.
    Cancer biology & therapy, 2005, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, Non-Hodgkin; Pyrazines; Tumor Cells, Cultured

2005
Missing the target: ubiquitin ligase drugs stall.
    Journal of the National Cancer Institute, 2005, Feb-02, Volume: 97, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; NEDD8 Protein; Nuclear Proteins; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitins

2005
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Cancer, 2005, Mar-15, Volume: 103, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome

2005
Multifunctional role of Erk5 in multiple myeloma.
    Blood, 2005, Jun-01, Volume: 105, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dexamethasone; Enzyme Activation; Humans; Interleukin-6; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Pyrazines; Signal Transduction; Tumor Cells, Cultured

2005
[Multiple myeloma -- therapy].
    Deutsche medizinische Wochenschrift (1946), 2005, Feb-11, Volume: 130, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2005
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
    Haematologica, 2005, Volume: 90, Issue:2

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous

2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Oncogene, 2005, Apr-28, Volume: 24, Issue:19

    Topics: Acyltransferases; Adenosine Triphosphate; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Immunoblotting; In Situ Nick-End Labeling; Multiple Myeloma; Necrosis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Proteins; Pyrazines; Time Factors; Treatment Outcome

2005
Multiple myeloma.
    The New England journal of medicine, 2005, Feb-24, Volume: 352, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide

2005
Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Archives of internal medicine, 2005, Feb-28, Volume: 165, Issue:4

    Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury, Chronic; Humans; L-Lactate Dehydrogenase; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines

2005
Bortezomib therapy following first relapse.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2005
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Leukemia research, 2005, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Sequence Deletion; Treatment Outcome

2005
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss

2005
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    Southern medical journal, 2005, Volume: 98, Issue:2

    Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide

2005
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:6

    Topics: Boronic Acids; Bortezomib; Humans; Isoenzymes; Microsomes, Liver; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2005
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
    Cancer cell, 2005, Volume: 7, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53

2005
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Fibroblasts; Green Fluorescent Proteins; Humans; Immunoprecipitation; Male; Membrane Glycoproteins; Membrane Proteins; Mice; Mitochondrial Proteins; Peptide Fragments; Plasmids; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor-alpha

2005
Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.
    Leukemia, 2005, Volume: 19, Issue:5

    Topics: Boronic Acids; Bortezomib; Hearing Loss, Bilateral; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2005
Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Membrane Glycoproteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1

    Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured

2005
NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.
    The Journal of biological chemistry, 2005, Jun-03, Volume: 280, Issue:22

    Topics: Animals; Antigens, Differentiation; Apoptosis; Arsenites; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Dexamethasone; DNA Damage; Extracellular Signal-Regulated MAP Kinases; Female; Gene Library; Genetic Vectors; I-kappa B Proteins; Inflammation; Lipopolysaccharides; Luciferases; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidative Stress; Promoter Regions, Genetic; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Messenger; Signal Transduction; Sodium Compounds; Thalidomide; Time Factors; Tissue Distribution; Tumor Necrosis Factor-alpha

2005
Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:3

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Electroporation; Flow Cytometry; Heat-Shock Proteins; Hot Temperature; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Immunoprecipitation; K562 Cells; Lactams, Macrocyclic; Mice; Mice, Transgenic; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyrazines; Quinones; Time Factors; Ubiquitin

2005
Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Mediastinal Neoplasms; Middle Aged; Plasmacytoma; Pyrazines; Treatment Outcome

2005
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms

2005
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
    European journal of haematology, 2005, Volume: 74, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cladribine; Dose-Response Relationship, Drug; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2005
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Oncogene, 2005, Jul-21, Volume: 24, Issue:31

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Kidney; Membrane Proteins; Mitochondrial Proteins; NF-kappa B; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2005
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
    Leukemia, 2005, Volume: 19, Issue:6

    Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Pyrazines; Spinal Fractures

2005
Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Annals of clinical and laboratory science, 2005,Winter, Volume: 35, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Phosphorylation; Protease Inhibitors; Proteome; Pyrazines; Tumor Suppressor Protein p53

2005
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
    Nature methods, 2005, Volume: 2, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leupeptins; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2005
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
    Cancer research, 2005, May-01, Volume: 65, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calcium; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Enzyme Activation; Gene Expression; Humans; Isoenzymes; Mitochondria; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines

2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
    Blood, 2005, Sep-01, Volume: 106, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Drug Synergism; Hodgkin Disease; Humans; Intracellular Signaling Peptides and Proteins; Ki-1 Antigen; Mice; NF-kappa B; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays

2005
Lung cancer - Second Annual Winter Conference.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:5

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines

2005
Genotypic guidance for chemotherapy choices.
    Drug discovery today, 2005, May-01, Volume: 10, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genotype; Humans; Membrane Proteins; Paclitaxel; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines

2005
Velcade displays promising activity in primary effusion lymphoma cells.
    Cancer biology & therapy, 2005, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Lymphoma, B-Cell; Pleural Effusion, Malignant; Pyrazines

2005
Measuring ubiquitin conjugation in cells.
    Methods in molecular biology (Clifton, N.J.), 2005, Volume: 301

    Topics: Benzoquinones; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Humans; Lactams, Macrocyclic; Protein Processing, Post-Translational; Pyrazines; Quinones; Ubiquitin

2005
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Cancer research, 2005, Jun-01, Volume: 65, Issue:11

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms

2005
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Flow Cytometry; Humans; Immunoblotting; Jurkat Cells; Leupeptins; Membrane Glycoproteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Jun-14, Volume: 102, Issue:24

    Topics: Anilides; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Inhibitory Concentration 50; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; RNA, Small Interfering; Tubulin

2005
Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Jun-15, Volume: 174, Issue:12

    Topics: Acute Disease; Animals; Arthritis, Experimental; Boronic Acids; Bortezomib; Dermatitis, Contact; Disease Models, Animal; Enzyme Induction; Female; Genetic Vectors; Lipopolysaccharides; Luciferases; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Organ Specificity; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sepsis; Serum Amyloid A Protein; Tumor Necrosis Factor-alpha

2005
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
    Haematologica, 2005, Volume: 90, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2005
Images in clinical Medicine. Bortezomib-induced skin lesions.
    The New England journal of medicine, 2005, Jun-16, Volume: 352, Issue:24

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines

2005
Bortezomib for myeloma -- much ado about something.
    The New England journal of medicine, 2005, Jun-16, Volume: 352, Issue:24

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Research Design

2005
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
    Blood, 2005, Nov-01, Volume: 106, Issue:9

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme Inhibitors; Female; Gastrointestinal Tract; Graft vs Host Disease; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger

2005
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
    Experimental hematology, 2005, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Multiple Myeloma; Pyrazines; Radiation-Sensitizing Agents; Radiation, Ionizing

2005
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
    Leukemia research, 2005, Volume: 29, Issue:12

    Topics: Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Salvage Therapy; Spinal Neoplasms

2005
Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calibration; Chromatography, High Pressure Liquid; Drug Packaging; Drug Stability; Drug Storage; Glass; Pharmaceutical Solutions; Plastics; Pyrazines; Reference Standards; Reproducibility of Results; Syringes; Temperature

2005
Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 289, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Death, Sudden, Cardiac; Dogs; Electrocardiography; G-Protein-Coupled Receptor Kinase 5; Immunoblotting; Ligation; Male; Microscopy, Confocal; Microscopy, Fluorescence; Myocardial Infarction; Myocardial Ischemia; Myocardium; Pericardium; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tachycardia, Ventricular

2005
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
    Leukemia, 2005, Volume: 19, Issue:9

    Topics: Boronic Acids; Bortezomib; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome

2005
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
    MMW Fortschritte der Medizin, 2005, Jun-16, Volume: 147, Issue:24

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; Multiple Myeloma; Prognosis; Pyrazines; Radioimmunotherapy; Thalidomide

2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cytokines; Female; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasm Recurrence, Local; NF-kappa B; Protease Inhibitors; Pyrazines; Stomatitis; Transcription Factor RelA

2005
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Fatal Outcome; Humans; Immunoglobulin D; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Thalidomide

2005
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide

2005
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:2

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Lung Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured

2005
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Cancer research, 2005, Jul-15, Volume: 65, Issue:14

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2005
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Cancer research, 2005, Jul-15, Volume: 65, Issue:14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cisplatin; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Up-Regulation; Xenograft Model Antitumor Assays

2005
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-15, Volume: 11, Issue:14

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; Disease Progression; DNA Damage; Drug Interactions; Humans; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Reactive Oxygen Species; Sulindac; Transplantation, Heterologous

2005
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Hepatocytes; Humans; Liver Neoplasms; Membrane Glycoproteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:3

    Topics: Acute Disease; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Enteritis; Female; Humans; Multiple Myeloma; Palliative Care; Pyrazines; Radiation Injuries; Spinal Neoplasms

2005
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:7

    Topics: Animals; Boronic Acids; Bortezomib; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Immunoprecipitation; Mice; Mice, Knockout; Mutation; Nuclear Matrix; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; Serine; Threonine; Transcription Factors; Transcription, Genetic; Ubiquitin

2005
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Leukemia research, 2006, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Multiple Myeloma; Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2006
Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Annals of clinical and laboratory science, 2005,Summer, Volume: 35, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; NF-kappa B; Pyrazines; RNA, Small Interfering; Transfection

2005
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Cancer biology & therapy, 2005, Volume: 4, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Colonic Neoplasms; Cysteine Proteinase Inhibitors; Cytochromes c; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Membrane Glycoproteins; Membrane Proteins; Mitochondrial Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2005
Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.
    The Journal of biological chemistry, 2005, Oct-14, Volume: 280, Issue:41

    Topics: Anthracyclines; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Proteasome Endopeptidase Complex; Pyrazines; Retinoblastoma Protein; RNA; RNA Interference; RNA Processing, Post-Transcriptional; RNA, Small Interfering; Time Factors; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitin

2005
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    British journal of haematology, 2005, Volume: 130, Issue:4

    Topics: Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Statistics, Nonparametric; Tumor Cells, Cultured

2005
Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:11

    Topics: Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Protease Inhibitors; Pyrazines; Recombinant Proteins

2005
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin

2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
    Blood, 2005, Dec-15, Volume: 106, Issue:13

    Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured

2005
[Proteasome inhibitors].
    La Revue de medecine interne, 2005, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured

2005
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
    Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:4

    Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2005
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
    Cancer research, 2005, Sep-01, Volume: 65, Issue:17

    Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; HeLa Cells; Humans; Interferon-gamma; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2005
Development of effective new treatments for multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Design; Humans; Multiple Myeloma; Pyrazines; United States; United States Food and Drug Administration

2005
[Bortezomib in second-line therapy].
    Medizinische Monatsschrift fur Pharmazeuten, 2005, Volume: 28, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasms; Pyrazines; Randomized Controlled Trials as Topic

2005
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Cancer research, 2005, Sep-15, Volume: 65, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Galectin 3; Humans; I-kappa B Proteins; Lymphocytes; Multiple Myeloma; NF-KappaB Inhibitor alpha; Polysaccharides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Vascular Endothelial Growth Factor A

2005
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Blood, 2006, Jan-01, Volume: 107, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Free Radical Scavengers; Humans; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation

2006
New therapies for the treatment of multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:5

    Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide

2005
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
    British journal of haematology, 2005, Volume: 131, Issue:1

    Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome

2005
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.
    Blood, 2006, Jan-15, Volume: 107, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Colon; Cytokines; Graft Survival; Graft vs Host Disease; H-2 Antigens; Heterocyclic Compounds, 3-Ring; Leukocyte Common Antigens; Mice; Mice, Knockout; NF-kappa B; Pyrazines; Pyridines; Survival Rate

2006
Bortezomib in multiple myeloma.
    The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Drug Costs; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate

2005
Bortezomib in multiple myeloma.
    The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Research Design; Survival Analysis

2005
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
    Casopis lekaru ceskych, 2005, Volume: 144, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence

2005
Bortezomib-induced Sweet syndrome.
    British journal of haematology, 2005, Volume: 131, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Sweet Syndrome

2005
Multiple myeloma: the present and the future.
    The Medical journal of Australia, 2005, Oct-03, Volume: 183, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2005
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
    International journal of cancer, 2006, Mar-15, Volume: 118, Issue:6

    Topics: Alcohol Deterrents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cycloheximide; Disulfiram; Dose-Response Relationship, Drug; Humans; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines; Pyrrolidines; Thiocarbamates; Tumor Necrosis Factor-alpha

2006
Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Survival Rate

2005
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Line; Gene Expression Regulation, Viral; Herpesvirus 8, Human; Humans; Immediate-Early Proteins; Phorbol Esters; Protease Inhibitors; Pyrazines; Trans-Activators; Viral Proteins; Virus Activation; Virus Latency

2005
Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
    Blood, 2006, Mar-15, Volume: 107, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sezary Syndrome; Skin Neoplasms; Transcription Factor RelA

2006
New agents and approaches in the treatment of multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2003
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:10

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Activation; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2005
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
    Acta haematologica, 2005, Volume: 114, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A

2005
N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Cancer research, 2005, Oct-15, Volume: 65, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Carrier Proteins; Cell Growth Processes; Cyclin D1; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Enzyme Activation; Fenretinide; Genes, myc; Humans; I-kappa B Kinase; I-kappa B Proteins; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oncogene Protein v-akt; Osteoclasts; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2005
Antimyeloma activity of heat shock protein-90 inhibition.
    Blood, 2006, Feb-01, Volume: 107, Issue:3

    Topics: Androgens; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Drug Synergism; Estrogens; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Kinase; Lactams, Macrocyclic; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Interleukin-6; Rifabutin; Signal Transduction; Tumor Cells, Cultured

2006
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome

2005
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
    The Journal of biological chemistry, 2006, Jan-13, Volume: 281, Issue:2

    Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Binding, Competitive; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Drug Antagonism; Fibroblasts; Free Radicals; Humans; Immunoblotting; Kinetics; Leupeptins; Melanocytes; Melanoma; Membrane Potentials; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Skin; Time Factors

2006
Proteasome inhibitors in non-Hodgkin's lymphoma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3 Suppl 1

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines

2005
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
    Blood, 2006, May-01, Volume: 107, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cytokines; Graft vs Host Disease; Humans; In Vitro Techniques; Isoantigens; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Protease Inhibitors; Pyrazines; T-Lymphocytes; Th1 Cells

2006
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Cancer cell, 2005, Volume: 8, Issue:5

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured

2005
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Drug Interactions; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Infant; Inhibitory Concentration 50; Leukemia; Male; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured

2006
The ubiquitin proteasome pathway from bench to bedside.
    Hematology. American Society of Hematology. Education Program, 2005

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2005
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Pharmacotherapy, 2005, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Tumor Lysis Syndrome

2005
Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
    Annals of hematology, 2006, Volume: 85, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Mobilization; Humans; Immunophenotyping; Leukemia, Plasma Cell; Pyrazines; Remission Induction; Treatment Outcome

2006
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
    Hematology (Amsterdam, Netherlands), 2005, Volume: 10, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Survival; Coculture Techniques; Cytarabine; Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Proteasome Inhibitors; Pyrazines

2005
Waldenström's macroglobulinemia and bortezomib.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Diseases; Humans; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Waldenstrom Macroglobulinemia

2005
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia

2005
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
    Cancer research, 2005, Dec-15, Volume: 65, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Caspase Inhibitors; Caspases; Caspases, Initiator; Cycloheximide; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Molecular Chaperones; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Pyrazines; RNA, Small Interfering; Thapsigargin; Transcription Factor CHOP; Ubiquitin

2005
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
    Cancer research, 2005, Dec-15, Volume: 65, Issue:24

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Calcium; Carcinogens; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cisplatin; Cytochromes c; Drug Interactions; Endoplasmic Reticulum; Enzyme Activation; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyrazines; RNA, Small Interfering; Thapsigargin; Tumor Stem Cell Assay; Tunicamycin

2005
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:12

    Topics: 14-3-3 Proteins; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cysteine Proteinase Inhibitors; DNA Damage; DNA Primers; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Pyrazines; Survivin; Tumor Suppressor Protein p53

2005
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
    Annals of the New York Academy of Sciences, 2005, Volume: 1059

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Ligands; Membrane Glycoproteins; Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53

2005
New treatment approaches in multiple myeloma.
    The Israel Medical Association journal : IMAJ, 2005, Volume: 7, Issue:12

    Topics: Aged; Boronic Acids; Bortezomib; Congresses as Topic; Female; Humans; Incidence; Israel; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide

2005
Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 51, Issue:2

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Pyrazines; Tomography, X-Ray Computed

2006
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    International journal of oncology, 2006, Volume: 28, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vincristine

2006
Velcade and vitamin C: too much of a good thing?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Pyrazines; Vitamins

2006
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Interactions; Humans; Proteasome Endopeptidase Complex; Pyrazines

2006
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Cancer research, 2006, Jan-01, Volume: 66, Issue:1

    Topics: Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Growth Processes; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A

2006
Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.
    Annals of hematology, 2006, Volume: 85, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Injections, Intravenous; Lymph Nodes; Male; Middle Aged; Peritoneal Neoplasms; Plasmacytoma; Pyrazines; Radiotherapy Dosage; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous

2006
Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3

    Topics: Acetylcysteine; Anthracenes; Boronic Acids; Bortezomib; Collagen Type I; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Matrix; Fibroblasts; Fibrosis; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Leupeptins; Matrix Metalloproteinase 1; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-jun; Pyrazines; RNA Polymerase II; RNA, Messenger; Scleroderma, Systemic; Skin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Up-Regulation

2006
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.
    Blood, 2006, May-01, Volume: 107, Issue:9

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Japan; Lung; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Protease Inhibitors; Pyrazines; Respiratory Insufficiency

2006
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
    Blood, 2006, May-15, Volume: 107, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Protease Inhibitors; Pyrazines; Radiopharmaceuticals

2006
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Acta haematologica, 2006, Volume: 115, Issue:1-2

    Topics: 14-3-3 Proteins; Antibiotics, Antineoplastic; Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 9; Caspase Inhibitors; Caspases; Cytochromes c; Depsipeptides; DNA-Binding Proteins; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HL-60 Cells; Humans; K562 Cells; Ku Autoantigen; Leukemia; Mitochondria; Mitochondrial Membranes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines

2006
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured

2006
Proteasome inhibition induces hepatic stellate cell apoptosis.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:2

    Topics: Animals; Apoptosis; Bile Ducts; Boronic Acids; Bortezomib; Cell Line; Humans; Leupeptins; Ligation; Liver; Liver Cirrhosis; Mice; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor

2006
Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
    Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Kinetics; Liver; Microsomes, Liver; Organ Size; Pyrazines; Rats; Rats, Sprague-Dawley

2006
[Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2005
PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
    The Journal of biological chemistry, 2006, Apr-28, Volume: 281, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 2; Cathepsin B; Cysteine Endopeptidases; Cytochromes c; Down-Regulation; Enzyme Inhibitors; Humans; Lysosomes; Membrane Proteins; Mitochondrial Membranes; Mitochondrial Proteins; Pancreatic Neoplasms; Permeability; Phosphatidylserines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA, Messenger; Tumor Cells, Cultured

2006
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
    European journal of haematology, 2006, Volume: 76, Issue:3

    Topics: Boronic Acids; Bortezomib; Cytokines; Humans; Inflammation; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Vasculitis, Leukocytoclastic, Cutaneous

2006
Bulbar palsy in multiple myeloma.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine

2005
Bortezomib-induced Sweet's syndrome.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases

2005
Skin lesions induced by bortezomib.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy

2005
Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
    Molecular microbiology, 2006, Volume: 59, Issue:5

    Topics: Binding Sites; Boronic Acids; Bortezomib; Crystallography, X-Ray; Dipeptides; Molecular Structure; Mycobacterium tuberculosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Substrate Specificity

2006
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
    Leukemia research, 2006, Volume: 30, Issue:10

    Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydroquinones; Imatinib Mesylate; Kinetics; Mutation; Oxidative Stress; Piperazines; Point Mutation; Pyrazines; Pyrimidines; Reactive Oxygen Species

2006
The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
    Neuroscience letters, 2006, May-08, Volume: 398, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Brain Infarction; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; Neuroprotective Agents; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley

2006
Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells.
    Cell death and differentiation, 2006, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle; Colonic Neoplasms; Cyclin B; Humans; Pyrazines; Transcription Factor RelA

2006
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Blood, 2006, Jun-15, Volume: 107, Issue:12

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Multiple Myeloma; Neoplasm Proteins; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines; Signal Transduction

2006
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
    Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Gene Expression Regulation; Male; Muscle Denervation; Muscle, Skeletal; Muscular Atrophy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sciatic Nerve; Testosterone; Ubiquitin

2006
Closing the gap.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Pharmacology; Pharmacology, Clinical; Pyrazines; Research; Research Support as Topic; United States

2006
Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Deubiquitinating Enzyme CYLD; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2006
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspases; Cell Line; Cell Line, Tumor; Fas Ligand Protein; Heat-Shock Proteins; Humans; Liver; Liver Neoplasms; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase 8; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Necrosis Factors

2006
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome

2006
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Structure (London, England : 1993), 2006, Volume: 14, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Crystallization; Leucine; Mammals; Models, Molecular; Peptides; Phenylalanine; Proteasome Endopeptidase Complex; Protein Structure, Quaternary; Pyrazinamide; Pyrazines; Structure-Activity Relationship; Substrate Specificity; Yeasts

2006
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
    Blood, 2006, Jul-15, Volume: 108, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Boronic Acids; Bortezomib; Cells, Cultured; Chemotaxis; Cytokines; Dendritic Cells; Gene Expression Regulation; Humans; Immune System; Immunologic Factors; Lipopolysaccharides; Myeloid Differentiation Factor 88; Phagocytosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Toll-Like Receptor 4

2006
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
    Thrombosis and haemostasis, 2006, Volume: 95, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Brain; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; NF-kappa B; Nitric Oxide Synthase Type III; Platelet Aggregation; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Recombinant Proteins; Stroke; Time Factors; Tissue Plasminogen Activator; Vascular Patency

2006
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Oropharyngeal Neoplasms; Pyrazines; SUMO-1 Protein

2006
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Enzyme Activation; ErbB Receptors; Female; Humans; Immediate-Early Proteins; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 1; Phosphoprotein Phosphatases; Phosphorylation; Proteasome Inhibitors; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2

2006
Medullary renal cell carcinoma and response to therapy with bortezomib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Humans; Kidney Medulla; Kidney Neoplasms; Neoplasm Metastasis; Pyrazines; Treatment Outcome

2006
Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
    Anti-cancer drugs, 2006, Volume: 17, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Resistance; Drug Resistance, Neoplasm; Female; Humans; Protease Inhibitors; Proteasome Inhibitors; PTEN Phosphohydrolase; Pyrazines; Trastuzumab

2006
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:12

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2005
[Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Humans; Interleukin-1beta; Interleukin-6; Mesenchymal Stem Cells; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Factor

2006
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
    Cancer research, 2006, Apr-01, Volume: 66, Issue:7

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Division; Cell Line, Tumor; Female; G2 Phase; Humans; Leupeptins; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Xenograft Model Antitumor Assays

2006
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Cancer research, 2006, Apr-01, Volume: 66, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Vorinostat; Xenograft Model Antitumor Assays

2006
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
    Journal of immunology (Baltimore, Md. : 1950), 2006, Apr-15, Volume: 176, Issue:8

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Immunization; Immunotherapy; In Vitro Techniques; Killer Cells, Natural; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Pyrazines; Tumor Necrosis Factor-alpha

2006
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Ki-1 Antigen; Molecular Structure; Multiple Myeloma; Pyrazines; Thalidomide

2006
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    Blood, 2006, Apr-15, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous

2006
Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.
    Chemical research in toxicology, 2006, Volume: 19, Issue:4

    Topics: Boranes; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Oxidation-Reduction; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species

2006
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
    Annals of hematology, 2006, Volume: 85, Issue:8

    Topics: Adult; Aged; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous

2006
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Leukemia, 2006, Volume: 20, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; In Vitro Techniques; Indoles; Injections, Intravenous; Leupeptins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2006
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
    Leukemia research, 2006, Volume: 30, Issue:12

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Pyrazines; Rituximab

2006
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
    Journal of immunology (Baltimore, Md. : 1950), 2006, May-15, Volume: 176, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Models, Animal; Growth Inhibitors; Interleukin-12; Interleukin-2; Liver Neoplasms; Male; Mice; Mice, Inbred A; Neuroblastoma; Proteasome Inhibitors; Pyrazines

2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-01, Volume: 12, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Genes, bcl-2; Humans; Kinetics; Lymphoma, B-Cell; Mice; Mice, SCID; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thionucleotides; Transplantation, Heterologous

2006
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
    BMC cancer, 2006, May-11, Volume: 6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left

2006
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:7

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Synergism; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leupeptins; Membrane Glycoproteins; Middle Aged; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-15, Volume: 12, Issue:10

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Approval; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; United States; United States Food and Drug Administration

2006
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A

2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Blood, 2006, Nov-15, Volume: 108, Issue:10

    Topics: Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydrolases; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Poly(ADP-ribose) Polymerase Inhibitors; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators; Tumor Cells, Cultured

2006
Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.
    Molecular and cellular biochemistry, 2006, Volume: 287, Issue:1-2

    Topics: Boronic Acids; Bortezomib; Caspase 8; Cell Line; Cell Line, Tumor; Humans; I-kappa B Proteins; Liver; Liver Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines

2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Cancer research, 2006, Jun-01, Volume: 66, Issue:11

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Melphalan; Multiple Myeloma; Panobinostat; Pyrazines

2006
Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast.
    Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:6

    Topics: Asthma; Boronic Acids; Bortezomib; Cell Line; Chemokine CCL11; Chemokine CCL26; Chemokines, CC; Drug Synergism; Enzyme Inhibitors; Fibroblasts; Humans; Hypersensitivity; Immunoblotting; Interleukin-4; Leupeptins; Lung; Mitogen-Activated Protein Kinases; NF-kappa B; Pyrazines; Recombinant Proteins; STAT6 Transcription Factor; Tumor Necrosis Factor-alpha

2006
Life-threatening motor neurotoxicity in association with bortezomib.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines

2006
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2006
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Haematologica, 2006, Volume: 91, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2006
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6

    Topics: Antineoplastic Agents; Bone Marrow Neoplasms; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Transplantation, Autologous; Treatment Outcome

2006
Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
    Cancer research, 2006, Jun-15, Volume: 66, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Enzyme Activation; Genes, ras; HCT116 Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Phosphorylation; Protease Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; ras Proteins; Signal Transduction

2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
    Cancer research, 2006, Jun-15, Volume: 66, Issue:12

    Topics: Apoptosis; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Glyoxal; HeLa Cells; Humans; Leucine; Leupeptins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity

2006
Inhibition of bortezomib-induced apoptosis by red blood cell uptake.
    Leukemia, 2006, Volume: 20, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Erythrocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines

2006
Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    American journal of physiology. Gastrointestinal and liver physiology, 2006, Volume: 291, Issue:4

    Topics: Animals; Bile Ducts; Boronic Acids; Bortezomib; Cell Count; Cholestasis; Hepatocytes; Liver Cirrhosis; Macrophage Activation; Macrophages; Mice; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2006
[Recurrent varicella in a woman with mantle cell lymphoma].
    Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chickenpox; Combined Modality Therapy; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Middle Aged; Postoperative Complications; Pyrazines; Recurrence; Transplantation, Autologous

2006
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Breast cancer research and treatment, 2006, Volume: 100, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Female; Humans; Immediate-Early Proteins; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Protease Inhibitors; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines

2006
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:5

    Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines

2006
Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction

2006
Perspective on the current use of bortezomib in multiple myeloma.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines

2006
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
    Leukemia research, 2007, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 5; Female; Humans; Interleukin-4; Interleukin-6; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Platelet Count; Pyrazines; Thrombocytosis; Tumor Necrosis Factor-alpha

2007
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence

2006
The safety and efficacy of bortezomib in relapsed multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate; Treatment Outcome

2006
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Survival Rate; Xenograft Model Antitumor Assays

2007
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome

2006
Enhancing care and managing side effects in patients receiving bortezomib.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Dose-Response Relationship, Drug; Humans; Kinetics; Oncology Nursing; Patient Education as Topic; Platelet Count; Pyrazines; Quality of Life; Treatment Outcome

2006
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    British journal of haematology, 2006, Volume: 134, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Tumor Cells, Cultured

2006
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
    Molecular and cellular biology, 2006, Volume: 26, Issue:15

    Topics: Animals; Biomarkers; Boronic Acids; Bortezomib; Carbonic Anhydrases; Cell Line; Enzyme Activation; Gene Expression Regulation; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; p300-CBP Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Structure, Tertiary; Pyrazines; Recombinant Fusion Proteins; Transcription, Genetic; Vascular Endothelial Growth Factor A

2006
[Molecular-targeted therapy for hormone-refractory prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6

    Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D

2006
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53

2006
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Cancer research, 2006, Jul-15, Volume: 66, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Depsipeptides; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Killer Cells, Natural; Membrane Glycoproteins; Neoplasms; Protease Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2006
Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.
    British journal of haematology, 2006, Volume: 134, Issue:5

    Topics: Blood Transfusion; Boronic Acids; Bortezomib; Castleman Disease; Female; Humans; Interleukin-6; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome

2006
Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Clinical therapeutics, 2006, Volume: 28, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Renal Insufficiency

2006
Severe pulmonary complication after bortezomib treatment for multiple myeloma.
    Blood, 2006, Aug-01, Volume: 108, Issue:3

    Topics: Aged; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Multiple Myeloma; Pyrazines

2006
Proteasome inhibitor drugs on the rise.
    Cancer research, 2006, Aug-15, Volume: 66, Issue:16

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Ubiquitin; United States; United States Food and Drug Administration

2006
Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress.
    Cancer biology & therapy, 2006, Volume: 5, Issue:7

    Topics: Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Humans; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2006
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
    Pharmacotherapy, 2006, Volume: 26, Issue:8

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Lysis Syndrome

2006
Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
    Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biotechnology; Boronic Acids; Bortezomib; Celecoxib; Cyanides; Drug Industry; Etanercept; Guanidines; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; NF-kappa B; Patents as Topic; Protein C; Pyrazines; Pyrazoles; Raloxifene Hydrochloride; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Rituximab; Sialoglycoproteins; Sulfonamides; United States

2006
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    American journal of hematology, 2006, Volume: 81, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction

2006
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Leukemia research, 2007, Volume: 31, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Failure

2007
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles

2006
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Clinical and laboratory haematology, 2006, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunohistochemistry; Liver Diseases; Male; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pyrazines; Tomography, X-Ray Computed

2006
Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system.
    The Journal of endocrinology, 2006, Volume: 190, Issue:2

    Topics: Animals; Base Sequence; Boronic Acids; Bortezomib; Carrier Proteins; Cytoplasm; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrous Cycle; Feedback, Physiological; Female; Gene Expression; Genes, Regulator; Mammary Glands, Animal; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Knockout; Molecular Sequence Data; Ovariectomy; PAX2 Transcription Factor; Progesterone; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Progesterone; Sequence Analysis, DNA; Time Factors; Wnt Proteins; Wnt4 Protein

2006
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
    Biochemical and biophysical research communications, 2006, Oct-06, Volume: 348, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2006
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Journal of the National Cancer Institute, 2006, Aug-16, Volume: 98, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Mice; Mitotic Index; Neovascularization, Pathologic; Neuroblastoma; Protease Inhibitors; Pyrazines; Transplantation, Heterologous; Tumor Stem Cell Assay

2006
[Multiple myeloma cell line U266 apoptosis induced by velcade].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger

2006
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
    The Journal of biological chemistry, 2006, Oct-20, Volume: 281, Issue:42

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; Humans; Mice; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2006
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Humans; Male; Prostatic Neoplasms; Pyrazines; Taxoids; Tumor Cells, Cultured

2006
Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
    European journal of haematology, 2006, Volume: 77, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Male; Pyrazines; Radiography; Remission Induction

2006
Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Leukemia research, 2007, Volume: 31, Issue:8

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasmacytoma; Pyrazines; Treatment Outcome

2007
Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2007, Volume: 292, Issue:1

    Topics: Animals; Blotting, Northern; Boronic Acids; Bortezomib; Burns; Down-Regulation; Glucocorticoids; Hormone Antagonists; Immunoblotting; Insulin-Like Growth Factor I; Leucine; Male; Mifepristone; Muscle Proteins; Muscle, Skeletal; Myocardium; Organ Size; Polyubiquitin; Protein Synthesis Inhibitors; Pyrazines; Rats; Rats, Wistar; RNA, Messenger; SKP Cullin F-Box Protein Ligases; Tripartite Motif Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Wasting Syndrome

2007
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Journal of the National Cancer Institute, 2006, Sep-06, Volume: 98, Issue:17

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Microarray Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; STAT3 Transcription Factor; Transplantation, Heterologous; Up-Regulation

2006
Bortezomib is effective in primary plasma cell leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:8

    Topics: Bone Marrow Examination; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2006
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
    Molecular cancer research : MCR, 2006, Volume: 4, Issue:9

    Topics: Adenosine Triphosphatases; Animals; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle Proteins; Chlorocebus aethiops; COS Cells; Endoplasmic Reticulum; Genes, erbB-2; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering; Tunicamycin; Ubiquitins; Vacuoles; Valosin Containing Protein

2006
[A cure for multiple myeloma?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Pt 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2006
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
    European journal of haematology, 2006, Volume: 77, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2006
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Pyrazines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2006
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2006
[Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:8

    Topics: Antineoplastic Agents; Bence Jones Protein; Biomarkers; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome

2006
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Leukemia research, 2007, Volume: 31, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Chromosome Deletion; Cyclin-Dependent Kinases; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Translocation, Genetic

2007
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Pathology oncology research : POR, 2006, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Mitochondria; Mitochondrial Proteins; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2006
Bortezomib-induced rhabdomyolysis in multiple myeloma.
    Acta haematologica, 2006, Volume: 116, Issue:3

    Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Rhabdomyolysis; Salvage Therapy

2006
Bortezomib-induced skin lesion.
    Acta haematologica, 2006, Volume: 116, Issue:3

    Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Multiple Myeloma; Pyrazines

2006
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Oncogene, 2007, Apr-05, Volume: 26, Issue:16

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Survival; Humans; Multiple Myeloma; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tumor Cells, Cultured

2007
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Cancer research, 2006, Oct-01, Volume: 66, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine

2006
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Leukemia; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2007
Bortezomib dosing in relapsed multiple myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate

2006
Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?
    Dermatology (Basel, Switzerland), 2006, Volume: 213, Issue:3

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Porphyria Cutanea Tarda; Pyrazines

2006
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.
    Leukemia research, 2007, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Dose-Response Relationship, Drug; Enterotoxins; Humans; In Vitro Techniques; Pyrazines; T-Lymphocytes

2007
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:5

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; Glucocorticoids; Histamine H1 Antagonists; Humans; Male; Medical Records; Middle Aged; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Skin; Skin Ulcer

2006
Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
    American journal of physiology. Gastrointestinal and liver physiology, 2007, Volume: 292, Issue:2

    Topics: Animals; Axin Protein; beta Catenin; Boronic Acids; Bortezomib; Casein Kinase 1 epsilon; Cell Nucleus; Citrobacter rodentium; Colon; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; DNA; Enterobacteriaceae Infections; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperplasia; Immunoprecipitation; Intestinal Mucosa; Mice; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Kinase C; Pyrazines; Repressor Proteins; Serine; TCF Transcription Factors; Threonine; Transcription Factor 7-Like 2 Protein

2007
Are the Scots getting a better deal on prescribed drugs than the English?
    BMJ (Clinical research ed.), 2006, Oct-28, Volume: 333, Issue:7574

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Delivery of Health Care; Drug Prescriptions; England; Humans; Multiple Myeloma; Pyrazines; Scotland; State Medicine

2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    The Lancet. Oncology, 2006, Volume: 7, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid

2006
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
    Immunology, 2007, Volume: 120, Issue:1

    Topics: Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Chymases; Cysteine Proteinase Inhibitors; Dendritic Cells; Endocytosis; Humans; Interleukin-12; Lymphocyte Activation; Monocytes; Oligopeptides; Pinocytosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Cell Surface

2007
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis

2007
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:2

    Topics: Anthracyclines; Antimetabolites, Antineoplastic; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cytarabine; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Pyrazines; Tumor Suppressor Protein p53

2007
Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    International journal of cancer, 2007, Feb-01, Volume: 120, Issue:3

    Topics: Adult; Amino Acid Sequence; Animals; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Drug Synergism; Epitopes, T-Lymphocyte; Female; Flow Cytometry; Gene Expression; HLA-A Antigens; HLA-A24 Antigen; Humans; Interferon-gamma; Mice; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Viral; Protease Inhibitors; Pyrazines; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Cytotoxic; Uterine Cervical Neoplasms

2007
New drugs for multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome

2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    British journal of haematology, 2006, Volume: 135, Issue:5

    Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2006
Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?
    Leukemia & lymphoma, 2006, Volume: 47, Issue:11

    Topics: Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, Mantle-Cell; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; Pyrazines; Survivin

2006
Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
    Blood, 2007, Mar-15, Volume: 109, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Physiologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sensitivity and Specificity; Up-Regulation

2007
Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
    Acta haematologica, 2006, Volume: 116, Issue:4

    Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Salvage Therapy; Treatment Outcome

2006
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Colonic Neoplasms; Drug Administration Routes; Drug Synergism; Female; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2006
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
    Annals of hematology, 2007, Volume: 86, Issue:4

    Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome

2007
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
    American journal of hematology, 2007, Volume: 82, Issue:5

    Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation

2007
Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Leukemia research, 2007, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Pyrazines; Respiratory Insufficiency; Vasculitis

2007
Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:11

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; I-kappa B Kinase; I-kappa B Proteins; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Sulfones; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase

2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
    Blood, 2007, Mar-15, Volume: 109, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies

2007
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Humans; NF-kappa B; Pyrazines; Receptor, ErbB-2; Trastuzumab

2006
EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.
    Journal of the American Society of Nephrology : JASN, 2007, Volume: 18, Issue:1

    Topics: Animals; Apoptosis; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cells, Cultured; ErbB Receptors; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Quinazolines; Rats; RNA Interference

2007
Management of toxicities associated with bortezomib.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:12

    Topics: Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome

2006
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Zhonghua yi xue za zhi, 2006, Sep-12, Volume: 86, Issue:34

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2006
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Blood, 2007, Mar-15, Volume: 109, Issue:6

    Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Resveratrol; STAT3 Transcription Factor; Stilbenes; Syndecan-1; Thalidomide; Tumor Cells, Cultured

2007
An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma.
    Leukemia, 2007, Volume: 21, Issue:1

    Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Humans; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines

2007
Novel agents for multiple myeloma treatment.
    Current pharmaceutical biotechnology, 2006, Volume: 7, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2006
Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
    The Journal of eukaryotic microbiology, 2006, Volume: 53 Suppl 1

    Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Line; Coumarins; Genes, Fungal; HIV Protease Inhibitors; Humans; Lopinavir; Models, Animal; Oligopeptides; Pneumocystis carinii; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidinones; Rats

2006
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2006
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Animals; Antineoplastic Agents; Binding, Competitive; Boronic Acids; Bortezomib; Drug Stability; Female; HeLa Cells; HT29 Cells; Humans; Lactones; Mice; Mice, Nude; Mice, SCID; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays

2006
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.
    Nature medicine, 2007, Volume: 13, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; CD4 Antigens; CD8 Antigens; Cell Line; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Gene Expression Profiling; Green Fluorescent Proteins; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Experimental; Leukemia, T-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Confocal; Mutation; NF-kappa B; Pyrazines; Receptor, Notch1; Signal Transduction; Survival Analysis

2007
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    British journal of haematology, 2007, Volume: 136, Issue:3

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2007
[Follicular keratosis and multiple myeloma].
    Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Keratolytic Agents; Keratosis; Middle Aged; Multiple Myeloma; Pyrazines; Skin

2006
Quantitative sensory findings in patients with bortezomib-induced pain.
    The journal of pain, 2007, Volume: 8, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cold Temperature; Female; Hot Temperature; Humans; Lymphoma, B-Cell; Male; Middle Aged; Multiple Myeloma; Pain; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrazines; Sensation; Sensation Disorders; Thermosensing; Touch

2007
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
    Blood, 2007, May-01, Volume: 109, Issue:9

    Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hodgkin Disease; Humans; Jurkat Cells; Neoplasm Proteins; NF-kappa B; Pyrazines; Reed-Sternberg Cells; X-Linked Inhibitor of Apoptosis Protein

2007
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h
    International journal of hematology, 2006, Volume: 84, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Approval; Female; Hematology; Humans; Japan; Lung Diseases; Lung Injury; Male; Multiple Myeloma; Pyrazines; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires

2006
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:6

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Salvage Therapy

2006
WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Jan-16, Volume: 104, Issue:3

    Topics: Actins; Animals; Arginine; Boronic Acids; Bortezomib; Calpain; Carrier Proteins; Cytoskeletal Proteins; Enzyme Inhibitors; Humans; Interleukin-2; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Lymphocytes; Mice; Mice, Knockout; Molecular Chaperones; Mutation, Missense; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Pyrazines; Wiskott-Aldrich Syndrome; Wiskott-Aldrich Syndrome Protein

2007
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
    Experimental neurology, 2007, Volume: 204, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Female; Ganglia, Spinal; Microscopy, Electron; Neural Conduction; Neurons, Afferent; Neurotoxins; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Tail

2007
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
    British journal of haematology, 2007, Volume: 136, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Colony-Forming Units Assay; Dendritic Cells; Flow Cytometry; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2007
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation.
    Cancer biology & therapy, 2007, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Head and Neck Neoplasms; Humans; Pyrazines; Radiation Dosage; Radiation-Sensitizing Agents

2007
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Blood, 2007, May-15, Volume: 109, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Mantle-Cell; Molecular Mimicry; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Peptide Fragments; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured

2007
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Hematology; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires

2006
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Adherens Junctions; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Desmoglein 2; Desmoplakins; Desmosomal Cadherins; Drug Synergism; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Pyrazines; Tongue Neoplasms

2007
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
    Cancer gene therapy, 2007, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured

2007
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays

2007
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines

2007
Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Acta haematologica, 2007, Volume: 117, Issue:4

    Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enterocolitis, Pseudomembranous; Female; Humans; Magnetic Resonance Imaging; Metronidazole; Multiple Myeloma; Pyrazines

2007
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Humans; Leupeptins; Membrane Proteins; Mitochondria; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand

2007
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
    Leukemia, 2007, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; G2 Phase; Humans; Lymphoma, Large B-Cell, Diffuse; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2007
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes

2007
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:6

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Autoradiography; Boronic Acids; Bortezomib; Carbon Radioisotopes; Chromatography, Liquid; Drug Administration Schedule; Injections, Intravenous; Male; Protease Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Scintillation Counting; Tandem Mass Spectrometry; Tissue Distribution

2007
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines

2007
Bortezomib-associated rash: a new recognizable and avoidable side-effect.
    The British journal of dermatology, 2007, Volume: 156, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2007
Medical management update: multiple myeloma.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:5

    Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Care for Chronically Ill; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Jaw Diseases; Jaw Neoplasms; Multiple Myeloma; Oral Hemorrhage; Osteonecrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide

2007
Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood.
    Analytical chemistry, 2007, Feb-15, Volume: 79, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Haplorhini; Mice; Molecular Structure; Pyrazines; Rats; Time Factors

2007
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
    Blood, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; Gamma Rays; HSP90 Heat-Shock Proteins; Humans; Interferon-gamma; Lactams, Macrocyclic; Leukocytes, Mononuclear; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines

2007
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Leukemia, 2007, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazines; Recurrence; Reproducibility of Results; Thalidomide

2007
Community experience with bortezomib in patients with multiple myeloma.
    American journal of hematology, 2007, Volume: 82, Issue:7

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Community Medicine; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate

2007
Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    American journal of hematology, 2007, Volume: 82, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Middle Aged; Multiple Myeloma; Pulmonary Fibrosis; Pyrazines; Recurrence; Respiratory Insufficiency; Steroids; Treatment Failure

2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation

2007
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; E1A-Associated p300 Protein; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; Male; Prostatic Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Immunoglobulin G; Immunoglobulin mu-Chains; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor AP-1

2007
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
    Cancer biology & therapy, 2007, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Ellipticines; Glioblastoma; Humans; Leupeptins; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; S-Phase Kinase-Associated Proteins; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases

2007
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous

2007
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Fatal Outcome; Humans; Male; Multiple Myeloma; Pyrazines; Respiratory Distress Syndrome

2007
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand

2007
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Immunohistochemistry; Proteasome Inhibitors; Pyrazines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms; TNF-Related Apoptosis-Inducing Ligand

2007
NICE: friend and foe.
    Nature clinical practice. Oncology, 2007, Volume: 4, Issue:3

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Government Agencies; Multiple Myeloma; Public Opinion; Public Policy; Pyrazines; Quality-Adjusted Life Years; United Kingdom

2007
Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.
    Neuroscience research, 2007, Volume: 58, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Boronic Acids; Bortezomib; Brain Edema; Cerebral Cortex; Cerebral Hemorrhage; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Gliosis; Inflammation Mediators; Male; Microglia; Neuroprotective Agents; Neutrophils; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Treatment Outcome

2007
Virus-associated tumor imaging by induction of viral gene expression.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-01, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; Boronic Acids; Bortezomib; Burkitt Lymphoma; Diagnostic Imaging; Gene Expression; Gene Transfer Techniques; Genes, Viral; Herpesvirus 4, Human; Humans; Immunoblotting; Mice; Neoplasms, Experimental; Oncogenic Viruses; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Kinase

2007
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Chemokines; Chemotaxis; DNA Replication; Female; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Pyrazines; Receptors, Chemokine; Recombinant Fusion Proteins; T-Lymphocytes; Tumor Stem Cell Assay

2007
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
    British journal of haematology, 2007, Volume: 136, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Pyrazines

2007
[Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2006, Volume: 27, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2006
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Human immunology, 2007, Volume: 68, Issue:3

    Topics: Adult; Antigen Presentation; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Dendritic Cells; Electrophoretic Mobility Shift Assay; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Interleukin-4; Lymphocyte Culture Test, Mixed; Monocytes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2007
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Fas Ligand Protein; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat

2007
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Cisplatin; Cytochromes c; Humans; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Up-Regulation

2007
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:3

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Nucleus; Colonic Neoplasms; Cysteine Proteinase Inhibitors; Cytochromes c; Humans; Leupeptins; Mice; Mitochondria; Proteasome Inhibitors; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2007
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Cancer research, 2007, Mar-15, Volume: 67, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Activation; Humans; Lymphoma, B-Cell; Mitosis; NF-kappa B; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Suppressor Protein p53

2007
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
    Blood, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; CCAAT-Binding Factor; Cell Differentiation; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Humans; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Protease Inhibitors; Pyrazines

2007
TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    International journal of cancer, 2007, Jul-15, Volume: 121, Issue:2

    Topics: Alternative Splicing; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; DNA-Binding Proteins; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum; Female; Gene Expression; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Fluorescence; Neoplasms, Experimental; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Protein Subunits; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factor RelA; Transcription Factors; Tumor Necrosis Factor-alpha; X-Box Binding Protein 1

2007
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
    Blood, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Mice; NF-kappa B; Osteosclerosis; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Survival Rate; Thrombopoietin

2007
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.
    Cancer biology & therapy, 2007, Volume: 6, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leupeptins; Male; Membrane Proteins; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Cells, Cultured

2007
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
    Cancer biology & therapy, 2007, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured

2007
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
    Molecular pharmacology, 2007, Volume: 71, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Therapy, Combination; Humans; Oxidation-Reduction; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Transcription, Genetic

2007
Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunoglobulin A; Immunoglobulin Light Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Pyrazines; Retreatment; Transplantation Chimera; Transplantation, Homologous

2007
Multiple myeloma therapies.
    Nature reviews. Drug discovery, 2007, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide

2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mice; Mice, Inbred Strains; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2008
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
    Breast cancer research and treatment, 2008, Volume: 107, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feedback, Physiological; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Temperature; Tetrazolium Salts; Thiazoles

2008
Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Skull; Tomography, X-Ray Computed; Treatment Outcome

2007
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Cancer, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Survival Rate

2007
Immune-modulatory effects of bortezomib in GVHD.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Graft vs Host Disease; Humans; Immune System; Inflammation; Multiple Myeloma; NF-kappa B; Plasmacytoma; Pyrazines; Spleen; Stem Cell Transplantation; T-Lymphocytes; Transplantation, Homologous

2007
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chronic Disease; gamma-Glutamyltransferase; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction

2007
[Induction of apoptosis in HL-60 cells by bortezomib alone or in combination with harringtonine in vitro].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; HL-60 Cells; Humans; Pyrazines

2007
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
    Cell cycle (Georgetown, Tex.), 2007, May-15, Volume: 6, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Dipeptides; Dystrophin; Dystrophin-Associated Proteins; Male; Mice; Mice, Inbred mdx; Microscopy, Fluorescence; Muscle, Skeletal; Muscular Dystrophy, Duchenne; NF-kappa B; Protease Inhibitors; Pyrazines

2007
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Leukemia, 2007, Volume: 21, Issue:7

    Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured

2007
Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
    Leukemia, 2007, Volume: 21, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Cytokines; Dendritic Cells; Humans; Immunity; Killer Cells, Natural; Neoplasms; Protease Inhibitors; Pyrazines

2007
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A

2007
Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Acta haematologica, 2007, Volume: 118, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stevens-Johnson Syndrome; Vasculitis, Leukocytoclastic, Cutaneous

2007
Proteasome inhibitors.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:4 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Contraindications; Female; Humans; NF-kappa B; Peptide Hydrolases; Protease Inhibitors; Pyrazines

2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Cancer research, 2007, May-15, Volume: 67, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Survivin; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2007
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Cell death and differentiation, 2007, Volume: 14, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides

2007
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Journal of cellular biochemistry, 2008, Jan-01, Volume: 103, Issue:1

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Glycoproteins; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Polyubiquitin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Tumor Suppressor Protein p53; Ubiquitination

2008
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genes, Intracisternal A-Particle; Glutamates; Guanine; Humans; Mesothelioma; Neoplasm Proteins; Pemetrexed; Pleural Neoplasms; Proteasome Inhibitors; Pyrazines; Survival Analysis

2008
Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:5

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Plasma Cell; Male; Pyrazines

2007
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Cell death and differentiation, 2007, Volume: 14, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Gossypol; Humans; Melanoma, Experimental; Mice; Neoplasm Transplantation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transplantation, Heterologous

2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; I-kappa B Kinase; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Pyrimidines

2007
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Female; Humans; Immunotherapy; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2007
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Cancer research, 2007, Jun-01, Volume: 67, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Membrane Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; RNA, Small Interfering; Up-Regulation

2007
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
    American journal of hematology, 2007, Volume: 82, Issue:9

    Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials as Topic; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Predictive Value of Tests; Pyrazines; Time Factors

2007
Drugs "refund" scheme proposed for England and Wales.
    BMJ (Clinical research ed.), 2007, Jun-09, Volume: 334, Issue:7605

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; England; Humans; Pyrazines; Reimbursement Mechanisms; State Medicine; Treatment Failure; Wales

2007
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intestinal Pseudo-Obstruction; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Radiography

2007
Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Plasmacytoma; Pyrazines; Stomach Neoplasms

2008
Unexpected cardiotoxicity in haematological bortezomib treated patients.
    British journal of haematology, 2007, Volume: 138, Issue:3

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines

2007
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5

    Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome

2007
Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cavernous Sinus; Fatal Outcome; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Sensitivity and Specificity; Treatment Outcome

2007
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
    Leukemia, 2007, Volume: 21, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines

2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Multiple Myeloma; Pyrazines

2007
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
    Blood, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Killer Cells, Natural; Leukemia, T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2007
Bortezomib inhibits human osteoclastogenesis.
    Leukemia, 2007, Volume: 21, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A

2007
Allografting or autografting for myeloma.
    The New England journal of medicine, 2007, Jun-21, Volume: 356, Issue:25

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Survival Rate; Transplantation, Autologous; Transplantation, Homologous

2007
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    British journal of haematology, 2007, Volume: 138, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays

2007
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Blood, 2007, Nov-01, Volume: 110, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Cells, Cultured; Ubiquitin

2007
Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
    Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:2

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Models, Biological; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53

2007
Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
    Oncology reports, 2007, Volume: 18, Issue:2

    Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; HSP72 Heat-Shock Proteins; Humans; Immunoprecipitation; Liver Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Suppressor Protein p53

2007
Bortezomib and lenalidomide effective in myeloma.
    Cancer biology & therapy, 2007, Volume: 6, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2007
Bortezomib plus doxorubicin combination slows progression of multiple myeloma.
    Cancer biology & therapy, 2007, Volume: 6, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Doxorubicin; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome

2007
A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
    Journal of the neurological sciences, 2007, Dec-15, Volume: 263, Issue:1-2

    Topics: Aged; Ataxia; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Male; Myelin Sheath; Neural Conduction; Protease Inhibitors; Pyrazines; Reaction Time

2007
Looking beyond the headlines.
    The Lancet. Oncology, 2007, Volume: 8, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Insurance Benefits; Multiple Myeloma; Pyrazines

2007
Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Treatment Outcome

2007
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
    Cancer research, 2007, Jul-01, Volume: 67, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chymotrypsin; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley

2007
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2007
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Journal of virology, 2007, Volume: 81, Issue:18

    Topics: Animals; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Transformation, Viral; Herpesvirus 4, Human; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor RelA; Ubiquitin-Protein Ligases; Viral Matrix Proteins; Virus Latency; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays

2007
PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
    Leukemia research, 2008, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Genes, Wilms Tumor; Humans; Leukemia, Megakaryoblastic, Acute; NF-kappaB-Inducing Kinase; Primary Myelofibrosis; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines

2008
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
    Swiss medical weekly, 2007, Jun-02, Volume: 137, Issue:21-22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome

2007
Drug pricing: No cure, no cost.
    BMJ (Clinical research ed.), 2007, Jul-21, Volume: 335, Issue:7611

    Topics: Antineoplastic Agents; Behavioral Research; Boronic Acids; Bortezomib; Drug Costs; Drug Industry; Humans; Interprofessional Relations; Marketing; Multiple Myeloma; Pyrazines; Remission Induction; State Medicine; Treatment Failure; United Kingdom

2007
Severe intestinal vasculitis in a patient under treatment with bortezomib.
    Annals of hematology, 2007, Volume: 86, Issue:12

    Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Gastrointestinal Hemorrhage; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Middle Aged; Multiple Myeloma; Postoperative Complications; Pyrazines; Salvage Therapy; Vasculitis, Leukocytoclastic, Cutaneous

2007
Choline induces transcriptional repression and proteasomal degradation of the malarial phosphoethanolamine methyltransferase.
    Eukaryotic cell, 2007, Volume: 6, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Choline; Cytidine Diphosphate Choline; Gene Expression Regulation; Methyltransferases; Plasmodium falciparum; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Protozoan Proteins; Pyrazines; Transcription, Genetic

2007
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
    Haematologica, 2007, Volume: 92, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome

2007
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Oncogene, 2008, Jan-31, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Up-Regulation

2008
TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade.
    FEBS letters, 2007, Aug-07, Volume: 581, Issue:20

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; Early Growth Response Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Harringtonines; Homoharringtonine; Humans; K562 Cells; Kruppel-Like Transcription Factors; Melanoma, Experimental; Mice; Mitochondria; Pyrazines; Transcription Factors

2007
Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gene Expression; Gene Expression Profiling; Hodgkin Disease; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Pyrazines; Reed-Sternberg Cells; Reverse Transcriptase Polymerase Chain Reaction; Tissue Array Analysis; TNF-Related Apoptosis-Inducing Ligand

2008
Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryptogenic Organizing Pneumonia; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Myeloma; Pyrazines; Tomography, X-Ray Computed

2007
[HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:7

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Electrophoresis; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Time Factors

2007
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Cancer research, 2007, Aug-01, Volume: 67, Issue:15

    Topics: Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Cycle Proteins; Cells, Cultured; DNA Damage; DNA Repair; DNA-Binding Proteins; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Female; Flow Cytometry; Gamma Rays; HeLa Cells; Humans; Leupeptins; Microscopy, Fluorescence; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Rad51 Recombinase; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin

2007
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
    Surgery, 2007, Volume: 142, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Pyrazines; Soft Tissue Neoplasms; Subcutaneous Tissue; Xenograft Model Antitumor Assays

2007
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids

2008
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    The Journal of surgical research, 2008, Volume: 145, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53

2008
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    World journal of gastroenterology, 2007, Sep-07, Volume: 13, Issue:33

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib

2007
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
    Leukemia, 2008, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Hydroxamic Acids; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Chronic; Megakaryocytes; Neoplasm Proteins; Pyrazines; Vorinostat; WT1 Proteins

2008
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    British journal of haematology, 2007, Volume: 138, Issue:6

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Models, Animal; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylcholine; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; RNA, Small Interfering; Survivin; Transplantation, Heterologous

2007
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
    British journal of haematology, 2007, Volume: 138, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytological Techniques; Diploidy; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Karyotyping; Mice; Mice, SCID; Models, Animal; Multiple Myeloma; Pyrazines

2007
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured

2007
Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Anti-cancer drugs, 2007, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Stomach Neoplasms

2007
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2007
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
    Haematologica, 2007, Volume: 92, Issue:9

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2007
The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
    International journal of oncology, 2007, Volume: 31, Issue:4

    Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Histone Deacetylases; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Ewing; Transplantation, Heterologous; Tumor Cells, Cultured

2007
Advances in the treatment of MDS, multiple myeloma, and CLL.
    ONS connect, 2007, Volume: 22, Issue:8 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide

2007
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
    ONS connect, 2007, Volume: 22, Issue:8 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide

2007
Multiple myeloma patient care: treatment options and nursing considerations.
    ONS connect, 2007, Volume: 22, Issue:8 Suppl

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide

2007
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Cancer gene therapy, 2008, Volume: 15, Issue:1

    Topics: Adenoviridae; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Female; Genetic Therapy; Humans; Interleukins; Lung Neoplasms; Lysosomes; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin; Ubiquitination

2008
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Lysis Syndrome

2008
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic

2007
Gene mutation revelation points to new target for myeloma treatment, studies say.
    Journal of the National Cancer Institute, 2007, Sep-19, Volume: 99, Issue:18

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; I-kappa B Kinase; Multiple Myeloma; Mutation; NF-kappa B; Pyrazines; Signal Transduction; TNF Receptor-Associated Factor 3

2007
Deafness associated with the use of Bortezomib in multiple myeloma.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Hearing Loss, Sensorineural; Humans; Immunoglobulin A; Multiple Myeloma; Pyrazines; Risk Factors

2008
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 9; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Phosphorylation; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2007
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Neutrophil Infiltration; Pyrazines

2007
Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Electrophoretic Mobility Shift Assay; Gene Expression; Gene Expression Profiling; Heme Oxygenase-1; Humans; I-kappa B Proteins; Leukemia, T-Cell; Mice; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protoporphyrins; Pyrazines; Rats; Reverse Transcriptase Polymerase Chain Reaction

2007
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
    British journal of haematology, 2007, Volume: 139, Issue:2

    Topics: Aldehyde Dehydrogenase; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Cells, Cultured; Fas-Associated Death Domain Protein; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Stem Cells; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2007
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Investigative ophthalmology & visual science, 2007, Volume: 48, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Flow Cytometry; Formazans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Indicators and Reagents; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; Retinal Neoplasms; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Tumor Cells, Cultured; Up-Regulation

2007
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Leukemia, 2008, Volume: 22, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cyclophosphamide; Drug Synergism; Immunophenotyping; In Vitro Techniques; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Poly(ADP-ribose) Polymerases; Pyrazines; Rituximab; Survival Rate; Transplantation, Heterologous

2008
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Male; Mesothelioma; Mice; Mice, Nude; NF-kappa B; Nitriles; Proteasome Inhibitors; Pyrazines; Sulfones; Tumor Necrosis Factor-alpha

2007
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    British journal of haematology, 2007, Volume: 139, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; Osteogenesis; Oxidative Stress; Proto-Oncogene Proteins; Pyrazines; Reactive Oxygen Species; Sulfonamides

2007
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
    British journal of haematology, 2007, Volume: 139, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Dose-Response Relationship, Drug; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred ICR; Organ Culture Techniques; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Skull

2007
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
    Thrombosis research, 2008, Volume: 121, Issue:4

    Topics: Adenosine Triphosphate; Blood Platelets; Boronic Acids; Bortezomib; Humans; Nitric Oxide; Platelet Aggregation; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2008
Satisfaction guaranteed--"payment by results" for biologic agents.
    The New England journal of medicine, 2007, Oct-18, Volume: 357, Issue:16

    Topics: Biological Products; Boronic Acids; Bortezomib; Drug Approval; Drug Costs; Drug Industry; Humans; Pyrazines; Quality Assurance, Health Care; Reimbursement Mechanisms; State Medicine; United Kingdom

2007
Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
    Cancer research, 2007, Oct-15, Volume: 67, Issue:20

    Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Boronic Acids; Bortezomib; Chondrocytes; Growth Disorders; Humans; Male; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Tumor Suppressor Protein p53; Ubiquitin; Up-Regulation

2007
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
    Blood, 2008, Feb-01, Volume: 111, Issue:3

    Topics: Boronic Acids; Bortezomib; Cell Membrane; Cell Survival; Down-Regulation; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, KIR; Sensitivity and Specificity; Tumor Cells, Cultured

2008
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Annals of hematology, 2008, Volume: 87, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Pyrazines; Radiography; Remission Induction; Spinal Neoplasms; Thalidomide; Transplantation, Autologous

2008
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.
    BMC clinical pharmacology, 2007, Oct-23, Volume: 7

    Topics: Animals; Antimalarials; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance; Erythrocytes; Inhibitory Concentration 50; Life Cycle Stages; Oligopeptides; Plasmodium falciparum; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2007
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:10

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays

2007
Proteasome inhibition therapies in childhood cancer.
    Leukemia, 2008, Volume: 22, Issue:4

    Topics: Animals; Bone Development; Boronic Acids; Bortezomib; Child; Chondrocytes; Humans; Mice; Neoplasms; Protease Inhibitors; Pyrazines

2008
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; DNA Fragmentation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Immunotherapy; Interleukin-6; Multiple Myeloma; Pyrazines; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Syndecan-1

2007
Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21

    Topics: Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Humans; Immunotherapy; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2007
Use of intrapleural bortezomib in myelomatous pleural effusion.
    British journal of haematology, 2007, Volume: 139, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pleural Effusion; Pyrazines

2007
Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
    Leukemia & lymphoma, 2007, Volume: 48, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cryopreservation; Dactinomycin; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Leukemia, Prolymphocytic, T-Cell; Pyrazines; Time Factors; Tumor Cells, Cultured

2007
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
    Acta haematologica, 2007, Volume: 118, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid

2007
Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
    Leukemia research, 2008, Volume: 32, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Plasmacytoma; Pyrazines; Radiotherapy Dosage

2008
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    European journal of haematology, 2008, Volume: 80, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Treatment Outcome; Vorinostat

2008
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
    Blood, 2008, Feb-01, Volume: 111, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays

2008
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
    Molecular cancer, 2007, Nov-17, Volume: 6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line, Tumor; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Sensitivity and Specificity

2007
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:11

    Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured

2007
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Humans; Kidney; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2007
Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Neurotoxicity Syndromes; Pain; Pyrazines

2007
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-04, Volume: 104, Issue:49

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles

2007
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-04, Volume: 104, Issue:49

    Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Drug Design; E2F1 Transcription Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanocytes; Melanoma; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Interference; RNA, Messenger; Skin Neoplasms; Transcriptional Activation; Tumor Suppressor Protein p53

2007
Fold up or perish: unfolded protein response and chemotherapy.
    Cell death and differentiation, 2008, Volume: 15, Issue:2

    Topics: Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Endoplasmic Reticulum; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines

2008
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Blood, 2008, Mar-01, Volume: 111, Issue:5

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays

2008
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
    Biochemical pharmacology, 2008, Feb-15, Volume: 75, Issue:4

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Isoquinolines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Topoisomerase II Inhibitors

2008
What is the correct philosophy for the treatment of multiple myeloma?
    Leukemia & lymphoma, 2007, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines

2007
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy

2007
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
    The Prostate, 2008, Feb-01, Volume: 68, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Cell Survival; Cells, Cultured; Epithelial Cells; Fas Ligand Protein; Half-Life; Humans; Male; Prostate; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand

2008
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
    Leukemia research, 2008, Volume: 32, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Immunophenotyping; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2008
Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
    Leukemia research, 2008, Volume: 32, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines

2008
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
    Blood, 2008, Feb-15, Volume: 111, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Protein Kinases; Pyrazines; Transcription, Genetic

2008
A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.
    Cancer research, 2007, Dec-15, Volume: 67, Issue:24

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Disease Models, Animal; Genes, Reporter; HTLV-I Infections; Humans; Jurkat Cells; Luciferases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Protease Inhibitors; Pyrazines

2007
Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
    Plastic and reconstructive surgery, 2007, Volume: 120, Issue:7

    Topics: Animals; Blood Vessels; Boronic Acids; Bortezomib; Drug Evaluation, Preclinical; Intercellular Adhesion Molecule-1; Intracellular Signaling Peptides and Proteins; Laser-Doppler Flowmetry; Male; Mice; Microscopy, Video; Muscle, Skeletal; NF-kappa B p50 Subunit; Nitric Oxide Synthase Type II; Protease Inhibitors; Proteasome Inhibitors; Proteins; Pyrazines; Random Allocation; Reperfusion Injury; Surgical Flaps; Tyrosine

2007
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Journal of immunology (Baltimore, Md. : 1950), 2008, Jan-01, Volume: 180, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytotoxicity, Immunologic; Fas Ligand Protein; Immunotherapy; Killer Cells, Natural; Leukemia; Mice; Mice, Inbred Strains; Neoplasms; Perforin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand

2008
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.
    Blood, 2008, Mar-01, Volume: 111, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Polyubiquitin; Protein Processing, Post-Translational; Pyrazines; Thermodynamics; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Ubiquitination

2008
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Haematologica, 2008, Volume: 93, Issue:1

    Topics: Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Middle Aged; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines

2008
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
    Cancer research, 2008, Jan-01, Volume: 68, Issue:1

    Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay

2008
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.
    Blood, 2008, Mar-15, Volume: 111, Issue:6

    Topics: Adaptation, Biological; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line; DNA-Binding Proteins; Humans; Hypoxia-Inducible Factor 1; Mixed Function Oxygenases; Neoplasms; p300-CBP Transcription Factors; Pyrazines; Repressor Proteins; Trans-Activators; Transcription Factors; Transcription, Genetic

2008
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
    Anti-cancer drugs, 2008, Volume: 19, Issue:2

    Topics: Antioxidants; Antipyrine; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Butylated Hydroxyanisole; Caspase 3; Caspase 9; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Edaravone; Endometrial Neoplasms; Ergothioneine; Female; Humans; Leupeptins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Ubiquitin; Vitamin E; Vitamins

2008
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cytokine, 2008, Volume: 41, Issue:3

    Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide

2008
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
    Cancer, 2008, Feb-01, Volume: 112, Issue:3

    Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines

2008
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
    Blood, 2008, Jan-15, Volume: 111, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Neoplasm Proteins; Predictive Value of Tests; Pyrazines; Risk Factors; Time Factors

2008
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
    International journal of cancer, 2008, May-01, Volume: 122, Issue:9

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Colorimetry; Cyclin D3; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Estradiol; Estrogen Receptor Modulators; Flow Cytometry; G1 Phase; Humans; Immunoprecipitation; Mitochondria; Multiple Myeloma; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Selective Estrogen Receptor Modulators; Signal Transduction; Tumor Cells, Cultured

2008
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Cell death and differentiation, 2008, Volume: 15, Issue:3

    Topics: Animals; Apoptosis; B-Lymphocyte Subsets; Bone Marrow Cells; Boronic Acids; Bortezomib; Cells, Cultured; Female; Lymphocyte Count; Lymphoid Tissue; Mice; Mice, Inbred BALB C; NF-kappa B; Precursor Cells, B-Lymphoid; Precursor Cells, T-Lymphoid; Protease Inhibitors; Proteasome Inhibitors; Protein Folding; Pyrazines; T-Lymphocyte Subsets; Thymus Gland

2008
Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
    Leukemia research, 2008, Volume: 32, Issue:8

    Topics: Boronic Acids; Bortezomib; Colony-Forming Units Assay; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Primary Myelofibrosis; Pyrazines; Tissue Culture Techniques

2008
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:3

    Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Catecholamines; Chymotrypsin; Coronary Vessels; Death, Sudden, Cardiac; Dogs; Electrocardiography; Electrophysiology; G-Protein-Coupled Receptor Kinase 3; Heart Ventricles; HSP72 Heat-Shock Proteins; Ligation; Male; Myocardial Infarction; Myocardial Ischemia; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tachycardia; Trypsin

2008
Concurrent radiation therapy and bortezomib in myeloma patient.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 86, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiotherapy Dosage

2008
Revealing targeted therapy for human cancer by gene module maps.
    Cancer research, 2008, Jan-15, Volume: 68, Issue:2

    Topics: Algorithms; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Chromosome Mapping; Electronic Data Processing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Targeting; Genes, Mitochondrial; Genetic Therapy; Humans; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Wounds and Injuries

2008
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Jan-29, Volume: 105, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cross-Priming; Dendritic Cells; Disease Progression; Histocompatibility Antigens Class I; Humans; Isoantibodies; Ligands; Multiple Myeloma; Prognosis; Pyrazines; Tumor Cells, Cultured

2008
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
    The British journal of dermatology, 2008, Volume: 158, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Female; Humans; Male; Melanoma; Protease Inhibitors; Pyrazines; Skin Neoplasms; Treatment Outcome

2008
Bortezomib-induced skin eruption.
    Dermatology (Basel, Switzerland), 2008, Volume: 216, Issue:2

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin

2008
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
    Immunology, 2008, Volume: 124, Issue:2

    Topics: Acetylcysteine; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Immunologic; Humans; Immunosuppressive Agents; Lymphocyte Activation; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translocation, Genetic; Tumor Suppressor Protein p53

2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
    The Journal of clinical investigation, 2008, Volume: 118, Issue:2

    Topics: Animals; Bone Regeneration; Boronic Acids; Bortezomib; Cell Differentiation; Female; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Osteoblasts; Protease Inhibitors; Pyrazines

2008
Bone building with bortezomib.
    The Journal of clinical investigation, 2008, Volume: 118, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines

2008
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    European journal of haematology, 2008, Volume: 80, Issue:5

    Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Caspases; Cell Line, Transformed; Cell Proliferation; Enzyme Activation; Herpesvirus 4, Human; Humans; Lymphocytes; Lymphoproliferative Disorders; Nitriles; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines

2008
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-15, Volume: 14, Issue:2

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Sulfonamides

2008
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand

2008
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
    Blood, 2008, Apr-01, Volume: 111, Issue:7

    Topics: Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; I-kappa B Proteins; Interferon Regulatory Factors; Lymphoma, T-Cell; Microdissection; Neoplasm Staging; NF-KappaB Inhibitor alpha; Positive Regulatory Domain I-Binding Factor 1; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; Survival Rate; Transcription Factors

2008
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Cancer research, 2008, Feb-01, Volume: 68, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Pyrazines; Pyrazoles; Sulfonamides; Transfection; Xenograft Model Antitumor Assays

2008
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
    Haematologica, 2008, Volume: 93, Issue:2

    Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Male; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide

2008
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation.
    European journal of immunology, 2008, Volume: 38, Issue:3

    Topics: Animals; Antibody Formation; Antibody-Producing Cells; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Differentiation; Immunoglobulin M; Immunoglobulin mu-Chains; Lipopolysaccharides; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Ovalbumin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Spleen

2008
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
    Onkologie, 2008, Volume: 31, Issue:1-2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin

2008
Persistent supravenous eruption induced by intravenous bortezomib therapy.
    The British journal of dermatology, 2008, Volume: 158, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Infusions, Intravenous; Male; Middle Aged; Pyrazines; Vascular Diseases; Veins

2008
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2008
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Receptor, TIE-2; Salvage Therapy; Treatment Outcome

2008
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured

2008
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Humans; Immunoglobulins; Lymphoma, B-Cell; Membrane Microdomains; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured

2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
    Blood, 2008, May-01, Volume: 111, Issue:9

    Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Death; Cell Movement; Cells, Cultured; Drug Delivery Systems; Drug Synergism; Humans; Lactones; Proteasome Inhibitors; Pyrazines; Pyrroles; Waldenstrom Macroglobulinemia

2008
Bortezomib-induced reversible posterior leucoencephalopathy syndrome.
    British journal of haematology, 2008, Volume: 141, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Magnetic Resonance Imaging; Male; Posterior Leukoencephalopathy Syndrome; Pyrazines

2008
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
    Blood, 2008, May-15, Volume: 111, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; NF-kappa B; Phosphorylcholine; Pyrazines; Signal Transduction; Waldenstrom Macroglobulinemia

2008
Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.
    Acta haematologica, 2008, Volume: 119, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells

2008
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
    British journal of haematology, 2008, Volume: 141, Issue:4

    Topics: Acetylcysteine; Activating Transcription Factor 4; Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glutathione; Homeostasis; Humans; Multiple Myeloma; Neoplasm Proteins; Oxidation-Reduction; Protease Inhibitors; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured

2008
Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
    British journal of haematology, 2008, Volume: 141, Issue:4

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, AIDS-Related; Lymphoma, Primary Effusion; Male; Middle Aged; Pyrazines

2008
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rhabdomyosarcoma; Transplantation, Heterologous; Tumor Cells, Cultured

2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia

2008
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine

2008
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine

2008
Multiple myeloma with testicular involvement.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome

2008
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
    Pigment cell & melanoma research, 2008, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines

2008
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Oncology reports, 2008, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Humans; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms; Taxoids; Tumor Suppressor Protein p53

2008
Treatment for elderly patients with multiple myeloma.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide

2008
[Effect of Velcade on the gene expression profiles of K562 cells: study of its molecular mechanism].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chymases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Oligonucleotide Array Sequence Analysis; Pyrazines

2008
[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].
    Revista clinica espanola, 2008, Volume: 208, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence

2008
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Journal of cellular physiology, 2008, Volume: 216, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction

2008
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.
    PloS one, 2008, Apr-02, Volume: 3, Issue:4

    Topics: Boronic Acids; Bortezomib; DNA; DNA Replication; Eukaryotic Initiation Factor-2; HeLa Cells; Humans; Leupeptins; Models, Biological; Poliovirus; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transfection; Vesiculovirus; Viral Proteins; Virus Replication

2008
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Leukemia research, 2008, Volume: 32, Issue:11

    Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Cell Nucleus; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured

2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    British journal of haematology, 2008, Volume: 141, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heat-Shock Proteins; Hematopoietic Stem Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyridines; Tumor Cells, Cultured

2008
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Lymphoma, Mantle-Cell; NF-kappa B; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Up-Regulation

2008
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.
    Cell cycle (Georgetown, Tex.), 2008, Apr-01, Volume: 7, Issue:7

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Fluorescent Antibody Technique; G2 Phase; Humans; Microtubule-Associated Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators

2008
[Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines

2008
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
    Medical hypotheses, 2008, Volume: 71, Issue:1

    Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Synovial Membrane

2008
Proteasome inhibition improves diaphragm function in congestive heart failure rats.
    American journal of physiology. Lung cellular and molecular physiology, 2008, Volume: 294, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Diaphragm; Heart Failure; Male; Myosin Heavy Chains; Myosins; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Ubiquitination

2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Journal of immunology (Baltimore, Md. : 1950), 2008, May-01, Volume: 180, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor

2008
[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].
    Anales de medicina interna (Madrid, Spain : 1984), 2008, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate

2008
Role of decorin in the antimyeloma effects of osteoblasts.
    Blood, 2008, Jul-01, Volume: 112, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor p21; Decorin; Extracellular Matrix Proteins; Genetic Vectors; Humans; Lentivirus; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Osteoblasts; Plasma Cells; Proteoglycans; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering

2008
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
    Haematologica, 2008, Volume: 93, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Protein Isoforms; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2008
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
    Neuro-oncology, 2008, Volume: 10, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mitochondria; Panobinostat; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering

2008
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Journal of the National Cancer Institute, 2008, May-07, Volume: 100, Issue:9

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2008
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Cancer research, 2008, May-01, Volume: 68, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
Adverse events of unapproved drugs in Japan.
    The Lancet. Oncology, 2008, Volume: 9, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consumer Product Safety; Drug Approval; Drug Labeling; Government Regulation; Health Knowledge, Attitudes, Practice; Humans; Japan; Marketing of Health Services; Patient Education as Topic; Patient Rights; Patient Selection; Pyrazines

2008
Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:6

    Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Hepatocytes; Humans; Immunosuppressive Agents; Inclusion Bodies; Keratin-8; Mice; Mice, Knockout; Mice, Transgenic; Models, Animal; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sirolimus; Transfection

2008
In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.
    American journal of respiratory cell and molecular biology, 2008, Volume: 39, Issue:4

    Topics: Animals; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Collagen Type I; Fibrosis; Hydroxyproline; Leupeptins; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta

2008
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
    Archives of gynecology and obstetrics, 2009, Volume: 279, Issue:1

    Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Survival; Female; HeLa Cells; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms

2009
Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.
    Journal of the American Chemical Society, 2008, Jun-04, Volume: 130, Issue:22

    Topics: Aldehydes; Amines; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalysis; Copper; Imines; Protease Inhibitors; Pyrazines; Sulfinic Acids

2008
Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1.
    Blood, 2008, May-15, Volume: 111, Issue:10

    Topics: Boronic Acids; Bortezomib; Cell Line; Humans; Hypoxia-Inducible Factor 1; Mixed Function Oxygenases; Pyrazines; Repressor Proteins; Transcription Factors

2008
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; Transfection; Ubiquitin

2008
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Leukemia research, 2008, Volume: 32, Issue:11

    Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured

2008
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Molecular cancer, 2008, May-19, Volume: 7

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2008
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:1

    Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Pyrazines; Renal Dialysis; Renal Insufficiency; Thalidomide

2008
Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Jurkat Cells; Point Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retroviridae; Tumor Stem Cell Assay

2008
[Treatment of myeloma in the elderly].
    Bulletin du cancer, 2008, May-28, Volume: 95 FMC Onco

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide

2008
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Killer Cells, Natural; Liver Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2008
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Molecular cancer, 2008, Jun-05, Volume: 7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Molecular Chaperones; Mutation; Neoplasm Proteins; Neuroblastoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Tumor Suppressor Protein p53

2008
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
    Blood, 2008, Oct-01, Volume: 112, Issue:7

    Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Aberrations; Clone Cells; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Melphalan; Models, Biological; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Rats; Stromal Cells; Tumor Cells, Cultured

2008
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
    Blood, 2008, Aug-15, Volume: 112, Issue:4

    Topics: Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cytokines; Female; Graft vs Leukemia Effect; Graft vs Tumor Effect; Interferon-gamma; Lymphocyte Depletion; Mice; Pyrazines; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome; Tumor Necrosis Factor-alpha

2008
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Nature medicine, 2008, Volume: 14, Issue:7

    Topics: Animals; Boronic Acids; Bortezomib; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Mice, Inbred NZB; Models, Immunological; Nephritis; Ovalbumin; Plasma Cells; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors

2008
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
    Journal of molecular medicine (Berlin, Germany), 2008, Volume: 86, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calreticulin; Cancer Vaccines; Drug Therapy, Combination; Mice; Mice, Inbred C57BL; Papillomavirus E7 Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Vaccines, DNA

2008
[Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Cells, Cultured

2008
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
    Cancer research, 2008, Jun-15, Volume: 68, Issue:12

    Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Colony-Forming Units Assay; Drug Synergism; Drug Therapy, Combination; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, SCID; Multiple Myeloma; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Oncogene, 2008, Oct-09, Volume: 27, Issue:46

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Cell Membrane Permeability; Colonic Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mitochondria; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein

2008
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Experimental hematology, 2008, Volume: 36, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Survival; Chymotrypsin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2008
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Blood, 2008, Sep-15, Volume: 112, Issue:6

    Topics: Binding Sites; Boronic Acids; Bortezomib; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Mutation; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering

2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

    Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Ketones; Membrane Potential, Mitochondrial; Mice; Mitochondria; Multiple Myeloma; Oxidative Stress; Protein Transport; Pyrazines; Pyridines; Signal Transduction; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2008
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Membrane Proteins; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Up-Regulation

2008
[Aggravated post-herpetic neuralgia due to bortezomib].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence

2008
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
    American journal of clinical dermatology, 2008, Volume: 9, Issue:4

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunoglobulins; Male; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Scleromyxedema; Thalidomide

2008
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
    Radiology, 2008, Volume: 248, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Random Allocation; Transplantation, Heterologous; Tumor Cells, Cultured; Ultrasonic Therapy

2008
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    International journal of oncology, 2008, Volume: 33, Issue:1

    Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta

2008
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
    Annals of hematology, 2008, Volume: 87, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine

2008
The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model.
    Transplantation proceedings, 2008, Volume: 40, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; DNA Primers; Gene Expression Regulation; Hyperplasia; Interleukins; Jugular Veins; Male; Models, Animal; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; RNA, Messenger; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Tunica Intima

2008
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Blood, 2008, Oct-01, Volume: 112, Issue:7

    Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Health; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Microscopy, Confocal; Molecular Mimicry; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tissue Donors; Xenograft Model Antitumor Assays

2008
Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.
    Cancer research, 2008, Jul-01, Volume: 68, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacitracin; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Fenretinide; Humans; Melanoma; Oxidative Stress; Protein Disulfide-Isomerases; Pyrazines; Treatment Outcome; Tumor Cells, Cultured

2008
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Nucleus; DNA; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Models, Biological; NF-kappa B; Phosphorylation; Pyrazines; Recurrence; Signal Transduction; Subcellular Fractions

2008
[Serum free light chains for diagnosis and follow-up of multiple myeloma].
    The Korean journal of laboratory medicine, 2008, Volume: 28, Issue:3

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Immunoelectrophoresis; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Reagent Kits, Diagnostic

2008
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.
    World journal of urology, 2008, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Down-Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured

2008
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Leukemia, 2008, Volume: 22, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mitochondria; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured

2008
A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
    Cancer cell, 2008, Jul-08, Volume: 14, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; Necrosis; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Time Factors; Up-Regulation

2008
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
    Cancer cell, 2008, Jul-08, Volume: 14, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Necrosis; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Up-Regulation; Xenograft Model Antitumor Assays

2008
New treatments in multiple myeloma: beyond optimal treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19 Suppl 5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide

2008
Productively combining proteasome inhibition with the immunotherapy of cancer.
    Journal of molecular medicine (Berlin, Germany), 2008, Volume: 86, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Drug Therapy, Combination; Humans; Immunotherapy; Models, Biological; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2008
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Leukemia research, 2008, Volume: 32, Issue:11

    Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Osteoclasts; Pulse Therapy, Drug; Pyrazines

2008
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms

2008
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
    Biochemical and biophysical research communications, 2008, Sep-19, Volume: 374, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Division; Cell Line; Cell Membrane; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; G2 Phase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myeloid Cell Leukemia Sequence 1 Protein; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-bcl-2; Pyrazines; rhoA GTP-Binding Protein; Simvastatin

2008
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Cancer research, 2008, Jul-15, Volume: 68, Issue:14

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasm Transplantation; Piperazines; Pyrazines; Pyridines

2008
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
    Blood, 2008, Nov-01, Volume: 112, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boric Acids; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cytochromes c; Diet; Flavonoids; Free Radical Scavengers; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Protease Inhibitors; Pyrazines; Quercetin

2008
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
    International journal of hematology, 2008, Volume: 88, Issue:2

    Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Failure; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines

2008
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
    International journal of hematology, 2008, Volume: 88, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Pyrazines; Thrombosis

2008
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
    Radiology, 2008, Volume: 248, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Ultrasonic Therapy

2008
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
    Blood, 2008, Oct-01, Volume: 112, Issue:7

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus Structures; Cycloheximide; Diploidy; Drug Synergism; Endoplasmic Reticulum; Fibroblasts; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Multiple Myeloma; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Small Interfering; Vorinostat

2008
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endoplasmic Reticulum; G2 Phase; Humans; Neoplasm Proteins; Proteasome Inhibitors; Protein Biosynthesis; Protein Folding; Protein Subunits; Pyrazines; Ritonavir; Sarcoma

2008
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:7

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Genes, Reporter; Head and Neck Neoplasms; Humans; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Transcription Factor AP-1; Ubiquitination; Xenograft Model Antitumor Assays

2008
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins; Male; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; United States

2008
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Thalidomide

2008
Targeted therapy--possible new therapeutic option for malignant mesothelioma?
    Connective tissue research, 2008, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Humans; Mesothelioma; Oligosaccharides; Proteasome Endopeptidase Complex; Proteoglycans; Pyrazines; Sodium Selenite; Thioredoxins

2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
    British journal of haematology, 2008, Volume: 143, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time; Treatment Outcome

2008
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
    Human reproduction (Oxford, England), 2008, Volume: 23, Issue:11

    Topics: Animals; Antigens, CD34; Azo Compounds; Boronic Acids; Bortezomib; Case-Control Studies; Endometriosis; Eosine Yellowish-(YS); Female; Ki-67 Antigen; Methyl Green; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrrolidines; Rats; Thiocarbamates

2008
Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.
    Molecular pharmacology, 2008, Volume: 74, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Models, Theoretical; NF-kappa B; Pyrazines; Tumor Necrosis Factor-alpha

2008
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid

2009
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Anti-cancer drugs, 2008, Volume: 19, Issue:8

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Humans; Interleukin-6; Interleukin-7; Luciferases; Multiple Myeloma; NF-kappa B; Phosphorylation; Pyrazines; Quinazolines; Signal Transduction; STAT3 Transcription Factor

2008
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
    International journal of hematology, 2008, Volume: 88, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2008
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2008
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays

2008
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Cancer research, 2008, Aug-15, Volume: 68, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Cycle; Down-Regulation; Flow Cytometry; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
Enhancing transduction of the liver by adeno-associated viral vectors.
    Gene therapy, 2009, Volume: 16, Issue:1

    Topics: Animals; Antibodies, Viral; Boronic Acids; Bortezomib; Dependovirus; Factor IX; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Injections, Intravenous; Liver; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Pyrazines; Transduction, Genetic; Transgenes

2009
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
    Molecular cancer research : MCR, 2008, Volume: 6, Issue:8

    Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genes, Reporter; Green Fluorescent Proteins; Humans; Multiple Myeloma; NF-kappa B; Proteasome Inhibitors; Pyrazines; Stromal Cells

2008
20S ways to apoptosis.
    Nature chemical biology, 2008, Volume: 4, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Humans; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Protein Folding; Pyrazines

2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
    British journal of haematology, 2008, Volume: 143, Issue:2

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pulmonary Embolism; Pyrazines; Recombinant Proteins; Recurrence; Risk; Treatment Outcome; Venous Thrombosis

2008
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
    Acta haematologica, 2008, Volume: 120, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand

2008
[Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Humans; Oxides; Protease Inhibitors; Pyrazines

2008
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Treatment Outcome

2008
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Caspase 2; Cell Line, Tumor; Endoplasmic Reticulum; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Pyrazines; RNA Interference; Subcellular Fractions

2008
Treatment of myeloma--are we making progress?
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines

2008
Response to bortezomib in refractory type I cryoglobulinemia.
    American journal of hematology, 2008, Volume: 83, Issue:11

    Topics: Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Vasculitis

2008
Infiltration of the spinal cord in a patient with multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-01, Volume: 26, Issue:25

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms

2008
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
    Terapevticheskii arkhiv, 2008, Volume: 80, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2008
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2008
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles

2008
Bortezomib as a therapeutic candidate for neuroblastoma.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines

2008
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
    Cancer cell, 2008, Sep-09, Volume: 14, Issue:3

    Topics: Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; HCT116 Cells; HSC70 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Lactams, Macrocyclic; Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Proto-Oncogene Proteins c-raf; Pyrazines; RNA, Small Interfering; Transfection; Ubiquitination

2008
Bortezomib-induced survival signals and genes in human proximal tubular cells.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Humans; I-kappa B Proteins; Kidney Tubules, Proximal; Mesangial Cells; Mitogen-Activated Protein Kinase 3; NF-KappaB Inhibitor alpha; Pyrazines; Signal Transduction; Transcription Factor RelA

2008
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.
    Nature medicine, 2008, Volume: 14, Issue:10

    Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Iodine Radioisotopes; Male; Mice; Mice, SCID; Pyrazines; Radiopharmaceuticals; Sarcoma, Kaposi; Stomach Neoplasms; Thymidine Kinase

2008
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
    Leukemia research, 2009, Volume: 33, Issue:1

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Down-Regulation; Humans; Macrophage Colony-Stimulating Factor; Monocytes; Multiple Myeloma; Osteoclasts; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; TNF Receptor-Associated Factor 6

2009
A C-terminal fragment of Cyclin E, generated by caspase-mediated cleavage, is degraded in the absence of a recognizable phosphodegron.
    The Journal of biological chemistry, 2008, Nov-07, Volume: 283, Issue:45

    Topics: Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cullin Proteins; Cyclin E; DNA-Binding Proteins; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Half-Life; Hematologic Neoplasms; Humans; Isoenzymes; Ku Autoantigen; Neoplasm Proteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-mdm2; Pyrazines; S-Phase Kinase-Associated Proteins; Ubiquitin-Protein Ligases; Ubiquitination

2008
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Esophageal Neoplasms; G2 Phase; Histones; Mice; Mice, Inbred NOD; Mitosis; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyrazines; Remission Induction; Xenograft Model Antitumor Assays

2008
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
    European journal of immunology, 2008, Volume: 38, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Brain; Cathepsins; Dipeptides; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Glycoproteins; Lymphoid Tissue; Lysosomes; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuroglia; Neurons; NF-kappa B; Peptide Fragments; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Sulfones; T-Lymphocytes

2008
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Psoriasis; Pyrazines; Remission Induction

2008
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Menthol; Middle Aged; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; TRPM Cation Channels

2008
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).
    Bone marrow transplantation, 2009, Volume: 43, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dendritic Cells; Humans; Immunosuppressive Agents; Monocytes; Protease Inhibitors; Pyrazines

2009
Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    International journal of molecular medicine, 2008, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dexamethasone; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Epoxy Compounds; Humans; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Mitochondria; Multiple Myeloma; NF-kappa B; Phenanthrenes; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Glucocorticoid; Up-Regulation

2008
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2008, Volume: 43, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents

2008
Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Dexamethasone; Fractures, Bone; Humans; Humerus; In Situ Hybridization, Fluorescence; Male; Multiple Myeloma; Pyrazines; Translocation, Genetic

2009
Immune-mediated neuropathies in myeloma patients treated with bortezomib.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2008, Volume: 119, Issue:11

    Topics: Action Potentials; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Polyneuropathies; Pyrazines; Reaction Time

2008
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.
    The Journal of biological chemistry, 2008, Dec-05, Volume: 283, Issue:49

    Topics: Amino Acids; Animals; Boronic Acids; Bortezomib; Cattle; Humans; Inhibitory Concentration 50; Kinetics; Mutation; Mycobacterium tuberculosis; Oligopeptides; Peptides; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Rhodococcus; Substrate Specificity

2008
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines

2009
Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
    Annals of hematology, 2009, Volume: 88, Issue:4

    Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Urinary Bladder, Neurogenic

2009
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation

2009
A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin G; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Pleura; Pleural Effusion, Malignant; Pyrazines; Tomography, X-Ray Computed

2009
[Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Orvosi hetilap, 2008, Oct-12, Volume: 149, Issue:41

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Leukemia, Plasma Cell; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Transplantation, Autologous; Treatment Outcome

2008
[Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:4

    Topics: Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger

2008
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Oncogene, 2009, Jan-15, Volume: 28, Issue:2

    Topics: Antibodies; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Integrin alpha Chains; Integrin alpha4; Integrin alpha4beta1; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Vincristine

2009
S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.
    The Journal of pathology, 2008, Volume: 216, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins

2008
Proteasome inhibitors in pediatric cancer treatment.
    Hawaii medical journal, 2008, Volume: 67, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Child; Humans; Leukemia; Neoplasms; Protease Inhibitors; Pyrazines

2008
A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Herpesviridae Infections; Herpesvirus 8, Human; HIV; Humans; Immunohistochemistry; Liposomes; Lymphoma, Primary Effusion; Male; Positron-Emission Tomography; Pyrazines; Rituximab

2008
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
    Blood, 2009, Jan-22, Volume: 113, Issue:4

    Topics: Adolescent; Adult; Antigens, CD34; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monomeric GTP-Binding Proteins; Pyrazines; Receptors, Death Domain; Up-Regulation

2009
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
    Cancer research, 2008, Oct-15, Volume: 68, Issue:20

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Caspase 8; Fas-Associated Death Domain Protein; Humans; Interferon-alpha; Kidney Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2008
[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:5

    Topics: Boronic Acids; Bortezomib; Humans; Intercellular Adhesion Molecule-1; K562 Cells; NF-kappa B; Protease Inhibitors; Pyrazines

2008
[Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:5

    Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Monocytic, Acute; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger

2008
Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
    Cell cycle (Georgetown, Tex.), 2008, Volume: 7, Issue:20

    Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Coumarins; Ergosterol; Genetic Vectors; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; S Phase; Signal Transduction; STAT3 Transcription Factor; Withanolides

2008
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
    Oncology reports, 2008, Volume: 20, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines

2008
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
    Oncology reports, 2008, Volume: 20, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Female; Glioma; Humans; Mice; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays

2008
Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Mice; Mice, SCID; Multiple Myeloma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rituximab

2008
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2009, Volume: 9, Issue:1

    Topics: Antibody Specificity; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Plasma Cells; Proteasome Inhibitors; Pyrazines

2009
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    American journal of hematology, 2009, Volume: 84, Issue:1

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Development; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protease Inhibitors; Pyrazines; Rabbits

2009
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.
    International journal of hematology, 2008, Volume: 88, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; Female; Fever; Humans; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stromal Cells

2008
A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial.
    Journal of biopharmaceutical statistics, 2008, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Health Status Indicators; Humans; Likelihood Functions; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Stochastic Processes; Time Factors; Treatment Outcome

2008
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Treatment Outcome

2008
Deborah Dunsire.
    Nature biotechnology, 2008, Volume: 26, Issue:11

    Topics: Anti-Inflammatory Agents; Biopharmaceutics; Biotechnology; Boronic Acids; Bortezomib; Drug Industry; Entrepreneurship; History, 21st Century; Humans; Inflammation; Neoplasms; Organizational Objectives; Pyrazines

2008
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine

2008
Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cooperative Behavior; Drug Industry; Health Knowledge, Attitudes, Practice; Humans; Interdisciplinary Communication; Internet; Japan; Lung Diseases; Mass Media; Medical Staff; Multiple Myeloma; Newspapers as Topic; Patient Selection; Periodicals as Topic; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Societies, Medical

2008
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A

2008
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Movement; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Immunohistochemistry; Immunoprecipitation; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tissue Array Analysis; Ubiquitin

2008
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
    Cancer research, 2008, Nov-15, Volume: 68, Issue:22

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line, Tumor; DNA-Binding Proteins; Endoplasmic Reticulum; Humans; Microtubule-Associated Proteins; Necrosis; Protease Inhibitors; Protein Folding; Pyrazines; Regulatory Factor X Transcription Factors; Signal Transduction; Stress, Physiological; Thapsigargin; Transcription Factors

2008
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxins; Drug Interactions; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2009
Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
    European journal of haematology, 2009, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Immunoglobulin G; Kidney Diseases; Kidney Glomerulus; Lung; Male; Middle Aged; Paraproteinemias; Pyrazines

2009
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    International journal of oncology, 2008, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine

2008
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    International journal of molecular medicine, 2008, Volume: 22, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53

2008
Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:11

    Topics: Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Resistance; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Prognosis; Pyrazines; Systems Biology; Tumor Suppressor Protein p53

2008
Delayed complete remission in a patient with multiple myeloma.
    European journal of clinical investigation, 2008, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Time Factors

2008
Novel agents in myeloma: an exciting saga.
    Cancer, 2009, Jan-15, Volume: 115, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis

2009
Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
    Cancer biology & therapy, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Male; Mice; Prostatic Neoplasms; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand

2009
Effects of bortezomib on bone disease in multiple myeloma.
    American journal of hematology, 2009, Volume: 84, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoclasts; Osteolysis; Pyrazines

2009
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome

2008
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.
    Investigational new drugs, 2009, Volume: 27, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; Pyrazines; Stress, Physiological; Time Factors; Up-Regulation

2009
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Biochimie, 2009, Volume: 91, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; E2F1 Transcription Factor; G2 Phase; Humans; Liver Neoplasms; Pyrazines; RNA, Messenger; S Phase; Time Factors

2009
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
    Blood, 2009, May-07, Volume: 113, Issue:19

    Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins

2009
Bortezomib-associated tumor lysis syndrome in multiple myeloma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:12

    Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome

2008
Bortezomib attenuates murine collagen-induced arthritis.
    Annals of the rheumatic diseases, 2009, Volume: 68, Issue:11

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Inflammation Mediators; Male; Mice; Mice, Inbred DBA; Protease Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome; X-Ray Microtomography

2009
Regulation of multiple myeloma survival and progression by CD1d.
    Blood, 2009, Mar-12, Volume: 113, Issue:11

    Topics: Antibodies, Monoclonal; Antigens, CD1d; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Aggregation; Cell Survival; Dexamethasone; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Plasma Cells; Pyrazines; Tumor Cells, Cultured

2009
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
    Journal of pharmaceutical and biomedical analysis, 2009, Jan-15, Volume: 49, Issue:1

    Topics: Aged; Antineoplastic Agents; Apolipoprotein C-I; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Chromatography, Liquid; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Mass Spectrometry; Middle Aged; Molecular Weight; Multiple Myeloma; Protein Isoforms; Pyrazines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Time Factors

2009
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies

2008
Treatment of light chain deposition disease with bortezomib and dexamethasone.
    Haematologica, 2009, Volume: 94, Issue:2

    Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Paraproteinemias; Pyrazines; Treatment Outcome

2009
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
    Cancer science, 2009, Volume: 100, Issue:2

    Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Immunoprecipitation; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Cutaneous; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation

2009
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Experimental cell research, 2009, Feb-01, Volume: 315, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; G1 Phase; Humans; Imidazoles; Melphalan; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Recombinant Proteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases

2009
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2008
Induction therapy in multiple myeloma.
    Hematology. American Society of Hematology. Education Program, 2008

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous

2008
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
    Blood, 2009, Apr-30, Volume: 113, Issue:18

    Topics: Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Case-Control Studies; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lymphocytes; Male; Mice; MicroRNAs; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Experimental; NF-kappa B; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Signal Transduction; Waldenstrom Macroglobulinemia

2009
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; DNA Fragmentation; Flow Cytometry; Humans; Inhibitory Concentration 50; Killer Cells, Natural; Lymphoma; Mitosis; Models, Biological; Multiple Myeloma; Pyrazines

2008
New evidence in oncologic and cardiocirculatory medicine.
    Internal and emergency medicine, 2009, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines

2009
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis].
    Zhonghua fu chan ke za zhi, 2008, Volume: 43, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction

2008
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Reproductive sciences (Thousand Oaks, Calif.), 2009, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression; Granulosa Cell Tumor; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; X-Linked Inhibitor of Apoptosis Protein

2009
High-content functional screen to identify proteins that correct F508del-CFTR function.
    Molecular & cellular proteomics : MCP, 2009, Volume: 8, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line; Cystic Fibrosis Transmembrane Conductance Regulator; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoblotting; Microscopy, Confocal; Mutant Proteins; Proteome; Proteomics; Pyrazines; Reproducibility of Results; Temperature

2009
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
    Cancer, 2009, Jan-01, Volume: 115, Issue:1

    Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Virus Activation

2009
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate

2008
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide

2008
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Dermatology online journal, 2008, Nov-15, Volume: 14, Issue:11

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine

2008
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    American journal of respiratory cell and molecular biology, 2009, Volume: 41, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Communication; Cell Line, Tumor; Diffusion; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Nitrophenols; Phosphatidylinositol 3-Kinases; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; Sulfonamides; Time Factors; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases

2009
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Biochemical pharmacology, 2009, Mar-01, Volume: 77, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2009
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Transplantation, 2008, Dec-27, Volume: 86, Issue:12

    Topics: Acute Disease; Biopsy; Boronic Acids; Bortezomib; Creatinine; Graft Rejection; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Paresthesia; Protease Inhibitors; Pyrazines; Thrombocytopenia; United States; United States Food and Drug Administration

2008
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin

2009
BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    FEBS letters, 2009, Jan-22, Volume: 583, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Humans; Leukemia; Mice; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering

2009
Combination therapy with TRAIL: Recent developments and potential pitfalls.
    Cancer biology & therapy, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Therapy, Combination; Humans; Male; Mice; Prostatic Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous

2009
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
    Blood, 2009, Apr-23, Volume: 113, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Survival; Daclizumab; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Inhibitor of Apoptosis Proteins; Leukemia-Lymphoma, Adult T-Cell; Male; Microtubule-Associated Proteins; Middle Aged; Pyrazines; RNA Interference; Survivin; Transcription Factor 4; Transcription Factors; Tumor Cells, Cultured

2009
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Blood, 2009, Apr-30, Volume: 113, Issue:18

    Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Survival; Coculture Techniques; Colony-Forming Units Assay; Cyclams; Drug Resistance, Neoplasm; Fibronectins; Flow Cytometry; Heterocyclic Compounds; Humans; Immunoblotting; Immunoenzyme Techniques; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lentivirus; Male; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Stromal Cells; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
    The Journal of biological chemistry, 2009, Mar-27, Volume: 284, Issue:13

    Topics: Actins; Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Adhesion; Cell Line, Transformed; Collagen; Cyclosporine; Cytoskeleton; Extracellular Matrix; Fibronectins; HMGB1 Protein; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Necrosis; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrans; Pyrazines; Sulfhydryl Compounds

2009
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Dexamethasone; Enzyme Inhibitors; Fibroblast Growth Factor 3; Humans; In Situ Hybridization, Fluorescence; Multiple Myeloma; Mutation; Protein-Tyrosine Kinases; Pyrazines; Translocation, Genetic

2009
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper Transporter 1; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Peritoneal Neoplasms; Proteasome Endopeptidase Complex; Pyrazines

2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53

2009
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Leukemia, 2009, Volume: 23, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured

2009
"Change can happen" by PKA: proteasomes in in vivo hearts.
    Journal of molecular and cellular cardiology, 2009, Volume: 46, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Cyclic AMP-Dependent Protein Kinases; Models, Biological; Myocardium; Myocytes, Cardiac; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2009
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Feb-17, Volume: 106, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Ubiquitin

2009
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Enzyme Activation; Humans; Leukocyte Common Antigens; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, IGF Type 1; Tumor Cells, Cultured

2009
Topical analgesic combinations for bortezomib neuropathy.
    Journal of pain and symptom management, 2009, Volume: 37, Issue:3

    Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; Clonidine; Cyclohexanecarboxylic Acids; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Gels; Humans; Ketamine; Male; Middle Aged; Pain Measurement; Paraproteinemias; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Walking

2009
Bortezomib-related colon mucositis in a multiple myeloma patient.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colonic Diseases; Humans; Male; Middle Aged; Mucositis; Multiple Myeloma; Pyrazines; Renal Insufficiency

2009
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:2

    Topics: Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lung Neoplasms; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand

2009
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxamic Acids; Pyrazines; Signal Transduction; Vorinostat

2009
[In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Harringtonines; HL-60 Cells; Humans; Male; Oxides; Pyrazines; Young Adult

2008
[The influence of bortezomib on HL-60 cell function induced by all-trans retinoic acid plus bufalin and its mechanism].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:12

    Topics: Boronic Acids; Bortezomib; Bufanolides; Cell Adhesion; Cell Proliferation; Focal Adhesion Kinase 2; HL-60 Cells; Humans; Paxillin; Pyrazines; Tretinoin

2008
Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation.
    Cancer research, 2009, Feb-01, Volume: 69, Issue:3

    Topics: Boronic Acids; Bortezomib; Epidermal Growth Factor; ErbB Receptors; Genes, Reporter; HeLa Cells; Humans; Luciferases, Firefly; Microscopy, Fluorescence; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Transfection; Ubiquitination

2009
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Blood, 2009, Apr-30, Volume: 113, Issue:18

    Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat

2009
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Imidazoles; Lymphoma, Mantle-Cell; Membrane Proteins; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; Pyrazines; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2009
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
    Blood, 2009, Jun-04, Volume: 113, Issue:23

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea

2009
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
    Cancer research, 2009, Feb-15, Volume: 69, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; G1 Phase; Humans; Leupeptins; Multiple Myeloma; Phosphorylation; Pyrazines; Resting Phase, Cell Cycle

2009
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
    Journal of the peripheral nervous system : JPNS, 2008, Volume: 13, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electrophysiology; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prevalence; Pyrazines; Thalidomide

2008
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
    Blood, 2009, Apr-30, Volume: 113, Issue:18

    Topics: Animals; beta Catenin; Boronic Acids; Bortezomib; Cadherins; Calcification, Physiologic; Calcium; Cell Differentiation; Cell Nucleus; Cells, Cultured; Fibroblasts; Fluorescent Antibody Technique; Humans; Immunoblotting; Luciferases; Mesenchymal Stem Cells; Mice; Osteoblasts; Protease Inhibitors; Protein Transport; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stem Cells; TCF Transcription Factors; Wnt Proteins

2009
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Blood, 2009, Jun-11, Volume: 113, Issue:24

    Topics: Adoptive Transfer; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Caspase 8; Cell Proliferation; Granzymes; Humans; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory

2009
Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.
    Pediatric blood & cancer, 2009, Volume: 53, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cerebellar Neoplasms; Disease Models, Animal; Gene Knock-In Techniques; Hedgehog Proteins; Humans; Immunoblotting; Immunoprecipitation; Loss of Heterozygosity; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; PAX7 Transcription Factor; Proteasome Endopeptidase Complex; Protein Isoforms; Protein Processing, Post-Translational; Pyrazines; Receptors, Cell Surface

2009
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
    BMC cancer, 2009, Feb-16, Volume: 9

    Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Adenosine Triphosphate; Apoptosis; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Glutathione Synthase; Humans; Intracellular Space; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry; Thyroid Neoplasms

2009
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
    European journal of haematology, 2009, Volume: 82, Issue:6

    Topics: Adult; Boronic Acids; Bortezomib; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Male; Pyrazines; Remission Induction; Shock, Septic

2009
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    European journal of haematology, 2009, Volume: 82, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; Pharmacokinetics; Pyrazines; Reactive Oxygen Species; Vorinostat

2009
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
    Clinical and experimental immunology, 2009, Volume: 155, Issue:3

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Female; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, SCID; Protease Inhibitors; Pyrazines; Receptors, Death Domain; RNA, Messenger; Xenograft Model Antitumor Assays

2009
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
    Leukemia, 2009, Volume: 23, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Gene Expression Regulation; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Biosynthesis; Protein Stability; Protein Subunits; Pyrazines; Ubiquitin; Up-Regulation

2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
    Leukemia, 2009, Volume: 23, Issue:6

    Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome

2009
Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
    International journal of hematology, 2009, Volume: 89, Issue:2

    Topics: Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Middle Aged; Multiple Myeloma; Platelet Transfusion; Pyrazines; Salvage Therapy; Transplantation, Homologous

2009
Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum; Female; Fenretinide; G2 Phase; Humans; Ki-67 Antigen; Melanoma; Mice; Pyrazines

2009
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Endoplasmic Reticulum; Fenretinide; Humans; Mice; Neuroblastoma; Pyrazines; Xenograft Model Antitumor Assays

2009
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
    Haematologica, 2009, Volume: 94, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 1; Proteasome Inhibitors; Pyrazines

2009
Bortezomib-induced histiocytoid Sweet syndrome.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:3

    Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Sweet Syndrome

2009
[Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger

2009
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
    Cancer research, 2009, Mar-01, Volume: 69, Issue:5

    Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactones; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Pyrroles; RNA, Messenger; Vascular Endothelial Growth Factor A

2009
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Molecular pharmacology, 2009, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Sulfonamides

2009
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
    Cellular and molecular life sciences : CMLS, 2009, Volume: 66, Issue:7

    Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Chromans; Cytokines; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thiazolidinediones; Troglitazone

2009
The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
    International journal of laboratory hematology, 2010, Volume: 32, Issue:1 Pt 1

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Chymotrypsin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; K562 Cells; Leukemia; Pyrazines

2010
Cutaneous involvement in multiple myeloma and bortezomib.
    Annals of hematology, 2009, Volume: 88, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia

2009
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    The Journal of biological chemistry, 2009, Apr-24, Volume: 284, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Liver Neoplasms; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand

2009
[Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lumbar Vertebrae; Male; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Plasmacytoma; Protease Inhibitors; Pyrazines; Spinal Neoplasms

2009
Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation.
    Molecular biology reports, 2010, Volume: 37, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Fragmentation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Humans; MAP Kinase Kinase 4; Phosphorylation; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Tetrazolium Salts; Thiazoles

2010
Inhibitors of the ubiquitin-proteasome system are not all alike: identification of a new necrotic pathway.
    Autophagy, 2009, Volume: 5, Issue:4

    Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fibroblasts; Mice; Necrosis; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2009
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Cancer biology & therapy, 2009, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction

2009
Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
    The Journal of trauma, 2009, Volume: 66, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Female; Injections, Intravenous; Isometric Contraction; Locomotion; Muscle, Skeletal; Muscular Atrophy; Nerve Compression Syndromes; Premedication; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retrograde Degeneration; Sciatic Nerve; Synaptic Transmission

2009
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Leukemia, 2009, Volume: 23, Issue:8

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Protein Kinases; Pyrazines; Signal Transduction; Vorinostat; Xenograft Model Antitumor Assays

2009
Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
    Leukemia research, 2009, Volume: 33, Issue:8

    Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cystitis; Female; Hemorrhage; Humans; Multiple Myeloma; Pyrazines

2009
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
    International journal of hematology, 2009, Volume: 89, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome

2009
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
    American journal of hematology, 2009, Volume: 84, Issue:5

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Enzyme Activation; Immunoglobulin G; Mice; Multiple Myeloma; Neoplasm Transplantation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Burden

2009
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Histopathology, 2009, Volume: 54, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazines

2009
Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-01, Volume: 27, Issue:13

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Leukocyte Common Antigens; Multiple Myeloma; Pyrazines; Virus Activation

2009
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
    Cytotherapy, 2009, Volume: 11, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Culture Techniques; Cell Proliferation; Cryopreservation; Cytokines; Cytotoxicity, Immunologic; Fas Ligand Protein; Humans; Immunophenotyping; Immunotherapy; K562 Cells; Killer Cells, Natural; Lymphocyte Activation; NK Cell Lectin-Like Receptor Subfamily K; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2009
2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.
    Electrophoresis, 2009, Volume: 30, Issue:6

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Protein Interaction Mapping; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2009
Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Anticancer research, 2009, Volume: 29, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; STAT3 Transcription Factor; Transfection

2009
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome

2009
Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.
    Physiological genomics, 2009, May-13, Volume: 37, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Enterotoxins; Gene Expression Profiling; Gene Expression Regulation; HLA-DR alpha-Chains; HLA-DR Antigens; Inflammation Mediators; Mice; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; Receptors, Chemokine; Receptors, Cytokine; Signal Transduction; Superantigens

2009
Targeted therapy and hematological malignancy.
    Targeted oncology, 2009, Volume: 4, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Benzamides; Biomedical Research; Boronic Acids; Bortezomib; CD52 Antigen; Drug Design; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glycoproteins; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Pyrimidines; Rituximab; Survival Rate

2009
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
    British journal of haematology, 2009, Volume: 145, Issue:4

    Topics: Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Interleukin-6; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence

2009
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide

2009
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-15, Volume: 15, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dexamethasone; DNA Fragmentation; Doxorubicin; Histocompatibility Antigens Class II; Humans; Mice; Mice, SCID; Multiple Myeloma; Pyrazines

2009
GC-1 mRHBDD1 knockdown spermatogonia cells lose their spermatogenic capacity in mouse seminiferous tubules.
    BMC cell biology, 2009, Apr-10, Volume: 10

    Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gene Expression Profiling; Gene Knockdown Techniques; Green Fluorescent Proteins; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Pyrazines; Recombinant Fusion Proteins; Regeneration; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Seminiferous Tubules; Spermatogenesis; Spermatogonia; Testis; Transfection; Ultraviolet Rays

2009
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Cancer research, 2009, May-01, Volume: 69, Issue:9

    Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides

2009
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
    Leukemia, 2009, Volume: 23, Issue:9

    Topics: Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Proteasome Inhibitors; Pyrazines

2009
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
    Internal medicine journal, 2009, Volume: 39, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Australia; Boronic Acids; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Recurrence; Treatment Outcome

2009
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Curcumin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2009
Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.
    American journal of physiology. Lung cellular and molecular physiology, 2009, Volume: 296, Issue:6

    Topics: Animals; Atrophy; Boronic Acids; Bortezomib; Caspase 3; Cysteine Proteinase Inhibitors; Diaphragm; Endotoxemia; Enzyme Activation; Leupeptins; Male; Muscle Contraction; Muscle Weakness; Oligopeptides; Organ Size; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Sepsis; Tyrosine

2009
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Blood, 2009, Jun-11, Volume: 113, Issue:24

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Boronic Acids; Bortezomib; Doxorubicin; Female; Gene Expression Profiling; Germinal Center; Humans; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Prognosis; Pyrazines; Survival Rate; Treatment Outcome; Young Adult

2009
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.
    Molecular oncology, 2008, Volume: 2, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Curcumin; Cytokines; Drug Synergism; Humans; Inflammation Mediators; Multiple Myeloma; Pyrazines; Stromal Cells

2008
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
    The Journal of biological chemistry, 2009, Jun-19, Volume: 284, Issue:25

    Topics: Anilides; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 3; Cell Line, Tumor; Cell Transformation, Viral; Drug Synergism; Enzyme Inhibitors; Genes, Viral; Herpesvirus 4, Human; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Protease Inhibitors; Pyrazines; Reactive Oxygen Species

2009
Hematology: Bortezomib in newly diagnosed multiple myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome

2009
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:6

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Brefeldin A; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Gene Expression; Heat-Shock Proteins; Humans; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thapsigargin; Transcription Factor CHOP; Transcription Factors; X-Box Binding Protein 1

2009
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
    Cancer immunology, immunotherapy : CII, 2009, Volume: 58, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Interferon Type I; Janus Kinases; Leukocytes, Mononuclear; Melanoma; Phosphorylation; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; Signal Transduction; STAT1 Transcription Factor; Up-Regulation

2009
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system.
    Journal of molecular medicine (Berlin, Germany), 2009, Volume: 87, Issue:8

    Topics: Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Humans; Leupeptins; Male; Monocytes; NF-kappa B; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2009
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
    Journal of hematology & oncology, 2009, Apr-28, Volume: 2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines; Remission Induction

2009
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
    Leukemia research, 2009, Volume: 33, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine

2009
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:2

    Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Virus Activation

2009
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    Experimental cell research, 2009, Aug-15, Volume: 315, Issue:14

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Topoisomerase II Inhibitors

2009
Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Anticancer research, 2009, Volume: 29, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Female; Humans; Immunoenzyme Techniques; Male; Mice; Mice, SCID; Mitosis; Neuroblastoma; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10

    Topics: Aged; Antineoplastic Agents; Apoptosis; Benzofurans; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma; Lymphoma, Non-Hodgkin; Male; Membrane Potential, Mitochondrial; Middle Aged; NF-kappa B; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured

2009
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Cancer research, 2009, May-15, Volume: 69, Issue:10

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunohistochemistry; Neoplasm Proteins; Polymerase Chain Reaction; Pyrazines; RNA, Neoplasm; RNA, Small Interfering

2009
Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets.
    Biochemical and biophysical research communications, 2009, Jul-17, Volume: 385, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; HIV Long Terminal Repeat; HIV-1; Humans; Mice; Mice, Inbred Strains; NF-kappa B; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Virus Replication

2009
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
    Experimental hematology, 2009, Volume: 37, Issue:7

    Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; DNA Primers; Drug Resistance, Neoplasm; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Mutation; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2009
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Blood, 2009, Jul-30, Volume: 114, Issue:5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; I-kappa B Proteins; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
[Bortezomib-induced eruption: Sweet syndrome? Two case reports].
    Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:5

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Colchicine; Dexamethasone; Female; Humans; Leukemia, Plasma Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Skin Ulcer; Sweet Syndrome; Treatment Outcome

2009
[Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration].
    Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:5

    Topics: Antigens, CD; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Ki-1 Antigen; Lymphocytes; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Skin Diseases

2009
[Bortezomib-induced acute neutrophilic dermatosis].
    Annales de dermatologie et de venereologie, 2009, Volume: 136, Issue:5

    Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neutrophils; Pyrazines; Skin Diseases; Sweet Syndrome

2009
High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.
    Biochemical and biophysical research communications, 2009, Jul-24, Volume: 385, Issue:2

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Inhibitors; Protein Biosynthesis; Protein Transport; Pyrazines; RNA, Transfer; Transfer RNA Aminoacylation

2009
New targets of PS-341: BAFF and APRIL.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Agents; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Delivery Systems; Female; Growth Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transcription Factors; Tumor Cells, Cultured

2010
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:6

    Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2009
The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; Creatinine; Cyclin-Dependent Kinase Inhibitor p21; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intravenous; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Necrosis; Nephritis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reperfusion Injury; Time Factors

2009
Piling up the JNK: drug synergy through ER stress.
    Cancer biology & therapy, 2009, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Nitriles; Protease Inhibitors; Pyrazines; Signal Transduction

2009
Abrogation of anti-HLA antibodies via proteasome inhibition.
    Transplantation, 2009, May-27, Volume: 87, Issue:10

    Topics: Adult; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; Histocompatibility Antigens Class I; HLA Antigens; HLA-D Antigens; Humans; Isoantibodies; Kidney Transplantation; Living Donors; Male; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transplantation, Homologous; Young Adult

2009
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Cell cycle (Georgetown, Tex.), 2009, Jun-15, Volume: 8, Issue:12

    Topics: Animals; Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chymotrypsin; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasms; Proteasome Inhibitors; Protein Conformation; Pyrazines; Serine Proteinase Inhibitors; Small Molecule Libraries; Xenograft Model Antitumor Assays

2009
Bortezomib-induced lupus erythematosus tumidus.
    The oncologist, 2009, Volume: 14, Issue:6

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Lupus Erythematosus, Cutaneous; Pyrazines

2009
Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis.
    European journal of pharmacology, 2009, Aug-15, Volume: 616, Issue:1-3

    Topics: Animals; Boronic Acids; Bortezomib; Heat-Shock Proteins; Male; Multienzyme Complexes; Pancreas; Pancreatitis; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar

2009
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine

2009
Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.
    British journal of haematology, 2009, Volume: 146, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Interactions; Flavonoids; Humans; Multiple Myeloma; Phenols; Polyphenols; Pyrazines

2009
Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2009, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Pancreatic Neoplasms; Plasmacytoma; Pyrazines; Retreatment; Treatment Outcome; Vincristine

2009
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
    Haematologica, 2009, Volume: 94, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Proliferation; Coculture Techniques; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Subsets; Phenotype; Proteasome Inhibitors; Pyrazines; T-Lymphocytes

2009
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-15, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cullin Proteins; Cyclopentanes; Humans; NEDD8 Protein; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidines; RING Finger Domains; Signal Transduction; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitins

2009
Effect of autophagy on multiple myeloma cell viability.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:7

    Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Proliferation; Chloroquine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunoblotting; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sirolimus; Thapsigargin; Tumor Cells, Cultured

2009
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
    Leukemia, 2009, Volume: 23, Issue:11

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Multiple Myeloma; Oligopeptides; Phenotype; Protease Inhibitors; Pyrazines

2009
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    European journal of haematology, 2009, Volume: 83, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Time Factors

2009
From orbital hybridization to chemotherapeutics neutralization.
    Blood, 2009, Jun-11, Volume: 113, Issue:24

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Flavonoids; Humans; Molecular Structure; Neoplasms; Phenols; Plant Extracts; Polyphenols; Protease Inhibitors; Pyrazines; Tea

2009
Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Pruritus; Pyrazines; Testis

2009
Rounding up apoptosis resistance targets in lung cancer.
    American journal of respiratory cell and molecular biology, 2009, Volume: 41, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; TNF-Related Apoptosis-Inducing Ligand

2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-20, Volume: 27, Issue:21

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Polyneuropathies; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome

2009
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
    Anticancer research, 2009, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2009
Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.
    International journal of hematology, 2009, Volume: 90, Issue:1

    Topics: Adult; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunoglobulin Light Chains; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation, Autologous

2009
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
    Cancer research, 2009, Jul-01, Volume: 69, Issue:13

    Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines

2009
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
    Journal of the National Cancer Institute, 2009, Jul-01, Volume: 101, Issue:13

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous

2009
Effects of the BH3-only protein human Noxa on mitochondrial dynamics.
    FEBS letters, 2009, Jul-21, Volume: 583, Issue:14

    Topics: Amino Acid Sequence; Animals; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Death; HeLa Cells; Humans; Leucine; Mitochondria; Molecular Sequence Data; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction

2009
Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Cutaneous and ocular toxicology, 2009, Volume: 28, Issue:3

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2009
[Apoptosis of Burkitt's lymphoma Raji cell line induced by bortezomib].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; NF-kappa B; Pyrazines; Tumor Suppressor Protein p53

2009
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cancer letters, 2009, Dec-28, Volume: 286, Issue:2

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dual Specificity Phosphatase 1; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Signal Transduction; Sulfones

2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Blood, 2009, Aug-27, Volume: 114, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide

2009
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
    Oncogene, 2009, Sep-10, Volume: 28, Issue:36

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 10; Caspase 8; Cell Line, Tumor; Drug Synergism; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, T-Cell; Membrane Microdomains; Microscopy, Confocal; Mitochondria; Multiple Myeloma; Phosphorylcholine; Pyrazines; Resveratrol; Signal Transduction; Stilbenes

2009
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
    Cardiovascular research, 2010, Jan-15, Volume: 85, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Leupeptins; Male; Myocardium; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar

2010
Bortezomib for the treatment of multiple myeloma patients.
    Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical

2009
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:7

    Topics: Aldehyde Reductase; Aldo-Keto Reductases; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Electrophoresis, Gel, Two-Dimensional; HSP72 Heat-Shock Proteins; Humans; Phosphorylation; Protease Inhibitors; Proteome; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured

2009
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:6

    Topics: Acyclovir; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies

2009
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Survival; Chloroquine; Colonic Neoplasms; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; HT29 Cells; Humans; Hydroxamic Acids; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Superoxides; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays

2010
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:7

    Topics: Animals; Antimalarials; Apoptosis; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chloroquine; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2009
Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Fibrosis; Gadolinium; Heart Failure; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Myocardium; Pyrazines

2010
Cutaneous myeloma and bortezomib.
    Annals of hematology, 2009, Volume: 88, Issue:10

    Topics: Aged; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Skin Neoplasms; Treatment Outcome

2009
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
    British journal of haematology, 2009, Volume: 146, Issue:6

    Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists; Histone Deacetylase Inhibitors; Lymphoma, Mantle-Cell; Mice; Protease Inhibitors; Pyrazines

2009
Worsening low back pain.
    The Journal of family practice, 2009, Volume: 58, Issue:7

    Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Family Practice; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Function Tests; Low Back Pain; Male; Multiple Myeloma; Pain Measurement; Plasmapheresis; Pyrazines; Renal Dialysis; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed

2009
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
    Leukemia research, 2010, Volume: 34, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor

2010
Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.
    Neurotoxicity research, 2010, Volume: 17, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Boronic Acids; Bortezomib; Cell Nucleus; Ganglia, Spinal; Gene Expression Regulation; Male; Microscopy, Electron, Transmission; Poly(A)-Binding Protein II; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sensory Receptor Cells; Time Factors; Ubiquitin; Uridine

2010
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhonghua nei ke za zhi, 2009, Volume: 48, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmacytoma; Prognosis; Pyrazines; Thalidomide

2009
[Establishment of a GFP-based cellular model for screening novel proteasome inhibitors].
    Sheng wu gong cheng xue bao = Chinese journal of biotechnology, 2009, Volume: 25, Issue:3

    Topics: Boronic Acids; Bortezomib; Cell Line; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Genetic Vectors; Green Fluorescent Proteins; Humans; Lentivirus; Models, Biological; Protease Inhibitors; Pyrazines

2009
Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cyclophosphamide; Dexamethasone; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome

2009
Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.
    Immunobiology, 2009, Volume: 214, Issue:9-10

    Topics: Animals; Boronic Acids; Bortezomib; Cell Differentiation; Dendritic Cells; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2009
Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Laboratory investigation; a journal of technical methods and pathology, 2009, Volume: 89, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Activation; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mitochondria; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Transplantation, Heterologous; Up-Regulation

2009
Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
    Annals of hematology, 2010, Volume: 89, Issue:2

    Topics: Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Middle Aged; POEMS Syndrome; Protease Inhibitors; Pyrazines; Treatment Outcome

2010
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Up-Regulation

2009
An audience with...Joseph Bolen. Interview by Bethan Hughes.
    Nature reviews. Drug discovery, 2009, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Industry; Humans; Medical Oncology; Neoplasms; Pyrazines

2009
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
    Cancer research, 2009, Aug-15, Volume: 69, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia; Mice; Mice, Nude; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Remission Induction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2009
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
    Leukemia research, 2010, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured

2010
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cyclin-Dependent Kinase Inhibitor p21; DNA Methylation; Gene Expression Profiling; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Microtubule-Associated Proteins; Mutation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Survivin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein

2009
Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Cells, Cultured; Endothelial Cells; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred C3H; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Protein C; Pyrazines; Thrombomodulin

2009
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Humans; Hyperthermia, Induced; Lymphoma, Mantle-Cell; Pyrazines

2009
Successful bortezomib-based treatment in POEMS syndrome.
    European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine

2009
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
    Human reproduction (Oxford, England), 2009, Volume: 24, Issue:11

    Topics: Animals; Boronic Acids; Bortezomib; Endometriosis; Female; Mice; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrrolidines; Thiocarbamates

2009
[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Time Factors

2009
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
    International journal of hematology, 2009, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tissue Donors; Transplantation, Homologous

2009
Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Basic research in cardiology, 2010, Volume: 105, Issue:1

    Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Boronic Acids; Bortezomib; Cells, Cultured; Female; Macrophages; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rabbits; Rupture, Spontaneous

2010
The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors.
    Journal of molecular neuroscience : MN, 2010, Volume: 40, Issue:1-2

    Topics: Animals; Boronic Acids; Bortezomib; Cell Compartmentation; Cell Membrane; Endoplasmic Reticulum; Enzyme Inhibitors; Golgi Apparatus; Nerve Tissue Proteins; Neurons; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Protein Subunits; Protein Transport; Pyrazines; Rats; Receptors, Nicotinic; Ubiquitin; Ubiquitination; Up-Regulation

2010
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
    European journal of pain (London, England), 2010, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Hot Temperature; Neural Conduction; Neurotoxicity Syndromes; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve

2010
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
    British journal of haematology, 2009, Volume: 147, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Follow-Up Studies; Gene Deletion; Humans; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53

2009
Activation of SHIP via a small molecule agonist kills multiple myeloma cells.
    Experimental hematology, 2009, Volume: 37, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Inositol Phosphates; Inositol Polyphosphate 5-Phosphatases; Mice; Multiple Myeloma; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Phosphorylation; Polycyclic Compounds; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction

2009
Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Clinical transplants, 2008

    Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Living Donors; Male; Middle Aged; Plasma Cells; Plasmapheresis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult

2008
[Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].
    Terapevticheskii arkhiv, 2009, Volume: 81, Issue:7

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Neoplasm Staging; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence

2009
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.
    Blood, 2009, Oct-29, Volume: 114, Issue:18

    Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2009
Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:4

    Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neuralgia, Postherpetic; Peripheral Nervous System Diseases; Pyrazines

2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome

2009
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Embryo, Nonmammalian; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyruvates; Reverse Transcriptase Polymerase Chain Reaction; Zebrafish

2009
Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.
    International journal of hematology, 2009, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Insomnia, Fatal Familial; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Transplantation Conditioning

2009
Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Hematological oncology, 2010, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Respiratory Insufficiency; Survival Rate

2010
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
    Acta haematologica, 2009, Volume: 122, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation

2009
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.
    Acta haematologica, 2009, Volume: 122, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prognosis; Pyrazines

2009
[PAD regimen for relapsed or refractory patients with multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2009
Bortezomib: a new therapeutic option for POEMS syndrome.
    European journal of haematology, 2010, Feb-01, Volume: 84, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Glycoproteins; Humans; Male; POEMS Syndrome; Pyrazines; Remission Induction

2010
Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.
    Journal of cellular biochemistry, 2009, Nov-01, Volume: 108, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; CD4-Positive T-Lymphocytes; Cytochromes c; Dendritic Cells; Dimerization; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Mitochondria; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2009
Therapeutic use of tea derivatives: all that glitters is not gold.
    Blood, 2009, Sep-10, Volume: 114, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea

2009
Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.
    Chembiochem : a European journal of chemical biology, 2009, Nov-02, Volume: 10, Issue:16

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Leukemia, Experimental; Magnetic Resonance Spectroscopy; Mice; Peptides, Cyclic; Proteasome Endopeptidase Complex; Pyrazines; Spectrometry, Mass, Electrospray Ionization

2009
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Oct-01, Volume: 183, Issue:7

    Topics: Benzoquinones; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; HSP90 Heat-Shock Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Lactams, Macrocyclic; Ligands; Multiple Myeloma; Protein Folding; Pyrazines; Up-Regulation

2009
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
    Journal of neuro-oncology, 2010, Volume: 97, Issue:2

    Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Drug Synergism; Esthesioneuroblastoma, Olfactory; Flow Cytometry; Humans; Immunohistochemistry; Male; Nose Neoplasms; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2010
Selectively killing transformed cells through proteasome inhibition.
    Cell cycle (Georgetown, Tex.), 2009, Oct-01, Volume: 8, Issue:19

    Topics: Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitination

2009
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Leukemia research, 2009, Volume: 33, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
    Leukemia research, 2010, Volume: 34, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Tissue Inhibitor of Metalloproteinase-1

2010
Relapse/Refractory myeloma patient: potential treatment guidelines.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2004
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4

    Topics: Boronic Acids; Bortezomib; Gene Expression Profiling; Humans; Paraproteinemias; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2004
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
    Cancer cell, 2009, Oct-06, Volume: 16, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Communication; Cell Proliferation; Cell Survival; Chemotaxis; Coculture Techniques; Cytokines; Dendritic Cells; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Immunologic; Signal Transduction; T-Lymphocytes; Time Factors; Toll-Like Receptors; Transplantation, Heterologous; Tumor Cells, Cultured

2009
Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
    Urology, 2010, Volume: 75, Issue:4

    Topics: Androgens; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured

2010
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells

2010
Home administration of bortezomib: making a difference to myeloma patients' lives.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2010, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Home Care Services; Humans; Injections, Intravenous; Ireland; Male; Multiple Myeloma; Pilot Projects; Pyrazines; Treatment Outcome

2010
Captivating bortezomib: an active but still mysterious drug.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Treatment Outcome

2010
BU-32: a novel proteasome inhibitor for breast cancer.
    Breast cancer research : BCR, 2009, Volume: 11, Issue:5

    Topics: Animals; Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chymotrypsin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays

2009
[Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2009, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Myeloma Proteins; Proteome; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2009
Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.
    Leukemia research, 2010, Volume: 34, Issue:2

    Topics: Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Humans; Lymphoma; Pyrazines; Pyrazoles; Stress, Physiological; Sulfonamides

2010
[Update in multiple myeloma: international criteria for treatment response and renal complications].
    La Revue de medecine interne, 2009, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; France; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Immunologic Factors; International Cooperation; Kidney Diseases; Multiple Myeloma; Practice Guidelines as Topic; Prevalence; Pyrazines; Renal Dialysis; Renal Insufficiency; Sensitivity and Specificity; Societies, Medical

2009
First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Plasmacytoma; Pyrazines; Spinal Cord Compression; Treatment Outcome

2010
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
    Blood, 2010, Jan-07, Volume: 115, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mesenchymal Stem Cells; Microtubule-Associated Proteins; Multiple Myeloma; Osteoclasts; Phenotype; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrazines; Risk Factors; Signal Transduction; Survivin

2010
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Jurkat Cells; Lymphoma, T-Cell; Proteasome Inhibitors; Pyrazines

2009
The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Nov-15, Volume: 183, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Epitopes; Interferon-gamma; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Mice; Mice, Inbred C57BL; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2009
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
    Cancer research, 2009, Nov-01, Volume: 69, Issue:21

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured

2009
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Blood, 2009, Dec-17, Volume: 114, Issue:26

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mast Cells; Mastocytosis, Systemic; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Staurosporine; Transfection

2009
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Lipoma; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines

2010
Bortezomib and restoration of chemosensitivity.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines

2009
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.
    Oncogene, 2010, Jan-21, Volume: 29, Issue:3

    Topics: Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Immunoblotting; Lactones; Lysosomes; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Activating Enzymes

2010
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:11

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Gene Expression Profiling; Glioblastoma; Glutathione; Humans; Microarray Analysis; Necrosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrans; Pyrazines; Sulfhydryl Compounds; Ubiquitin

2009
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence

2010
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
    Leukemia, 2010, Volume: 24, Issue:1

    Topics: Acetylcysteine; ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Hydroxamic Acids; Ki-1 Antigen; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Sulfonamides; Syndecan-1

2010
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine

2010
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.
    International journal of cancer, 2010, Jul-01, Volume: 127, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Mice; Mice, Nude; Osteosarcoma; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous

2010
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
    Neoplasma, 2010, Volume: 57, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide

2010
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.
    Cell cycle (Georgetown, Tex.), 2009, Volume: 8, Issue:23

    Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Neoplasms; Pyrazines; Quinacrine; RNA, Small Interfering; Transcription Factors

2009
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
    Haematologica, 2010, Volume: 95, Issue:3

    Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Recurrence; Transplantation, Autologous

2010
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:1

    Topics: Animals; Antigen Presentation; Boronic Acids; Bortezomib; Capsid Proteins; CD8-Positive T-Lymphocytes; Cell Line; Dependovirus; Genes, MHC Class I; Genetic Vectors; Hemophilia B; Humans; Mice; Protease Inhibitors; Pyrazines; Transduction, Genetic

2010
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
    Leukemia, 2009, Volume: 23, Issue:11

    Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Drug Interactions; Humans; Multiple Myeloma; Pyrazines

2009
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
    Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:1

    Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide

2010
CYT997 causes apoptosis in human multiple myeloma.
    Investigational new drugs, 2011, Volume: 29, Issue:2

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Fluorescent Antibody Technique; G2 Phase; Humans; Mice; Mitosis; Multiple Myeloma; Polymerization; Pyrazines; Pyridines; Pyrimidines; Survival Analysis; Time Factors; Tubulin

2011
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid

2010
Bortezomib induces autophagic death in proliferating human endothelial cells.
    Experimental cell research, 2010, Apr-01, Volume: 316, Issue:6

    Topics: Adenine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Endothelial Cells; Fibroblast Growth Factors; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Protease Inhibitors; Pyrazines; Reactive Oxygen Species

2010
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    British journal of haematology, 2010, Volume: 148, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine

2010
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured

2010
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape

2010
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.
    Leukemia, 2010, Volume: 24, Issue:1

    Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; Hot Temperature; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, B-Cell; NF-kappa B; Protein Biosynthesis; Pyrazines; Signal Transduction; Transcription Factor RelA; Transcription Factors; Ubiquitin-Protein Ligases

2010
High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay.
    International journal of cancer, 2010, Jul-15, Volume: 127, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD40 Ligand; Cell Nucleus; Enzyme-Linked Immunosorbent Assay; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luminescent Measurements; Lymphocytes; NF-kappa B; Oligonucleotides; Pyrazines; Tumor Necrosis Factor-alpha

2010
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays

2010
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide

2010
Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
    Toxicology, 2010, Jan-31, Volume: 268, Issue:1-2

    Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Chlorocebus aethiops; Cytokines; Enzyme Inhibitors; Inflammation; Mice; Mice, Inbred BALB C; Proteasome Inhibitors; Pyrazines; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vero Cells; Virus Replication

2010
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:12

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Magnetic Resonance Imaging; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays

2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53

2009
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Cancer research, 2009, Dec-15, Volume: 69, Issue:24

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB

2009
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
    International journal of cancer, 2010, Jul-15, Volume: 127, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Luciferases; Multiple Myeloma; Pentacyclic Triterpenes; Protease Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Triterpenes; Tumor Cells, Cultured

2010
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
    The Journal of investigative dermatology, 2010, Volume: 130, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms

2010
Hematology: first-line bortezomib benefits patients with multiple myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Prognosis; Pyrazines

2009
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
    Oncogene, 2010, Mar-11, Volume: 29, Issue:10

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Chymotrypsin; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Polymerase II; Signal Transduction

2010
[IgA pemphigus accompanying multiple myeloma].
    Vnitrni lekarstvi, 2009, Volume: 55, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Proteasome Inhibitors; Pyrazines

2009
Bortezomib inhibits hepatitis B virus replication in transgenic mice.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Cytokines; DNA, Viral; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Immunohistochemistry; Liver; Mice; Mice, Transgenic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication

2010
[Effect of bortezomib on acute graft-versus-host disease in mice model and its mechanism].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:6

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Disease Models, Animal; Female; Graft vs Host Disease; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Tumor Necrosis Factor-alpha

2009
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:6

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome

2009
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Haematologica, 2010, Volume: 95, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays

2010
Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Annals of hematology, 2010, Volume: 89, Issue:8

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2010
[Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome

2009
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    British journal of haematology, 2010, Volume: 148, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2010
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; Flow Cytometry; Humans; Mesothelioma; Pilot Projects; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Time Factors

2010
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4

    Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation

2010
Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.
    Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:21-22

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Erythema Multiforme; Humans; Male; Middle Aged; Pyrazines

2009
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Transplantation proceedings, 2009, Volume: 41, Issue:10

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Pyrazines; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2009
The potential effect of proteasome inhibitor PS-341 on severe acute pancreatitis detected by positron emission tomography in ICR mice.
    The Journal of surgical research, 2010, Volume: 162, Issue:2

    Topics: Amylases; Animals; Apoptosis; Boronic Acids; Bortezomib; C-Reactive Protein; Ceruletide; Female; Inflammation; Interleukin-1beta; L-Lactate Dehydrogenase; Mice; Mice, Inbred ICR; Pancreatitis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiography

2010
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Life sciences, 2010, Jan-30, Volume: 86, Issue:5-6

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Down-Regulation; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Humans; In Situ Nick-End Labeling; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2010
Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Tomography, X-Ray Computed; Vincristine

2009
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells.
    Acta biochimica et biophysica Sinica, 2009, Volume: 41, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Catechin; Cell Line, Tumor; Humans; Multiple Myeloma; Polymerase Chain Reaction; Pyrazines; RNA, Messenger; Tea; Transcription Factor RelA

2009
Salmonella enteritidis necrotising fasciitis in a multiple myeloma patient receiving bortezomib.
    International journal of hematology, 2010, Volume: 91, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fasciitis, Necrotizing; Humans; Male; Multiple Myeloma; Pyrazines; Salmonella enteritidis; Salmonella Infections

2010
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
    International journal of hematology, 2010, Volume: 91, Issue:1

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Protease Inhibitors; Pyrazines

2010
Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.
    The Journal of biological chemistry, 2010, Feb-26, Volume: 285, Issue:9

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Fenretinide; Humans; Neuroectodermal Tumors; Pyrazines; Signal Transduction; Stress, Physiological

2010
Treatment of multiple myeloma: 2009 update.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2009
Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
    Journal of immunology (Baltimore, Md. : 1950), 2010, Feb-01, Volume: 184, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Clone Cells; Coculture Techniques; Cytotoxicity Tests, Immunologic; Epitopes, T-Lymphocyte; Immunity, Innate; Immunization; Killer Cells, Natural; Melanoma, Experimental; Mice; Mice, SCID; Pyrazines; T-Lymphocytes, Cytotoxic

2010
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
    Cancer research, 2010, Jan-01, Volume: 70, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; Gene Expression; Histones; Humans; Immunoprecipitation; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2010
Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
    Transplantation, 2009, Dec-27, Volume: 88, Issue:12

    Topics: Animals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance; Graft Rejection; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Macaca mulatta; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines; Sirolimus; Swine; Swine, Miniature; T-Lymphocytes; T-Lymphocytes, Regulatory

2009
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines

2009
[Retrospective analysis of 71 cases of multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2009
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine

2010
[IgA multiple myeloma with adverse prognostic factors--a case report].
    Przeglad lekarski, 2009, Volume: 66, Issue:8

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Humans; Immunoglobulin A; Male; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide

2009
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Imidazoles; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Osteoblasts; Proteoglycans; Pyrazines; Quinoxalines; Receptor Cross-Talk; Receptor, TIE-2; Signal Transduction

2010
The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
    The Journal of biological chemistry, 2010, Mar-05, Volume: 285, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Protease Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Death Domain; Signal Transduction; Transgenes

2010
Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:8

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Ki-1 Antigen; Male; Multiple Myeloma; Pyrazines; T-Lymphocyte Subsets

2009
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
    The Prostate, 2010, Jun-01, Volume: 70, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Nitrophenols; Nucleosides; Peptides; Piperazines; Prostate; Pyrazines; Pyrimidines; Sulfonamides; Thiostrepton

2010
Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recovery of Function; Renal Insufficiency; Time Factors; Treatment Outcome

2010
Acute humoral rejection in a lung recipient: reversion with bortezomib.
    Transplantation, 2010, Jan-15, Volume: 89, Issue:1

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Cadaver; Female; Graft Rejection; Humans; Immunity, Humoral; Lung Transplantation; Middle Aged; Postoperative Complications; Protease Inhibitors; Pyrazines; T-Lymphocytes; Tissue Donors; Treatment Outcome

2010
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
    PLoS genetics, 2010, Volume: 6, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line; Cells, Cultured; Cystathionine beta-Synthase; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Gene Expression; Homocystinuria; HSP70 Heat-Shock Proteins; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Proteasome Inhibitors; Pyrazines; Saccharomyces cerevisiae

2010
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Mice; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays

2010
Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis.
    Cancer research, 2010, Jan-15, Volume: 70, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Line, Tumor; Down-Regulation; Endopeptidases; Etoposide; Gene Silencing; Humans; Interferon alpha-2; Interferon-alpha; Protease Inhibitors; Pyrazines; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Ubiquitin Thiolesterase

2010
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
    Blood, 2010, Mar-18, Volume: 115, Issue:11

    Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2010
[IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:12

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Vincristine

2009
The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Graft Rejection; Histocompatibility Testing; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Plasmapheresis; Pyrazines; Rituximab; Transplantation Immunology

2010
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
    Leukemia, 2010, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2010
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Melphalan; Mice; Mice, SCID; Molecular Structure; Multiple Myeloma; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyridines; STAT3 Transcription Factor; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Drug discovery and assay development in the ubiquitin-proteasome system.
    Biochemical Society transactions, 2010, Volume: 38, Issue:Pt 1

    Topics: Antineoplastic Agents; Biological Assay; Boronic Acids; Bortezomib; Drug Discovery; Drug Resistance, Neoplasm; Molecular Structure; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2010
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Leukemia research, 2010, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Bone Remodeling; Boronic Acids; Bortezomib; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Osteoblasts; Osteolysis, Essential; Pyrazines; Sp7 Transcription Factor; Transcription Factors

2010
[The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
    Zhonghua nei ke za zhi, 2009, Volume: 48, Issue:9

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome

2009
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous

2010
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
    Talanta, 2010, Feb-15, Volume: 80, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence

2010
A proteasome inhibitor to treat acute pancreatitis? Maybe...
    The Journal of surgical research, 2010, Volume: 162, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Pancreatitis, Acute Necrotizing; Proteasome Inhibitors; Pyrazines

2010
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome

2010
Bortezomib: a new pro-apoptotic agent in cancer treatment.
    Current cancer drug targets, 2010, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Humans; Mice; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Proteasome Inhibitors; Pyrazines

2010
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.
    Journal of experimental & clinical cancer research : CR, 2010, Jan-22, Volume: 29

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasms; Pyrazines; RNA, Small Interfering; Survivin

2010
Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.
    Cancer science, 2010, Volume: 101, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Size; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Transcription Factors; Transcriptional Activation

2010
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide

2010
Functional evaluation of therapeutic response for a mouse model of medulloblastoma.
    Transgenic research, 2010, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Ataxia; Boronic Acids; Bortezomib; Cerebellar Neoplasms; Disease Models, Animal; Disease Progression; Drug Screening Assays, Antitumor; Gait Disorders, Neurologic; Lameness, Animal; Magnetic Resonance Imaging; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; Protease Inhibitors; Psychomotor Performance; Pyrazines; Receptors, Cell Surface

2010
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.
    Blood, 2010, Jan-28, Volume: 115, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin M; Protease Inhibitors; Pyrazines

2010
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
    Autophagy, 2010, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cathepsins; Cell Death; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Estrogen Receptor Modulators; Female; Humans; Metabolism; Pyrazines; Receptors, Estrogen; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured

2010
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:3

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Survival; HLA Antigens; Humans; Immunohistochemistry; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome

2010
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
    Veterinary pathology, 2010, Volume: 47, Issue:2

    Topics: Acetylcysteine; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Oligopeptides; PC12 Cells; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Ubiquitin

2010
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
    International journal of oncology, 2010, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2010
[2-methoxyestradiol disrupts aggresomes induction by bortezomib and potentiates apoptosis in multiple myeloma cells.].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:11

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Pyrazines

2009
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous

2010
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Risk Management; Risk Reduction Behavior; Thalidomide

2010
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Transplantation, 2010, Feb-15, Volume: 89, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunologic Factors; Immunosuppression Therapy; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Protease Inhibitors; Pyrazines; Rituximab; Transplantation, Homologous; Young Adult

2010
Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:3

    Topics: Aged; Boronic Acids; Bortezomib; Capillary Leak Syndrome; Dexamethasone; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Secondary Prevention

2010
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
    Anticancer research, 2010, Volume: 30, Issue:1

    Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines

2010
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Cancer research, 2010, Mar-01, Volume: 70, Issue:5

    Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2010
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
    Cancer research, 2010, Mar-01, Volume: 70, Issue:5

    Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Combined Modality Therapy; Enzyme Activation; Granzymes; Humans; Immunotherapy, Adoptive; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Melanoma; Mitochondria; Mitochondrial Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Cell Surface; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Transfection; X-Linked Inhibitor of Apoptosis Protein

2010
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice.
    Experimental neurology, 2010, Volume: 223, Issue:2

    Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Female; Ganglia, Spinal; Immunohistochemistry; Mice; Microscopy, Electron; Motor Neurons; Myelin Sheath; Nerve Fibers, Unmyelinated; Neural Conduction; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Skin; Tibial Nerve

2010
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
    European journal of haematology, 2010, Volume: 85, Issue:1

    Topics: 3T3 Cells; Acyltransferases; Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Fibroblast Growth Factor 2; Humans; Mice; Models, Biological; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; RNA, Messenger; Transcription Factors

2010
[Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Jurkat Cells; Poly(ADP-ribose) Polymerases; Pyrazines

2009
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
    Blood, 2010, May-06, Volume: 115, Issue:18

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Biotinylation; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunoprecipitation; Lymphoma, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger

2010
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
    Leukemia, 2010, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Galectins; Gene Expression Profiling; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Multiple Myeloma; Mutation; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Whole-Body Irradiation; Xenograft Model Antitumor Assays

2010
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
    Stroke, 2010, Volume: 41, Issue:5

    Topics: Aging; Animals; Boronic Acids; Bortezomib; Brain Ischemia; Drug Administration Schedule; Drug Therapy, Combination; Intracranial Embolism; Male; Neuroprotective Agents; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Tissue Plasminogen Activator

2010
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
    Cancer immunology, immunotherapy : CII, 2010, Volume: 59, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Transgenic; Oligodeoxyribonucleotides; Pyrazines; Rats; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 9; Treatment Outcome

2010
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
    Clinical neurosurgery, 2009, Volume: 56

    Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured

2009
Multiple myeloma patients experience high response rate with new three-drug combination.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2009
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Molecular cancer, 2010, Mar-10, Volume: 9

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Inflammation; Inflammation Mediators; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Pleural Effusion, Malignant; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2010
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Calreticulin; Caspase 8; Cell Line, Tumor; Child; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrazines; Vorinostat

2010
Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Pyrazines

2010
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Blood, 2010, Jun-03, Volume: 115, Issue:22

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Mitochondria; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays

2010
[Effect of bortezomib and arabinoside on proliferation and apoptosis of K562 cell.].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2010, Volume: 31, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; K562 Cells; Pyrazines

2010
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
    The American journal of pathology, 2010, Volume: 176, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Dystroglycans; Evans Blue; Gene Expression Regulation; Glycoproteins; Mice; Mice, Inbred C57BL; Muscular Dystrophy, Duchenne; Mutation; Proteasome Inhibitors; Pyrazines; Sarcoglycans; Ubiquitin

2010
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.
    Oncogene, 2010, Jun-03, Volume: 29, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Growth Processes; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphorylation; Piperazines; Pyrazines; Pyrimidines; Retinoblastoma Protein

2010
Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
    Bone marrow transplantation, 2011, Volume: 46, Issue:2

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Tissue Donors; Transplantation, Homologous

2011
A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Division; Cell Line, Tumor; Chymotrypsin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Organometallic Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrones

2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
    The Journal of biological chemistry, 2010, May-21, Volume: 285, Issue:21

    Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Calpain; Caspase 8; Cell Line, Tumor; Cell Nucleus; Humans; I-kappa B Proteins; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Transcription Factor RelA

2010
Acute dyspnea from treatment of AL amyloidisis with bortezomib.
    American journal of therapeutics, 2011, Volume: 18, Issue:4

    Topics: Acute Disease; Aged; Amyloidosis; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Dyspnea; Humans; Kidney Diseases; Male; Middle Aged; Protease Inhibitors; Pyrazines

2011
Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
    Transplantation, 2010, Jun-15, Volume: 89, Issue:11

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Male; Monitoring, Immunologic; Nephritis, Interstitial; Protease Inhibitors; Pyrazines; Renal Dialysis

2010
Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:11

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lupus Erythematosus, Cutaneous; Male; Multiple Myeloma; Pyrazines

2010
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
    Blood, 2010, Jul-08, Volume: 116, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Vincristine

2010
Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
    British journal of haematology, 2010, Volume: 150, Issue:2

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Protease Inhibitors; Pyrazines; Skin Diseases, Vascular; Vasculitis

2010
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Frail Elderly; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Treatment Outcome

2010
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
    Blood, 2010, Jul-22, Volume: 116, Issue:3

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Depsipeptides; Down-Regulation; Drug Synergism; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sp1 Transcription Factor; Xenograft Model Antitumor Assays

2010
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays

2010
Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Leukemia research, 2010, Volume: 34, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hyperlipidemias; Multiple Myeloma; Pyrazines

2010
[Waldenström's macroglobulinemia].
    La Revue de medecine interne, 2010, Volume: 31, Issue:5

    Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Male; Nucleosides; Phosphorylcholine; Prognosis; Protease Inhibitors; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia

2010
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
    Cancer science, 2010, Volume: 101, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Capillary Permeability; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cells, Cultured; Cyclin B; Cyclin-Dependent Kinases; Endothelial Cells; G2 Phase; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vascular Endothelial Growth Factor A

2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Acyclovir; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; T-Lymphocytes

2010
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide

2010
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat

2010
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Aged; Asian People; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fatal Outcome; Hematologic Neoplasms; Humans; Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Male; Pyrazines

2010
Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:6

    Topics: Acetylcysteine; Animals; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Cytokines; HLA-DR3 Antigen; Lipopolysaccharides; Liver; Mice; Mice, Transgenic; NF-kappa B; Proteasome Inhibitors; Pyrazines; Superantigens; Systemic Inflammatory Response Syndrome

2010
Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.
    Yonsei medical journal, 2010, Volume: 51, Issue:3

    Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Pyrazines; Thalidomide

2010
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
    Haematologica, 2010, Volume: 95, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination

2010
[Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:3

    Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pulse Therapy, Drug; Pyrazines; Risk; Survival Rate; Thalidomide; Transplantation, Autologous

2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Blood, 2010, Jun-24, Volume: 115, Issue:25

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Doxorubicin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Spindle Apparatus; Time Factors; Transplantation, Heterologous; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2010
Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
    Die Pharmazie, 2010, Volume: 65, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression; Humans; Indicators and Reagents; Neuroblastoma; NF-kappa B; Oncogene Protein p21(ras); Poly(ADP-ribose) Polymerases; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Up-Regulation

2010
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
    Cancer research, 2010, May-01, Volume: 70, Issue:9

    Topics: Adipocytes; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Communication; Coculture Techniques; Enzyme Activation; Female; HeLa Cells; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Transduction, Genetic; Uterine Cervical Neoplasms

2010
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
    Onkologie, 2010, Volume: 33, Issue:4

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome

2010
Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Pyrazines; Stomach Neoplasms; TNF-Related Apoptosis-Inducing Ligand

2010
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
    International journal of colorectal disease, 2010, Volume: 25, Issue:7

    Topics: Apoptosis; Aspirin; bcl-Associated Death Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines

2010
Complete heart block secondary to bortezomib use in multiple myeloma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System; Boronic Acids; Bortezomib; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Block; Humans; Multiple Myeloma; Pacemaker, Artificial; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2011
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
    Cancer research, 2010, May-01, Volume: 70, Issue:9

    Topics: Benzoquinones; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clathrin; Down-Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lysosomes; Mass Spectrometry; Microscopy, Fluorescence; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Ubiquitination

2010
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 139, Issue:5

    Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat

2010
What should work, may not.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:3

    Topics: Boronic Acids; Bortezomib; Drug Approval; Drug Labeling; Drug Prescriptions; Humans; Immunosuppressive Agents; Off-Label Use; Organ Transplantation; Pyrazines; Research Design; United States; United States Food and Drug Administration

2010
The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
    Journal of leukocyte biology, 2010, Volume: 88, Issue:1

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Dermatitis, Allergic Contact; Interferon-gamma; Mice; Mice, Inbred C57BL; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; T-Lymphocytes

2010
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Cancer biology & therapy, 2010, Jun-01, Volume: 9, Issue:11

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2010
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous

2010
Treatment of newly diagnosed multiple myeloma.
    Current hematologic malignancy reports, 2008, Volume: 3, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2008
Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
    American journal of hematology, 2010, Volume: 85, Issue:5

    Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Protease Inhibitors; Pyrazines; von Willebrand Diseases

2010
Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Boronic Acids; Bortezomib; Cell Line; Collagen; Collagen Type I; Fibroblasts; Gene Expression; Immunoglobulins; Matrix Metalloproteinase 1; Protease Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; RNA, Messenger; Skin; Transcription, Genetic

2010
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
    Journal of the peripheral nervous system : JPNS, 2010, Volume: 15, Issue:1

    Topics: Age Factors; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Incidence; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neurologic Examination; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Severity of Illness Index; Vincristine

2010
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Molecular cancer research : MCR, 2010, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2010
Bortezomib-induced acute pancreatitis.
    JOP : Journal of the pancreas, 2010, May-05, Volume: 11, Issue:3

    Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines

2010
Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.
    International journal of hematology, 2010, Volume: 91, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Coronary Vessels; Dexamethasone; Female; Humans; Multiple Myeloma; Myocardial Infarction; Pyrazines

2010
Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
    Cancer research, 2010, Jun-01, Volume: 70, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; DNA Damage; Gene Knockdown Techniques; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Protease Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrazines; Ribosomes; RNA, Small Interfering; TOR Serine-Threonine Kinases; Transfection

2010
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    British journal of cancer, 2010, Jun-08, Volume: 102, Issue:12

    Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Interactions; Drug Synergism; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2010
Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:11

    Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Graft Rejection; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Lymphocyte Depletion; Male; Plasma Cells; Pyrazines; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus; Spleen; T-Lymphocytes; Transplantation, Homologous

2010
[Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin A; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Severity of Illness Index

2010
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2010
Clinical management of myeloma--state of the art.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2010
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Carcinogenesis, 2010, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line; GTP-Binding Protein alpha Subunits, G12-G13; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger

2010
Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Molecular cancer, 2010, May-18, Volume: 9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Mesothelioma; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcription Factor CHOP; Transfection; Unfolded Protein Response

2010
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
    Journal of virology, 2010, Volume: 84, Issue:15

    Topics: Animals; Boronic Acids; Bortezomib; Cats; Cell Line; Chlorocebus aethiops; Coronavirus Infections; Coronavirus, Feline; Leupeptins; Mice; Murine hepatitis virus; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Severe acute respiratory syndrome-related coronavirus; Ubiquitin; Virus Internalization; Virus Release; Virus Replication

2010
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
    Journal of virology, 2010, Volume: 84, Issue:15

    Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Coronavirus Infections; Hepatitis, Viral, Animal; Mice; Mice, Inbred C57BL; Murine hepatitis virus; Protease Inhibitors; Pyrazines; Survival Analysis

2010
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid

2010
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14

    Topics: Aminopterin; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspase 9; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lymphoma, T-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Xenograft Model Antitumor Assays

2010
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
    Blood, 2010, Aug-26, Volume: 116, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Pyrazines; Receptors, Glucocorticoid; Survival Rate; Thalidomide; Treatment Outcome

2010
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Journal of the National Cancer Institute, 2010, Jul-21, Volume: 102, Issue:14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyquinolines; Immunoblotting; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Transplantation, Heterologous

2010
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
    Leukemia research, 2010, Volume: 34, Issue:10

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide

2010
Treatment with bortezomib of a patient having hyper IgG4 disease.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Eyelid Diseases; Female; Humans; Immune System Diseases; Immunoglobulin G; Middle Aged; Plasma Cell Granuloma, Pulmonary; Prednisone; Pyrazines; Tomography, X-Ray Computed

2010
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
    Mayo Clinic proceedings, 2010, Volume: 85, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide

2010
Regulation of autophagy by ATF4 in response to severe hypoxia.
    Oncogene, 2010, Aug-05, Volume: 29, Issue:31

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Base Sequence; Boronic Acids; Bortezomib; Cell Hypoxia; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Oxygen; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Unfolded Protein Response; Validation Studies as Topic

2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Caspase 3; Cell Adhesion; Cell Death; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Protein Binding; Pyrazines; Sesquiterpenes; Transcription Factor RelA

2010
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Humans; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2010
Cardiotoxicity of the anticancer therapeutic agent bortezomib.
    The American journal of pathology, 2010, Volume: 176, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Respiration; Echocardiography; Female; Heart; Heart Diseases; Humans; Male; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Myocytes, Cardiac; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Ventricular Dysfunction, Left

2010
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
    The Journal of investigative dermatology, 2010, Volume: 130, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Vitro Techniques; Male; Melanoma; Middle Aged; Mutation; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Pyrazines; RNA, Small Interfering; Skin Neoplasms; Stress, Physiological; X-Linked Inhibitor of Apoptosis Protein

2010
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol.
    Clinical transplants, 2009

    Topics: Adrenal Cortex Hormones; Adult; Biopsy; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Follow-Up Studies; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; India; Kidney Transplantation; Living Donors; Prednisone; Protease Inhibitors; Pyrazines; Young Adult

2009
A summary of bortezomib use in transplantation across 29 centers.
    Clinical transplants, 2009

    Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Lung Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Safety

2009
Bortezomib in kidney transplant desensitization: a case report.
    Clinical transplants, 2009

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; B-Lymphocytes; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Histocompatibility Testing; HLA-A Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Mycophenolic Acid; Pyrazines; Rituximab; Waiting Lists

2009
Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Clinical transplants, 2009

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; HLA-DQ Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Immunologic Factors; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Peritoneal Dialysis; Plasmapheresis; Polycystic Kidney Diseases; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Rituximab; Treatment Failure

2009
Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
    Clinical transplants, 2009

    Topics: Autoantibodies; Boronic Acids; Bortezomib; Desensitization, Immunologic; Flow Cytometry; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines

2009
Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
    Clinical transplants, 2009

    Topics: Adult; Boronic Acids; Bortezomib; Creatinine; Desensitization, Immunologic; Graft Survival; Humans; Isoantibodies; Kidney Neoplasms; Living Donors; Lymphocytes; Male; Protease Inhibitors; Pyrazines; Treatment Outcome

2009
Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
    Clinical transplants, 2009

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility Testing; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Plasma Exchange; Protease Inhibitors; Pyrazines; Rituximab; Treatment Outcome

2009
Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
    Clinical transplants, 2009

    Topics: Adult; Autoantibodies; Biopsy; Boronic Acids; Bortezomib; Cadaver; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Living Donors; Male; Mexico; Protease Inhibitors; Pyrazines; T-Lymphocytes; Tissue Donors; Treatment Outcome

2009
The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
    Clinical transplants, 2009

    Topics: Adult; Autoantibodies; Boronic Acids; Bortezomib; Cadaver; Creatinine; Female; Histocompatibility Antigens Class I; HLA Antigens; HLA-D Antigens; HLA-DQ Antigens; Humans; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Male; Middle Aged; Protease Inhibitors; Pyrazines; Tissue Donors

2009
Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Clinical transplants, 2009

    Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Boronic Acids; Bortezomib; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Plasmapheresis; Protease Inhibitors; Pyrazines; Rituximab

2009
Bortezomib affects the function of human B cells: possible implications for desensitization protocols.
    Clinical transplants, 2009

    Topics: Antigens, CD19; Apoptosis; Autoantibodies; B-Lymphocytes; Blood Banks; Boronic Acids; Bortezomib; Desensitization, Immunologic; HLA Antigens; Humans; Immunoglobulin G; Immunoglobulin M; Leukocytes, Mononuclear; Lymphocyte Activation; Protease Inhibitors; Pyrazines

2009
Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
    Clinical transplants, 2009

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Cardiomyopathies; Desensitization, Immunologic; Female; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Isoantibodies; Lung Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Transfusion Reaction; Waiting Lists

2009
Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
    Clinical transplants, 2009

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Male; Protease Inhibitors; Pyrazines; Renal Dialysis; Rituximab; T-Lymphocytes; Treatment Failure; Treatment Outcome

2009
Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Clinical transplants, 2009

    Topics: Adrenal Cortex Hormones; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; Rituximab; Treatment Outcome

2009
Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
    Clinical transplants, 2009

    Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Flow Cytometry; Graft Rejection; Humans; Immunization; Immunophenotyping; Kidney Transplantation; Male; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Renal Dialysis

2009
Bortezomib in lung transplantation: a promising start.
    Clinical transplants, 2009

    Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Lung Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines

2009
Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Clinical transplants, 2009

    Topics: B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Follow-Up Studies; Graft Rejection; Hepatitis C; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; T-Lymphocytes

2009
Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Clinical transplants, 2009

    Topics: Acute Disease; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Immunoglobulins, Intravenous; Immunologic Factors; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines

2009
Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
    Clinical transplants, 2009

    Topics: Adult; Boronic Acids; Bortezomib; Female; HLA Antigens; HLA-DQ Antigens; Humans; Isoantibodies; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Failure; Treatment Outcome

2009
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
    Clinical transplants, 2009

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus

2009
Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Clinical transplants, 2009

    Topics: Adult; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Humans; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pancreas Transplantation; Protease Inhibitors; Pyrazines; Transplantation, Homologous; Treatment Outcome

2009
Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Clinical transplants, 2009

    Topics: Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pancreas Transplantation; Pyrazines; Transplantation, Homologous; Young Adult

2009
Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
    Clinical transplants, 2009

    Topics: Adult; Antilymphocyte Serum; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Tissue Donors; Treatment Outcome

2009
Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
    Clinical transplants, 2009

    Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Biopsy; Boronic Acids; Bortezomib; Child, Preschool; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intestines; Protease Inhibitors; Pyrazines; Short Bowel Syndrome; Tacrolimus; Treatment Outcome; Viscera

2009
Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
    Clinical transplants, 2009

    Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Histocompatibility Antigens Class I; HLA-A Antigens; HLA-B Antigens; HLA-D Antigens; HLA-DR Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Protease Inhibitors; Pyrazines

2009
Bortezomib for refractory antibody-mediated cardiac allograft rejection.
    Clinical transplants, 2009

    Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Cardiomyopathies; Female; Flow Cytometry; Graft Rejection; Heart Transplantation; Humans; Isoantibodies; Protease Inhibitors; Pyrazines; Transplantation, Homologous; Treatment Outcome

2009
Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Clinical transplants, 2009

    Topics: Acute Disease; Adult; B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Female; Flow Cytometry; Graft Rejection; HLA-DQ Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Pyrazines; Reoperation; T-Lymphocytes

2009
Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
    Clinical transplants, 2009

    Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Drug Resistance, Multiple; Graft Rejection; Humans; Immunization; Kidney Transplantation; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines

2009
Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.
    Clinical transplants, 2009

    Topics: ABO Blood-Group System; Antiviral Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Doxorubicin; Ganciclovir; Hemagglutinins; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Valganciclovir

2009
Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
    Clinical transplants, 2009

    Topics: ABO Blood-Group System; Adult; Boronic Acids; Bortezomib; Female; Histocompatibility Testing; HLA Antigens; HLA-DQ Antigens; HLA-DR Antigens; HLA-DRB4 Chains; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Diseases; Kidney Transplantation; Lupus Erythematosus, Systemic; Male; Protease Inhibitors; Pyrazines; Reoperation; Siblings; Tissue Donors; Treatment Failure

2009
Use of bortezomib for prevention and treatment of rejection in sensitized patients.
    Clinical transplants, 2009

    Topics: Adult; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Plasmapheresis; Protease Inhibitors; Pyrazines; Young Adult

2009
Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
    Clinical transplants, 2009

    Topics: Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Histocompatibility Antigens Class I; HLA-D Antigens; Humans; Immunity, Humoral; Kidney Transplantation; Living Donors; Male; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Treatment Outcome

2009
PRDM1 is required for mantle cell lymphoma response to bortezomib.
    Molecular cancer research : MCR, 2010, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Nuclear Proteins; Positive Regulatory Domain I-Binding Factor 1; Proliferating Cell Nuclear Antigen; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Repressor Proteins

2010
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
    Annals of hematology, 2010, Volume: 89, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors

2010
Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
    Leukemia research, 2011, Volume: 35, Issue:1

    Topics: Adult; Aged; Albumins; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis

2011
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Molecular immunology, 2010, Volume: 47, Issue:14

    Topics: Adult; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA Primers; Down-Regulation; Humans; In Vitro Techniques; Interleukin-2; K562 Cells; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2010
Targeting GRP78 to enhance melanoma cell death.
    Pigment cell & melanoma research, 2010, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Fenretinide; Heat-Shock Proteins; Humans; Melanoma; Pyrazines; RNA, Small Interfering; Unfolded Protein Response

2010
Frontline regimens for multiple myeloma patients.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2010
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Multiple Myeloma; Mutation; Neoplasm Proteins; Point Mutation; Proteasome Endopeptidase Complex; Protein Denaturation; Pyrazines; Ubiquitin

2010
Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Pyrazines

2010
IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
    Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:9-10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; IgA Deficiency; Middle Aged; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Remission Induction

2010
Reversible posterior encephalopathy syndrome associated with bortezomib.
    Internal medicine journal, 2010, Volume: 40, Issue:1

    Topics: Boronic Acids; Bortezomib; Female; Humans; Hypertensive Encephalopathy; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrazines

2010
[Effect of bortezomib on sensitization of HL-60 cells to TRAIL].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 8; HL-60 Cells; Humans; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2010
[Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:3

    Topics: Annexin A2; Antigens, Neoplasm; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Line; Down-Regulation; Endothelial Cells; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pyrazines; Vascular Endothelial Growth Factor A

2010
Bortezomib: friend or foe of hemolytic anemia?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Anemia, Hemolytic; Animals; Autoimmune Diseases; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors

2011
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Cancer, 2010, Jul-01, Volume: 116, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Time Factors

2010
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure

2010
Mantle cell lymphoma activation enhances bortezomib sensitivity.
    Blood, 2010, Nov-18, Volume: 116, Issue:20

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Clone Cells; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lymphocyte Activation; Lymphoma, Mantle-Cell; Mice; Oligodeoxyribonucleotides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinal Dehydrogenase; Toll-Like Receptor 9; Unfolded Protein Response

2010
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Xenograft Model Antitumor Assays

2010
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
    Pharmacotherapy, 2010, Volume: 30, Issue:7

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Humans; Itraconazole; Japan; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Secondary Prevention; Thrombocytopenia; Treatment Outcome

2010
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cyclin D1; Cyclin D2; Cyclin D3; DNA; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Polymerase Chain Reaction; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome

2010
Individualizing cancer therapy.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Precision Medicine; Pyrazines; Treatment Outcome

2010
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
    Gut, 2010, Volume: 59, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Colitis; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Immunity, Mucosal; Inflammation Mediators; Interleukin-17; Mice; Mice, Inbred C57BL; Multienzyme Complexes; Neutrophil Infiltration; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; T-Lymphocyte Subsets; Th1 Cells

2010
[Mechanism of bortezomib in inducing apoptosis and improving chemosensitivity of Ishikawa cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species

2010
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
    European radiology, 2010, Volume: 20, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome

2010
The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
    Journal of virology, 2010, Volume: 84, Issue:18

    Topics: Antiviral Agents; Boronic Acids; Bortezomib; Cell Line; Epithelial Cells; GTP-Binding Proteins; Humans; Influenza A virus; Interferon Type I; Interleukin-6; Myxovirus Resistance Proteins; Pyrazines; Vesiculovirus

2010
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
    Cardiovascular research, 2010, Dec-01, Volume: 88, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Calcineurin; Cells, Cultured; Desmin; Heart Failure; Mice; Mice, Transgenic; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological

2010
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
    Molecular cancer, 2010, Jul-06, Volume: 9

    Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; Interleukin-8; Multiple Myeloma; NF-kappa B; Pyrazines; Stromal Cells

2010
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cyanoacrylates; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; NF-kappa B; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrazines; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Survival Analysis; Xenograft Model Antitumor Assays

2010
Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
    Acta haematologica, 2010, Volume: 124, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence; Remission Induction; Salvage Therapy

2010
Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.
    Journal of neurology, 2010, Volume: 257, Issue:12

    Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Muscular Diseases; Plaque, Amyloid; Protease Inhibitors; Pyrazines

2010
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Jul-20, Volume: 107, Issue:29

    Topics: Aged, 80 and over; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chlorocebus aethiops; DNA Replication; Down-Regulation; E2F3 Transcription Factor; Fatal Outcome; Gene Expression Regulation, Neoplastic; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Male; Mice; NF-kappa B; Proto-Oncogene Proteins c-myc; Pyrazines; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vero Cells; Virion; Xenograft Model Antitumor Assays

2010
MicroCT-based virtual histology evaluation of preclinical medulloblastoma.
    Molecular imaging and biology, 2011, Volume: 13, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cerebellum; Magnetic Resonance Imaging; Medulloblastoma; Mice; Organ Size; Pyrazines; Tumor Burden; User-Computer Interface; X-Ray Microtomography

2011
Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Annals of hematology, 2011, Volume: 90, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Endothelial Cells; Enzyme Inhibitors; Humans; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2011
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.
    PloS one, 2010, Jul-06, Volume: 5, Issue:7

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; beta Catenin; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Etoposide; Flow Cytometry; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Pyrazines; Signal Transduction; Stem Cells; Wnt Proteins

2010
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    The Biochemical journal, 2010, Sep-15, Volume: 430, Issue:3

    Topics: Amino Acid Sequence; Binding Sites; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; HCT116 Cells; HT29 Cells; Humans; Kinetics; Luciferases; Models, Molecular; Molecular Sequence Data; Molecular Structure; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Structure, Tertiary; Protein Subunits; Pyrazines; RNA Interference; Sequence Homology, Amino Acid; Ubiquitin

2010
Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:9

    Topics: Adult; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Boronic Acids; Bortezomib; Catheters, Indwelling; Creatinine; Desensitization, Immunologic; Drainage; Drug Therapy, Combination; Female; Femoral Vein; Humans; Iliac Vein; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Plasmapheresis; Protease Inhibitors; Pyrazines; Splanchnic Circulation; Therapies, Investigational; Tissue and Organ Procurement; Vena Cava, Inferior; Vena Cava, Superior; Venous Thrombosis

2010
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine

2010
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
    Transplantation, 2010, Jul-27, Volume: 90, Issue:2

    Topics: Adolescent; Adult; Aged; Boronic Acids; Bortezomib; Child; Clonal Deletion; Female; Follow-Up Studies; Humans; Immune Tolerance; Informed Consent; Kidney Transplantation; Male; Middle Aged; Patient Selection; Protease Inhibitors; Pyrazines; Transplantation, Homologous

2010
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Fluorescent Antibody Technique; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lymphoma, Mantle-Cell; Mice; Microscopy, Confocal; Panobinostat; Protein Folding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological; Survival Rate; Transcription Factor CHOP; Xenograft Model Antitumor Assays

2010
The treatment of traumatic brain injury with velcade.
    Journal of neurotrauma, 2010, Volume: 27, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Brain Injuries; Disease Models, Animal; Male; Pyrazines; Rats; Rats, Wistar; Spatial Behavior; Treatment Outcome

2010
Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
    Anticancer research, 2010, Volume: 30, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lymphoma; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; STAT1 Transcription Factor; STAT3 Transcription Factor; U937 Cells

2010
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
    Anticancer research, 2010, Volume: 30, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines

2010
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calcium Channel Blockers; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response; Verapamil

2010
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Pyrazines; Remission Induction

2010
NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
    Leukemia research, 2011, Volume: 35, Issue:1

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Immunohistochemistry; Mesoderm; Multiple Myeloma; NF-kappa B; Plasma Cells; Pyrazines

2011
Rectal bleeding and diarrhea caused by bortezomib-induced colitis.
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colitis; Diarrhea; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Rectum

2010
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
    Gut, 2010, Volume: 59, Issue:10

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Combined Modality Therapy; Endoplasmic Reticulum; Female; Immunity, Cellular; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays

2010
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2011
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
    BMC cancer, 2010, Aug-04, Volume: 10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; DNA, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide

2010
Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
    Clinical therapeutics, 2010, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Retrospective Studies

2010
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
    Blood, 2010, Nov-25, Volume: 116, Issue:22

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Proliferation; Cells, Cultured; Drug Synergism; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Rapamycin-Insensitive Companion of mTOR Protein; TOR Serine-Threonine Kinases

2010
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:11

    Topics: Animals; Blood Coagulation; Boronic Acids; Bortezomib; Cell Nucleus; Combined Modality Therapy; Dependovirus; Disease Models, Animal; Dogs; Factor IX; Factor VIII; Female; Genetic Therapy; Genetic Vectors; Genome, Viral; Hemophilia B; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Pyrazines; Transgenes

2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
    Cancer science, 2010, Volume: 101, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2

2010
Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma.
    The Journal of biological chemistry, 2010, Oct-15, Volume: 285, Issue:42

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Biomarkers; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Profiling; Humans; Inflammation; Interleukin-8; Microarray Analysis; Mouth Neoplasms; NF-kappa B; Pyrazines; RNA, Small Interfering

2010
Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
    Investigative ophthalmology & visual science, 2010, Volume: 51, Issue:12

    Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Fibroblasts; Flow Cytometry; Gene Expression Regulation; Genes, bcl-2; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tenon Capsule; Tetrazolium Salts; Thiazoles; Time Factors; Transforming Growth Factor beta; Tumor Suppressor Protein p53

2010
The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.
    Leukemia, 2010, Volume: 24, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Follicular; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2010
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:10

    Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Gene Expression Profiling; Humans; Hydroxamic Acids; Lung Neoplasms; Multigene Family; Pyrazines; Vorinostat

2010
γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
    The Journal of biological chemistry, 2010, Oct-22, Volume: 285, Issue:43

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Chromans; Enzyme Induction; G1 Phase; gamma-Tocopherol; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 1; Janus Kinase 2; Mice; Neoplasm Proteins; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; RNA, Small Interfering; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Vitamin E

2010
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    American journal of hematology, 2010, Volume: 85, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Male; Metaphase; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome

2010
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:11

    Topics: Analysis of Variance; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Diseases; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Flow Cytometry; Immunohistochemistry; Inflammation; Joints; Pyrazines; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Synovial Membrane; Toll-Like Receptors; Treatment Outcome

2010
[Effect of bortezomib on lymphoma cell line CA46 and its relative mechanisms].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2010
[Adverse effects of PAD and VAD regimens in multiple myeloma patients].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine

2010
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Oncogene, 2010, Nov-25, Volume: 29, Issue:47

    Topics: Animals; Apoptosis; Autoantigens; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Phosphoproteins; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Transcription, Genetic; Up-Regulation; Xenograft Model Antitumor Assays

2010
Optimising bortezomib in newly diagnosed multiple myeloma.
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome

2010
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Leukemia, 2010, Volume: 24, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome

2010
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:8

    Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis

2010
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Annals of hematology, 2011, Volume: 90, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2011
Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Dermatitis; Eosinophilia; Eosinophils; Gene Expression Profiling; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Tissue Proteins; NF-kappa B p50 Subunit; Phenotype; Phosphorylation; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription Factor RelA

2011
Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2010, Volume: 35, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proteome; Proteomics; Pyrazines

2010
[Effect of Velcade combined with Dexamethasone on multiple myeloma].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2010, Volume: 35, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2010
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
    Annals of hematology, 2011, Volume: 90, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome

2011
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult

2010
Lenalidomide for bortezomib-resistant multiple myeloma.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure

2010
Lenalidomide efficacy in bortezomib-resistant myeloma.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9

    Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure

2010
Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.
    Glia, 2010, Volume: 58, Issue:16

    Topics: Adaptation, Physiological; Animals; Axons; Boronic Acids; Bortezomib; Disease Models, Animal; Endoplasmic Reticulum; Female; Macrophages; Mice; Mice, Inbred C57BL; Myelin Proteins; Myelin Sheath; Oligonucleotide Array Sequence Analysis; Peripheral Nerves; Peripheral Nervous System Diseases; Protease Inhibitors; Protein Unfolding; Pyrazines; Schwann Cells; Stress, Physiological

2010
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
    Experimental neurology, 2010, Volume: 226, Issue:2

    Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve

2010
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Thromboembolism

2011
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays

2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination

2010
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
    Cancer letters, 2010, Dec-28, Volume: 299, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lymphoma, Mantle-Cell; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53

2010
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
    Cell biology and toxicology, 2011, Volume: 27, Issue:2

    Topics: Acetylcysteine; Animals; Biological Assay; Boronic Acids; Bortezomib; Cell Extracts; Cells, Cultured; Chymotrypsin; High-Throughput Screening Assays; Inhibitory Concentration 50; Leupeptins; Mice; Models, Biological; Oligopeptides; Ornithine Decarboxylase; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Time Factors

2011
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
    Journal of virology, 2010, Volume: 84, Issue:23

    Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Coronavirus Infections; Cytokines; DNA Primers; Gene Expression Regulation; Histological Techniques; Leupeptins; Lung; Mice; Murine hepatitis virus; Phosphorylation; Pneumonia; Proline; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; STAT Transcription Factors; Survival Analysis; Thiocarbamates; Ubiquitination; Virus Replication

2010
Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.
    Angiogenesis, 2010, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Child; Child, Preschool; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; Molecular Targeted Therapy; Neoplastic Stem Cells; Neoplastic Syndromes, Hereditary; NF-kappa B; Pyrazines; Skin Neoplasms; Vascular Endothelial Growth Factor A

2010
Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2010, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hepatitis B; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2010
Continual reassessment method with multiple toxicity constraints.
    Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2

    Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine

2011
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    British journal of haematology, 2010, Volume: 151, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hodgkin Disease; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation

2010
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
    British journal of pharmacology, 2010, Volume: 161, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inositol Polyphosphate 5-Phosphatases; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphoric Monoester Hydrolases; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide; Vanadates

2010
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
    International journal of hematology, 2010, Volume: 92, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2010
Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail.
    Cardiovascular research, 2010, Dec-01, Volume: 88, Issue:3

    Topics: Adaptation, Physiological; Animals; Boronic Acids; Bortezomib; Calcineurin; Dose-Response Relationship, Drug; Heart Failure; Hypertrophy, Left Ventricular; Mice; Models, Animal; Myocytes, Cardiac; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Stress, Physiological; Ubiquitin

2010
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.
    BMC cancer, 2010, Oct-04, Volume: 10

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Nucleus; Cell Proliferation; Gene Expression Regulation; Gene Silencing; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Membrane Potentials; Multiple Myeloma; Phosphorylation; Pyrazines; RNA Interference; Signal Transduction

2010
The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
    Journal of immunology (Baltimore, Md. : 1950), 2010, Nov-01, Volume: 185, Issue:9

    Topics: Animals; Antibody Formation; B-Lymphocyte Subsets; B-Lymphocytes; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunoblotting; Mice; Mice, Inbred BALB C; Plasma Cells; Protease Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spleen

2010
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
    International journal of hematology, 2010, Volume: 92, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Secondary Prevention; Young Adult

2010
Stability of unused reconstituted bortezomib in original manufacturer vials.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:4

    Topics: Boronic Acids; Bortezomib; Chromatography, Liquid; Drug Packaging; Drug Stability; Drug Storage; Mass Spectrometry; Pyrazines; Tandem Mass Spectrometry; Time Factors

2011
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
    PloS one, 2010, Sep-29, Volume: 5, Issue:9

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Multiple Myeloma; Phosphoproteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteomics; Pyrazines

2010
Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Transplantation, Autologous

2010
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Diseases; Cyclophosphamide; Dexamethasone; Humans; Hyperammonemia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Time Factors; Treatment Outcome

2010
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
    Blood, 2010, Dec-16, Volume: 116, Issue:25

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Immunoprecipitation; Lymphoma, B-Cell; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination

2010
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
    Oncotarget, 2010, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; MAP Kinase Kinase 1; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured

2010
Amino acid starvation sensitizes cancer cells to proteasome inhibition.
    IUBMB life, 2010, Volume: 62, Issue:10

    Topics: Amino Acids; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Humans; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; Tumor Suppressor Protein p53

2010
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
    International journal of laboratory hematology, 2011, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation

2011
Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Anticancer research, 2010, Volume: 30, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Pyrazines; Tomography, X-Ray Computed

2010
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    European journal of haematology, 2011, Volume: 86, Issue:1

    Topics: Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Diagnostic Imaging; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Protective Agents; Pyrazines

2011
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3

    Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome

2011
The impact of bortezomib on the risk of thrombosis in multiple myeloma.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Risk Factors; Thrombosis

2011
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
    Haematologica, 2011, Volume: 96, Issue:2

    Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Parathyroid Hormone; Prognosis; Prospective Studies; Protease Inhibitors; Pyrazines

2011
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
    Haematologica, 2011, Volume: 96, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Everolimus; Humans; Immunosuppressive Agents; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protease Inhibitors; Pyrazines; Radiation, Ionizing; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Whole-Body Irradiation

2011
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
    Cell cycle (Georgetown, Tex.), 2010, Oct-15, Volume: 9, Issue:20

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cisplatin; Humans; Kidney Neoplasms; Leiomyomatosis; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Reactive Oxygen Species; Transplantation, Heterologous

2010
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
    Blood, 2011, Jan-13, Volume: 117, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cytokines; Dendritic Cells; DNA-Binding Proteins; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Homeostasis; Humans; Microscopy, Confocal; Protease Inhibitors; Protein Transport; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; Toll-Like Receptors; Transcription Factors; X-Box Binding Protein 1

2011
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Animals; Antineoplastic Agents; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Clonazepam; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Multiple Myeloma; Neurilemmoma; Protein Folding; Proteostasis Deficiencies; Pyrazines; Rats; Schwann Cells

2010
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine

2012
First-line treatment of elderly multiple myeloma patients.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2010
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
    International journal of hematology, 2010, Volume: 92, Issue:4

    Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Echocardiography; Heart Diseases; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Myocardium; Protease Inhibitors; Pyrazines; Stroke Volume; Treatment Outcome

2010
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Experimental hematology, 2011, Volume: 39, Issue:1

    Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid

2011
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
    International journal of hematology, 2010, Volume: 92, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult

2010
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome

2010
[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
    Zhonghua fu chan ke za zhi, 2010, Volume: 45, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Protease Inhibitors; Pyrazines

2010
Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease.
    Experimental and molecular pathology, 2011, Volume: 90, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Cytochrome P-450 CYP2E1; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Synthase; Liver; Liver Diseases, Alcoholic; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors; Up-Regulation

2011
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines

2010
Protective immunity remains intact after antibody removal by means of proteasome inhibition.
    Transplantation, 2010, Dec-27, Volume: 90, Issue:12

    Topics: Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatinine; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Graft Survival; HLA Antigens; Humans; Immunity; Immunoglobulin G; Kidney Transplantation; Living Donors; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Homologous; Treatment Failure

2010
The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
    Transplantation, 2010, Dec-27, Volume: 90, Issue:12

    Topics: Actuarial Analysis; Adrenal Cortex Hormones; Adult; Aged; Antibody Specificity; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatinine; Female; Graft Rejection; Graft Survival; Humans; Isoantibodies; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2010
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
    The Lancet. Oncology, 2010, Volume: 11, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine

2010
The combination of bortezomib and resveratrol may prevent muscle wasting in diabetes.
    Medical hypotheses, 2011, Volume: 76, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Boronic Acids; Bortezomib; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Inflammation; Models, Biological; Muscular Atrophy; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Resveratrol; Stilbenes

2011
Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Journal of medicinal chemistry, 2010, Dec-23, Volume: 53, Issue:24

    Topics: Amino Acids; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dipeptides; Drug Screening Assays, Antitumor; Humans; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship

2010
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors

2012
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.
    Blood, 2011, Jan-27, Volume: 117, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Endoribonucleases; Humans; Mice; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Substrate Specificity; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays

2011
Role of bortezomib for the treatment of previously untreated multiple myeloma.
    Expert review of hematology, 2008, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous

2008
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding.
    PLoS pathogens, 2010, Nov-11, Volume: 6, Issue:11

    Topics: Amino Acid Sequence; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Chlorocebus aethiops; Cytoplasm; Fluorescent Antibody Technique; HeLa Cells; Henipavirus Infections; Humans; Immunoprecipitation; Kidney; Molecular Sequence Data; Mutation; Nipah Virus; Nuclear Localization Signals; Protease Inhibitors; Protein Processing, Post-Translational; Protein Transport; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Ubiquitin; Vero Cells; Viral Matrix Proteins; Virus Assembly; Virus Shedding

2010
Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.
    Blood, 2011, Jan-27, Volume: 117, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Epithelial Cells; Humans; I-kappa B Kinase; Immunoglobulin Light Chains; Kidney; NF-kappa B; Phosphorylation; Pyrazines; Signal Transduction; src-Family Kinases; Tyrosine

2011
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Blood, 2011, Jan-27, Volume: 117, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Molecular Chaperones; Pyrazines; Receptors, Estrogen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Chemotherapy: Failure of bevacizumab in early-stage colon cancer.
    Nature reviews. Clinical oncology, 2011, Volume: 8, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Failure

2011
Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
    Cancer letters, 2011, Feb-01, Volume: 301, Issue:1

    Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Butyrates; Caspase 3; Cell Line, Tumor; Cyclin D1; DNA; G1 Phase; Humans; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor

2011
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Blood reviews, 2010, Volume: 24 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome

2010
[Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA-Binding Proteins; Gene Silencing; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; RNA, Small Interfering; Transcription Factors; X-Box Binding Protein 1

2010
[Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:5

    Topics: 3T3 Cells; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Mice; Multiple Myeloma; Pyrazines

2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
    Leukemia & lymphoma, 2011, Volume: 52, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult

2011
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
    British journal of cancer, 2011, Jan-04, Volume: 104, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Coumarins; Cyclin D1; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoprecipitation; Lymphoma, Mantle-Cell; Mutation; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2011
A new standard of care in newly diagnosed multiple myeloma.
    Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome

2010
Successful treatment with bortezomib and thalidomide for POEMS syndrome.
    Annals of hematology, 2011, Volume: 90, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; POEMS Syndrome; Pyrazines; Radionuclide Imaging; Remission Induction; Thalidomide; Treatment Outcome

2011
Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
    Yonsei medical journal, 2011, Volume: 52, Issue:1

    Topics: Atrioventricular Block; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines

2011
Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
    Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:5

    Topics: Antigens, CD20; Bone Marrow Cells; Boronic Acids; Bortezomib; Graft Rejection; Humans; Immunity, Humoral; Intestines; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Short Bowel Syndrome; Syndecan-1; Transplantation, Homologous; Treatment Outcome

2011
[Bortezomib-based regimen for the treatment of 110 multiple myeloma patients].
    Zhonghua yi xue za zhi, 2010, Oct-19, Volume: 90, Issue:38

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome

2010
Radiosensitizing properties of bortezomib depend on therapeutic schedule.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Mice; Mice, Nude; NF-kappa B; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays

2011
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    International journal of cancer, 2011, Nov-01, Volume: 129, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Enzyme Activation; Epstein-Barr Virus Infections; Female; Humans; Killer Cells, Natural; Lymphoma; Lymphoma, T-Cell; Male; NF-kappa B; Proteasome Inhibitors; Pyrazines; T-Lymphocytes

2011
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    European journal of pharmacology, 2011, Mar-01, Volume: 654, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Multiple Myeloma; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide

2011
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Annals of the rheumatic diseases, 2011, Volume: 70, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome

2011
Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
    International journal of oncology, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HL-60 Cells; Humans; Lysosomes; Macrolides; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stress, Physiological; U937 Cells; Unfolded Protein Response

2011
Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2010, Volume: 14, Issue:5

    Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Treatment Outcome

2010
[Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; MAP Kinase Signaling System; Pyrazines

2010
Hematology: Bortezomib and dexamethasone induction for multiple myeloma.
    Nature reviews. Clinical oncology, 2011, Volume: 8, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction

2011
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Annals of hematology, 2011, Volume: 90, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2011
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
    Biochemical and biophysical research communications, 2011, Feb-04, Volume: 405, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrimidines

2011
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide

2011
Bortezomib-induced inflammatory neuropathy.
    Journal of the peripheral nervous system : JPNS, 2010, Volume: 15, Issue:4

    Topics: Boronic Acids; Bortezomib; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Pyrazines

2010
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
    Cancer research, 2011, Mar-01, Volume: 71, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cell Separation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group Proteins; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction

2011
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured

2011
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
    Chemico-biological interactions, 2011, May-30, Volume: 191, Issue:1-3

    Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Hydroxyprostaglandin Dehydrogenases; Isothiocyanates; Leupeptins; Maleates; Multidrug Resistance-Associated Protein 2; NF-E2-Related Factor 2; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Sulfoxides; Thiocyanates; Time Factors

2011
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Glioma; Humans; NF-kappa B; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Transfection

2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
    British journal of haematology, 2011, Volume: 152, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinases; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; Signal Transduction; Stromal Cells; Survival Analysis; Transcription, Genetic; Treatment Outcome; Tumor Cells, Cultured

2011
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:2

    Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; I-kappa B Proteins; Leupeptins; Lymphoma, T-Cell, Cutaneous; Molecular Sequence Data; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Protein Binding; Protein Subunits; Protein Transport; Pyrazines; Transcription Factor RelA; Transcription, Genetic

2011
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome

2011
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
    Haematologica, 2011, Volume: 96, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Boronic Acids; Bortezomib; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; I-kappa B Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; NF-kappa B p52 Subunit; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; TNF Receptor-Associated Factor 3; Treatment Outcome

2011
Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Pharmacogenetics and genomics, 2011, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; Cathepsins; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Randomized Controlled Trials as Topic; Schwann Cells; Transcription Factor 4; Transcription Factors

2011
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.
    Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:2

    Topics: Animals; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Bone Marrow Cells; Boronic Acids; Bortezomib; Enzyme-Linked Immunospot Assay; Glomerulonephritis; Macrophages; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Peroxidase; Plasma Cells; Protease Inhibitors; Pyrazines; Spleen

2011
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
    Journal of immunology (Baltimore, Md. : 1950), 2011, Feb-15, Volume: 186, Issue:4

    Topics: Animals; Autoantibodies; Boronic Acids; Bortezomib; Female; Lymphocyte Depletion; Myasthenia Gravis, Autoimmune, Experimental; Plasma Cells; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew

2011
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.
    Autophagy, 2011, Volume: 7, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Biological; Multiple Myeloma; Phagosomes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Denaturation; Pyrazines

2011
Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Factor VIII; Immunoglobulin G; Male; Mice; Mice, Inbred C57BL; Pyrazines; Serine Proteinase Inhibitors

2011
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Flow Cytometry; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Survival Rate; Translocation, Genetic

2011
Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Luminescent Proteins; Melanoma; Mice; Microscopy, Fluorescence; Microtubule-Associated Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins B-raf; Pyrazines; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2011
Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide.
    American journal of hematology, 2011, Volume: 86, Issue:3

    Topics: Anemia, Hemolytic, Autoimmune; Boronic Acids; Bortezomib; Complement System Proteins; Cyclophosphamide; Female; Humans; Immunoglobulin G; Middle Aged; Pyrazines

2011
Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Multiple Myeloma; Plasma Cells; Point Mutation; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2011
Re-transplantation after bortezomib-based therapy.
    British journal of haematology, 2011, Volume: 153, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies

2011
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Health Services for the Aged; Humans; Male; Multiple Myeloma; Pyrazines

2011
Bortezomib-induced peripheral neuropathy: facts and genes.
    The Lancet. Oncology, 2011, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Humans; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index

2011
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
    Cancer biology & therapy, 2011, Mar-15, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction; Young Adult

2011
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Blood, 2011, Apr-07, Volume: 117, Issue:14

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome, Human; High-Throughput Screening Assays; Humans; Microarray Analysis; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured

2011
Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Fluorescent Antibody Technique; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia; Polyneuropathies; Pyrazines; Skin

2011
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays

2011
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.
    Oncogene, 2011, Jun-02, Volume: 30, Issue:22

    Topics: ADP-Ribosylation Factors; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasms; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53

2011
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult

2010
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines

2010
Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    The Tokai journal of experimental and clinical medicine, 2010, Apr-20, Volume: 35, Issue:1

    Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2010
Development of a brain metastatic canine prostate cancer cell line.
    The Prostate, 2011, Volume: 71, Issue:12

    Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous

2011
Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.
    European journal of haematology, 2011, Volume: 86, Issue:5

    Topics: Adipogenesis; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines

2011
Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation.
    Transplantation, 2011, Mar-15, Volume: 91, Issue:5

    Topics: Aged; Blood Grouping and Crossmatching; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunity, Humoral; Incidence; Infant; Liver Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Pyrazines; Retrospective Studies

2011
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
    Annals of hematology, 2011, Volume: 90, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Signal Transduction; Valproic Acid

2011
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Immunology, 2011, Volume: 133, Issue:1

    Topics: Antigen Presentation; Blotting, Western; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line; Epitopes, T-Lymphocyte; Epstein-Barr Virus Nuclear Antigens; Fluorescent Antibody Technique; Humans; Leupeptins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; T-Lymphocytes, Cytotoxic

2011
De novo AL amyloidosis in the kidney allograft.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:3

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome

2011
Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
    Journal of cellular biochemistry, 2011, Volume: 112, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Iridoid Glycosides; Iridoids; Multiple Myeloma; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor

2011
Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Cancer investigation, 2011, Volume: 29, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; Time Factors

2011
A new combination for advanced multiple myeloma.
    The Lancet. Oncology, 2011, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines

2011
Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Glutamate-Cysteine Ligase; Glutathione; Humans; Microscopy, Confocal; NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Plasmids; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Small Interfering; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation; Translocation, Genetic

2011
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Neurology, 2011, Mar-29, Volume: 76, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide

2011
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
    PloS one, 2011, Feb-11, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Pyrazines

2011
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
    Annals of hematology, 2011, Volume: 90, Issue:10

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Association Studies; Humans; Interferon-alpha; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; NF-kappa B p50 Subunit; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Pyrazines; Recombinant Proteins; Survival Analysis; Thalidomide

2011
Recent advances in myeloma treatment.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide

2011
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Chymotrypsin; Coculture Techniques; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma; Mice; Mice, SCID; Oligopeptides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; Serine Proteinase Inhibitors; Unfolded Protein Response; Waldenstrom Macroglobulinemia

2011
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azocines; Benzhydryl Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, bcl-2; Gossypol; Humans; Mice; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2011
Out foxing bcr-abl.
    Cancer biology & therapy, 2011, Apr-15, Volume: 11, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2011
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Arthritis and rheumatism, 2011, Volume: 63, Issue:3

    Topics: Animals; Arthritis; Bone and Bones; Bone Resorption; Boronic Acids; Bortezomib; Cartilage, Articular; Chronic Disease; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RANK Ligand; Synovial Membrane; Tumor Necrosis Factor-alpha

2011
[Screening drugs for regulating tissue factor gene expression].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Gene Expression; Humans; Molecular Sequence Data; Promoter Regions, Genetic; Pyrazines; Thromboplastin; Transcription Factors; Transcriptional Activation; U937 Cells

2011
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Endopeptidases; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Hep G2 Cells; Humans; Male; Models, Biological; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley

2011
Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.
    PloS one, 2011, Feb-18, Volume: 6, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; HCT116 Cells; Humans; Neoplasms; Pyrazines; Thiazoles; Thiostrepton

2011
[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatine; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency

2011
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Oncology, 2010, Volume: 79, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome

2010
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
    Annals of hematology, 2011, Volume: 90, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome

2011
Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
    Bratislavske lekarske listy, 2010, Volume: 111, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Eye Neoplasms; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Plasmacytoma; Prednisolone; Pyrazines; Recurrence; Stem Cell Transplantation

2010
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2011, Jan-10, Volume: 100, Issue:1

    Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid

2011
Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells.
    Experimental hematology, 2011, Volume: 39, Issue:6

    Topics: Acute Disease; Animals; Boronic Acids; Bortezomib; Cytokines; Dendritic Cells; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines

2011
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:5

    Topics: Animals; Antibodies, Neoplasm; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2011
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5

    Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Catechin; Chromatography, Liquid; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazines; Tandem Mass Spectrometry; Tea; Xenograft Model Antitumor Assays

2011
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:2

    Topics: Aged; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome

2011
[A case of aggressive multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines

2011
Calibration of prior variance in the Bayesian continual reassessment method.
    Statistics in medicine, 2011, Jul-30, Volume: 30, Issue:17

    Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lymphoma, B-Cell; Maximum Tolerated Dose; Models, Statistical; Pyrazines

2011
Cutaneous macroglobulinosis treated with bortezomib and rituximab.
    European journal of haematology, 2011, Volume: 87, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Male; Pyrazines; Recurrence; Rituximab; Skin Diseases; Waldenstrom Macroglobulinemia

2011
[Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Female; Glutathione; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Reactive Oxygen Species

2011
[In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Pyrazines

2011
Renal failure caused by plasma cell infiltration in multiple myeloma.
    Clinical and experimental nephrology, 2011, Volume: 15, Issue:4

    Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Female; Humans; Kidney; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Renal Insufficiency

2011
Velcade combinations in mantle cell lymphoma: are we learning anything?
    Leukemia & lymphoma, 2011, Volume: 52, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Protease Inhibitors; Pyrazines

2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous

2011
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
    Cellular signalling, 2011, Volume: 23, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Glioma; Humans; Leupeptins; Mutagenesis, Site-Directed; Neoplastic Stem Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C-epsilon; Proto-Oncogene Proteins c-akt; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2011
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cysteine Proteinase Inhibitors; Enzyme Activation; Female; Humans; Leupeptins; Lymphoma, Mantle-Cell; Male; Membrane Proteins; Palatine Tonsil; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tonsillar Neoplasms; Transcription Factor RelA; Tumor Necrosis Factor-alpha

2011
[Meningeal plasmacytoma: delayed diagnosis with sequelae].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2011, Volume: 183, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Edema; Cerebral Hemorrhage; Contrast Media; Delayed Diagnosis; Dexamethasone; Diagnostic Errors; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Multiple Myeloma; Neurologic Examination; Pyrazines; Tomography, X-Ray Computed

2011
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Oncotarget, 2011, Volume: 2, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; HCT116 Cells; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis Deficiencies; Puromycin; Pyrazines

2011
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    International journal of cancer, 2012, Feb-15, Volume: 130, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2012
Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Activating Transcription Factor 4; Activating Transcription Factor 6; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; HEK293 Cells; Herpesvirus 4, Human; Humans; Pyrazines; Regulatory Factor X Transcription Factors; Response Elements; Thapsigargin; Trans-Activators; Transcription Factor CHOP; Transcription Factors; Unfolded Protein Response; Virus Activation; X-Box Binding Protein 1

2011
Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
    Journal of cellular physiology, 2011, Volume: 226, Issue:11

    Topics: Anilides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cisplatin; Humans; Male; Nitriles; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, Androgen; Tosyl Compounds

2011
Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
    International journal of hematology, 2011, Volume: 93, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Child, Preschool; Drug Interactions; Female; Humans; Male; Mice; Mice, SCID; Myelodysplastic Syndromes; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Tumor Cells, Cultured

2011
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies

2011
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1

    Topics: Aged; Amyloidosis; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin M; Lymphatic Diseases; Male; Middle Aged; Pyrazines; Rituximab

2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Male; Polymerase Chain Reaction; Pyrazines; Waldenstrom Macroglobulinemia

2011
Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.
    The Journal of biological chemistry, 2011, May-06, Volume: 286, Issue:18

    Topics: Antibodies; Boronic Acids; Bortezomib; Cell Line; DNA; Epitopes; Humans; Methyltransferases; Multiprotein Complexes; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-mdm2; Pyrazines; Repressor Proteins; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitination

2011
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
    The Journal of biological chemistry, 2011, May-20, Volume: 286, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Jurkat Cells; Lymphocytes; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2011
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.
    Cell death and differentiation, 2011, Volume: 18, Issue:10

    Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Boronic Acids; Bortezomib; Caspase 3; Caspase 7; Caspase 8; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescence Resonance Energy Transfer; HeLa Cells; Humans; Immunoblotting; Mice; Mice, Mutant Strains; Microscopy, Fluorescence; Microtubule-Associated Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; X-Linked Inhibitor of Apoptosis Protein

2011
Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile.
    AAPS PharmSciTech, 2011, Volume: 12, Issue:2

    Topics: Boronic Acids; Bortezomib; Chemistry, Pharmaceutical; Drug Contamination; Humans; Pyrazines; Random Allocation

2011
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3

    Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin

2011
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chick Embryo; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Mitochondria; Pyrazines; Receptors, Death Domain; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2011
Proteasome inhibition improves diaphragm function in an animal model for COPD.
    American journal of physiology. Lung cellular and molecular physiology, 2011, Volume: 301, Issue:1

    Topics: Animals; Biomechanical Phenomena; Boronic Acids; Bortezomib; Contractile Proteins; Cricetinae; Diaphragm; Disease Models, Animal; Male; Organ Specificity; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyrazines

2011
Cervical amyloidoma successfully treated with bortezomib and dexamethasone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-10, Volume: 29, Issue:17

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cervical Vertebrae; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Pyrazines; Spinal Neoplasms

2011
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
    Leukemia, 2011, Volume: 25, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Transformation, Neoplastic; Gene Expression Profiling; Humans; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Mutation; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Survival Rate

2011
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease Progression; Drug Therapy, Combination; Graft vs Tumor Effect; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2011
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Boronic Acids; Bortezomib; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Fibronectins; Focal Adhesion Kinase 1; Gene Knockdown Techniques; Gene Silencing; Humans; Integrin beta Chains; Melphalan; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-maf; Pyrazines; rac1 GTP-Binding Protein; src-Family Kinases; Stem Cell Transplantation; Sumoylation; Transcription Factor RelA; Transplantation, Autologous; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines

2011
Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Immunoglobulin kappa-Chains; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction

2012
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Pancreas, 2011, Volume: 40, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays

2011
Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.
    BMC cancer, 2011, Apr-14, Volume: 11

    Topics: Animals; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cerebellar Neoplasms; Curcumin; Ditiocarb; Humans; I-kappa B Proteins; Medulloblastoma; Mice; Mice, Inbred C57BL; Mice, Nude; NF-kappa B; Pyrazines; Pyrrolidines; Signal Transduction; Sulfasalazine; Thiocarbamates; Transgenes; Tumor Burden; Xenograft Model Antitumor Assays

2011
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2011, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors

2011
Subcutaneous bortezomib: a step towards optimised drug use.
    The Lancet. Oncology, 2011, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Quality of Life; Recurrence

2011
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides

2011
History of multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane

2011
Allogeneic transplantation in multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2011
Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
    The American journal of pathology, 2011, Volume: 178, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle; Colorectal Neoplasms; Cyclins; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Prognosis; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tissue Array Analysis; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays

2011
[NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transfection

2011
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-15, Volume: 17, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Glioblastoma; Humans; Mitochondria; Neoplastic Stem Cells; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2011
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
    International journal of hematology, 2011, Volume: 93, Issue:6

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells

2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Annals of hematology, 2012, Volume: 91, Issue:1

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome

2012
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:9

    Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2011
[Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; K562 Cells; Leukemia; Pyrazines; X-Linked Inhibitor of Apoptosis Protein

2011
Toxicity burden score: a novel approach to summarize multiple toxic effects.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Health Status Indicators; Humans; Neoplasms; Pyrazines; Toxicity Tests

2012
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Comorbidity; Endemic Diseases; Female; Hepatitis B; Humans; Immunologic Factors; Incidence; Lamivudine; Male; Middle Aged; Multiple Myeloma; Prevalence; Prospective Studies; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Stem Cell Transplantation; Transplantation, Autologous; Virus Activation

2012
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
    International journal of hematology, 2011, Volume: 93, Issue:6

    Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome

2011
[The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines

2011
[Effect of different regimens on bone disease of multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand; Thalidomide

2011
[The clinical study on treatment with bortezomib for multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2011
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines

2011
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.
    Blood, 2011, Jul-28, Volume: 118, Issue:4

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Protease Inhibitors; Pyrazines

2011
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
    Chemistry & biology, 2011, May-27, Volume: 18, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Cell Membrane Permeability; Humans; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Trypsin

2011
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:7

    Topics: Acyclovir; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome

2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
    Blood, 2011, Sep-29, Volume: 118, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Middle Aged; Multiple Myeloma; Pharmacogenetics; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Risk; RNA-Binding Proteins; Up-Regulation

2011
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
    American journal of hematology, 2011, Volume: 86, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance, Neoplasm; Hospitals, University; Humans; Immunologic Factors; Leukemia, Plasma Cell; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis

2011
Proteasome inhibitor treatment in alcoholic liver disease.
    World journal of gastroenterology, 2011, May-28, Volume: 17, Issue:20

    Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Humans; Liver Diseases, Alcoholic; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rats; Reactive Oxygen Species

2011
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
    Journal of neuro-oncology, 2011, Volume: 105, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cerebellar Neoplasms; Gene Expression Profiling; Immunohistochemistry; Medulloblastoma; Mice; Mice, Mutant Strains; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering

2011
Proteotoxic stress targeted therapy (PSTT).
    Oncotarget, 2011, Volume: 2, Issue:5

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Heat-Shock Proteins; Humans; Hyperthermia, Induced; Molecular Chaperones; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Folding; Pyrazines

2011
p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; CELF1 Protein; Cyclin-Dependent Kinase Inhibitor p21; Cytoplasmic Granules; Drug Resistance, Neoplasm; HeLa Cells; Humans; Protein Binding; Protein Biosynthesis; Pyrazines; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Stress, Physiological; Up-Regulation

2011
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
    Cancer research, 2011, Jul-15, Volume: 71, Issue:14

    Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Hematopoietic Stem Cells; Humans; Magnetics; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Rituximab; Transplantation, Autologous

2011
Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Mice; Multiple Endocrine Neoplasia; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Signal Transduction; TOR Serine-Threonine Kinases

2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; p38 Mitogen-Activated Protein Kinases; Pyrazines; Stress, Physiological; Vorinostat; Waldenstrom Macroglobulinemia

2011
Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
    Leukemia research, 2011, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Vitro Techniques; Interferon-gamma; Lymphocyte Activation; Lymphocyte Depletion; Proteasome Inhibitors; Pyrazines; T-Lymphocytes; Transplantation, Homologous

2011
Renal improvement in myeloma with bortezomib plus plasma exchange.
    The New England journal of medicine, 2011, Jun-16, Volume: 364, Issue:24

    Topics: Acute Kidney Injury; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines

2011
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
    European journal of haematology, 2011, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide

2011
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Time Factors; Treatment Outcome

2012
An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.
    Clinical transplants, 2010

    Topics: Acute Disease; Boronic Acids; Bortezomib; Chronic Disease; Down-Regulation; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Isoantibodies; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Transplants; Treatment Outcome

2010
Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.
    Clinical transplants, 2010

    Topics: Adult; Boronic Acids; Bortezomib; Down-Regulation; Female; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Mexico; Middle Aged; Patient Selection; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Tissue Donors; Treatment Outcome; Waiting Lists

2010
Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Clinical transplants, 2010

    Topics: Acute Disease; Adjuvants, Immunologic; Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Saudi Arabia; Time Factors; Treatment Outcome

2010
Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Clinical transplants, 2010

    Topics: Biopsy; Boronic Acids; Bortezomib; Chronic Disease; Complement C4b; Drug Therapy, Combination; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Peptide Fragments; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2010
Targeting alloantibody production with bortezomib: does it make more sense?
    Clinical transplants, 2010

    Topics: Biopsy; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2010
1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
    Clinical transplants, 2010

    Topics: BK Virus; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Middle Aged; Polyomavirus Infections; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2010
Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
    Clinical transplants, 2010

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2010
Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
    Clinical transplants, 2010

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome

2010
Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
    Clinical transplants, 2010

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; New York City; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteinuria; Pyrazines; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome

2010
Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
    Clinical transplants, 2010

    Topics: Academies and Institutes; Acute Disease; Adult; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Mexico; Middle Aged; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2010
Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
    Clinical transplants, 2010

    Topics: Adult; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2010
Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
    Clinical transplants, 2010

    Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome

2010
Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients.
    The journal of pain, 2011, Volume: 12, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines

2011
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15

    Topics: Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Gene Expression Profiling; Humans; Lymphoma, Mantle-Cell; NF-E2-Related Factor 2; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Transcription, Genetic; Tumor Cells, Cultured

2011
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2011, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction

2011
Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:10

    Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Survival; Coculture Techniques; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Up-Regulation

2011
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
    Annals of hematology, 2012, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Transcriptome

2012
The challenge of recurrent follicular lymphoma.
    The Lancet. Oncology, 2011, Volume: 12, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Follicular; Male; Pyrazines; Rituximab

2011
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays

2011
[Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; JNK Mitogen-Activated Protein Kinases; K562 Cells; p38 Mitogen-Activated Protein Kinases; Protease Inhibitors; Pyrazines

2011
[Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:3

    Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Drug Therapy, Combination; Humans; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA

2011
[Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:5

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome; Young Adult

2011
Apoptotic role of IKK in T-ALL therapeutic response.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-myc; Pyrazines; Receptor, Notch1; Signal Transduction; Vincristine

2011
Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
    Annals of surgical oncology, 2012, Volume: 19 Suppl 3

    Topics: Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Boronic Acids; Bortezomib; Brain; Cell Line, Tumor; Cell Nucleus; DNA-Binding Proteins; Gene Knockdown Techniques; Glioblastoma; Heat Shock Transcription Factors; Hot Temperature; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyrrolidinones; RNA, Small Interfering; Transcription Factors; Up-Regulation

2012
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Anticancer research, 2011, Volume: 31, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2011
The micros in harmony: microRNA and microenvironment.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:9

    Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Pyrazines

2011
Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.
    Cornea, 2011, Volume: 30, Issue:10

    Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Corneal Dystrophies, Hereditary; Dexamethasone; DNA Mutational Analysis; Extracellular Matrix Proteins; Gelsolin; Glucocorticoids; Humans; Immunoglobulin Heavy Chains; Male; Mass Spectrometry; Melphalan; Microscopy, Confocal; Middle Aged; Mutation; Nephrotic Syndrome; Paraproteinemias; Pyrazines; Sequence Analysis, Protein; Transforming Growth Factor beta

2011
Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Treatment Outcome

2011
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue

2012
Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
    Journal of the American Chemical Society, 2011, Aug-10, Volume: 133, Issue:31

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechols; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Hydrogen-Ion Concentration; Molecular Structure; Polymers; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship

2011
Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Current opinion in organ transplantation, 2011, Volume: 16, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; Heart Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Isoantibodies; Kidney Transplantation; Lung Transplantation; Organ Transplantation; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transplantation Tolerance; Transplantation, Homologous; Treatment Outcome

2011
Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Dexamethasone; Doxorubicin; Female; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor I; Interleukin-6; Lactones; Mice; Mitosis; Multiple Myeloma; Protective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Stromal Cells; Xenograft Model Antitumor Assays

2011
Bortezomib in patients with renal impairment.
    Hematology (Amsterdam, Netherlands), 2011, Volume: 16, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Diarrhea; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Survival Analysis

2011
Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Segregation; Genes, Fungal; Genetic Testing; Metaphase; Mitosis; Models, Biological; Mutation; Proteasome Endopeptidase Complex; Pyrazines; Schizosaccharomyces

2011
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Current cancer drug targets, 2011, Volume: 11, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms

2011
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dependovirus; Drug Synergism; Endothelial Cells; Fibroblast Growth Factor 2; Galectin 3; Green Fluorescent Proteins; Humans; Immunoglobulin E; Immunoglobulin lambda-Chains; Integrin alphaVbeta3; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2011
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Experimental hematology, 2011, Volume: 39, Issue:10

    Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein

2011
SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
    Molecular and cellular biology, 2011, Volume: 31, Issue:18

    Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Chromatin; Cyclopentanes; Epigenesis, Genetic; F-Box Proteins; Gene Expression Regulation; HEK293 Cells; HeLa Cells; Histone Demethylases; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Mass Spectrometry; Methylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitination

2011
[Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines

2011
Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    International journal of oncology, 2011, Volume: 39, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Male; MAP Kinase Kinase 4; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays

2011
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Leukemia, 2011, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Janus Kinase 1; Melphalan; Multiple Myeloma; Phosphorylation; Pyrazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Stromal Cells

2011
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
    Oncotarget, 2011, Volume: 2, Issue:5

    Topics: Animals; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Neoplasms; Proteasome Inhibitors; Protein Folding; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape

2011
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.
    Cancer letters, 2011, Nov-28, Volume: 310, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioma; HEK293 Cells; Humans; Immunohistochemistry; Jurkat Cells; Male; Mice; Mice, Nude; Neural Stem Cells; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2011
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Oct-15, Volume: 17, Issue:20

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Neoplasm; Autophagy; Boronic Acids; Bortezomib; Cancer Vaccines; Cross Reactions; Methylcholanthrene; Mice; Mice, Inbred C57BL; Phagosomes; Protein Synthesis Inhibitors; Proteins; Pyrazines; Sarcoma, Experimental; Sequestosome-1 Protein; T-Lymphocytes

2011
The TEMPI syndrome--a novel multisystem disease.
    The New England journal of medicine, 2011, Aug-04, Volume: 365, Issue:5

    Topics: Adult; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Hydronephrosis; Lymphangiectasis; Male; Middle Aged; Paraproteinemias; Polycythemia; Protease Inhibitors; Pyrazines; Syndrome; Telangiectasis

2011
A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.
    Medical physics, 2011, Volume: 38, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Iodine Radioisotopes; Lymphoma; Mice; Models, Biological; Monte Carlo Method; Pyrazines; Radiometry; Radiopharmaceuticals

2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4

    Topics: Aged; Apoptosis; Basophils; Benzamides; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrimidines

2011
Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo.
    Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:9

    Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cells, Cultured; Cholesterol; Hep G2 Cells; Humans; Lipoproteins; Lipoproteins, HDL; Macrophages; Mice; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitination

2011
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous

2012
Response to bortezomib of a patient with scleromyxedema refractory to other therapies.
    Leukemia research, 2011, Volume: 35, Issue:11

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Male; Pyrazines; Salvage Therapy; Scleromyxedema; Treatment Outcome

2011
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1

    Topics: Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Melphalan; Pyrazines; Stem Cell Transplantation

2011
Bortezomib in systemic AL amyloidosis: a single center experience.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines

2011
Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1

    Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin Light Chains; Indiana; Male; Middle Aged; Pyrazines

2011
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Echocardiography; Female; Humans; Immunoglobulin Light Chains; Pyrazines; Recurrence

2011
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response.
    Journal of biomolecular screening, 2011, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Proliferation; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Genes, Reporter; High-Throughput Screening Assays; Humans; Luciferases; Mouth Neoplasms; Mycotoxins; Pyrazines; Signal Transduction; Transcription Factor CHOP; Transduction, Genetic; Unfolded Protein Response

2011
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:3

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Child; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Prognosis; Pyrazines; Rituximab; Survival Rate; Young Adult

2012
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide

2011
Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Pyrazines; Tumor Lysis Syndrome

2010
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; G1 Phase; HSP90 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinases; Multiple Myeloma; Pyrazines; Pyridones; Pyrimidines; Signal Transduction; STAT3 Transcription Factor

2011
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Blood, 2011, Nov-03, Volume: 118, Issue:18

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases

2011
Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    International journal of hematology, 2011, Volume: 94, Issue:3

    Topics: Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome

2011
Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
    Cancer research, 2011, Sep-01, Volume: 71, Issue:17

    Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasms, Hormone-Dependent; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription, Genetic; Ubiquitination

2011
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
    Pharmacology, 2011, Volume: 88, Issue:1-2

    Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dinitrofluorobenzene; Disease Models, Animal; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Hypersensitivity, Delayed; Imiquimod; Immunologic Factors; Irritants; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peritonitis; Psoriasis; Pyrazines; Random Allocation; Temperature; Thioglycolates

2011
[Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Multiple; Gene Expression Profiling; Humans; Jurkat Cells; Mutation; Proteasome Endopeptidase Complex; Pyrazines

2011
[Proteasome inhibitor bortezomib inducing apoptosis of K562 cells not affected by bone marrow mesenchymal stem cells in vitro].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4

    Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Coculture Techniques; Humans; K562 Cells; Mesenchymal Stem Cells; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Vascular Cell Adhesion Molecule-1

2011
[Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; Neoplasm Proteins; Oxides; Pyrazines; RNA, Messenger

2011
[Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Treatment Outcome

2011
Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration.
    Anticancer research, 2011, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Drug Administration Routes; Humans; Pyrazines

2011
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.
    Bone marrow transplantation, 2012, Volume: 47, Issue:6

    Topics: ABO Blood-Group System; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Red-Cell Aplasia, Pure; Transplantation, Homologous

2012
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
    Cancer discovery, 2011, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mice, 129 Strain; NF-kappa B; Nitriles; Pyrazines; Signal Transduction; Sulfones; Survival Rate; Transcription Factor RelA

2011
Cardiac amyloidosis: a treatable disease, often overlooked.
    Circulation, 2011, Aug-30, Volume: 124, Issue:9

    Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2011
Proteasome inhibition prevents development of experimental dermal fibrosis.
    Inflammation, 2012, Volume: 35, Issue:3

    Topics: Actins; Animals; Bleomycin; Boronic Acids; Bortezomib; Collagen Type I; Female; Fibrosis; Inflammation; Interleukin-4; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 8; NF-kappa B; Proteasome Inhibitors; Pyrazines; Random Allocation; Scleroderma, Localized; Skin; Transforming Growth Factor beta1

2012
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
    ACS chemical biology, 2011, Nov-18, Volume: 6, Issue:11

    Topics: Actinobacteria; Biological Products; Boronic Acids; Bortezomib; Drug Resistance, Bacterial; Humans; Lactones; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Pyrroles; Substrate Specificity

2011
Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Prognosis; Proteinuria; Pyrazines; Remission Induction

2012
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combination; Humans; Male; POEMS Syndrome; Pyrazines; Thalidomide; Vascular Endothelial Growth Factor A

2011
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Journal of medical economics, 2011, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide

2011
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    BJU international, 2012, Volume: 109, Issue:8

    Topics: Acetylation; Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Fluorine Radioisotopes; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; Mice; Pyrazines; Tumor Cells, Cultured; Ubiquitination; Vorinostat

2012
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23

    Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2011
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:2

    Topics: Animals; Antibody-Producing Cells; Autoantibodies; Boronic Acids; Bortezomib; Disease Progression; Humans; Interferon Type I; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Oligopeptides; Protease Inhibitors; Pyrazines

2012
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
    The American journal of pathology, 2011, Volume: 179, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protease Inhibitors; Pyrazines; Receptors, Neuropeptide; RNA, Messenger; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vincristine; Young Adult

2011
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
    Cancer cell, 2011, Sep-13, Volume: 20, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Cell Proliferation; Centrosome; Drug Screening Assays, Antitumor; Ependymoma; Fluorouracil; High-Throughput Screening Assays; Insulin; Mice; Mice, Nude; Neural Stem Cells; Pyrazines; Signal Transduction; Tumor Cells, Cultured

2011
[Pneumonia and Rothia dentocariosa].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:11

    Topics: Actinomycetales Infections; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunocompromised Host; Melphalan; Micrococcaceae; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Pyrazines

2011
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
    Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic

2012
Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.
    British journal of haematology, 2012, Volume: 156, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Organoselenium Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2012
Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
    Transplantation proceedings, 2011, Volume: 43, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Multiple Myeloma; Plasmapheresis; Pyrazines; Remission Induction

2011
Managing light chain deposition disease.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Multiple Myeloma; Pyrazines

2012
[POEMS syndrome. An interdisciplinary clinical challenge].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2011, Volume: 62, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cooperative Behavior; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin lambda-Chains; Interdisciplinary Communication; Male; Middle Aged; Paraproteinemias; POEMS Syndrome; Pyrazines; Vascular Endothelial Growth Factor A

2011
Renal improvement in myeloma with plasma exchange.
    The New England journal of medicine, 2011, 09-15, Volume: 365, Issue:11

    Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Multiple Myeloma; Plasma Exchange; Pyrazines

2011
Renal improvement in myeloma with plasma exchange.
    The New England journal of medicine, 2011, 09-15, Volume: 365, Issue:11

    Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines

2011
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Blood, 2011, Dec-08, Volume: 118, Issue:24

    Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Line, Tumor; Cells, Cultured; DNA Repair; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rad51 Recombinase; RNA, Messenger; Survival Analysis; Xenograft Model Antitumor Assays

2011
Sudden significant total protein concentration change: not an analytical problem.
    Journal of clinical laboratory analysis, 2011, Volume: 25, Issue:5

    Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide

2011
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
    Experimental hematology, 2011, Volume: 39, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation

2011
A third-generation IMiD for MM.
    Blood, 2011, Sep-15, Volume: 118, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide

2011
Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.
    Thorax, 2012, Volume: 67, Issue:2

    Topics: Animals; Autocrine Communication; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; PPAR gamma; Proteasome Inhibitors; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta1

2012
An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
    Molecular medicine reports, 2012, Volume: 5, Issue:1

    Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Green Fluorescent Proteins; Humans; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins

2012
Radioresistance of prostate cancer cells with low proteasome activity.
    The Prostate, 2012, Jun-01, Volume: 72, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Phenotype; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Radiation Tolerance; Radiotherapy; Treatment Failure

2012
FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.
    Cell cycle (Georgetown, Tex.), 2011, Oct-01, Volume: 10, Issue:19

    Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Thiostrepton

2011
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Leukemia, 2012, Volume: 26, Issue:4

    Topics: Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
    British journal of haematology, 2011, Volume: 155, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Immunohistochemistry; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays

2011
Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.
    Cardiovascular toxicology, 2012, Volume: 12, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines

2012
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome

2012
Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.
    Journal of biomolecular screening, 2012, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; Nocodazole; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitin-Protein Ligases

2012
Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model.
    Inflammation, 2012, Volume: 35, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Female; I-kappa B Kinase; Inflammation; Inflammation Mediators; Joint Prosthesis; Mice; Mice, Inbred BALB C; NF-kappa B; Osteolysis; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; Titanium; Tumor Necrosis Factor-alpha

2012
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.
    Cellular oncology (Dordrecht), 2011, Volume: 34, Issue:6

    Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction

2011
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Leukemia research, 2012, Volume: 36, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multiple Myeloma; Polyploidy; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2012
Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes.
    International immunopharmacology, 2011, Volume: 11, Issue:12

    Topics: 3-Hydroxyanthranilic Acid; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Humans; Lymphocyte Activation; Lymphocytes; Manganese; Pyrazines

2011
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Humans; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Quality-Adjusted Life Years; State Medicine; Thalidomide; Treatment Outcome; United Kingdom

2011
Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells.
    Scandinavian journal of immunology, 2012, Volume: 75, Issue:2

    Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; Isoenzymes; Jurkat Cells; Lupus Erythematosus, Systemic; Male; Middle Aged; Organ Specificity; Primary Cell Culture; Proteasome Inhibitors; Protein Kinase C; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase C-theta; Pyrazines; T-Lymphocytes

2012
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
    Cancer letters, 2012, Jan-01, Volume: 314, Issue:1

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Activation; Head and Neck Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Squamous Cell Carcinoma of Head and Neck

2012
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Haematologica, 2012, Volume: 97, Issue:1

    Topics: Activating Transcription Factor 6; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; HEK293 Cells; HeLa Cells; Humans; Immunoglobulins; Jurkat Cells; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Transcription Factors; Treatment Outcome; Unfolded Protein Response; X-Box Binding Protein 1

2012
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
    Blood, 2011, Dec-01, Volume: 118, Issue:23

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin

2011
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Leukemia research, 2012, Volume: 36, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazines; Spiro Compounds; Survival Rate

2012
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    International journal of oncology, 2012, Volume: 40, Issue:2

    Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult

2012
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
    Oncogene, 2012, Jun-21, Volume: 31, Issue:25

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Endoplasmic Reticulum Stress; Humans; Mice; Multiple Myeloma; Neoplasm Transplantation; Oncolytic Virotherapy; Orthoreovirus, Mammalian; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transplantation, Heterologous

2012
Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.
    Journal of the peripheral nervous system : JPNS, 2011, Volume: 16, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Immunohistochemistry; Mice; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines; Risk Factors

2011
Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.
    The Biochemical journal, 2012, Feb-01, Volume: 441, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Enzyme Inhibitors; HEK293 Cells; HeLa Cells; Humans; NEDD8 Protein; Pyrazines; Transfection; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination; Ubiquitins

2012
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
    Journal of surgical oncology, 2012, Mar-15, Volume: 105, Issue:4

    Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Neoplasms; Tumor Cells, Cultured

2012
Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
    Molecular carcinogenesis, 2013, Volume: 52, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Pyrazines; STAT1 Transcription Factor; Tumor Cells, Cultured

2013
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
    International journal of molecular medicine, 2012, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergism; Humans; Immunoblotting; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
    Cancer science, 2012, Volume: 103, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line; Cell Survival; Child; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Pyrazines; T-Lymphocytes; Valproic Acid

2012
Molecular pathways: targeting proteasomal protein degradation in cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin

2012
AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
    Blood, 2011, Dec-15, Volume: 118, Issue:25

    Topics: Acute Disease; Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Core Binding Factor Alpha 2 Subunit; Cytoplasm; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; I-kappa B Kinase; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; NF-kappa B; Protein Binding; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays

2011
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
    Experimental hematology, 2012, Volume: 40, Issue:2

    Topics: Antigens, CD19; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Leukocyte Common Antigens; Lymphoma, Mantle-Cell; Neoplastic Stem Cells; NF-kappa B; Pyrazines

2012
Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.
    American journal of hematology, 2011, Volume: 86, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Scleromyxedema

2011
Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.
    Biochemical and biophysical research communications, 2011, Nov-18, Volume: 415, Issue:2

    Topics: alpha-Glucosidases; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Enzyme Stability; Fibroblasts; Glycogen Storage Disease Type II; Humans; Leupeptins; Mutation; Proteasome Inhibitors; Protein Transport; Pyrazines

2011
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    Biochemical pharmacology, 2012, Jan-15, Volume: 83, Issue:2

    Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines

2012
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
    Hematological oncology, 2012, Volume: 30, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide

2012
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2012
[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:5

    Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Movement; Female; Hepatocyte Growth Factor; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines

2011
[Bortezomib combined with autologous peripheral blood hematopoietic stem cell transplantation for therapy of patients with multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:5

    Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning

2011
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:21

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin D; Multiple Myeloma; Pyrazines; Treatment Outcome

2011
Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
    British journal of cancer, 2011, Nov-22, Volume: 105, Issue:11

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Flow Cytometry; Humans; Multiple Myeloma; Neoplasm Transplantation; Pyrazines; Real-Time Polymerase Chain Reaction; Turkeys; Xenograft Model Antitumor Assays

2011
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Human pathology, 2012, Volume: 43, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Nucleus; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Pyrazines

2012
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
    International journal of cancer, 2012, Sep-15, Volume: 131, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Morphogenetic Proteins; Bone Remodeling; Boronic Acids; Bortezomib; Female; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines

2012
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Microarray Analysis; Multicenter Studies as Topic; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Treatment Failure; Up-Regulation

2012
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
    Nature medicine, 2011, Nov-06, Volume: 17, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination

2011
Fluorescence-based proteasome activity profiling.
    Methods in molecular biology (Clifton, N.J.), 2012, Volume: 803

    Topics: Animals; Biochemistry; Biological Assay; Boron Compounds; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Chromatography, Reverse-Phase; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorescent Dyes; Humans; Mice; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Spectrometry, Fluorescence; Staining and Labeling

2012
Proteasome inhibitors suppress expression of NPM and ARF proteins.
    Cell cycle (Georgetown, Tex.), 2011, Nov-15, Volume: 10, Issue:22

    Topics: ADP-Ribosylation Factors; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; HeLa Cells; Humans; Leupeptins; Nuclear Proteins; Nucleophosmin; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Thiostrepton

2011
Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity.
    Biochemistry. Biokhimiia, 2011, Volume: 76, Issue:9

    Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression; Humans; Multidrug Resistance-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Y-Box-Binding Protein 1

2011
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
    Cancer letters, 2012, Apr-01, Volume: 317, Issue:1

    Topics: Animals; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; Chemoradiotherapy; Dose-Response Relationship, Drug; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Pyrazines; Radiation-Sensitizing Agents; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays

2012
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Molecular carcinogenesis, 2013, Volume: 52, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Central Nervous System Neoplasms; Cytochromes c; DNA Damage; Glioblastoma; Glioma; Histones; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vorinostat

2013
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Neuroblastoma; Protease Inhibitors; Pyrazines; Rats; Tretinoin; Xenograft Model Antitumor Assays

2011
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
    Journal of alternative and complementary medicine (New York, N.Y.), 2011, Volume: 17, Issue:11

    Topics: Adult; Aged; Antibiotic Prophylaxis; Boronic Acids; Bortezomib; Drugs, Chinese Herbal; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Isatis; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plant Roots; Pyrazines

2011
Amyloidosis.
    BMJ (Clinical research ed.), 2011, Nov-16, Volume: 343

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Delayed Diagnosis; Dexamethasone; Dyspnea; Heart Diseases; Humans; Kidney; Kidney Diseases; Male; Narration; Pyrazines; Quality of Life; Serum Amyloid A Protein; Thalidomide

2011
Intramural delivery of bortezomib inhibits restenosis following arterial injury.
    VASA. Zeitschrift fur Gefasskrankheiten, 2011, Volume: 40, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Constriction, Pathologic; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Iliac Artery; Immunoenzyme Techniques; Male; Muscle, Smooth, Vascular; Neointima; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rabbits

2011
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
    Molecular medicine reports, 2012, Volume: 5, Issue:2

    Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Humans; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Up-Regulation

2012
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
    British journal of haematology, 2012, Volume: 156, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2012
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Proliferation; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering

2011
Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
    Biochemistry. Biokhimiia, 2011, Volume: 76, Issue:11

    Topics: Acetates; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytostatic Agents; Fluocinolone Acetonide; Humans; K562 Cells; Leukemia; Ligands; NF-kappa B; Pyrazines; Receptors, Glucocorticoid; Tacrolimus Binding Proteins; Transcription Factor AP-1; Tyramine

2011
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Biochemical and biophysical research communications, 2011, Dec-09, Volume: 416, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Glioma; Humans; Leupeptins; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation

2011
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
    Blood, 2012, Jan-19, Volume: 119, Issue:3

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Unfolded Protein Response

2012
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
    Journal of hematology & oncology, 2011, Dec-01, Volume: 4

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 2; Xenograft Model Antitumor Assays

2011
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome

2011
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Blood, 2012, Feb-09, Volume: 119, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Panobinostat; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors

2012
Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    International journal of laboratory hematology, 2012, Volume: 34, Issue:3

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2012
[Renal tolerance of targeted therapies].
    Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3

    Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2012
Inhibition of intraerythrocytic proteasome retards the generation of hemorphins.
    Peptides, 2012, Volume: 33, Issue:1

    Topics: Boronic Acids; Bortezomib; Cells, Cultured; Dose-Response Relationship, Drug; Erythrocytes; Hemoglobins; Humans; Peptide Fragments; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
    Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011

    Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2011
From the observation DAC: romidepsin revisited.
    Blood, 2011, Dec-08, Volume: 118, Issue:24

    Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Depsipeptides; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Pyrazines

2011
Innovation in myeloma treatments PARP excellence!
    Blood, 2011, Dec-08, Volume: 118, Issue:24

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2011
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment.
    British journal of cancer, 2012, Jan-17, Volume: 106, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Female; Flow Cytometry; Humans; Indoles; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction; Xenograft Model Antitumor Assays

2012
[Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:6

    Topics: B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger; Tumor Necrosis Factor Ligand Superfamily Member 13

2011
[Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:6

    Topics: 2-Methoxyestradiol; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Humans; Pyrazines

2011
Drugs: More shots on target.
    Nature, 2011, Dec-14, Volume: 480, Issue:7377

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine

2011
Orthopaedics: Structural support.
    Nature, 2011, Dec-14, Volume: 480, Issue:7377

    Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosphonates; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Kyphoplasty; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines

2011
Hyponatremia is not a rare adverse event in bortezomib-treated patients.
    Chemotherapy, 2011, Volume: 57, Issue:5

    Topics: Aged; Boronic Acids; Bortezomib; Humans; Hyponatremia; Male; Pyrazines; Treatment Outcome

2011
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Transplantation, 2012, Feb-15, Volume: 93, Issue:3

    Topics: Adolescent; Adult; Boronic Acids; Bortezomib; Child; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Infant; Isoantibodies; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors

2012
The proteasome as a target for prevention of restenosis following vascular injury.
    VASA. Zeitschrift fur Gefasskrankheiten, 2011, Volume: 40, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Iliac Artery; Male; Neointima; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2011
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
    Pharmaceutical biology, 2012, Volume: 50, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neuroblastoma; Peptides, Cyclic; Proteasome Inhibitors; Pyrazines; Urea

2012
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
    International journal of oncology, 2012, Volume: 40, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clarithromycin; Cytotoxicity, Immunologic; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression; Humans; Pyrazines; Transcription Factor CHOP

2012
Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:1

    Topics: Boronic Acids; Bortezomib; Female; Graft Rejection; HLA Antigens; Humans; Isoantibodies; Lung Transplantation; Middle Aged; Protease Inhibitors; Pyrazines; Tissue Donors; Treatment Outcome

2012
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    British journal of haematology, 2012, Volume: 156, Issue:5

    Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Signal Transduction; Sulfonamides; Tumor Cells, Cultured

2012
Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice.
    International archives of allergy and immunology, 2012, Volume: 158, Issue:1

    Topics: Allergens; Animals; Anti-Asthmatic Agents; Asthma; Boronic Acids; Bortezomib; Chronic Disease; Disease Models, Animal; Eosinophils; Female; Immunoglobulin E; Immunoglobulin G; Lung; Mice; Mice, Inbred BALB C; Plasma Cells; Pyrazines; Treatment Failure

2012
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Pyrazines

2011
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Cell cycle (Georgetown, Tex.), 2012, Jan-15, Volume: 11, Issue:2

    Topics: Acetates; Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Receptors, Androgen; Receptors, Glucocorticoid; Transcription Factor CHOP; Transcriptional Activation; Tyramine

2012
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Annals of hematology, 2012, Volume: 91, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Lymphoma, Mantle-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2012
[Lung injury associated with bortezomib therapy in Japan].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Product Surveillance, Postmarketing; Pyrazines

2011
Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Transplantation, 2012, Mar-27, Volume: 93, Issue:6

    Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Immunoglobulins, Intravenous; Incidence; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Pyrazines; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Tissue Donors; Treatment Outcome

2012
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NEDD8 Protein; Pyrazines; Treatment Outcome; Ubiquitin-Activating Enzymes; Ubiquitination; Ubiquitins; Xenograft Model Antitumor Assays

2012
Durability of antibody removal following proteasome inhibitor-based therapy.
    Transplantation, 2012, Mar-27, Volume: 93, Issue:6

    Topics: Adult; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prognosis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors; Transplantation, Homologous

2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Blood, 2012, Mar-15, Volume: 119, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Male; Mice; Mice, SCID; Plasmacytoma; Pyrazines; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Microscale functional cytomics for studying hematologic cancers.
    Blood, 2012, Mar-08, Volume: 119, Issue:10

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cells, Cultured; Cellular Microenvironment; Coculture Techniques; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Immunohistochemistry; Multiple Myeloma; NF-kappa B; Pyrazines; STAT3 Transcription Factor; Stromal Cells; Tumor Necrosis Factor-alpha

2012
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    International journal of oncology, 2012, Volume: 40, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1

2012
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
    Experimental hematology, 2012, Volume: 40, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine

2012
Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
    Haematologica, 2012, Volume: 97, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; Humans; Immunohistochemistry; Ki-67 Antigen; Lymphoma, Large B-Cell, Diffuse; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Molecular Targeted Therapy; Primary Cell Culture; Proliferating Cell Nuclear Antigen; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thiostrepton; Tumor Stem Cell Assay

2012
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Haematologica, 2012, Volume: 97, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays

2012
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:10

    Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide

2012
[Unusual skin alterations in a 72-year-old patient with multiple myeloma].
    Der Internist, 2012, Volume: 53, Issue:4

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome

2012
[Modern times: back to past, back to future].
    Medicina clinica, 2012, Jul-07, Volume: 139, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine

2012
The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
    Nephron. Experimental nephrology, 2012, Volume: 120, Issue:2

    Topics: Animals; Boronic Acids; Bortezomib; Collagen Type IV; Disease Models, Animal; Female; Humans; Immunohistochemistry; Injections, Intravenous; Kidney Glomerulus; Kidney Tubules; Lupus Nephritis; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Microscopy, Electron; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome

2012
Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation.
    Transplant immunology, 2012, Volume: 26, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Chemokine CXCL2; Disease Models, Animal; Fatty Liver; Humans; Inflammation Mediators; Interleukin-1beta; Liver; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Transcription Factor RelA; Tumor Necrosis Factor-alpha

2012
HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.
    The oncologist, 2012, Volume: 17, Issue:1

    Topics: Adult; Boronic Acids; Bortezomib; Castleman Disease; Ganciclovir; Herpesviridae Infections; Herpesvirus 8, Human; HIV; Humans; Male; Pyrazines; Rare Diseases

2012
Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.
    Carcinogenesis, 2012, Volume: 33, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; NF-kappa B; Pyrazines

2012
Incorporating monoclonal antibodies into the therapy of multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines

2012
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Blood, 2012, Mar-15, Volume: 119, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; GTP-Binding Proteins; Humans; Immunoenzyme Techniques; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monoterpenes; NF-kappa B; Perilla; Protein Glutamine gamma Glutamyltransferase 2; Pyrazines; Transglutaminases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    British journal of haematology, 2012, Volume: 157, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide

2012
Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Urology, 2012, Volume: 79, Issue:4

    Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Endoplasmic Reticulum; Histones; HIV Protease Inhibitors; Mice; Mice, Nude; Pyrazines; Ritonavir; Ubiquitinated Proteins; Ubiquitination; Xenograft Model Antitumor Assays

2012
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Clinical journal of oncology nursing, 2012, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Severity of Illness Index

2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    European journal of haematology, 2012, Volume: 88, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2012
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
    Cancer research, 2012, Mar-15, Volume: 72, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide

2012
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Feb-14, Volume: 109, Issue:7

    Topics: Apoptosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Humans; Leukemia; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrazines; Translocation, Genetic

2012
Abrogation of antibodies improves outcome of renal transplantation.
    Transplantation proceedings, 2012, Volume: 44, Issue:1

    Topics: Adult; Biomarkers; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Immunization; Immunosuppression Therapy; Immunosuppressive Agents; India; Isoantibodies; Kidney Transplantation; Living Donors; Lymphatic Irradiation; Male; Mesenchymal Stem Cell Transplantation; Pyrazines; T-Lymphocytes; Time Factors; Treatment Outcome; Young Adult

2012
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
    Cancer biology & therapy, 2012, Volume: 13, Issue:6

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured

2012
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Annals of hematology, 2012, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide

2012
Multiple myeloma presenting with hepatosplenomegaly.
    The Journal of the Association of Physicians of India, 2011, Volume: 59

    Topics: Abdomen; Adult; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Fatal Outcome; Female; Hepatomegaly; Humans; Multiple Myeloma; Pyrazines; Splenomegaly; Tomography, X-Ray Computed; Ultrasonography

2011
Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
    The Journal of biological chemistry, 2012, Mar-23, Volume: 287, Issue:13

    Topics: Acetylcysteine; Alleles; Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Proteinase Inhibitors; Distal Myopathies; Dysferlin; Humans; Membrane Proteins; Muscle Fibers, Skeletal; Muscle Proteins; Muscular Atrophy; Muscular Dystrophies, Limb-Girdle; Mutation, Missense; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; RNA, Messenger

2012
Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Comparative Genomic Hybridization; Female; Fibrosarcoma; Gene Amplification; Gene Dosage; Guanine Nucleotide Exchange Factors; Humans; Male; Mice; Mice, SCID; Middle Aged; Prognosis; Protein Serine-Threonine Kinases; Pyrazines; Racemases and Epimerases; RNA, Messenger; S-Phase Kinase-Associated Proteins; Up-Regulation; Xenograft Model Antitumor Assays

2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Bombesin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Endothelin-1; Humans; Interleukin-8; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Signal Transduction; Translocation, Genetic; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2012
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Transplant immunology, 2012, Volume: 26, Issue:4

    Topics: Boronic Acids; Bortezomib; Epitopes; Female; Follow-Up Studies; Graft Rejection; HLA Antigens; Humans; Immunity, Humoral; Immunization; Immunoglobulin G; Kidney Transplantation; Lymphocyte Activation; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Reoperation; Transplantation Conditioning

2012
Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Chemotherapy, 2012, Volume: 58, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Neuroblastoma; Pyrazines

2012
Using transcriptome sequencing to identify mechanisms of drug action and resistance.
    Nature chemical biology, 2012, Feb-12, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazines; Sequence Analysis, DNA; Transcriptome

2012
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
    Blood, 2012, May-10, Volume: 119, Issue:19

    Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clonal Evolution; Cohort Studies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
    Blood, 2012, May-10, Volume: 119, Issue:19

    Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Humans; Kidney; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors

2012
[Effect of omega-3 fish oil fat emulsion on the peripheral neuropathy caused by bortezomib].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:9

    Topics: Boronic Acids; Bortezomib; Fatty Acids, Omega-3; Fish Oils; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines

2011
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid; Panobinostat; Pyrazines; Signal Transduction

2011
Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2012, Volume: 120, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Inhibitory Concentration 50; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor Protein-Tyrosine Kinases; Signal Transduction; TOR Serine-Threonine Kinases

2012
[Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:10

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Treatment Outcome

2011
[Autologous hematopoietic stem cell transplantation following bortezomib-based chemotherapy for one case with POEMS syndrome].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:11

    Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; POEMS Syndrome; Pyrazines

2011
[Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2012, Volume: 25, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Male; Mass Spectrometry; Multiple Myeloma; Proteomics; Pyrazines

2012
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
    Methods in molecular biology (Clifton, N.J.), 2012, Volume: 832

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine

2012
Timing of the high-dose therapy in the area of new drugs.
    Srpski arhiv za celokupno lekarstvo, 2011, Volume: 139 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2011
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
    Cancer biology & therapy, 2012, Feb-01, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Mice; Mice, Nude; Nanocapsules; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Thiostrepton; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays

2012
Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Feb-22, Volume: 32, Issue:8

    Topics: Analysis of Variance; Animals; Boronic Acids; Bortezomib; Cells, Cultured; Dendrites; Disks Large Homolog 4 Protein; Drosophila Proteins; Embryo, Mammalian; Enzyme Inhibitors; Female; Fragile X Mental Retardation Protein; Gene Expression Regulation; Green Fluorescent Proteins; Hippocampus; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Leupeptins; Male; Membrane Proteins; Methoxyhydroxyphenylglycol; Mutation; Neurons; Okadaic Acid; Phosphoprotein Phosphatases; Phosphorylation; Protein Biosynthesis; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger; Serine; Signal Transduction; Synapses; Transfection; Ubiquitination

2012
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Immunohistochemistry; Kidney Diseases, Cystic; Kidney Neoplasms; Metformin; Mice; Pyrazines; Treatment Outcome; Tuberous Sclerosis

2012
[Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Hyperbilirubinemia; Leukemia, Plasma Cell; Prednisolone; Pyrazines; Severity of Illness Index; Treatment Outcome

2012
Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fanconi Syndrome; Humans; Kidney; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Pyrazines; Renal Insufficiency, Chronic; Treatment Outcome

2012
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines

2012
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
    Inflammation, 2012, Volume: 35, Issue:4

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Arthroplasty, Replacement; Boronic Acids; Bortezomib; Female; Inflammation; Mice; Mice, Inbred BALB C; Osteolysis; Osteoprotegerin; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; RANK Ligand; Titanium; TNF Receptor-Associated Factor 6; Vascular Endothelial Growth Factors

2012
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:3

    Topics: Annexins; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Glioma; Humans; Mitochondrial Diseases; NF-kappa B; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazines; Sulfonamides

2012
Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 341, Issue:3

    Topics: Acetylcysteine; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Transfection; Tumor Cells, Cultured

2012
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Flow Cytometry; Gene Expression; Humans; I-kappa B Proteins; Lymphoma; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2012
HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2012, Volume: 90, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Survival; Cold-Shock Response; Cricetinae; Cysteine Proteinase Inhibitors; Fibroblasts; Gene Expression; HSP70 Heat-Shock Proteins; Humans; Leupeptins; Pyrazines; Recombinant Proteins; Stress, Physiological

2012
The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.
    European journal of haematology, 2012, Volume: 88, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Pyrazines; Scleromyxedema

2012
Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
    The Journal of biological chemistry, 2012, Apr-27, Volume: 287, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Enzyme Activation; HeLa Cells; Humans; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2012
Bortezomib is effective to treat acute humoral rejection after liver transplantation.
    Transplantation proceedings, 2012, Volume: 44, Issue:2

    Topics: Acute Disease; Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Plasmapheresis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pulse Therapy, Drug; Pyrazines; Retrospective Studies; Rituximab; Steroids; Taiwan; Time Factors; Treatment Outcome

2012
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calreticulin; Cell Line; Dendritic Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Low Density Lipoprotein Receptor-Related Protein-1; Lymphoma, Primary Effusion; Phagocytosis; Protein Transport; Pyrazines; Tyrphostins

2012
Low-dose cyclosporine mediates donor hyporesponsiveness in a fully mismatched rat kidney transplant model.
    Transplant immunology, 2012, Volume: 26, Issue:4

    Topics: Adoptive Transfer; Animals; Antibodies; Boronic Acids; Bortezomib; Cyclosporine; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Proteasome Inhibitors; Pyrazines; Rats; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning

2012
Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.
    European journal of haematology, 2012, Volume: 88, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Male; Paraneoplastic Syndromes; POEMS Syndrome; Pyrazines; Recurrence

2012
In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adipose Tissue; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Coculture Techniques; Culture Media, Conditioned; Gene Expression; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand

2012
Regulatory mechanism of transforming growth factor beta receptor type II degradation by interleukin-1 in primary chondrocytes.
    Biochimica et biophysica acta, 2012, Volume: 1823, Issue:5

    Topics: Aged; Aged, 80 and over; Biological Transport; Boronic Acids; Bortezomib; Caveolae; Caveolin 1; Cells, Cultured; Chondrocytes; Humans; Interleukin-1beta; Lysosomes; Middle Aged; Nystatin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proteolysis; Pyrazines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta

2012
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
    International journal of hematology, 2012, Volume: 95, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Metaphase; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2012
Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells.
    Inflammation, 2012, Volume: 35, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Chemokine CCL2; Cyclooxygenase 2; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; Macrophage Inflammatory Proteins; Macrophages; Mice; Nitric Oxide Synthase Type II; Proteasome Inhibitors; Pyrazines; Titanium; Tumor Necrosis Factor-alpha

2012
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
    British journal of haematology, 2012, Volume: 157, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Neoplasms, Plasma Cell; Pyrazines; Scleromyxedema; Thalidomide

2012
Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
    Leukemia, 2012, Volume: 26, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Hodgkin Disease; Humans; Mast Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Pyrazines; Tumor Microenvironment

2012
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Molecular pharmaceutics, 2012, May-07, Volume: 9, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
[Current perspectives in the treatment of multiple myeloma - news and views].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:13

    Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous

2012
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.
    BMC cancer, 2012, Mar-21, Volume: 12

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Mice; Mice, SCID; Microarray Analysis; Neuroblastoma; NF-kappa B; Pyrazines; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays

2012
Bortezomib and panobinostat combination is effective against PTCL.
    Leukemia research, 2012, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multimodal Imaging; Panobinostat; Positron-Emission Tomography; Pyrazines; Tomography, X-Ray Computed; Treatment Outcome

2012
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
    Experimental and molecular pathology, 2012, Volume: 93, Issue:1

    Topics: Alcohol Drinking; Animals; Antineoplastic Agents; Apolipoproteins; Boronic Acids; Bortezomib; Cholesterol; Down-Regulation; Fatty Acids; Fatty Liver, Alcoholic; Intestinal Absorption; Lipid Metabolism; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Triglycerides

2012
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
    Biochemical and biophysical research communications, 2012, Apr-13, Volume: 420, Issue:3

    Topics: 2-Methoxyestradiol; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; Tretinoin; Tumor Cells, Cultured; X-Box Binding Protein 1

2012
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, myc; Humans; Mice; Mice, Congenic; Mice, Inbred C57BL; Mice, Transgenic; Multiple Myeloma; Myeloma Proteins; Neoplasm Transplantation; Predictive Value of Tests; Pyrazines

2012
Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
    Clinical toxicology (Philadelphia, Pa.), 2012, Volume: 50, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Cholestasis; Fatal Outcome; Humans; Liver Failure; Male; Multiple Myeloma; Pyrazines; Renal Dialysis

2012
Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish.
    Journal of the peripheral nervous system : JPNS, 2012, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Agents; Axons; Behavior, Animal; Boronic Acids; Bortezomib; Immunohistochemistry; Larva; Pyrazines; Vincristine; Zebrafish

2012
High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    American journal of hematology, 2012, Volume: 87, Issue:6

    Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2012
The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats.
    Experimental and molecular pathology, 2012, Volume: 93, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); HSP70 Heat-Shock Proteins; Liver Regeneration; Liver Transplantation; Male; Mitochondria, Liver; Nitric Oxide Synthase Type III; Organ Size; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury

2012
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
    Endocrine, 2012, Volume: 42, Issue:3

    Topics: Antineoplastic Agents; Aurora Kinases; Benzazepines; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Indicators and Reagents; Protein Serine-Threonine Kinases; Pyrazines; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor A

2012
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrazines; Tumor Suppressor Protein p53

2012
Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colitis; Dextran Sulfate; Enzyme Inhibitors; Interferon-gamma; Intestines; Mice; Mice, Inbred C57BL; Proteasome Inhibitors; Pyrazines

2012
AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo.
    Human gene therapy, 2012, Volume: 23, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzaldehydes; Boronic Acids; Bortezomib; Dependovirus; Disease Models, Animal; DNA End-Joining Repair; Gene Targeting; Genetic Vectors; Immunohistochemistry; Mice; Mice, Knockout; Plasmids; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Pyrazines; Recombinant Proteins

2012
Curative resection of double primary lung cancer after 15-month bortezomib administration.
    Onkologie, 2012, Volume: 35, Issue:4

    Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pneumonectomy; Pyrazines; Treatment Outcome

2012
Involvement of the ubiquitin-proteasome system in the formation of experimental postsurgical peritoneal adhesions.
    Mediators of inflammation, 2012, Volume: 2012

    Topics: Animals; Boronic Acids; Bortezomib; Interleukin-6; Male; NF-kappa B; Peritoneal Diseases; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Tumor Necrosis Factor-alpha; Ubiquitin

2012
Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
    Artificial organs, 2012, Volume: 36, Issue:9

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Multiple Myeloma; Pyrazines

2012
Multiple myeloma: treatment evolution.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult

2012
New developments in the field of diffuse large cell lymphoma.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Breast Implants; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Pyrazines

2012
Frontline treatment of multiple myeloma.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide

2012
Myeloma: diagnosis complications and supportive care.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid

2012
Stem cell transplantation for multiple myeloma: current and future status.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide

2012
Targeted therapy of multiple myeloma.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2012
Why is management of cancer pain still a problem?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16

    Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines

2012
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
    Cell cycle (Georgetown, Tex.), 2012, 05-01, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins

2012
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.
    Stem cells (Dayton, Ohio), 2012, Volume: 30, Issue:7

    Topics: Adipogenesis; Adult Stem Cells; Animals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Flow Cytometry; Immunohistochemistry; Mice; Osteoblasts; Osteogenesis; Osteogenesis Imperfecta; Pyrazines

2012
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
    Die Pharmazie, 2012, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Survival; Coloring Agents; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; I-kappa B Proteins; Indicators and Reagents; K562 Cells; NF-kappa B; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Signal Transduction; Tetrazolium Salts; Thiazoles; Transcription Factor RelA

2012
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic

2012
Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Cytokines; Dependovirus; Flow Cytometry; Genetic Vectors; Immunity; Male; Mice; Proteasome Inhibitors; Pyrazines

2012
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
    Future oncology (London, England), 2012, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Proteasome Inhibitors; Pyrazines; Recurrence

2012
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Boronic Acids; Bortezomib; Chemokine CCL2; Cholesterol; Computational Biology; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Inflammation Mediators; Injections, Intraperitoneal; Interleukin-6; Lipid Peroxidation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, LDL; Superoxides; Time Factors; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents

2012
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Cancer, 2012, Nov-15, Volume: 118, Issue:22

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Membrane Proteins; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting

2012
Bortezomib-induced severe autonomic neuropathy.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2012, Volume: 22, Issue:4

    Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index

2012
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Female; Flow Cytometry; Graft vs Host Disease; Graft vs Tumor Effect; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrazines; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Transplantation, Homologous

2012
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:6

    Topics: Antigens, Neoplasm; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; MART-1 Antigen; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic

2012
[Prognostic significance of morphology in multiple myeloma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2012, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous

2012
[Improved prognosis in light chain nephropathy due to multiple myeloma].
    Ugeskrift for laeger, 2012, Apr-23, Volume: 174, Issue:17

    Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Diseases; Middle Aged; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation

2012
Characterization of the protein ubiquitination response induced by Doxorubicin.
    The FEBS journal, 2012, Volume: 279, Issue:12

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; HSP27 Heat-Shock Proteins; Humans; Immunoprecipitation; L-Lactate Dehydrogenase; Phosphopyruvate Hydratase; Pyrazines; Ubiquitination

2012
CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Breast cancer research : BCR, 2012, Apr-26, Volume: 14, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Estrogen; Xenograft Model Antitumor Assays

2012
Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
    Investigative ophthalmology & visual science, 2012, Jun-26, Volume: 53, Issue:7

    Topics: Animals; Anterior Chamber; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Immunohistochemistry; Male; NF-kappa B; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew; Uveitis, Anterior

2012
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Blood, 2012, Jun-14, Volume: 119, Issue:24

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Activation; Enzyme Inhibitors; Humans; Interleukin-6; Lactams, Macrocyclic; Mice; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Signal Transduction; Stromal Cells; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1

2012
Cellular signal transduction can be induced by TRAIL conjugated to microcapsules.
    Journal of biomedical materials research. Part A, 2012, Volume: 100, Issue:10

    Topics: Annexin A5; Apoptosis; Boronic Acids; Bortezomib; Capsules; Cell Line, Tumor; Contrast Media; Doxorubicin; Flow Cytometry; Humans; Lactic Acid; Melanoma; Membranes, Artificial; Particle Size; Polyesters; Polymers; Pyrazines; Signal Transduction; Staining and Labeling; TNF-Related Apoptosis-Inducing Ligand; Ultrasonics

2012
[Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Humans; Multiple Myeloma; Phenanthrenes; Pyrazines

2012
Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
    Swiss medical weekly, 2012, Volume: 142

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Switzerland; Time Factors; Treatment Outcome

2012
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
    International journal of oncology, 2012, Volume: 41, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Cyclin B; Cyclin-Dependent Kinases; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Humans; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrazines; Reactive Oxygen Species; Tumor Suppressor Proteins

2012
Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:12

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Induction Chemotherapy; Male; Middle Aged; POEMS Syndrome; Pyrazines; Renal Insufficiency; Treatment Outcome

2012
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    BMC cancer, 2012, May-04, Volume: 12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2012
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Leukemia research, 2012, Volume: 36, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Imidazoles; Lymphoma, Mantle-Cell; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinolines; TOR Serine-Threonine Kinases

2012
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
    Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:11

    Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome

2012
Bortezomib to treat the TEMPI syndrome.
    The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Lymphangiectasis; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis

2012
Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
    European journal of haematology, 2012, Volume: 89, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Histiocytosis; Humans; Paraproteinemias; Pyrazines; Thalidomide

2012
Survivin is a therapeutic target in Merkel cell carcinoma.
    Science translational medicine, 2012, May-09, Volume: 4, Issue:133

    Topics: Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; Carcinoma, Merkel Cell; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Merkel cell polyomavirus; Mice; Mice, Inbred NOD; Mice, SCID; Naphthoquinones; Polyomavirus Infections; Pyrazines; RNA, Messenger; RNA, Neoplasm; Survivin; Translational Research, Biomedical; Tumor Virus Infections; Xenograft Model Antitumor Assays

2012
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
    International journal of hematology, 2012, Volume: 96, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Gastrointestinal Tract; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Transplantation; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Thalidomide; Treatment Outcome

2012
Proteasomal insensitivity of apoptin in tumor cells.
    Biochemical and biophysical research communications, 2012, May-25, Volume: 422, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Cell Line; Cell Line, Tumor; Fibroblasts; Humans; Mutation; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Pyrazines; Tumor Suppressor Protein p53

2012
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
    British journal of haematology, 2012, Volume: 158, Issue:3

    Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Coculture Techniques; Humans; Interleukin-6; Lipopolysaccharide Receptors; Macrophages; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines

2012
[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Dexamethasone; Female; Humans; Intestinal Pseudo-Obstruction; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence

2012
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Annals of hematology, 2012, Volume: 91, Issue:11

    Topics: Antineoplastic Agents; Antiprotozoal Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Italy; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2012
Bortezomib and bilateral herpes zoster.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2012, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation

2012
Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.
    Annals of the rheumatic diseases, 2012, Volume: 71, Issue:10

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Boronic Acids; Bortezomib; Disease Models, Animal; Flow Cytometry; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Rats; Rats, Inbred F344; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; T-Lymphocytes

2012
Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
    International journal of molecular sciences, 2012, Volume: 13, Issue:4

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Curcumin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines; Transcription Factor RelA

2012
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Cell research, 2012, Volume: 22, Issue:8

    Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation

2012
Effects of brucine on bone metabolism in multiple myeloma.
    Molecular medicine reports, 2012, Volume: 6, Issue:2

    Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone and Bones; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Culture Media; Humans; Inhibitory Concentration 50; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteoprotegerin; Polymerase Chain Reaction; Pyrazines; RANK Ligand; RNA, Messenger; RNA, Neoplasm; Stem Cells; Strychnine

2012
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
    Cell cycle (Georgetown, Tex.), 2012, Jun-15, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured

2012
Anti-myeloma effects of the novel anthracycline derivative INNO-206.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Hydrazones; Mice; Multiple Myeloma; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrazines

2012
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
    Leukemia, 2012, Volume: 26, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Stem Cells; Thalidomide; Vincristine

2012
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome

2012
Cutaneous lesion induced by a subcutaneous administration of bortezomib.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Infusions, Subcutaneous; Male; Multiple Myeloma; Pyrazines

2012
[Urological cancers: ECCO/ESMO congress 2011].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:12 Pt 1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Medical Oncology; Pyrazines; Societies, Medical; Sulfonamides; Sweden; Urologic Neoplasms

2012
Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells.
    Cancer letters, 2012, Nov-28, Volume: 324, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Cell Death; Cell Line, Tumor; Clonazepam; Curcumin; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Female; Humans; Mitochondria; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sodium-Calcium Exchanger; Thiazepines; Time Factors

2012
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
    American journal of hematology, 2012, Volume: 87, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Paraproteinemias; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous

2012
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:12

    Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Gene Expression; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Valproic Acid

2012
Do not super-excess me!
    Blood, 2012, May-31, Volume: 119, Issue:22

    Topics: Alpha-Globulins; Animals; Antineoplastic Agents; beta-Thalassemia; Boronic Acids; Bortezomib; Erythroid Precursor Cells; Female; Humans; Male; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitination

2012
Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
    Leukemia research, 2012, Volume: 36, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Jurkat Cells; K562 Cells; Leukemia; Lymphoma; Mitochondria; Pyrazines; ras Proteins; RNA, Small Interfering; Up-Regulation

2012
Expression of heme oxygenase-1 in response to proteasomal inhibition.
    Protein and peptide letters, 2012, Volume: 19, Issue:12

    Topics: Animals; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Induction; Female; Genes, p53; Heme Oxygenase-1; Humans; Leupeptins; Melanoma, Experimental; Mice; Molecular Sequence Data; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Regulatory Sequences, Nucleic Acid

2012
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.
    BMC cancer, 2012, Jun-06, Volume: 12

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Fluid; Humans; Male; Mice; Mice, Nude; Neoplasms; Pyrazines; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012
In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
    Cancer science, 2012, Volume: 103, Issue:9

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Female; Genes, Reporter; Green Fluorescent Proteins; HEK293 Cells; Humans; Mice; Mice, Nude; Molecular Imaging; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2012
Bortezomib for acute antibody-mediated rejection in liver transplantation.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012, Volume: 12, Issue:9

    Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrazines; Retrospective Studies

2012
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Journal of hematology & oncology, 2012, Jun-08, Volume: 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Vincristine

2012
NFκB pathway is down-regulated by 1α,25(OH)(2)-vitamin D(3) in endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein coupled receptor.
    Steroids, 2012, Volume: 77, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cell Line, Transformed; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Herpesvirus 8, Human; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Protein Transport; Pyrazines; Receptors, Calcitriol; Receptors, Chemokine; Receptors, Virus; Signal Transduction

2012
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
    Blood, 2012, Jul-26, Volume: 120, Issue:4

    Topics: Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase II as Topic; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Lysosomes; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; TNF Receptor-Associated Factor 6

2012
The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Biochemical pharmacology, 2012, Aug-15, Volume: 84, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Recombinant Fusion Proteins; Ribosome Inactivating Proteins, Type 1; Signal Transduction; Toxins, Biological; Transplantation, Heterologous

2012
Breathless on bortezomib.
    BMJ case reports, 2011, Aug-17, Volume: 2011

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines

2011
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure

2012
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
    European journal of haematology, 2012, Volume: 89, Issue:4

    Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines

2012
Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
    BMC cancer, 2012, Jun-12, Volume: 12

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Proteasome Endopeptidase Complex; Pyrazines; Rhabdomyosarcoma; Ubiquitin

2012
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:10

    Topics: Administration, Oral; Aged; Analgesics, Opioid; Antineoplastic Agents; Boronic Acids; Bortezomib; Delayed-Action Preparations; Humans; Middle Aged; Multiple Myeloma; Oxycodone; Peripheral Nervous System Diseases; Pyrazines; Rome

2012
Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
    Genes to cells : devoted to molecular & cellular mechanisms, 2012, Volume: 17, Issue:7

    Topics: Animals; beta Catenin; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line; Core Binding Factor Alpha 1 Subunit; Gene Expression Profiling; Gene Expression Regulation; Mice; MicroRNAs; Muscle Fibers, Skeletal; Osteoblasts; Osteocalcin; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Smad1 Protein; Smad4 Protein; Transcriptional Activation

2012
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:4

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasma Cells; Pyrazines

2012
Extramedullary involvement: an emerging problem in multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines

2012
Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
    Journal of clinical and experimental hematopathology : JCEH, 2012, Volume: 52, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation

2012
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide

2012
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-20, Volume: 30, Issue:27

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Neoplasms; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lymphoproliferative Disorders; Plasmacytoma; Pyrazines

2012
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Journal of inorganic biochemistry, 2012, Volume: 113

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzothiazoles; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasm Proteins; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Toluene; Tumor Suppressor Protein p53

2012
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Blood, 2012, Aug-02, Volume: 120, Issue:5

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytotoxins; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factors; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Substrate Specificity; Time Factors; Xenograft Model Antitumor Assays

2012
Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:6

    Topics: Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Biopsy; Blood Transfusion; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Glucocorticoids; Humans; Jejunal Diseases; Pyrazines

2012
Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:8

    Topics: Aging; Animals; Boronic Acids; Bortezomib; Cells, Cultured; Down-Regulation; Drug Therapy, Combination; Humans; Male; MicroRNAs; Neuroprotective Agents; NF-kappa B; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Stroke; Tissue Plasminogen Activator; Toll-Like Receptors

2012
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11

    Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation

2012
Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
    Molecular pharmaceutics, 2012, Aug-06, Volume: 9, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Oligopeptides; Peptides; Proteasome Inhibitors; Pyrazines; Verapamil

2012
Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytokine-Induced Killer Cells; Humans; Immunotherapy, Adoptive; Male; Multiple Myeloma; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome

2013
[Effect of bortezomib and low concentration cytarabine on apoptosis in U937 cell line].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cytarabine; Humans; Pyrazines; U937 Cells

2012
Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:1

    Topics: Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Chromans; Humans; Killer Cells, Natural; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Thiazolidinediones; Troglitazone; Up-Regulation; Valproic Acid

2013
Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.
    Leukemia research, 2012, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines

2012
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat

2012
High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Clinical transplants, 2011

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Desensitization, Immunologic; Fatal Outcome; Female; Graft Rejection; Graft Survival; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Male; Monitoring, Immunologic; Phlebography; Pyrazines; Risk Assessment; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome

2011
The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Clinical transplants, 2011

    Topics: Adult; Biopsy; Boronic Acids; Bortezomib; Female; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Missouri; Monitoring, Immunologic; Plasmapheresis; Pyrazines; Retrospective Studies; Time Factors; Treatment Outcome

2011
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine

2013
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Epoxy Compounds; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Oligopeptides; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment

2013
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
    International journal of oncology, 2012, Volume: 41, Issue:3

    Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1

2012
Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
    Cancer gene therapy, 2012, Volume: 19, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; Esophageal Neoplasms; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Humans; Phenotype; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Receptor, ErbB-2; Repressor Proteins; RNA Caps; RNA, Messenger; RNA, Small Interfering; Sirolimus; Ubiquitin

2012
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
    Biochemical and biophysical research communications, 2012, Aug-03, Volume: 424, Issue:3

    Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Female; Hydroxamic Acids; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Pyrazines; Receptors, Notch; Sarcoma; Vorinostat; Wnt Proteins

2012
[Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Zhonghua yi xue za zhi, 2012, Mar-27, Volume: 92, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Plasmacytoma; Prognosis; Pyrazines; Retrospective Studies

2012
[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Zhonghua nei ke za zhi, 2012, Volume: 51, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome

2012
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:1

    Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured

2013
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide

2012
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
    Biomaterials, 2012, Volume: 33, Issue:29

    Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines

2012
Shoulder X-ray--a clue to multiple myeloma.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Radiography; Shoulder Joint; Shoulder Pain; Synovitis; Treatment Outcome

2012
Deaths reported from the accidental intrathecal administration of bortezomib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Spinal; Medication Errors; Pyrazines; Syringes

2012
Transplantation for myeloma: work in progress.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-20, Volume: 30, Issue:24

    Topics: Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines

2012
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Jul-31, Volume: 109, Issue:31

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Jurkat Cells; Kinetics; Multiple Myeloma; Neoplasm Proteins; Proteome; Pyrazines

2012
Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
    Irish medical journal, 2012, Volume: 105, Issue:5

    Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Ireland; Kidney Function Tests; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis

2012
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Animals; B-Cell Maturation Antigen; Bone Marrow; Boronic Acids; Bortezomib; Cell Membrane; Culture Media, Conditioned; Cyclophosphamide; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunoglobulin G; Kaplan-Meier Estimate; Mice; Mice, SCID; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Plasma Cells; Pyrazines; Tumor Burden; Tumor Cells, Cultured

2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-01, Volume: 18, Issue:17

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cyclohexanones; Doxorubicin; Epoxy Compounds; Humans; Leukocytes, Mononuclear; Mice; Multiple Myeloma; NF-kappa B; Osteoclasts; Pyrazines; RANK Ligand; Signal Transduction; Transplantation, Heterologous

2012
Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.
    Critical care medicine, 2012, Volume: 40, Issue:8

    Topics: Animals; Boronic Acids; Bortezomib; Calpain; Caspase 3; Diaphragm; Male; Muscle Contraction; Muscular Atrophy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Wistar; Respiration, Artificial

2012
Proteasome inhibition and ventilator-induced diaphragmatic dysfunction: is the glass half full or half empty?
    Critical care medicine, 2012, Volume: 40, Issue:8

    Topics: Animals; Boronic Acids; Bortezomib; Diaphragm; Male; Proteasome Inhibitors; Pyrazines; Respiration, Artificial

2012
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
    British journal of haematology, 2012, Volume: 159, Issue:1

    Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2012
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.
    Molecular oncology, 2012, Volume: 6, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib

2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
    Blood, 2012, Dec-13, Volume: 120, Issue:25

    Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, SCID; Multiple Myeloma; Patched Receptors; Patched-1 Receptor; Plasma Cells; Pyrazines; Pyridines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Syndecan-1

2012
[Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2012, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Butylene Glycols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Flow Cytometry; Glucosides; Humans; Lung Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger

2012
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
    Cell death & disease, 2012, Jul-19, Volume: 3

    Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous

2012
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.
    Transplantation, 2012, Aug-27, Volume: 94, Issue:4

    Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thrombocytopenia

2012
Bortezomib alleviates experimental pulmonary arterial hypertension.
    American journal of respiratory cell and molecular biology, 2012, Volume: 47, Issue:5

    Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Heart Ventricles; Humans; Hypertension, Pulmonary; Liver; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Monocrotaline; Nitric Oxide Synthase Type III; Proteasome Inhibitors; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley

2012
PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:10

    Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Lung Neoplasms; Phosphorylation; Protein Binding; Protein Kinase C-delta; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Ribosomal Protein S6 Kinases, 90-kDa; Time Factors; Transcription Factor CHOP; Up-Regulation

2012
Fatalities resulting from accidental intrathecal administration of bortezomib: strategies for prevention.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-20, Volume: 30, Issue:27

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Labeling; Drug Packaging; Humans; Injections, Spinal; Medication Errors; Pyrazines

2012
Bortezomib-induced thrombotic thrombocytopaenic purpura.
    BMJ case reports, 2012, Aug-01, Volume: 2012

    Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Boronic Acids; Bortezomib; Confusion; Female; Humans; Multiple Myeloma; Plasma Exchange; Plasmapheresis; Platelet Count; Prognosis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Severity of Illness Index; Treatment Outcome

2012
Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.
    Cancer letters, 2012, Dec-30, Volume: 326, Issue:2

    Topics: Acetylation; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; NF-kappa B; Panobinostat; Poly(ADP-ribose) Polymerases; Proteolysis; Proto-Oncogene Proteins c-akt; Pyrazines

2012
Graft-versus-host disease: have we solved the problem?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26

    Topics: Antigens, CD34; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Pyrazines; Siblings; T-Lymphocyte Subsets

2012
Minor clone provides a reservoir for relapse in multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53

2013
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Cell death & disease, 2012, Aug-09, Volume: 3

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; T-Lymphocytes; Tumor Suppressor Protein p53

2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome

2013
Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2012, Volume: 32, Issue:4

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2012
Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; I-kappa B Kinase; I-kappa B Proteins; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays

2013
Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.
    Cell cycle (Georgetown, Tex.), 2012, Sep-15, Volume: 11, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Neoplasms; Mice; Phenobarbital; Pyrazines; Thiostrepton

2012
Immune mechanism of the antitumor effects generated by bortezomib.
    Journal of immunology (Baltimore, Md. : 1950), 2012, Sep-15, Volume: 189, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chaperonin 60; Female; HSP90 Heat-Shock Proteins; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Mitochondrial Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Pyrazines; Up-Regulation

2012
Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
    Hematological oncology, 2013, Volume: 31, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; Fatal Outcome; Genes, myc; Herpesvirus 4, Human; Humans; Immunoglobulin M; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Retroperitoneal Neoplasms; Transcriptome; Translocation, Genetic

2013
Polyubiquitin is required for growth, development and pathogenicity in the rice blast fungus Magnaporthe oryzae.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Boronic Acids; Bortezomib; Cluster Analysis; Fungal Proteins; Gene Expression Profiling; Gene Expression Regulation, Fungal; Germination; Magnaporthe; Mutation; Nitrogen; Oryza; Plant Diseases; Polyubiquitin; Proteasome Inhibitors; Proteolysis; Proteomics; Pyrazines; Ubiquitination

2012
[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed

2012
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
    Asian journal of andrology, 2012, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; DNA Primers; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction

2012
Complete and partial responses of the TEMPI syndrome to bortezomib.
    The New England journal of medicine, 2012, Aug-23, Volume: 367, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Male; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis

2012
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
    British journal of haematology, 2012, Volume: 159, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vasodilator Agents; Verapamil

2012
Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
    Mini reviews in medicinal chemistry, 2012, Volume: 12, Issue:12

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Copper; Ditiocarb; Humans; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Blood, 2012, Oct-18, Volume: 120, Issue:16

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Profiling; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:4

    Topics: 14-3-3 Proteins; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; NF-kappa B; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured; Up-Regulation

2013
Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins.
    International journal of hematology, 2012, Volume: 96, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines

2012
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
    Experimental neurology, 2012, Volume: 238, Issue:2

    Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Citrate (si)-Synthase; Disease Models, Animal; Electron Transport Complex II; Ganglia, Spinal; Hyperalgesia; Male; Mitochondria; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Schwann Cells; Sciatic Nerve; Time Factors; Ubiquitin Thiolesterase

2012
Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
    The Journal of investigative dermatology, 2013, Volume: 133, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; CTLA-4 Antigen; Female; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Polyubiquitin; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Pyrazines; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes

2013
Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
    International journal of hematology, 2012, Volume: 96, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythema; Humans; Injections, Subcutaneous; Multiple Myeloma; Phlebitis; Pyrazines

2012
Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
    Molecular cancer research : MCR, 2012, Volume: 10, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Estrogen Receptor alpha; Female; HCT116 Cells; Humans; MCF-7 Cells; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2012
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin

2012
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis.
    Acta dermato-venereologica, 2013, Mar-27, Volume: 93, Issue:2

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome

2013
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    American journal of hematology, 2012, Volume: 87, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines

2012
Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
    Journal of agricultural and food chemistry, 2012, Oct-03, Volume: 60, Issue:39

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Multiple Myeloma; Protein Binding; Pyrazines

2012
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
    European journal of haematology, 2012, Volume: 89, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome

2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Cancer cell, 2012, Sep-11, Volume: 22, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays

2012
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Cellular signalling, 2013, Volume: 25, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured

2013
[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:8

    Topics: Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Drug Therapy, Combination; Humans; Intestinal Pseudo-Obstruction; Itraconazole; Middle Aged; Multiple Myeloma; Mycoses; Pyrazines; Pyrimidines; Triazoles; Voriconazole

2012
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Salvage Therapy; Stem Cell Transplantation

2013
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Haematologica, 2013, Volume: 98, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Membrane Proteins; Mice; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription, Genetic; Xenograft Model Antitumor Assays

2013
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Respiratory Function Tests; Risk Factors; Thalidomide

2012
A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    The American journal of the medical sciences, 2013, Volume: 345, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2013
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
    Cell cycle (Georgetown, Tex.), 2012, Nov-01, Volume: 11, Issue:21

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Pyrazines; Recurrence

2012
How to select among available options for the treatment of multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
New agents for the treatment of lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Immunotoxins; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines

2012
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; ErbB Receptors; Hepatocytes; Humans; Liver Neoplasms; Molecular Targeted Therapy; Pyrazines; Recombinant Fusion Proteins; TNF-Related Apoptosis-Inducing Ligand

2013
Role of carfilzomib in the treatment of multiple myeloma.
    Expert review of hematology, 2012, Volume: 5, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Multiple Myeloma; Oligopeptides; Peptide Hydrolases; Proteasome Inhibitors; Pyrazines; Thalidomide

2012
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Autophagy, 2012, Volume: 8, Issue:12

    Topics: Activating Transcription Factor 4; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Head and Neck Neoplasms; Humans; Models, Biological; Oligopeptides; Proteasome Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Unfolded Protein Response

2012
Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Nude; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Xenograft Model Antitumor Assays

2012
Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
    Journal of gastroenterology, 2013, Volume: 48, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Death; Liver Cirrhosis; Liver Neoplasms; Male; Pyrazines; Rats; Rats, Wistar

2013
Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
    Cancer investigation, 2012, Volume: 30, Issue:9

    Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A

2012
Bortezomib: 3 deaths following intrathecal injection.
    Prescrire international, 2012, Volume: 21, Issue:130

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cause of Death; Humans; Infusions, Intravenous; Injections, Intravenous; Injections, Spinal; Medication Errors; Pyrazines

2012
Changes in protein profiles of multiple myeloma cells in response to bortezomib.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Matrix Metalloproteinases; Multiple Myeloma; Proteome; Proteomics; Pyrazines

2013
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein

2012
Intracranial mass of multiple myeloma with good response to chemotherapy.
    BMJ case reports, 2012, Sep-30, Volume: 2012

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome

2012
[Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2012
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Dec-15, Volume: 18, Issue:24

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Clinical Trials, Phase II as Topic; Drug Synergism; Everolimus; Humans; Mechanistic Target of Rapamycin Complex 1; MicroRNAs; Multiprotein Complexes; Pyrazines; Rituximab; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Waldenstrom Macroglobulinemia

2012
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Inbred BALB C; Organ Specificity; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays

2012
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2013, Volume: 15, Issue:2

    Topics: Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Therapy, Combination; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Male; Methotrexate; Plasma Cells; Pyrazines; Treatment Outcome

2013
Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Phenotype; Pyrazines; Remission Induction; Scleredema Adultorum

2013
Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Experimental hematology, 2013, Volume: 41, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Coculture Techniques; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Signal Transduction; Stromal Cells; Superoxide Dismutase; Transcriptional Activation; Tumor Cells, Cultured

2013
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
    Oncology reports, 2013, Volume: 29, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carboplatin; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uterine Cervical Neoplasms

2013
Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Ascorbic Acid; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cell Transformation, Viral; Female; Herpesvirus 4, Human; Humans; Mice; Pyrazines; Reactive Oxygen Species; Virus Replication

2013
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Molecular cancer, 2012, Oct-18, Volume: 11

    Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays

2012
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Pyrazines

2013
Bortezomib-induced cutaneous lupus in a patient with myeloma.
    The Journal of dermatology, 2013, Volume: 40, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2013
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
    Cellular signalling, 2013, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calcium; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; HSP70 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction

2013
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2012
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:3

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2013
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Humans; Hyperbilirubinemia; Liver; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines

2013
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    The Journal of urology, 2012, Volume: 188, Issue:6

    Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxamic Acids; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrazines; Random Allocation; RNA, Small Interfering; Sensitivity and Specificity; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays

2012
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Humans; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Oxidation-Reduction; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species

2012
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Molecular pharmacology, 2013, Volume: 83, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Boronic Acids; Bortezomib; Caspase 3; Child; Child, Preschool; Cytochromes c; fas Receptor; Fas-Associated Death Domain Protein; Gene Silencing; Humans; Jurkat Cells; Leukemia, Myeloid; Membrane Potential, Mitochondrial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcriptome

2013
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1

    Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2013
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1

    Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2013
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
    Gynecologic oncology, 2013, Volume: 128, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum Stress; Female; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Membrane Potential, Mitochondrial; Pyrazines; Transcription Factor CHOP; Ubiquitin; Up-Regulation; Uterine Cervical Neoplasms

2013
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
    Acta haematologica, 2013, Volume: 129, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome

2013
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
    Biochemical and biophysical research communications, 2012, Nov-30, Volume: 428, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzoflavones; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Pyrazines; Receptors, Notch; Up-Regulation

2012
Expression of vascular endothelial growth factor receptors VEGFR1 in cultured multiple myeloma cells: correlation with immunophenotype and drug resistance.
    Bulletin of experimental biology and medicine, 2012, Volume: 153, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Immunophenotyping; Leukocyte Common Antigens; Multiple Myeloma; Organ Specificity; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-1

2012
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:5

    Topics: Acetylation; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines

2012
Making light of an interstitial process.
    American journal of respiratory and critical care medicine, 2012, Nov-01, Volume: 186, Issue:9

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Microscopy, Polarization; Middle Aged; Pyrazines; Radiography, Thoracic; Respiratory Sounds; Tomography, X-Ray Computed

2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Transplantation Conditioning; Treatment Outcome

2013
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult

2013
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
    Epigenomics, 2012, Volume: 4, Issue:5

    Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Depsipeptides; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma, T-Cell, Cutaneous; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines

2012
[Proteasome oncology: pioneer a new field in drug development].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin

2012
[Diagnosis and treatment for plasma cell leukemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide

2012
Extramedullary plasmacytomas presenting as asymptomatic nodules on the buttocks and thighs.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Buttocks; Dexamethasone; Humans; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Skin Diseases; Thigh; Tomography, X-Ray Computed

2012
Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms.
    Proteomics, 2013, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evaluation Studies as Topic; Humans; Leukemia, Promyelocytic, Acute; Peptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Receptors, Retinoic Acid; Stress, Physiological; Tretinoin; Ubiquitin

2013
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2013
TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.
    Neuro-oncology, 2013, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Combined Modality Therapy; Female; Ferric Compounds; Gamma Rays; Glioma; Humans; Immunoenzyme Techniques; In Vitro Techniques; Nanoparticles; Neoplastic Stem Cells; Pyrazines; Rats; Rats, Nude; Recombinant Proteins; Survival Rate; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
    Expert review of hematology, 2012, Volume: 5, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Checkpoint Kinase 1; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyrazines

2012
Bortezomib-related diffuse alveolar hemorrhage.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Dec-20, Volume: 30, Issue:36

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Hemorrhage; Humans; Lung Diseases; Male; Multiple Myeloma; Pulmonary Alveoli; Pyrazines

2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
    British journal of haematology, 2013, Volume: 160, Issue:2

    Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia

2013
Detrimental effects of proteasome inhibition activity in Drosophila melanogaster: implication of ER stress, autophagy, and apoptosis.
    Cell biology and toxicology, 2013, Volume: 29, Issue:1

    Topics: Animals; Animals, Genetically Modified; Apoptosis; Autophagy; Behavior, Animal; Boronic Acids; Bortezomib; Drosophila melanogaster; Endoplasmic Reticulum Stress; Female; Kaplan-Meier Estimate; Larva; Longevity; Male; Motor Activity; Ovarian Follicle; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Survival Rate

2013
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
    Blood, 2013, Feb-07, Volume: 121, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome

2013
Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.
    British journal of cancer, 2012, Nov-20, Volume: 107, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Methylation; Down-Regulation; Humans; Multiple Myeloma; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Pyrazines; Telomerase

2012
Accidental intrathecal administration of bortezomib: preventing fatalities.
    Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Spinal; Medication Errors; Pyrazines

2013
Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Adult; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Chemokine CCL19; Chemokine CXCL9; Chemotaxis; Depression, Chemical; Down-Regulation; Drug Evaluation, Preclinical; Graft vs Host Disease; Humans; Lymphocyte Activation; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptors, CCR7; Receptors, CXCR3; T-Lymphocyte Subsets

2012
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy

2012
Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
    Autophagy, 2013, Feb-01, Volume: 9, Issue:2

    Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Lineage; Curcumin; Elongation Factor 2 Kinase; Endoplasmic Reticulum Stress; Enzyme Activation; Gene Silencing; Humans; Models, Biological; Phosphorylation; Phosphoserine; Pyrazines; Thapsigargin; Transcription Factors; Tunicamycin

2013
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Annals of hematology, 2013, Volume: 92, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine

2013
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies

2013
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:10

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide

2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
    Cell death & disease, 2012, Nov-29, Volume: 3

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; MicroRNAs; Multiple Myeloma; Pyrazines; Sp1 Transcription Factor; Tumor Cells, Cultured

2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency.
    British journal of pharmacology, 2013, Volume: 168, Issue:8

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Aorta; Ascorbic Acid Deficiency; Boronic Acids; Bortezomib; Drug Tolerance; Female; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Animal; Nitroglycerin; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitination

2013
Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
    ACS chemical biology, 2013, Mar-15, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HeLa Cells; Humans; I-kappa B Proteins; Imidazoles; Mice; Molecular Structure; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured

2013
Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease.
    Molecular cell, 2013, Jan-10, Volume: 49, Issue:1

    Topics: Amino Acid Substitution; Base Sequence; Binding Sites; Boronic Acids; Bortezomib; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; DNA, Mitochondrial; Gene Knockdown Techniques; Genome, Mitochondrial; HEK293 Cells; HeLa Cells; Humans; Mitochondria; Mitochondrial Proteins; Models, Molecular; Phosphorylation; Protease La; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proteolysis; Pyrazines; RNA Interference; Transcription Factors; Transcriptional Activation

2013
Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2012, Volume: 10, Issue:6

    Topics: Adult; Antibodies; Boronic Acids; Bortezomib; Graft Rejection; Humans; Kidney Transplantation; Male; Plasma Cells; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors

2012
A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
    Muscle & nerve, 2012, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nerves; Pyrazines; Systemic Vasculitis

2012
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Anticancer research, 2012, Volume: 32, Issue:12

    Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation

2012
Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bone Development; Boronic Acids; Bortezomib; Cartilage; Caspases; Cell Line; Chondrocytes; Chondrogenesis; Enzyme Activation; Growth Plate; Homeostasis; Humans; Metatarsal Bones; Mice; Mitochondrial Membranes; Proteasome Inhibitors; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats; Time Factors; Tumor Suppressor Protein p53

2012
Have drug combinations supplanted stem cell transplantation in myeloma?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy; Female; Genomics; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Stem Cell Transplantation; Time Factors; Treatment Outcome

2012
News & views in ... Immunotherapy.
    Immunotherapy, 2012, Volume: 4, Issue:12

    Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines

2012
Iron increases the susceptibility of multiple myeloma cells to bortezomib.
    Haematologica, 2013, Volume: 98, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Ferritins; Humans; Inhibitory Concentration 50; Iron; Multiple Myeloma; Plasma Cells; Pyrazines

2013
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Pyrazines; Random Allocation; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT1 Transcription Factor; Tretinoin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Jan-02, Volume: 110, Issue:1

    Topics: Boronic Acids; Bortezomib; Cisplatin; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair; DNA Primers; DNA Sequence, Unstable; Gene Dosage; Gene Expression Regulation; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Models, Molecular; Mutation, Missense; MutS Homolog 2 Protein; Plasmids; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; Pyrazines; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Ubiquitin; Ubiquitin-Protein Ligases

2013
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Diterpenes; DNA-Binding Proteins; Down-Regulation; Epoxy Compounds; Female; Gene Knockdown Techniques; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasm Transplantation; Phenanthrenes; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Resorcinols; RNA, Small Interfering; Transcription Factors; Transplantation, Heterologous

2013
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
    Cell cycle (Georgetown, Tex.), 2013, Jan-01, Volume: 12, Issue:1

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured

2013
[Mechanism of apoptosis synergistically induced by bortezomib combined with cytarabine in U937 cell line].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Phosphorylation; Pyrazines; Reactive Oxygen Species; U937 Cells

2012
[Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:6

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; K562 Cells; NF-kappa B; Oxides; Pyrazines

2012
High frequencies of response after limited primary therapy for multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome

2013
Topical evening primrose oil for reduction of bortezomib-induced skin reactions.
    Annals of hematology, 2013, Volume: 92, Issue:7

    Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Boronic Acids; Bortezomib; Drug Eruptions; Drug Evaluation; gamma-Linolenic Acid; Humans; Injections, Subcutaneous; Linoleic Acids; Oenothera biennis; Phytotherapy; Plant Oils; Protease Inhibitors; Pyrazines

2013
Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
    BMJ case reports, 2012, Dec-20, Volume: 2012

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction

2012
Causal co-expression method with module analysis to screen drugs with specific target.
    Gene, 2013, Apr-10, Volume: 518, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Data Mining; DNA Damage; Drug Discovery; Drug Evaluation, Preclinical; Gene Regulatory Networks; Humans; Oligonucleotide Array Sequence Analysis; Peptides, Cyclic; Pyrazines; Transcription Factors

2013
BlyS: a potential hallmark of multiple myeloma.
    Frontiers in bioscience (Landmark edition), 2013, 01-01, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Apoptosis; B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocytes; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2013
Total cost comparison in relapsed/refractory multiple myeloma.
    Journal of medical economics, 2013, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide

2013
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
    The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1

    Topics: ADAM Proteins; ADAMTS13 Protein; Autoantibodies; B-Lymphocytes; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Middle Aged; Plasma Cells; Protease Inhibitors; Purpura, Thrombotic Thrombocytopenic; Pyrazines

2013
HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Acetylation; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carnitine; Caspases; Cell Death; Cell Proliferation; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Activation; Hep G2 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Male; Mice; Models, Biological; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Unfolded Protein Response; Xenograft Model Antitumor Assays

2012
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy

2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
    European journal of haematology, 2013, Volume: 90, Issue:5

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Treatment Outcome

2013
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
    The oncologist, 2013, Volume: 18, Issue:1

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide

2013
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
    The oncologist, 2013, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States

2013
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spheroids, Cellular; Up-Regulation; Vorinostat

2012
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
    Experimental and molecular pathology, 2013, Volume: 94, Issue:2

    Topics: Adiponectin; Animals; Boronic Acids; Bortezomib; Cold Ischemia; Cysteine Proteinase Inhibitors; Cytoprotection; Fatty Liver; Interleukin-1; Leupeptins; Liver Transplantation; Mitochondria, Liver; Organ Preservation; Organ Preservation Solutions; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Tumor Necrosis Factor-alpha

2013
Multiple myeloma, version 1.2013.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat

2013
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Amino Acid Sequence; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; HEK293 Cells; Humans; Molecular Sequence Data; Neuroblastoma; Peptides; Proteasome Inhibitors; Proteomics; Pyrazines

2013
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    European journal of haematology, 2013, Volume: 90, Issue:4

    Topics: Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteopontin; Proteasome Inhibitors; Pyrazines; Receptors, Calcitriol; Recombinant Proteins; RNA, Messenger; Signal Transduction; Transfection; Up-Regulation; Vitamin D Deficiency

2013
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
    Blood, 2013, Apr-11, Volume: 121, Issue:15

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment

2013
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
    British journal of cancer, 2013, Jan-15, Volume: 108, Issue:1

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Dichloroacetic Acid; Glucose; Glycolysis; Humans; Lactate Dehydrogenases; Lactic Acid; Molecular Targeted Therapy; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering

2013
[Cutaneous manifestations revealing cryofibrinogenaemia associated with monoclonal gammopathy].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:1

    Topics: Acute Kidney Injury; Adult; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cryoglobulinemia; Cryoglobulins; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fibrinogens, Abnormal; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Leg Ulcer; Microscopy, Fluorescence; Necrosis; Paraproteinemias; Plasmapheresis; Prednisone; Pyrazines; Skin

2013
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured

2013
Regulatory role of proteasome in determination of platelet life span.
    The Journal of biological chemistry, 2013, Mar-08, Volume: 288, Issue:10

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Platelets; Blotting, Western; Boronic Acids; Bortezomib; Humans; Macrophages; Mice; Microscopy, Fluorescence; Oligopeptides; Phagocytosis; Platelet Count; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines; Time Factors; Up-Regulation

2013
Bortezomib downregulates MGMT expression in T98G glioblastoma cells.
    Cellular and molecular neurobiology, 2013, Volume: 33, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; NF-kappa B; Pyrazines; Signal Transduction; Tumor Suppressor Proteins

2013
Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines.
    The Journal of veterinary medical science, 2013, Volume: 75, Issue:6

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dogs; Gene Expression Regulation, Neoplastic; Lymphocytes; NF-kappa B; Pyrazines

2013
Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    International journal of oncology, 2013, Volume: 42, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Proteins; Interleukin-6; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; NF-KappaB Inhibitor alpha; Poly(ADP-ribose) Polymerases; Pyrazines; Radiation-Sensitizing Agents; Transcription Factor RelA; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2013
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.
    Journal of Korean medical science, 2013, Volume: 28, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Registries; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome

2013
Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats.
    The journal of trauma and acute care surgery, 2013, Volume: 74, Issue:2

    Topics: Adenosine Triphosphate; Animals; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Inbred Lew; Shock, Hemorrhagic

2013
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
    International journal of hematology, 2013, Volume: 97, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infections; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors

2013
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-15, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Leukemia, B-Cell; Mice; NF-kappa B; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Pyrazines; Transcription Factor RelA; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    British journal of haematology, 2013, Volume: 161, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured

2013
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
    Acta haematologica, 2013, Volume: 130, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sweden; Treatment Outcome; Vincristine

2013
[Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:11

    Topics: Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia; NF-kappa B; Pyrazines; RNA, Messenger

2012
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:11

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines

2012
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid

2013
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Acridine Orange; Autoantigens; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Phosphorylation; Proteasome Endopeptidase Complex; Protein Phosphatase 2; Pyrazines; Time Factors

2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors

2013
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
    British journal of haematology, 2013, Volume: 161, Issue:1

    Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2013
[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:1

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome

2013
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
    Leukemia research, 2013, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Substrate Specificity

2013
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Experimental hematology, 2013, Volume: 41, Issue:6

    Topics: Antigens, CD34; Boronic Acids; Bortezomib; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinoxalines; Recombinant Proteins; RNA, Small Interfering; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2013
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
    Bone, 2013, Volume: 55, Issue:1

    Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulation; Diphosphonates; Drug Therapy, Combination; Humans; Models, Biological; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Pamidronate; Pyrazines; Reproducibility of Results; User-Computer Interface

2013
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Cell cycle (Georgetown, Tex.), 2013, Mar-15, Volume: 12, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Repressor Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53; Ubiquitination

2013
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:12

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Pyrazines

2012
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
    Pharmacological research, 2013, Volume: 71

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Down-Regulation; Female; Gene Deletion; Mice; Mice, Inbred C57BL; Models, Molecular; Neoplasms; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic; Tumor Suppressor Protein p53

2013
The clinical relevance of cancer cell lines.
    Journal of the National Cancer Institute, 2013, Apr-03, Volume: 105, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcriptome; Translational Research, Biomedical; Xenograft Model Antitumor Assays

2013
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genes, Reporter; Graft Survival; Humans; Injections; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Melphalan; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Paraproteins; Plasma Cells; Pyrazines; Syndecan-1; Tibia; Tumor Microenvironment

2013
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    American journal of hematology, 2013, Volume: 88, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous

2013
Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
    The British journal of dermatology, 2013, Volume: 168, Issue:3

    Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leupeptins; Lymphoma, T-Cell, Cutaneous; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, Notch1; Skin Neoplasms; Tumor Suppressor Protein p53

2013
Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:11

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Treatment Outcome

2013
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
    Leukemia, 2013, Volume: 27, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Treatment Outcome; Vorinostat

2013
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Cell death & disease, 2013, Feb-28, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Janus Kinases; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Phosphorylation; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Transcription Factors; Transplantation, Heterologous

2013
Bortezomib influences the expression of malignant plasma cells membrane antigens.
    European journal of pharmacology, 2013, Apr-15, Volume: 706, Issue:1-3

    Topics: Animals; Antigens; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Membrane Proteins; Mice; Mice, SCID; Multiple Myeloma; Plasma Cells; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2013
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Time Factors

2013
Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
    International journal of cancer, 2013, Sep-15, Volume: 133, Issue:6

    Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Cyclophilins; Drug Resistance, Neoplasm; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; Peptidyl-Prolyl Isomerase F; Pyrazines; Reactive Oxygen Species; Superoxide Dismutase; Transcriptome

2013
In human monocyte derived dendritic cells SOCS1 interacting with CYTIP induces the degradation of CYTIP by the proteasome.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Dendritic Cells; Flow Cytometry; Humans; Monocytes; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Transcription Factors; Two-Hybrid System Techniques; Ubiquitination

2013
Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Polycomb-Group Proteins; Primary Cell Culture; Pyrazines; Side-Population Cells; Signal Transduction; Syndecan-1; Ubiquitins

2013
Plasma cell-rich acute rejection with monoclonal gammopathy in a renal transplant recipient.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2013, Volume: 11, Issue:2

    Topics: Acute Disease; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Paraproteinemias; Patient Compliance; Plasma Cells; Pyrazines

2013
[Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Receptors, IgE

2013
Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury.
    Critical care medicine, 2013, Volume: 41, Issue:5

    Topics: Animals; Blood Gas Analysis; Blood-Brain Barrier; Blotting, Western; Boronic Acids; Bortezomib; Brain Edema; Brain Injuries; Dexamethasone; Disease Models, Animal; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Multivariate Analysis; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Real-Time Polymerase Chain Reaction; Receptors, Glucocorticoid; Reference Values; RNA, Messenger; Sensitivity and Specificity; Statistics, Nonparametric

2013
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Herpesvirus 4, Human; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrazines; Reactive Oxygen Species; Signal Transduction; Tumor Burden; Virus Replication; Vorinostat

2013
Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade.
    Cancer research, 2013, May-15, Volume: 73, Issue:10

    Topics: Acetanilides; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Purines; Pyrazines; Thioctic Acid; Transient Receptor Potential Channels; TRPA1 Cation Channel

2013
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Biochimica et biophysica acta, 2013, Volume: 1833, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Middle Aged; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ribosomal Protein S6 Kinases, 70-kDa; Tumor Cells, Cultured

2013
Bortezomib and bone health in adults: can we extend these findings to children?
    European journal of haematology, 2013, Volume: 90, Issue:6

    Topics: Adult; Animals; Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Male; Mice; Multiple Myeloma; Pyrazines

2013
"IM iD"eally treating multiple myeloma.
    Blood, 2013, Mar-14, Volume: 121, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide

2013
Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
    The Journal of rheumatology, 2013, Volume: 40, Issue:5

    Topics: Adult; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Catalytic Domain; Cells, Cultured; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Outpatients; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sjogren's Syndrome

2013
Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.
    Clinical laboratory, 2013, Volume: 59, Issue:1-2

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory

2013
Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
    Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2013
[Proteasome inhibitors: from early stages to future prospects].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin

2012
[Molecular targeting agents for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide

2012
Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation.
    Chemical research in toxicology, 2013, Apr-15, Volume: 26, Issue:4

    Topics: Amides; Biotransformation; Boronic Acids; Bortezomib; Cytosol; Glutathione; Humans; Microsomes, Liver; Proteasome Inhibitors; Pyrazines

2013
cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Computational Biology; DNA Primers; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Luciferases; Lymphoma, T-Cell; Mice; MicroRNAs; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Skin Neoplasms

2013
Carfilzomib for the treatment of multiple myeloma.
    Drugs of today (Barcelona, Spain : 1998), 2013, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Pyrazines

2013
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib.
    British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8

    Topics: Aerobiosis; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Chloroacetates; Drug Synergism; Glycolysis; Humans; Mice; Multiple Myeloma; Oxygen Consumption; Pyrazines; Pyruvate Dehydrogenase Complex; Superoxides

2013
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

    Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays

2013
Children are not large mice.
    European journal of haematology, 2013, Volume: 90, Issue:6

    Topics: Adolescent; Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Chondrocytes; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Infant; Mice; Pyrazines

2013
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:6

    Topics: Animals; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Transgenic; Multiple Myeloma; Pyrazines

2013
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
    Leukemia research, 2013, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A

2013
The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:7

    Topics: Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Histocompatibility Antigens Class I; Humans; MCF-7 Cells; Oligopeptides; Peptides; Proteasome Inhibitors; Proteome; Pyrazines

2013
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
    Bone marrow transplantation, 2013, Volume: 48, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Multiple myeloma: so much progress, but so many unsolved questions.
    Haematologica, 2013, Volume: 98, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2013
NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
    Molecular medicine reports, 2013, Volume: 7, Issue:5

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; Multiple Myeloma; NF-kappa B; Nitrobenzenes; Pyrazines; Signal Transduction; Sulfonamides; Treatment Outcome

2013
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
    International journal of oncology, 2013, Volume: 42, Issue:5

    Topics: Animals; Apoptosis; Autophagy; Azithromycin; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Endoplasmic Reticulum Stress; Erythromycin; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Mice; Multiple Myeloma; Pyrazines; Transcription Factor CHOP

2013
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.
    Molecular and cellular biology, 2013, Volume: 33, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Chick Embryo; Cytoplasmic Granules; Eukaryotic Initiation Factor-4E; HeLa Cells; Humans; Indoles; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Phosphoproteins; Phosphorylation; Purines; Pyrazines; TOR Serine-Threonine Kinases

2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Heterozygote; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Sequence Analysis, DNA; Treatment Outcome; Young Adult

2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous

2013
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
    Leukemia, 2013, Volume: 27, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays

2013
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays

2013
The unfolded protein response selectively targets active smoothened mutants.
    Molecular and cellular biology, 2013, Volume: 33, Issue:12

    Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Carcinoma, Basal Cell; Cell Line; DNA-Binding Proteins; Drosophila melanogaster; Drosophila Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Green Fluorescent Proteins; Hedgehog Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Medulloblastoma; Mice; Mutant Proteins; Pyrazines; Receptors, G-Protein-Coupled; RNA Interference; RNA, Small Interfering; Signal Transduction; Smoothened Receptor; Thapsigargin; Ubiquitin-Protein Ligases; Unfolded Protein Response

2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Cancer, 2013, Jul-01, Volume: 119, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Chymotrypsin; Collagen; Dogs; Dystroglycans; Dystrophin-Associated Protein Complex; Gene Expression; Immunohistochemistry; Inflammation; Muscle, Skeletal; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Proteasome Endopeptidase Complex; Pyrazines

2013
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cellular Microenvironment; Coculture Techniques; Drug Resistance, Neoplasm; Fluorescent Dyes; Gene Expression Regulation; Humans; Multiple Myeloma; Pyrazines; Rhodamine 123; Stromal Cells

2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:9

    Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous

2013
Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
    Human mutation, 2013, Volume: 34, Issue:8

    Topics: Animals; Boronic Acids; Bortezomib; Cystathionine beta-Synthase; Female; Homocystinuria; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation, Missense; Oligopeptides; Proteasome Inhibitors; Protein Folding; Pyrazines

2013
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Discovery; Humans; Immunoblotting; Neoplasms; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tetrazolium Salts; Thiazoles

2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
    Blood, 2013, Jun-06, Volume: 121, Issue:23

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult

2013
Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    International journal of hematology, 2013, Volume: 97, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Risk Factors; Transplantation, Autologous; Treatment Outcome

2013
Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
    The Journal of biological chemistry, 2013, May-31, Volume: 288, Issue:22

    Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation; Humans; Immunosuppressive Agents; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-myc; Pyrazines; Rats; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factor CHOP; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Unfolded Protein Response

2013
Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; CD27 Ligand; Cell Death; Cell Line, Tumor; Humans; Interferon-gamma; Kidney Neoplasms; Mice; Necrosis; Phosphorylation; Protein Binding; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases; Recombinant Fusion Proteins; Signal Transduction; Species Specificity; STAT1 Transcription Factor

2013
Focusing on boron in medicinal chemistry.
    Future medicinal chemistry, 2013, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Chemistry, Pharmaceutical; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines

2013
Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report.
    Transplantation proceedings, 2013, Volume: 45, Issue:3

    Topics: ABO Blood-Group System; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Infant; Kidney Transplantation; Pyrazines; Wilms Tumor

2013
Proteasome inhibition profoundly affects activated human B cells.
    Transplantation, 2013, Jun-15, Volume: 95, Issue:11

    Topics: Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro Techniques; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines

2013
Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
    Experimental physiology, 2013, Volume: 98, Issue:9

    Topics: Acetylcysteine; Animals; Antioxidants; Boronic Acids; Bortezomib; Cachexia; Diaphragm; Electron Transport Chain Complex Proteins; Female; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitochondria; Mitochondrial Diseases; Mitogen-Activated Protein Kinases; Muscle Strength; Muscle, Skeletal; NF-kappa B; Oxidative Stress; Pyrazines

2013
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; HEK293 Cells; Herpesviridae Infections; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53; Virus Latency; Virus Replication; Vorinostat; Xenograft Model Antitumor Assays

2013
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Cutaneous and ocular toxicology, 2014, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide

2014
BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
    Oncogene, 2014, Mar-27, Volume: 33, Issue:13

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; HEK293 Cells; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Up-Regulation

2014
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-akt; Pyrazines; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53

2013
Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:1

    Topics: Boronic Acids; Bortezomib; CD40 Ligand; Cell Adhesion; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Activation; Fibroblasts; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Interferon Regulatory Factors; NF-kappa B; Pyrazines

2014
Vitamin D analogue TX 527 down-regulates the NF-κB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus.
    British journal of pharmacology, 2013, Volume: 169, Issue:7

    Topics: Alkynes; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Transformed; Cell Proliferation; Cholecalciferol; Endothelial Cells; Gene Expression Regulation; Herpesvirus 8, Human; I-kappa B Proteins; Mice; NF-kappa B; Pyrazines; Sarcoma, Kaposi; Signal Transduction; Vitamin D

2013
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine

2013
MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression.
    Journal of clinical immunology, 2013, Volume: 33, Issue:6

    Topics: Animals; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; Mice; Mice, Inbred DBA; MicroRNAs; Molecular Targeted Therapy; Pyrazines; RNA, Small Interfering; Scleroderma, Diffuse; Signal Transduction; Skin; Smad7 Protein; Transforming Growth Factor beta

2013
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Enzyme Activation; Humans; I-kappa B Kinase; Interferon-gamma; Kidney Neoplasms; Necrosis; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases

2013
Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
    Molecular medicine reports, 2013, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Pyrazines

2013
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide

2014
Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
    The American journal of pathology, 2013, Volume: 183, Issue:1

    Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Administration Schedule; Estradiol; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Isothiocyanates; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Random Allocation; Reactive Oxygen Species; RNA Interference; Transplantation, Heterologous; Treatment Outcome

2013
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:4

    Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic

2013
[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome

2013
[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome

2013
[Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Retrospective Studies; Transplantation, Autologous

2013
[Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:4

    Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Treatment Outcome

2013
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
    Leukemia research, 2013, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; HSP72 Heat-Shock Proteins; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Leupeptins; Myeloid Cell Leukemia Sequence 1 Protein; NF-KappaB Inhibitor alpha; Oligonucleotides, Antisense; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; X-Linked Inhibitor of Apoptosis Protein

2013
Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
    Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:8

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Liver Transplantation; Male; Plasmapheresis; Pyrazines; Rituximab; Splenectomy

2013
Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jul-01, Volume: 19, Issue:13

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Signal Transduction; Unfolded Protein Response; Xenograft Model Antitumor Assays

2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine

2013
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
    Oncogene, 2014, Apr-24, Volume: 33, Issue:17

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Polycomb Repressive Complex 1; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Side-Population Cells; Up-Regulation

2014
The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Boronic Acids; Bortezomib; Cell Count; Chymotrypsin; Gene Expression Regulation; Inflammation Mediators; Male; NF-kappa B; Nitric Oxide Synthase Type II; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Retina; Retinal Ganglion Cells; RNA, Messenger

2013
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
    European journal of haematology, 2013, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome

2013
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin

2013
Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Humans; I-kappa B Proteins; Immunoblotting; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Survivin; X-Linked Inhibitor of Apoptosis Protein

2014
Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Anti-cancer drugs, 2013, Volume: 24, Issue:6

    Topics: Aminoglycosides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Enediynes; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Pyrazines

2013
Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice.
    The FEBS journal, 2013, Volume: 280, Issue:15

    Topics: Animals; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Fatty Liver; Gene Expression; Gene Expression Regulation, Enzymologic; Hepatocytes; Liver; Mice; Mice, Knockout; NF-E2-Related Factor 1; Proteasome Endopeptidase Complex; Pyrazines

2013
The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:8

    Topics: Administration, Oral; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2013
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
    International journal of hematology, 2013, Volume: 98, Issue:1

    Topics: 3T3 Cells; Activating Transcription Factor 4; Animals; Antineoplastic Agents; Biomarkers; Bone Marrow Cells; Boronic Acids; Bortezomib; Calcification, Physiologic; Cells, Cultured; Endoplasmic Reticulum Stress; Gene Expression Regulation; Gene Silencing; Humans; Mice; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Stromal Cells

2013
Bortezomib-induced polyneuropathy.
    The Netherlands journal of medicine, 2013, Volume: 71, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Humans; Multiple Myeloma; Polyneuropathies; Pyrazines; Retrospective Studies

2013
Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.
    Cell biology international, 2013, Volume: 37, Issue:10

    Topics: Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; RNA, Small Interfering

2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy

2013
Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection.
    Clinical transplants, 2012

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; HLA Antigens; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Organ Transplantation; Plasmapheresis; Pyrazines; Steroids; Tissue Donors

2012
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Multiple Myeloma; Prognosis; Pyrazines; Receptors, CXCR4; Sarcoma, Myeloid; Survival Rate

2013
Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:1

    Topics: Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Cytidine Deaminase; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Inhibitory Concentration 50; Mutation; Mutation Rate; Pyrazines

2014
Effect of mycophenolic acid and bortezomib on purified human B cells: an in vitro study of long-term functionally stable MICA-sensitized renal recipients.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2013, Volume: 11, Issue:6

    Topics: Aged; Antigens, CD19; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Histocompatibility Antigens Class I; Humans; Immunoglobulin M; In Vitro Techniques; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Proteasome Inhibitors; Pyrazines

2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Mesothelioma; Mice; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Transcription, Genetic

2013
Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Cloning, Molecular; Culicidae; Cysteine Proteinase Inhibitors; Drug Resistance; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation; Insect Proteins; Insecticides; Larva; Leupeptins; Nitriles; Phylogeny; Proteasome Endopeptidase Complex; Proteomics; Pyrazines; Pyrethrins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2013
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Journal of clinical apheresis, 2013, Volume: 28, Issue:5

    Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome

2013
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
    Clinical and experimental medicine, 2014, Volume: 14, Issue:3

    Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression Profiling; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Smad Proteins; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Remodeling

2014
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2013
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
    British journal of haematology, 2013, Volume: 162, Issue:6

    Topics: Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin D; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome; Vincristine

2013
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
    Onkologie, 2013, Volume: 36, Issue:6

    Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome

2013
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
    Journal of the National Cancer Institute, 2013, Jul-03, Volume: 105, Issue:13

    Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat

2013
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
    Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Databases, Pharmaceutical; France; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Multiple Myeloma; Pharmacovigilance; Pyrazines; Treatment Outcome

2014
Inhibition of the human proteasome by imidazoline scaffolds.
    Journal of medicinal chemistry, 2013, Jul-25, Volume: 56, Issue:14

    Topics: Boronic Acids; Bortezomib; Cell Line; Humans; Imidazolines; NF-kappa B; Proteasome Inhibitors; Pyrazines

2013
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Biochemical and biophysical research communications, 2013, Jul-19, Volume: 437, Issue:1

    Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Clarithromycin; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inclusion Bodies; Intracellular Space; Mice; Proteolysis; Pyrazines; Transcription Factor CHOP; Vorinostat

2013
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
    Journal of clinical and experimental hematopathology : JCEH, 2013, Volume: 53, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunohistochemistry; Multiple Myeloma; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia

2013
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Journal of clinical apheresis, 2013, Volume: 28, Issue:5

    Topics: Adult; Aged; Antigens, CD34; Blood Component Removal; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2013
Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.
    Clinical and experimental immunology, 2013, Volume: 174, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Autoantigens; B-Lymphocytes; Boronic Acids; Bortezomib; Cyclophosphamide; Disease Models, Animal; Disease Susceptibility; DNA; Female; Humans; Lupus Erythematosus, Systemic; Lymphocyte Depletion; Mice; Mice, Inbred MRL lpr; Peptide Fragments; Pyrazines; Receptors, IgG; Recombinant Fusion Proteins

2013
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2014
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide

2013
Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Dexamethasone; Female; Humans; Immunocompromised Host; Infant; Intestine, Small; Liver Transplantation; Lymphoproliferative Disorders; Pyrazines

2013
PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:7

    Topics: Animals; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Mice; Myoblasts; Nitrophenols; Oligopeptides; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
    Voprosy onkologii, 2013, Volume: 59, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting

2013
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide

2013
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
    Annals of hematology, 2014, Volume: 93, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine

2014
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Glucocorticoids; Humans; Hydrocortisone; Jurkat Cells; Leukemia; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA, Messenger

2013
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    British journal of haematology, 2013, Volume: 162, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Cycle Checkpoints; Cytotoxicity, Immunologic; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lymphoma, B-Cell; Neoplasm Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Rituximab; Tumor Cells, Cultured; Up-Regulation

2013
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome

2014
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitroimidazoles; Phosphoramide Mustards; Pyrazines; Signal Transduction

2013
Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
    Pediatric transplantation, 2013, Volume: 17, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Antibodies; Biopsy; Boronic Acids; Bortezomib; Complement C4b; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney Transplantation; Male; Patient Compliance; Peptide Fragments; Polycystic Kidney, Autosomal Recessive; Protease Inhibitors; Pyrazines; Renal Dialysis; Treatment Outcome

2013
Pomalidomide in the treatment of relapsed multiple myeloma.
    Future oncology (London, England), 2013, Volume: 9, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide

2013
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid

2013
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomal Instability; Clinical Trials as Topic; Comparative Genomic Hybridization; DNA Damage; DNA Repair; Humans; Multiple Myeloma; Multivariate Analysis; Prognosis; Proportional Hazards Models; Pyrazines; Risk; Transcriptome; Treatment Outcome

2013
Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
    Internal medicine journal, 2013, Volume: 43, Issue:7

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Hepatitis B; Humans; Male; Multiple Myeloma; Pyrazines

2013
Predictive biomarkers may help individualize treatment for patients with follicular lymphoma.
    CA: a cancer journal for clinicians, 2013, Volume: 63, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Follicular; Precision Medicine; Proteasome Endopeptidase Complex; Pyrazines; Rituximab

2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult

2013
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide

2013
Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma.
    The Journal of dermatology, 2013, Volume: 40, Issue:9

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines

2013
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome

2014
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
    Cell death & disease, 2013, Jul-18, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brefeldin A; Caspases, Initiator; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endoplasmic Reticulum Stress; Epithelial Cells; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Orthoreovirus, Mammalian; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Reoviridae; Tunicamycin; Virus Replication; Xenograft Model Antitumor Assays

2013
Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Methylation; DNA Primers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HSP72 Heat-Shock Proteins; Humans; Immunoblotting; Microarray Analysis; Protein Isoforms; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms

2013
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cholangiocarcinoma; Endoplasmic Reticulum Stress; Humans; Janus Kinase 3; Luciferases; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured; Unfolded Protein Response

2013
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured

2013
Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.
    Pain, 2013, Volume: 154, Issue:11

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Axons; Boronic Acids; Bortezomib; Energy Metabolism; Hyperalgesia; Male; Mitochondria; Neoplasm Transplantation; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nerves; Peroxynitrous Acid; Physical Stimulation; Protein Processing, Post-Translational; Pyrazines; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Superoxide Dismutase

2013
Multiple myeloma: a descriptive study of 217 Egyptian patients.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine

2014
Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
    Journal of immunology (Baltimore, Md. : 1950), 2013, Sep-01, Volume: 191, Issue:5

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromatin Immunoprecipitation; Enzyme-Linked Immunosorbent Assay; Humans; I-kappa B Kinase; Interleukin-8; Male; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Transfection

2013
Structures of an ATP-independent Lon-like protease and its complexes with covalent inhibitors.
    Acta crystallographica. Section D, Biological crystallography, 2013, Volume: 69, Issue:Pt 8

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Bacterial Proteins; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Deinococcus; Lactones; Models, Molecular; Molecular Sequence Data; Protease Inhibitors; Protease La; Protein Conformation; Pyrazines

2013
Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.
    Pediatric transplantation, 2013, Volume: 17, Issue:7

    Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Hypotension; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Male; Methylprednisolone Hemisuccinate; Patient Compliance; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Rituximab; Treatment Outcome

2013
Sweet-like syndrome induced by bortezomib.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:12

    Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome; Treatment Outcome

2013
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
    Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide

2014
[Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2013
Chaperone-mediated autophagy degrades mutant p53.
    Genes & development, 2013, Aug-01, Volume: 27, Issue:15

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Lysosomes; Molecular Chaperones; Mutation; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Tumor Suppressor Protein p53; Ubiquitination

2013
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
    Molecular oncology, 2013, Volume: 7, Issue:6

    Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; HIV Protease Inhibitors; Humans; Nelfinavir; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Pyrazines; TOR Serine-Threonine Kinases; Up-Regulation

2013
Anticancer agent ukrain and bortezomib combination is synergistic in 4T1 breast cancer cells.
    Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Berberine Alkaloids; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Melanoma, Experimental; Phenanthridines; Pyrazines

2014
Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines; Tomography, X-Ray Computed

2014
[Right cervical lymph node enlargement].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2013, Volume: 42, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Diagnosis, Differential; Follow-Up Studies; Histiocytic Necrotizing Lymphadenitis; Humans; Infectious Mononucleosis; Ki-67 Antigen; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neck; Pyrazines; SOXC Transcription Factors

2013
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid

2013
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Pyrazines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2013
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
    Expert opinion on drug delivery, 2013, Volume: 10, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Synergism; Epithelial Cells; Gold; Humans; Nanoparticles; Pancreatic Ducts; Pancreatic Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2013
Meningeal myelomatosis developed after treatment with novel agents.
    International journal of hematology, 2013, Volume: 98, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cerebrospinal Fluid; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Multiple Myeloma; Plasma Cells; Pyrazines; Thalidomide

2013
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:2

    Topics: Aged; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2014
Transplants for the elderly in myeloma.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide

2013
Light chain deposition.
    Blood, 2013, Jun-27, Volume: 121, Issue:26

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Kidney Diseases; Kidney Tubules; Male; Multiple Myeloma; Prognosis; Pyrazines

2013
Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2014, Volume: 125, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Female; Humans; Male; Membrane Potentials; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Sodium-Potassium-Exchanging ATPase

2014
Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    The Journal of international medical research, 2013, Volume: 41, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteocytes; p38 Mitogen-Activated Protein Kinases; Pyrazines; Signal Transduction; Time Factors

2013
A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.
    The Journal of biological chemistry, 2013, Oct-11, Volume: 288, Issue:41

    Topics: Adaptor Proteins, Signal Transducing; Boronic Acids; Bortezomib; Codon, Nonsense; HEK293 Cells; Humans; Immunoblotting; Intellectual Disability; Lysine; Microscopy, Fluorescence; Mutant Proteins; Nuclear Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Ubiquitin-Protein Ligases; Ubiquitination

2013
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adult; Aged; Angiopoietin-2; Animals; beta 2-Microglobulin; Bioreactors; Bone and Bones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Culture Techniques; Female; Genetic Markers; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Tibia; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2013
Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Interferons; Lymph Nodes; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Rituximab; Transplantation, Homologous

2013
Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
    Transplant immunology, 2013, Volume: 29, Issue:1-4

    Topics: Adult; Allografts; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines

2013
Myeloma presenting during pregnancy.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous

2014
[Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Young Adult

2013
[Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and SHIP gene expression in K562 cells].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Inositol Polyphosphate 5-Phosphatases; K562 Cells; Phosphoric Monoester Hydrolases; Proteasome Inhibitors; Pyrazines

2013
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2013
Core-shell Fe3O4 polydopamine nanoparticles serve multipurpose as drug carrier, catalyst support and carbon adsorbent.
    ACS applied materials & interfaces, 2013, Sep-25, Volume: 5, Issue:18

    Topics: Adsorption; Boronic Acids; Bortezomib; Carbon; Catalysis; Drug Carriers; Ferrosoferric Oxide; Indoles; Magnetite Nanoparticles; Particle Size; Polymers; Pyrazines; Rhodamines; Water

2013
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
    Antioxidants & redox signaling, 2014, Dec-10, Volume: 21, Issue:17

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Oxidative Stress; Piperidones; Polymerase Chain Reaction; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Ubiquitin-Specific Proteases

2014
Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target.
    Arthritis and rheumatism, 2013, Volume: 65, Issue:12

    Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Endoplasmic Reticulum Stress; Mice; Muscle Weakness; Muscle, Skeletal; Myositis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination

2013
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
    Cancer cell, 2013, Sep-09, Volume: 24, Issue:3

    Topics: Activating Transcription Factor 6; Boronic Acids; Bortezomib; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Immunophenotyping; Membrane Proteins; Multiple Myeloma; Mutation; Plasma Cells; Precursor Cells, B-Lymphoid; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factors; X-Box Binding Protein 1

2013
Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:12

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Chronic Disease; Female; Glomerular Filtration Rate; Graft Rejection; HLA Antigens; Humans; Immunoglobulins, Intravenous; Isoantibodies; Kidney; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab

2013
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
    Veterinary journal (London, England : 1997), 2013, Volume: 198, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms

2013
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
    Neurotoxicology, 2013, Volume: 39

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Axonal Transport; Boronic Acids; Bortezomib; Cell Death; Cells, Cultured; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Embryo, Mammalian; Ganglia, Spinal; Microscopy, Electron, Transmission; Microtubules; Neurons; Organ Culture Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Time Factors

2013
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Repair; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Rad51 Recombinase; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays

2013
Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2013, Volume: 32, Issue:12

    Topics: Aged; Antibodies; Biopsy; Boronic Acids; Bortezomib; Graft Rejection; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2013
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
    Leukemia, 2014, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Serum Response Element; Thalidomide; Transplantation, Autologous

2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies

2013
The ubiquitin-proteasome-system.
    Biochimica et biophysica acta, 2014, Volume: 1843, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Ubiquitination

2014
Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II.
    Toxicology letters, 2013, Nov-25, Volume: 223, Issue:2

    Topics: 17-Hydroxysteroid Dehydrogenases; Androstadienes; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Insulin-Like Growth Factor II; Leupeptins; Male; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polymerase Chain Reaction; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Sequence Analysis, DNA; Signal Transduction; Steryl-Sulfatase; Sulfones; Sulfotransferases; Wortmannin

2013
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Haematologica, 2013, Volume: 98, Issue:12

    Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines

2013
Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons.
    Cellular and molecular life sciences : CMLS, 2014, Volume: 71, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; DNA Damage; DNA Repair; Ganglia, Sensory; Gene Expression; Male; Microscopy, Confocal; Nissl Bodies; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger

2014
Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
    Experimental hematology, 2013, Volume: 41, Issue:12

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Cricetinae; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Mice; Multiple Myeloma; NF-kappa B; Oncolytic Virotherapy; Pyrazines; Real-Time Polymerase Chain Reaction; Vesicular Stomatitis; Vesicular stomatitis Indiana virus; Virus Replication

2013
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Activating Transcription Factor 3; Animals; Boronic Acids; Bortezomib; Electrophysiology; Female; Mice; Mice, Inbred BALB C; Peripheral Nervous System Diseases; Pyrazines

2013
BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Morphogenetic Protein 7; Boronic Acids; Bortezomib; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Pyrazines; Recurrence; RNA Interference; Treatment Outcome

2013
The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
    Biochemical pharmacology, 2013, Dec-01, Volume: 86, Issue:11

    Topics: Aging; Animals; Animals, Newborn; Boronic Acids; Bortezomib; Calcium; Calsequestrin; Cells, Cultured; Gene Expression; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Myocytes, Cardiac; Pyrazines; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Severity of Illness Index; Tachycardia, Ventricular

2013
OTUB1 enhances TGFβ signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3.
    Nature communications, 2013, Volume: 4

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Deubiquitinating Enzymes; Gene Expression Regulation; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Phosphoproteins; Phosphorylation; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Pyrazines; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Ubiquitin; Ubiquitination

2013
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Clinical therapeutics, 2013, Volume: 35, Issue:10

    Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia

2013
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
    Oncology, 2013, Volume: 85, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2013
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Failure

2014
Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
    The Journal of biological chemistry, 2013, Nov-08, Volume: 288, Issue:45

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dipeptides; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; I-kappa B Kinase; I-kappa B Proteins; Interleukin-8; Ketones; Leupeptins; Lysosomes; Microtubule-Associated Proteins; Mutation, Missense; NF-kappa B; NF-KappaB Inhibitor alpha; Proteasome Inhibitors; Proteolysis; Pyrazines; Thiophenes; Time Factors

2013
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
    Blood, 2013, Nov-28, Volume: 122, Issue:23

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Carriers; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Experimental; Leukemia, Myeloid, Acute; Liposomes; Mice; Mice, Mutant Strains; MicroRNAs; Mutation; Myeloid-Lymphoid Leukemia Protein; Proteasome Inhibitors; Pyrazines; RNA, Neoplasm; Tandem Repeat Sequences

2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adenosine Triphosphate; Analysis of Variance; Apoptosis; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Casein Kinase II; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Molecular Sequence Data; Multiple Myeloma; Naphthyridines; NF-kappa B; Phenazines; Pyrazines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor

2013
JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Enzyme Activation; Gene Knockdown Techniques; Humans; Lymphoma, Primary Effusion; MAP Kinase Kinase 4; Microscopy, Electron; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2013
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Journal of neurosurgery, 2013, Volume: 119, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2013
Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
    Transplant immunology, 2013, Volume: 29, Issue:1-4

    Topics: Allografts; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Transplantation; Isoantibodies; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2013
Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.
    Transplant immunology, 2013, Volume: 29, Issue:1-4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Humans; I-kappa B Kinase; NF-kappa B; Proteasome Inhibitors; Pyrazines

2013
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
    Leukemia, 2014, Volume: 28, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, T-Cell, Peripheral; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazines

2014
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
    Molecular and cellular biochemistry, 2014, Volume: 385, Issue:1-2

    Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mitochondria; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Signal Transduction; Ubiquitin-Activating Enzymes

2014
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:5

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome

2013
Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.
    Anti-cancer drugs, 2014, Volume: 25, Issue:2

    Topics: Androgens; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Hot Temperature; Humans; Male; Molecular Mimicry; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Engineering; Pyrazines; Recombinant Fusion Proteins; Tumor Cells, Cultured

2014
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
    European journal of haematology, 2014, Volume: 92, Issue:1

    Topics: ADAM Proteins; ADAMTS13 Protein; Adolescent; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Treatment Outcome

2014
Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model.
    Experimental dermatology, 2013, Volume: 22, Issue:11

    Topics: Animals; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models, Animal; Eczema; Female; Immune System; Immunoglobulin E; Immunohistochemistry; Inflammation; Mice; Mice, Inbred BALB C; Organ Culture Techniques; Proteasome Inhibitors; Pyrazines; Skin

2013
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Pathology, Molecular; Prognosis; Pyrazines

2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    American journal of hematology, 2014, Volume: 89, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome

2014
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
    Biomaterials, 2014, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanospheres; Pyrazines; Silicon Dioxide; Spectrophotometry, Ultraviolet

2014
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
    International journal of oncology, 2013, Volume: 43, Issue:6

    Topics: Aldehyde Oxidoreductases; Antigens, CD20; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Humans; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Neoplastic Stem Cells; Oxygen; PAX5 Transcription Factor; Peptides; Pyrazines; Receptors, CXCR4; Syndecan-1; Tretinoin; Tumor Microenvironment

2013
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways.
    The Journal of pharmacy and pharmacology, 2014, Volume: 66, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Boronic Acids; Bortezomib; Fatty Liver; Liver; Organ Preservation; Organ Preservation Solutions; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Solutions; TOR Serine-Threonine Kinases

2014
Initial treatment of nontransplant patients with multiple myeloma.
    Seminars in oncology, 2013, Volume: 40, Issue:5

    Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome

2013
Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Nov-05, Volume: 110, Issue:45

    Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Circular Dichroism; DNA Primers; Erythroid Cells; Humans; Mice; Models, Molecular; Mutation, Missense; Porphyria, Erythropoietic; Porphyrins; Proteasome Inhibitors; Protein Folding; Pyrazines; Real-Time Polymerase Chain Reaction; Spectrometry, Fluorescence; Uroporphyrinogen III Synthetase

2013
Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Monitoring; Home Care Services; Humans; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Scotland; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome

2014
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles

2013
[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines

2013
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.
    Experimental & molecular medicine, 2013, Oct-25, Volume: 45

    Topics: 2-Methoxyestradiol; Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Humans; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Pyrazines; Reactive Oxygen Species

2013
Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
    British journal of haematology, 2014, Volume: 164, Issue:3

    Topics: Aged; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines

2014
Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.
    International journal of hematology, 2013, Volume: 98, Issue:6

    Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; POEMS Syndrome; Positron-Emission Tomography; Pyrazines; Radiotherapy; Tomography Scanners, X-Ray Computed; Transplantation, Autologous; Treatment Outcome

2013
Global cellular response to chemotherapy-induced apoptosis.
    eLife, 2013, Oct-29, Volume: 2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genome, Human; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Ribosomes; Stress, Physiological; Transcription Factors; Transcription, Genetic

2013
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Ceramides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Morpholines; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrazines

2014
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lectins, C-Type; Mice; Multiple Myeloma; Plasma Cells; Pyrazines

2013
Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Angiotensin II; Animals; Aorta; Boronic Acids; Bortezomib; Cell Proliferation; Extracellular Matrix; Gene Expression Regulation; Hypertension; Male; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vascular Cell Adhesion Molecule-1

2013
Bortezomib: a therapeutic resource for the veterinary oncologist?
    Veterinary journal (London, England : 1997), 2013, Volume: 198, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Dog Diseases; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms

2013
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cohort Studies; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Incidence; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous; Vincristine

2014
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013
Is bortezomib a rare cause of acute pancreatitis?
    JOP : Journal of the pancreas, 2013, Nov-10, Volume: 14, Issue:6

    Topics: Abdominal Pain; Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines

2013
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous

2014
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Nov-26, Volume: 110, Issue:48

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; BRCA1 Protein; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Microarray Analysis; Oncogene Proteins; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering

2013
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
    Leukemia, 2014, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide

2014
Dissecting apoptosis the omics way.
    eLife, 2013, Nov-12, Volume: 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transcription Factors

2013
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Flow Cytometry; Humans; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, Interleukin-2

2013
An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway.
    British journal of cancer, 2014, Jan-07, Volume: 110, Issue:1

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Thiadiazines; Xenograft Model Antitumor Assays

2014
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    British journal of haematology, 2014, Volume: 164, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia

2014
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Nov-13, Volume: 33, Issue:6

    Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Hemodiafiltration; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Ion Exchange Resins; Male; Membranes, Artificial; Middle Aged; Multiple Myeloma; Myeloma Proteins; Polymers; Pyrazines; Serum Albumin; Thalidomide; Treatment Outcome

2013
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Nov-13, Volume: 33, Issue:6

    Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide

2013
High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.
    International journal of hematology, 2013, Volume: 98, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors

2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Patient Preference; Pyrazines

2013
Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
    Cell death & disease, 2013, Nov-21, Volume: 4

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; G2 Phase; Humans; Immunoprecipitation; Microtubules; Pyrazines

2013
Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
    Biochimica et biophysica acta, 2014, Volume: 1842, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Nucleolus; Cell Nucleus; Coiled Bodies; Cytoplasm; Ganglia, Sensory; Humans; Neurodegenerative Diseases; Proteasome Endopeptidase Complex; Pyrazines; Rats; Sensory Receptor Cells; Signal Transduction

2014
The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension.
    International journal of molecular medicine, 2014, Volume: 33, Issue:1

    Topics: Animals; Blood Flow Velocity; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; I-kappa B Proteins; Lung; Male; NF-KappaB Inhibitor alpha; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Transcription Factor RelA

2014
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    American journal of hematology, 2014, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
    BMB reports, 2014, Volume: 47, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Syndecan-1; Thalidomide; Ubiquitination

2014
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:10

    Topics: Acetophenones; Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Glucose; Humans; MCF-7 Cells; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C-delta; Pyrazines; Ubiquitin

2013
The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
    Toxicology letters, 2014, Jan-30, Volume: 224, Issue:3

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Enzyme Activation; Flow Cytometry; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Proteasome Endopeptidase Complex; Pyrazines; Xanthones; Xenograft Model Antitumor Assays

2014
Hyperammonemic encephalopathy in multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid

2014
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
    International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cannabidiol; Cell Cycle; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; In Situ Hybridization, Fluorescence; Membrane Potential, Mitochondrial; Multiple Myeloma; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TRPV Cation Channels; Tumor Cells, Cultured; Tumor Stem Cell Assay

2014
[Sensitivity to bortezomib of RPIM8226 cells after co-cultured with down-regulated Cav-1 expression HUVECs].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:11

    Topics: Apoptosis; Boronic Acids; Bortezomib; Caveolin 1; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Pyrazines

2013
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous

2014
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
    International journal of oncology, 2014, Volume: 44, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Proliferation; Drug Synergism; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Triazines; Tumor Cells, Cultured

2014
TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
    International journal of oncology, 2014, Volume: 44, Issue:2

    Topics: Anthracyclines; Antineoplastic Agents; Apoptosis; ATPases Associated with Diverse Cellular Activities; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2014
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-15, Volume: 20, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic

2014
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Anti-cancer drugs, 2014, Volume: 25, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Immunotherapy; Interleukin-12; Killer Cells, Natural; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Pyrazines

2014
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Leukemia, 2014, Volume: 28, Issue:6

    Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chromatin Immunoprecipitation; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured

2014
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
    British journal of haematology, 2014, Volume: 164, Issue:5

    Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome

2014
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
    Blood, 2014, Jan-30, Volume: 123, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Piperidones; Protease Inhibitors; Pyrazines; Ubiquitin Thiolesterase; Up-Regulation

2014
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
    Bulletin of experimental biology and medicine, 2013, Volume: 156, Issue:2

    Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms

2013
Bortezomib in multiple myeloma: a practice guideline.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2014, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2014
Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model.
    Anticancer research, 2013, Volume: 33, Issue:12

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Hyperalgesia; Pyrazines; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha

2013
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Anticancer research, 2013, Volume: 33, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning

2013
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
    Genes, chromosomes & cancer, 2014, Volume: 53, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Interleukin-6; MAP Kinase Signaling System; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Transcriptome

2014
Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.
    Neuro-oncology, 2014, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Radiation-Sensitizing Agents

2014
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.
    Cancer science, 2014, Volume: 105, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk

2014
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
    Cancer cell, 2013, Dec-09, Volume: 24, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Piperidones; Proteasome Inhibitors; Pyrazines; Ubiquitination

2013
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
    Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Ganglia, Spinal; Neurons; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Sciatic Nerve; Tubulin

2014
Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
    Molecules (Basel, Switzerland), 2013, Dec-11, Volume: 18, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Molecular Structure; Pyrazines; Structure-Activity Relationship

2013
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Survival Rate

2014
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
    The Journal of biological chemistry, 2014, Jan-31, Volume: 289, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Chemokine CCL2; Chemokine CXCL5; Early Growth Response Protein 1; Female; Gene Expression Regulation, Leukemic; Humans; I-kappa B Kinase; Interleukin-8; Multiple Myeloma; Ovarian Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription Factor RelA

2014
Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
    Pharmacotherapy, 2014, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome

2014
The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Acetylation; Boronic Acids; Bortezomib; Chromatin; E1A-Associated p300 Protein; Enhancer Elements, Genetic; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Histones; Humans; MCF-7 Cells; Molecular Targeted Therapy; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; RNA, Messenger

2013
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
    British journal of haematology, 2014, Volume: 164, Issue:6

    Topics: ADAM Proteins; ADAMTS13 Protein; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction

2014
Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Acta haematologica, 2014, Volume: 132, Issue:1

    Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Line; Depsipeptides; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Integrin alpha4; Integrin beta1; Melphalan; Multiple Myeloma; Pyrazines; RNA, Messenger; RNA, Neoplasm; Syndecan-1

2014
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome

2014
IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-01, Volume: 192, Issue:3

    Topics: Acute Disease; Animals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Transplantation; Cyclophosphamide; Cytokines; Dendritic Cells; Gene Expression Regulation; Graft vs Host Disease; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protease Inhibitors; Pyrazines; Signal Transduction; Specific Pathogen-Free Organisms; Spleen; Toll-Like Receptor 4; Transplantation Conditioning; Whole-Body Irradiation

2014
Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.
    AJR. American journal of roentgenology, 2014, Volume: 202, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiation Dosage; Retrospective Studies; Risk Factors; Sclerosis; Tomography, X-Ray Computed; Whole Body Imaging

2014
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2013
Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines.
    International journal of nanomedicine, 2014, Volume: 9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hyperthermia, Induced; Magnetic Field Therapy; Magnetic Fields; Magnetite Nanoparticles; Neoplasms, Experimental; Pyrazines; Treatment Outcome

2014
Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression.
    Transplant immunology, 2014, Volume: 30, Issue:2-3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Chitinase-3-Like Protein 1; Enzyme Activation; Extracellular Matrix Proteins; Fatty Liver; Gene Expression Regulation; Glycoproteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury

2014
HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
    Biochimica et biophysica acta, 2014, Volume: 1842, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; NF-E2-Related Factor 2; Nuclear Proteins; Oncogene Proteins; Pyrazines; Risk; Up-Regulation

2014
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:2

    Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha

2014
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231.
    Molecular and cellular biochemistry, 2014, Volume: 389, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; beta-Galactosidase; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Female; Fibroblasts; HSP70 Heat-Shock Proteins; Humans; Hypoxia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2014
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
    Bone, 2014, Volume: 61

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Male; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Receptor, Parathyroid Hormone, Type 1

2014
Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.
    Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2014, Volume: 32, Issue:2

    Topics: Acupuncture Therapy; Aged; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neuralgia; Pyrazines

2014
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
    Artificial organs, 2014, Volume: 38, Issue:10

    Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide

2014
Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.
    Blood, 2014, Apr-17, Volume: 123, Issue:16

    Topics: Antigens, CD34; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Congenital Bone Marrow Failure Syndromes; Granulocytes; HEK293 Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoid Enhancer-Binding Factor 1; Neutropenia; Proteolysis; Pyrazines; STAT5 Transcription Factor

2014
Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Decompression, Surgical; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Invasiveness; Prognosis; Pyrazines; Retrospective Studies; Spinal Canal; Spinal Cord Compression; Treatment Outcome

2015
Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
    Angewandte Chemie (International ed. in English), 2014, Feb-03, Volume: 53, Issue:6

    Topics: Binding Sites; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; HeLa Cells; Humans; Leupeptins; Molecular Dynamics Simulation; Oligopeptides; Peptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Pyrazines

2014
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
    Anticancer research, 2014, Volume: 34, Issue:1

    Topics: Adrenal Gland Neoplasms; Amifostine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cyclin B2; Epothilones; Microtubule-Associated Proteins; Neurites; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pheochromocytoma; Pyrazines; Radiation-Protective Agents; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured

2014
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
    Experimental neurology, 2014, Volume: 253

    Topics: Action Potentials; Animals; Antibodies; Boronic Acids; Bortezomib; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Mice; Motor Activity; Neural Conduction; Neurotoxicity Syndromes; Pain Measurement; Pain Threshold; Proteasome Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Time Factors; Tumor Necrosis Factor-alpha

2014
Correcting the cystic fibrosis disease mutant, A455E CFTR.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Anilides; Animals; Boronic Acids; Bortezomib; Chlorocebus aethiops; COS Cells; Cycloheximide; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Expression; Genetic Complementation Test; Half-Life; Humans; Hydroxamic Acids; Leupeptins; Mutation; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Small Molecule Libraries; Transfection

2014
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Journal of hematology & oncology, 2014, Jan-13, Volume: 7

    Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Histocompatibility Antigens Class I; HLA Antigens; Humans; Interferon-gamma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Up-Regulation

2014
Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line.
    Journal of experimental & clinical cancer research : CR, 2013, Oct-23, Volume: 32

    Topics: Boronic Acids; Bortezomib; Cell Line; Cell Membrane; Glucose Transporter Type 1; Herpesvirus 8, Human; Humans; Monocytes; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyrazines; Sarcoma, Kaposi; Signal Transduction

2013
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
    Haematologica, 2014, Volume: 99, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency

2014
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:2

    Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cytoplasm; Dexamethasone; Fanconi Syndrome; Humans; Immunoglobulin Light Chains; Kidney Tubules, Proximal; Male; Microscopy, Fluorescence; Microscopy, Immunoelectron; Multiple Myeloma; Myeloma Proteins; Phagosomes; Proteinuria; Pyrazines; Thalidomide

2014
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
    Journal of nephrology, 2014, Volume: 27, Issue:1

    Topics: Boronic Acids; Bortezomib; Female; Glomerulonephritis, Membranous; Humans; Middle Aged; Nephrotic Syndrome; Proteasome Inhibitors; Pyrazines

2014
Bortezomib-induced lung toxicity.
    Archivos de bronconeumologia, 2014, Volume: 50, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide

2014
Comparative cost-effectiveness models for the treatment of multiple myeloma.
    International journal of technology assessment in health care, 2014, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom

2014
A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma.
    Dermatology online journal, 2014, Jan-15, Volume: 20, Issue:1

    Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Eosinophilia; Herpes Simplex; Herpes Zoster; Humans; Insect Bites and Stings; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Paraneoplastic Syndromes; Pemphigoid, Bullous; Pyrazines; Skin Diseases

2014
Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
    Hematological oncology, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome

2014
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Benzylamines; Boronic Acids; Bortezomib; Chemokine CXCL12; Computer Simulation; Cyclams; Drug Delivery Systems; Drug Synergism; Heterocyclic Compounds; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Multiple Myeloma; Neoplastic Stem Cells; Paracrine Communication; Pyrazines; Tumor Microenvironment

2014
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
    Radiology, 2014, Volume: 271, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging

2014
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
    Leukemia, 2014, Volume: 28, Issue:8

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9

2014
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
    International journal of oncology, 2014, Volume: 44, Issue:4

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Kinase; I-kappa B Proteins; Imidazoles; MCF-7 Cells; NF-KappaB Inhibitor alpha; Phosphorylation; Pyrazines; Quinoxalines; Transcription Factor RelA

2014
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:3

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Histones; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Up-Regulation

2014
Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.
    Biochemical pharmacology, 2014, Mar-15, Volume: 88, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Beclin-1; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; HCT116 Cells; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Xenograft Model Antitumor Assays

2014
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
    International journal of hematology, 2014, Volume: 99, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 8; Disease-Free Survival; Female; Follow-Up Studies; Gene Amplification; Gene Expression; Genes, myc; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies

2014
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
    Oncotarget, 2014, Feb-15, Volume: 5, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays

2014
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines

2014
Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.
    Journal of medicinal chemistry, 2014, Mar-27, Volume: 57, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Comet Assay; DNA Damage; Drug Design; Drug Synergism; Enzyme Inhibitors; Glutathione S-Transferase pi; Humans; Isoenzymes; Models, Molecular; Neoplasms; Nitric Oxide; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Pyrazines; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2014
Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.
    Biochemical and biophysical research communications, 2014, Mar-07, Volume: 445, Issue:2

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; M Phase Cell Cycle Checkpoints; Mice; Muscle Fibers, Skeletal; Proteasome Inhibitors; Pyrazines

2014
Bendamustine: the remedy that came in from the cold.
    Blood, 2014, Feb-13, Volume: 123, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines

2014
CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    European journal of haematology, 2014, Volume: 93, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Rituximab

2014
TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy.
    Brain, behavior, and immunity, 2014, Volume: 38

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Ganglia, Spinal; Hyperalgesia; JNK Mitogen-Activated Protein Kinases; Male; Mice, Inbred C57BL; Neurons; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha

2014
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
    Transplantation, 2014, Feb-27, Volume: 97, Issue:4

    Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome

2014
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
    Haematologica, 2014, Volume: 99, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
    Biochimica et biophysica acta, 2014, Volume: 1840, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Humans; Jatropha; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Ubiquitin-Specific Proteases

2014
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Peripheral Nervous System Diseases; Pyrazines; Risk Factors

2014
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
    Biotechnology letters, 2014, Volume: 36, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Epithelial Cells; Humans; Pyrazines

2014
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays

2014
Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.
    The Journal of biological chemistry, 2014, Apr-25, Volume: 289, Issue:17

    Topics: Acetamides; Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Mice; Oxadiazoles; Proteasome Inhibitors; Pyrazines

2014
Simple benchmark for complex dose finding studies.
    Biometrics, 2014, Volume: 70, Issue:2

    Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Benchmarking; Biometry; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Lymphoma; Models, Statistical; Pyrazines; Stroke; Urinary Bladder Neoplasms

2014
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
    Gene therapy, 2014, Volume: 21, Issue:4

    Topics: Animals; Boronic Acids; Bortezomib; Dependovirus; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Pyrazines; Rats; Sarcoplasmic Reticulum Calcium-Transporting ATPases

2014
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
    World journal of gastroenterology, 2014, Jan-21, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Proliferation; Cyclins; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Phenotype; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Messenger; Transfection

2014
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
    International journal of hematology, 2014, Volume: 99, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome

2014
New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Neuroblastoma; Proteasome Inhibitors; Pyrazines

2014
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Drug Administration Schedule; Femur; Growth Plate; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Metatarsal Bones; Mice; Mice, Nude; Neuroblastoma; Proteasome Inhibitors; Pyrazines; Time Factors

2014
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Checkpoint Kinase 1; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins; Pyrazines; Syndecan-1; Up-Regulation

2014
Hypoxia enhances the senescence effect of bortezomib--the proteasome inhibitor--on human skin fibroblasts.
    BioMed research international, 2014, Volume: 2014

    Topics: Apoptosis; beta-Galactosidase; Blotting, Western; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Survival; Cellular Senescence; Fibroblasts; HSP70 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Proteasome Inhibitors; Pyrazines; Skin

2014
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Bone Marrow Cells; Boronic Acids; Bortezomib; Butadienes; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flavonoids; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Nitriles; Nuclear Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines

2014
Use of bortezomib in heavy-chain deposition disease: a report of 3 cases.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 64, Issue:1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Glomerular Filtration Rate; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney; Male; Middle Aged; Pyrazines; Treatment Outcome

2014
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
    Journal of cellular physiology, 2014, Volume: 229, Issue:11

    Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Butadienes; Cachexia; Cell Line, Tumor; Inflammation; Lung Neoplasms; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; NF-kappa B; Nitriles; Oxidation-Reduction; Proteolysis; Pyrazines; Signal Transduction; Sulfasalazine; Tyrosine; Weight Gain

2014
Bortezomib for the treatment of multiple myeloma.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Transplantation, Autologous

2014
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Cancer biology & therapy, 2014, Jun-01, Volume: 15, Issue:6

    Topics: Acetylation; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Middle Aged; Protein Processing, Post-Translational; Pyrazines; Urinary Bladder Neoplasms; Urothelium

2014
The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes.
    The Journal of biological chemistry, 2014, May-02, Volume: 289, Issue:18

    Topics: Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; DNA-Binding Proteins; Gene Expression; Heat Shock Transcription Factors; Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Microscopy, Confocal; Promoter Regions, Genetic; Proteasome Inhibitors; Protein Binding; Protein Multimerization; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; Transcription Factors

2014
Dissecting the first and the second meiotic divisions using a marker-less drug-hypersensitive fission yeast.
    Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:8

    Topics: Antifungal Agents; Aurora Kinases; Boronic Acids; Bortezomib; Brefeldin A; Cycloheximide; Drug Resistance, Multiple, Fungal; M Phase Cell Cycle Checkpoints; Meiosis; Prometaphase; Protein Serine-Threonine Kinases; Pyrazines; Schizosaccharomyces; Schizosaccharomyces pombe Proteins

2014
URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
    Cell death & disease, 2014, Mar-13, Volume: 5

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Pyrazines; Repressor Proteins; RNA Interference; Side-Population Cells; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
    Oncology reports, 2014, Volume: 31, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms

2014
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
    The Journal of biological chemistry, 2014, May-02, Volume: 289, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Epidermal Growth Factor; HEK293 Cells; HeLa Cells; Humans; Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; STAT3 Transcription Factor; Tyrosine; Up-Regulation

2014
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy

2014
Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
    The American journal of pathology, 2014, Volume: 184, Issue:5

    Topics: Animals; Apoptosis; Body Weight; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Laminin; Locomotion; Mice, Inbred C57BL; MicroRNAs; Muscle Cells; Muscles; Muscular Dystrophy, Animal; Organ Specificity; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis

2014
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
    Blood, 2014, May-08, Volume: 123, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mucin-1; Multiple Myeloma; Peptides; Phosphoric Monoester Hydrolases; Protein Subunits; Pyrazines; Reactive Oxygen Species

2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
    Transfusion, 2014, Volume: 54, Issue:8

    Topics: ADAM Proteins; ADAMTS13 Protein; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance; Female; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Recurrence; Remission Induction; Rituximab; Staphylococcal Infections

2014
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Copy Number Variations; Doxorubicin; Heterografts; Humans; Immunophenotyping; Melphalan; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Phenotype; Plasma Cells; Precursor Cells, B-Lymphoid; Pyrazines; Syndecan-1

2014
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:5

    Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome

2014
[Culture and regulation of osteoblasts in multiple myeloma patients].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3

    Topics: Adult; Aged; Bone Marrow Cells; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Serum; Tumor Cells, Cultured; Young Adult

2014
[Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Treatment Outcome

2014
Proteasomal serine hydrolases are up-regulated by and required for influenza virus infection.
    Journal of proteome research, 2014, May-02, Volume: 13, Issue:5

    Topics: Animals; Aprotinin; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dogs; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Leupeptins; Madin Darby Canine Kidney Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteome; Proteomics; Pyrazines; RNA Interference; Serine Proteases; Sulfones; Up-Regulation; Virus Replication

2014
Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.
    BMJ case reports, 2014, Mar-26, Volume: 2014

    Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Fasciitis, Necrotizing; Fatal Outcome; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia

2014
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    European journal of haematology, 2014, Volume: 93, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome

2014
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
    International journal of laboratory hematology, 2014, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom

2014
Inhibition of the ubiquitin-proteasome pathway does not protect against ventilator-induced accelerated proteolysis or atrophy in the diaphragm.
    Anesthesiology, 2014, Volume: 121, Issue:1

    Topics: Anesthesia; Animals; Antibiotics, Antineoplastic; Atrophy; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Diaphragm; DNA, Complementary; Female; Muscle Contraction; Muscle Proteins; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Respiration, Artificial; SKP Cullin F-Box Protein Ligases; Tripartite Motif Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Ventilator-Induced Lung Injury

2014
Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice.
    Journal of pharmacological sciences, 2014, Volume: 124, Issue:4

    Topics: Adrenergic Neurons; Amines; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Mice; Mice, Inbred C57BL; Norepinephrine; Pyrazines; Spinal Cord

2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases

2014
A rare cause of severe hepatomegaly with an improving outcome.
    BMJ case reports, 2014, Apr-03, Volume: 2014

    Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Hepatomegaly; Humans; Male; Multiple Myeloma; Pyrazines

2014
Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    International journal of hematology, 2014, Volume: 99, Issue:6

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Fibronectins; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Tumor Microenvironment

2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
    Blood, 2014, May-22, Volume: 123, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Multiple Myeloma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitin-Activating Enzymes; Up-Regulation

2014
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Leukemia, 2014, Volume: 28, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Thalidomide

2014
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Adipose Tissue; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cycloheximide; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous

2014
Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
    Pediatric transplantation, 2014, Volume: 18, Issue:4

    Topics: Boronic Acids; Bortezomib; Child; Graft Rejection; Humans; Kidney Transplantation; Male; Proteasome Inhibitors; Pyrazines

2014
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
    BMJ case reports, 2014, Apr-12, Volume: 2014

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Imidazoles; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyridazines; Recurrence; Remission Induction

2014
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
    Journal of biomedical nanotechnology, 2014, Volume: 10, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gold; Humans; Male; Metal Nanoparticles; Prostatic Neoplasms; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2014
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
    Cancer cell, 2014, Apr-14, Volume: 25, Issue:4

    Topics: Adult; Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Histone-Lysine N-Methyltransferase; Humans; M Phase Cell Cycle Checkpoints; Mice; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Transcriptional Elongation Factors; Transfection; Translocation, Genetic

2014
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
    Science signaling, 2014, Apr-15, Volume: 7, Issue:321

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes; Computational Biology; Core Binding Factor Alpha 2 Subunit; Cytogenetics; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Introns; Leukemia, Myeloid, Acute; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; NF-kappa B; Phenotype; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53

2014
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Molecular pharmacology, 2014, Volume: 86, Issue:1

    Topics: Actinobacteria; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Up-Regulation

2014
[Bortezomib enhances the sensitivity of prostate cancer cells to natural killer cell-mediated cytotoxicity].
    Zhonghua nan ke xue = National journal of andrology, 2014, Volume: 20, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Male; Prostatic Neoplasms; Pyrazines

2014
Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.
    Leukemia research, 2014, Volume: 38, Issue:6

    Topics: Antigens, CD19; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-kit; Pyrazines

2014
Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
    Biochemical and biophysical research communications, 2014, May-16, Volume: 447, Issue:4

    Topics: Adipogenesis; Alkaline Phosphatase; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Female; Humans; Integrin-Binding Sialoprotein; Mesenchymal Stem Cells; Osteoblasts; Osteogenesis; Osteoporosis; Placenta; Pregnancy; Pyrazines; Sp7 Transcription Factor; Transcription Factors; Up-Regulation

2014
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma.
    Oncogene, 2015, Mar-26, Volume: 34, Issue:13

    Topics: Animals; Bombesin; Boronic Acids; Bortezomib; Cisplatin; GTP-Binding Protein alpha Subunits, G12-G13; GTP-Binding Protein alpha Subunits, Gq-G11; Hedgehog Proteins; HEK293 Cells; Humans; Lung Neoplasms; Mice; NIH 3T3 Cells; Oncogene Proteins; Pyrazines; Receptors, Bombesin; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Zinc Finger Protein GLI1

2015
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
    European journal of haematology, 2014, Volume: 93, Issue:4

    Topics: Amides; Animals; Antineoplastic Agents; Blood Platelets; Bone Marrow; Boronic Acids; Bortezomib; Colony-Forming Units Assay; Disease Models, Animal; Male; Megakaryocyte Progenitor Cells; Megakaryocytes; Mice; Multiple Myeloma; Platelet Count; Pyrazines; Pyridines; rho-Associated Kinases; Thrombocytopenia; Thrombopoiesis; Thrombopoietin

2014
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
    Orvosi hetilap, 2014, Apr-27, Volume: 155, Issue:17

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    American journal of hematology, 2014, Volume: 89, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant.
    Transplantation, 2014, May-15, Volume: 97, Issue:9

    Topics: Adult; Aged; Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Rejection; Graft Survival; HLA Antigens; Humans; Kidney Transplantation; Male; Middle Aged; Neutrophils; Preoperative Period; Prospective Studies; Proteasome Inhibitors; Pyrazines; Renal Insufficiency; Steroids; Time Factors; Treatment Outcome

2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
    Haematologica, 2014, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Bortezomib protects from varicose-like venous remodeling.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014, Volume: 28, Issue:8

    Topics: Animals; Animals, Outbred Strains; Boronic Acids; Bortezomib; Cell Division; Cell Movement; Cells, Cultured; Collagen; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Pyrazines; Spheroids, Cellular; Trans-Activators; Varicose Veins

2014
Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Patient Outcome Assessment; Peripheral Nervous System Diseases; Pyrazines

2014
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Proliferation; Depsipeptides; DNA Damage; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Fluoresceins; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Reactive Oxygen Species

2014
The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).
    Blood, 2014, Jun-12, Volume: 123, Issue:24

    Topics: Animals; Boronic Acids; Bortezomib; Carotid Artery Thrombosis; Cells, Cultured; Coronary Occlusion; Cytoprotection; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Transcription Factors; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Whole Blood Coagulation Time

2014
Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.
    American journal of respiratory cell and molecular biology, 2014, Volume: 51, Issue:4

    Topics: Administration, Inhalation; Aerosols; Anti-Inflammatory Agents; Blood-Air Barrier; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Interleukin-8; Kinetics; Promoter Regions, Genetic; Proteasome Inhibitors; Pyrazines; Reproducibility of Results; Respiratory Mucosa; Transcriptional Activation; Tumor Necrosis Factor-alpha; Up-Regulation

2014
Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
    Journal of chromatography. A, 2014, Jun-06, Volume: 1345

    Topics: Boronic Acids; Bortezomib; Cell Survival; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Proteasome Inhibitors; Pyrazines; Tandem Mass Spectrometry

2014
Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
    Cancer letters, 2014, Aug-01, Volume: 350, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Herpesvirus 4, Human; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Niacinamide; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase C; Pyrazines; RNA Interference; RNA, Small Interfering; Sorafenib; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation

2014
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29

2014
Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
    Molecular medicine reports, 2014, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Down-Regulation; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Nude; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic; Transplantation, Heterologous

2014
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
    Chinese medical journal, 2014, Volume: 127, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction; Young Adult

2014
Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Humans; Integrins; Lipopeptides; Multiple Myeloma; Pyrazines; Stromal Cells; Toll-Like Receptor 1; Toll-Like Receptor 2

2014
Differential effect of bortezomib on HLA class I and class II antibody.
    Transplantation, 2014, Sep-27, Volume: 98, Issue:6

    Topics: Antibodies; Apoptosis; Boronic Acids; Bortezomib; Cell Membrane; Female; Graft Rejection; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lymphocytes; Male; Proteasome Inhibitors; Pyrazines; Retrospective Studies

2014
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
    Toxicology, 2014, Aug-01, Volume: 322

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Heart Diseases; Homeostasis; Immunoprecipitation; Lysosomes; Membrane Potential, Mitochondrial; Mice; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Oxides; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin; Ubiquitin-Protein Ligases; Voltage-Dependent Anion Channel 1

2014
Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.
    Transfusion medicine (Oxford, England), 2014, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Red-Cell Aplasia, Pure

2014
Bortezomib resistance and MUC1 in myeloma.
    Blood, 2014, May-08, Volume: 123, Issue:19

    Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Humans; Intracellular Signaling Peptides and Proteins; Mucin-1; Peptides; Phosphoric Monoester Hydrolases; Pyrazines; Reactive Oxygen Species

2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
    Nature medicine, 2014, Volume: 20, Issue:6

    Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Analysis of Variance; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; DNA Damage; DNA Primers; Doxorubicin; Fluorescent Antibody Technique; Genetic Vectors; Genomic Instability; Hematologic Neoplasms; Humans; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrazines; Real-Time Polymerase Chain Reaction; Transcription Factors; YAP-Signaling Proteins

2014
Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
    Pediatric transplantation, 2014, Volume: 18, Issue:5

    Topics: Adolescent; Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab; Steroids; Tissue Donors; Treatment Outcome; Young Adult

2014
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jul-15, Volume: 20, Issue:14

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Herpesvirus 1, Human; Humans; Mice, Nude; Necrosis; Oncolytic Virotherapy; Oncolytic Viruses; Pyrazines; Unfolded Protein Response; Virus Replication; Xenograft Model Antitumor Assays

2014
Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Janus Kinases; K562 Cells; Pyrazines; RNA, Messenger; Signal Transduction; STAT Transcription Factors

2014
Access to expensive cancer drugs in Dutch daily practice: should we be concerned?
    The Netherlands journal of medicine, 2014, Volume: 72, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Costs; Drug Prescriptions; Health Policy; Health Services Accessibility; Humans; Interviews as Topic; Netherlands; Practice Patterns, Physicians'; Pyrazines

2014
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53

2014
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering

2014
Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
    Macromolecular bioscience, 2014, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Capsid Proteins; Carcinoma, Hepatocellular; Catechols; Drug Delivery Systems; Humans; Liver Neoplasms; Nanocomposites; Pyrazines

2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors

2014
Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diplopia; Female; Humans; Mucin-1; Multiple Myeloma; Pyrazines; Remission Induction

2014
USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling.
    Open biology, 2014, Volume: 4, Issue:5

    Topics: Animals; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Line; Gene Expression Regulation, Developmental; HEK293 Cells; HeLa Cells; Humans; Mice; Phosphorylation; Pyrazines; Signal Transduction; Smad1 Protein; Ubiquitin-Specific Proteases; Ubiquitination; Xenopus laevis; Xenopus Proteins

2014
Use of bortezomib as anti-humoral therapy in kidney transplantation.
    Journal of Korean medical science, 2014, Volume: 29, Issue:5

    Topics: Adult; Boronic Acids; Bortezomib; Desensitization, Immunologic; Female; Graft Rejection; HLA Antigens; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Pyrazines; Treatment Outcome

2014
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
    Genetics and molecular research : GMR, 2014, May-09, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; NF-kappa B; Prostatic Neoplasms; Pyrazines

2014
[Analysis of Bortezomib-containing combinations in newly-diagnosed multiple myeloma patients: a comparative study].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
    Haematologica, 2014, Volume: 99, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Protein Aggregates; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome

2014
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
    Leukemia research, 2014, Volume: 38, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2014
Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.
    BioMed research international, 2014, Volume: 2014

    Topics: Animals; Behavior, Animal; Boronic Acids; Bortezomib; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Nerve Tissue Proteins; Nociception; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Substance P; TRPV Cation Channels

2014
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide

2014
Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin E; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome

2014
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome

2015
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-10, Volume: 32, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid

2014
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
    Journal of medicinal chemistry, 2014, Jun-26, Volume: 57, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Esters; Humans; Liposomes; Mice, SCID; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Prodrugs; Proteasome Endopeptidase Complex; Pyrazines

2014
Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Humans; I-kappa B Proteins; K562 Cells; NF-kappa B; Pyrazines

2014
Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.
    BMJ case reports, 2014, Jun-05, Volume: 2014

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neuroimaging; Posterior Leukoencephalopathy Syndrome; Pyrazines

2014
Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat.
    Neuroscience, 2014, Aug-22, Volume: 274

    Topics: Animals; Antineoplastic Agents; Astrocytes; Boronic Acids; Bortezomib; Glial Fibrillary Acidic Protein; Hyperalgesia; Male; Microglia; Minocycline; Neuroprotective Agents; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Spinal Nerves

2014
Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1172

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Fractionation; Cell Line, Tumor; Cell Nucleus; Complex Mixtures; Cytoplasm; Electrophoresis, Polyacrylamide Gel; Female; Gene Expression; HMGB1 Protein; Humans; Interleukin-8; Male; Pyrazines

2014
Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1172

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Gene Expression; Humans; Interleukin-6; Interleukin-8; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha

2014
Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1172

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromatin Immunoprecipitation; Humans; Interleukin-1beta; Lipopolysaccharides; Macrophages; NF-kappa B; Promoter Regions, Genetic; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tetradecanoylphorbol Acetate; Transcription, Genetic; Tumor Necrosis Factor-alpha

2014
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
    Oncogene, 2015, Apr-16, Volume: 34, Issue:16

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Drug Synergism; Female; Hepatocytes; Humans; Ovarian Neoplasms; Protein Binding; Pyrazines; Receptors, IgG; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins

2015
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
    Scientific reports, 2014, Jun-10, Volume: 4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; HEK293 Cells; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Organometallic Compounds; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Pyridines; Ubiquitin; Ubiquitin-Specific Proteases

2014
ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
    International journal of molecular medicine, 2014, Volume: 34, Issue:2

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mice; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Primary Cell Culture; Pyrazines

2014
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Cancer biology & therapy, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat

2014
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome

2014
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
    International journal of hematology, 2014, Volume: 100, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
    Blood, 2014, Jul-24, Volume: 124, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Cell Proliferation; Cytokines; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    British journal of haematology, 2014, Volume: 166, Issue:6

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome

2014
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Nephrology (Carlton, Vic.), 2014, Volume: 19, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Remission Induction; Renal Dialysis; Thalidomide; Treatment Outcome

2014
Bortezomib use in a pediatric cardiac transplant center.
    Pediatric transplantation, 2014, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Antibodies; Biopsy; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Heart Defects, Congenital; Heart Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Male; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
    Thrombosis research, 2014, Volume: 134, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Pyrazines; Thalidomide; Venous Thromboembolism

2014
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Transplantation, 2014, Jun-27, Volume: 97, Issue:12

    Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Baltimore; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Drug Substitution; Female; Graft Rejection; Graft Survival; Humans; Immunity, Humoral; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Plasmapheresis; Pyrazines; Retrospective Studies; Risk Factors; Rituximab; Time Factors; Treatment Outcome

2014
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
    Molecular medicine reports, 2014, Volume: 10, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger

2014
[Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies

2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
    Pathology oncology research : POR, 2014, Volume: 20, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Survival Rate

2014
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    European journal of medicinal chemistry, 2014, Aug-18, Volume: 83

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cattle; Cell Line, Tumor; Cell Proliferation; Drug Design; Endopeptidases; Humans; Hydrolysis; Molecular Docking Simulation; Peptidomimetics; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Proteolysis; Pyrazines; Trypsin

2014
Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
    Brain research, 2014, Jul-29, Volume: 1574

    Topics: Action Potentials; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Lumbar Vertebrae; Male; Motor Activity; Neurons; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Pyrazines; Rats, Sprague-Dawley; Spinal Cord; Temperature; Touch

2014
Bortezomib treatment causes long-term testicular dysfunction in young male mice.
    Molecular cancer, 2014, Jun-20, Volume: 13

    Topics: Animals; Boronic Acids; Bortezomib; Follicle Stimulating Hormone; Humans; Male; Mice; Neoplasms; Proteasome Inhibitors; Pyrazines; Spermatogenesis; Testicular Diseases; Testis; Testosterone

2014
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
    Oncotarget, 2014, Jul-15, Volume: 5, Issue:13

    Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays

2014
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
    BMC cancer, 2014, Jun-21, Volume: 14

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Autophagic-lysosomal inhibition compromises ubiquitin-proteasome system performance in a p62 dependent manner in cardiomyocytes.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenine; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Heat-Shock Proteins; Lysosomes; Mice; Mice, Transgenic; Myocytes, Cardiac; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Rats; Sequestosome-1 Protein; Ubiquitin

2014
CSNK1α1 mediates malignant plasma cell survival.
    Leukemia, 2015, Volume: 29, Issue:2

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction

2015
Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:3

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Neural Conduction; Pure Autonomic Failure; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2014
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.
    International journal of oncology, 2014, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; YY1 Transcription Factor

2014
Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Aug-01, Volume: 193, Issue:3

    Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents; Autoantibodies; Boronic Acids; Bortezomib; Cells, Cultured; Endoplasmic Reticulum Stress; Female; Humans; Male; Plasma Cells; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyrazines; Thymus Gland; Young Adult

2014
Chalazia associated with bortezomib therapy for multiple myeloma.
    Ophthalmology, 2014, Volume: 121, Issue:9

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chalazion; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous

2014
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
    Molecular cancer, 2014, Jun-30, Volume: 13

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation

2014
Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:11

    Topics: Boronic Acids; Bortezomib; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purpura, Thrombocytopenic, Idiopathic; Pyrazines; Vincristine

2014
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide

2014
Engineered nanomedicine for myeloma and bone microenvironment targeting.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-15, Volume: 111, Issue:28

    Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Delivery Systems; Heterografts; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Tumor Microenvironment; Xenograft Model Antitumor Assays

2014
New data on subcutaneous bortezomib.
    Acta haematologica, 2015, Volume: 133, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines

2015
An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
    Acta haematologica, 2015, Volume: 133, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Boronic Acids; Bortezomib; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index

2015
The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
    BioMed research international, 2014, Volume: 2014

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines

2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib

2014
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
    Current biology : CB, 2014, Jul-21, Volume: 24, Issue:14

    Topics: Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; HEK293 Cells; Humans; Leupeptins; Nuclear Proteins; Nuclear Respiratory Factor 1; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; RNA Interference; RNA, Small Interfering; Ubiquitin Thiolesterase; Ubiquitination; Unfolded Protein Response

2014
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
    Molecular and cellular biology, 2014, Sep-15, Volume: 34, Issue:18

    Topics: Activating Transcription Factor 4; Amino Acid Transport System y+; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glutathione; Glycine; HEK293 Cells; HeLa Cells; Humans; Leupeptins; NF-E2-Related Factor 2; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Sulfasalazine; Urinary Bladder Neoplasms

2014
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
    Molecular and cellular biology, 2014, Sep-15, Volume: 34, Issue:18

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Cyclin T; Cyclin-Dependent Kinase 9; Cycloheximide; Flavonoids; Gene Expression Regulation; Heat-Shock Proteins; Humans; Indoles; Leupeptins; Membrane Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Piperidines; Protein Transport; Pyrazines; Pyrroles; RNA, Small Interfering; Sequestosome-1 Protein

2014
EGFR inhibitors may induce tumor stemness.
    Cancer discovery, 2014, Volume: 4, Issue:7

    Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Integrin beta3; Neoplastic Stem Cells; Pyrazines; Quinazolines

2014
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
    Leukemia, 2014, Volume: 28, Issue:11

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured

2014
Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
    Clinical biochemistry, 2014, Volume: 47, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Erythrocyte Count; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma; Pyrazines

2014
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms

2014
[Gastrointestinal amyloidosis in a patient with multiple myeloma].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158

    Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines

2014
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
    Leukemia, 2014, Volume: 28, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Pyrazines; Thalidomide; Treatment Outcome

2014
Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Transplantation, 2015, Volume: 99, Issue:1

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; B-Lymphocytes; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Child; Female; France; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Young Adult

2015
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide

2014
POEMS syndrome: a challenging diagnosis of a rare disease.
    British journal of hospital medicine (London, England : 2005), 2014, Volume: 75, Issue:7

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Male; POEMS Syndrome; Pyrazines; Rare Diseases

2014
Treatment strategies to treat antibody-mediated rejection and to reduce donor-specific antibodies.
    Pediatric transplantation, 2014, Volume: 18, Issue:5

    Topics: Antibodies; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Pyrazines; Steroids

2014
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Journal of controlled release : official journal of the Controlled Release Society, 2014, Oct-28, Volume: 192

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Liposomes; Mice; Mice, Nude; Neuroblastoma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2014
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
    Cancer biology & therapy, 2014, Volume: 15, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Coculture Techniques; Endopeptidases; Gelatinases; Humans; Membrane Proteins; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Serine Endopeptidases; Signal Transduction

2014
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
    Journal of biomedical materials research. Part A, 2015, Volume: 103, Issue:4

    Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endocytosis; Humans; Lactic Acid; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteasome Inhibitors; Pyrazines; Spectroscopy, Fourier Transform Infrared; Telomerase; Transferrin

2015
The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
    Annals of hematology, 2015, Volume: 94, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Taiwan; Treatment Outcome

2015
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.
    International journal of oncology, 2014, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Ubiquitin-Protein Ligases

2014
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections

2014
Hepcidin and GDF15 in anemia of multiple myeloma.
    International journal of hematology, 2014, Volume: 100, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Dexamethasone; Female; Ferritins; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Hemoglobins; Hepcidins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; RNA, Messenger

2014
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
    Leukemia, 2014, Volume: 28, Issue:12

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Middle Aged; Pyrazines; Treatment Outcome

2014
Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
    Blood, 2014, Jul-24, Volume: 124, Issue:4

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DEAD-box RNA Helicases; Humans; Multiple Myeloma; Mutation; Pyrazines; Ribonuclease III; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2014
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Acute Disease; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Disease Models, Animal; Female; Graft vs Host Disease; Interleukin-6; Liver Diseases; Mice; Organ Specificity; Pyrazines; Skin Diseases

2014
[Hyperammonemic encephalopathy in multiple myeloma].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:30

    Topics: Alkalosis, Respiratory; Ammonia; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Dyspnea; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Rett Syndrome

2014
Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition.
    Scientific reports, 2014, Jul-31, Volume: 4

    Topics: Animals; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; CHO Cells; Cricetinae; Cricetulus; Membrane Potential, Mitochondrial; Mitochondria; Neurodegenerative Diseases; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Reactive Oxygen Species; Resveratrol; Stilbenes; Ubiquitination

2014
Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; HEK293 Cells; Humans; Inhibitory Concentration 50; Intracellular Space; Leupeptins; Oligopeptides; Peptides; Proteasome Inhibitors; Pyrazines

2014
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning

2014
Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2014, Volume: 12, Issue:4

    Topics: Adult; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Creatinine; Female; Graft Rejection; Graft Survival; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Length of Stay; Male; Middle Aged; Plasmapheresis; Pyrazines; Retrospective Studies; Time Factors; Treatment Outcome

2014
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3

    Topics: Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian People; Boronic Acids; Bortezomib; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Benzodiazepinones; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Depsipeptides; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Interleukin-2 Receptor alpha Subunit; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Burden

2015
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine

2014
Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat.
    Neuropharmacology, 2014, Volume: 86

    Topics: Analgesics; Animals; Boronic Acids; Bortezomib; Ceftriaxone; Cell Line, Tumor; Cell Survival; Central Nervous System Agents; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Hyperalgesia; Injections, Spinal; Male; Neural Conduction; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Random Allocation; Rats; Receptor, Metabotropic Glutamate 5

2014
Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:16

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome

2014
Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:16

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Syndrome

2014
Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:12

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Prognosis; Pyrazines; Severe Combined Immunodeficiency; Transplantation, Homologous

2014
The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations.
    The FEBS journal, 2014, Volume: 281, Issue:19

    Topics: Boronic Acids; Bortezomib; Carrier Proteins; Cells, Cultured; Cholesterol; Endosomes; Fibroblasts; Humans; Intracellular Signaling Peptides and Proteins; Leupeptins; Membrane Glycoproteins; Mutation, Missense; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Protein Transport; Proteolysis; Pyrazines

2014
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
    Bone marrow transplantation, 2014, Volume: 49, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2014
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
    British journal of haematology, 2014, Volume: 164, Issue:5

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed

2014
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes.
    American journal of physiology. Cell physiology, 2014, Nov-01, Volume: 307, Issue:9

    Topics: Boronic Acids; Bortezomib; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose; Glycogen; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Male; Muscle, Skeletal; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Carbonylation; Proteome; Pyrazines; RNA Interference; Signal Transduction

2014
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    Genes, chromosomes & cancer, 2015, Volume: 54, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines

2015
MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
    Nucleic acids research, 2014, Volume: 42, Issue:16

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Binding Sites; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Genes, p16; Genes, p53; Membrane Proteins; Mice; Promoter Regions, Genetic; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; Transcription, Genetic

2014
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Anti-cancer drugs, 2014, Volume: 25, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Unfolded Protein Response

2014
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    British journal of haematology, 2014, Volume: 167, Issue:5

    Topics: Animals; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Epstein-Barr Virus Infections; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Up-Regulation; Viral Proteins; Xenograft Model Antitumor Assays

2014
Subcutaneous bortezomib for treatment of TEMPI syndrome.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6

    Topics: Boronic Acids; Bortezomib; Edema; Female; Humans; Middle Aged; Paraproteinemias; Polycythemia; Proteasome Inhibitors; Pyrazines; Skin; Telangiectasis; Treatment Outcome

2014
Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes.
    Biochemical and biophysical research communications, 2014, Sep-26, Volume: 452, Issue:3

    Topics: Boronic Acids; Bortezomib; Chondrocytes; Collagen Type II; Gene Expression Regulation; Humans; Interferon Regulatory Factor-1; Janus Kinase 2; Matrix Metalloproteinase 13; Osteoarthritis; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; STAT1 Transcription Factor; Tumor Necrosis Factor-alpha

2014
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Molecular medicine reports, 2014, Volume: 10, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Multiple Myeloma; Propiophenones; Proteasome Inhibitors; Pyrazines

2014
HLA desensitization with bortezomib in a highly sensitized pediatric patient.
    Pediatric transplantation, 2014, Volume: 18, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cardiomyopathy, Dilated; Child; Combined Modality Therapy; Drug Therapy, Combination; Graft Rejection; Heart Transplantation; HLA Antigens; Humans; Immunologic Factors; Isoantibodies; Male; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Rituximab; Transplantation Conditioning

2014
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    BMC urology, 2014, Aug-30, Volume: 14

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Stress; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Kidney Neoplasms; Mice, Inbred BALB C; Panobinostat; Pyrazines; Ubiquitinated Proteins

2014
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
    Haematologica, 2014, Volume: 99, Issue:9

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Pyrazines

2014
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis

2015
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
    Clinical laboratory, 2014, Volume: 60, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome

2014
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Proteasome: target for acute and chronic GVHD?
    Blood, 2014, Sep-04, Volume: 124, Issue:10

    Topics: Animals; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Pyrazines

2014
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Journal of medical case reports, 2014, Sep-08, Volume: 8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous

2014
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Blood, 2014, Oct-23, Volume: 124, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Membrane Proteins; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins; Pyrazines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays

2014
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
    Annals of hematology, 2015, Volume: 94, Issue:4

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Pyrazines

2015
Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
    International journal of hematology, 2014, Volume: 100, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Incidence; Infections; Levofloxacin; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2014
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
    Oncotarget, 2014, Aug-30, Volume: 5, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Boronic Acids; Bortezomib; Bridged-Ring Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Hedgehog Proteins; Humans; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; Pyridines; Signal Transduction; Taxoids

2014
Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
    European journal of pharmacology, 2014, Nov-05, Volume: 742

    Topics: Alprostadil; Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Jurkat Cells; Leukemia, B-Cell; Lymphoma, B-Cell; NF-kappa B; Pyrazines; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; U937 Cells

2014
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
    Oncogene, 2015, Volume: 34, Issue:28

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Male; NF-kappa B; Nitriles; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays

2015
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
    Cell research, 2014, Volume: 24, Issue:10

    Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Library; HEK293 Cells; Humans; Luminescent Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Array Analysis; Protein Interaction Maps; Proteolysis; Proto-Oncogene Proteins; Pyrazines; Transcriptome

2014
Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.
    Scientific reports, 2014, Sep-18, Volume: 4

    Topics: Action Potentials; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Behavior, Animal; Boronic Acids; Bortezomib; Cisplatin; Electrophysiology; Gait; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Polyneuropathies; Pyrazines; Vincristine

2014
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lentivirus; Mice; Mice, Inbred NOD; MicroRNAs; Multiple Myeloma; Neoplasm Transplantation; Nuclear Proteins; Ornithine Decarboxylase; Phagosomes; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Signal Transduction; Survival Analysis

2015
[Modified bortezomib-based combination therapy for multiple myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2014
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:4

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies

2014
Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Birth Weight; Boronic Acids; Bortezomib; DNA Damage; Doxorubicin; Female; Fertility; Humans; Litter Size; Mice; Ovarian Follicle; Ovarian Neoplasms; Ovary; Primary Ovarian Insufficiency; Pyrazines

2014
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Mice; Multiple Myeloma; Polycomb Repressive Complex 2; Pyrazines; Syndecan-1; Xenograft Model Antitumor Assays

2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
    Haematologica, 2015, Volume: 100, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Matched-Pair Analysis; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Survival Rate

2015
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
    Cell reports, 2014, Oct-09, Volume: 9, Issue:1

    Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Metastasis; Oligonucleotides; Polyethylene Glycols; Pyrazines

2014
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    BMC nephrology, 2014, Sep-30, Volume: 15

    Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies

2014
Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Anticancer research, 2014, Volume: 34, Issue:10

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Vorinostat

2014
Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells.
    The Journal of nutritional biochemistry, 2014, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; NF-kappa B; Pyrazines

2014
Delayed flare reaction of draining vein due to subcutaneous bortezomib more likely to occur at the inner thigh.
    International journal of hematology, 2015, Volume: 101, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Hypersensitivity; Erythema; Humans; Hypersensitivity, Delayed; Pyrazines; Skin; Thigh

2015
Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.
    Rheumatology (Oxford, England), 2015, Volume: 54, Issue:1

    Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Lupus Erythematosus, Systemic; Proteasome Inhibitors; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome

2015
Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
    Journal of neuropathology and experimental neurology, 2014, Volume: 73, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; HEK293 Cells; Humans; Meningioma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2014
A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Journal of proteomics, 2015, Jan-15, Volume: 113

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; DNA Replication; DNA, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Energy Metabolism; Female; Humans; Proteasome Endopeptidase Complex; Protein Folding; Protein Processing, Post-Translational; Proteome; Proteomics; Pyrazines; Tumor Suppressor Protein p53

2015
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
    Leukemia, 2015, Volume: 29, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Monomeric GTP-Binding Proteins; Multiple Myeloma; Mutation; Neoplasm Transplantation; Pyrazines; Pyrazoles; Retinal Pigment Epithelium

2015
"Multiplexed viability, cytotoxicity, and caspase activity assays".
    Methods in molecular biology (Clifton, N.J.), 2015, Volume: 1219

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Culture Techniques; Enzyme Activation; Humans; K562 Cells; Molecular Biology; Pyrazines; Toxicity Tests

2015
Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Cell Extracts; Drug Synergism; Endocytosis; HCT116 Cells; Humans; Leucine; Lysosomes; Macrolides; Proteolysis; Pyrazines; Receptors, Death Domain; Signal Transduction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53

2014
Inhibition of Nek2 by small molecules affects proteasome activity.
    BioMed research international, 2014, Volume: 2014

    Topics: Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Mitosis; NIMA-Related Kinases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteolysis; Pyrazines; Small Molecule Libraries

2014
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.
    Cancer gene therapy, 2014, Volume: 21, Issue:11

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cloning, Molecular; Dimerization; Enzyme Activation; Gene Knockdown Techniques; Genes, Transgenic, Suicide; Genetic Vectors; Green Fluorescent Proteins; Humans; Immunoblotting; Luciferases, Firefly; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, SCID; Organic Chemicals; Pyrazines; X-Linked Inhibitor of Apoptosis Protein

2014
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
    BMJ case reports, 2014, Oct-17, Volume: 2014

    Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Electrophoresis; Humans; Immunoglobulin Light Chains; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Thalidomide

2014
Cell-type variation in stress responses as a consequence of manipulating GRP78 expression in neuroectodermal cells.
    Journal of cellular biochemistry, 2015, Volume: 116, Issue:3

    Topics: Biomarkers; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Shape; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fenretinide; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Neural Plate; Pyrazines; RNA, Small Interfering; Stress, Physiological; Unfolded Protein Response

2015
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine

2014
[Effects of bortezomib combined with 5-azacytidine on the apoptosis of K562 cells and expression of SHIP mRNA].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:5

    Topics: Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Inositol Polyphosphate 5-Phosphatases; K562 Cells; Phosphoric Monoester Hydrolases; Pyrazines; RNA, Messenger

2014
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases

2015
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:10

    Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones

2014
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Cell death & disease, 2014, Oct-23, Volume: 5

    Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; HEK293 Cells; Humans; Oncogene Proteins, Viral; Papillomaviridae; Protein Stability; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein

2014
Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis.
    Blood, 2014, Oct-23, Volume: 124, Issue:17

    Topics: Animals; Benzylamines; Boronic Acids; Bortezomib; Cyclams; Drug Synergism; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Integrin alpha4beta1; Mice, Inbred BALB C; Mice, Knockout; Proteasome Inhibitors; Pyrazines; Time Factors; Vascular Cell Adhesion Molecule-1

2014
Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.
    Clinical nephrology, 2015, Volume: 83, Issue:6

    Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Paraproteinemias; Pyrazines

2015
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Annals of hematology, 2015, Volume: 94, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure

2015
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
    Cell death & disease, 2014, Oct-30, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Kinetics; Melphalan; Membrane Proteins; Mice; Mitochondria; Phosphorylation; Phosphoserine; Pyrazines; Sirolimus

2014
Differential impact of bortezomib on HL-60 and K562 cells.
    General physiology and biophysics, 2015, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Leukemic; Heat-Shock Proteins; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Leukemia; Proteasome Endopeptidase Complex; Pyrazines; Time Factors

2015
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Vincristine

2014
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.
    Lab on a chip, 2015, Jan-07, Volume: 15, Issue:1

    Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Microfluidic Analytical Techniques; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A

2015
Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Retinal cases & brief reports, 2014,Fall, Volume: 8, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Macular Edema; Male; Multiple Myeloma; Pyrazines; Retinal Detachment; Treatment Outcome

2014
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
    Cell death & disease, 2014, Nov-06, Volume: 5

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cisplatin; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; MAP Kinase Kinase 4; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phagosomes; Phosphorylation; Proteasome Inhibitors; Pyrazines; Signal Transduction

2014
[Bortezomib-based therapy in patients with light chain deposition disease].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:10

    Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Paraproteinemias; Pyrazines; Treatment Outcome

2014
In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:10

    Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Coculture Techniques; Humans; I-kappa B Proteins; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serum; Signal Transduction; Tumor Necrosis Factor-alpha

2014
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
    International journal of oncology, 2015, Volume: 46, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat

2015
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
    Cell death & disease, 2014, Nov-27, Volume: 5

    Topics: Aurovertins; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cyclin D3; eIF-2 Kinase; Electron Transport; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Humans; Mitochondrial Proton-Translocating ATPases; Molecular Targeted Therapy; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Purinergic; Tumor Stem Cell Assay; Ubiquitin; Unfolded Protein Response; Vacuoles

2014
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    International journal of hematology, 2015, Volume: 101, Issue:2

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome

2015
Inhibition of PGC-1α after chemotherapy-mediated insult confines multiple myeloma cell survival by affecting ROS accumulation.
    Oncology reports, 2015, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Catalase; Cell Line, Tumor; Cell Survival; Dexamethasone; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Multiple Myeloma; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pyrazines; Reactive Oxygen Species; RNA, Small Interfering; Superoxide Dismutase; Transcription Factors

2015
Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy.
    Journal of vascular and interventional radiology : JVIR, 2014, Volume: 25, Issue:12

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Catheter Ablation; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Liposomes; Liver; Pyrazines; Rats; Rats, Inbred F344; Up-Regulation

2014
Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction.
    Biochemical and biophysical research communications, 2015, Jan-02, Volume: 456, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Catalase; Cell Line; Cell Survival; Hair Cells, Auditory; Hearing Loss; Humans; Lipids; Organ of Corti; Peroxisomes; Phenotype; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species

2015
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger

2015
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
    Oncotarget, 2014, Dec-15, Volume: 5, Issue:23

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockout Techniques; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Pyrazines; Transfection

2014
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
    Oncology research and treatment, 2014, Volume: 37, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries

2014
Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; NF-kappa B; Positron-Emission Tomography; Prednisone; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Vincristine

2014
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:7

    Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide

2015
Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
    Leukemia, 2014, Volume: 28, Issue:12

    Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Treatment Outcome

2014
XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Cell death & disease, 2014, Dec-11, Volume: 5

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Mutation; Phosphatidylinositol 3-Kinases; Pyrazines; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2014
The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture.
    Yonsei medical journal, 2015, Volume: 56, Issue:1

    Topics: Animals; Boronic Acids; Bortezomib; Cecum; Cell Adhesion Molecules; Cell Line; Cell Proliferation; Cell Survival; Chymotrypsin; Cytokines; Disease Models, Animal; Inflammation Mediators; Ligation; Lipopolysaccharides; Lung; Male; Mice, Inbred C57BL; Nitric Oxide; Proteasome Inhibitors; Punctures; Pyrazines; Sepsis

2015
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
    Cell death & disease, 2014, Dec-18, Volume: 5

    Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Down-Regulation; Female; Gene Silencing; Humans; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; RNA, Small Interfering; Signal Transduction

2014
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    International journal of oncology, 2015, Volume: 46, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Imidazoles; Indoles; Multiple Myeloma; Naphthoquinones; Necrosis; Proteasome Inhibitors; Purine Nucleosides; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; X-Box Binding Protein 1

2015
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    International journal of cancer, 2015, Aug-01, Volume: 137, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prognosis; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Prospective iterative trial of proteasome inhibitor-based desensitization.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Desensitization, Immunologic; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Histocompatibility Testing; HLA Antigens; Humans; Immunoglobulins, Intravenous; Kidney Diseases; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Prognosis; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Factors; Rituximab; Young Adult

2015
Refractory primary Sjögren syndrome successfully treated with bortezomib.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Boronic Acids; Bortezomib; Drug Resistance; Fatigue; Female; Globulins; Humans; Incidence; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Sjogren's Syndrome; Treatment Outcome

2015
[Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies

2014
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
    Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Communication; Cell Growth Processes; Cytokines; Disease Progression; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Pyrazines; T-Lymphocytes, Regulatory; Treatment Outcome

2015
Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Feb-15, Volume: 194, Issue:4

    Topics: ADP Ribose Transferases; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Bacterial Toxins; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Exotoxins; Female; Immunotherapy; Mesothelin; Mice; Mice, Inbred BALB C; Proteasome Inhibitors; Pseudomonas aeruginosa Exotoxin A; Pyrazines; Recombinant Proteins; Virulence Factors

2015
2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.
    World journal of gastroenterology, 2014, Dec-28, Volume: 20, Issue:48

    Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Colitis; Colon; Disease Models, Animal; Fibrosis; Male; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats, Sprague-Dawley; Signal Transduction; Tight Junction Proteins; Transforming Growth Factor beta1; Trinitrobenzenesulfonic Acid

2014
A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.
    Blood, 2015, Mar-12, Volume: 125, Issue:11

    Topics: Antigens, CD19; Antilymphocyte Serum; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Survival; Diphtheria-Tetanus Vaccine; Humans; Immunity, Humoral; Immunoglobulin G; Immunologic Memory; Inflammation; Lymphocyte Depletion; Models, Immunological; Mutation; Phenotype; Plasma Cells; Pyrazines; V(D)J Recombination

2015
Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
    Toxicology and applied pharmacology, 2015, Feb-15, Volume: 283, Issue:1

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cycloheximide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liposarcoma; MAP Kinase Kinase 4; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tumor Burden; Xenograft Model Antitumor Assays

2015
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    American journal of hematology, 2015, Volume: 90, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2015
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
    British journal of haematology, 2015, Volume: 169, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Genes, ras; Humans; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2015
[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome

2014
How I treat relapsed myeloma.
    Blood, 2015, Mar-05, Volume: 125, Issue:10

    Topics: Adult; Allografts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation

2015
[Clinical features of peripheral neuropathy in paraproteinemic hemoblastosis].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Polyneuropathies; Pyrazines

2014
Persistent dizziness.
    Journal of the American Geriatrics Society, 2015, Volume: 63, Issue:1

    Topics: Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Humans; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia

2015
CyBorD induction therapy in clinical practice.
    Bone marrow transplantation, 2015, Volume: 50, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction

2015
Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Structure (London, England : 1993), 2015, Feb-03, Volume: 23, Issue:2

    Topics: Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Neoplasm; Models, Molecular; Molecular Structure; Mutagenesis; Mutation; Oligopeptides; Proteasome Endopeptidase Complex; Protein Conformation; Pyrazines; X-Ray Diffraction; Yeasts

2015
Bortezomib inhibits gastric carcinoma HGC-27 cells through the phospho-Jun N-terminal kinase (p-JNK) pathway in vitro.
    Gene, 2015, Apr-01, Volume: 559, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Shape; Cell Survival; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Pyrazines; Stomach Neoplasms; Up-Regulation

2015
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin

2015
Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015, Volume: 15, Issue:2

    Topics: Animals; Animals, Genetically Modified; Autoimmune Diseases; Boronic Acids; Bortezomib; Complement C1 Inhibitor Protein; Cytomegalovirus; Galactosyltransferases; Gene Knockout Techniques; Graft Survival; Heterografts; Immunity, Innate; Immunosuppressive Agents; Kidney; Kidney Transplantation; Models, Animal; Papio anubis; Plasma Exchange; Pyrazines; Sus scrofa; Virus Replication

2015
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
    British journal of haematology, 2015, Volume: 169, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine

2015
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
    Leukemia research, 2015, Volume: 39, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured

2015
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Cancer science, 2015, Volume: 106, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzyl Alcohols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Janus Kinase 2; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quantitative Structure-Activity Relationship; STAT3 Transcription Factor

2015
[Multiple myeloma and renal impairment].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Kidney Diseases; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines

2015
[The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment

2015
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide

2015
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome

2015
Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 69

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Pyrazines; Reactive Oxygen Species; Transcription, Genetic

2015
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Mar-15, Volume: 194, Issue:6

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Interleukin-10; Interleukin-17; Interleukin-8; Lymphoma, T-Cell, Cutaneous; Models, Genetic; NF-kappa B; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Skin Neoplasms; Transforming Growth Factor beta1

2015
[Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Lymphoma, Follicular; Prednisolone; Pyrazines; Treatment Outcome; Vincristine

2015
[Latest advances on the maintenance therapy of multiple myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2015
Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
    Cancer letters, 2015, May-01, Volume: 360, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Farnesol; Female; Humans; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2015
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
    American journal of hematology, 2015, Volume: 90, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Pyrazines; Retrospective Studies; Waldenstrom Macroglobulinemia

2015
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    British journal of haematology, 2015, Volume: 169, Issue:4

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytarabine; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Male; Mice; Mice, SCID; Pyrazines; Pyridines; Rituximab; Xenograft Model Antitumor Assays

2015
FOXP3-miR-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate.
    Cancer research, 2015, Apr-15, Volume: 75, Issue:8

    Topics: Animals; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Cells, Cultured; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; MicroRNAs; Precancerous Conditions; Prostate; Prostatic Neoplasms; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays

2015
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
    Anti-cancer drugs, 2015, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Mouth Neoplasms; Pyrazines

2015
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
    Cancer letters, 2015, May-28, Volume: 361, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptotic Protease-Activating Factor 1; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Immunoprecipitation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Thiazoles; Tumor Cells, Cultured

2015
[Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:1

    Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrocardiography; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines

2015
Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
    Cancer research, 2015, May-15, Volume: 75, Issue:10

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycolysis; Hexokinase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Mice, SCID; Multiple Myeloma; Pyrazines; Xenograft Model Antitumor Assays

2015
Bortezomib treatment for patients with mantle-cell lymphoma.
    The Lancet. Oncology, 2015, Volume: 16, Issue:4

    Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Pyrazines

2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-20, Volume: 33, Issue:12

    Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Translocation, Genetic; Treatment Outcome

2015
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
    Turkish journal of medical sciences, 2015, Volume: 45, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Interleukin-6; Mice; Mice, Inbred BALB C; Multiple Myeloma; NF-kappa B; Phenylethyl Alcohol; Pyrazines; Survival Analysis

2015
Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
    Biochemical and biophysical research communications, 2015, May-01, Volume: 460, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Interleukin-8; Macrophages; p38 Mitogen-Activated Protein Kinases; Pyrazines; Real-Time Polymerase Chain Reaction; U937 Cells

2015
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
    Blood cancer journal, 2015, Mar-20, Volume: 5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Pyrazines; Thalidomide

2015
A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Transplantation, 2015, Volume: 99, Issue:8

    Topics: Acute Disease; Adult; Atrophy; Biomarkers; Biopsy; Boronic Acids; Bortezomib; Chi-Square Distribution; Chronic Disease; Complement C4b; Drug Monitoring; Female; Fibrosis; Graft Rejection; Humans; Immunity, Humoral; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Middle Aged; Peptide Fragments; Predictive Value of Tests; Pyrazines; Time Factors; Treatment Outcome

2015
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide

2015
[Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Multiple Myeloma; Pyrazines

2015
[Complications and managements in treatment of melphalan, prednisone and new agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide

2015
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
    Acta haematologica, 2015, Volume: 134, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide

2015
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    American journal of hematology, 2015, Volume: 90, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Induction Chemotherapy; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis

2015
[Carfilzomib in multiple myeloma relapses].
    Bulletin du cancer, 2015, Volume: 102, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide

2015
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:3

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation, Autologous

2015
The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis.
    Toxicology and applied pharmacology, 2015, Jun-01, Volume: 285, Issue:2

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Enzyme Activation; Fertility; Germ Cells; Gonadal Steroid Hormones; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrazines; Sertoli Cells; Spermatogenesis; Testicular Diseases; Testis; Up-Regulation

2015
Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.
    Leukemia research, 2015, Volume: 39, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Pyrazines; Vinblastine; Vinorelbine

2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9

2015
CCMCL1: a new model of aggressive mantle cell lymphoma.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured

2015
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
    American journal of hematology, 2015, Volume: 90, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis

2015
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome

2015
[Multiple myeloma recurring as small intestinal polyposis after autologous hematopoietic stem cell transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyposis; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence

2015
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
    Blood, 2015, Jul-30, Volume: 126, Issue:5

    Topics: Amyloid; Amyloidosis; Boronic Acids; Bortezomib; Cooperative Behavior; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Europe; Heart Diseases; Humans; Kidney Diseases; Pyrazines; Treatment Outcome

2015
How I treat Waldenström macroglobulinemia.
    Blood, 2015, Aug-06, Volume: 126, Issue:6

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia

2015
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML-RARA.
    Anticancer research, 2015, Volume: 35, Issue:6

    Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Pyrazines; Transcriptional Activation; Ubiquitin-Conjugating Enzymes

2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    British journal of haematology, 2015, Volume: 169, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome

2015
FDA approves new agent for multiple myeloma.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration

2015
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines

2015
Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report.
    Progress in transplantation (Aliso Viejo, Calif.), 2015, Volume: 25, Issue:2

    Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Isoantibodies; Methylprednisolone; Prospective Studies; Pyrazines; Rituximab; Treatment Outcome

2015
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines

2015
A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
    Blood, 2015, Aug-06, Volume: 126, Issue:6

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genetic Loci; Heavy Chain Disease; Humans; Immunoglobulin Heavy Chains; Kidney Diseases; Kidney Glomerulus; Mice; Mice, Transgenic; Molecular Sequence Data; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Aggregation, Pathological; Protein Structure, Tertiary; Pyrazines; Sequence Deletion; Unfolded Protein Response

2015
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Cancer letters, 2015, Oct-01, Volume: 366, Issue:2

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Butanes; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays

2015
129-Derived Mouse Strains Express an Unstable but Catalytically Active DNA Polymerase Iota Variant.
    Molecular and cellular biology, 2015, Sep-01, Volume: 35, Issue:17

    Topics: Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Line; DNA Damage; DNA Polymerase iota; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Pyrazines; RNA, Messenger; Sequence Analysis, DNA; Ubiquitination; Xeroderma Pigmentosum

2015
Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption.
    Journal of dental research, 2015, Volume: 94, Issue:9

    Topics: Alveolar Process; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Porphyromonas gingivalis; Pyrazines

2015
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
    Molecular cell, 2015, Jul-16, Volume: 59, Issue:2

    Topics: 3' Untranslated Regions; Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; HCT116 Cells; Hep G2 Cells; Humans; MCF-7 Cells; Mice; MicroRNAs; Molecular Chaperones; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Protein p53

2015
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 354, Issue:3

    Topics: Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Logic; Multiple Myeloma; NF-kappa B; Poly(ADP-ribose) Polymerases; Pyrazines; Signal Transduction

2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
    Anti-cancer drugs, 2015, Volume: 26, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin B; Cyclin D1; Cyclin D3; Drug Synergism; Fenretinide; G2 Phase Cell Cycle Checkpoints; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; NF-KappaB Inhibitor alpha; Pyrazines

2015
Pseudo-Peritoneal Carcinomatosis Presentation of a Crystal-Storing Histiocytosis With an Unmutated Monoclonal κ Light Chain.
    Medicine, 2015, Volume: 94, Issue:32

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallization; Histiocytosis; Humans; Immunoglobulin kappa-Chains; Kidney; Lymph Nodes; Macrophages; Male; Monoclonal Gammopathy of Undetermined Significance; Peritoneal Neoplasms; Pyrazines

2015
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Yonsei medical journal, 2015, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Plasmapheresis; Pyrazines; Transplantation, Homologous

2015
[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Formazans; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Neoplasm Proteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Purines; Pyrazines; Quinazolinones; Signal Transduction; Software; Tetrazolium Salts

2015
Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
    Bone marrow transplantation, 2016, Volume: 51, Issue:5

    Topics: Adult; Aged; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pyrazines; Retrospective Studies; Transplantation, Autologous

2016
Life beyond bortezomib: increasing treatment options in refractory myeloma.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines

2016
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Zhonghua nei ke za zhi, 2016, Sep-01, Volume: 55, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome

2016
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents".
    Cancer research, 2016, 09-01, Volume: 76, Issue:17

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2016
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    Zhonghua nei ke za zhi, 2016, Oct-01, Volume: 55, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome

2016
"The Second Time is Sweeter After All".
    British journal of haematology, 2017, Volume: 176, Issue:4

    Topics: Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines

2017
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
    Acta haematologica, 2017, Volume: 137, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome

2017
Bortezomib Comes to the Rescue: Comment on the Article by Nachmias et al. Entitled "A Bortezomib-Based Protocol Induces a High Rate of CR with Minor Toxicity in Adult Patients with Relapsed/Refractory ALL".
    Acta haematologica, 2018, Volume: 140, Issue:4

    Topics: Adult; Boronic Acids; Bortezomib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Remission Induction

2018
[Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome

2018
Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib.
    Physiological research, 2019, 10-25, Volume: 68, Issue:5

    Topics: Acetanilides; Analgesics; Animals; Bortezomib; Disease Models, Animal; Ganglia, Spinal; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Male; Neuralgia; p38 Mitogen-Activated Protein Kinases; Pain Threshold; Phosphorylation; Proteasome Inhibitors; Purines; Pyrazines; Quinoxalines; Rats, Sprague-Dawley; Receptors, Interleukin-6; Sensory Receptor Cells; Signal Transduction; TRPA1 Cation Channel

2019
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 09-01, Volume: 117, Issue:35

    Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Heat-Shock Response; Hot Temperature; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination

2020
[Analysis of Risk Factors of Herpes Zoster in Patients with Multiple Myeloma Treated with Bortezomib].
    Zhongguo shi yan xue ye xue za zhi, 2020, Volume: 28, Issue:6

    Topics: Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors

2020
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
    Scientific reports, 2021, 01-22, Volume: 11, Issue:1

    Topics: Animals; Benzimidazoles; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Mice; Microtubules; Multiple Myeloma; Polymerization; Proteasome Inhibitors; Pyrazines; Tubulin; Xenograft Model Antitumor Assays

2021
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:7

    Topics: Acyclovir; Amyloidosis; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Encephalitis, Herpes Simplex; Herpesvirus 3, Human; Humans; Middle Aged; Multiple Myeloma; Pyrazines

2022
Bortezomib inhibits the proteasome, leading to cell death via apoptosis in feline injection site sarcoma cells in vitro.
    American journal of veterinary research, 2022, May-08, Volume: 83, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cat Diseases; Cats; Cell Line, Tumor; Proteasome Endopeptidase Complex; Pyrazines; Sarcoma

2022
Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
    Current cancer drug targets, 2022, Volume: 22, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechols; Flavonoids; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2022
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Molecular cancer research : MCR, 2022, 09-02, Volume: 20, Issue:9

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Humans; Hyaluronic Acid; Matrix Metalloproteinase 2; Multiple Myeloma; NF-kappa B; Proteoglycans; Pyrazines; Signal Transduction; Tumor Microenvironment

2022
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
    Biomolecules, 2022, 05-28, Volume: 12, Issue:6

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Metformin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2022
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
    JCI insight, 2022, 10-10, Volume: 7, Issue:19

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Exonucleases; Humans; Interferons; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2022
Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023, Volume: 23, Issue:6

    Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kidney Transplantation; Mice; Pilot Projects; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, CXCR4

2023
High-content microscopy reveals a morphological signature of bortezomib resistance.
    eLife, 2023, 09-27, Volume: 12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Microscopy; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2023
A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
    Cancer research, 2023, 10-02, Volume: 83, Issue:19

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2023
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
    Blood cancer journal, 2023, 11-06, Volume: 13, Issue:1

    Topics: Bortezomib; Humans; Multiple Myeloma; Physicians; Pyrazines; Standard of Care

2023